PT J
AU Wakata, N
   Konno, S
   Nomoto, N
   Sugimoto, H
   Nemoto, H
   Kurihara, T
   Kishi, M
AF Wakata, Nobuo
   Konno, Shinngo
   Nomoto, Nobuatsu
   Sugimoto, Hideki
   Nemoto, Hiroshi
   Kurihara, Teruyuki
   Kishi, Masahiko
TI Myasthenia gravis with concomitant severe paraspinal muscle degeneration and mitochondrial DNA<SUP>4977</SUP> deletion
SO INTERNAL MEDICINE
LA English
DT Article
DE myasthenia gravis; mitochondrial DNA(4977) deletion; paraspinal muscle degeneration; sensorineural deafness
ID dropped head syndrome; para-spinal muscles; dna deletion; hearing-loss; myopathy; camptocormia
AB Recent reports have discussed the many causes of dropped head syndrome and bent spine syndrome. We described a case of myasthenia gravis with concomitant severe degeneration of spinal muscle, mitochondrial DNA(4977) deletion and sensorineural deafness. These associations were thought to be independent, however this is an important case to consider the etiology of bent spine syndrome.
C1 [Wakata, Nobuo; Konno, Shinngo; Nomoto, Nobuatsu; Sugimoto, Hideki; Nemoto, Hiroshi; Kurihara, Teruyuki] Toho Univ, Dept Neurol, Oohashi Hosp, Tokyo, Japan.
   [Kishi, Masahiko] Miyazaki Higashi Natl Hosp, Dept Neurol, Miyazaki, Japan.
C3 Toho University
RP Wakata, N (corresponding author), Toho Univ, Dept Neurol, Oohashi Hosp, Tokyo, Japan.
EM waka@oha.toho-u.ac.jp
CR Bai UM, 2001, HEARING RES, V154, P73, DOI 10.1016/S0378-5955(01)00221-0
   HADAR H, 1983, AM J ROENTGENOL, V141, P895, DOI 10.2214/ajr.141.5.895
   Katz JS, 1996, NEUROLOGY, V46, P917, DOI 10.1212/WNL.46.4.917
   KUNCL RW, 1988, MUSCLE NERVE, V11, P484, DOI 10.1002/mus.880110512
   LANGE DJ, 1986, ANN NEUROL, V20, P133
   LEFORESTIER N, 1995, MUSCLE NERVE, V18, P1338, DOI 10.1002/mus.880181120
   LOEBECK LJ, 1992, MUSCLE NERVE, V15, P1206
   MITSIKOSTAS D, 1995, FUNCT NEUROL, V10, P209
   Oerlemans WGH, 1998, J NEUROL NEUROSUR PS, V65, P258, DOI 10.1136/jnnp.65.2.258
   Plewnia K, 1997, J SUBMICR CYTOL PATH, V29, P335
   Schäbitz WR, 2003, MOVEMENT DISORD, V18, P408, DOI 10.1002/mds.10385
   Serratrice G, 1996, J NEUROL NEUROSUR PS, V60, P51, DOI 10.1136/jnnp.60.1.51
   Ueda N, 1998, LARYNGOSCOPE, V108, P580, DOI 10.1097/00005537-199804000-00022
   Umapathi T, 2002, J NEUROL NEUROSUR PS, V73, P1, DOI 10.1136/jnnp.73.1.1
NR 14
TC 5
Z9 5
U1 0
U2 0
PU JAPAN SOC INTERNAL MEDICINE
PI TOKYO
PA 34-3 3-CHOME HONGO BUNKYO-KU, TOKYO, 113, JAPAN
SN 0918-2918
EI 
J9 INTERNAL MED
JI Intern. Med.
PD JUN 15
PY 2007
VL 46
IS 11
BP 747
EP 750
DI 10.2169/internalmedicine.46.6400
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA 343HG
UT WOS:000258843500012
PM 17541228
DA 2024-11-01
ER

PT J
AU Craig, K
   Elliott, HR
   Keers, SM
   Lambert, C
   Pyle, A
   Graves, TD
   Woodward, C
   Sweeney, MG
   Davis, MB
   Hanna, MG
   Chinnery, PF
AF Craig, K.
   Elliott, H. R.
   Keers, S. M.
   Lambert, C.
   Pyle, A.
   Graves, T. D.
   Woodward, C.
   Sweeney, M. G.
   Davis, M. B.
   Hanna, M. G.
   Chinnery, P. F.
TI Episodic ataxia and hemiplegia caused by the 8993T→C mitochondrial DNA mutation
SO JOURNAL OF MEDICAL GENETICS
LA English
DT Article
ID nucleotide 8993; heteroplasmy; migraine; disease; gene
AB The m.8993T-->C MTATP6 mutation of mitochondrial DNA ( mtDNA) usually causes mitochondrial disease in childhood, but was recently described in a family with adult onset ataxia and polyneuropathy. Cytochrome c oxidase muscle histochemistry, which is the standard clinical investigation for mitochondrial disease in adults, is usually normal in patients with MTATP6 mutations. This raises the possibility that these cases have been missed in the past. We therefore studied 308 patients with unexplained ataxia and 96 patients with suspected Charcot-Marie-Tooth disease to determine whether the m.8993T-->C MTATP6 mutation is common in unexplained inherited ataxia and/or polyneuropathy. We identified a three-generation family with the m.8993T-->C mutation of mtDNA. One subject had episodic ataxia ( EA) and transient hemipareses, broadening the phenotype. However, no further cases were identified in an additional cohort of 191 patients with suspected EA. In conclusion, m.8993T-->C MTATP6 should be considered in patients with unexplained ataxia, CMT or EA, but cases are uncommon.
C1 Mitochondrial Res Ctr, Inst Neurol, London, England.
   Dept Mol Neurosci, Inst Neurol, London, England.
   Univ Newcastle Upon Tyne, Inst Human Genet, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
C3 University of London; University College London; University of London; University College London; Newcastle University - UK
RP Chinnery, PF (corresponding author), The Med Sch, M41014,Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM p.f.chinnery@ncl.ac.uk
FU NINDS NIH HHS [U54 NS059065, U54 NS059065-04] Funding Source: Medline; Wellcome Trust Funding Source: Medline
CR Chinnery PF, 2000, TRENDS GENET, V16, P500, DOI 10.1016/S0168-9525(00)02120-X
   DEVRIES DD, 1993, ANN NEUROL, V34, P410, DOI 10.1002/ana.410340319
   Ducros A, 1999, AM J HUM GENET, V64, P89, DOI 10.1086/302192
   HOLT IJ, 1990, AM J HUM GENET, V46, P428
   McFarland R, 2002, LANCET NEUROL, V1, P343, DOI 10.1016/S1474-4422(02)00159-X
   Pyle A, 2007, J MED GENET, V44, P69, DOI 10.1136/jmg.2006.043109
   Rantamäki MT, 2005, ANN NEUROL, V58, P337, DOI 10.1002/ana.20555
   Thomsen LL, 2007, BRAIN, V130, P346, DOI 10.1093/brain/awl334
   White SL, 1999, AM J HUM GENET, V65, P474, DOI 10.1086/302488
   White SL, 1999, J INHERIT METAB DIS, V22, P899, DOI 10.1023/A:1005639407166
NR 10
TC 25
Z9 28
U1 3
U2 5
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-2593
EI 
J9 J MED GENET
JI J. Med. Genet.
PD DEC 15
PY 2007
VL 44
IS 12
BP 797
EP 799
DI 10.1136/jmg.2007.052902
PG 3
WC Genetics & Heredity
SC Genetics & Heredity
GA 236QE
UT WOS:000251317700009
PM 18055910
DA 2024-11-01
ER

PT J
AU Lee, YC
   Lu, YC
   Chang, MH
   Soong, BW
AF Lee, Yi-Chung
   Lu, Yi-Chun
   Chang, Ming-Hon
   Soong, Bing-Wen
TI Common mitochondrial DNA and <i>POLG1</i> mutations are rare in the Chinese patients with adult-onset ataxia on Taiwan
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Article
DE SCA; ataxia; POLG1; POLG; mitochondria; MIRAS
ID red fibers merrf; progressive external ophthalmoplegia; spinocerebellar ataxia; myoclonic epilepsy; epidemiology; family
AB Background and purpose: Spinocerebellar ataxia (SCA) is a heterogeneous group of neurodegenerative disorders with common features of adult-onset cerebellar ataxia. Many patients with clinically suspected SCA are subsequently diagnosed with common SCA gene mutations. Previous reports suggest some common mitochondrial DNA (mtDNA) point mutations and mitochondrial DNA polymerase gene (POLG1) mutations might be additional underlying genetic causes of cerebellar ataxia. We tested whether mtDNA point mutations A3243G, A8344G, T8993G, and T8993C, or POLG1 mutations W748S and A467T are found in patients with adult-onset ataxia who did not have common SCA mutations. Methods: Four hundred seventy-six unrelated patients with suspected SCA underwent genetic testing for SCA 1, 2, 3, 6, 7, 8, 10, 12, 17, and DRPLA gene mutations. After excluding these SCA mutations and patients with paternal transmission history, 265 patients were tested for mtDNA mutations A3243G, A8344G, T8993G, T8993C, and POLG1 W748S and A467T mutations. Results: No mtDNA A3243G, A8344G, T8993G, T8993C, or POLG1 W748S and A467T mutation was detected in any of the 265 ataxia patients, suggesting that the upper limit of the 95% confidence interval for the prevalence of these mitochondrial mutations in Chinese patients with adult-onset non-SCA ataxia is no higher than 1.1%. Conclusions: The mtDNA mutations A3243G, A8344G, T8993G, T8993C, or POLG1 W748S and A467T are very rare causes of adult-onset ataxia in Taiwan. Routine screening for these mutations in ataxia patients with Chinese origin is of limited clinical value. (c) 2007 Elsevier B.V. All rights reserved.
C1 Vet Gen Hosp, Neurol Inst, Taipei 11217, Taiwan.
   Taichung Vet Gen Hosp, Neurol Sect, Taichung, Taiwan.
   Natl Yang Ming Univ, Sch Med, Dept Neurol, Taipei 112, Taiwan.
   Natl Yang Ming Univ, Sch Med, Inst Clin Med, Taipei 112, Taiwan.
C3 Taichung Veterans General Hospital; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University
RP Soong, BW (corresponding author), Vet Gen Hosp, Neurol Inst, 201,Sec 2,Shih Pai Rd, Taipei 11217, Taiwan.
EM bwsoong@vghtpe.gov.tw
CR Abele M, 2002, BRAIN, V125, P961, DOI 10.1093/brain/awf107
   Brusco A, 2004, ARCH NEUROL-CHICAGO, V61, P727, DOI 10.1001/archneur.61.5.727
   Carelli V, 2002, ARCH NEUROL-CHICAGO, V59, P264, DOI 10.1001/archneur.59.2.264
   FANG W, 1994, MUSCLE NERVE, V17, P52, DOI 10.1002/mus.880170107
   Goodship JA, 2002, J MED GENET, V39, P221, DOI 10.1136/jmg.39.3.221
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   HAMMANS SR, 1993, BRAIN, V116, P617, DOI 10.1093/brain/116.3.617
   HARDING AE, 1982, BRAIN, V105, P1, DOI 10.1093/brain/105.1.1
   HUANG CC, 1994, J NEUROL NEUROSUR PS, V57, P586, DOI 10.1136/jnnp.57.5.586
   Kaplan J, 2002, NEUROCHEM INT, V40, P553, DOI 10.1016/S0197-0186(01)00127-9
   Labuda M, 2000, NEUROLOGY, V54, P2322, DOI 10.1212/WNL.54.12.2322
   Majamaa K, 1998, AM J HUM GENET, V63, P447, DOI 10.1086/301959
   Modi G, 2000, J NEUROL NEUROSUR PS, V68, P393, DOI 10.1136/jnnp.68.3.393
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   MORGANHUGHES JA, 1995, BBA-MOL BASIS DIS, V1271, P135, DOI 10.1016/0925-4439(95)00020-5
   Moseley ML, 1998, NEUROLOGY, V51, P1666, DOI 10.1212/WNL.51.6.1666
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   NEWMAN TB, 1995, JAMA-J AM MED ASSOC, V274, P1013, DOI 10.1001/jama.1995.03530130019013
   Quinzii C, 2006, AM J HUM GENET, V78, P345, DOI 10.1086/500092
   Remes AM, 2003, J NEUROL NEUROSUR PS, V74, P1158, DOI 10.1136/jnnp.74.8.1158
   Rovio AT, 2001, NAT GENET, V29, P261, DOI 10.1038/ng759
   Schöls L, 2000, HUM GENET, V107, P132, DOI 10.1007/s004390000346
   van de Warrenburg BPC, 2005, J NEUROPATH EXP NEUR, V64, P171, DOI 10.1093/jnen/64.3.171
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Vilarinho L, 2001, J INHERIT METAB DIS, V24, P883, DOI 10.1023/A:1013908728445
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
NR 27
TC 11
Z9 12
U1 1
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0022-510X
EI 1878-5883
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD MAR 15
PY 2007
VL 254
IS 1-2
BP 65
EP 68
DI 10.1016/j.jns.2007.01.005
PG 4
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 152VX
UT WOS:000245391200013
PM 17300808
DA 2024-11-01
ER

PT J
AU Zifa, E
   Giannouli, S
   Theotokis, P
   Stamatis, O
   Mamuris, Z
   Stathopoulos, C
AF Zifa, Emily
   Giannouli, Stamatina
   Theotokis, Paschalis
   Stamatis, Ostas
   Mamuris, Zissis
   Stathopoulos, Constantinos
TI Mitochondrial tRNA mutations - Clinical and functional perturbations
SO RNA BIOLOGY
LA English
DT Review
DE tRNA; mitochondrion; encephalopathies; myopathies; mitochondrial tRNA mutations
ID stroke-like episodes; progressive external ophthalmoplegia; ragged-red fibers; maternally inherited cardiomyopathy; merrf/melas overlap syndrome; hereditary optic neuropathy; complex-i deficiency; mtdna point mutation; idiopathic sideroblastic anemia; anticodon wobble nucleotide
AB During the last decade, there has been a progressive accumulation of reports that connect the identification of specific mitochondrial tRNA gene mutations to severe disorders in human. As a result, mitochondrial tRNA genes and their products have emerged as novel and essential molecular markers for wide biochemical and genetic screenings among different human populations. So far, 139 pathogenic and 243 polymorphic mt tRNA mutations have been described and they have become the foreground of numerous case reports. Given the complexity of mitochondrial genetics and biochemistry, the clinical manifestations of mitochondrial disorders are extremely heterogeneous. They range from lesions of single tissues or structures to more severe impairements including myopathies, encephalomyopothies, cardiomyopothies, or complex multisystem syndromes. Moreover, the exact mechanisms by which biochemical cascades can be dramatically affected by mitochondrial tRNA mutations still remain uncharacterized. However and regardless of the vast amount of information that daily emerges, only few efforts have been carried out to systematically record all the mitochondrial tRNA-associated pathogenic mutations or polymorphisms. in this report, we summarize all the clinical phenotypes associated with mitochondrial tRNA pathogenic mutations that have been reported so for. In a next step we describe in detail all the pathogenic and polymorphic mutations that have been recorded so far and we categorize them per tRNA species and per associated disease. Finally, we discuss the impact of the frequency of mitochondrial tRNA mutations in general population surveys and we preview any relevant implications on the essential functional integrity of mitochondrial biochemical pathways.
C1 [Zifa, Emily; Giannouli, Stamatina; Theotokis, Paschalis; Stamatis, Ostas; Mamuris, Zissis; Stathopoulos, Constantinos] Univ Thessaly, Dept Biochem & Biotechnol, Larisa 41221, Greece.
   [Stathopoulos, Constantinos] CERETETH, Inst Biomed Res & Technol BIOMED, Larisa, Greece.
C3 University of Thessaly
RP Stathopoulos, C (corresponding author), Univ Thessaly, Dept Biochem & Biotechnol, 26 Ploutonos St, Larisa 41221, Greece.
EM cstath@bio.uth.gr
CR AATO, 1998, J NEUROLSCIE, V127, P235
   Abu-Amero EK, 2006, J CHILD NEUROL, V21, P971, DOI 10.2310/7010.2006.00208
   Akita Y, 2000, HUM MUTAT, V15, P382, DOI 10.1002/(SICI)1098-1004(200004)15:4<382::AID-HUMU15>3.0.CO;2-B
   Allen JF, 1996, J MOL EVOL, V42, P482, DOI 10.1007/BF02352278
   AN, 2002, J MED, V39, P262
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Anitori R, 2005, MOL GENET METAB, V84, P176, DOI 10.1016/j.ymgme.2004.10.003
   Annunen-Rasila J, 2007, MITOCHONDRION, V7, P96, DOI 10.1016/j.mito.2006.11.004
   Arenas J, 1999, NEUROLOGY, V52, P377, DOI 10.1212/WNL.52.2.377
   Austin SA, 1998, NEUROLOGY, V51, P1447, DOI 10.1212/WNL.51.5.1447
   Bataillard M, 2001, NEUROLOGY, V56, P405, DOI 10.1212/WNL.56.3.405
   BAU, 2005, SCRABISMUS, V13, P133
   Bau V, 2005, STRABISMUS, V13, P133, DOI 10.1080/09273970500216432
   BETA, 2001, NEUROLYG, V56, P405
   Bidooki S, 2004, NEUROMUSCULAR DISORD, V14, P417, DOI 10.1016/j.nmd.2004.03.004
   Bidooki SK, 1997, AM J HUM GENET, V60, P1430, DOI 10.1086/515460
   BINDOFF LA, 1993, J BIOL CHEM, V268, P19559
   Blakely EL, 2004, J NEUROL SCI, V225, P99, DOI 10.1016/j.jns.2004.07.007
   BLAKELY EL, 2007, IN PRESS J NEUROL, V0, P0
   Blondon H, 2005, GASTROEN CLIN BIOL, V29, P773, DOI 10.1016/S0399-8320(05)86346-8
   Börner GV, 2000, HUM MOL GENET, V9, P467, DOI 10.1093/hmg/9.4.467
   Borthwick Gillian M, 2006, ANN NEUROL, V59, P570, DOI 10.1002/ana.20758
   Brown MD, 1996, AM J MED GENET, V61, P283, DOI 10.1002/(SICI)1096-8628(19960122)61:3<283::AID-AJMG15>3.0.CO;2-P
   BROWN MD, 1992, AM J HUM GENET, V51, P446
   Brulé H, 1998, NUCLEIC ACIDS RES, V26, P537, DOI 10.1093/nar/26.2.537
   Bruno C, 2003, J CHILD NEUROL, V18, P300, DOI 10.1177/08830738030180040401
   Bruno C, 1999, J PEDIATR-US, V135, P197, DOI 10.1016/S0022-3476(99)70022-3
   Campos Y, 2001, NEUROMUSCULAR DISORD, V11, P477, DOI 10.1016/S0960-8966(00)00223-6
   Campos Y, 1996, MUSCLE NERVE, V19, P187, DOI 10.1002/(SICI)1097-4598(199602)19:2<187::AID-MUS10>3.0.CO;2-S
   Campos Y, 2000, NEUROMUSCULAR DISORD, V10, P493, DOI 10.1016/S0960-8966(00)00107-3
   Cardaioli E, 2005, BIOCHEM BIOPH RES CO, V327, P675, DOI 10.1016/j.bbrc.2004.11.170
   Carnpos Y, 2003, NEUROMUSCULAR DISORD, V13, P416, DOI 10.1016/S0960-8966(03)00039-7
   Casali C, 1999, NEUROLOGY, V52, P1103, DOI 10.1212/WNL.52.5.1103
   Casali C, 1999, J AM COLL CARDIOL, V33, P1584, DOI 10.1016/S0735-1097(99)00079-0
   Chalmers RM, 1997, NEUROLOGY, V49, P589, DOI 10.1212/WNL.49.2.589
   CHANG TS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1254, DOI 10.1001/archopht.1993.01090090106028
   Chapiro E, 2002, EUR J HUM GENET, V10, P851, DOI 10.1038/sj.ejhg.5200894
   Chen Y, 2000, DIABETES RES CLIN PR, V48, P29, DOI 10.1016/S0168-8227(99)00138-2
   Cheong HI, 1999, PEDIATR NEPHROL, V13, P477, DOI 10.1007/s004670050641
   Chinnery PF, 2000, ANN NEUROL, V48, P188, DOI 10.1002/1531-8249(200008)48:2<188::AID-ANA8>3.3.CO;2-G
   Chinnery PF, 1997, ANN NEUROL, V41, P408, DOI 10.1002/ana.410410319
   Chinnery PF, 1997, NEUROLOGY, V49, P1166, DOI 10.1212/WNL.49.4.1166
   Chomyn A, 1998, AM J HUM GENET, V62, P745, DOI 10.1086/301813
   Chomyn A, 2000, J BIOL CHEM, V275, P19198, DOI 10.1074/jbc.M908734199
   CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221
   Corona P, 2002, ANN NEUROL, V51, P118, DOI 10.1002/ana.10059
   Coulbault L, 2005, BIOCHEM BIOPH RES CO, V329, P1152, DOI 10.1016/j.bbrc.2005.02.083
   Crimi M, 2004, MITOCHONDRION, V3, P279, DOI 10.1016/j.mito.2004.02.004
   Crimi M, 2003, NEUROLOGY, V60, P1200, DOI 10.1212/01.WNL.0000055865.30580.39
   Damore ME, 1999, J PEDIATR ENDOCR MET, V12, P207
   Darin N, 2006, NEUROMUSCULAR DISORD, V16, P504, DOI 10.1016/j.nmd.2006.05.010
   Darin N, 2001, ANN NEUROL, V49, P377, DOI 10.1002/ana.75
   de Coo IFM, 1998, NEUROLOGY, V50, P293, DOI 10.1212/WNL.50.1.293
   Deschauer M, 2004, J NEUROL NEUROSUR PS, V75, P1204, DOI 10.1136/jnnp.2003.026278
   Deschauer M, 2006, ARCH NEUROL-CHICAGO, V63, P902, DOI 10.1001/archneur.63.6.902
   Dey R, 2000, NEUROMUSCULAR DISORD, V10, P488, DOI 10.1016/S0960-8966(00)00125-5
   DiMauro S, 2005, NEUROMUSCULAR DISORD, V15, P276, DOI 10.1016/j.nmd.2004.12.008
   DiMauro S, 1998, CURR OPIN CARDIOL, V13, P190
   DIMAURO S, 2007, IN PRESS BIOSCI REP, V0, P0
   DIMAURO S, 2007, BIOSCIENCE REP, V0, P125
   DiMauro S, 2006, CURR OPIN RHEUMATOL, V18, P636, DOI 10.1097/01.bor.0000245729.17759.f2
   Dinour D, 2004, CLIN NEPHROL, V62, P149
   Dittmar KA, 2006, PLOS GENET, V2, P2107, DOI 10.1371/journal.pgen.0020221
   Egensperger R, 1997, NEUROPATH APPL NEURO, V23, P315, DOI 10.1046/j.1365-2990.1997.4098040.x
   El Meziane A, 1998, HUM MOL GENET, V7, P2141, DOI 10.1093/hmg/7.13.2141
   Elson JL, 2006, HUM GENET, V119, P241, DOI 10.1007/s00439-005-0123-8
   ENRIQUEZ JA, 1995, NAT GENET, V10, P47, DOI 10.1038/ng0595-47
   Estivill X, 1998, AM J HUM GENET, V62, P27, DOI 10.1086/301676
   Fabrizi GM, 1996, J NEUROL NEUROSUR PS, V61, P47, DOI 10.1136/jnnp.61.1.47
   Feigenbaum A, 2006, AM J MED GENET A, V140A, P2216, DOI 10.1002/ajmg.a.31436
   Finnilä S, 2001, J MOL MED, V79, P641, DOI 10.1007/s001090100268
   Fischel-Ghodsian N, 1998, AM J HUM GENET, V62, P15, DOI 10.1086/301695
   FISCHELGHODSIAN N, 1995, AM J OTOLARYNG, V16, P403, DOI 10.1016/0196-0709(95)90078-0
   Florentz C, 2003, CELL MOL LIFE SCI, V60, P1356, DOI 10.1007/s00018-003-2343-1
   Florentz C, 2002, BIOSCIENCE REP, V22, P81, DOI 10.1023/A:1016065107165
   Florentz C, 2001, EMBO REP, V2, P481, DOI 10.1093/embo-reports/kve111
   FOLGERO T, 1995, EUR NEUROL, V35, P168, DOI 10.1159/000117115
   Franceschina L, 1998, J NEUROL, V245, P755, DOI 10.1007/s004150050283
   Fu K, 1996, HUM MOL GENET, V5, P1835, DOI 10.1093/hmg/5.11.1835
   Gámez J, 1998, NEUROLOGY, V51, P258, DOI 10.1212/WNL.51.1.258
   GARC, 2000, HUMAN MUTAT, V15, P120
   Garcia-Lozano J R, 2000, HUM MUTAT, V15, P120, DOI 10.1002/(SICI)1098-1004(200001)15:1<120::AID-HUMU33>3.0.CO;2-8
   GARDNER JL, 2007, BIOSCIENCE REP, V0, P139
   Gattermann N, 2000, LEUKEMIA RES, V24, P141, DOI 10.1016/S0145-2126(99)00160-5
   Gattermann N, 1996, BRIT J HAEMATOL, V93, P845, DOI 10.1046/j.1365-2141.1996.d01-1724.x
   Giegé R, 1998, NUCLEIC ACIDS RES, V26, P5017, DOI 10.1093/nar/26.22.5017
   Goldstein JD, 1999, PEDIATR DEVEL PATHOL, V2, P78, DOI 10.1007/s100249900094
   GOTO Y, 1992, ANN NEUROL, V31, P672, DOI 10.1002/ana.410310617
   GOTO Y, 1991, BIOCHIM BIOPHYS ACTA, V1097, P238, DOI 10.1016/0925-4439(91)90042-8
   GOTO YI, 1994, BIOCHEM BIOPH RES CO, V202, P1624, DOI 10.1006/bbrc.1994.2119
   Graf WD, 2000, J CHILD NEUROL, V15, P357, DOI 10.1177/088307380001500601
   Grafakou O, 2003, J INHERIT METAB DIS, V26, P593, DOI 10.1023/A:1025960300710
   Grasbon-Frodl EM, 1999, NEUROGENETICS, V2, P121, DOI 10.1007/s100480050063
   Grasso M, 2001, EUR J HUM GENET, V9, P311, DOI 10.1038/sj.ejhg.5200622
   Grünewald T, 1999, DRUG DEVELOP RES, V46, P80
   GRUNEWELD, 1999, DRUG DEVELOP RES, V46, P80
   Guillausseau PJ, 2001, ANN INTERN MED, V134, P721, DOI 10.7326/0003-4819-134-9_Part_1-200105010-00008
   Hadjigeorgiou GM, 1999, J NEUROL SCI, V164, P153, DOI 10.1016/S0022-510X(99)00062-3
   HAMMANS SR, 1993, BRAIN, V116, P617, DOI 10.1093/brain/116.3.617
   Hanna MG, 1998, J NEUROL NEUROSUR PS, V65, P512, DOI 10.1136/jnnp.65.4.512
   HANNA MG, 1995, AM J HUM GENET, V56, P1026
   Hansrote S, 2002, J NEUROL SCI, V197, P63, DOI 10.1016/S0022-510X(02)00048-5
   Hao HL, 1997, MOL CELL BIOL, V17, P6831, DOI 10.1128/MCB.17.12.6831
   HAO HL, 1995, AM J HUM GENET, V56, P1017
   Hao HL, 1996, J BIOL CHEM, V271, P2347, DOI 10.1074/jbc.271.4.2347
   Hao R, 2005, NUCLEIC ACIDS RES, V33, P3606, DOI 10.1093/nar/gki677
   HATTORI Y, 1994, J NEUROL SCI, V125, P50, DOI 10.1016/0022-510X(94)90241-0
   Helm M, 1999, NUCLEIC ACIDS RES, V27, P756, DOI 10.1093/nar/27.3.756
   HESS JF, 1991, NATURE, V351, P236, DOI 10.1038/351236a0
   Hino N, 2004, GENES CELLS, V9, P243, DOI 10.1111/j.1356-9597.2004.00718.x
   HIRANO M, 1994, NEUROLOGY, V44, P721, DOI 10.1212/WNL.44.4.721
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Horváth R, 2003, J MED GENET, V40, P752, DOI 10.1136/jmg.40.10.752
   Houshmand M, 1999, HUM MUTAT, V13, P203, DOI 10.1002/(SICI)1098-1004(1999)13:3<203::AID-HUMU4>3.0.CO;2-3
   Houshmand M, 1996, HUM GENET, V97, P269, DOI 10.1007/BF02185750
   Howell N, 2005, TRENDS GENET, V21, P583, DOI 10.1016/j.tig.2005.08.012
   Huerta C, 2005, J NEUROL SCI, V236, P49, DOI 10.1016/j.jns.2005.04.016
   Hunter Senyene Eyo, 2004, RNA BIOL, V1, P95, DOI 10.4161/rna.1.2.1034
   HUTCHIN T, 1995, P NATL ACAD SCI USA, V92, P6892, DOI 10.1073/pnas.92.15.6892
   Hutchin TP, 2000, J MED GENET, V37, P692, DOI 10.1136/jmg.37.9.692
   Ingman M, 2000, NATURE, V408, P708, DOI 10.1038/35047064
   INGMAN M, 2000, NATRE, V408, P7808
   Inoue K, 2000, NAT GENET, V26, P176, DOI 10.1038/82826
   IONASESCU VV, 1994, NEUROLOGY, V44, P975, DOI 10.1212/WNL.44.5.975
   Jaksch M, 1998, J MED GENET, V35, P895, DOI 10.1136/jmg.35.11.895
   Jaksch M, 2001, NEUROLOGY, V57, P1930, DOI 10.1212/WNL.57.10.1930
   Janssen GMC, 1999, J BIOL CHEM, V274, P29744, DOI 10.1074/jbc.274.42.29744
   JENO, 2004, IRAL HEART, V5, P460
   Jeppesen TD, 2003, J NEUROL SCI, V214, P17, DOI 10.1016/S0022-510X(03)00168-0
   Jones CI, 2006, J MOL BIOL, V362, P771, DOI 10.1016/j.jmb.2006.07.036
   Kalman B, 1999, ACTA NEUROL SCAND, V99, P16
   Kameoka K, 1998, BIOCHEM BIOPH RES CO, V245, P523, DOI 10.1006/bbrc.1998.8437
   Karadimas C, 2001, J CHILD NEUROL, V16, P531, DOI 10.1177/088307380101600715
   Karadimas CL, 2002, NEUROMUSCULAR DISORD, V12, P865, DOI 10.1016/S0960-8966(02)00072-X
   Kasahara T, 2006, MOL PSYCHIATR, V11, P577, DOI 10.1038/sj.mp.4001824
   Kato T, 2000, BIPOLAR DISORD, V2, P180, DOI 10.1034/j.1399-5618.2000.020305.x
   Kawarai T, 1997, NEUROLOGY, V49, P598, DOI 10.1212/WNL.49.2.598
   Kelley SO, 2001, J BIOL CHEM, V276, P10607, DOI 10.1074/jbc.M008320200
   KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480
   Kirino Y, 2005, P NATL ACAD SCI USA, V102, P7127, DOI 10.1073/pnas.0500563102
   Kirino Yohei, 2005, RNA BIOL, V2, P41, DOI 10.4161/rna.2.2.1610
   KISH SJ, 1992, J NEUROCHEM, V59, P776, DOI 10.1111/j.1471-4159.1992.tb09439.x
   Kleinle S, 1998, BIOCHEM BIOPH RES CO, V247, P112, DOI 10.1006/bbrc.1998.8729
   Klopstock T, 1997, MOL CELL BIOCHEM, V174, P271, DOI 10.1023/A:1006877012241
   Koga Y, 2000, ARCH DIS CHILD, V82, P407, DOI 10.1136/adc.82.5.407
   KOGA Y, 1995, MUSCLE NERVE, V0, PS119
   Kolesnikova OA, 2000, SCIENCE, V289, P1931, DOI 10.1126/science.289.5486.1931
   Kolesnikova OA, 2004, HUM MOL GENET, V13, P2519, DOI 10.1093/hmg/ddh267
   LARSSON NG, 1995, MUSCLE NERVE S, V3, P102
   LAUBER J, 1991, NUCLEIC ACIDS RES, V19, P1393, DOI 10.1093/nar/19.7.1393
   LEROY D, 1994, CLIN GENET, V45, P109
   Levinger L, 2004, NUCLEIC ACIDS RES, V32, P5430, DOI 10.1093/nar/gkh884
   Levinger L, 2003, NUCLEIC ACIDS RES, V31, P1904, DOI 10.1093/nar/gkg282
   LI R, 2006, GENE, V47, P475
   Li RH, 2005, BIOCHEM BIOPH RES CO, V328, P32, DOI 10.1016/j.bbrc.2004.12.140
   Li XM, 2004, NUCLEIC ACIDS RES, V32, P867, DOI 10.1093/nar/gkh226
   Limongelli A, 2004, J MED GENET, V41, P342, DOI 10.1136/jmg.2003.016048
   Lu JX, 2006, BIOCHEM BIOPH RES CO, V348, P115, DOI 10.1016/j.bbrc.2006.07.010
   Lynn S, 1998, DIABETES, V47, P1800, DOI 10.2337/diabetes.47.11.1800
   Maassen JA, 2004, DIABETES, V53, PS103, DOI 10.2337/diabetes.53.2007.S103
   Maeso E, 2007, NEUROMUSCULAR DISORD, V17, P415, DOI 10.1016/j.nmd.2007.01.015
   Mahata B, 2006, SCIENCE, V314, P471, DOI 10.1126/science.1129754
   Majamaa K, 1998, AM J HUM GENET, V63, P447, DOI 10.1086/301959
   Majamaa-Voltti K, 2004, ANN MED, V36, P225, DOI 10.1080/07853890410028456
   Man PYW, 2003, AM J HUM GENET, V72, P333, DOI 10.1016/j.ajhg.2016.05.015
   Man PYW, 2002, J MED GENET, V39, P162, DOI 10.1136/jmg.39.3.162
   Mancuso M, 2004, NEUROLOGY, V62, P2119, DOI 10.1212/01.WNL.0000127608.48406.F1
   Manfredi G, 1996, HUM MUTAT, V7, P158
   Maniura-Weber K, 2004, EUR J HUM GENET, V12, P509, DOI 10.1038/sj.ejhg.5201185
   Manwaring N, 2007, MITOCHONDRION, V7, P230, DOI 10.1016/j.mito.2006.12.004
   Martín-Hernández E, 2005, PEDIATR NEPHROL, V20, P1299, DOI 10.1007/s00467-005-1948-z
   Matsumoto Joyce, 2005, REV NEUROL DIS, V2, P30
   Mayr-Wohlfart U, 1997, EUR J MED RES, V2, P111
   MayrWohlfart U, 1996, ACTA NEUROL SCAND, V94, P167, DOI 10.1111/j.1600-0404.1996.tb07048.x
   McFarland R, 2007, CURR TOP DEV BIOL, V77, P113, DOI 10.1016/S0070-2153(06)77005-3
   McFarland R, 2004, TRENDS GENET, V20, P591, DOI 10.1016/j.tig.2004.09.014
   McFarland R, 2004, ANN NEUROL, V55, P478, DOI 10.1002/ana.20004
   McFarland R, 2004, NEUROMUSCULAR DISORD, V14, P162, DOI 10.1016/j.nmd.2003.10.011
   McFarland R, 2002, NAT GENET, V30, P145, DOI 10.1038/ng819
   Melone MAB, 2004, ARCH NEUROL-CHICAGO, V61, P269, DOI 10.1001/archneur.61.2.269
   Menotti Francesca, 2004, ITAL HEART J, V5, P460
   MERANTE F, 1994, AM J HUM GENET, V55, P437
   Merante F, 1996, HUM MUTAT, V8, P216, DOI 10.1002/(SICI)1098-1004(1996)8:3<216::AID-HUMU4>3.0.CO;2-7
   Mimaki M, 2003, J HUM GENET, V48, P47, DOI 10.1007/s100380300005
   Möllers M, 2005, NUCLEIC ACIDS RES, V33, P5647, DOI 10.1093/nar/gki876
   Mongini T, 2002, CLIN NEUROPATHOL, V21, P72
   MORAES CT, 1993, NAT GENET, V4, P284, DOI 10.1038/ng0793-284
   MORTEN KJ, 1993, HUM MOL GENET, V2, P2081, DOI 10.1093/hmg/2.12.2081
   Moslemi AR, 2004, NEUROMUSCULAR DISORD, V14, P46, DOI 10.1016/S0960-8966(03)00168-8
   Mukherjee S, 2007, EMBO REP, V8, P589, DOI 10.1038/sj.embor.7400979
   Müller T, 2005, ACTA NEUROPATHOL, V110, P426, DOI 10.1007/s00401-005-1063-z
   Munakata K, 2005, BIOL PSYCHIAT, V57, P525, DOI 10.1016/j.biopsych.2004.11.041
   MUNSCHER C, 1993, BIOL CHEM H-S, V374, P1099, DOI 10.1515/bchm3.1993.374.7-12.1099
   NAKAMURA M, 1995, BIOCHEM BIOPH RES CO, V214, P86, DOI 10.1006/bbrc.1995.2260
   Nakamura Y, 2000, NUCLEIC ACIDS RES, V28, P292, DOI 10.1093/nar/28.1.292
   NELSON I, 1995, ANN NEUROL, V37, P400, DOI 10.1002/ana.410370317
   Nishigaki Y, 2003, NEUROMUSCULAR DISORD, V13, P334, DOI 10.1016/S0960-8966(02)00283-3
   Nishigaki Y, 2002, NEUROLOGY, V58, P1282, DOI 10.1212/WNL.58.8.1282
   Nishino I, 1996, BIOCHEM BIOPH RES CO, V225, P180, DOI 10.1006/bbrc.1996.1150
   Ohkubo K, 2001, CLIN CHEM, V47, P1641
   Ozawa M, 1997, MUSCLE NERVE, V20, P271, DOI 10.1002/(SICI)1097-4598(199703)20:3<271::AID-MUS2>3.0.CO;2-8
   Pandya A, 1999, AM J HUM GENET, V65, P1803, DOI 10.1086/302658
   Park H, 2003, BIOCHEMISTRY-US, V42, P958, DOI 10.1021/bi026882r
   Perucca-Lostanlen D, 2002, BBA-MOL BASIS DIS, V1588, P210, DOI 10.1016/S0925-4439(02)00167-9
   Pesole G, 1999, J MOL EVOL, V48, P427, DOI 10.1007/PL00006487
   Petruzzella V, 2004, CLIN GENET, V65, P64, DOI 10.1111/j..2004.00185.x
   PETRUZZELLA V, 1994, HUM MOL GENET, V3, P449, DOI 10.1093/hmg/3.3.449
   Pineda M, 2004, PEDIATR RES, V56, P55, DOI 10.1203/01.PDR.0000130475.20571.98
   Pulkes T, 2000, NEUROLOGY, V55, P1210, DOI 10.1212/WNL.55.8.1210
   Pulkes T, 2005, NEUROMUSCULAR DISORD, V15, P364, DOI 10.1016/j.nmd.2005.01.006
   Pulkes T, 2003, NEUROLOGY, V61, P1144, DOI 10.1212/01.WNL.0000090465.27024.3D
   Pulkes T, 2000, LANCET, V356, P2068, DOI 10.1016/S0140-6736(00)03408-5
   Qu J, 2006, INVEST OPHTH VIS SCI, V47, P475, DOI 10.1167/iovs.05-0665
   Rabilloud T, 2002, BIOCHEMISTRY-US, V41, P144, DOI 10.1021/bi0114776
   Raffelsberger T, 2001, NEUROLOGY, V57, P2298, DOI 10.1212/WNL.57.12.2298
   Ramelli GP, 2006, J CHILD NEUROL, V21, P253, DOI 10.2310/7010.2006.00047
   REID FM, 1994, HUM MUTAT, V3, P243, DOI 10.1002/humu.1380030311
   Remes AM, 2003, J NEUROL NEUROSUR PS, V74, P1158, DOI 10.1136/jnnp.74.8.1158
   Rigoli L, 1999, ACTA DIABETOL, V36, P163, DOI 10.1007/s005920050161
   Rigoli L, 2001, DIABETIC MED, V18, P334, DOI 10.1046/j.1464-5491.2001.00429-2.x
   Ronghua L, 2006, GENE, V376, P79, DOI 10.1016/j.gene.2006.02.014
   Rossmanith W, 2003, ANN NEUROL, V54, P820, DOI 10.1002/ana.10753
   Rossmanith W, 1998, FEBS LETT, V433, P269, DOI 10.1016/S0014-5793(98)00928-4
   Rötig A, 2003, J NEPHROL, V16, P286
   Sacconi S, 2002, ARCH NEUROL-CHICAGO, V59, P1013, DOI 10.1001/archneur.59.6.1013
   Sahashi K, 2001, J MED GENET, V38, P703, DOI 10.1136/jmg.38.10.703
   Sakuta R, 2002, PEDIATR NEUROL, V27, P397, DOI 10.1016/S0887-8994(02)00456-3
   SAKUTA R, 1993, J NEUROL SCI, V115, P158, DOI 10.1016/0022-510X(93)90219-O
   Saneto RP, 2006, J CHILD NEUROL, V21, P77, DOI 10.1177/08830738060210010601
   Sanger TD, 1996, PEDIATR NEUROL, V14, P57, DOI 10.1016/0887-8994(95)00226-X
   SANTORELLI FM, 1995, BIOCHEM BIOPH RES CO, V216, P835, DOI 10.1006/bbrc.1995.2697
   Santorelli FM, 1996, PEDIATR NEUROL, V15, P145, DOI 10.1016/0887-8994(96)00163-4
   Santorelli FM, 1997, ANN NEUROL, V42, P256, DOI 10.1002/ana.410420220
   Santorelli FM, 1996, AM J HUM GENET, V58, P933
   Santorelli FM, 1997, NEUROMUSCULAR DISORD, V7, P156, DOI 10.1016/S0960-8966(97)00444-6
   Santorelli FM, 1998, ANN NEUROL, V44, P962, DOI 10.1002/ana.410440616
   Santorelli FM, 2001, AM HEART J, V141, P1
   SARO W, 1994, J NEUROL SCI, V127, P236
   SATO W, 1994, BIOCHEM MOL BIOL INT, V33, P1055
   Scaglia F, 2004, AM J MED GENET A, V131A, P109, DOI 10.1002/ajmg.a.30319
   SCHAEFER AM, 2004, BIOCHIM BIOPHYS ACTA, V1695, P115
   Schapira AHV, 2006, LANCET, V368, P70, DOI 10.1016/S0140-6736(06)68970-8
   SCHAPR, 2006, LACNET, V368, P70
   Scheffler IE, 2001, ADV DRUG DELIVER REV, V49, P3, DOI 10.1016/S0169-409X(01)00123-5
   Scheper GC, 2007, NAT GENET, V39, P534, DOI 10.1038/ng2013
   Schon EA, 2000, TRENDS BIOCHEM SCI, V25, P555, DOI 10.1016/S0968-0004(00)01688-1
   Schuelke M, 1998, ANN NEUROL, V44, P700, DOI 10.1002/ana.410440420
   Schwartz M, 2002, NEW ENGL J MED, V347, P576, DOI 10.1056/NEJMoa020350
   Scuderi C, 2007, NEUROMUSCULAR DISORD, V17, P258, DOI 10.1016/j.nmd.2006.11.006
   SEIBEL P, 1994, BIOCHEM BIOPH RES CO, V204, P482, DOI 10.1006/bbrc.1994.2485
   Seki A, 1997, PEDIATR NEUROL, V17, P161, DOI 10.1016/S0887-8994(97)00080-5
   Seneca S, 2000, J INHERIT METAB DIS, V23, P853, DOI 10.1023/A:1026729223050
   Seneca S, 2005, AM J MED GENET A, V137A, P170, DOI 10.1002/ajmg.a.30854
   Seneca S, 2001, ARCH NEUROL-CHICAGO, V58, P1113, DOI 10.1001/archneur.58.7.1113
   Seneca S, 1998, J MED GENET, V35, P963, DOI 10.1136/jmg.35.11.963
   Sevior KB, 1998, AM J MED GENET, V75, P179, DOI 10.1002/(SICI)1096-8628(19980113)75:2<179::AID-AJMG11>3.0.CO;2-M
   Shaag A, 1997, BIOCHEM BIOPH RES CO, V233, P637, DOI 10.1006/bbrc.1997.6496
   Shin WS, 2000, AM J HUM GENET, V67, P1617, DOI 10.1086/316896
   SHOFFNER JM, 1993, AM J HUM GENET, V53, P949
   SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N
   SHOFFNER JM, 1995, NEUROLOGY, V45, P286, DOI 10.1212/WNL.45.2.286
   Shtilbans A, 2000, J CHILD NEUROL, V15, P759, DOI 10.1177/088307380001501109
   Shtilbans A, 1999, J CHILD NEUROL, V14, P610, DOI 10.1177/088307389901400910
   SILVESTRI G, 1994, HUM MUTAT, V3, P37, DOI 10.1002/humu.1380030107
   Silvestri G, 1998, NEUROMUSCULAR DISORD, V8, P291, DOI 10.1016/S0960-8966(98)00037-6
   Silvestri G, 2000, NEUROLOGY, V54, P1693, DOI 10.1212/WNL.54.8.1693
   SILVESTRI G, 1993, NEUROLOGY, V43, P1200, DOI 10.1212/WNL.43.6.1200
   SILVESTRI G, 1992, AM J HUM GENET, V51, P1213
   Silvestri G, 1996, BIOCHEM BIOPH RES CO, V220, P623, DOI 10.1006/bbrc.1996.0453
   Simon DK, 2000, NEUROLOGY, V54, P703, DOI 10.1212/WNL.54.3.703
   Sissler M, 2004, RNA, V10, P841, DOI 10.1261/rna.5267604
   Skladal D, 2003, BRAIN, V126, P1905, DOI 10.1093/brain/awg170
   Spagnolo M, 2001, NEUROMUSCULAR DISORD, V11, P481, DOI 10.1016/S0960-8966(01)00195-X
   Spinazzola A, 2004, NEUROMUSCULAR DISORD, V14, P815, DOI 10.1016/j.nmd.2004.09.002
   Sprinzl M, 2005, NUCLEIC ACIDS RES, V33, PD139, DOI 10.1093/nar/gki012
   Sternberg D, 2001, BRAIN, V124, P984, DOI 10.1093/brain/124.5.984
   SUE, 1900, V52, V0, P107
   Sue CM, 1999, NEUROLOGY, V52, P1905, DOI 10.1212/WNL.52.9.1905
   Suzuki H, 2007, J BIOL CHEM, V282, P4076, DOI 10.1074/jbc.M608187200
   SUZUKI S, 1994, DIABETES CARE, V17, P1428, DOI 10.2337/diacare.17.12.1428
   Suzuki Y, 1997, DIABETES CARE, V20, P1138, DOI 10.2337/diacare.20.7.1138
   Suzuki Y, 2004, DIABETES RES CLIN PR, V63, P225, DOI 10.1016/j.diabres.2003.10.024
   Swalwell H, 2006, NEUROLOGY, V66, P447, DOI 10.1212/01.wnl.0000196490.36349.83
   SWEENEY MG, 1993, Q J MED, V86, P435
   SWEENEY MG, 1993, Q J MED, V86, P709
   SZUR, 2004, J MED GENT, V14, P124
   TANAKA M, 1990, LANCET, V336, P1452, DOI 10.1016/0140-6736(90)93162-I
   TANIIKE M, 1992, BIOCHEM BIOPH RES CO, V186, P47, DOI 10.1016/S0006-291X(05)80773-9
   Tanji K, 2003, ACTA NEUROPATHOL, V105, P69, DOI 10.1007/s00401-002-0604-y
   Tay SKH, 2005, J CHILD NEUROL, V20, P142, DOI 10.1177/08830738050200022301
   Taylor RW, 1998, BIOCHEM BIOPH RES CO, V243, P47, DOI 10.1006/bbrc.1997.8055
   Taylor RW, 2004, NEUROLOGY, V62, P1420, DOI 10.1212/01.WNL.0000120667.77372.46
   Taylor RW, 2003, J AM COLL CARDIOL, V41, P1786, DOI 10.1016/S0735-1097(03)00300-0
   Taylor RW, 2002, NEUROMUSCULAR DISORD, V12, P659, DOI 10.1016/S0960-8966(02)00026-3
   Taylor RW, 2004, NEUROMUSCULAR DISORD, V14, P237, DOI 10.1016/j.nmd.2003.12.004
   Terasaki F, 2001, JPN CIRC J, V65, P691, DOI 10.1253/jcj.65.691
   Thambisetty M, 2004, EXPERT REV MOL DIAGN, V4, P631, DOI 10.1586/14737159.4.5.631
   Tiranti V, 1999, NEUROMUSCULAR DISORD, V9, P66, DOI 10.1016/S0960-8966(98)00103-5
   Tiranti V, 1998, ANN NEUROL, V43, P98, DOI 10.1002/ana.410430116
   TIRANTI V, 1995, HUM MOL GENET, V4, P1421, DOI 10.1093/hmg/4.8.1421
   Tomari Y, 2003, J BIOL CHEM, V278, P16828, DOI 10.1074/jbc.M213216200
   Toompuu M, 1999, HUM MOL GENET, V8, P2275, DOI 10.1093/hmg/8.12.2275
   Toompuu M, 2004, BIOCHEM BIOPH RES CO, V322, P803, DOI 10.1016/j.bbrc.2004.07.181
   Toompuu M, 2002, J BIOL CHEM, V277, P22240, DOI 10.1074/jbc.M200338200
   Toyono M, 2001, NEUROMUSCULAR DISORD, V11, P300, DOI 10.1016/S0960-8966(00)00176-0
   Tryoen-Tóth P, 2003, J BIOL CHEM, V278, P24314, DOI 10.1074/jbc.M301530200
   Tsao CY, 2003, J CHILD NEUROL, V18, P62, DOI 10.1177/08830738030180011401
   Tsukuda K, 1997, DIABETIC MED, V14, P1032, DOI 10.1002/(SICI)1096-9136(199712)14:12<1032::AID-DIA504>3.0.CO;2-Y
   Tulinius M, 2003, NEUROPEDIATRICS, V34, P87
   Tysoe C, 1996, J MED GENET, V33, P1002, DOI 10.1136/jmg.33.12.1002
   Tzen CY, 2001, KIDNEY INT, V59, P846, DOI 10.1046/j.1523-1755.2001.00567.x
   Ueda Y, 2004, PEDIATR NEPHROL, V19, P107, DOI 10.1007/s00467-003-1318-7
   Uziel G, 2000, NEUROMUSCULAR DISORD, V10, P415, DOI 10.1016/S0960-8966(99)00115-7
   Valente L, 2007, AM J HUM GENET, V80, P44, DOI 10.1086/510559
   Van Camp G, 2000, CLIN GENET, V57, P409, DOI 10.1034/j.1399-0004.2000.570601.x
   VANDENOUWELAND JMW, 1994, DIABETES, V43, P746, DOI 10.2337/diabetes.43.6.746
   VANDENOUWELAND JMW, 1992, NUCLEIC ACIDS RES, V20, P679, DOI 10.1093/nar/20.4.679
   Verhoeven K, 1999, EUR J HUM GENET, V7, P45, DOI 10.1038/sj.ejhg.5200247
   Verma A, 1996, NEUROLOGY, V46, P1334, DOI 10.1212/WNL.46.5.1334
   Verma A, 1997, PEDIATR RES, V42, P448, DOI 10.1203/00006450-199710000-00005
   Vialettes BH, 1997, DIABETES CARE, V20, P1731, DOI 10.2337/diacare.20.11.1731
   Vilarinho L, 1997, J INHERIT METAB DIS, V20, P704, DOI 10.1023/A:1005330611147
   Vilarinho L, 1997, J MED GENET, V34, P607, DOI 10.1136/jmg.34.7.607
   Vissing J, 1998, NEUROLOGY, V50, P1875, DOI 10.1212/WNL.50.6.1875
   Vives-Bauza C, 2003, J INHERIT METAB DIS, V26, P507, DOI 10.1023/A:1025133629685
   Vives-Bauza C, 2001, ANN MED, V33, P493, DOI 10.3109/07853890109002099
   Wang YL, 1999, AM J HEMATOL, V60, P83, DOI 10.1002/(SICI)1096-8652(199901)60:1<83::AID-AJH19>3.0.CO;2-N
   Weber K, 1997, AM J HUM GENET, V60, P373
   Wedel T, 2003, EUR J PEDIATR SURG, V13, P201
   Wilson FH, 2004, SCIENCE, V306, P1190, DOI 10.1126/science.1102521
   Wittenhagen LM, 2003, TRENDS BIOCHEM SCI, V28, P605, DOI 10.1016/j.tibs.2003.09.006
   Wittenhagen LM, 2003, NUCLEIC ACIDS RES, V31, P596, DOI 10.1093/nar/gkg131
   Wittenhagen LM, 2002, NAT STRUCT BIOL, V9, P586, DOI 10.1038/nsb820
   Wong LJC, 2006, J MED GENET, V43, P0, DOI 10.1136/jmg.2005.040626
   WONG LJ, 2007, IN PRESS MUSCLE NERV, V0, P0
   Wong LJC, 2002, AM J MED GENET, V113, P59, DOI 10.1002/ajmg.10767
   Yasukawa T, 2000, NUCLEIC ACIDS RES, V28, P3779, DOI 10.1093/nar/28.19.3779
   Yasukawa T, 2000, J BIOL CHEM, V275, P4251, DOI 10.1074/jbc.275.6.4251
   Yasukawa T, 2000, FEBS LETT, V467, P175, DOI 10.1016/S0014-5793(00)01145-5
   Yasukawa T, 2001, EMBO J, V20, P4794, DOI 10.1093/emboj/20.17.4794
   YOON KL, 1991, BIOCHEM BIOPH RES CO, V176, P1112, DOI 10.1016/0006-291X(91)90399-R
   ZEVIANI M, 1991, LANCET, V338, P143, DOI 10.1016/0140-6736(91)90136-D
   Zeviani M, 2004, BRAIN, V127, P2153, DOI 10.1093/brain/awh259
   Zeviani Massimo, 1993, EUROPEAN JOURNAL OF HUMAN GENETICS, V1, P80
   Zsurka G, 2004, J MED GENET, V41, P0, DOI 10.1136/jmg.2004.022566
   2001, 1900, V29, V0, P4334
NR 346
TC 50
Z9 54
U1 0
U2 12
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1547-6286
EI 1555-8584
J9 RNA BIOL
JI RNA Biol.
PD JAN-MAR 15
PY 2007
VL 4
IS 1
BP 38
EP 66
DI 10.4161/rna.4.1.4548
PG 29
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 256WS
UT WOS:000252761200007
PM 17617745
DA 2024-11-01
ER

PT J
AU Stark, R
   Roden, M
AF Stark, R.
   Roden, M.
TI ESCI Award 2006 - Mitochondrial function and endocrine diseases
SO EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
DE apoptosis; cortisol; free fatty acids; reactive oxygen species; relatives of type 2 diabetic patients; triiodothyronine
ID human skeletal-muscle; marrow-pancreas-syndrome; free fatty-acids; thyroid-hormone; insulin-resistance; oxidative-phosphorylation; glucose-metabolism; diabetes-mellitus; lactic-acidosis; transition pore
AB Mitochondria are fundamental for oxidative energy production and impairment of their functionality can lead to reduced ATP synthesis and contribute to initiation of apoptosis. Endocrine tissues critically rely on oxidative phosphorylation so that mitochondrial abnormalities may either be causes or consequences of diminished hormone production or action. Abnormalities typical for diseases caused by mitochondrial DNA mutations such as Kearns-Sayre syndrome or mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes syndrome are also seen in certain endocrine diseases. Lack or excess of thyroid hormones, major ubiquitous regulators of mitochondrial content and activity, cause muscular abnormalities and multisystem disorders. Mitochondria are a further prerequisite for steroidogenesis as well as insulin secretion and action. Recent studies showed that reduced mitochondrial ATP synthesis in skeletal muscle is a feature of certain hereditary and acquired forms of insulin resistance and diabetes mellitus. Finally, ageing is not only accompanied by various degrees of hormonal deficiency and insulin resistance but is also associated with a progressive decline of mitochondrial number and function. Future research is needed to examine whether mitochondrial abnormalities are the cause or consequence of ageing and frequent metabolic diseases such as obesity and type 2 diabetes mellitus, and to address mitochondria as a target for novel therapeutic regimes.
C1 Hanusch Hosp, Dept Med 1, Karl Landsteiner Inst Endocrinol & Metab, A-1140 Vienna, Austria.
C3 WGKK - Hanusch Hospital
RP Roden, M (corresponding author), Hanusch Hosp, Dept Med 1, Karl Landsteiner Inst Endocrinol & Metab, Heinrich Collin Str 30, A-1140 Vienna, Austria.
EM michael.roden@meduniwien.ac.at
CR Asmann YW, 2006, DIABETES, V55, P3309, DOI 10.2337/db05-1230
   Bahi L, 2005, J CELL PHYSIOL, V203, P589, DOI 10.1002/jcp.20273
   Balestri P, 2000, J CHILD NEUROL, V15, P755, DOI 10.1177/088307380001501108
   Bassett DR, 2000, MED SCI SPORT EXER, V32, P70, DOI 10.1097/00005768-200001000-00012
   Becher MW, 1999, HUM PATHOL, V30, P577, DOI 10.1016/S0046-8177(99)90204-6
   Boelaert K, 2005, J ENDOCRINOL, V187, P1, DOI 10.1677/joe.1.06131
   Brehm A, 2006, DIABETES, V55, P136, DOI 10.2337/diabetes.55.01.06.db05-1286
   Chan DC, 2006, CELL, V125, P1241, DOI 10.1016/j.cell.2006.06.010
   COCK HR, 1995, NEUROLOGY, V45, P0
   COOPER JM, 1992, J NEUROL SCI, V113, P91, DOI 10.1016/0022-510X(92)90270-U
   Cortopassi GA, 1999, BBA-BIOENERGETICS, V1410, P183, DOI 10.1016/S0005-2728(98)00166-2
   Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233
   FERRANNINI E, 1988, METABOLISM, V37, P287, DOI 10.1016/0026-0495(88)90110-2
   Fridlyand LE, 2006, DIABETES OBES METAB, V8, P136, DOI 10.1111/j.1463-1326.2005.00496.x
   Froment P, 2006, J ENDOCRINOL, V189, P199, DOI 10.1677/joe.1.06667
   HARVEY JN, 1992, CLIN ENDOCRINOL, V37, P97, DOI 10.1111/j.1365-2265.1992.tb02289.x
   James AM, 2002, J BIOMED SCI, V9, P475, DOI 10.1159/000064721
   Jansen RPS, 2004, MITOCHONDRION, V4, P577, DOI 10.1016/j.mito.2004.07.038
   Joko T, 1997, ENDOCR J, V44, P805, DOI 10.1507/endocrj.44.805
   Jucker BM, 2000, P NATL ACAD SCI USA, V97, P6880, DOI 10.1073/pnas.120131997
   Jucker BM, 2001, P NATL ACAD SCI USA, V98, P3624
   Kacerovsky G, 2006, DIABETOLOGIA, V49, P466
   Kelley DE, 2000, DIABETES, V49, P677, DOI 10.2337/diabetes.49.5.677
   Kelley DE, 2005, J CLIN INVEST, V115, P1699, DOI 10.1172/JCI25758
   Kelley DE, 2002, DIABETES, V51, P2944, DOI 10.2337/diabetes.51.10.2944
   Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994
   Lane N, 2006, NATURE, V440, P600, DOI 10.1038/440600a
   Lanni A, 2003, FEBS LETT, V543, P5, DOI 10.1016/S0014-5793(03)00320-X
   Lebon V, 2001, J CLIN INVEST, V108, P733, DOI 10.1172/JCI11775
   Ling C, 2004, J CLIN INVEST, V114, P1518, DOI 10.1172/JCI200421889
   Loeb LA, 2005, P NATL ACAD SCI USA, V102, P18769, DOI 10.1073/pnas.0509776102
   Lowell BB, 2005, SCIENCE, V307, P384, DOI 10.1126/science.1104343
   Maassen JA, 2004, DIABETES, V53, PS103, DOI 10.2337/diabetes.53.2007.S103
   McGarry JD, 1999, DIABETOLOGIA, V42, P128, DOI 10.1007/s001250051130
   Menshikova EV, 2006, J GERONTOL A-BIOL, V61, P534, DOI 10.1093/gerona/61.6.534
   Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180
   Morinaka Mikihito, 2006, JOURNAL OF THE OSAKA CITY MEDICAL CENTER, V55, P9
   Morino K, 2005, J CLIN INVEST, V115, P3587, DOI 10.1172/JCI25151
   Nicholls DG, 2002, INT J BIOCHEM CELL B, V34, P1372, DOI 10.1016/S1357-2725(02)00077-8
   Nicolino M, 1997, J CLIN ENDOCR METAB, V82, P3063, DOI 10.1210/jc.82.9.3063
   Noda M, 2002, J BIOL CHEM, V277, P41817, DOI 10.1074/jbc.M207690200
   Ohkoshi N, 1998, J MED, V29, P13
   PARISI MA, 1991, SCIENCE, V252, P965, DOI 10.1126/science.2035027
   Patti ME, 2004, CURR OPIN CLIN NUTR, V7, P383, DOI 10.1097/01.mco.0000134359.23288.72
   Perseghin G, 1999, DIABETES, V48, P1600, DOI 10.2337/diabetes.48.8.1600
   Perseghin G, 1996, NEW ENGL J MED, V335, P1357, DOI 10.1056/NEJM199610313351804
   Petersen KF, 2005, PLOS MED, V2, P879, DOI 10.1371/journal.pmed.0020233
   Petersen KF, 2004, NEW ENGL J MED, V350, P664, DOI 10.1056/NEJMoa031314
   Petersen KF, 2003, SCIENCE, V300, P1140, DOI 10.1126/science.1082889
   Pitteloud N, 2005, DIABETES CARE, V28, P1636, DOI 10.2337/diacare.28.7.1636
   Psarra AMG, 2006, MOL CELL ENDOCRINOL, V246, P21, DOI 10.1016/j.mce.2005.11.025
   Rasmussen UF, 2000, MOL CELL BIOCHEM, V208, P37, DOI 10.1023/A:1007046028132
   Rhodes CJ, 2002, EUR J CLIN INVEST, V32, P3, DOI 10.1046/j.1365-2362.32.s3.2.x
   Richardson DK, 2005, J BIOL CHEM, V280, P10290, DOI 10.1074/jbc.M408985200
   Ritov VB, 2005, DIABETES, V54, P8, DOI 10.2337/diabetes.54.1.8
   Roden M, 1996, J CLIN INVEST, V97, P2859, DOI 10.1172/JCI118742
   Roden M, 2005, INT J OBESITY, V29, PS111, DOI 10.1038/sj.ijo.0803102
   Roden M, 2003, BEST PRACT RES CL EN, V17, P365, DOI 10.1016/S1521-690X(03)00031-9
   Roden M, 1999, DIABETES, V48, P358, DOI 10.2337/diabetes.48.2.358
   Roden M, 2004, NEWS PHYSIOL SCI, V19, P92, DOI 10.1152/nips.01459.2003
   Roden M, 2006, NAT CLIN PRACT ENDOC, V2, P335, DOI 10.1038/ncpendmet0190
   Sakai K, 2003, BIOCHEM BIOPH RES CO, V300, P216, DOI 10.1016/S0006-291X(02)02832-2
   Sakuraba H, 2002, DIABETOLOGIA, V45, P85, DOI 10.1007/s125-002-8248-z
   Scaglia F, 2006, CNS DRUGS, V20, P443, DOI 10.2165/00023210-200620060-00002
   Schapira AHV, 2006, LANCET, V368, P70, DOI 10.1016/S0140-6736(06)68970-8
   Schrauwen P, 2004, DIABETES, V53, P1412, DOI 10.2337/diabetes.53.6.1412
   Short KR, 2005, P NATL ACAD SCI USA, V102, P5618, DOI 10.1073/pnas.0501559102
   Short KR, 2003, DIABETES, V52, P1888, DOI 10.2337/diabetes.52.8.1888
   Simmons RA, 2006, FREE RADICAL BIO MED, V40, P917, DOI 10.1016/j.freeradbiomed.2005.12.018
   Simmons RA, 2005, J BIOL CHEM, V280, P28785, DOI 10.1074/jbc.M505695200
   SMITH OP, 1995, BRIT J HAEMATOL, V90, P469, DOI 10.1111/j.1365-2141.1995.tb05178.x
   Solakidi S, 2005, HUM REPROD, V20, P3481, DOI 10.1093/humrep/dei267
   Sparks LM, 2005, DIABETES, V54, P1926, DOI 10.2337/diabetes.54.7.1926
   Stump CS, 2003, P NATL ACAD SCI USA, V100, P7996, DOI 10.1073/pnas.1332551100
   SUGANUMA N, 1993, HORM RES, V39, P16, DOI 10.1159/000182752
   Szendroedi J, 2006, DIABETES, V55, P0
   Upadhyay G, 2004, HEPATOLOGY, V39, P1120, DOI 10.1002/hep.20085
   Venditti P, 2006, CELL MOL LIFE SCI, V63, P414, DOI 10.1007/s00018-005-5457-9
   Verhoeven AJ, 2005, TRANSFUSION, V45, P82, DOI 10.1111/j.1537-2995.2005.04023.x
   Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751
   Weitzel JM, 2003, EXP PHYSIOL, V88, P121, DOI 10.1113/eph8802506
   Wilson FH, 2004, SCIENCE, V306, P1190, DOI 10.1126/science.1102521
   Wrutniak C, 1998, ANN NY ACAD SCI, V839, P93, DOI 10.1111/j.1749-6632.1998.tb10738.x
   Wrutniak-Cabello C, 2001, J MOL ENDOCRINOL, V26, P67, DOI 10.1677/jme.0.0260067
   YEH PM, 1994, TRENDS ENDOCRIN MET, V5, P65
   Yehuda-Shnaidman E, 2005, ENDOCRINOLOGY, V146, P2462, DOI 10.1210/en.2004-1161
   Zaffanello M, 2005, MINERVA PEDIATR, V57, P143
NR 87
TC 54
Z9 57
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2972
EI 1365-2362
J9 EUR J CLIN INVEST
JI Eur. J. Clin. Invest.
PD APR 15
PY 2007
VL 37
IS 4
BP 236
EP 248
DI 10.1111/j.1365-2362.2007.01773.x
PG 13
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA 147BR
UT WOS:000244978900002
PM 17373958
DA 2024-11-01
ER

PT J
AU Kouzaki, H
   Suzuki, M
   Shimizu, T
AF Kouzaki, Hideaki
   Suzuki, Mikio
   Shimizu, Takeshi
TI Immunohistochemical and ultrastructural abnormalities in muscle from a patient with sensorineural hearing loss related to a 1555 A-to-G mitochondrial mutation
SO JOURNAL OF CLINICAL NEUROSCIENCE
LA English
DT Article
DE hearing loss; cytochrome c oxidase; ragged-red fibres mitochondria; point mutation
ID cytochrome-c-oxidase; progressive external ophthalmoplegia; 16s ribosomal-rna; lactic-acidosis; episodes melas; encephalomyopathy; translation; pathology; gene; dna
AB Genetic studies indicate that hereditary susceptibility of the inner ear to aminoglycoside antibiotic toxicity is caused by a nucleotide 1555 A-to-G mutation in the mitochondrial 12S rRNA gene. Although the phenotype associated with this mutation is nonsyndromic hearing loss, the possibility remains that there could be effects on other tissues that, like the inner ear, contain numerous mitochondria, particularly muscle. We obtained a temporalis muscle specimen from a deaf patient with the A1555G mutation and found informative pathologic features, including mosaic activity of cytochrome c oxidase immunoreactivity and mitochondrial ultrastructure. These findings suggest that mitochondrial dysfunction from the A1555G mutation extends beyond the inner ear. (c) 2006 Elsevier Ltd. All rights reserved.
C1 Shiga Univ Med Sci, Dept Otolaryngol, Otsu, Shiga 5202192, Japan.
C3 Shiga University of Medical Science
RP Kouzaki, H (corresponding author), Shiga Univ Med Sci, Dept Otolaryngol, Tsukinowa Cho, Otsu, Shiga 5202192, Japan.
EM hkohzaki@belle.shiga-med.ac.jp
CR BONILLA E, 1992, BRAIN PATHOL, V2, P113, DOI 10.1111/j.1750-3639.1992.tb00679.x
   Bonilla Eduardo, 1998, BIOFACTORS, V7, P231
   CORTOPASSI G, 1994, HEARING RES, V78, P27, DOI 10.1016/0378-5955(94)90040-X
   FUKUHARA N, 1986, NEUROL MED CHIR TOKY, V24, P125
   HUI AS, 1988, EMBO J, V7, P4383, DOI 10.1002/j.1460-2075.1988.tb03337.x
   HUTCHIN T, 1993, NUCLEIC ACIDS RES, V21, P4174, DOI 10.1093/nar/21.18.4174
   Inoue K, 1996, BIOCHEM BIOPH RES CO, V223, P496, DOI 10.1006/bbrc.1996.0923
   JOHNSON MA, 1983, J NEUROL SCI, V60, P31, DOI 10.1016/0022-510X(83)90125-9
   KOO B, 1993, ANN NEUROL, V34, P25, DOI 10.1002/ana.410340107
   MATSUOKA T, 1993, MUSCLE NERVE, V16, P206, DOI 10.1002/mus.880160215
   MOAZED D, 1986, CELL, V47, P985, DOI 10.1016/0092-8674(86)90813-5
   MORAES CT, 1992, AM J HUM GENET, V50, P934
   MORAES CT, 1992, NAT GENET, V1, P359, DOI 10.1038/ng0892-359
   MULLERHOCKER J, 1990, J NEUROL SCI, V100, P14, DOI 10.1016/0022-510x(90)90006-9
   NOLLER HF, 1991, ANNU REV BIOCHEM, V60, P191, DOI 10.1146/annurev.bi.60.070191.001203
   NONAKA I, 1989, J NEUROL SCI, V92, P193, DOI 10.1016/0022-510X(89)90136-6
   SUZUKI M, 1998, OTOL JPN, V8, P526
   Tanji K, 2001, METHOD CELL BIOL, V65, P311, DOI 10.1016/S0091-679X(01)65019-2
   Treem WR, 1998, SEMIN LIVER DIS, V18, P237, DOI 10.1055/s-2007-1007160
   WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523
   Yamasoba T, 2002, NEUROMUSCULAR DISORD, V12, P506, DOI 10.1016/S0960-8966(01)00329-7
NR 21
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0967-5868
EI 1532-2653
J9 J CLIN NEUROSCI
JI J. Clin. Neurosci.
PD JUN 15
PY 2007
VL 14
IS 6
BP 603
EP 607
DI 10.1016/j.jocn.2005.10.012
PG 5
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 167ZA
UT WOS:000246490200019
PM 16935512
DA 2024-11-01
ER

PT J
AU Choi, JH
   Yoon, HR
   Kim, GH
   Park, SJ
   Shin, YL
   Yoo, HW
AF Choi, Jin-Ho
   Yoon, Hye-Ran
   Kim, Gu-Hwan
   Park, Seong-Jong
   Shin, Young-Lim
   Yoo, Han-Wook
TI Identification of novel mutations of the <i>HADHA</i> and <i>HADHB</i> genes in patients with mitochondrial trifunctional protein deficiency
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE HADHA; HADHB; mitochondrial trifunctional deficiency; long-chain 3-hydroxyacyl coenzyme A dehydrogenase; deficiency; long-chain 2,3-enoyl-CoA hydratase; long chain 3-ketoacyl CoA thiolase
ID 3-hydroxyacyl-coa dehydrogenase-deficiency; tandem mass-spectrometry; acid oxidation disorder; inborn-errors; liver; metabolism; diagnosis
AB Patients with long-chain 3-hydroxyacyl coenzyme A dehydrogenase (LCHAD) deficiency manifest hypoketotic hypoglycemia, hepatomegaly, hypotonia, lactic acidemia, acute renal failure, cardiomyopathy, and sudden death. We describe four novel mutations of the alpha- and beta-subunits of the mitochondrial trifunctional protein in four patients from three unrelated families. Their plasma acylcarnitine profiles suggested the presence of LCHAD deficiency by demonstrating highly elevated 3-hydroxyacyl carnitines by tandem mass spectrometry (MS/MS). Patients 1 and 2 had siblings who had died of lactic acidemia during the neonatal period. These patients also manifested lactic acidemia and died in the neonatal period. Patient 3 had a family history of Reye-like syndrome. She exhibited acute renal failure, rhabdomyolysis, pericardial effusion, and myopathy at the age of 12 years. DNA analysis of patients 1 and 2 revealed homozygosity for a c.1689+2T > G mutation of the HADHA gene, resulting in the skipping of exon 16 with an in-frame 69-bp deletion. Patient 3 was a compound heterozygosity of the HADHB gene, N307D/N389D. Patient 4, a 25-month-old baby, manifested recurrent episodes of lethargy, metabolic acidosis, elevated liver enzymes, and dark urine from the age of 10 months. Mutation analysis of the HADHB gene of patient 4 identified compound heterozygosity of N114D/N307D.
C1 Univ Ulsan, Coll Med, Dept Pediat, Asan Med Ctr, Seoul 138736, South Korea.
   Chungnam Natl Univ Hosp, Coll Med, Dept Pediat, Taejon 301721, South Korea.
   Duksung Womens Univ, Biomed & Pharmaceut Anal Lab, Coll Pharm, Seoul 132714, South Korea.
   Univ Ulsan, Coll Med, Med Genet Clin & Lab, Seoul 138736, South Korea.
C3 University of Ulsan; Chungnam National University; Chungnam National University Hospital; Duksung Women's University; University of Ulsan
RP Yoo, HW (corresponding author), Univ Ulsan, Coll Med, Dept Pediat, Asan Med Ctr, 388-1 Pungnap Dong, Seoul 138736, South Korea.
EM hwyoo@amc.seoul.kr
CR Das AM, 2000, EUR J PEDIATR, V159, P243, DOI 10.1007/s004310050063
   den Boer MEJ, 2003, J PEDIATR-US, V142, P684, DOI 10.1067/mpd.2003.231
   den Boer MEJ, 2002, PEDIATRICS, V109, P99, DOI 10.1542/peds.109.1.99
   Hintz SR, 2002, MOL GENET METAB, V75, P120, DOI 10.1006/mgme.2001.3282
   Ibdah JA, 1999, NEW ENGL J MED, V340, P1723, DOI 10.1056/NEJM199906033402204
   IJIST L, 1996, J CLIN INVEST, V98, P1028
   Ijist Lodewijk, 1994, BIOCHIMICA ET BIOPHYSICA ACTA, V1215, P347
   Matern D, 1999, PEDIATR RES, V46, P45, DOI 10.1203/00006450-199907000-00008
   MILLINGTON DS, 1990, J INHERIT METAB DIS, V13, P321, DOI 10.1007/BF01799385
   Rakheja D, 2002, LAB INVEST, V82, P815, DOI 10.1097/01.LAB.0000021175.50201.46
   Rashed MS, 1997, CLIN CHEM, V43, P1129
   Rinaldo P, 2001, SEMIN LIVER DIS, V21, P489, DOI 10.1055/s-2001-19037
   Sander J, 2005, MOL GENET METAB, V85, P108, DOI 10.1016/j.ymgme.2005.02.002
   SIMS HF, 1995, P NATL ACAD SCI USA, V92, P841, DOI 10.1073/pnas.92.3.841
   Spiekerkoetter U, 2003, HUM MUTAT, V21, P598, DOI 10.1002/humu.10211
   Tyni T, 1999, ACTA PAEDIATR, V88, P237, DOI 10.1080/08035259950169954
   Tyni T, 1996, NEUROMUSCULAR DISORD, V6, P327, DOI 10.1016/0960-8966(96)00352-5
   UCHIDA Y, 1992, J BIOL CHEM, V267, P1034
NR 18
TC 34
Z9 35
U1 0
U2 12
PU PROFESSOR D A SPANDIDOS
PI ATHENS
PA 1, S MERKOURI ST, EDITORIAL OFFICE,, ATHENS 116 35, GREECE
SN 1107-3756
EI 
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD JAN 15
PY 2007
VL 19
IS 1
BP 81
EP 87
DI 
PG 7
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 121GZ
UT WOS:000243147400011
PM 17143551
DA 2024-11-01
ER

PT J
AU Mancuso, M
   Petrozzi, L
   Filosto, M
   Nesti, C
   Rocchi, A
   Choub, A
   Pistolesi, S
   Massetani, R
   Fontanini, G
   Siciliano, G
AF Mancuso, Michelangelo
   Petrozzi, Lucia
   Filosto, Massimiliano
   Nesti, Claudia
   Rocchi, Anna
   Choub, Anna
   Pistolesi, Sabina
   Massetani, Roberto
   Fontanini, Gabriella
   Siciliano, Gabriele
TI MERRF syndrome without ragged-red fibers: The need for molecular diagnosis
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE MERRF; mtDNA; ragged-red fibers; genetic testing
ID myoclonic epilepsy; oxidase deficiency; mutation; genetics
AB We report a patient with myoclonic epilepsy who underwent muscle biopsy for suspected mitochondrial disease (myoclonic epilepsy with ragged-red fibers, MERRF). In spite of normal histochemical studies and of the absence of a severe COX deficiency, the molecular analysis showed the common MERRF mutation (A8344G) in the tRNA(Lys), gene on mitochondrial DNA. The case serves to illustrate the importance of pursuing the proposed mitochondrial genetic abnormality, even in patients with normal biopsy findings. (c) 2007 Elsevier Inc. All rights reserved.
C1 Univ Pisa, Dept Neurosci, Neurol Clin, I-56126 Pisa, Italy.
   Univ Brescia, Neurol Inst, I-25121 Brescia, Italy.
   Univ Pisa, Dept Surg, I-56100 Pisa, Italy.
   Neurol Clin, Carrara, Italy.
C3 University of Pisa; University of Brescia; University of Pisa
RP Mancuso, M (corresponding author), Univ Pisa, Dept Neurosci, Neurol Clin, Via Roma 67, I-56126 Pisa, Italy.
EM mmancuso@inwind.it
CR Carnpos Y, 2003, NEUROMUSCULAR DISORD, V13, P416, DOI 10.1016/S0960-8966(03)00039-7
   DiMauro S, 2002, ADV NEUROL, V89, P217
   DiMauro S, 2004, ANN NY ACAD SCI, V1011, P232, DOI 10.1196/annals.1293.023
   DIMAURO S, 1987, ANN NEUROL, V22, P498, DOI 10.1002/ana.410220409
   Hirano M, 1996, HANDBOOK OF MUSCLE DISEASE, V0, P479
   LOMBES A, 1989, ANN NEUROL, V26, P20, DOI 10.1002/ana.410260104
   Mancuso M, 2006, J NEUROL SCI, V243, P97, DOI 10.1016/j.jns.2005.11.021
   Mancuso M, 2004, NEUROLOGY, V62, P2119, DOI 10.1212/01.WNL.0000127608.48406.F1
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   PETRUZZELLA V, 1994, HUM MOL GENET, V3, P449, DOI 10.1093/hmg/3.3.449
   Sciacco M, 1996, METHODS ENZYMOL, V264, P509, DOI 10.1016/S0076-6879(96)64045-2
   Shahwan A, 2005, LANCET NEUROL, V4, P239, DOI 10.1016/S1474-4422(05)70043-0
   Van Zandijcke M, 2003, ACTA NEUROL BELG, V103, P66
NR 13
TC 20
Z9 24
U1 0
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD MAR 23
PY 2007
VL 354
IS 4
BP 1058
EP 1060
DI 10.1016/j.bbrc.2007.01.099
PG 3
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 139DF
UT WOS:000244411800036
PM 17275787
DA 2024-11-01
ER

PT J
AU Sato, A
   Nakada, K
   Shitara, H
   Kasahara, A
   Yonekawa, H
   Hayashi, JI
AF Sato, Akitsugu
   Nakada, Kazuto
   Shitara, Hiroshi
   Kasahara, Atsuko
   Yonekawa, Hiromichi
   Hayashi, Jun-Ichi
TI Deletion-mutant mtDNA increases in somatic tissues but decreases in female germ cells with age
SO GENETICS
LA English
DT Article
ID mitochondrial-dna deletion; kearns-sayre-syndrome; mouse mtdna; mito-mice; mutation; segregation; genm; hybrids; dysfunction; expression
AB The proportions Of mutant. and wild-type mtDNA are crucial in determining the severity of mitochondrial diseases. It has been generally considered that deletion-mutant mtDNA has replication advantages and accumulates with time. Here, we examine the tissue-by-tissue Proportions Of mutant mtDNA with a 4696-bp deletion (Delta mtDNA) and wild-type mtDNA in mitochondrial disease model mice (mito-mice). Comparison Of the proportions of Delta mtDNA in each tissue at various ages showed that the rate of accumulation of Delta mtDNA differed among tissues. The heart, skeletal muscles, kidney, liver, testis, and ovary, showed increases in the proportion of Delta mtDNA with age, but the pancreas, spleen, brain, and blood showed only a slight or no increase in proportion. In contrast to the somatic tissues, however, the germ cells of female mito-mice and resultant offspring showed a strong decrease in Delta mtDNA with maternal age. The decrease was so acute that some offspring showed complete disappearance of Delta mtDNA, even though their elder brothers and sisters had high proportions of Delta mtDNA. Female germ cells have a machinery that prevents the inheritence of defective mtDNA to the following generation since germ cells are kept for a long time until they are ovulated.
C1 [Sato, Akitsugu; Nakada, Kazuto; Kasahara, Atsuko; Hayashi, Jun-Ichi] Univ Tsukuba, Grad Sch Life & Environm Sci, Tsukuba, Ibaraki 3058572, Japan.
   [Nakada, Kazuto; Kasahara, Atsuko] Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058572, Japan.
   [Sato, Akitsugu; Shitara, Hiroshi; Yonekawa, Hiromichi] Tokyo Metropolitan Inst Med Sci, Dept Lab Anim Sci, Tokyo 1138613, Japan.
C3 University of Tsukuba; University of Tsukuba; Tokyo Metropolitan Institute of Medical Science
RP Sato, A (corresponding author), Univ Tsukuba, Grad Sch Life & Environm Sci, 1-1-1 Tennoudai, Tsukuba, Ibaraki 3058572, Japan.
EM asato@biol.tsukuba.ac.jp
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   BALLINGER SW, 1992, NAT GENET, V1, P11, DOI 10.1038/ng0492-11
   Battersby BJ, 2003, NAT GENET, V33, P183, DOI 10.1038/ng1073
   BERNES SM, 1993, J PEDIATR-US, V123, P598, DOI 10.1016/S0022-3476(05)80962-X
   BIRKY CW, 1994, J HERED, V85, P355, DOI 10.1093/oxfordjournals.jhered.a111480
   Brenner CA, 1998, MOL HUM REPROD, V4, P887, DOI 10.1093/molehr/4.9.887
   Chinnery PF, 2004, LANCET, V364, P592, DOI 10.1016/S0140-6736(04)16851-7
   DEVRIES D, 1994, J NEUROL SCI, V124, P77, DOI 10.1016/0022-510X(94)90014-0
   DUNBAR DR, 1995, P NATL ACAD SCI USA, V92, P6562, DOI 10.1073/pnas.92.14.6562
   Elmore SP, 2004, ARCH BIOCHEM BIOPHYS, V422, P145, DOI 10.1016/j.abb.2003.12.031
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   HAMMANS SR, 1993, BRAIN, V116, P617, DOI 10.1093/brain/116.3.617
   HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614
   HAYASHI JI, 1987, EXP CELL RES, V172, P218, DOI 10.1016/0014-4827(87)90108-X
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Inoue K, 2000, NAT GENET, V26, P176, DOI 10.1038/82826
   Inoue SI, 2007, FEBS LETT, V581, P1910, DOI 10.1016/j.febslet.2007.03.092
   Jenuth JP, 1997, NAT GENET, V16, P93, DOI 10.1038/ng0597-93
   Johnson J, 2004, NATURE, V428, P145, DOI 10.1038/nature02316
   Johnson J, 2005, CELL, V122, P303, DOI 10.1016/j.cell.2005.06.031
   KANEDA H, 1995, P NATL ACAD SCI USA, V92, P4542, DOI 10.1073/pnas.92.10.4542
   Kono T, 1996, NAT GENET, V13, P91, DOI 10.1038/ng0596-91
   Larsson NG, 1995, ANNU REV GENET, V29, P151, DOI 10.1146/annurev.ge.29.120195.001055
   LARSSON NG, 1990, PEDIATR RES, V28, P131, DOI 10.1203/00006450-199028020-00011
   LESTIENNE P, 1988, LANCET, V1, P885
   Nakada K, 2004, BIOCHEM BIOPH RES CO, V323, P175, DOI 10.1016/j.bbrc.2004.08.073
   Nakada K, 2001, NAT MED, V7, P934, DOI 10.1038/90976
   Nakada K, 2006, P NATL ACAD SCI USA, V103, P15148, DOI 10.1073/pnas.0604641103
   Puoti G, 2003, J MED GENET, V40, P858, DOI 10.1136/jmg.40.11.858
   Sato A, 2005, P NATL ACAD SCI USA, V102, P16765, DOI 10.1073/pnas.0506197102
   Shitara H, 1998, GENETICS, V148, P851
   Tang YY, 2000, MOL BIOL CELL, V11, P2349, DOI 10.1091/mbc.11.7.2349
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   WALLACE DC, 1981, SOMAT CELL MOLEC GEN, V12, P41
NR 35
TC 40
Z9 42
U1 0
U2 9
PU GENETICS SOCIETY AMERICA
PI BETHESDA
PA 9650 ROCKVILLE AVE, BETHESDA, MD 20814 USA
SN 0016-6731
EI 1943-2631
J9 GENETICS
JI Genetics
PD DEC 15
PY 2007
VL 177
IS 4
BP 2031
EP 2037
DI 10.1534/genetics.107.081026
PG 7
WC Genetics & Heredity
SC Genetics & Heredity
GA 245QF
UT WOS:000251949800007
PM 18073422
DA 2024-11-01
ER

PT J
AU Kato, T
   Kubota, M
   Kasahara, T
AF Kato, Tadafumi
   Kubota, Mie
   Kasahara, Takaoki
TI Animal models of bipolar disorder
SO NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
LA English
DT Review
DE bipolar disorder; animal model; Transgenic mice; calcium; mitochondrial DNA; polymerase gamma (POLG); cyclophilin D; cyclosporin A; lithium; circadian rhythm; wheel running
ID magnetic-resonance spectroscopy; endoplasmic-reticulum stress; progressive external ophthalmoplegia; mitochondrial-dna polymorphisms; glucocorticoid-receptor gene; brain energy-metabolism; central-nervous-system; wolfram-syndrome; phosphorus-metabolism; calcium mobilization
AB Animal models of human diseases should meet three sets of criteria: construct validity, face validity, and predictive validity. To date, several putative animal models of bipolar disorder have been reported. They are classified into various categories: pharmacological models, nutritional models, environmental models, and genetic models. None of them, however, totally fulfills the three validity criteria., and thus may not be useful for drug development. Mounting evidence suggests that mitochondrial dysfunction has a role in bipolar disorder. To test whether accumulation of mtDNA deletions in the brain can cause bipolar disorder, we generated transgenic mice with neuron-specific expression of mutant Polg (D181A). These mice showed altered diurnal activity rhythm and periodic activity change associated with the estrous cycle. These phenotypes were worsened by administration of a tricyclic antidepressant, but improved after lithium treatment. This mouse model of bipolar disorder potentially fulfills the three validity criteria, and therefore might be used for future drug development studies. (c) 2007 Elsevier Ltd. All rights reserved.
C1 RIKEN, Lab Mol Dynam Mental Disorders, Brain Sci Inst, Wako, Saitama 3510198, Japan.
C3 RIKEN
RP Kato, T (corresponding author), RIKEN, Lab Mol Dynam Mental Disorders, Brain Sci Inst, Hirosawa 2-1, Wako, Saitama 3510198, Japan.
EM kato@brain.riken.jp
CR Antelman SM, 1998, PROG NEURO-PSYCHOPH, V22, P495, DOI 10.1016/S0278-5846(98)00020-7
   Arban R, 2005, BEHAV BRAIN RES, V158, P123, DOI 10.1016/j.bbr.2004.08.015
   BARBIROLI B, 1993, J CEREBR BLOOD F MET, V13, P469, DOI 10.1038/jcbfm.1993.61
   CAPPELIEZ P, 1990, PROG NEURO-PSYCHOPH, V14, P347, DOI 10.1016/0278-5846(90)90023-A
   Chen G, 1999, J NEUROCHEM, V72, P879, DOI 10.1046/j.1471-4159.1999.720879.x
   Chen G, 1999, J NEUROCHEM, V72, P1327, DOI 10.1046/j.1471-4159.2000.0721327.x
   Dager SR, 2004, ARCH GEN PSYCHIAT, V61, P450, DOI 10.1001/archpsyc.61.5.450
   Decker S, 2000, PROG NEURO-PSYCHOPH, V24, P455, DOI 10.1016/S0278-5846(99)00111-6
   DEICKEN RF, 1995, AM J PSYCHIAT, V152, P915
   DeMar JC, 2006, J LIPID RES, V47, P172, DOI 10.1194/jlr.M500362-JLR200
   Dokucu ME, 2005, NEUROPSYCHOPHARMACOL, V30, P2216, DOI 10.1038/sj.npp.1300764
   DRUMMOND AH, 1988, NATURE, V331, P388, DOI 10.1038/331388a0
   Du J, 2003, ANN NY ACAD SCI, V1003, P378, DOI 10.1196/annals.1300.031
   DUBOVSKY SL, 1989, ARCH GEN PSYCHIAT, V46, P632
   EINAT H, 2007, NEUROSCIENCE BIOBEHA, V0, P0
   Einat Haim, 2003, PSYCHOPHARMACOL BULL, V37, P47
   El-Mallakh RS, 2006, PROG NEURO-PSYCHOPH, V30, P1261, DOI 10.1016/j.pnpbp.2006.04.003
   El-Mallakh RS, 2003, BIPOLAR DISORD, V5, P362, DOI 10.1034/j.1399-5618.2003.00053.x
   Evans KL, 2000, AM J MED GENET, V96, P158, DOI 10.1002/(SICI)1096-8628(20000403)96:2<158::AID-AJMG6>3.0.CO;2-8
   Frey BN, 2006, J PSYCHIATR NEUROSCI, V31, P326
   Frey BN, 2006, BEHAV PHARMACOL, V17, P311, DOI 10.1097/01.fbp.0000205013.59455.09
   Gambarana C, 2000, BRAIN RES, V877, P218, DOI 10.1016/S0006-8993(00)02644-5
   Gessa GL, 1995, EUR NEUROPSYCHOPHARM, V5, P89, DOI 10.1016/0924-977X(95)00023-I
   Goodwin FK, 1990, MANIC DEPRESSIVE ILL, V36, P0
   Gould TJ, 2001, BEHAV BRAIN RES, V118, P95, DOI 10.1016/S0166-4328(00)00318-1
   Hahn CG, 2005, AM J PSYCHIAT, V162, P616, DOI 10.1176/appi.ajp.162.3.616
   HALLCHER LM, 1980, J BIOL CHEM, V255, P896
   Hamakawa H, 2004, PSYCHIAT CLIN NEUROS, V58, P82, DOI 10.1111/j.1440-1819.2004.01197.x
   Hattori N, 1998, GENOMICS, V49, P52, DOI 10.1006/geno.1997.5192
   Hibbeln JR, 2002, J AFFECT DISORDERS, V69, P15, DOI 10.1016/S0165-0327(01)00374-3
   Inoue H, 1998, NAT GENET, V20, P143, DOI 10.1038/2441
   Ishizuka K, 2006, BIOL PSYCHIAT, V59, P1189, DOI 10.1016/j.biopsych.2006.03.065
   KADOWAKI T, 1994, NEW ENGL J MED, V330, P962, DOI 10.1056/NEJM199404073301403
   Kakiuchi C, 2006, J NEUROCHEM, V97, P545, DOI 10.1111/j.1471-4159.2006.03772.x
   Kakiuchi C, 2003, NAT GENET, V35, P171, DOI 10.1038/ng1235
   Kasahara T, 2006, MOL PSYCHIATR, V11, P577, DOI 10.1038/sj.mp.4001824
   KATO T, 1995, PSYCHOL MED, V25, P557, DOI 10.1017/S003329170003347X
   Kato T, 1997, BIOL PSYCHIAT, V42, P871, DOI 10.1016/S0006-3223(97)00012-7
   Kato T, 2001, J AFFECT DISORDERS, V62, P151, DOI 10.1016/S0165-0327(99)00173-1
   KATO T, 1994, J AFFECT DISORDERS, V31, P125, DOI 10.1016/0165-0327(94)90116-3
   KATO T, 1993, J AFFECT DISORDERS, V27, P53, DOI 10.1016/0165-0327(93)90097-4
   Kato T, 2000, BIPOLAR DISORD, V2, P180, DOI 10.1034/j.1399-5618.2000.020305.x
   Kazuno AA, 2006, PLOS GENET, V2, P1167, DOI 10.1371/journal.pgen.0020128
   Keck PE, 2006, BIOL PSYCHIAT, V60, P1020, DOI 10.1016/j.biopsych.2006.03.056
   Kirk R, 1999, AM J HUM GENET, V65, P508, DOI 10.1086/302507
   Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455
   Kramer A, 2001, SCIENCE, V294, P2511, DOI 10.1126/science.1067716
   Kroes RA, 2006, NEUROSCIENCE, V137, P37, DOI 10.1016/j.neuroscience.2005.08.076
   Kubota M, 2006, J NEUROSCI, V26, P12314, DOI 10.1523/JNEUROSCI.3933-06.2006
   Kucinski BJ, 1998, SYNAPSE, V30, P30, DOI 10.1002/(SICI)1098-2396(199809)30:1<30::AID-SYN4>3.3.CO;2-9
   KUSUMI I, 1994, PSYCHOPHARMACOLOGY, V113, P322, DOI 10.1007/BF02245204
   KUSUMI I, 1992, BIOL PSYCHIAT, V32, P731, DOI 10.1016/0006-3223(92)90305-J
   Lenox RH, 2002, AM J MED GENET, V114, P391, DOI 10.1002/ajmg.10360
   Levine J, 2005, PROG NEURO-PSYCHOPH, V29, P1181, DOI 10.1016/j.pnpbp.2005.06.029
   LEWY AJ, 1981, LANCET, V1, P383
   Li R, 1997, MOL CHEM NEUROPATHOL, V31, P65, DOI 10.1007/BF02815161
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Machado-Vieira R, 2004, PROG NEURO-PSYCHOPH, V28, P209, DOI 10.1016/j.pnpbp.2003.10.015
   Malatynska E, 2005, NEUROSCI BIOBEHAV R, V29, P715, DOI 10.1016/j.neubiorev.2005.03.014
   McClung CA, 2005, P NATL ACAD SCI USA, V102, P9377, DOI 10.1073/pnas.0503584102
   MCMAHON FJ, 1995, AM J HUM GENET, V56, P1277
   McMahon FJ, 2000, AM J PSYCHIAT, V157, P1058, DOI 10.1176/appi.ajp.157.7.1058
   Mott JL, 2006, BBA-BIOENERGETICS, V1757, P596, DOI 10.1016/j.bbabio.2006.04.014
   Munakata K, 2005, BIOL PSYCHIAT, V57, P525, DOI 10.1016/j.biopsych.2004.11.041
   Munakata K, 2004, GENOMICS, V84, P1041, DOI 10.1016/j.ygeno.2004.08.015
   Murashita J, 2000, PSYCHOL MED, V30, P107, DOI 10.1017/S0033291799001439
   Namima M, 1999, BRAIN RES PROTOC, V4, P11, DOI 10.1016/S1385-299X(99)00002-1
   Nievergelt CM, 2006, AM J MED GENET B, V141B, P234, DOI 10.1002/ajmg.b.30252
   Nishiguchi N, 2006, NEUROSCI LETT, V394, P243, DOI 10.1016/j.neulet.2005.10.042
   Nonaka S, 1998, P NATL ACAD SCI USA, V95, P2642, DOI 10.1073/pnas.95.5.2642
   OTuathaigh CMP, 2007, NEUROSCI BIOBEHAV R, V31, P60, DOI 10.1016/j.neubiorev.2006.04.002
   Okamoto Yasumasa, 1995, LIFE SCIENCES, V56, P327
   Orth M, 2002, NEUROCHEM INT, V40, P533, DOI 10.1016/S0197-0186(01)00124-3
   Overstreet DH, 2005, NEUROSCI BIOBEHAV R, V29, P739, DOI 10.1016/j.neubiorev.2005.03.015
   Özcan U, 2004, SCIENCE, V306, P457, DOI 10.1126/science.1103160
   Panov AV, 2002, NAT NEUROSCI, V5, P731, DOI 10.1038/nn884
   Parker G, 2006, AM J PSYCHIAT, V163, P969, DOI 10.1176/appi.ajp.163.6.969
   Paylor R, 2001, HUM MOL GENET, V10, P2645, DOI 10.1093/hmg/10.23.2645
   Paylor R, 2006, BIOL PSYCHIAT, V59, P1172, DOI 10.1016/j.biopsych.2006.01.018
   PETTY F, 1981, J AFFECT DISORDERS, V3, P381, DOI 10.1016/0165-0327(81)90006-9
   Prickaerts J, 2006, J NEUROSCI, V26, P9022, DOI 10.1523/JNEUROSCI.5216-05.2006
   Rango M, 2001, J CEREBR BLOOD F MET, V21, P85, DOI 10.1097/00004647-200101000-00011
   ROYBAL K, 2007, P NATL ACAD SCI 0322, V0, P0
   SCHWARTZ JM, 1982, PSYCHIAT RES, V7, P153, DOI 10.1016/0165-1781(92)90088-K
   Shaldivin A, 2001, BIPOLAR DISORD, V3, P30, DOI 10.1034/j.1399-5618.2001.030104.x
   Shaldubina A, 2002, J NEURAL TRANSM, V109, P433, DOI 10.1007/s007020200035
   Siciliano G, 2003, NEUROMUSCULAR DISORD, V13, P162, DOI 10.1016/S0960-8966(02)00221-3
   STINE OC, 1993, BIOL PSYCHIAT, V42, P311
   Stoll AL, 1999, ARCH GEN PSYCHIAT, V56, P407, DOI 10.1001/archpsyc.56.5.407
   SUOMALAINEN A, 1992, J CLIN INVEST, V90, P61, DOI 10.1172/JCI115856
   SWIFT RG, 1990, LANCET, V336, P667, DOI 10.1016/0140-6736(90)92157-D
   SWIFT RG, 1991, AM J PSYCHIAT, V148, P775
   Takao M, 2000, NEUROSCIENCE, V97, P779, DOI 10.1016/S0306-4522(00)00053-1
   VALE AL, 1987, PSYCHOPHARMACOLOGY, V91, P352, DOI 10.1007/BF00518190
   van der Walt JM, 2003, AM J HUM GENET, V72, P804, DOI 10.1086/373937
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   van Rossum EFC, 2006, BIOL PSYCHIAT, V59, P681, DOI 10.1016/j.biopsych.2006.02.007
   van West D, 2006, NEUROPSYCHOPHARMACOL, V31, P620, DOI 10.1038/sj.npp.1300898
   WANG HY, 1989, PSYCHOPHARMACOLOGY, V99, P213, DOI 10.1007/BF00442810
   WASHIZUKA S, 2004, BIOL PSYCHIAT, V0, P0
   Wei Q, 2004, P NATL ACAD SCI USA, V101, P11851, DOI 10.1073/pnas.0402208101
   Yamada T, 2006, HUM MOL GENET, V15, P1600, DOI 10.1093/hmg/ddl081
   Yamawaki S, 1998, LIFE SCI, V62, P1665, DOI 10.1016/S0024-3205(98)00125-8
   Zhang D, 2003, CARDIOVASC RES, V57, P147, DOI 10.1016/S0008-6363(02)00695-8
   Zhou R, 2005, J NEUROSCI, V25, P4493, DOI 10.1523/JNEUROSCI.4530-04.2005
NR 105
TC 54
Z9 61
U1 1
U2 22
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0149-7634
EI 
J9 NEUROSCI BIOBEHAV R
JI Neurosci. Biobehav. Rev.
PD JUN 15
PY 2007
VL 31
IS 6
BP 832
EP 842
DI 10.1016/j.neubiorev.2007.03.003
PG 11
WC Behavioral Sciences; Neurosciences
SC Behavioral Sciences; Neurosciences & Neurology
GA 216LI
UT WOS:000249879100002
PM 17466374
DA 2024-11-01
ER

PT J
AU Janssen, GMC
   Hensbergen, PJ
   van Bussel, FJ
   Balog, CIA
   Maassen, JA
   Deelder, AM
   Raap, AK
AF Janssen, George M. C.
   Hensbergen, Paul J.
   van Bussel, Frans J.
   Balog, Crina I. A.
   Maassen, J. Antonie
   Deelder, Andre M.
   Raap, Anton K.
TI The A3243G tRNA<SUP>Leu(UUR)</SUP> mutation induces mitochondrial dysfunction and variable disease expression without dominant negative acting translational defects in complex IV subunits at UUR codons
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID cytochrome-c-oxidase; wobble modification deficiency; aminoacyl-transfer-rna; muscle-fiber analysis; mutant transfer-rnas; protein-synthesis; lactic-acidosis; myoclonus epilepsy; diabetes-mellitus; melas mutation
AB Mutations in the mitochondrial tRNA (Leu( UUR)) gene are associated with a large variety of human diseases through a largely undisclosed mechanism. The A3243G tRNA (Leu(UUR)) mutation leads to reduction of mitochondrial DNA (mtDNA)-encoded proteins and oxidative phosphorylation activity even when the cells are competent in mitochondrial translation. These two aspects led to the suggestion that a dominant negative factor may underlie the diversity of disease expression. Here we test the hypothesis that A3243G tRNA Leu( UUR) generates such a dominant negative gain-of-function defect through misincorporation of amino acids at UUR codons of mtDNA-encoded proteins. Using an anti-complex IV immunocapture technique and mass spectrometry, we show that the mtDNA- encoded cytochrome c oxidase I (COX I) and COX II exist exclusively with the correct amino acid sequences in A3243G cells in a misassembled complex IV. A dominant negative component therefore cannot account for disease phenotype, leaving tissue-specific accumulation by mtDNA segregation as the most likely cause of variable mitochondrial disease expression.
C1 Leiden Univ, Ctr Med, Dept Mol Cell Biol, NL-2300 RC Leiden, Netherlands.
   Leiden Univ, Ctr Med, Biomol Mass Spectrometry Unit, Dept Parasitol, NL-2300 RC Leiden, Netherlands.
C3 Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC
RP Janssen, GMC (corresponding author), Leiden Univ, Ctr Med, Dept Mol Cell Biol, Post Zone S1-P,Einthovenweg 20,POB 9600, NL-2300 RC Leiden, Netherlands.
EM G.M.C.Janssen@lumc.nl
CR Börner GV, 2000, HUM MOL GENET, V9, P467, DOI 10.1093/hmg/9.4.467
   Chomyn A, 1996, METHODS ENZYMOL, V264, P197, DOI 10.1016/S0076-6879(96)64020-8
   Chomyn A, 2000, J BIOL CHEM, V275, P19198, DOI 10.1074/jbc.M908734199
   CHOMYN A, 1991, MOL CELL BIOL, V11, P2236, DOI 10.1128/MCB.11.4.2236
   CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221
   Dunbar DR, 1996, HUM MOL GENET, V5, P123, DOI 10.1093/hmg/5.1.123
   Durham SE, 2007, AM J HUM GENET, V81, P189, DOI 10.1086/518901
   El Meziane A, 1998, NAT GENET, V18, P350
   El Meziane A, 1998, HUM MOL GENET, V7, P2141, DOI 10.1093/hmg/7.13.2141
   ENRIQUEZ JA, 1995, NAT GENET, V10, P47, DOI 10.1038/ng0595-47
   Flierl A, 1997, J BIOL CHEM, V272, P27189, DOI 10.1074/jbc.272.43.27189
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   HAYASHI JI, 1993, BIOCHEM BIOPH RES CO, V197, P1049, DOI 10.1006/bbrc.1993.2584
   Ibba M, 2000, ANNU REV BIOCHEM, V69, P617, DOI 10.1146/annurev.biochem.69.1.617
   Jacobs HT, 2003, HUM MOL GENET, V12, PR293, DOI 10.1093/hmg/ddg285
   Jacobs HT, 2000, HUM MOL GENET, V9, P463, DOI 10.1093/hmg/9.4.463
   JAHANGIR TRS, 2005, MUTAT RES, V578, P43
   Janssen GMC, 1999, J BIOL CHEM, V274, P29744, DOI 10.1074/jbc.274.42.29744
   KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480
   Kirino Y, 2006, HUM MOL GENET, V15, P897, DOI 10.1093/hmg/ddl007
   Kirino Y, 2004, P NATL ACAD SCI USA, V101, P15070, DOI 10.1073/pnas.0405173101
   Kobayashi T, 1997, DIABETES, V46, P1567, DOI 10.2337/diabetes.46.10.1567
   KOGA Y, 1995, MUSCLE NERVE, V0, PS119
   Larsson NG, 1995, ANNU REV GENET, V29, P151, DOI 10.1146/annurev.ge.29.120195.001055
   Lee JW, 2006, NATURE, V443, P50, DOI 10.1038/nature05096
   Lynn S, 2003, DIABETOLOGIA, V46, P296, DOI 10.1007/s00125-002-1018-z
   Maassen JA, 2004, DIABETES, V53, PS103, DOI 10.2337/diabetes.53.2007.S103
   Maassen JA, 2001, EXP CLIN ENDOCR DIAB, V109, P127, DOI 10.1055/s-2001-14834
   Mita S, 1998, MUSCLE NERVE, V21, P490, DOI 10.1002/(SICI)1097-4598(199804)21:4<490::AID-MUS7>3.0.CO;2-4
   Murray J, 2004, BBA-BIOENERGETICS, V1659, P206, DOI 10.1016/j.bbabio.2004.07.005
   NEGRUTSKII BS, 1991, P NATL ACAD SCI USA, V88, P4991, DOI 10.1073/pnas.88.11.4991
   Nijtmans LGJ, 1998, EUR J BIOCHEM, V254, P389, DOI 10.1046/j.1432-1327.1998.2540389.x
   NIJTMANS LGJ, 1995, BBA-MOL CELL RES, V1265, P117, DOI 10.1016/0167-4889(94)00203-Q
   Ozawa M, 1998, J NEUROL SCI, V159, P170, DOI 10.1016/S0022-510X(98)00152-X
   Park H, 2003, BIOCHEMISTRY-US, V42, P958, DOI 10.1021/bi026882r
   Qiu H, 2001, EMBO J, V20, P1425, DOI 10.1093/emboj/20.6.1425
   Rabilloud T, 2002, BIOCHEMISTRY-US, V41, P144, DOI 10.1021/bi0114776
   REARDON W, 1992, LANCET, V340, P1376, DOI 10.1016/0140-6736(92)92560-3
   Rossmanith W, 1998, FEBS LETT, V433, P269, DOI 10.1016/S0014-5793(98)00928-4
   Schägger H, 2000, EMBO J, V19, P1777, DOI 10.1093/emboj/19.8.1777
   Silva JP, 2000, NAT GENET, V26, P336, DOI 10.1038/81649
   Silvestri G, 2000, AM J MED GENET, V94, P201, DOI 10.1002/1096-8628(20000918)94:3<201::AID-AJMG5>3.0.CO;2-2
   STEEN H, 2002, SCI STKE, V154, P0
   Suzuki T, 2002, EMBO J, V21, P6581, DOI 10.1093/emboj/cdf656
   Szuhai K, 2001, NUCLEIC ACIDS RES, V29, P0, DOI 10.1093/nar/29.3.e13
   Taanman JW, 1996, BBA-MOL BASIS DIS, V1315, P199, DOI 10.1016/0925-4439(95)00127-1
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Tryoen-Tóth P, 2003, J BIOL CHEM, V278, P24314, DOI 10.1074/jbc.M301530200
   Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136
   van den Ouweland JMW, 1999, DIABETOLOGIA, V42, P485, DOI 10.1007/s001250051183
   VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368
   Wang JM, 1999, NAT GENET, V21, P133, DOI 10.1038/5089
   Yasukawa T, 2005, FEBS LETT, V579, P2948, DOI 10.1016/j.febslet.2005.04.038
   Yasukawa T, 2000, J BIOL CHEM, V275, P4251, DOI 10.1074/jbc.275.6.4251
   YONEDA M, 1994, MOL CELL BIOL, V14, P2699, DOI 10.1128/MCB.14.4.2699
NR 55
TC 25
Z9 28
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD OCT 15
PY 2007
VL 16
IS 20
BP 2472
EP 2481
DI 10.1093/hmg/ddm203
PG 10
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 227SP
UT WOS:000250678400008
PM 17656376
DA 2024-11-01
ER

PT J
AU McFarland, R
   Chinnery, PF
   Blakely, EL
   Schaefer, AM
   Morris, AAM
   Foster, SM
   Tuppen, HAL
   Ramesh, V
   Dorman, PJ
   Turnbull, M
   Taylor, RW
AF McFarland, R.
   Chinnery, P. F.
   Blakely, E. L.
   Schaefer, A. M.
   Morris, A. A. M.
   Foster, S. M.
   Tuppen, H. A. L.
   Ramesh, V.
   Dorman, P. J.
   Turnbull, M.
   Taylor, R. W.
TI Homoplasmy, heteroplasmy, and mitochondrial dystonia
SO NEUROLOGY
LA English
DT Article
ID hereditary optic neuropathy; dna mutation; point mutations; genome database; transfer-rna; gene; dehydrogenase; disorders; encephalopathy; pathogenesis
AB Background: In clinical practice, mitochondrial disease is seldom considered until a variable combination of seizures, alteration in tone, muscle weakness, and developmental problems is evident. However, it is not uncommon for one symptom to occur in isolation and dominate the clinical phenotype. We report six patients from two families where dystonia was the principal clinical manifestation. A mitochondrial etiology was considered in each case because of the association of dystonia with other less prominent clinical features such as epilepsy. Methods: Histochemical and biochemical analyses were undertaken in skeletal muscle biopsies from individuals in both families. Sequencing of skeletal muscle mtDNA was also performed and suspected mutations were quantified by hot last cycle PCR-RFLP or primer extension assay. Functional consequences of one of the mutations were investigated by measurement of steady state levels of mitochondrial tRNA. Results: Two distinct mitochondrial pathologies were identified: a novel, homoplasmic mitochondrial tRNACys (MTTC) mutation and the primary, m. 11778G>A Leber hereditary optic neuropathy (LHON) mutation. The mild nature of both mutations has permitted very high levels of mutated mtDNA to accumulate. Patients with the mutation in the MTTC gene have no wild type mtDNA detectable and although the LHON mutation is heteroplasmic in the patients we report, it is commonly observed to be homoplasmic. Conclusions: The mitochondrial etiology identified in these patients emphasizes the pathologic potential of homoplasmic mutations and has important implications for the investigation and genetic counseling of families where dystonia is the principal clinical feature. We advocate that mitochondrial disease should be given serious consideration in patients with familial, progressive dystonia, particularly when additional neurologic features such as epilepsy are present.
C1 Willink Biochem Genet Unit, Manchester, Lancs, England.
   Newcastle Upon Tyne NHS Trust, Newcastle Upon Tyne, Tyne & Wear, England.
C3 Newcastle Upon Tyne Hospitals NHS Foundation Trust
RP McFarland, R (corresponding author), Univ Newcastle Upon Tyne, Sch Med, Sch Neurol Neurobiol & Psychiat, Mitochondrial Res Grp, 4th Floor,Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM robert.mcfarland@ncl.ac.uk
FU MRC [G108/539] Funding Source: UKRI; Medical Research Council [G108/539] Funding Source: Medline; Wellcome Trust [074454] Funding Source: Medline
CR Aguiar PMD, 2002, LANCET NEUROL, V1, P316, DOI 10.1016/S1474-4422(02)00137-0
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Brandon MC, 2005, NUCLEIC ACIDS RES, V33, P0
   Chapiro E, 2002, EUR J HUM GENET, V10, P851, DOI 10.1038/sj.ejhg.5200894
   Chinnery PF, 2001, BRAIN, V124, P209, DOI 10.1093/brain/124.1.209
   DeVries DD, 1996, AM J HUM GENET, V58, P703
   Head RA, 2004, DEV MED CHILD NEUROL, V46, P710
   Ingman M, 2006, NUCLEIC ACIDS RES, V34, PD749, DOI 10.1093/nar/gkj010
   JUN AS, 1994, P NATL ACAD SCI USA, V91, P6206, DOI 10.1073/pnas.91.13.6206
   Manfredi G, 1996, HUM MUTAT, V7, P158
   McFarland R, 2004, ANN NEUROL, V55, P478, DOI 10.1002/ana.20004
   McFarland R, 2002, NAT GENET, V30, P145, DOI 10.1038/ng819
   MEIRE FM, 1995, OPHTHALMIC GENET, V16, P119, DOI 10.3109/13816819509059971
   Möllers M, 2005, NUCLEIC ACIDS RES, V33, P5647, DOI 10.1093/nar/gki876
   NIKOSKELAINEN EK, 1995, J NEUROL NEUROSUR PS, V59, P160, DOI 10.1136/jnnp.59.2.160
   OLD SL, 1989, HISTOCHEM J, V21, P545, DOI 10.1007/BF01753355
   Roesch K, 2002, HUM MOL GENET, V11, P477, DOI 10.1093/hmg/11.5.477
   Ross CA, 2002, NEURON, V35, P819, DOI 10.1016/S0896-6273(02)00872-3
   Santorelli FM, 1997, NEUROMUSCULAR DISORD, V7, P156, DOI 10.1016/S0960-8966(97)00444-6
   Schaefer AM, 2004, BBA-BIOENERGETICS, V1659, P115, DOI 10.1016/j.bbabio.2004.09.005
   SCUDERI C, 2007, IN PRESS NEUROMUSCUL, V0, P0
   SHOFFNER JM, 1995, ANN NEUROL, V38, P163, DOI 10.1002/ana.410380207
   Sudarsky L, 1999, MOVEMENT DISORD, V14, P488, DOI 10.1002/1531-8257(199905)14:3<488::AID-MDS1017>3.0.CO;2-4
   Svetel M, 2001, MOVEMENT DISORD, V16, P719, DOI 10.1002/mds.1118
   Taylor RW, 2003, J AM COLL CARDIOL, V41, P1786, DOI 10.1016/S0735-1097(03)00300-0
   Taylor RW, 2001, NUCLEIC ACIDS RES, V29, Part. no., DOI 10.1093/nar/29.15.e74
   Taylor RW, 1997, ORGANELLE DIS, V0, P0
   Wilson FH, 2004, SCIENCE, V306, P1190, DOI 10.1126/science.1102521
NR 28
TC 48
Z9 53
U1 0
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 
J9 NEUROLOGY
JI Neurology
PD AUG 28
PY 2007
VL 69
IS 9
BP 911
EP 916
DI 10.1212/01.wnl.0000267843.10977.4a
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA 204EA
UT WOS:000249025200015
PM 17724295
DA 2024-11-01
ER

PT J
AU Spinazzola, A
   Zeviani, M
AF Spinazzola, Antonella
   Zeviani, Massimo
TI Disorders of nuclear-mitochondrial intergenomic communication
SO BIOSCIENCE REPORTS
LA English
DT Article; Proceedings Paper
DE mitochondrial disease; mitochondrial DNA; mtDNA depletion; mtDNA multiple deletions; nucleus-mitochondrion cross-talk
ID progressive external ophthalmoplegia; neurogastrointestinal encephalomyopathy mngie; adenine-nucleotide translocator; onset spinocerebellar ataxia; polymerase-gamma mutations; dna depletion; autosomal-dominant; multiple deletions; polg mutations; thymidine phosphorylase
AB In the course of evolution, mitochondria lost their independence, and mtDNA became "slave" of nDNA, depending on numerous nucleus-encoded factors for its integrity, replication and expression. Mutations in any of these factors may alter the cross-talk between the two genomes and cause diseases that affect mtDNA integrity or expression, being inherited as mendelian traits.
C1 Fdn IRCCS, C Besta Neurol Inst, I-20126 Milan, Italy.
RP Zeviani, M (corresponding author), Fdn IRCCS, C Besta Neurol Inst, Via Libero Temolo 4, I-20126 Milan, Italy.
EM zeviani@istituto-besta.it
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   Antonicka H, 2006, HUM MOL GENET, V15, P1835, DOI 10.1093/hmg/ddl106
   Bykhovskaya Y, 2004, AM J HUM GENET, V74, P1303, DOI 10.1086/421530
   Calvo S, 2006, NAT GENET, V38, P576, DOI 10.1038/ng1776
   Clayton DA, 2000, EXP CELL RES, V255, P4, DOI 10.1006/excr.1999.4763
   Coenen MJH, 2004, NEW ENGL J MED, V351, P2080, DOI 10.1056/NEJMoa041878
   Contamine V, 2000, MICROBIOL MOL BIOL R, V64, P281, DOI 10.1128/MMBR.64.2.281-315.2000
   Davidzon G, 2005, ANN NEUROL, V57, P921, DOI 10.1002/ana.20498
   Deschauer M, 2003, NEUROMUSCULAR DISORD, V13, P568, DOI 10.1016/S0960-8966(03)00071-3
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Fernandez-Vizarra E, 2007, J MED GENET, V44, P173, DOI 10.1136/jmg.2006.045252
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Ferraro P, 2005, J BIOL CHEM, V280, P24472, DOI 10.1074/jbc.M502869200
   Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279
   Gao J, 2001, GENOMICS, V74, P109, DOI 10.1006/geno.2001.6536
   Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805
   Hirano M, 2001, SEMIN CELL DEV BIOL, V12, P417, DOI 10.1006/scdb.2001.0279
   HIRANO M, 1994, NEUROLOGY, V44, P721, DOI 10.1212/WNL.44.4.721
   Holt IJ, 2000, CELL, V100, P515, DOI 10.1016/S0092-8674(00)80688-1
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Jacobi CA, 2005, CHIR GASTROENTEROL, V21, P6, DOI 10.1159/000083359
   Kajander OA, 2000, HUM MOL GENET, V9, P2821, DOI 10.1093/hmg/9.19.2821
   Karadimas CL, 2006, AM J HUM GENET, V79, P544, DOI 10.1086/506913
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Koc EC, 2002, J BIOL CHEM, V277, P35541, DOI 10.1074/jbc.M202498200
   KOSKINEN T, 1994, MUSCLE NERVE, V17, P509, DOI 10.1002/mus.880170507
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Ling MF, 1997, GENE, V197, P325, DOI 10.1016/S0378-1119(97)00279-5
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   MA L, 1995, J BIOL CHEM, V270, P1859, DOI 10.1074/jbc.270.4.1859
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Martí R, 2005, ANN NEUROL, V58, P649, DOI 10.1002/ana.20615
   Martinková Z, 2004, PLANT SOIL ENVIRON, V50, P1, DOI 10.17221/3635-PSE
   Miller C, 2004, ANN NEUROL, V56, P734, DOI 10.1002/ana.20282
   MIZUSAWA H, 1988, J NEUROL SCI, V86, P171, DOI 10.1016/0022-510X(88)90096-2
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Moslemi AR, 1996, ANN NEUROL, V40, P707, DOI 10.1002/ana.410400506
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Nikali K, 2005, HUM MOL GENET, V14, P2981, DOI 10.1093/hmg/ddi328
   Nishigaki Y, 2003, J CLIN INVEST, V111, P1913, DOI 10.1172/JCI200317828
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Oskoui M, 2006, ARCH NEUROL-CHICAGO, V63, P1122, DOI 10.1001/archneur.63.8.1122
   Palmieri L, 2005, HUM MOL GENET, V14, P3079, DOI 10.1093/hmg/ddi341
   Pontarin G, 2006, J BIOL CHEM, V281, P22720, DOI 10.1074/jbc.M604498200
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Salviati L, 2002, ANN NEUROL, V52, P311, DOI 10.1002/ana.10284
   SERVIDEI S, 1991, NEUROLOGY, V41, P1053, DOI 10.1212/WNL.41.7.1053
   Smeitink JAM, 2006, AM J HUM GENET, V79, P869, DOI 10.1086/508434
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Spinazzola A, 2005, GENE, V354, P162, DOI 10.1016/j.gene.2005.03.025
   Spinazzola A, 2002, J BIOL CHEM, V277, P4128, DOI 10.1074/jbc.M111028200
   Suomalainen A, 1997, NEUROLOGY, V48, P1244, DOI 10.1212/WNL.48.5.1244
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   TRITSCHLER HJ, 1992, NEUROLOGY, V42, P209, DOI 10.1212/WNL.42.1.209
   Valente L, 2007, AM J HUM GENET, V80, P44, DOI 10.1086/510559
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Van Goethem G, 2003, EUR J HUM GENET, V11, P547, DOI 10.1038/sj.ejhg.5201002
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Vu TH, 2001, HEPATOLOGY, V34, P116, DOI 10.1053/jhep.2001.25921
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
   XIN H, 1995, J BIOL CHEM, V270, P17243, DOI 10.1074/jbc.270.29.17243
   YUZAKI M, 1989, BIOCHEM BIOPH RES CO, V164, P1352, DOI 10.1016/0006-291X(89)91818-4
   Zeharia A, 2005, J CHILD NEUROL, V20, P449, DOI 10.1177/08830738050200051301
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
   Zhang YL, 1998, BBA-GENE STRUCT EXPR, V1443, P245, DOI 10.1016/S0167-4781(98)00223-1
NR 68
TC 46
Z9 54
U1 0
U2 7
PU PORTLAND PRESS LTD
PI LONDON
PA THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND
SN 0144-8463
EI 
J9 BIOSCIENCE REP
JI Biosci. Rep.
PD JUN 15
PY 2007
VL 27
IS 1-3
BP 39
EP 51
DI 10.1007/s10540-007-9036-1
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 178YM
UT WOS:000247256300006
PM 17510790
DA 2024-11-01
ER

PT J
AU McFarland, R
   Taylor, RW
   Turnbull, DM
AF McFarland, R.
   Taylor, R. W.
   Turnbull, D. M.
TI Mitochondrial disease - Its impact, etiology, and pathology
SO MITOCHONDRION IN THE GERMLINE AND EARLY DEVELOPMENT
LA English
DT Review
ID hereditary optic neuropathy; progressive external ophthalmoplegia; cytochrome-c-oxidase; stroke-like episodes; complex-i deficiency; ragged-red fibers; respiratory-chain activity; transfer rnaleu(uur) gene; substantia-nigra neurons; dna replication bubble
AB Mitochondria are ubiquitous organelles that are intimately involved in many cellular processes, but whose principal task is to provide the energy necessary for normal cell functioning and maintenance. Disruption of this energy supply can have devastating consequences for the cell, organ, and individual. Over the last two decades, mutations in both mitochondrial DNA (mtDNA) and nuclear DNA have been identified as causative in a number of well-characterized clinical syndromes, although for mtDNA mutations in particular, this relationship between genotype and phenotype is often not straightforward. Despite this, a number of epidemiological studies have been undertaken to assess the prevalence of mtDNA mutations and these have highlighted the impact that mtDNA disease has on both the community and individual families. Although there has been considerable improvement in the diagnosis of mitochondrial disorders, disappointingly this has not been matched by developments toward effective treatment. Nevertheless, our understanding of mitochondrial biology is gathering pace and progress in this area will be crucial to devising future treatment strategies. In addition to mitochondrial disease, evidence for a central role of mitochondria in other processes, such as aging and neurodegeneration, is slowly accumulating, although their role in cancer remains controversial. In this chapter, we discuss these issues and offer our own views based on our cumulative experience of investigating and managing these diseases over the last 20 years. (c) 2007, Elsevier Inc.
C1 Newcastle Univ, Sch Med, Mitochondrial Res Grp, Sch Neurol Neurobiol & Psychiat, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
C3 Newcastle University - UK
RP McFarland, R (corresponding author), Newcastle Univ, Sch Med, Mitochondrial Res Grp, Sch Neurol Neurobiol & Psychiat, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
FU MRC [G108/539] Funding Source: UKRI; Medical Research Council [G108/539] Funding Source: Medline; Wellcome Trust Funding Source: Medline
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   Awadalla P, 1999, SCIENCE, V286, P2524, DOI 10.1126/science.286.5449.2524
   BALLINGER SW, 1992, NAT GENET, V1, P11, DOI 10.1038/ng0492-11
   Bataillard M, 2001, NEUROLOGY, V56, P405, DOI 10.1212/WNL.56.3.405
   Battersby BJ, 2003, NAT GENET, V33, P183, DOI 10.1038/ng1073
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Biggin A, 2005, MOL GENET METAB, V84, P61, DOI 10.1016/j.ymgme.2004.09.011
   Birch-Machin MA, 2001, METHOD CELL BIOL, V65, P97, DOI 10.1016/S0091-679X(01)65006-4
   BOGENHAGEN D, 1977, CELL, V11, P719, DOI 10.1016/0092-8674(77)90286-0
   Bogenhagen DF, 2003, TRENDS BIOCHEM SCI, V28, P357, DOI 10.1016/S0968-0004(03)00132-4
   Bogenhagen DF, 2003, TRENDS BIOCHEM SCI, V28, P404, DOI 10.1016/S0968-0004(03)00165-8
   Bohlega S, 1996, NEUROLOGY, V46, P1329, DOI 10.1212/WNL.46.5.1329
   BOULET L, 1992, AM J HUM GENET, V51, P1187
   Bowmaker M, 2003, J BIOL CHEM, V278, P50961, DOI 10.1074/jbc.M308028200
   Brierley EJ, 1998, ANN NEUROL, V43, P217, DOI 10.1002/ana.410430212
   Brown TA, 2005, GENE DEV, V19, P2466, DOI 10.1101/gad.1352105
   Bykhovskaya Y, 2004, MOL GENET METAB, V83, P199, DOI 10.1016/j.ymgme.2004.07.009
   Calabrese V, 2005, J NEUROL SCI, V233, P145, DOI 10.1016/j.jns.2005.03.012
   Campos Y, 2001, NEUROMUSCULAR DISORD, V11, P477, DOI 10.1016/S0960-8966(00)00223-6
   Canafoglia L, 2001, NEUROLOGY, V56, P1340, DOI 10.1212/WNL.56.10.1340
   Carrozzo R, 2001, NEUROLOGY, V56, P687, DOI 10.1212/WNL.56.5.687
   Casari G, 1998, CELL, V93, P973, DOI 10.1016/S0092-8674(00)81203-9
   Chagnon P, 1999, AM J MED GENET, V85, P20, DOI 10.1002/(SICI)1096-8628(19990702)85:1<20::AID-AJMG6>3.0.CO;2-K
   CHANG DD, 1985, P NATL ACAD SCI USA, V82, P351, DOI 10.1073/pnas.82.2.351
   CHANG DD, 1984, CELL, V36, P635, DOI 10.1016/0092-8674(84)90343-X
   CHANG DD, 1985, EMBO J, V4, P1559, DOI 10.1002/j.1460-2075.1985.tb03817.x
   Chinnery PF, 2000, ANN NEUROL, V48, P188, DOI 10.1002/1531-8249(200008)48:2<188::AID-ANA8>3.3.CO;2-G
   Chinnery PF, 2005, LANCET, V366, P1650, DOI 10.1016/S0140-6736(05)67492-2
   Chinnery PF, 1999, AM J HUM GENET, V64, P1158, DOI 10.1086/302311
   Chinnery PF, 1997, BRAIN, V120, P1713, DOI 10.1093/brain/120.10.1713
   Chinnery PF, 2000, ANN NEUROL, V47, P381, DOI 10.1002/1531-8249(200003)47:3<381::AID-ANA17>3.0.CO;2-2
   Chomyn A, 2000, J BIOL CHEM, V275, P19198, DOI 10.1074/jbc.M908734199
   CLAYTON DA, 1991, ANNU REV CELL BIOL, V7, P453, DOI 10.1146/annurev.cb.07.110191.002321
   CLAYTON DA, 1992, INT REV CYTOL, V141, P217, DOI 10.1016/S0074-7696(08)62067-7
   CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6
   Coenen MJH, 2004, NEW ENGL J MED, V351, P2080, DOI 10.1056/NEJMoa041878
   Coller HA, 2001, NAT GENET, V28, P147, DOI 10.1038/88859
   DAurelio M, 2004, HUM MOL GENET, V13, P3171, DOI 10.1093/hmg/ddh326
   DAMIAN MS, 1995, ACTA NEUROL SCAND, V92, P409
   de Coo IFM, 1998, NEUROLOGY, V50, P293, DOI 10.1212/WNL.50.1.293
   de Lonlay P, 2001, NAT GENET, V29, P57, DOI 10.1038/ng706
   De Meirleir L, 2003, AM J MED GENET A, V121A, P126, DOI 10.1002/ajmg.a.20171
   Deschauer M, 1999, NEUROMUSCULAR DISORD, V9, P305, DOI 10.1016/S0960-8966(99)00019-X
   Dimauro S, 2001, AM J MED GENET, V106, P18, DOI 10.1002/ajmg.1392
   Ekstrand MI, 2004, HUM MOL GENET, V13, P935, DOI 10.1093/hmg/ddh109
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Elson JL, 2001, AM J HUM GENET, V68, P145, DOI 10.1086/316938
   Engelgau MM, 2004, ANN INTERN MED, V140, P945, DOI 10.7326/0003-4819-140-11-200406010-00035
   ENRIQUEZ JA, 1995, NAT GENET, V10, P47, DOI 10.1038/ng0595-47
   Excoffier L, 1999, MOL BIOL EVOL, V16, P1357, DOI 10.1093/oxfordjournals.molbev.a026046
   Falkenberg M, 2002, NAT GENET, V31, P289, DOI 10.1038/ng909
   FANG W, 1993, ARCH NEUROL-CHICAGO, V50, P977, DOI 10.1001/archneur.1993.00540090074013
   Farina L, 2002, AM J NEURORADIOL, V23, P1095
   Fernández-Silva P, 2003, EXP PHYSIOL, V88, P41, DOI 10.1113/eph8802514
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Filosto M, 2003, ANN NEUROL, V54, P524, DOI 10.1002/ana.10709
   FISHER RP, 1987, CELL, V50, P247, DOI 10.1016/0092-8674(87)90220-0
   Fliss MS, 2000, SCIENCE, V287, P2017, DOI 10.1126/science.287.5460.2017
   Gabaldón T, 2004, BBA-BIOENERGETICS, V1659, P212, DOI 10.1016/j.bbabio.2004.07.011
   Gaspari M, 2004, EMBO J, V23, P4606, DOI 10.1038/sj.emboj.7600465
   GERBITZ KD, 1995, BBA-MOL BASIS DIS, V1271, P253, DOI 10.1016/0925-4439(95)00036-4
   GOTO Y, 1992, ANN NEUROL, V31, P672, DOI 10.1002/ana.410310617
   GOTO Y, 1991, BIOCHIM BIOPHYS ACTA, V1097, P238, DOI 10.1016/0925-4439(91)90042-8
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   GOTO YI, 1994, BIOCHEM BIOPH RES CO, V202, P1624, DOI 10.1006/bbrc.1994.2119
   Griggs RC, 1999, NEW ENGL J MED, V341, P1077, DOI 10.1056/NEJM199909303411411
   GROHMANN K, 1978, NUCLEIC ACIDS RES, V5, P637, DOI 10.1093/nar/5.3.637
   Gu M, 1998, ANN NEUROL, V44, P177, DOI 10.1002/ana.410440207
   Guan MX, 2001, HUM MOL GENET, V10, P573, DOI 10.1093/hmg/10.6.573
   GUENTHARD J, 1995, ARCH DIS CHILD, V72, P223, DOI 10.1136/adc.72.3.223
   HAMMANS SR, 1995, BRAIN, V118, P721, DOI 10.1093/brain/118.3.721
   HAMMANS SR, 1993, BRAIN, V116, P617, DOI 10.1093/brain/116.3.617
   HANNA MG, 1995, J NEUROL SCI, V130, P154, DOI 10.1016/0022-510X(95)00022-T
   Hao R, 2004, FEBS LETT, V578, P135, DOI 10.1016/j.febslet.2004.11.004
   HARDING AE, 1995, MUSCLE NERVE, V0, PS82
   HARMAN D, 1992, MUTAT RES, V275, P257, DOI 10.1016/0921-8734(92)90030-S
   He L, 2003, LEUKEMIA, V17, P2487, DOI 10.1038/sj.leu.2403146
   He LP, 2002, NUCLEIC ACIDS RES, V30, P0, DOI 10.1093/nar/gnf067
   Helgason A, 2005, NAT GENET, V37, P90, DOI 10.1038/ng1492
   Herrnstadt C, 2002, AM J HUM GENET, V70, P1152, DOI 10.1086/339933
   HIRANO M, 1994, NEUROLOGY, V44, P721, DOI 10.1212/WNL.44.4.721
   Holt IJ, 2000, CELL, V100, P515, DOI 10.1016/S0092-8674(00)80688-1
   HOLT IJ, 1990, AM J HUM GENET, V46, P428
   Hudson G, 2005, AM J HUM GENET, V77, P1086, DOI 10.1086/498176
   Huoponen K, 2001, NEUROGENETICS, V3, P119, DOI 10.1007/s100480100115
   HUTTENLOCHER PR, 1976, ARCH NEUROL-CHICAGO, V33, P186, DOI 10.1001/archneur.1976.00500030042009
   JACKSON MJ, 1995, BRAIN, V118, P339, DOI 10.1093/brain/118.2.339
   Jaksch M, 2000, HUM MOL GENET, V9, P795, DOI 10.1093/hmg/9.5.795
   Jerónimo C, 2001, ONCOGENE, V20, P5195, DOI 10.1038/sj.onc.1204646
   Jin H, 1996, NAT GENET, V14, P177, DOI 10.1038/ng1096-177
   Jones JB, 2001, CANCER RES, V61, P1299
   JUN AS, 1994, P NATL ACAD SCI USA, V91, P6206, DOI 10.1073/pnas.91.13.6206
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Khogali SS, 2001, LANCET, V357, P1265, DOI 10.1016/S0140-6736(00)04422-6
   KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480
   Kirby DM, 2004, J MED GENET, V41, P784, DOI 10.1136/jmg.2004.020537
   Kirches E, 2001, INT J CANCER, V93, P534, DOI 10.1002/ijc.1375
   Kleiner L, 1996, OPTOM CLIN, V5, P77
   Korhonen JA, 2003, J BIOL CHEM, V278, P48627, DOI 10.1074/jbc.M306981200
   Koutnikova H, 1997, NAT GENET, V16, P345, DOI 10.1038/ng0897-345
   Kraytsberg Y, 2006, NAT GENET, V38, P518, DOI 10.1038/ng1778
   Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125
   LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561
   LEIGH D, 1951, J NEUROL NEUROSUR PS, V14, P216, DOI 10.1136/jnnp.14.3.216
   Lightowlers RN, 1997, TRENDS GENET, V13, P450, DOI 10.1016/S0168-9525(97)01266-3
   Liolitsa D, 2003, ANN NEUROL, V53, P128, DOI 10.1002/ana.10435
   Lister R, 2005, MOL MEMBR BIOL, V22, P87, DOI 10.1080/09687860500041247
   Lodi R, 1999, P NATL ACAD SCI USA, V96, P11492, DOI 10.1073/pnas.96.20.11492
   Loeffen JLCM, 2000, HUM MUTAT, V15, P123, DOI 10.1002/(SICI)1098-1004(200002)15:2<123::AID-HUMU1>3.3.CO;2-G
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Lutsenko S, 1998, P NATL ACAD SCI USA, V95, P6004, DOI 10.1073/pnas.95.11.6004
   MACKEY DA, 1992, AUST NZ J OPHTHALMOL, V20, P177, DOI 10.1111/j.1442-9071.1992.tb00937.x
   Majamaa K, 1998, AM J HUM GENET, V63, P447, DOI 10.1086/301959
   Man PYW, 2003, AM J HUM GENET, V72, P333, DOI 10.1016/j.ajhg.2016.05.015
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Margineantu DH, 2002, MITOCHONDRION, V1, P425, DOI 10.1016/S1567-7249(02)00006-5
   MARGULIS L, 1976, EXP PARASITOL, V39, P277, DOI 10.1016/0014-4894(76)90127-2
   MARTINUZZI A, 1992, J NEUROL SCI, V113, P222, DOI 10.1016/0022-510X(92)90250-O
   MATTHES M, 1982, J VIROL, V42, P301, DOI 10.1128/JVI.42.1.301-305.1982
   McFarland R, 2002, LANCET NEUROL, V1, P343, DOI 10.1016/S1474-4422(02)00159-X
   McFarland R, 2004, ANN NEUROL, V55, P478, DOI 10.1002/ana.20004
   McFarland R, 2004, NEUROMUSCULAR DISORD, V14, P162, DOI 10.1016/j.nmd.2003.10.011
   McFarland R, 2004, ANN NEUROL, V55, P58, DOI 10.1002/ana.10787
   McFarland R, 2002, NAT GENET, V30, P145, DOI 10.1038/ng819
   McNaught KSP, 2001, NAT REV NEUROSCI, V2, P589, DOI 10.1038/35086067
   Meirelles FV, 1997, GENETICS, V145, P445
   Miller C, 2004, ANN NEUROL, V56, P734, DOI 10.1002/ana.20282
   *MITOMAP, 2005, HUM MIT GEN DAT, V0, P0
   *MITOMAP, 2006, HUM MIT GEN DAT, V0, P0
   MONTOYA J, 1982, P NATL ACAD SCI-BIOL, V79, P7195, DOI 10.1073/pnas.79.23.7195
   MONTOYA J, 1981, NATURE, V290, P465, DOI 10.1038/290465a0
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   MORIKAWA Y, 1993, VIRCHOWS ARCH A, V423, P227, DOI 10.1007/BF01614775
   MORTEN KJ, 1995, HUM MOL GENET, V4, P1689
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   OBERMAIERKUSSER B, 1991, FEBS LETT, V286, P67, DOI 10.1016/0014-5793(91)80942-V
   OJALA D, 1981, NATURE, V290, P470, DOI 10.1038/290470a0
   OLDFORS A, 1995, ACTA NEUROPATHOL, V90, P328
   OZAWA T, 1995, BBA-MOL BASIS DIS, V1271, P177, DOI 10.1016/0925-4439(95)00026-Z
   Papadopoulou LC, 1999, NAT GENET, V23, P333
   PARISI MA, 1991, SCIENCE, V252, P965, DOI 10.1126/science.2035027
   Park H, 2003, BIOCHEMISTRY-US, V42, P958, DOI 10.1021/bi026882r
   Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108
   Poulton J, 1998, AM J HUM GENET, V62, P752, DOI 10.1086/301811
   Poulton J, 2002, HUM MOL GENET, V11, P1581, DOI 10.1093/hmg/11.13.1581
   POULTON J, 1995, MUSCLE NERVE S, V3, P154
   PREZANT TR, 1993, NAT GENET, V4, P289, DOI 10.1038/ng0793-289
   Pyle A, 2005, ANN NEUROL, V57, P564, DOI 10.1002/ana.20417
   Rahman S, 1996, ANN NEUROL, V39, P343, DOI 10.1002/ana.410390311
   REID FM, 1994, HUM MUTAT, V3, P243, DOI 10.1002/humu.1380030311
   Rigoli L, 2001, DIABETIC MED, V18, P334, DOI 10.1046/j.1464-5491.2001.00429-2.x
   Ross OA, 2003, EXP GERONTOL, V38, P397, DOI 10.1016/S0531-5565(02)00266-8
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Saker PJ, 1997, DIABETIC MED, V14, P42, DOI 10.1002/(SICI)1096-9136(199701)14:1<42::AID-DIA295>3.0.CO;2-T
   Santorelli F M, 2001, AM HEART J, V141, PE1, DOI 10.1067/mhj.2001.112088
   Sato A, 2005, P NATL ACAD SCI USA, V102, P6057, DOI 10.1073/pnas.0408666102
   SAUNIER P, 1995, NEUROMUSCULAR DISORD, V5, P285, DOI 10.1016/0960-8966(94)00071-G
   Schaefer AM, 2004, BBA-BIOENERGETICS, V1659, P115, DOI 10.1016/j.bbabio.2004.09.005
   SCHON EA, 1992, BIOCHIM BIOPHYS ACTA, V1101, P206, DOI 10.1016/0005-2728(92)90226-R
   Schwartz M, 2002, NEW ENGL J MED, V347, P576, DOI 10.1056/NEJMoa020350
   SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N
   Shoubridge EA, 2002, NAT GENET, V31, P227, DOI 10.1038/ng0702-227
   SILVESTRI G, 1993, NEUROLOGY, V43, P1200, DOI 10.1212/WNL.43.6.1200
   Sissler M, 2004, RNA, V10, P841, DOI 10.1261/rna.5267604
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Spinazzola A, 2004, NEUROMUSCULAR DISORD, V14, P815, DOI 10.1016/j.nmd.2004.09.002
   Spinazzola A, 2002, J BIOL CHEM, V277, P4128, DOI 10.1074/jbc.M111028200
   Sternberg D, 2001, BRAIN, V124, P984, DOI 10.1093/brain/124.5.984
   Steuerwald N, 2000, ZYGOTE, V8, P209, DOI 10.1017/S0967199400001003
   STONE EM, 1992, J CLIN NEURO-OPHTHAL, V12, P10
   Sue CM, 1999, NEUROLOGY, V52, P1905, DOI 10.1212/WNL.52.9.1905
   Swerdlow RH, 1996, ANN NEUROL, V40, P663, DOI 10.1002/ana.410400417
   Taylor RW, 2003, J CLIN INVEST, V112, P1351, DOI 10.1172/JCI200319435
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Taylor RW, 2003, J AM COLL CARDIOL, V41, P1786, DOI 10.1016/S0735-1097(03)00300-0
   Taylor RW, 2004, NEUROMUSCULAR DISORD, V14, P237, DOI 10.1016/j.nmd.2003.12.004
   THYAGARAJAN D, 1995, ANN NEUROL, V38, P468, DOI 10.1002/ana.410380321
   TIRANTI V, 1995, HUM MOL GENET, V4, P1421, DOI 10.1093/hmg/4.8.1421
   Tiranti V, 1998, AM J HUM GENET, V63, P1609, DOI 10.1086/302150
   Toompuu M, 2002, J BIOL CHEM, V277, P22240, DOI 10.1074/jbc.M200338200
   TRAFF J, 1995, ACTA NEUROL SCAND, V92, P394
   Triepels RH, 2001, AM J MED GENET, V106, P37, DOI 10.1002/ajmg.1397
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Twelves D, 2003, MOVEMENT DISORD, V18, P19, DOI 10.1002/mds.10305
   Uusimaa J, 2000, PEDIATRICS, V105, P598, DOI 10.1542/peds.105.3.598
   Valente EM, 2004, SCIENCE, V304, P1158, DOI 10.1126/science.1096284
   van den Bosch BJC, 2000, NUCLEIC ACIDS RES, V28, P0, DOI 10.1093/nar/28.20.e89
   van der Walt JM, 2004, NEUROSCI LETT, V365, P28, DOI 10.1016/j.neulet.2004.04.051
   van der Walt JM, 2003, AM J HUM GENET, V72, P804, DOI 10.1086/373937
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368
   Vives-Bauza C, 2002, BIOCHEM BIOPH RES CO, V290, P1593, DOI 10.1006/bbrc.2002.6388
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   Wilson FH, 2004, SCIENCE, V306, P1190, DOI 10.1126/science.1102521
   Wong VA, 2002, OPHTHALMOLOGY, V109, P1023, DOI 10.1016/S0161-6420(02)01009-6
   Yang MY, 2002, CELL, V111, P495, DOI 10.1016/S0092-8674(02)01075-9
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
   ZEVIANI M, 1990, AM J HUM GENET, V47, P904
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
   Zhu ZQ, 1998, NAT GENET, V20, P337, DOI 10.1038/3804
   Zsurka G, 2005, NAT GENET, V37, P873, DOI 10.1038/ng1606
   ZUPANC ML, 1991, ANN NEUROL, V29, P680, DOI 10.1002/ana.410290619
NR 206
TC 150
Z9 167
U1 0
U2 24
PU ELSEVIER ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0070-2153
EI 
J9 CURR TOP DEV BIOL
JI Curr. Top. Dev. Biol.
PD JUN 15
PY 2007
VL 77
IS 
BP 113
EP +
DI 10.1016/S0070-2153(06)77005-3
PG 46
WC Developmental Biology
SC Developmental Biology
GA BFR59
UT WOS:000244033600005
PM 17222702
DA 2024-11-01
ER

PT J
AU Spruijt, L
   Smeets, HJ
   Hendrickx, A
   Bettink-Remeijer, MW
   Maat-Kievit, A
   Schoonderwoerd, KC
   Sluiter, W
   de Coo, IF
   Hintzen, RQ
AF Spruijt, Liesbeth
   Smeets, Hubert J.
   Hendrickx, Alexandra
   Bettink-Remeijer, Marijke Wefers
   Maat-Kievit, A.
   Schoonderwoerd, Kees C.
   Sluiter, Wim
   de Coo, Ireneaus F.
   Hintzen, Rogier Q.
TI A MELAS-associated ND1 mutation causing Leber hereditary optic neuropathy and spastic dystonia
SO ARCHIVES OF NEUROLOGY
LA English
DT Article
ID mitochondrial-dna mutation; plus dystonia; gene; defects; family
AB Objective: To report a novel mutation that is associated with Leber hereditary optic neuropathy ( LHON) within the same family affected by spastic dystonia. Design: Leber hereditary optic neuropathy is a mitochondrial disorder characterized by isolated central visual loss. Of patients with LHON, 95% carry a mutation in 1 of 3 mitochondrial DNA - encoded complex i genes. The complete mitochondrial DNA was screened for mutations in a patient with LHON without 1 of these 3 primary mutations. The heteroplasmy level and biochemical consequence of the mutation were determined. Results: A pathogenic 3697G > A/ND1 mutation was detected and seemed associated with an isolated complex I deficiency. This family has similar clinical characteristics as the previously described families with LHON and dystonia with an ND6 mutation. Conclusions: The 3697G > A/ND1 mitochondrial DNA mutation causes the LHON and spastic dystonia phenotype in the same family. This mutation can also cause MELAS syndrome ( which encompasses mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke), and other genetic factors may contribute to the clinical expression.
C1 Univ Maastricht, Dept Genet & Cell Biol, NL-6200 MD Maastricht, Netherlands.
   Univ Maastricht, Res Inst Growth & Dev, NL-6200 MD Maastricht, Netherlands.
   Univ Med Ctr Nijmegen, Dept Human Genet, Nijmegen, Netherlands.
   Rotterdam Eye Hosp, Rotterdam, Netherlands.
   Erasmus MC, Dept Clin Genet, Rotterdam, Netherlands.
   Erasmus MC, Dept Biochem, Rotterdam, Netherlands.
   Erasmus MC, Dept Neurol, Rotterdam, Netherlands.
C3 Maastricht University; Maastricht University; Radboud University Nijmegen; Rotterdam Eye Hospital; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC
RP Smeets, HJ (corresponding author), Univ Maastricht, Dept Genet & Cell Biol, POB 616, NL-6200 MD Maastricht, Netherlands.
EM bert.smeets@molcelb.unimaas.nl
CR Abu-Amero KK, 2005, BRIT J OPHTHALMOL, V89, P1380, DOI 10.1136/bjo.2005.072819
   Blakely EL, 2005, EUR J HUM GENET, V13, P623, DOI 10.1038/sj.ejhg.5201363
   DeVries DD, 1996, AM J HUM GENET, V58, P703
   FINNILAS, 2001, AM J HUM GENET, V68, P1475
   Forster P, 1996, AM J HUM GENET, V59, P935
   Gropman A, 2004, AM J MED GENET A, V124A, P377, DOI 10.1002/ajmg.a.20456
   JUN AS, 1994, P NATL ACAD SCI USA, V91, P6206, DOI 10.1073/pnas.91.13.6206
   Kirby DM, 2004, J MED GENET, V41, P784, DOI 10.1136/jmg.2004.020537
   Man PYW, 2003, AM J HUM GENET, V72, P333, DOI 10.1016/j.ajhg.2016.05.015
   NOVOTNY EJ, 1986, NEUROLOGY, V36, P1053, DOI 10.1212/WNL.36.8.1053
   Schapira AHV, 1998, BBA-BIOENERGETICS, V1364, P261, DOI 10.1016/S0005-2728(98)00032-2
   SCHOLTE HR, 1987, J INHERIT METAB DIS, V10, P81, DOI 10.1007/BF01812849
   SCHOLTE HR, 1995, BBA-MOL BASIS DIS, V1271, P75, DOI 10.1016/0925-4439(95)00013-T
   SHOFFNER JM, 1995, ANN NEUROL, V38, P163, DOI 10.1002/ana.410380207
   SRERE PA, 1992, CURR TOP CELL REGUL, V33, P261
   Tarnopolsky MA, 2004, AM J MED GENET A, V124A, P372, DOI 10.1002/ajmg.a.20449
   Trounce I A, 1996, METHODS ENZYMOL, V264, P484, DOI 10.1016/S0076-6879(96)64044-0
   van Eijsden RGE, 2006, GENET MED, V8, P620, DOI 10.1097/01.gim.0000237782.94878.05
   Watanabe M, 2006, J NEUROL SCI, V243, P31, DOI 10.1016/j.jns.2005.11.003
NR 19
TC 35
Z9 42
U1 0
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0003-9942
EI 
J9 ARCH NEUROL-CHICAGO
JI Arch. Neurol.
PD JUN 15
PY 2007
VL 64
IS 6
BP 890
EP 893
DI 10.1001/archneur.64.6.890
PG 4
WC Clinical Neurology
SC Neurosciences & Neurology
GA 177HF
UT WOS:000247143500016
PM 17562939
DA 2024-11-01
ER

PT J
AU Blok, MJ
   Spruijt, L
   de Coo, IFM
   Schoonderwoerd, K
   Hendrickx, A
   Smeets, HJ
AF Blok, M. J.
   Spruijt, L.
   de Coo, I. F. M.
   Schoonderwoerd, K.
   Hendrickx, A.
   Smeets, H. J.
TI Mutations in the ND5 subunit of complex I of the mitochondrial DNA are a frequent cause of oxidative phosphorylation disease
SO JOURNAL OF MEDICAL GENETICS
LA English
DT Article
ID mouse mitochondria; clinical-features; g13513a mutation; leigh-syndrome; hot-spot; melas; gene; mtdna
AB Background: Detection of mutations in the mitochondrial DNA (mtDNA) is usually limited to common mutations and the transfer RNA genes. However, mutations in other mtDNA regions can be an important cause of oxidative phosphorylation (OXPHOS) disease as well. Objective: To investigate whether regions in the mtDNA are preferentially mutated in patients with OXPHOS disease. Methods: Screening of the mtDNA for heteroplasmic mutations was performed by denaturing high-performance liquid chromatography analysis of 116 patients with OXPHOS disease but without the common mtDNA mutations. Results: An mtDNA sequence variant was detected in 15 patients, 5 of which were present in the ND5 gene. One sequence variant was new and three were known, one of which was found twice. The novel sequence variant m. 13511A -> T occurred in a patient with a Leigh-like syndrome. The known mutation m. 13513G -> A, associated with mitochondrial encephalomyopathy lactic acidosis and stroke-like syndrome (MELAS) and MELAS/Leigh/Leber hereditary optic neuropathy overlap syndrome, was found in a relatively low percentage in two patients from two different families, one with a MELAS/Leigh phenotype and one with a MELAS/chronic progressive external ophthalmoplegia phenotype. The known mutation m. 13042G -> A, detected previously in a patient with a MELAS/myoclonic epilepsy, ragged red fibres phenotype and in a family with a prevalent ocular phenotype, was now found in a patient with a Leigh-like phenotype. The sequence variant m. 12622GRA was reported once in a control database as a polymorphism, but is reported in this paper as heteroplasmic in three brothers, all with infantile encephalopathy (Leigh syndrome) fatal within the first 15 days of life. Therefore, a causal relationship between the presence of this sequence variant and the onset of mitochondrial disease cannot be entirely excluded at this moment. Conclusions: Mutation screening of the ND5 gene is advised for routine diagnostics of patients with OXPHOS disease, especially for those with MELAS- and Leigh-like syndrome with a complex I deficiency.
C1 Univ Hosp, Dept Clin Genet, NL-6202 AZ Maastricht, Netherlands.
   Univ Maastricht, Dept Genet & Cell Biol, Res Inst Growth & Dev, Maastricht, Netherlands.
   Erasmus MC, Dept Child Neurol, Rotterdam, Netherlands.
   Erasmus MC, Dept Clin Genet, Rotterdam, Netherlands.
C3 Maastricht University; Maastricht University; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC
RP Blok, MJ (corresponding author), Univ Hosp, Dept Clin Genet, POB 5800, NL-6202 AZ Maastricht, Netherlands.
EM rien.blok@gen.unimaas.nl
CR Bai YD, 2004, ANN NY ACAD SCI, V1011, P272, DOI 10.1196/annals.1293.026
   Bai YD, 2000, MOL CELL BIOL, V20, P805, DOI 10.1128/MCB.20.3.805-815.2000
   Chinnery PF, 2001, BRAIN, V124, P209, DOI 10.1093/brain/124.1.209
   Chol M, 2003, J MED GENET, V40, P188, DOI 10.1136/jmg.40.3.188
   Chomyn A, 2001, J BIOENERG BIOMEMBR, V33, P251, DOI 10.1023/A:1010791204961
   Corona P, 2001, ANN NEUROL, V49, P106, DOI 10.1002/1531-8249(200101)49:1<106::AID-ANA16>3.0.CO;2-T
   Fisher N, 2000, J MOL BIOL, V296, P1153, DOI 10.1006/jmbi.2000.3509
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Jacobs LJAM, 2006, HUM REPROD UPDATE, V12, P119, DOI 10.1093/humupd/dmi042
   Janssen RJRJ, 2004, EXPERT REV MOL DIAGN, V4, P143, DOI 10.1586/14737159.4.2.143
   Kirby DM, 2003, ANN NEUROL, V54, P473, DOI 10.1002/ana.10687
   Lim PS, 2000, FREE RADICAL BIO MED, V29, P454, DOI 10.1016/S0891-5849(00)00334-8
   Liolitsa D, 2003, ANN NEUROL, V53, P128, DOI 10.1002/ana.10435
   Makino M, 2000, J HUM GENET, V45, P69, DOI 10.1007/s100380050014
   Mitchell AL, 2006, J MED GENET, V43, P175, DOI 10.1136/jmg.2005.032474
   Mootha VK, 2003, CELL, V115, P629, DOI 10.1016/S0092-8674(03)00926-7
   Naini AB, 2005, ARCH NEUROL-CHICAGO, V62, P473, DOI 10.1001/archneur.62.3.473
   Penisson-Besnier I, 2000, NEUROLOGY, V55, P317, DOI 10.1212/WNL.55.2.317
   Pulkes T, 1999, ANN NEUROL, V46, P916, DOI 10.1002/1531-8249(199912)46:6<916::AID-ANA16>3.0.CO;2-R
   Santorelli FM, 1997, BIOCHEM BIOPH RES CO, V238, P326, DOI 10.1006/bbrc.1997.7167
   Smeitink J, 2001, NAT REV GENET, V2, P342, DOI 10.1038/35072063
   Sudo A, 2004, J HUM GENET, V49, P92, DOI 10.1007/s10038-003-0116-1
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Thorburn DR, 2004, J INHERIT METAB DIS, V27, P349, DOI 10.1023/B:BOLI.0000031098.41409.55
   Valentino ML, 2006, J MED GENET, V43, P0, DOI 10.1136/jmg.2005.037507
   van den Bosch BJC, 2000, NUCLEIC ACIDS RES, V28, P0, DOI 10.1093/nar/28.20.e89
NR 26
TC 51
Z9 60
U1 0
U2 7
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-2593
EI 
J9 J MED GENET
JI J. Med. Genet.
PD APR 15
PY 2007
VL 44
IS 4
BP 
EP 
DI 10.1136/jmg.2006.045716
PG 5
WC Genetics & Heredity
SC Genetics & Heredity
GA 152GV
UT WOS:000245350500013
PM 17400793
DA 2024-11-01
ER

PT J
AU Ostergaard, E
   Hansen, FJ
   Sorensen, N
   Duno, M
   Vissing, J
   Larsen, PL
   Faeroe, O
   Thorgrimsson, S
   Wibrand, F
   Christensen, E
   Schwartz, M
AF Ostergaard, Elsebet
   Hansen, Flemming J.
   Sorensen, Nicolina
   Duno, Morten
   Vissing, John
   Larsen, Pernille L.
   Faeroe, Oddmar
   Thorgrimsson, Sigurdur
   Wibrand, Flemming
   Christensen, Ernst
   Schwartz, Marianne
TI Mitochondrial encephalomyopathy with elevated methylmalonic acid is caused by <i>SUCLA2</i> mutations
SO BRAIN
LA English
DT Article
DE methylmalonic acid; Leigh syndrome; mitochondrial encephalomyopathies; mitochondrial diseases
ID dna depletion; faroe-islands; respiratory-chain; disease; encephalopathy; prevalence; deficiency; deletions; children; tissue
AB We have identified 12 patients with autosomal recessive mitochondrial encephalomyopathy with elevated methylmalonic acid. The disorder has a high incidence of 1 in 1700 in the Faroe Islands due to a founder effect, and a carrier frequency of 1 in 33. The symptoms comprise hypotonia, muscle atrophy, hyperkinesia, severe hearing impairment and postnatal growth retardation. Neuroimaging showed demyelination and central and cortical atrophy, including atrophy of the basal ganglia, and some of the patients fulfilled the criteria for Leigh syndrome. Urine and plasma methylmalonic acid were elevated. Homozygosity mapping with the Affymetrix 10K array revealed a homozygous region on chromosome 13q14 harbouring the SUCLA2 gene. Mutations in SUCLA2 were recently shown to cause a similar disorder in a small Israeli family. Mutation analysis identified a novel splice site mutation in SUCLA2, IVS4 + 1G -> A, leading to skipping of exon 4. The SUCLA2 gene encodes the ATP-forming beta subunit of the Krebs cycle enzyme succinyl-CoA ligase. The hallmark of the condition, elevated methylmalonic acid, can be explained by an accumulation of the substrate of the enzyme, succinyl-CoA, which in turn leads to elevated methylmalonic acid, because the conversion of methylmalonyl-CoA to succinyl-CoA is inhibited.
C1 Copenhagen Univ Hosp, Rigshosp, Dept Clin Genet, DK-2100 Copenhagen, Denmark.
   Copenhagen Univ Hosp, Rigshosp, Dept Pediat, Cent Hosp Hillerod, DK-2100 Copenhagen, Denmark.
   Copenhagen Univ Hosp, Rigshosp, Dept Neurol, DK-2100 Copenhagen, Denmark.
   John F Kennedy Inst, DK-2600 Glostrup, Denmark.
   Landssjukrahusid, Dept Paediat, Torshavn, Faroe Islands, Denmark.
   Univ Hosp Iceland, Reykjavik, Iceland.
C3 University of Copenhagen; Rigshospitalet; Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen; Landspitali National University Hospital
RP Ostergaard, E (corresponding author), Copenhagen Univ Hosp, Rigshosp, Dept Clin Genet, Blegdamsvej 9,4062, DK-2100 Copenhagen, Denmark.
EM elsebet.oestergaard@rh.hosp.dk
CR Barshop BA, 2004, MITOCHONDRION, V4, P521, DOI 10.1016/j.mito.2004.07.010
   Birch-Machin MA, 2001, METHOD CELL BIOL, V65, P97, DOI 10.1016/S0091-679X(01)65006-4
   BIRCHMACHIN MA, 1994, BIOCHEM MED METAB B, V51, P35, DOI 10.1006/bmmb.1994.1004
   Böhm M, 2006, PEDIATR RES, V59, P21, DOI 10.1203/01.pdr.0000190572.68191.13
   CHRISTENSEN E, 1981, CLIN CHIM ACTA, V116, P331, DOI 10.1016/0009-8981(81)90052-8
   Darin N, 2001, ANN NEUROL, V49, P377, DOI 10.1002/ana.75
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   Johnson JD, 1998, J BIOL CHEM, V273, P27580, DOI 10.1074/jbc.273.42.27580
   Jorgensen TH, 2002, EUR J HUM GENET, V10, P381, DOI 10.1038/sj.ejhg.5200816
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   KLEITRETZOW JC, 1998, AM J HUM GENET, V63, P428
   Kowluru A, 2002, ARCH BIOCHEM BIOPHYS, V398, P160, DOI 10.1006/abbi.2001.2710
   KRAHENBUHL S, 1994, CLIN CHIM ACTA, V230, P177, DOI 10.1016/0009-8981(94)90270-4
   MANDERBACKA K, 2001, SCANDINAVIAN J P S55, V29, P41
   Mayatepek E, 1996, EUR J PEDIATR, V155, P398, DOI 10.1007/BF01955272
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   RASMUSSEN K, 1989, CLIN CHEM, V35, P260
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Santer R, 2001, EUR J HUM GENET, V9, P388, DOI 10.1038/sj.ejhg.5200632
   SCHWARTZ M, 1995, HUM GENET, V95, P703
   Skladal D, 2003, BRAIN, V126, P1905, DOI 10.1093/brain/awg170
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   STROMME P, 1995, CLIN GENET, V48, P1
   Tiranti V, 2004, AM J HUM GENET, V74, P239, DOI 10.1086/381653
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   West JohnF, 1972, EMERGENCE NATION, V0, P0
   Yano S, 2003, J INHERIT METAB DIS, V26, P481, DOI 10.1023/A:1025125427868
   Young GVC, 1979, VIKINGS REFORMATION, V0, P0
NR 30
TC 133
Z9 146
U1 0
U2 10
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
EI 
J9 BRAIN
JI Brain
PD MAR 15
PY 2007
VL 130
IS 
BP 853
EP 861
DI 10.1093/brain/awl383
PG 9
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 145BJ
UT WOS:000244840000024
PM 17287286
DA 2024-11-01
ER

PT J
AU Krishnan, KJ
   Greaves, LC
   Reeve, AK
   Turnbull, D
AF Krishnan, Kim J.
   Greaves, Laura C.
   Reeve, Amy K.
   Turnbull, Doug
TI The ageing mitochondrial genome
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID dna polymerase-gamma; substantia-nigra neurons; somatic mtdna mutations; cytochrome-c-oxidase; muscle-fiber atrophy; human skin; point mutations; control region; in-vivo; parkinsons-disease
AB The population of elderly individuals has increased significantly over the past century and is predicted to rise even more rapidly in the future. Ageing is a major risk factor for many diseases such as neurodegenerative disease, diabetes and cancer. This highlights the importance of understanding the mechanisms involved in the ageing process. One plausible mechanism for ageing is accumulation of mutations in the mitochondrial genome. In this review, we discuss some of the most convincing data surrounding age-related mtDNA mutations and the evidence that these mutations contribute to the ageing process.
C1 [Krishnan, Kim J.; Greaves, Laura C.; Reeve, Amy K.; Turnbull, Doug] Univ Newcastle, Sch Med, Sch Neurol Neurobiol & Psychiat, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Krishnan, Kim J.; Greaves, Laura C.; Reeve, Amy K.; Turnbull, Doug] Univ Newcastle, Sch Med, Inst Ageing & Hlth, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
C3 Newcastle University - UK; Newcastle University - UK
RP Krishnan, KJ (corresponding author), Univ Newcastle, Sch Med, Sch Neurol Neurobiol & Psychiat, Mitochondrial Res Grp, Framlington Place, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM k.j.krishnan@ncl.ac.uk; d.m.turnbull@ncl.ac.uk
FU Medical Research Council [G0700718] Funding Source: Medline; Wellcome Trust Funding Source: Medline
CR Andziak B, 2006, AGING CELL, V5, P463, DOI 10.1111/j.1474-9726.2006.00237.x
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Berneburg M, 2004, J INVEST DERMATOL, V122, P1277, DOI 10.1111/j.0022-202X.2004.22502.x
   Birch-Machin MA, 1998, J INVEST DERMATOL, V110, P149, DOI 10.1046/j.1523-1747.1998.00099.x
   Birket MJ, 2007, AGING CELL, V6, P557, DOI 10.1111/j.1474-9726.2007.00310.x
   Brierley EJ, 1998, ANN NEUROL, V43, P217, DOI 10.1002/ana.410430212
   Bua EA, 2002, J APPL PHYSIOL, V92, P2617, DOI 10.1152/japplphysiol.01102.2001
   Bua E, 2006, AM J HUM GENET, V79, P469, DOI 10.1086/507132
   Chan CS, 2007, NATURE, V447, P1081, DOI 10.1038/nature05865
   Chinnery PF, 2001, AM J HUM GENET, V68, P529, DOI 10.1086/318204
   CORBISIER P, 1993, MECH AGEING DEV, V71, P47, DOI 10.1016/0047-6374(93)90034-O
   CORBISIER P, 1990, EUR J CELL BIOL, V51, P173
   CORRALDEBRINSKI M, 1992, MUTAT RES, V275, P169, DOI 10.1016/0921-8734(92)90021-G
   CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324
   CORTOPASSI GA, 1992, P NATL ACAD SCI USA, V89, P7370, DOI 10.1073/pnas.89.16.7370
   Cottrell DA, 2001, NEUROBIOL AGING, V22, P265, DOI 10.1016/S0197-4580(00)00234-7
   Ekstrand MI, 2007, P NATL ACAD SCI USA, V104, P1325, DOI 10.1073/pnas.0605208103
   Elson JL, 2001, AM J HUM GENET, V68, P802, DOI 10.1086/318801
   FEARNLEY JM, 1991, BRAIN, V114, P2283, DOI 10.1093/brain/114.5.2283
   HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x
   Hoyt KR, 1997, NEUROCHEM RES, V22, P333, DOI 10.1023/A:1022403224901
   Hudson G, 2007, ARCH NEUROL-CHICAGO, V64, P553, DOI 10.1001/archneur.64.4.553
   Hudson G, 2006, HUM MOL GENET, V15, PR244, DOI 10.1093/hmg/ddl233
   Jang YM, 2004, FEBS LETT, V577, P483, DOI 10.1016/j.febslet.2004.10.053
   Jou MJ, 2005, ANN NY ACAD SCI, V1042, P221, DOI 10.1196/annals.1338.024
   Keller JN, 1998, J NEUROSCI, V18, P687
   Kraytsberg Y, 2006, NAT GENET, V38, P518, DOI 10.1038/ng1778
   Krishnan KJ, 2006, J INVEST DERMATOL, V126, P408, DOI 10.1038/sj.jid.5700099
   Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125
   Lee CM, 1998, FREE RADICAL BIO MED, V25, P964, DOI 10.1016/S0891-5849(98)00185-3
   LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4
   Loeb LA, 2005, P NATL ACAD SCI USA, V102, P18769, DOI 10.1073/pnas.0509776102
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   McDonald SAC, 2006, CELL CYCLE, V5, P808, DOI 10.4161/cc.5.8.2641
   Michikawa Y, 1999, SCIENCE, V286, P774, DOI 10.1126/science.286.5440.774
   MULLERHOCKER J, 1992, MUTAT RES, V275, P115, DOI 10.1016/0921-8734(92)90016-I
   Murdock DG, 2000, NUCLEIC ACIDS RES, V28, P4350, DOI 10.1093/nar/28.21.4350
   Nekhaeva E, 2002, P NATL ACAD SCI USA, V99, P5521, DOI 10.1073/pnas.072670199
   Schriner SE, 2005, SCIENCE, V308, P1909, DOI 10.1126/science.1106653
   Short KR, 1999, JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, V22, P95
   SOMEYA S, 2007, NEUROBIOL AGING, V0, P0
   SOONG NW, 1992, NAT GENET, V2, P318
   Sörensen L, 2001, J NEUROSCI, V21, P8082, DOI 10.1523/JNEUROSCI.21-20-08082.2001
   Taylor RW, 2003, J CLIN INVEST, V112, P1351, DOI 10.1172/JCI200319435
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Trifunovic A, 2005, P NATL ACAD SCI USA, V102, P17993, DOI 10.1073/pnas.0508886102
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Van Remmen H, 2003, PHYSIOL GENOMICS, V16, P29, DOI 10.1152/physiolgenomics.00122.2003
   Vermulst M, 2007, NAT GENET, V39, P540, DOI 10.1038/ng1988
   Vives-Bauza C, 2006, NEUROSCI LETT, V391, P136, DOI 10.1016/j.neulet.2005.08.049
   Wanagat J, 2001, FASEB J, V15, P322, DOI 10.1096/fj.00-0320com
   Wang JM, 2001, P NATL ACAD SCI USA, V98, P4038, DOI 10.1073/pnas.061038798
   Wang Y, 2001, P NATL ACAD SCI USA, V98, P4022, DOI 10.1073/pnas.061013598
   Yakubovskaya E, 2006, J BIOL CHEM, V281, P374, DOI 10.1074/jbc.M509730200
   YANG JH, 1995, ARCH DERMATOL RES, V287, P641
   Yao YG, 2007, HUM MOL GENET, V16, P286, DOI 10.1093/hmg/ddl457
NR 56
TC 62
Z9 69
U1 0
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD DEC 15
PY 2007
VL 35
IS 22
BP 7399
EP 7405
DI 10.1093/nar/gkm635
PG 7
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 248BI
UT WOS:000252125900006
PM 17913753
DA 2024-11-01
ER

PT J
AU Horvath, R
   Kley, RA
   Lochmüller, H
   Vorgerd, M
AF Horvath, Rita
   Kley, Rudolf Andre
   Lochmueller, Hanns
   Vorgerd, Matthias
TI Parkinson syndrome, neuropathy, and myopathy caused by the mutation A8344G (MERRF) in tRNA<SUP>Lys</SUP>
SO NEUROLOGY
LA English
DT Article
ID mitochondrial; disease; deletions; family
AB We describe a patient who presented with parkinsonism associated with the A8344G myoclonus epilepsy, ataxia, and myopathy with ragged red fibers mutation in the tRNALys gene. In addition, neurogenic changes and mitochondrial myopathy with ragged red fibers were observed. Neither myoclonus epilepsy nor other clinical signs described in association with A8344G were noted. Similar to previously reported patients with parkinsonism and mtDNA deletions, the symptoms of our patient responded favorably to levodopa therapy.
C1 Med Genet Ctr Munich, D-80335 Munich, Germany.
   Univ Munich, Friedrich Baur Inst, Munich, Germany.
   Univ Munich, Dept Neurol, Munich, Germany.
   Ruhr Univ Bochum, Neuromuscular Ctr Ruhrgebiet, D-4630 Bochum, Germany.
C3 University of Munich; University of Munich; Ruhr University Bochum
RP Horvath, R (corresponding author), Med Genet Ctr Munich, Bayerstr 3-5, D-80335 Munich, Germany.
EM Rita.Horvath@lrz.uni-muenchen.de
CR Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Casali C, 2001, NEUROLOGY, V56, P802, DOI 10.1212/WNL.56.6.802
   De Coo IFM, 1999, ANN NEUROL, V45, P130, DOI 10.1002/1531-8249(199901)45:1<130::AID-ART21>3.0.CO;2-Z
   Jain S, 2005, CLIN SCI, V109, P355, DOI 10.1042/CS20050106
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Mancuso M, 2004, ARCH NEUROL-CHICAGO, V61, P1777, DOI 10.1001/archneur.61.11.1777
   SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N
   Siciliano G, 2001, J NEUROL NEUROSUR PS, V71, P685, DOI 10.1136/jnnp.71.5.685
   SILVESTRI G, 1993, NEUROLOGY, V43, P1200, DOI 10.1212/WNL.43.6.1200
   VANERVEN PMM, 1989, DEV MED CHILD NEUROL, V31, P81
NR 10
TC 56
Z9 61
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 
J9 NEUROLOGY
JI Neurology
PD JAN 2
PY 2007
VL 68
IS 1
BP 56
EP 58
DI 10.1212/01.wnl.0000250334.48038.7a
PG 3
WC Clinical Neurology
SC Neurosciences & Neurology
GA 122KA
UT WOS:000243224000014
PM 17200493
DA 2024-11-01
ER

PT J
AU DiMauro, S
   Mancuso, M
AF DiMauro, Salvatore
   Mancuso, Michelangelo
TI Mitochondrial diseases: Therapeutic approaches
SO BIOSCIENCE REPORTS
LA English
DT Article; Proceedings Paper
DE mtDNA; mitochondrial diseases; therapy
ID progressive external ophthalmoplegia; systemic carnitine deficiency; nadh-quinone oxidoreductase; complex-iii deficiency; skeletal-muscle; coenzyme q(10); oxidase activity; lactic-acidosis; point mutation; dna depletion
AB Therapy of mitochondrial encephalomyopathies (defined restrictively as defects of the mitochondrial respiratory chain) is woefully inadequate, despite great progress in our understanding of the molecular bases of these disorders. In this review, we consider sequentially several different therapeutic approaches. Palliative therapy is dictated by good medical practice and includes anticonvulsant medication, control of endocrine dysfunction, and surgical procedures. Removal of noxious metabolites is centered on combating lactic acidosis, but extends to other metabolites. Attempts to bypass blocks in the respiratory chain by administration of electron acceptors have not been successful, but this may be amenable to genetic engineering. Administration of metabolites and cofactors is the mainstay of real-life therapy and is especially important in disorders due to primary deficiencies of specific compounds, such as carnitine or coenzyme Q10. There is increasing interest in the administration of reactive oxygen species scavengers both in primary mitochondrial diseases and in neurodegenerative diseases directly or indirectly related to mitochondrial dysfunction. Aerobic exercise and physical therapy prevent or correct deconditioning and improve exercise tolerance in patients with mitochondrial myopathies due to mitochondrial DNA (mtDNA) mutations. Gene therapy is a challenge because of polyplasmy and heteroplasmy, but interesting experimental approaches are being pursued and include, for example, decreasing the ratio of mutant to wild-type mitochondrial genomes (gene shifting), converting mutated mtDNA genes into normal nuclear DNA genes (allotopic expression), importing cognate genes from other species, or correcting mtDNA mutations with specific restriction endonucleases. Germline therapy raises ethical problems but is being considered for prevention of maternal transmission of mtDNA mutations. Preventive therapy through genetic counseling and prenatal diagnosis is becoming increasingly important for nuclear DNA-related disorders. Progress in each of these approaches provides some glimmer of hope for the future, although much work remains to be done.
C1 Columbia Univ, Med Ctr, Dept Neurol, New York, NY 10032 USA.
   Univ Pisa, Dept Neurosci, I-56100 Pisa, Italy.
C3 Columbia University; University of Pisa
RP DiMauro, S (corresponding author), Columbia Univ, Med Ctr, Dept Neurol, 4-420 Coll Phys & Surg,630 W 168th St, New York, NY 10032 USA.
EM sd12@columbia.edu
CR ALLEN RJ, 1983, ANN NEUROL, V13, P679, DOI 10.1002/ana.410130620
   Andrews RM, 1999, EYE, V13, P769, DOI 10.1038/eye.1999.225
   ARGOV Z, 1986, ANN NEUROL, V19, P598, DOI 10.1002/ana.410190615
   Bai YD, 2001, J BIOL CHEM, V276, P38808, DOI 10.1074/jbc.M106363200
   Barritt JA, 2001, HUM REPROD, V16, P513, DOI 10.1093/humrep/16.3.513
   BAYONABAFULUY MP, 2002, P NATL ACAD SCI USA, V102, P14392
   Beal MF, 2005, ANN NEUROL, V58, P495, DOI 10.1002/ana.20624
   BERNES SM, 1993, J PEDIATR-US, V123, P598, DOI 10.1016/S0022-3476(05)80962-X
   Bohlega S, 1996, NEUROLOGY, V46, P1329, DOI 10.1212/WNL.46.5.1329
   Chinnery P, 2006, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD004426.pub2
   Chinnery PF, 1999, GENE THER, V6, P1919, DOI 10.1038/sj.gt.3301061
   Clark KM, 1997, NAT GENET, V16, P222, DOI 10.1038/ng0797-222
   DEVIVO DC, 1999, PEDIAT NEUROLOGY PRI, V0, P494
   Di Giovanni S, 2001, NEUROLOGY, V57, P515, DOI 10.1212/WNL.57.3.515
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   DIMAURO S, 1976, J NEUROL SCI, V27, P217, DOI 10.1016/0022-510X(76)90063-0
   DiMauro S, 2006, MITOCHONDRIAL MEDICINE, V0, P261
   Dubern B, 2001, TRANSPLANTATION, V71, P633, DOI 10.1097/00007890-200103150-00009
   ELEFF S, 1984, P NATL ACAD SCI-BIOL, V81, P3529, DOI 10.1073/pnas.81.11.3529
   Ferrante KL, 2005, NEUROLOGY, V65, P1834, DOI 10.1212/01.wnl.0000187070.35365.d7
   Fu K, 1996, HUM MOL GENET, V5, P1835, DOI 10.1093/hmg/5.11.1835
   Guy J, 2002, ANN NEUROL, V52, P534, DOI 10.1002/ana.10354
   HAYDAR NA, 1971, ANN INTERN MED, V74, P548, DOI 10.7326/0003-4819-74-4-548
   Jaksch M, 2001, HUM MOL GENET, V10, P3025, DOI 10.1093/hmg/10.26.3025
   Karadimas CL, 2000, NEUROLOGY, V55, P644, DOI 10.1212/WNL.55.5.644
   Kaufmann P, 2006, NEUROLOGY, V66, P324, DOI 10.1212/01.wnl.0000196641.05913.27
   Kaufmann P, 2004, NEUROLOGY, V62, P1297, DOI 10.1212/01.WNL.0000120557.83907.A8
   Keightley JA, 2000, AM J HUM GENET, V67, P1400, DOI 10.1086/316900
   KENNAWAY NG, 1984, PEDIATR RES, V18, P991
   Kolesnikova OA, 2000, SCIENCE, V289, P1931, DOI 10.1126/science.289.5486.1931
   Kolesnikova OA, 2004, HUM MOL GENET, V13, P2519, DOI 10.1093/hmg/ddh267
   Mancuso M, 2006, J ALZHEIMERS DIS, V10, P59
   Manfred G, 1999, J BIOL CHEM, V274, P9386, DOI 10.1074/jbc.274.14.9386
   Manfredi G, 2002, NAT GENET, V30, P394, DOI 10.1038/ng851
   MATSUOKA T, 1992, NEUROMUSCULAR DISORD, V1, P443
   Nezu JI, 1999, NAT GENET, V21, P91, DOI 10.1038/5030
   Nishino I, 2000, ANN NEUROL, V47, P792
   Ojaimi J, 2002, MOL BIOL CELL, V13, P3836, DOI 10.1091/mbc.E02-05-0306
   Papadopoulou LC, 1999, NAT GENET, V23, P333
   Puoti G, 2003, J MED GENET, V40, P858, DOI 10.1136/jmg.40.11.858
   Qi XP, 2004, ANN NEUROL, V56, P182, DOI 10.1002/ana.20175
   Qi XP, 2003, INVEST OPHTH VIS SCI, V44, P1088, DOI 10.1167/iovs.02-0864
   Qi XP, 2003, ANN NEUROL, V53, P198, DOI 10.1002/ana.10426
   Quinzii CM, 2007, NEUROCHEM RES, V32, P723, DOI 10.1007/s11064-006-9190-z
   Salviati L, 2002, ANN NEUROL, V52, P311, DOI 10.1002/ana.10284
   Salviati L, 2002, BIOCHEM J, V363, P321, DOI 10.1042/0264-6021:3630321
   Santorelli FM, 2002, NEUROMUSCULAR DISORD, V12, P56, DOI 10.1016/S0960-8966(01)00248-6
   Santra S, 2004, ANN NEUROL, V56, P662, DOI 10.1002/ana.20240
   Seo BB, 1998, P NATL ACAD SCI USA, V95, P9167, DOI 10.1073/pnas.95.16.9167
   Shanske S, 2002, AM J HUM GENET, V71, P679, DOI 10.1086/342482
   Shoubridge EA, 1997, HUM MOL GENET, V6, P2239, DOI 10.1093/hmg/6.13.2239
   Shults CW, 2002, ARCH NEUROL-CHICAGO, V59, P1541, DOI 10.1001/archneur.59.10.1541
   Spinazzola A, 2002, J BIOL CHEM, V277, P4128, DOI 10.1074/jbc.M111028200
   STACPOOLE PW, 1989, METABOLISM, V38, P1124, DOI 10.1016/0026-0495(89)90051-6
   Sue CM, 1998, ANN NEUROL, V43, P350, DOI 10.1002/ana.410430313
   Taanman JW, 2003, HUM MOL GENET, V12, P1839, DOI 10.1093/hmg/ddg192
   Taivassalo T, 1999, HUM MOL GENET, V8, P1047, DOI 10.1093/hmg/8.6.1047
   Taivassalo T, 2005, MED SCI SPORT EXER, V37, P2094, DOI 10.1249/01.mss.0000177446.97671.2a
   Taivassalo T, 2004, BBA-BIOENERGETICS, V1659, P221, DOI 10.1016/j.bbabio.2004.09.007
   Tanaka M, 2002, J BIOMED SCI, V9, P534, DOI 10.1007/BF02254980
   Tarnopolsky MA, 1997, MUSCLE NERVE, V20, P1502, DOI 10.1002/(SICI)1097-4598(199712)20:12<1502::AID-MUS4>3.0.CO;2-C
   Taylor RW, 1997, NAT GENET, V15, P212, DOI 10.1038/ng0297-212
   TEIN I, 1990, PEDIATR RES, V28, P247, DOI 10.1203/00006450-199009000-00020
   TEIN I, 1993, PEDIATR RES, V34, P281, DOI 10.1203/00006450-199309000-00008
NR 64
TC 96
Z9 108
U1 0
U2 16
PU PORTLAND PRESS LTD
PI LONDON
PA 5TH FLR, 90 HIGH HOLBORN, LONDON WC1V 6LJ, ENGLAND
SN 0144-8463
EI 1573-4935
J9 BIOSCIENCE REP
JI Biosci. Rep.
PD JUN 15
PY 2007
VL 27
IS 1-3
BP 125
EP 137
DI 10.1007/s10540-007-9041-4
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 178YM
UT WOS:000247256300012
PM 17486439
DA 2024-11-01
ER

PT J
AU Alemi, M
   Prigione, A
   Wong, A
   Schoenfeld, R
   DiMauro, S
   Hirano, M
   Taroni, F
   Cortopassi, G
AF Alemi, Mansour
   Prigione, Alessandro
   Wong, Alice
   Schoenfeld, Robert
   DiMauro, Salvatore
   Hirano, Michio
   Taroni, Franco
   Cortopassi, Gino
TI Mitochondrial DNA deletions inhibit proteasomal activity and stimulate an autophagic transcript
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Article
ID progressive external ophthalmoplegia; skeletal-muscle; oxidized proteins; oxidative stress; amino-acids; human-cells; gene-expression; energy demand; transfer-rna; mtdna
AB Deletions within the mitochondrial DNA (mtDNA) cause Kearns Sayre syndrome (KSS) and chronic progressive external opthalmoplegia (CPEO). The clinical signs of KSS include muscle weakness, heart block, pigmentary retinopathy, ataxia, deafness, short stature, and dementia. The identical deletions occur and rise exponentially as humans age; particularly in substantia nigra. Deletions at > 30% concentration cause deficits in basic bioenergetic parameters, including membrane potential and ATP synthesis, but it is poorly understood how these alterations cause the pathologies observed in patients. To better understand the consequences of mtDNA deletions, we microarrayed six cell types containing mtDNA deletions from KSS and CPEO patients. There was a prominent inhibition of transcripts encoding ubiquitin-mediated proteasome activity, and a prominent induction of transcripts involved in the AMP kinase pathway, macroautophagy, and amino acid degradation. In mutant cells, we confirmed a decrease in proteasome biochemical activity, significantly lower concentration of several amino acids, and induction of an autophagic transcript. An interpretation consistent with the data is that mtDNA deletions increase protein damage, inhibit the ubiquitin-proteasome system, decrease amino acid salvage, and activate autophagy. This provides a novel pathophysiological mechanism for these diseases, and suggests potential therapeutic strategies. (c) 2006 Elsevier Inc. All rights reserved.
C1 Univ Calif Davis, Dept Mol Biosci, Davis, CA 95616 USA.
   Columbia Univ, Ctr Med, Dept Neurol, New York, NY 10032 USA.
   Ist Nazl Neurol Carlo Besta, Div Biochem & Genet, Milan, Italy.
C3 University of California System; University of California Davis; Columbia University; Fondazione IRCCS Istituto Neurologico Carlo Besta
RP Cortopassi, G (corresponding author), Univ Calif Davis, Dept Mol Biosci, 1311 Haring Hall, Davis, CA 95616 USA.
EM gcortopassi@ucdavis.edu
FU NCI NIH HHS [R01 CA042742] Funding Source: Medline; NEI NIH HHS [EY12245, R01 EY012245] Funding Source: Medline; NIA NIH HHS [R01 AG011967, R03 AG023311, R01 AG016719, AG16719, R01 AG11967] Funding Source: Medline; NIEHS NIH HHS [P30 ES005707] Funding Source: Medline; NINDS NIH HHS [R01 NS077777] Funding Source: Medline; PHS HHS [V440C21] Funding Source: Medline
CR Anthony JC, 2000, J NUTR, V130, P2413
   Anthony JC, 1999, J NUTR, V129, P1102, DOI 10.1093/jn/129.6.1102
   ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cb.04.110188.001445
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Betarbet R, 2006, NEUROBIOL DIS, V22, P404, DOI 10.1016/j.nbd.2005.12.003
   Bolster DR, 2002, J BIOL CHEM, V277, P23977, DOI 10.1074/jbc.C200171200
   Bossy-Wetzel E, 1999, MUTAT RES-DNA REPAIR, V434, P243, DOI 10.1016/S0921-8777(99)00032-4
   Brierley EJ, 1997, MOL CELL BIOCHEM, V174, P325, DOI 10.1023/A:1006847319162
   Cao ZJ, 2001, NUCLEIC ACIDS RES, V29, P4502, DOI 10.1093/nar/29.21.4502
   Carelli V, 2002, BBA-MOL BASIS DIS, V1588, P7, DOI 10.1016/S0925-4439(02)00097-2
   Charrueau C, 2000, J GASTROEN HEPATOL, V15, P1199, DOI 10.1046/j.1440-1746.2000.02310.x
   CHEN X, 1995, AM J HUM GENET, V57, P239
   Cherkasova VA, 2003, GENE DEV, V17, P859, DOI 10.1101/gad.1069003
   Chinnery PF, 2003, J NEUROL NEUROSUR PS, V74, P1188, DOI 10.1136/jnnp.74.9.1188
   CORTOPASSI G, 2006, IN PRESS MITOCHONDRI, V0, P0
   CORTOPASSI GA, 1992, P NATL ACAD SCI USA, V89, P7370, DOI 10.1073/pnas.89.16.7370
   Danielson SR, 2005, BRAIN, V128, P1026, DOI 10.1093/brain/awh447
   Darsow T, 1997, J CELL BIOL, V138, P517, DOI 10.1083/jcb.138.3.517
   Davies KJA, 2006, NEUROLOGY, V66, PS93, DOI 10.1212/01.wnl.0000192308.43151.63
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Gellerich FN, 2002, BBA-BIOENERGETICS, V1556, P41, DOI 10.1016/S0005-2728(02)00305-5
   Gibson BW, 2005, INT J BIOCHEM CELL B, V37, P927, DOI 10.1016/j.biocel.2004.11.013
   Grune T, 2004, INT J BIOCHEM CELL B, V36, P2519, DOI 10.1016/j.biocel.2004.04.020
   HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Inoue K, 2000, NAT GENET, V26, P176, DOI 10.1038/82826
   Ishihara N, 2001, MOL BIOL CELL, V12, P3690, DOI 10.1091/mbc.12.11.3690
   Iwata A, 2005, J BIOL CHEM, V280, P40282, DOI 10.1074/jbc.M508786200
   Jacobs HT, 2003, HUM MOL GENET, V12, PR293, DOI 10.1093/hmg/ddg285
   James AM, 1999, EUR J BIOCHEM, V259, P462, DOI 10.1046/j.1432-1327.1999.00066.x
   Jefferson LS, 2003, J NUTR, V133, P2046S, DOI 10.1093/jn/133.6.2046S
   JOHNS DR, 1989, P NATL ACAD SCI USA, V86, P8059, DOI 10.1073/pnas.86.20.8059
   Jou MJ, 2005, ANN NY ACAD SCI, V1042, P221, DOI 10.1196/annals.1338.024
   Kadowaki M, 2003, J NUTR, V133, P2052S, DOI 10.1093/jn/133.6.2052S
   KATAYAMA M, 1991, BIOCHEM INT, V25, P47
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kemp BE, 1999, TRENDS BIOCHEM SCI, V24, P22, DOI 10.1016/S0968-0004(98)01340-1
   Khatri P, 2002, GENOMICS, V79, P266, DOI 10.1006/geno.2002.6698
   Kimball S R, 2001, PROG MOL SUBCELL BIOL, V26, P155
   KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Kopsidas G, 1998, MUTAT RES-FUND MOL M, V421, P27, DOI 10.1016/S0027-5107(98)00150-X
   Kraytsberg Y, 2006, NAT GENET, V38, P518, DOI 10.1038/ng1778
   Li F, 2005, MOL CELL BIOL, V25, P6225, DOI 10.1128/MCB.25.14.6225-6234.2005
   Lim PS, 2002, J BIOMED SCI, V9, P549, DOI 10.1159/000064728
   Lindsley JE, 2004, COMP BIOCHEM PHYS B, V139, P543, DOI 10.1016/j.cbpc.2004.06.014
   Lu CY, 1999, MUTAT RES-FUND MOL M, V423, P11, DOI 10.1016/S0027-5107(98)00220-6
   McFarland R, 2002, LANCET NEUROL, V1, P343, DOI 10.1016/S1474-4422(02)00159-X
   Miceli MV, 2005, EXP CELL RES, V302, P270, DOI 10.1016/j.yexcr.2004.09.006
   MITA S, 1989, P NATL ACAD SCI USA, V86, P9509, DOI 10.1073/pnas.86.23.9509
   Mizushima N, 2003, INT J BIOCHEM CELL B, V35, P553, DOI 10.1016/S1357-2725(02)00343-6
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   MORAES CT, 1995, MUSCLE NERVE, V0, PS150
   Nakada K, 2002, MITOCHONDRION, V2, P59, DOI 10.1016/S1567-7249(02)00007-7
   NAKASE H, 1990, AM J HUM GENET, V46, P418
   Pesce V, 2001, FREE RADICAL BIO MED, V30, P1223, DOI 10.1016/S0891-5849(01)00517-2
   Porteous WK, 1998, EUR J BIOCHEM, V257, P192, DOI 10.1046/j.1432-1327.1998.2570192.x
   Powell SR, 2005, FREE RADICAL BIO MED, V38, P1093, DOI 10.1016/j.freeradbiomed.2005.01.003
   Reggiori F, 2004, MOL BIOL CELL, V15, P2189, DOI 10.1091/mbc.E03-07-0479
   Rollins S, 2001, AM J CLIN PATHOL, V116, P326
   ROTIG A, 1990, J CLIN INVEST, V86, P1601, DOI 10.1172/JCI114881
   Santorelli FM, 1996, NEUROLOGY, V47, P1320, DOI 10.1212/WNL.47.5.1320
   Schadt EE, 2001, J CELL BIOCHEM, V84, P120, DOI 10.1002/jcb.10073
   SCHON EA, 1989, SCIENCE, V244, P346, DOI 10.1126/science.2711184
   Shamoto-Nagai M, 2003, J NEUROSCI RES, V74, P589, DOI 10.1002/jnr.10777
   Shorer H, 2005, J BIOL CHEM, V280, P16219, DOI 10.1074/jbc.M500554200
   Short KR, 2005, P NATL ACAD SCI USA, V102, P5618, DOI 10.1073/pnas.0501559102
   SIMONETTI S, 1992, BIOCHIM BIOPHYS ACTA, V1180, P113, DOI 10.1016/0925-4439(92)90059-V
   Simonsen A, 1998, EUR J CELL BIOL, V75, P223, DOI 10.1016/S0171-9335(98)80116-7
   Slocum RH, 1991, TECHNIQUES DIAGNOSTI, V0, P87
   SOONG NW, 1992, NAT GENET, V2, P318
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   SUDOYO H, 1993, J NEUROL SCI, V117, P83, DOI 10.1016/0022-510X(93)90159-V
   Sullivan PG, 2004, J BIOL CHEM, V279, P20699, DOI 10.1074/jbc.M313579200
   Vabulas RM, 2005, SCIENCE, V310, P1960, DOI 10.1126/science.1121925
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Vielhaber S, 2000, BIOCHEM SOC T, V28, P159, DOI 10.1042/bst0280159
   Wang ED, 1997, MUTAT RES-FUND MOL M, V377, P157, DOI 10.1016/S0027-5107(97)00091-2
   Wang Y, 2005, MOL MEMBR BIOL, V22, P313, DOI 10.1080/09687860500143829
   Wei YH, 2001, ANN NY ACAD SCI, V928, P97
   WEK SA, 1995, MOL CELL BIOL, V15, P4497
   Wonsey DR, 2005, CANCER RES, V65, P5181, DOI 10.1158/0008-5472.CAN-04-4059
   Wonsey DR, 2002, P NATL ACAD SCI USA, V99, P6649, DOI 10.1073/pnas.102523299
   ZEVIANI M, 1995, BBA-MOL BASIS DIS, V1271, P153, DOI 10.1016/0925-4439(95)00022-V
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
NR 85
TC 40
Z9 45
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0891-5849
EI 1873-4596
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD JAN 1
PY 2007
VL 42
IS 1
BP 32
EP 43
DI 10.1016/j.freeradbiomed.2006.09.014
PG 12
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 118WW
UT WOS:000242975200003
PM 17157191
DA 2024-11-01
ER

PT J
AU Caballero, PEJ
   Candela, MS
   Alvarez, CIC
   Tejerina, AA
AF Jimenez Caballero, Pedro Enrique
   Servia Candela, Monica
   Cabeza Alvarez, Clara Isabel
   Alvarez Tejerina, Araceli
TI Chronic progressive external ophthalmoplegia - A report of 6 cases and a review of the literature
SO NEUROLOGIST
LA English
DT Article
DE chronic progressive external ophthalmoplegia; mitochondrial disease; ragged-red fibers; jitter
ID mitochondrial-dna; a3243g mutation; deletions; encephalomyopathy; myopathy; features; disease
AB Introduction: Chronic progressive external ophthalmoplegia is a common mitochondrial disease that shares clinical, enzymatic, and genetic features with other mitochondrial disorders. Effective treatment does not exist, and corrective surgery of the ptosis as a palliative measure is a treatment option. Patients and Methods: This was a retrospective study of 10 years' duration gathering patients with the diagnosis. Information related to clinical features, ancillary tests, and genetic data was obtained from our patients. Results: Six patients were identified with this disease, 5 of them women, aged 44 to 72 years. All patients presented with ptosis, and in 50% of the patients it was asymmetric. Half of the patients noted mild dysphagia for liquids. The CPK and acetylcholine receptor antibody levels were normal. Jitter was increased in half of the patients and ragged-red fibers were present in 5 of them. The most common enzyme alteration was the combined deficit of complexes I and IV. Familial forms were not found among our patients. The most common genetic anomaly was a single deletion in the mitochondrial DNA. Conclusion: Knowledge of this disorder enables us to avoid the use of drugs with significant side effects in cases of ptosis and ophthalmoplegia that do not respond to anticholinesterases.
C1 Hosp Virgen Salud, Dept Neurol, Toledo, Spain.
   Hosp Virgen Salud, Dept Clin Biochem, Toledo, Spain.
C3 Complejo Hospitalario de Toledo; Complejo Hospitalario de Toledo
RP Caballero, PEJ (corresponding author), Calle Murillo 14, Bargas, Toledo, Spain.
EM pjimenez1010j@yahoo.es
CR Arpa-Gutiérrez FJ, 2005, REV NEUROLOGIA, V41, P449, DOI 10.33588/rn.4108.2005206
   Becker R, 2002, METABOLISM, V51, P796, DOI 10.1053/meta.2002.32625
   BERENBERG RA, 1977, ANN NEUROL, V1, P37, DOI 10.1002/ana.410010104
   CESEN W, 1972, ARCH NEUROL-CHICAGO, V26, P193
   COHEN JM, 1997, J AM OPTOM ASSOC, V155, P57
   Daut PM, 2000, AM J OPHTHALMOL, V130, P519, DOI 10.1016/S0002-9394(00)00558-4
   Deschauer M, 2001, NERVENARZT, V72, P122, DOI 10.1007/s001150050724
   Drouet A, 1996, REV MED INTERNE, V17, P200, DOI 10.1016/0248-8663(96)81246-X
   HAMMANS SR, 1991, LANCET, V337, P1311, DOI 10.1016/0140-6736(91)92981-7
   Hansrote S, 2002, J NEUROL SCI, V197, P63, DOI 10.1016/S0022-510X(02)00048-5
   Hart PE, 2002, MITOCHONDRIAL DISORDERS IN NEUROLOGY, V2, P35
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   HOLT IJ, 1989, ANN NEUROL, V26, P699, DOI 10.1002/ana.410260603
   Koga Y, 2000, ACTA NEUROPATHOL, V99, P186, DOI 10.1007/PL00007423
   Kornblum C, 2004, KLIN MONATSBL AUGENH, V221, P1057, DOI 10.1055/s-2004-813830
   MARIOTTI C, 1995, J NEUROL, V242, P304, DOI 10.1007/BF00878873
   MITSIKOSTAS D, 1995, FUNCT NEUROL, V10, P209
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   Okulla T, 2005, GRAEF ARCH CLIN EXP, V243, P380, DOI 10.1007/s00417-004-1000-1
   PETTY RKH, 1986, BRAIN, V109, P915, DOI 10.1093/brain/109.5.915
   Pineda M, 2004, REV NEUROLOGIA, V38, P1023, DOI 10.33588/rn.3811.2004019
   Richardson C, 2005, EYE, V19, P258, DOI 10.1038/sj.eye.6701488
   ROBERTS NK, 1979, AM J CARDIOL, V44, P1396, DOI 10.1016/0002-9149(79)90459-4
   Rossier J, 1996, KLIN MONATSBL AUGENH, V208, P366, DOI 10.1055/s-2008-1035241
   ROWLAND LP, 1991, REV NEUROL-FRANCE, V147, P467
   Schaefer AM, 2005, MUSCLE NERVE, V32, P104, DOI 10.1002/mus.20319
   TRUONG DD, 1990, MOVEMENT DISORD, V5, P109, DOI 10.1002/mds.870050204
   Walker UA, 1996, EUR NEUROL, V36, P260, DOI 10.1159/000117269
   Wong VA, 2002, OPHTHALMOLOGY, V109, P1023, DOI 10.1016/S0161-6420(02)01009-6
NR 29
TC 26
Z9 27
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1074-7931
EI 2331-2637
J9 NEUROLOGIST
JI Neurologist
PD JAN 15
PY 2007
VL 13
IS 1
BP 33
EP 36
DI 10.1097/01.nrl.0000252953.49721.f5
PG 4
WC Clinical Neurology
SC Neurosciences & Neurology
GA 123ML
UT WOS:000243299900005
PM 17215725
DA 2024-11-01
ER

PT J
AU Coulbault, L
   Deslandes, B
   Herlicoviez, D
   Read, MH
   Leporrier, N
   Schaeffer, S
   Mouadil, A
   Lombès, A
   Chapon, F
   Jauzac, P
   Allouche, S
AF Coulbault, L.
   Deslandes, B.
   Herlicoviez, D.
   Read, M. H.
   Leporrier, N.
   Schaeffer, S.
   Mouadil, A.
   Lombes, A.
   Chapon, F.
   Jauzac, P.
   Allouche, S.
TI A novel mutation 3090 G &gt; A of the mitochondrial 16S ribosomal RNA associated with myopathy
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE mitochondrial myopathy; mtDNA; 16S ribosomal RNA gene mutation; combined respiratory chain deficiency
ID dna; sequence; gene
AB We describe a young woman who presented with a progressive myopathy since the age of 9. Spectrophotometric analysis of the respiratory chain in muscle tissue revealed combined and profound complex I, III, II + III, and IV deficiency ranging from 60% to 95% associated with morphological and histochemical abnormalities of the muscle. An exhaustive screening of mitochondrial transfer and ribosomal RNAs showed a novel G > A substitution at nucleotide position 3090 which was detected only in urine sediment and muscle of the patient and was not found in her mother's blood cells and urine sample. We suggest that this novel de novo mutation in the 16S ribosomal RNA, a nucleotide which is highly conserved in different species, would impair mitochondrial protein synthesis and would cause a severe myopathy. (c) 2007 Elsevier Inc. All rights reserved.
C1 Ctr Hosp Univ Caen, Biochem Lab, Ave Cote de Nacre, F-14033 Caen, France.
   Ctr Hosp Univ Caen, Serv Anat Pathol, F-14033 Caen, France.
   Ctr Hosp Univ Caen, Dept Genet & Reprod, F-14033 Caen, France.
   Ctr Hosp Univ Caen, Serv Neurol, F-14033 Caen, France.
   Ctr Hosp Univ Caen, Lab Explorat Fonctionnelles, F-14033 Caen, France.
   INSERM, U 582, CHUPS, Inst Myol, F-75013 Paris, France.
C3 CHU de Caen NORMANDIE; Universite de Caen Normandie; CHU de Caen NORMANDIE; Universite de Caen Normandie; Universite de Caen Normandie; CHU de Caen NORMANDIE; CHU de Caen NORMANDIE; Universite de Caen Normandie; Universite de Caen Normandie; CHU de Caen NORMANDIE; Institut National de la Sante et de la Recherche Medicale (Inserm); Sorbonne Universite
RP Allouche, S (corresponding author), Ctr Hosp Univ Caen, Biochem Lab, Ave Cote de Nacre, F-14033 Caen, France.
EM allouche-s@chu-caen.fr
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Bayona-Bafaluy MP, 2003, NUCLEIC ACIDS RES, V31, P5349, DOI 10.1093/nar/gkg739
   Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500
   Di Fonzo A, 2003, HUM MUTAT, V22, P0, DOI 10.1002/humu.9203
   DiMauro S, 2005, CURR OPIN NEUROL, V18, P538, DOI 10.1097/01.wco.0000179761.63486.1a
   Hsieh RH, 2001, J BIOMED SCI, V8, P328, DOI 10.1159/000054051
   Malgat M, 1999, MITOCHONDRIAL DISEASES, V0, PP357, DOI 10.1007/978-3-642-59884-5_27
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   May-Panloup P, 2003, HUM REPROD, V18, P550, DOI 10.1093/humrep/deg096
   Mollet J, 2007, J CLIN INVEST, V117, P765, DOI 10.1172/JCI29089
   Napoli L, 2001, NEUROLOGY, V57, P2295, DOI 10.1212/WNL.57.12.2295
   Nishibori M, 2005, ANIM GENET, V36, P367, DOI 10.1111/j.1365-2052.2005.01318.x
   REYNIER P, 1999, MITOCHONDRIAL DIS, V0, P379
   Romero NB, 1999, MITOCHONDRIAL DISEASES- MODELS AND METHODS, V0, P343
   Schlick NE, 2006, AM J PHYSIOL-CELL PH, V291, PC1183, DOI 10.1152/ajpcell.00234.2006
   SHOFFNER JM, 1993, GENOMICS, V17, P171, DOI 10.1006/geno.1993.1299
   Tang J, 1997, PEDIATR NEUROL, V17, P327, DOI 10.1016/S0887-8994(97)00151-3
NR 18
TC 18
Z9 19
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD OCT 26
PY 2007
VL 362
IS 3
BP 601
EP 605
DI 10.1016/j.bbrc.2007.08.040
PG 5
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 212NG
UT WOS:000249602700011
PM 17761147
DA 2024-11-01
ER

PT J
AU Scuderi, C
   Borgione, E
   Musumeci, S
   Elia, M
   Castello, F
   Fichera, M
   Davidzon, G
   DiMauro, S
AF Scuderi, Carmela
   Borgione, Eugenia
   Musumeci, Sebastiano
   Elia, Maurizio
   Castello, Filippa
   Fichera, Marco
   Davidzon, Guido
   DiMauro, Salvatore
TI Severe encephalomyopathy in a patient with homoplasmic A5814G point mutation in mitochondrial tRNA<SUP>Cys</SUP> gene
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE mitochondrial DNA; tRNA(Cys); homoplasmic mutation; nuclear factors
ID myopathy; mutant; dna
AB We report a patient with severe encephalomyopathy and homoplasmic A5814G point mutation in the mitochondrial DNA tRNA gene for cysteine. This mutation had been reported in heteroplasmic condition in patients with different clinical phenotypes. Our results confirm the pathogenicity of the mutation and support the concept that homoplasmic mutations in tRNA genes can be responsible for mitochondrial disorders with variable penetrance. This report also extends the clinical spectrum associated with the A5814G mutation. (C) 2006 Elsevier B.V. All rights reserved.
C1 IRCCS Oasi Maria SS, Dipartimento Neurol, Troina, Italy.
   IRCCS Oasi Maria SS, Lab Neuropatol Clin, Troina, Italy.
   IRCCS Oasi Maria SS, Lab Diag Genet, Troina, Italy.
   Columbia Univ, Med Ctr, Dept Neurol, New York, NY 10032 USA.
C3 IRCCS Oasi Maria SS; IRCCS Oasi Maria SS; IRCCS Oasi Maria SS; Columbia University
RP Scuderi, C (corresponding author), IRCCS Oasi Maria SS, Dipartimento Neurol, Troina, Italy.
EM cscuderi@oasi.en.it
FU NICHD NIH HHS [HD32062] Funding Source: Medline; NINDS NIH HHS [NS11766] Funding Source: Medline
CR Carelli V, 2002, MITOCHONDRIAL DISORD, V0, P115
   Chinnery PF, 1999, AM J MED GENET, V85, P498
   DiMauro S, 2005, NEUROMUSCULAR DISORD, V15, P276, DOI 10.1016/j.nmd.2004.12.008
   DUNBAR DR, 1995, P NATL ACAD SCI USA, V92, P6562, DOI 10.1073/pnas.92.14.6562
   Karadimas C, 2001, J CHILD NEUROL, V16, P531, DOI 10.1177/088307380101600715
   Manfredi G, 1996, HUM MUTAT, V7, P158
   McFarland R, 2004, ANN NEUROL, V55, P478, DOI 10.1002/ana.20004
   PREZANT TR, 1993, NAT GENET, V4, P289, DOI 10.1038/ng0793-289
   Santorelli FM, 1996, PEDIATR NEUROL, V15, P145, DOI 10.1016/0887-8994(96)00163-4
   Santorelli FM, 1997, NEUROMUSCULAR DISORD, V7, P156, DOI 10.1016/S0960-8966(97)00444-6
   Taylor RW, 2003, J AM COLL CARDIOL, V41, P1786, DOI 10.1016/S0735-1097(03)00300-0
   TULINIUS MH, 1991, J PEDIATR-US, V119, P251, DOI 10.1016/S0022-3476(05)80735-8
NR 12
TC 13
Z9 14
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD MAR 15
PY 2007
VL 17
IS 3
BP 258
EP 261
DI 10.1016/j.nmd.2006.11.006
PG 4
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 162WG
UT WOS:000246119600011
PM 17241783
DA 2024-11-01
ER

PT J
AU Hakonen, AH
   Isohanni, P
   Paetau, A
   Herva, R
   Suomalainen, A
   Lönnqvist, T
AF Hakonen, Anna H.
   Isohanni, Pirjo
   Paetau, Anders
   Herva, Riitta
   Suomalainen, Anu
   Loennqvist, Tuula
TI Recessive Twinkle mutations in early onset encephalopathy with mtDNA depletion
SO BRAIN
LA English
DT Article
DE twinkle; IOSCA; Alpers; encephalopathy; mtDNA
ID mitochondrial-dna depletion; progressive external ophthalmoplegia; spinocerebellar ataxia; multiple deletions; polg mutations; sensory neuropathy; alpers-syndrome; gene; disease; degeneration
AB Twinkle is a mitochondrial replicative helicase, the mutations of which have been associated with autosomal dominant progressive external ophthalmoplegia (adPEO), and recessively inherited infantile onset spinocerebellar ataxia (IOSCA). We report here a new phenotype in two siblings with compound heterozygous Twinkle mutations (A318T and Y508C), characterized by severe early onset encephalopathy and signs of liver involvement. The clinical manifestations included hypotonia, athetosis, sensory neuropathy, ataxia, hearing deficit, ophthalmoplegia, intractable epilepsy and elevation of serum transaminases. The liver showed mtDNA depletion, whereas the muscle mtDNA was only slightly affected. Alpers-Huttenlocher syndrome has previously been associated with mutations of polymerase gamma, a replicative polymerase of mtDNA. We show here that recessive mutations of the close functional partner of the polymerase, the Twinkle helicase, can also manifest as early encephalopathy with liver involvement, a phenotype reminiscent of Alpers syndrome, and are a new genetic cause underlying tissue-specific mtDNA depletion.
C1 Univ Helsinki, Biomed Helsinki, Res Program Mol Neurol, FIN-00290 Helsinki, Finland.
   Univ Helsinki, Cent Hosp, Dept Child Neurol, Hosp Childrens & Adolescents, Helsinki, Finland.
   Univ Helsinki, Dept Pathol, Helsinki, Finland.
   HUSLAB, Helsinki, Finland.
   Oulu Univ Hosp, Oulu, Finland.
   Univ Helsinki, Cent Hosp, Dept Neurol, FIN-00014 Helsinki, Finland.
C3 University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; University of Oulu; University of Helsinki; Helsinki University Central Hospital
RP Suomalainen, A (corresponding author), Univ Helsinki, Biomed Helsinki, Res Program Mol Neurol, R C523B,POB 63, FIN-00290 Helsinki, Finland.
EM anu.wartiovaara@helsinki.fi
CR Alpers BJ, 1931, ARCH NEURO PSYCHIATR, V25, P469, DOI 10.1001/archneurpsyc.1931.02230030027002
   Baloh RH, 2007, ARCH NEUROL-CHICAGO, V64, P998, DOI 10.1001/archneur.64.7.998
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Davidzon G, 2005, ANN NEUROL, V57, P921, DOI 10.1002/ana.20498
   Deschauer M, 2003, NEUROMUSCULAR DISORD, V13, P568, DOI 10.1016/S0960-8966(03)00071-3
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Hudson G, 2005, NEUROLOGY, V64, P371, DOI 10.1212/01.WNL.0000149767.51152.83
   HUTTENLOCHER PR, 1976, ARCH NEUROL-CHICAGO, V33, P186, DOI 10.1001/archneur.1976.00500030042009
   KOSKINEN T, 1994, J NEUROL SCI, V121, P50, DOI 10.1016/0022-510X(94)90156-2
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lönnqvist T, 1998, J NEUROL SCI, V161, P57, DOI 10.1016/S0022-510X(98)00249-4
   MANDERBACKA K, 2001, SCANDINAVIAN J P S55, V29, P41
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Nikali K, 2005, HUM MOL GENET, V14, P2981, DOI 10.1093/hmg/ddi328
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Suomalainen A, 1997, NEUROLOGY, V48, P1244, DOI 10.1212/WNL.48.5.1244
   SUOMALAINEN A, 1992, J CLIN INVEST, V90, P61, DOI 10.1172/JCI115856
   Tyynismaa H, 2004, HUM MOL GENET, V13, P3219, DOI 10.1093/hmg/ddh342
   Tzoulis C, 2006, BRAIN, V129, P1685, DOI 10.1093/brain/awl097
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
NR 27
TC 150
Z9 159
U1 0
U2 13
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
EI 
J9 BRAIN
JI Brain
PD NOV 15
PY 2007
VL 130
IS 
BP 3032
EP 3040
DI 10.1093/brain/awm242
PG 9
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 227RJ
UT WOS:000250675200028
PM 17921179
DA 2024-11-01
ER

PT J
AU Yao, YG
   Bandelt, HJ
   Young, NS
AF Yao, Yong-Gang
   Bandelt, Hans-Juergen
   Young, Neal S.
TI External Contamination in Single Cell mtDNA Analysis
SO PLOS ONE
LA English
DT Article
ID mitochondrial-dna mutations; central-nervous-system; stem-cells; sequence; inheritance; accumulation; penetrance; phylogeny; deletions; abundant
AB Background. Mitochondrial DNA (mtDNA) variation in single hematopoietic cells, muscle fibers, oocytes, and from tiny amount of tumor tissues and degraded clinical specimens has been reported in many medical publications. External DNA contamination, notoriously difficult to avoid, threatens the integrity of such studies. Methodology/Principal Findings. Employing a phylogenetic approach, we analyzed the geographic origins of mtDNA sequence anomalies observed during multiple studies of mtDNA sequence variation in a total of 7094 single hematopoietic cells. 40 events with irregular mtDNA patterns were detected: eight instances (from seven different haplotypes) could be traced to laboratory personnel; six cases were caused by sample cross-contamination. The sources of the remaining events could not be identified, and the anomalous sequence variation referred to matrilines from East Asia, Africa, or West Eurasia, respectively. These mtDNA sequence anomalies could be best explained by contamination. Conclusions. Using the known world mtDNA phylogeny, we could distinguish the geographic origin of the anomalous mtDNA types, providing some useful information regarding the source of contamination. Our data suggest that routine mtDNA sequence analysis of laboratory personnel is insufficient to identify and eliminate all contaminants. A rate of 0.6% of external contamination in this study, while low, is not negligible: Unrecognized contaminants will be mistaken as evidence of remarkable somatic mutations associated with the development of cancer and other diseases. The effective contamination rate can increase by a factor of more than an order of magnitude in some studies that did not institute high standards. Our results are of particular relevance to mtDNA research in medicine, and such an approach should be adopted to maintain and improve quality control in single-cell analyses.
C1 [Yao, Yong-Gang; Young, Neal S.] NHLBI, Hematol Branch, NIH, Bethesda, MD 20892 USA.
   [Bandelt, Hans-Juergen] Univ Hamburg, Dept Math, Hamburg, Germany.
C3 National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Hamburg
RP Yao, YG (corresponding author), NHLBI, Hematol Branch, NIH, Bethesda, MD 20892 USA.
EM yaoy3@nhlbi.nih.gov
FU NIH
CR Alonso A, 2005, J CLIN PATHOL, V58, P83, DOI 10.1136/jcp.2004.017673
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Bandelt HJ, 2007, EUR J HUM GENET, V15, P400, DOI 10.1038/sj.ejhg.5201781
   Bandelt HJ, 2007, BIOCHEM BIOPH RES CO, V352, P283, DOI 10.1016/j.bbrc.2006.10.131
   Bandelt HJ, 2006, NUCL ACID M, V18, P117
   Bandelt HJ, 2005, J MED GENET, V42, P957, DOI 10.1136/jmg.2005.033589
   Bandelt HJ, 2005, BIOCHEM BIOPH RES CO, V333, P122, DOI 10.1016/j.bbrc.2005.04.055
   Behar DM, 2006, AM J HUM GENET, V78, P487, DOI 10.1086/500307
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Brandon M, 2006, ONCOGENE, V25, P4647, DOI 10.1038/sj.onc.1209607
   Brierley EJ, 1998, ANN NEUROL, V43, P217, DOI 10.1002/ana.410430212
   Brown DT, 2001, AM J HUM GENET, V68, P533, DOI 10.1086/318190
   Bua E, 2006, AM J HUM GENET, V79, P469, DOI 10.1086/507132
   Carew Jennifer S, 2002, MOL CANCER, V1, P9, DOI 10.1186/1476-4598-1-9
   Chan CCW, 2005, MOL HUM REPROD, V11, P843, DOI 10.1093/molehr/gah243
   Chatterjee A, 2006, ONCOGENE, V25, P4663, DOI 10.1038/sj.onc.1209604
   Chinnery PF, 2003, J NEUROL NEUROSUR PS, V74, P1188, DOI 10.1136/jnnp.74.9.1188
   Chinnery PF, 2000, TRENDS GENET, V16, P500, DOI 10.1016/S0168-9525(00)02120-X
   Chomyn A, 2003, BIOCHEM BIOPH RES CO, V304, P519, DOI 10.1016/S0006-291X(03)00625-9
   Cormio A, 2005, NEUROBIOL AGING, V26, P655, DOI 10.1016/j.neurobiolaging.2004.06.014
   Czarnecka AM, 2006, J APPL GENET, V47, P67, DOI 10.1007/BF03194602
   Del Bo R, 2003, NEUROBIOL AGING, V24, P829, DOI 10.1016/S0197-4580(02)00233-6
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Durham SE, 2006, NEUROMUSCULAR DISORD, V16, P381, DOI 10.1016/j.nmd.2006.03.012
   Fliss MS, 2000, SCIENCE, V287, P2017, DOI 10.1126/science.287.5460.2017
   Gilbert MTP, 2005, TRENDS ECOL EVOL, V20, P541, DOI 10.1016/j.tree.2005.07.005
   Greaves LC, 2006, P NATL ACAD SCI USA, V103, P714, DOI 10.1073/pnas.0505903103
   Hofreiter M, 2001, NAT REV GENET, V2, P353, DOI 10.1038/35072071
   Jakupciak JP, 2005, J MOL DIAGN, V7, P258, DOI 10.1016/S1525-1578(10)60553-3
   Johns DR, 2003, ANN NEUROL, V54, P422, DOI 10.1002/ana.10771
   Kirches E, 2001, INT J CANCER, V93, P534, DOI 10.1002/ijc.1375
   Kong QP, 2006, HUM MOL GENET, V15, P2076, DOI 10.1093/hmg/ddl130
   Kraytsberg Y, 2006, NAT GENET, V38, P518, DOI 10.1038/ng1778
   LEONARD JL, 2007, J ARCHAEOL IN PRESS, V0, P0, DOI DOI 10.1016/J.JAS.2006.1010.1023
   Maitra A, 2004, GENOME RES, V14, P812, DOI 10.1101/gr.2228504
   Malmström H, 2005, MOL BIOL EVOL, V22, P2040, DOI 10.1093/molbev/msi195
   MORAES CT, 1992, AM J HUM GENET, V50, P934
   Nagley P, 1998, TRENDS GENET, V14, P513, DOI 10.1016/S0168-9525(98)01580-7
   Nekhaeva E, 2002, P NATL ACAD SCI USA, V99, P5521, DOI 10.1073/pnas.072670199
   Ogasawara Y, 2005, BLOOD, V106, P3271, DOI 10.1182/blood-2005-01-0150
   Olivieri A, 2006, SCIENCE, V314, P1767, DOI 10.1126/science.1135566
   Pääbo S, 2004, ANNU REV GENET, V38, P645, DOI 10.1146/annurev.genet.37.110801.143214
   Pak JW, 2003, AGING CELL, V2, P1, DOI 10.1046/j.1474-9728.2003.00034.x
   Palanichamy MG, 2004, AM J HUM GENET, V75, P966, DOI 10.1086/425871
   Penta JS, 2001, MUTAT RES-REV MUTAT, V488, P119, DOI 10.1016/S1383-5742(01)00053-9
   Reidla M, 2003, AM J HUM GENET, V73, P1178, DOI 10.1086/379380
   Salas A, 2005, PLOS MED, V2, P1158, DOI 10.1371/journal.pmed.0020296
   Sampietro ML, 2006, MOL BIOL EVOL, V23, P1801, DOI 10.1093/molbev/msl047
   Schwartz M, 2002, NEW ENGL J MED, V347, P576, DOI 10.1056/NEJMoa020350
   Shin MG, 2004, BLOOD, V103, P553, DOI 10.1182/blood-2003-05-1724
   Sun C, 2006, MOL BIOL EVOL, V23, P683, DOI 10.1093/molbev/msj078
   Taylor RW, 2003, J CLIN INVEST, V112, P1351, DOI 10.1172/JCI200319435
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Taylor RW, 2001, NUCLEIC ACIDS RES, V29, Part. no., DOI 10.1093/nar/29.15.e74
   Torroni A, 2006, TRENDS GENET, V22, P339, DOI 10.1016/j.tig.2006.04.001
   Vega A, 2004, ONCOGENE, V23, P1314, DOI 10.1038/sj.onc.1207214
   Verma Mukesh, 2007, CANCER RES, V67, P437, DOI 10.1158/0008-5472.CAN-06-4119
   Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751
   Wang CY, 2007, INT J CANCER, V121, P1253, DOI 10.1002/ijc.22822
   Willerslev E, 2005, P ROY SOC B-BIOL SCI, V272, P3, DOI 10.1098/rspb.2004.2813
   Yao YG, 2006, HUM GENET, V119, P505, DOI 10.1007/s00439-006-0154-9
   Yao YG, 2007, BLOOD, V109, P756, DOI 10.1182/blood-2006-01-011007
   Yao YG, 2007, HUM MOL GENET, V16, P286, DOI 10.1093/hmg/ddl457
   Zanssen S, 2005, PLOS MED, V2, P1082, DOI 10.1371/journal.pmed.0020401
NR 64
TC 20
Z9 22
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
EI 
J9 PLOS ONE
JI PLoS One
PD AUG 1
PY 2007
VL 2
IS 8
BP 
EP 
DI 10.1371/journal.pone.0000681
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA V10GK
UT WOS:000207452300017
PM 17668059
DA 2024-11-01
ER

PT J
AU Au, KM
   Lau, SC
   Mak, YF
   Lai, WM
   Chow, TC
   Chen, ML
   Chiu, MC
   Chan, AYW
AF Au, Kam Ming
   Lau, Shing Chi
   Mak, Yuen Fun
   Lai, Wai Ming
   Chow, Tat Chong
   Chen, Mo Lung
   Chiu, Man Chun
   Chan, Albert Yan Wo
TI Mitochondrial DNA deletion in a girl with Fanconi's syndrome
SO PEDIATRIC NEPHROLOGY
LA English
DT Article
DE mtDNA deletion; Fanconi's syndrome; cytochrome c oxidase deficiency; mitochondriopathy
ID progressive external ophthalmoplegia; marrow-pancreas syndrome; kearns-sayre syndrome; tubulointerstitial nephritis; acidosis; patient
AB We report a sporadic large-scale mitochondrial deletion in a paediatric patient with Fanconi's syndrome. Renal biopsy disclosed chronic interstitial nephritis. Ultrastructural examination of the renal tissue showed many giant atypical mitochondria. Histochemical stains revealed markedly reduced cytochrome c oxidase (COX). Genetic analysis disclosed a novel mitochondrial deletion of 7.3 kb in both peripheral blood and renal tissue. Mitochondrial diseases have heterogeneous clinical phenotypes; mutation analysis has proved to be an effective tool in confirming the diagnosis.
C1 Princess Margaret Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China.
   Princess Margaret Hosp, Dept Paediat & Adolescent Med, Hong Kong, Hong Kong, Peoples R China.
RP Au, KM (corresponding author), Princess Margaret Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China.
EM aukm@ha.org.hk
CR BERNES SM, 1993, J PEDIATR-US, V123, P598, DOI 10.1016/S0022-3476(05)80962-X
   CAMPOS Y, 1995, PEDIATR NEUROL, V13, P69, DOI 10.1016/0887-8994(95)00082-Q
   CHENG S, 1994, NAT GENET, V7, P350, DOI 10.1038/ng0794-350
   EVIATAR L, 1990, NEUROLOGY, V40, P1761, DOI 10.1212/WNL.40.11.1761
   Grunfeld JP, 1996, NEPHROL DIAL TRANSPL, V11, P760, DOI 10.1093/oxfordjournals.ndt.a027391
   KREUDER J, 1995, EUR J PEDIATR, V154, P996, DOI 10.1007/BF01958647
   Martín-Hernández E, 2005, PEDIATR NEPHROL, V20, P1299, DOI 10.1007/s00467-005-1948-z
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   Moraes CT, 2003, J MOL DIAGN, V5, P197, DOI 10.1016/S1525-1578(10)60474-6
   NIAUDET P, 1994, PEDIATR NEPHROL, V8, P164, DOI 10.1007/BF00865468
   ROTIG A, 1990, J CLIN INVEST, V86, P1601, DOI 10.1172/JCI114881
   ROTIG A, 1995, J PEDIATR-US, V126, P597, DOI 10.1016/S0022-3476(95)70359-4
   SZABOLCS MJ, 1994, KIDNEY INT, V45, P1388, DOI 10.1038/ki.1994.181
   Thorburn DR, 2001, AM J MED GENET, V106, P102, DOI 10.1002/ajmg.1380
   Tzen CY, 2001, KIDNEY INT, V59, P846, DOI 10.1046/j.1523-1755.2001.00567.x
   Wong LJC, 2001, GENET MED, V3, P399, DOI 10.1097/00125817-200111000-00004
NR 16
TC 20
Z9 28
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0931-041X
EI 1432-198X
J9 PEDIATR NEPHROL
JI Pediatr. Nephrol.
PD JAN 15
PY 2007
VL 22
IS 1
BP 136
EP 140
DI 10.1007/s00467-006-0288-y
PG 5
WC Pediatrics; Urology & Nephrology
SC Pediatrics; Urology & Nephrology
GA 112GG
UT WOS:000242513200024
PM 16967281
DA 2024-11-01
ER

PT J
AU Debray, FG
   Lambert, M
   Chevalier, I
   Robitaille, Y
   Decarie, JC
   Shoubridge, EA
   Robinson, BH
   Mitchell, GA
AF Debray, Francois-Guillaume
   Lambert, Marie
   Chevalier, Isabelle
   Robitaille, Yves
   Decarie, Jean-Claude
   Shoubridge, Eric A.
   Robinson, Brian H.
   Mitchell, Grant A.
TI Long-term outcome and clinical spectrum of 73 pediatric patients with mitochondrial diseases
SO PEDIATRICS
LA English
DT Article
DE mitochondrial diseases; long-term outcome; functional status
ID pyruvate-dehydrogenase complex; respiratory-chain disorders; c-oxidase deficiency; oxidative-phosphorylation; skeletal-muscle; lactic-acidosis; children; mutations; electrophoresis; cardiomyopathy
AB OBJECTIVES. We sought to determine the clinical spectrum, survival, and long-term functional outcome of a cohort of pediatric patients with mitochondrial diseases and to identify prognostic factors. METHODS. Medical charts were reviewed for 73 children diagnosed between 1985 and 2005. The functional status of living patients was assessed prospectively by using the standardized Functional Independence Measure scales. RESULTS. Patients fell into 7 phenotypic categories: neonatal-onset lactic acidosis (10%), Leigh syndrome (18%), nonspecific encephalopathy (32%), mitochondrial (encephalo) myopathy (19%), intermittent neurologic (5%), visceral (11%), and Leber hereditary optic neuropathy (5%). Age at first symptoms ranged from prenatal to 16 years ( median: 7 months). Neurologic symptoms were the most common (90%). Visceral involvement was observed in 29% of the patients. A biochemical or molecular diagnosis was identified for 81% of the patients as follows: deficiency of complex IV (27%), of pyruvate dehydrogenase or complex I (25% each), of multiple complexes (13%), and of pyruvate carboxylase (5%) or complexes II + III (5%). A mitochondrial DNA mutation was found in 20% of patients. At present, 46% of patients have died (median age: 13 months), 80% of whom were < 3 years of age. Multivariate analysis showed that age at first symptoms was a major independent predictor of mortality: patients with first symptoms before 6 months had a highly increased risk of mortality. Cardiac or visceral involvement and neurologic crises were not independent prognostic factors. Living patients showed a wide range of independence levels that correlated positively with age at first symptoms. Among patients aged > 5 years (n = 32), 62% had Functional Independence Measure quotients of > 0.75. CONCLUSIONS. Mitochondrial diseases in children span a wide range of symptoms and severities. Age at first symptoms is the strongest predictor mortality. Despite a high mortality rate in the cohort, 62% of patients aged > 5 years have only mild impairment or normal functional outcome.
C1 Univ Montreal, CHU St Justine, Dept Pediat, Div Med Genet, Montreal, PQ H31 1C5, Canada.
   Univ Montreal, CHU St Justine, Dept Pediat, Div Pediat, Montreal, PQ H3C 3J7, Canada.
   Univ Montreal, CHU St Justine, Dept Pathol, Montreal, PQ H3C 3J7, Canada.
   Univ Montreal, CHU St Justine, Dept Med Imaging, Montreal, PQ H3C 3J7, Canada.
   McGill Univ, Montreal Neurol Inst, Dept Human Genet, Montreal, PQ H3A 2T5, Canada.
   Univ Toronto, Hosp Sick Children, Res Inst, Dept Pediat,Metab Res Program, Toronto, ON M5G 1X8, Canada.
   Univ Toronto, Hosp Sick Children, Res Inst, Dept Biochem,Metab Res Program, Toronto, ON M5G 1X8, Canada.
C3 Universite de Montreal; Centre Hospitalier Universitaire Sainte-Justine; Universite de Montreal; Centre Hospitalier Universitaire Sainte-Justine; Universite de Montreal; Centre Hospitalier Universitaire Sainte-Justine; Universite de Montreal; Centre Hospitalier Universitaire Sainte-Justine; McGill University; University of Toronto; Hospital for Sick Children (SickKids); University of Toronto; Hospital for Sick Children (SickKids)
RP Mitchell, GA (corresponding author), Univ Montreal, CHU St Justine, Dept Pediat, Div Med Genet, 3175 Cote St Catherine, Montreal, PQ H31 1C5, Canada.
EM mitchell@recherche-ste-justine.qc.ca
CR [Anonymous], 1997, GUID UN DAT SET MED, V0, P0
   Antonicka H, 2003, AM J HUM GENET, V72, P101, DOI 10.1086/345489
   Applegarth DA, 2000, PEDIATRICS, V105, Part. no., DOI 10.1542/peds.105.1.e10
   Berendzen K, 2006, MITOCHONDRION, V6, P126, DOI 10.1016/j.mito.2006.04.001
   Bernier FP, 2002, NEUROLOGY, V59, P1406, DOI 10.1212/01.WNL.0000033795.17156.00
   BROWN GK, 1988, EUR J PEDIATR, V147, P10, DOI 10.1007/BF00442603
   Brun N, 1999, AM J MED GENET, V84, P94, DOI 10.1002/(SICI)1096-8628(19990521)84:2<94::AID-AJMG3>3.0.CO;2-1
   Carter SL, 2001, CAN J PHYSIOL PHARM, V79, P386, DOI 10.1139/cjpp-79-5-386
   CHARIOT P, 1994, ARCH PATHOL LAB MED, V118, P695
   Chretien D, 2003, J INHERIT METAB DIS, V26, P189, DOI 10.1023/A:1024437201166
   Darin N, 2001, ANN NEUROL, V49, P377, DOI 10.1002/ana.75
   Debray FG, 2006, EUR J PEDIATR, V165, P462, DOI 10.1007/s00431-006-0104-5
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Fouque F, 2003, PEDIATR RES, V53, P793, DOI 10.1203/01.PDR.0000057987.46622.64
   García-Cazorla A, 2005, PEDIATRICS, V116, P1170, DOI 10.1542/peds.2004-2407
   Holmgren D, 2003, EUR HEART J, V24, P280, DOI 10.1016/S0195-668X(02)00387-1
   Ibdah JA, 1999, NEW ENGL J MED, V340, P1723, DOI 10.1056/NEJM199906033402204
   Marin-Garcia J, 1999, PEDIATR NEUROL, V21, P538, DOI 10.1016/S0887-8994(99)00038-7
   McKenzie S, 2000, AM J PHYSIOL-ENDOC M, V278, PE580, DOI 10.1152/ajpendo.2000.278.4.E580
   MIYABAYASHI S, 1985, EUR J PEDIATR, V143, P278, DOI 10.1007/BF00442301
   Mootha VK, 2003, P NATL ACAD SCI USA, V100, P605, DOI 10.1073/pnas.242716699
   MORIN C, 1993, AM J HUM GENET, V53, P488
   MSALL ME, 1994, CLIN PEDIATR, V33, P421, DOI 10.1177/000992289403300708
   Munnich A, 1996, J INHERIT METAB DIS, V19, P521, DOI 10.1007/BF01799112
   Naito E, 1998, EUR J PEDIATR, V157, P648, DOI 10.1007/s004310050903
   Nijtmans LGJ, 2002, METHODS, V26, P327, DOI 10.1016/S1046-2023(02)00038-5
   Nissenkorn A, 2000, J CHILD NEUROL, V15, P44, DOI 10.1177/088307380001500110
   Nissenkorn A, 1999, ARCH DIS CHILD, V81, P209, DOI 10.1136/adc.81.3.209
   Ottenbacher KJ, 1996, DEV MED CHILD NEUROL, V38, P907
   Rahman S, 1996, ANN NEUROL, V39, P343, DOI 10.1002/ana.410390311
   Robinson BH, 2001, METABOLIC MOL BASIS, VII, P2275
   Scaglia F, 2004, PEDIATRICS, V114, P925, DOI 10.1542/peds.2004-0718
   SHEU KFR, 1981, J CLIN INVEST, V67, P1463, DOI 10.1172/JCI110176
   Skladal D, 2003, CLIN PEDIATR, V42, P703, DOI 10.1177/000992280304200806
   Skladal D, 2003, BRAIN, V126, P1905, DOI 10.1093/brain/awg170
   Swaine BR, 2000, AM J PHYS MED REHAB, V79, P412, DOI 10.1097/00002060-200009000-00002
   Thorburn D R, 2000, HUM REPROD, V15 Suppl 2, P57
   Touati G, 1997, ARCH DIS CHILD, V76, P16, DOI 10.1136/adc.76.1.16
   Van Coster R, 2001, PEDIATR RES, V50, P658, DOI 10.1203/00006450-200111000-00020
   von Kleist-Retzow JC, 2003, J PEDIATR-US, V143, P208, DOI 10.1067/S0022-3476(03)00130-6
   Wexler ID, 1997, NEUROLOGY, V49, P1655, DOI 10.1212/WNL.49.6.1655
   Wong LJC, 2002, CLIN CHEM, V48, P1901
   Zeviani M, 1996, J INHERIT METAB DIS, V19, P504, DOI 10.1007/BF01799111
   ZUH Z, 1998, NAT GENET, V20, P337
NR 44
TC 124
Z9 132
U1 0
U2 4
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0031-4005
EI 1098-4275
J9 PEDIATRICS
JI Pediatrics
PD APR 15
PY 2007
VL 119
IS 4
BP 722
EP 733
DI 10.1542/peds.2006-1866
PG 12
WC Pediatrics
SC Pediatrics
GA 153BH
UT WOS:000245406200034
PM 17403843
DA 2024-11-01
ER

PT J
AU Kärkkäinen, S
   Peuhkurinen, K
AF Karkkainen, Satu
   Peuhkurinen, Keijo
TI Genetics of dilated cardiomyopathy
SO ANNALS OF MEDICINE
LA English
DT Review
DE cardiomyopathy; dilated; gene
ID lamin a/c gene; girdle muscular-dystrophy; delta-sarcoglycan gene; converting enzyme gene; troponin-t mutation; muscle lim protein; cardiac actin gene; x-linked gene; mitochondrial-dna; heart-failure
AB Dilated cardiomyopathy (DCM) is a myocardial disease characterized by dilatation and impaired systolic function of the left or both ventricles. The etiology of DCM is multifactorial, and many different clinical conditions can lead to the phenotype of DCM. During recent years it has become evident that genetic factors play an important role in the etiology and pathogenesis of idiopathic DCM. The genetics of DCM have been under intensive investigation lately, and thereby the knowledge on the genetic basis of DCM has increased rapidly. The genetic background of the disease seems to be relatively heterogeneous, and the disease-associated mutations concern mostly single families and only few affected patients. Disease-associated mutations have been detected e.g. in genes encoding sarcomere, cytoskeletal, and nuclear proteins, as well as proteins involved with regulation of Ca2+ metabolism. The mechanisms, by which mutations eventually result in clinical heart failure, are complex and not yet totally resolved. DCM causes considerable morbidity and mortality. Better knowledge of the genetic background and disease-causing mechanisms would probably help us in focusing early treatment on right subjects and potentially also developing new treatment modalities and improving cardiac outcome in the affected patients. This review deals with DCM of genetic origin.
C1 Kuopio Univ Hosp, Dept Internal Med, Kuopio 70211, Finland.
   Univ Kuopio, FIN-70211 Kuopio, Finland.
C3 Kuopio University Hospital; University of Eastern Finland; University of Eastern Finland
RP Kärkkäinen, S (corresponding author), Kuopio Univ Hosp, Dept Internal Med, POB 1777, Kuopio 70211, Finland.
EM satu.karkkainen@kuh.fi
CR ABELMANN WH, 1982, HOSP PRACT, V17, P17
   ANAN R, 1995, CIRCULATION, V91, P955, DOI 10.1161/01.CIR.91.4.955
   Andersson B, 1996, J AM COLL CARDIOL, V28, P162, DOI 10.1016/0735-1097(96)00098-8
   Arbustini E, 2000, J AM COLL CARDIOL, V35, P1760, DOI 10.1016/S0735-1097(00)00650-1
   Arbustini E, 2002, J AM COLL CARDIOL, V39, P981, DOI 10.1016/S0735-1097(02)01724-2
   Arimura T, 2004, J BIOL CHEM, V279, P6746, DOI 10.1074/jbc.M311849200
   Arola A, 1997, AM J EPIDEMIOL, V146, P385, DOI 10.1093/oxfordjournals.aje.a009291
   Badorff C, 2000, J BIOL CHEM, V275, P11191, DOI 10.1074/jbc.275.15.11191
   BAGGER JP, 1984, BRIT HEART J, V52, P327
   Baidasseroni S, 2002, EUR HEART J, V23, P1692, DOI 10.1053/euhj.2001.3157
   Baig MK, 1998, J AM COLL CARDIOL, V31, P195, DOI 10.1016/S0735-1097(97)00433-6
   BELKIN AM, 1988, J CELL BIOL, V107, P545, DOI 10.1083/jcb.107.2.545
   BERKO BA, 1987, NEW ENGL J MED, V316, P1186, DOI 10.1056/NEJM198705073161904
   Bezzina C, 1999, CIRC RES, V85, P1206
   Bienengraeber M, 2004, NAT GENET, V36, P382, DOI 10.1038/ng1329
   Bies RD, 1997, J MOL CELL CARDIOL, V29, P3175, DOI 10.1006/jmcc.1997.0568
   Bione S, 1996, NAT GENET, V12, P385, DOI 10.1038/ng0496-385
   Blair E, 2002, CIRC RES, V90, P263, DOI 10.1161/hh0302.104532
   BLONDHEIM DS, 1991, AM HEART J, V122, P763, DOI 10.1016/0002-8703(91)90523-K
   Bonne G, 1999, NAT GENET, V21, P285, DOI 10.1038/6799
   Bowles KR, 1996, J CLIN INVEST, V98, P1355, DOI 10.1172/JCI118922
   Brodsky GL, 2000, CIRCULATION, V101, P473, DOI 10.1161/01.CIR.101.5.473
   Cao HN, 2003, J HUM GENET, V48, P271, DOI 10.1007/s10038-003-0025-3
   Chaouch M, 2003, NEUROMUSCULAR DISORD, V13, P60, DOI 10.1016/S0960-8966(02)00196-7
   CODD MB, 1989, CIRCULATION, V80, P564, DOI 10.1161/01.CIR.80.3.564
   Cox GF, 1997, CURR OPIN CARDIOL, V12, P329
   DAdamo P, 1997, AM J HUM GENET, V61, P862, DOI 10.1086/514886
   Daehmlow S, 2002, BIOCHEM BIOPH RES CO, V298, P116, DOI 10.1016/S0006-291X(02)02374-4
   Dalakas MC, 2000, NEW ENGL J MED, V342, P770, DOI 10.1056/NEJM200003163421104
   DEC GW, 1994, NEW ENGL J MED, V331, P1564, DOI 10.1056/NEJM199412083312307
   Dechat T, 1998, EMBO J, V17, P4887, DOI 10.1093/emboj/17.16.4887
   Dimauro S, 2005, ANN MED, V37, P222, DOI 10.1080/07853890510007368
   DURAND JB, 1995, CIRCULATION, V92, P3387, DOI 10.1161/01.CIR.92.12.3387
   EMERY AEH, 1989, J MED GENET, V26, P637, DOI 10.1136/jmg.26.10.637
   EVANS W, 1949, BRIT HEART J, V11, P68
   Fatkin D, 2002, PHYSIOL REV, V82, P945, DOI 10.1152/physrev.00012.2002
   Fatkin D, 1999, NEW ENGL J MED, V341, P1715, DOI 10.1056/NEJM199912023412302
   Fauchier L, 2000, EUR HEART J, V21, P306, DOI 10.1053/euhj.1999.1761
   Feng JN, 2002, MOL GENET METAB, V77, P119, DOI 10.1016/S1096-7192(02)00153-1
   Feng JO, 2002, J AM COLL CARDIOL, V40, P1120, DOI 10.1016/S0735-1097(02)02126-5
   FOISNER R, 1993, CELL, V73, P1267, DOI 10.1016/0092-8674(93)90355-T
   Franz WM, 2000, LANCET, V355, P1781, DOI 10.1016/S0140-6736(00)02266-2
   Franz WM, 2001, LANCET, V358, P1627, DOI 10.1016/S0140-6736(01)06657-0
   Fuchs E, 1998, SCIENCE, V279, P514, DOI 10.1126/science.279.5350.514
   Gavazzi A, 2000, AM J CARDIOL, V85, P1114, DOI 10.1016/S0002-9149(00)00706-2
   Genschel J, 2000, HUM MUTAT, V16, P451, DOI 10.1002/1098-1004(200012)16:6<451::AID-HUMU1>3.0.CO;2-9
   Gerull B, 2006, J MOL MED-JMM, V84, P478, DOI 10.1007/s00109-006-0060-6
   GERULL B, 2002, NAT GENET, V14, P14
   GILLUM RF, 1994, EPIDEMIOLOGY, V5, P383, DOI 10.1097/00001648-199405000-00026
   Goedel-Meinen L, 2001, AM J CARDIOL, V87, P809, DOI 10.1016/S0002-9149(00)01514-9
   Goldfarb LG, 1998, NAT GENET, V19, P402, DOI 10.1038/1300
   Goldman RD, 2002, GENE DEV, V16, P533, DOI 10.1101/gad.960502
   Gregori D, 2001, J APPL STAT, V28, P53, DOI 10.1080/02664760120011590
   Grünig E, 1998, J AM COLL CARDIOL, V31, P186, DOI 10.1016/S0735-1097(97)00434-8
   Hanson EL, 2002, J CARD FAIL, V8, P28, DOI 10.1054/jcaf.2002.31157
   HART KA, 1987, HUM GENET, V75, P281, DOI 10.1007/BF00281075
   Hayashi T, 2004, J AM COLL CARDIOL, V44, P2192, DOI 10.1016/j.jacc.2004.08.058
   Hein S, 2000, CARDIOVASC RES, V45, P273, DOI 10.1016/S0008-6363(99)00268-0
   Hershberger RE, 2002, AM HEART J, V144, P1081, DOI 10.1067/mhj.2002.126737
   HOFMANN T, 1988, AM HEART J, V116, P1455, DOI 10.1016/0002-8703(88)90728-4
   Hung J, 1998, AM J CARDIOL, V82, P1301, DOI 10.1016/S0002-9149(98)00624-9
   Hutchison CJ, 2001, J CELL SCI, V114, P9
   Itoh-Satoh M, 2002, BIOCHEM BIOPH RES CO, V291, P385, DOI 10.1006/bbrc.2002.6448
   Jakobs PM, 2001, J CARD FAIL, V7, P249, DOI 10.1054/jcaf.2001.26339
   Johns DR, 1996, NAT MED, V2, P1065, DOI 10.1038/nm1096-1065
   Jung M, 1999, AM J HUM GENET, V65, P1068, DOI 10.1086/302580
   JUNKER A, 1993, CARDIOLOGY, V83, P14, DOI 10.1159/000175942
   Kamisago M, 2000, NEW ENGL J MED, V343, P1688, DOI 10.1056/NEJM200012073432304
   Kärkkäinen S, 2006, HEART, V92, P524, DOI 10.1136/hrt.2004.056721
   Kärkkäinen S, 2004, EUR J HEART FAIL, V6, P861, DOI 10.1016/j.ejheart.2004.04.017
   Kärkkäinen S, 2004, EUR HEART J, V25, P885, DOI 10.1016/j.ehj.2004.01.020
   Kärkkäinen S, 2003, J MOL MED-JMM, V81, P795, DOI 10.1007/s00109-003-0480-5
   KEELING PJ, 1995, BRIT HEART J, V73, P417
   KEOGH AM, 1990, AM J CARDIOL, V65, P903, DOI 10.1016/0002-9149(90)91434-8
   KLAPPACHER G, 1995, AM J CARDIOL, V75, P913, DOI 10.1016/S0002-9149(99)80686-9
   Knöll R, 2002, CELL, V111, P943, DOI 10.1016/S0092-8674(02)01226-6
   Koelling TM, 2002, AM HEART J, V144, P524, DOI 10.1067/mhj.2002.123575
   KOENIG M, 1987, CELL, V50, P509, DOI 10.1016/0092-8674(87)90504-6
   Komajda M, 1999, EUR J HEART FAIL, V1, P121, DOI 10.1016/S1388-9842(99)00026-4
   Kong YF, 1997, MOL CELL BIOL, V17, P4750, DOI 10.1128/MCB.17.8.4750
   Kostin S, 1998, CELL TISSUE RES, V294, P449, DOI 10.1007/s004410051196
   KRAJINOVIC M, 1995, AM J HUM GENET, V57, P846
   LABEIT S, 1995, SCIENCE, V270, P293, DOI 10.1126/science.270.5234.293
   Li DX, 1999, CIRCULATION, V100, P461, DOI 10.1161/01.CIR.100.5.461
   Li DX, 2001, CIRCULATION, V104, P2188, DOI 10.1161/hc4301.098285
   Liggett SB, 1998, J CLIN INVEST, V102, P1534, DOI 10.1172/JCI4059
   MacLeod Heather M, 2003, BMC MED GENET, V4, P4, DOI 10.1186/1471-2350-4-4
   Maeda M, 1997, CIRCULATION, V95, P17, DOI 10.1161/01.CIR.95.1.17
   Majamaa-Voltti Kirsi, 2002, BMC CARDIOVASC DISORD, V2, P12
   MANCINI DM, 1991, CIRCULATION, V83, P778, DOI 10.1161/01.CIR.83.3.778
   MANOLIO TA, 1992, AM J CARDIOL, V69, P1458, DOI 10.1016/0002-9149(92)90901-A
   MarinGarcia J, 1996, CARDIOVASC RES, V31, P306
   Maruyama K, 1997, FASEB J, V11, P341, DOI 10.1096/fasebj.11.5.9141500
   Mayosi BM, 1999, J MED GENET, V36, P796, DOI 10.1136/jmg.36.10.796
   McNair WP, 2004, CIRCULATION, V110, P2163, DOI 10.1161/01.CIR.0000144458.58660.BB
   McNamara DM, 2004, J AM COLL CARDIOL, V44, P2019, DOI 10.1016/j.jacc.2004.08.048
   Messina DN, 1997, AM J HUM GENET, V61, P909, DOI 10.1086/514896
   Mestroni L, 1999, EUR HEART J, V20, P93, DOI 10.1053/euhj.1998.1145
   Mestroni L, 1999, J AM COLL CARDIOL, V34, P181, DOI 10.1016/S0735-1097(99)00172-2
   Mestroni L, 1997, CURR OPIN CARDIOL, V12, P303, DOI 10.1097/00001573-199705000-00012
   Meune C, 2006, NEW ENGL J MED, V354, P209, DOI 10.1056/NEJMc052632
   MICHELS VV, 1992, NEW ENGL J MED, V326, P77, DOI 10.1056/NEJM199201093260201
   Milasin J, 1996, HUM MOL GENET, V5, P73, DOI 10.1093/hmg/5.1.73
   Miyamoto Y, 2001, EUR HEART J, V22, P2284, DOI 10.1053/euhj.2001.2836
   Mogensen J, 2004, J AM COLL CARDIOL, V44, P2033, DOI 10.1016/j.jacc.2004.08.027
   Mogensen J, 1999, J CLIN INVEST, V103, PR39, DOI 10.1172/JCI6460
   Mohapatra B, 2003, MOL GENET METAB, V80, P207, DOI 10.1016/S1096-7192(03)00142-2
   Mounkes LC, 2001, TRENDS CARDIOVAS MED, V11, P280, DOI 10.1016/S1050-1738(01)00126-8
   MUNTONI F, 1995, J CLIN INVEST, V96, P693, DOI 10.1172/JCI118112
   Muntoni F, 1997, HEART, V78, P608, DOI 10.1136/hrt.78.6.608
   MUNTONI F, 1993, NEW ENGL J MED, V329, P921, DOI 10.1056/NEJM199309233291304
   Murphy RT, 2004, LANCET, V363, P371, DOI 10.1016/S0140-6736(04)15468-8
   Niebauer J, 1999, LANCET, V353, P1838, DOI 10.1016/S0140-6736(98)09286-1
   Nigro V, 1997, HUM MOL GENET, V6, P601, DOI 10.1093/hmg/6.4.601
   Nigro V, 1996, NAT GENET, V14, P195, DOI 10.1038/ng1096-195
   Nikolova V, 2004, J CLIN INVEST, V113, P357, DOI 10.1172/JCI200419448
   Novelli G, 2002, AM J HUM GENET, V71, P426, DOI 10.1086/341908
   OToole L, 1998, J CARDIOVASC PHARM, V32, P988, DOI 10.1097/00005344-199812000-00017
   Olson TM, 1996, J CLIN INVEST, V97, P528, DOI 10.1172/JCI118445
   Olson TM, 2001, J MOL CELL CARDIOL, V33, P723, DOI 10.1006/jmcc.2000.1339
   Olson TM, 1998, SCIENCE, V280, P750, DOI 10.1126/science.280.5364.750
   Olson TM, 2002, CIRCULATION, V105, P431, DOI 10.1161/hc0402.102930
   OrtizLopez R, 1997, CIRCULATION, V95, P2434, DOI 10.1161/01.CIR.95.10.2434
   Richardson P, 1996, CIRCULATION, V93, P841, DOI 10.1161/01.CIR.93.5.841
   Robinson P, 2002, J BIOL CHEM, V277, P40710, DOI 10.1074/jbc.M203446200
   Schmitt JP, 2003, SCIENCE, V299, P1410, DOI 10.1126/science.1081578
   SCHOELLER R, 1993, AM J CARDIOL, V71, P720, DOI 10.1016/0002-9149(93)91017-C
   Schönberger J, 2001, AM J HUM GENET, V69, P249, DOI 10.1086/321978
   SCHOWENGERDT KO, 1995, CURR OPIN CARDIOL, V10, P312, DOI 10.1097/00001573-199505000-00013
   Sébillon P, 2003, J MED GENET, V40, P560, DOI 10.1136/jmg.40.8.560
   SIMPSON DG, 1994, J CELL PHYSIOL, V161, P89, DOI 10.1002/jcp.1041610112
   Sinagra G, 2001, ITAL HEART J, V2, P280
   Siu BL, 1999, CIRCULATION, V99, P1022, DOI 10.1161/01.CIR.99.8.1022
   Sjöberg G, 1999, HUM MOL GENET, V8, P2191, DOI 10.1093/hmg/8.12.2191
   Stefanelli CB, 2004, MOL GENET METAB, V83, P188, DOI 10.1016/j.ymgme.2004.04.013
   Stelken AM, 1996, J AM COLL CARDIOL, V27, P345, DOI 10.1016/0735-1097(95)00464-5
   Stuurman N, 1998, J STRUCT BIOL, V122, P42, DOI 10.1006/jsbi.1998.3987
   SUGRUE DD, 1992, ANN INTERN MED, V117, P117, DOI 10.7326/0003-4819-117-2-117
   SUOMALAINEN A, 1992, LANCET, V340, P1319, DOI 10.1016/0140-6736(92)92496-3
   Sylvius N, 2001, AM J HUM GENET, V68, P241, DOI 10.1086/316929
   Takai E, 1999, AM J MED GENET, V86, P325, DOI 10.1002/(SICI)1096-8628(19991008)86:4<325::AID-AJMG5>3.0.CO;2-U
   Taylor MRG, 2005, HUM MUTAT, V26, P566, DOI 10.1002/humu.20250
   Taylor MRG, 2003, J AM COLL CARDIOL, V41, P771, DOI 10.1016/S0735-1097(02)02954-6
   Tesson F, 2000, EUR HEART J, V21, P1872, DOI 10.1053/euhj.2000.2245
   TOWBIN JA, 1993, CIRCULATION, V87, P1854, DOI 10.1161/01.CIR.87.6.1854
   Towbin JA, 2006, JAMA-J AM MED ASSOC, V296, P1867, DOI 10.1001/jama.296.15.1867
   Tsubata S, 2000, J CLIN INVEST, V106, P655, DOI 10.1172/JCI9224
   VALANTINE HA, 1989, AM J CARDIOL, V63, P959, DOI 10.1016/0002-9149(89)90148-3
   Valle G, 1997, FEBS LETT, V415, P163, DOI 10.1016/S0014-5793(97)01108-3
   van Berlo JH, 2005, J MOL MED, V83, P79, DOI 10.1007/s00109-004-0589-1
   vanderKooi AJ, 1997, AM J HUM GENET, V60, P891
   Vasile VC, 2006, MOL GENET METAB, V87, P169, DOI 10.1016/j.ymgme.2005.08.006
   Vatta M, 2003, J AM COLL CARDIOL, V42, P2014, DOI 10.1016/j.jacc.2003.10.021
   Vatta M, 2004, J AM COLL CARDIOL, V43, P811, DOI 10.1016/j.jacc.2003.09.052
   Verga L, 2003, VIRCHOWS ARCH, V443, P664, DOI 10.1007/s00428-003-0865-4
   Villard E, 2005, EUR HEART J, V26, P794, DOI 10.1093/eurheartj/ehi193
   Vlcek S, 2002, J BIOL CHEM, V277, P18898, DOI 10.1074/jbc.M200048200
   WILLIAMS DG, 1985, BRIT HEART J, V54, P153
   Yoshida K, 1998, HUM MOL GENET, V7, P1129, DOI 10.1093/hmg/7.7.1129
   Zannad F, 2001, HYPERTENSION, V38, P1227, DOI 10.1161/hy1101.099484
   Zhou Q, 2001, J CELL BIOL, V155, P605, DOI 10.1083/jcb.200107092
NR 162
TC 94
Z9 113
U1 0
U2 10
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0785-3890
EI 1365-2060
J9 ANN MED
JI Ann. Med.
PD JUN 15
PY 2007
VL 39
IS 2
BP 91
EP 107
DI 10.1080/07853890601145821
PG 17
WC Medicine, General & Internal
SC General & Internal Medicine
GA 159UH
UT WOS:000245892500002
PM 17453673
DA 2024-11-01
ER

PT J
AU Finsterer, J
AF Finsterer, Josef
TI Hematological manifestations of primary mitochondrial disorders
SO ACTA HAEMATOLOGICA
LA English
DT Article
DE bone marrow; disease, multisystem; encephalomyopathy; mitochondrial cytopathy; mitochondriopathy; oxidative phosphorylation; respiratory chain
ID kearns-sayre-syndrome; linked sideroblastic anemia; marrow-pancreas syndrome; respiratory-chain disorders; hereditary optic neuropathy; dna deletion; megaloblastic-anemia; pearson-syndrome; lactic-acidosis; barth-syndrome
AB At onset mitochondrial disorders ( MID) frequently manifest as a mono- organic problem but turn into multisystem disease during the disease course in most of the cases. Organs/ tissues most frequently affected in MID are the cerebrum, peripheral nerves, and the skeletal muscle. Additionally, most of the inner organs may be affected alone or in combination. Hematological manifestations of MID include aplastic, megaloblastic, or sideroblastic anemia, leukopenia, neutropenia, thrombocytopenia, or pancytopenia. In single cases either permanent or recurrent eosinophilia has been observed. Hematological abnormalities may occur together with syndromic or nonsyndromic MIDs. Syndromic MIDs, in which hematological manifestations predominate, are the Pearson syndrome ( pancytopenia), Kearns- Sayre syndrome ( anemia), Barth syndrome ( neutropenia), and the autosomal recessive mitochondrial myopathy, lactic acidosis and sideroblastic anemia syndrome. In single cases with Leigh's syndrome, MERRF ( myoclonic epilepsy and ragged- red fiber) syndrome, Leber's hereditary optic neuropathy, and Friedreich's ataxia anemia has been described. Anemia, leukopenia, thrombocytopenia, eosinophilia, or pancytopenia can frequently also be found in nonsyndromic MIDs with or without involvement of other tissues. Therapy of blood cell involvement in MID comprises application of antioxidants, vitamins, iron, bone marrow- stimulating factors, or substitution of cells. Copyright circle star 2007 S. Karger AG, Basel.
C1 Krankenanstalt Rudolfstiftung Wien, AT-1180 Vienna, Austria.
C3 Rudolfstiftung Hospital
RP Finsterer, J (corresponding author), Krankenanstalt Rudolfstiftung Wien, Postfach 20, AT-1180 Vienna, Austria.
EM duarte@aonmail.at
CR Abramowicz MJ, 1996, J INHERIT METAB DIS, V19, P109, DOI 10.1007/BF01799405
   ADACHI K, 1993, BIOCHEM BIOPH RES CO, V195, P945, DOI 10.1006/bbrc.1993.2135
   Akman CI, 2004, J CHILD NEUROL, V19, P258, DOI 10.1177/088307380401900403
   Angelini C, 2006, EUR J NEUROL, V13, P923, DOI 10.1111/j.1468-1331.2006.01482.x
   Bader-Meunier B, 1999, PEDIATR RES, V46, P158, DOI 10.1203/00006450-199908000-00005
   Barth PG, 2004, AM J MED GENET A, V126A, P349, DOI 10.1002/ajmg.a.20660
   BERNES SM, 1993, J PEDIATR-US, V123, P598, DOI 10.1016/S0022-3476(05)80962-X
   Bernier FP, 2002, NEUROLOGY, V59, P1406, DOI 10.1212/01.WNL.0000033795.17156.00
   Bindoff LA, 2004, EUR J NEUROL, V11, P5
   BLATT J, 1994, BRIT J HAEMATOL, V86, P207, DOI 10.1111/j.1365-2141.1994.tb03280.x
   BOURGERON T, 1994, J CLIN INVEST, V93, P2514, DOI 10.1172/JCI117261
   Brunmair B, 2004, J PHARMACOL EXP THER, V311, P109, DOI 10.1124/jpet.104.068312
   Carod-Artal FJ, 2006, NEUROLOGIA, V21, P357
   CASADEMONT J, 1994, HUM MOL GENET, V3, P1945, DOI 10.1093/hmg/3.11.1945
   Chinnery PF, 1997, J NEUROL NEUROSUR PS, V63, P559, DOI 10.1136/jnnp.63.5.559
   Cocco T, 2002, J BIOENERG BIOMEMBR, V34, P251, DOI 10.1023/A:1020248300766
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   DiMauro S, 2006, MUSCLE NERVE, V34, P265, DOI 10.1002/mus.20598
   Fadic R, 1996, SEMIN NEUROL, V16, P11, DOI 10.1055/s-2008-1040954
   Finsterer J, 2004, EUR J NEUROL, V11, P163, DOI 10.1046/j.1351-5101.2003.00728.x
   Finsterer J, 2005, CLIN NEUROPHARMACOL, V28, P148, DOI 10.1097/01.wnf.0000165352.10841.21
   FISCHELGHODSIAN N, 1992, PEDIATR RES, V31, P557, DOI 10.1203/00006450-199206000-00004
   Fleming MD, 2002, SEMIN HEMATOL, V39, P270, DOI 10.1053/shem.2002.35637
   Fleming MD, 2001, GENE DEV, V15, P652, DOI 10.1101/gad.873001
   Fontenay M, 2006, ONCOGENE, V25, P4757, DOI 10.1038/sj.onc.1209606
   FROMENTY B, 1995, PHARMACOL THERAPEUT, V67, P101, DOI 10.1016/0163-7258(95)00012-6
   Furuyama K, 2006, EUR J HAEMATOL, V76, P33, DOI 10.1111/j.1600-0609.2005.00541.x
   Gillis L, 2002, PEDIATR CLIN N AM, V49, P203, DOI 10.1016/S0031-3955(03)00115-9
   Goyal S, 2004, EYE, V18, P1017, DOI 10.1038/sj.eye.6701388
   Heller T, 2004, DEUT MED WOCHENSCHR, V129, P141
   Hellier KD, 2001, J NEUROL NEUROSUR PS, V70, P65, DOI 10.1136/jnnp.70.1.65
   INBAL A, 1995, AM J MED GENET, V55, P372, DOI 10.1002/ajmg.1320550325
   Inoue SI, 2007, FEBS LETT, V581, P1910, DOI 10.1016/j.febslet.2007.03.092
   JACKSONLEWIS V, 1994, ANN NEUROL, V35, P244, DOI 10.1002/ana.410350221
   KEARNS TP, 1958, ARCH OPHTHALMOL-CHIC, V60, P280, DOI 10.1001/archopht.1958.00940080296016
   Klepper J, 2004, KLIN PADIATR, V216, P277, DOI 10.1055/s-2004-44906
   Knerr I, 2003, J PEDIAT HEMATOL ONC, V25, P948, DOI 10.1097/00043426-200312000-00008
   Kubat K, 1995, VNITR LEK, V41, P320
   Kuijpers TW, 2004, BLOOD, V103, P3915, DOI 10.1182/blood-2003-11-3940
   Leonard JV, 2000, LANCET, V355, P299, DOI 10.1016/S0140-6736(99)05225-3
   Leung TF, 1999, J INHERIT METAB DIS, V22, P86, DOI 10.1023/A:1005415802893
   Lewis JA, 1996, J BIOL CHEM, V271, P13184, DOI 10.1074/jbc.271.22.13184
   Lill R, 2001, RES MICROBIOL, V152, P331, DOI 10.1016/S0923-2508(01)01204-9
   Limongelli A, 2004, J MED GENET, V41, P342, DOI 10.1136/jmg.2003.016048
   Maassen JA, 2002, PANMINERVA MED, V44, P295
   Maguire A, 2001, BRIT J HAEMATOL, V115, P910, DOI 10.1046/j.1365-2141.2001.03015.x
   MAJANDER A, 1991, PEDIATR RES, V30, P327, DOI 10.1203/00006450-199110000-00007
   Man PYW, 2002, J MED GENET, V39, P162, DOI 10.1136/jmg.39.3.162
   Marriage B, 2003, J AM DIET ASSOC, V103, P1029, DOI 10.1016/S0002-8223(03)00476-0
   Matthes T, 2006, EUR J HAEMATOL, V77, P169, DOI 10.1111/j.1600-0609.2006.00674.x
   McFarland R, 2002, LANCET NEUROL, V1, P343, DOI 10.1016/S1474-4422(02)00159-X
   McIntosh LJ, 1998, BRAIN RES, V791, P209, DOI 10.1016/S0006-8993(98)00115-2
   MCSHANE MA, 1991, AM J HUM GENET, V48, P39
   Mohri I, 1998, J NEUROL SCI, V158, P106, DOI 10.1016/S0022-510X(98)00082-3
   MORIKAWA Y, 1993, VIRCHOWS ARCH A, V423, P227, DOI 10.1007/BF01614775
   Muraki K, 1997, J INHERIT METAB DIS, V20, P697, DOI 10.1023/A:1005378527077
   Nagashima T, 1999, ACTA NEUROPATHOL, V97, P416, DOI 10.1007/s004010051007
   NELSON I, 1992, NEUROPEDIATRICS, V23, P199, DOI 10.1055/s-2008-1071341
   Ozdemir Mehmet Akif, 2002, PEDIATR DIABETES, V3, P205
   Patton JR, 2005, J BIOL CHEM, V280, P19823, DOI 10.1074/jbc.M500216200
   Reichenbach J, 2006, PEDIATR RES, V60, P321, DOI 10.1203/01.pdr.0000233252.60457.cf
   Ricketts CJ, 2006, ACTA PAEDIATR, V95, P99, DOI 10.1080/08035250500323715
   Riess ML, 2005, ANESTH ANALG, V100, P46, DOI 10.1213/01.ANE.0000139346.76784.72
   Riess ML, 2004, ANESTHESIOLOGY, V100, P498, DOI 10.1097/00000542-200403000-00007
   RIGGS JE, 1984, NEUROLOGY, V34, P48, DOI 10.1212/WNL.34.1.48
   ROTIG A, 1990, J CLIN INVEST, V86, P1601, DOI 10.1172/JCI114881
   SAMAD FU, 1973, SOUTHERN MED J, V66, P135, DOI 10.1097/00007611-197301000-00022
   Schapira AHV, 1999, EUR J CLIN INVEST, V29, P886
   Scharfe C, 2000, J MED GENET, V37, P669, DOI 10.1136/jmg.37.9.669
   Schlame M, 2005, CHEM PHYS LIPIDS, V138, P38, DOI 10.1016/j.chemphyslip.2005.08.002
   Servidei Serenella, 2004, NEUROMUSCUL DISORD, V14, P107
   Silva MFB, 1997, J INHERIT METAB DIS, V20, P397, DOI 10.1023/A:1005398516208
   SIMONSZ HJ, 1992, DOC OPHTHALMOL, V82, P73, DOI 10.1007/BF00156996
   Sirvent P, 2005, BIOCHEM BIOPH RES CO, V338, P1426, DOI 10.1016/j.bbrc.2005.10.108
   Sztark F, 1999, ANN FR ANESTH, V18, P261, DOI 10.1016/S0750-7658(99)80081-1
   Tarnopolsky MA, 2005, MED SCI SPORT EXER, V37, P2086, DOI 10.1249/01.mss.0000177341.89478.06
   TULINIUS MH, 1995, EUR J PEDIATR, V154, P35, DOI 10.1007/BF01972970
   Vallance HD, 2004, PEDIATR CARDIOL, V25, P538, DOI 10.1007/s00246-003-0446-y
   VANHOVE JLK, 1994, AM J MED GENET, V51, P114, DOI 10.1002/ajmg.1320510207
   Vreken P, 2000, BIOCHEM BIOPH RES CO, V279, P378, DOI 10.1006/bbrc.2000.3952
   Waldhauser KM, 2006, J PHARMACOL EXP THER, V319, P1413, DOI 10.1124/jpet.106.108993
   Walker U A, 2002, PRAXIS (BERN 1994), V91, P2129
   Walker UA, 2000, MED KLIN, V95, P689, DOI 10.1007/PL00002087
   Wang YL, 1999, AM J HEMATOL, V60, P83, DOI 10.1002/(SICI)1096-8652(199901)60:1<83::AID-AJH19>3.0.CO;2-N
   WEI YH, 1985, BIOCHEM PHARMACOL, V34, P911, DOI 10.1016/0006-2952(85)90589-1
   Zaffanello M, 2005, MINERVA PEDIATR, V57, P143
   Zeharia A, 2005, J CHILD NEUROL, V20, P449, DOI 10.1177/08830738050200051301
   Zeviani M, 2004, BRAIN, V127, P2153, DOI 10.1093/brain/awh259
   Zeviani M, 2003, CURR OPIN NEUROL, V16, P585, DOI 10.1097/00019052-200310000-00004
   Zeviani M, 2003, CURR OPIN GENET DEV, V13, P262, DOI 10.1016/S0959-437X(03)00052-2
NR 90
TC 58
Z9 64
U1 0
U2 7
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0001-5792
EI 1421-9662
J9 ACTA HAEMATOL-BASEL
JI Acta Haematol.
PD JUN 15
PY 2007
VL 118
IS 2
BP 88
EP 98
DI 10.1159/000105676
PG 11
WC Hematology
SC Hematology
GA 208JU
UT WOS:000249316400007
PM 17637511
DA 2024-11-01
ER

PT J
AU Zeviani, M
   Carelli, V
AF Zeviani, Massimo
   Carelli, Valerio
TI Mitochondrial disorders
SO CURRENT OPINION IN NEUROLOGY
LA English
DT Review
DE maternal inheritance; mitochondrial disease; mitochondrial DNA; oxidative phosphorylation; respiratory chain
ID dna-polymerase-gamma; progressive external ophthalmoplegia; sideroblastic anemia mlasa; oxidative-phosphorylation deficiency; dominant optic atrophy; complex-i deficiency; marie-tooth-disease; neurogastrointestinal encephalomyopathy; missense mutation; saccharomyces-cerevisiae
AB Purpose of review Mitochondrial disorders are increasingly acknowledged as a major category in clinical neurology. In this review we highlight the most recent advances in the field, including the characterization of new disease genes, new 1 physiopathological insights, and the role of mitochondrial dysfunction in neurodegeneration. Recent findings Substantial progress has been made on the genetic basis and pathogenic mechanisms in disorders associated with altered mitochondrial DNA stability and expression. These I defects include a wide spectrum of neurological conditions caused by genetic abnormalities of the mitochondrial replication and translation machineries, and of the metabolic pathways controlling the nucleotide supply to organelles, cells and tissues. Another relevant contribution I has been given to the molecular dissection of coenzyme 0 deficiency, a clinically heterogeneous, potentially treatable condition, thanks to the biochemical and genetic characterization of the first defects in coenzyme 0 biosynthesis. Finally, the genetic determinants controlling the penetrance of mitochondrial disorders, as well as the role of mitochondrial dysfunction in neurodegenerative conditions such as Parkinson's and Huntington's diseases, have been investigated in both patients and animal models. Summary The dual genetic contribution controlling mitochondrial biogenesis, and the intricacy and universality of the metabolic pathways operating in the mitochondrion explain the complexity of what is now known as 'mitochondrial medicine'.
C1 Fdn Ist Neurol Carlos Besta, IRCCS, Div Neurogenet Mol, I-20126 Milan, Italy.
   Fdn IRCCS, Inst Neurol, Unit Mol Neurogenet, Milan, Italy.
   Univ Bologna, Dept Neurobiol Sci, Neurogenet Lab, Bologna, Italy.
C3 Fondazione IRCCS Istituto Neurologico Carlo Besta; University of Bologna
RP Zeviani, M (corresponding author), Fdn Ist Neurol Carlos Besta, IRCCS, Div Neurogenet Mol, Via Temolo 4, I-20126 Milan, Italy.
EM zeviani@istituto-besta.it
CR Alavi MV, 2007, BRAIN, V130, P1029, DOI 10.1093/brain/awm005
   Antonicka H, 2006, HUM MOL GENET, V15, P1835, DOI 10.1093/hmg/ddl106
   Ashley N, 2007, HUM MOL GENET, V16, P1400, DOI 10.1093/hmg/ddm090
   Baloh RH, 2007, J NEUROSCI, V27, P422, DOI 10.1523/JNEUROSCI.4798-06.2007
   Bandelt HJ, 2006, J HUM GENET, V51, P1073, DOI 10.1007/s10038-006-0066-5
   Bandelt HJ, 2005, BIOCHEM BIOPH RES CO, V333, P122, DOI 10.1016/j.bbrc.2005.04.055
   Baruffini E, 2006, HUM MOL GENET, V15, P2846, DOI 10.1093/hmg/ddl219
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Blok MJ, 2007, J MED GENET, V44, P0, DOI 10.1136/jmg.2006.045716
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Bykhovskaya Y, 2004, AM J HUM GENET, V74, P1303, DOI 10.1086/421530
   Bykhovskaya Y, 2007, MOL GENET METAB, V91, P148, DOI 10.1016/j.ymgme.2007.02.006
   Calvo S, 2006, NAT GENET, V38, P576, DOI 10.1038/ng1776
   Cao LQ, 2007, NAT GENET, V39, P386, DOI 10.1038/ng1970
   Carelli V, 2006, AM J HUM GENET, V78, P564, DOI 10.1086/501236
   Carelli V, 2007, BIOSCIENCE REP, V27, P173, DOI 10.1007/s10540-007-9045-0
   Carrozzo R, 2007, BRAIN, V130, P862, DOI 10.1093/brain/awl389
   Castagna AE, 2007, AM J MED GENET A, V143A, P808, DOI 10.1002/ajmg.a.31637
   Chae JH, 2007, PEDIATR RES, V61, P622, DOI 10.1203/pdr.0b013e3180459f2d
   Chan DC, 2006, CELL, V125, P1241, DOI 10.1016/j.cell.2006.06.010
   Chan SSL, 2006, HUM MOL GENET, V15, P3473, DOI 10.1093/hmg/ddl424
   Chen HC, 2006, CURR OPIN CELL BIOL, V18, P453, DOI 10.1016/j.ceb.2006.06.004
   Chung KW, 2006, BRAIN, V129, P2103, DOI 10.1093/brain/awl174
   Cipolat S, 2006, CELL, V126, P163, DOI 10.1016/j.cell.2006.06.021
   Coenen MJH, 2004, NEW ENGL J MED, V351, P2080, DOI 10.1056/NEJMoa041878
   Davies VJ, 2007, HUM MOL GENET, V16, P1307, DOI 10.1093/hmg/ddm079
   de Vries MC, 2007, EUR J PEDIATR, V166, P229, DOI 10.1007/s00431-006-0234-9
   DellAgnello C, 2007, HUM MOL GENET, V16, P431, DOI 10.1093/hmg/ddl477
   Djarmati A, 2006, MOVEMENT DISORD, V21, P1526, DOI 10.1002/mds.20977
   Duvezin-Caubet S, 2006, J BIOL CHEM, V281, P37972, DOI 10.1074/jbc.M606059200
   Ekstrand MI, 2007, P NATL ACAD SCI USA, V104, P1325, DOI 10.1073/pnas.0605208103
   Fernandez-Vizarra E, 2007, J MED GENET, V44, P173, DOI 10.1136/jmg.2006.045252
   Freisinger P, 2006, ARCH NEUROL-CHICAGO, V63, P1129, DOI 10.1001/archneur.63.8.1129
   Frezza C, 2006, CELL, V126, P177, DOI 10.1016/j.cell.2006.06.025
   Fukui H, 2007, HUM MOL GENET, V16, P783, DOI 10.1093/hmg/ddm023
   Giordano C, 2006, GASTROENTEROLOGY, V130, P893, DOI 10.1053/j.gastro.2006.01.004
   Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805
   Greaves LC, 2006, IUBMB LIFE, V58, P143, DOI 10.1080/15216540600686888
   Hakonen AH, 2007, EUR J HUM GENET, V15, P779, DOI 10.1038/sj.ejhg.5201831
   He JY, 2007, J CELL BIOL, V176, P141, DOI 10.1083/jcb.200609158
   Hirano M, 2006, NEUROLOGY, V67, P1458, DOI 10.1212/01.wnl.0000240853.97716.24
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Hudson G, 2005, AM J HUM GENET, V77, P1086, DOI 10.1086/498176
   Hudson G, 2006, HUM MOL GENET, V15, PR244, DOI 10.1093/hmg/ddl233
   Ibáñez P, 2006, BRAIN, V129, P686, DOI 10.1093/brain/awl005
   Ishihara N, 2006, EMBO J, V25, P2966, DOI 10.1038/sj.emboj.7601184
   Jacobs HT, 2005, TRENDS GENET, V21, P312, DOI 10.1016/j.tig.2005.04.003
   Karadimas CL, 2006, AM J HUM GENET, V79, P544, DOI 10.1086/506913
   Kollberg G, 2006, J NEUROPATH EXP NEUR, V65, P758, DOI 10.1097/01.jnen.0000229987.17548.6e
   Le Ber I, 2007, NEUROLOGY, V68, P295, DOI 10.1212/01.wnl.0000252366.10731.43
   Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292
   Loiseau D, 2007, ANN NEUROL, V61, P315, DOI 10.1002/ana.21086
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   López LC, 2006, AM J HUM GENET, V79, P1125, DOI 10.1086/510023
   López-Martín JM, 2007, HUM MOL GENET, V16, P1091, DOI 10.1093/hmg/ddm058
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Maeso E, 2007, NEUROMUSCULAR DISORD, V17, P415, DOI 10.1016/j.nmd.2007.01.015
   Malfatti E, 2007, BRAIN, V130, P1894, DOI 10.1093/brain/awm114
   McFarland R, 2007, CURR TOP DEV BIOL, V77, P113, DOI 10.1016/S0070-2153(06)77005-3
   McGill JK, 2006, CELL, V127, P465, DOI 10.1016/j.cell.2006.10.023
   Miller C, 2004, ANN NEUROL, V56, P734, DOI 10.1002/ana.20282
   Mollet J, 2007, J CLIN INVEST, V117, P765, DOI 10.1172/JCI29089
   Moreno-Loshuertos R, 2006, NAT GENET, V38, P1261, DOI 10.1038/ng1897
   Naïmi M, 2006, EUR J HUM GENET, V14, P917, DOI 10.1038/sj.ejhg.5201627
   Neupert W, 2007, ANNU REV BIOCHEM, V76, P723, DOI 10.1146/annurev.biochem.76.052705.163409
   Nguyen KV, 2006, J HEPATOL, V45, P108, DOI 10.1016/j.jhep.2005.12.026
   Olichon A, 2007, CELL DEATH DIFFER, V14, P682, DOI 10.1038/sj.cdd.4402048
   Olichon A, 2006, BBA-MOL CELL RES, V1763, P500, DOI 10.1016/j.bbamcr.2006.04.003
   Olichow A, 2007, J CELL PHYSIOL, V211, P423, DOI 10.1002/jcp.20950
   Oskoui M, 2006, ARCH NEUROL-CHICAGO, V63, P1122, DOI 10.1001/archneur.63.8.1122
   Ostergaard E, 2007, BRAIN, V130, P853, DOI 10.1093/brain/awl383
   Pagnamenta AT, 2006, HUM REPROD, V21, P2467, DOI 10.1093/humrep/del076
   Patton JR, 2005, J BIOL CHEM, V280, P19823, DOI 10.1074/jbc.M500216200
   Pereira C, 2007, BIOCHEM BIOPH RES CO, V354, P937, DOI 10.1016/j.bbrc.2007.01.068
   Pontarin G, 2006, J BIOL CHEM, V281, P22720, DOI 10.1074/jbc.M604498200
   Quinzii C, 2006, AM J HUM GENET, V78, P345, DOI 10.1086/500092
   Quinzii CM, 2007, MITOCHONDRION, V7, PS122, DOI 10.1016/j.mito.2007.03.004
   Ribai P, 2007, ARCH NEUROL-CHICAGO, V64, P558, DOI 10.1001/archneur.64.4.558
   Rötig A, 2007, MITOCHONDRION, V7, PS112, DOI 10.1016/j.mito.2007.02.008
   Rugarli EI, 2006, TRENDS MOL MED, V12, P262, DOI 10.1016/j.molmed.2006.04.002
   Ryan MT, 2007, ANNU REV BIOCHEM, V76, P701, DOI 10.1146/annurev.biochem.76.052305.091720
   Schapira AHV, 2006, LANCET, V368, P70, DOI 10.1016/S0140-6736(06)68970-8
   Shoubridge EA, 2007, CURR TOP DEV BIOL, V77, P87, DOI 10.1016/S0070-2153(06)77004-1
   Smeitink JA, 2006, CELL METAB, V3, P9, DOI 10.1016/j.cmet.2005.12.001
   Smeitink JAM, 2006, AM J HUM GENET, V79, P869, DOI 10.1086/508434
   Solans A, 2006, HUM MOL GENET, V15, P3063, DOI 10.1093/hmg/ddl248
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Spinazzola A, 2007, BIOSCIENCE REP, V27, P39, DOI 10.1007/s10540-007-9036-1
   Stuart GR, 2006, HUM MOL GENET, V15, P363, DOI 10.1093/hmg/ddi454
   Tan EK, 2006, MOVEMENT DISORD, V21, P789, DOI 10.1002/mds.20810
   Toft M, 2007, J NEUROL NEUROSUR PS, V78, P82, DOI 10.1136/jnnp.2006.097840
   Tong JJY, 2007, NAT GENET, V39, P476, DOI 10.1038/ng2004
   Tzoulis C, 2006, BRAIN, V129, P1685, DOI 10.1093/brain/awl097
   Valente L, 2007, AM J HUM GENET, V80, P44, DOI 10.1086/510559
   Verhoeven K, 2006, BRAIN, V129, P2093, DOI 10.1093/brain/awl126
   Vermulst M, 2007, NAT GENET, V39, P540, DOI 10.1038/ng1988
   Wallace DC, 2007, ANNU REV BIOCHEM, V76, P781, DOI 10.1146/annurev.biochem.76.081205.150955
   Wang YS, 2006, J BIOL CHEM, V281, P25791, DOI 10.1074/jbc.M604501200
   Waterham HR, 2007, NEW ENGL J MED, V356, P1736, DOI 10.1056/NEJMoa064436
   Weydt P, 2006, CELL METAB, V4, P349, DOI 10.1016/j.cmet.2006.10.004
   WONG LJ, 2007, MUSCLE NERVE 0517, V0, P0
   Yakubovskaya E, 2006, J BIOL CHEM, V281, P374, DOI 10.1074/jbc.M509730200
   Yavuz H, 2007, ARCH NEUROL-CHICAGO, V64, P435, DOI 10.1001/archneur.64.3.435
   Züchner S, 2006, ANN NEUROL, V59, P276, DOI 10.1002/ana.20797
NR 105
TC 102
Z9 115
U1 0
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1350-7540
EI 
J9 CURR OPIN NEUROL
JI Curr. Opin. Neurol.
PD OCT 15
PY 2007
VL 20
IS 5
BP 564
EP 571
DI 10.1097/WCO.0b013e3282ef58cd
PG 8
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 216GJ
UT WOS:000249866200009
PM 17885446
DA 2024-11-01
ER

PT J
AU Finsterer, J
AF Finsterer, Josef
TI Neuromuscular implications in CADASIL
SO CEREBROVASCULAR DISEASES
LA English
DT Review
DE skeletal muscle; cardiomyopathy; neuromuscular disorder; peripheral nervous system; neuropathy; myopathy
ID autosomal-dominant arteriopathy; subcortical infarcts; mitochondrial-dna; skeletal-muscle; notch3 gene; skin biopsy; leukoencephalopathy; mutation; patient
AB Objectives: Recent studies indicate that Notch3 gene mutations not only manifest as cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) but also in the peripheral nerves and skeletal muscles. Methods: A MEDLINE search with appropriate terms was carried out. Six articles, dealing with neuromuscular involvement in CADASIL, were selected and reviewed. Results: Several case studies presented CADASIL patients with clinical features of myopathy. Neurological diagnostic workup in these patients revealed weakness, wasting, reduced/ exaggerated tendon reflexes, abnormal nerve conduction and electromyography, muscle biopsy with ragged red muscle fibers, reduced COX staining, decreased complex I respiratory chain activity, abnormally structured mitochondria, or mitochondrial DNA ( mtDNA) mutations, such as G5650A in the tRNAAla gene, or various other mtDNA substitutions. Additionally, fibroblasts in skin biopsy may show reduced complex V respiratory chain activity. Conclusions: These findings suggest Notch3 mutations to be associated with mitochondrial disease, particularly affecting the skeletal muscle. Whether mtDNA mutations were induced by Notch3 mutations, by oxidative stress due to chronic hypoxia, resulting from arteriopathy, or occurred spontaneously remains elusive. Patients carrying Notch3 mutations should be systematically investigated for neuromuscular involvement, which may have therapeutic and prognostic implications for these patients. Copyright (c) 2007 S. Karger AG, Basel.
C1 Krankenanstalt Rudolfstiftung Wien, AT-1180 Vienna, Austria.
C3 Rudolfstiftung Hospital
RP Finsterer, J (corresponding author), Krankenanstalt Rudolfstiftung Wien, Postfach 20, AT-1180 Vienna, Austria.
EM duarte@aonmail.at
CR Annunen-Rasila J, 2007, MITOCHONDRION, V7, P96, DOI 10.1016/j.mito.2006.11.004
   Annunen-Rasila J, 2006, NEUROGENETICS, V7, P185, DOI 10.1007/s10048-006-0049-x
   Cumurciuc R, 2006, STROKE, V37, P1100, DOI 10.1161/01.STR.0000209242.68844.20
   de la Peña P, 2001, NEUROLOGY, V57, P1235, DOI 10.1212/WNL.57.7.1235
   Dichgans M, 2002, CEREBROVASC DIS, V13, P37, DOI 10.1159/000049148
   Dotti MT, 2004, ARCH NEUROL-CHICAGO, V61, P942, DOI 10.1001/archneur.61.6.942
   Finnilä S, 2001, J MOL MED, V79, P641, DOI 10.1007/s001090100268
   Goebel HH, 1997, MUSCLE NERVE, V20, P625, DOI 10.1002/(SICI)1097-4598(199705)20:5<625::AID-MUS17>3.0.CO;2-V
   Guidetti D, 2006, CLIN EXP HYPERTENS, V28, P271, DOI 10.1080/10641960600549223
   Ishiko A, 2006, ACTA NEUROPATHOL, V112, P333, DOI 10.1007/s00401-006-0116-2
   Joutel A, 1997, LANCET, V350, P1511, DOI 10.1016/S0140-6736(97)08083-5
   Kalaria RN, 2004, J NEUROL SCI, V226, P35, DOI 10.1016/j.jns.2004.09.008
   Lewandowska E, 2006, FOLIA NEUROPATHOL, V44, P265
   Luft FC, 2001, J MOL MED-JMM, V79, P613, DOI 10.1007/s00109-001-0285-3
   Malandrini A, 2002, NEUROLOGY, V59, P617, DOI 10.1212/WNL.59.4.617
   Mayer M, 1999, J NEUROL, V246, P526, DOI 10.1007/s004150050398
   Miranda M, 2006, MOVEMENT DISORD, V21, P1008, DOI 10.1002/mds.20879
   Mourad A, 2006, REV NEUROL-FRANCE, V162, P827, DOI 10.1016/S0035-3787(06)75085-8
   Opherk C, 2004, BRAIN, V127, P2533, DOI 10.1093/brain/awh282
   Roine S, 2006, OPHTHALMOLOGY, V113, P1411, DOI 10.1016/j.ophtha.2006.03.030
   RUCHOUX MM, 1995, ACTA NEUROPATHOL, V89, P500
   Schröder JM, 2005, ACTA NEUROPATHOL, V110, P587, DOI 10.1007/s00401-005-1082-9
   Sicurelli F, 2005, J NEUROL, V252, P1206, DOI 10.1007/s00415-005-0837-5
   Singhal S, 2004, BRAIN, V127, P2031, DOI 10.1093/brain/awh223
   Viswanathan A, 2006, STROKE, V37, P2690, DOI 10.1161/01.STR.0000245091.28429.6a
   Walsh JS, 2000, J AM ACAD DERMATOL, V43, P1125, DOI 10.1067/mjd.2000.110895
NR 26
TC 14
Z9 14
U1 0
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1015-9770
EI 1421-9786
J9 CEREBROVASC DIS
JI Cerebrovasc. Dis.
PD JUN 15
PY 2007
VL 24
IS 5
BP 401
EP 404
DI 10.1159/000108428
PG 4
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA 216VR
UT WOS:000249907600001
PM 17878719
DA 2024-11-01
ER

PT J
AU Krishnan, KJ
   Reeve, AK
   Turnbull, DM
AF Krishnan, K. J.
   Reeve, A. K.
   Turnbull, D. M.
TI Do mitochondrial DNA mutations have a role in neurodegenerative disease?
SO BIOCHEMICAL SOCIETY TRANSACTIONS
LA English
DT Article; Proceedings Paper
DE mitochondrial DNA (mtDNA); mitochondrial DNA mutation; mitochondrial dysfunction; neurodegenerative disease; oxidative stress; Parkinson's disease
ID progressive external ophthalmoplegia; mtdna control-region; substantia-nigra neurons; parkinsons-disease; alzheimers-disease; alpha-synuclein; elderly-patients; point mutations; transgenic mice; pars-compacta
AB A decline in mitochondrial function has long been shown to exist in neurodegenerative disease. Whether this decline is a secondary consequence of other factors or whether it causes the eventual death of a cell is unknown. In this review, we will discuss some of the major evidence surrounding mitochondrial DNA mutations leading to mitochondrial dysfunction in neurodegenerative disease and discuss their possible role in neurodegeneration.
C1 Univ Newcastle Upon Tyne, Sch Med, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
C3 Newcastle University - UK
RP Krishnan, KJ (corresponding author), Univ Newcastle Upon Tyne, Sch Med, Mitochondrial Res Grp, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM k.j.krishnan@ncl.ac.uk
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   Aliev G, 2002, ANN NY ACAD SCI, V977, P45, DOI 10.1111/j.1749-6632.2002.tb04798.x
   Aomi Y, 2001, BIOCHEM BIOPH RES CO, V280, P265, DOI 10.1006/bbrc.2000.4113
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   BINDOFF LA, 1989, LANCET, V2, P49, DOI 10.1016/S0140-6736(89)90291-2
   BOULET L, 1992, AM J HUM GENET, V51, P1187
   BURNS RS, 1983, P NATL ACAD SCI-BIOL, V80, P4546, DOI 10.1073/pnas.80.14.4546
   Chagnon P, 1999, AM J MED GENET, V85, P20, DOI 10.1002/(SICI)1096-8628(19990702)85:1<20::AID-AJMG6>3.0.CO;2-K
   Chinnery PF, 2001, AM J HUM GENET, V68, P529, DOI 10.1086/318204
   CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221
   Coskun PE, 2004, P NATL ACAD SCI USA, V101, P10726, DOI 10.1073/pnas.0403649101
   Cottrell DA, 2001, NEUROLOGY, V57, P260, DOI 10.1212/WNL.57.2.260
   Dauer W, 2002, P NATL ACAD SCI USA, V99, P14524, DOI 10.1073/pnas.172514599
   Davidzon G, 2006, ANN NEUROL, V59, P859, DOI 10.1002/ana.20831
   Ekstrand MI, 2007, P NATL ACAD SCI USA, V104, P1325, DOI 10.1073/pnas.0605208103
   Elson JL, 2006, HUM GENET, V119, P241, DOI 10.1007/s00439-005-0123-8
   Gai WP, 2000, EXP NEUROL, V166, P324, DOI 10.1006/exnr.2000.7527
   Gu M, 1998, J NEUROL SCI, V158, P24, DOI 10.1016/S0022-510X(98)00095-1
   Hudson G, 2007, ARCH NEUROL-CHICAGO, V64, P553, DOI 10.1001/archneur.64.4.553
   Ito S, 1999, P NATL ACAD SCI USA, V96, P2099, DOI 10.1073/pnas.96.5.2099
   JANETZKY B, 1994, NEUROSCI LETT, V169, P126, DOI 10.1016/0304-3940(94)90372-7
   KISH SJ, 1992, J NEUROCHEM, V59, P776, DOI 10.1111/j.1471-4159.1992.tb09439.x
   Kraytsberg Y, 2006, NAT GENET, V38, P518, DOI 10.1038/ng1778
   LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561
   LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Mancuso M, 2004, ARCH NEUROL-CHICAGO, V61, P1777, DOI 10.1001/archneur.61.11.1777
   Melberg A, 2005, ACTA NEUROPATHOL, V110, P315, DOI 10.1007/s00401-005-1047-z
   Michikawa Y, 1999, SCIENCE, V286, P774, DOI 10.1126/science.286.5440.774
   Parker WD, 2005, BIOCHEM BIOPH RES CO, V326, P667, DOI 10.1016/j.bbrc.2004.11.093
   PARKER WD, 1994, NEUROLOGY, V44, P1090, DOI 10.1212/WNL.44.6.1090
   Pyle A, 2005, ANN NEUROL, V57, P564, DOI 10.1002/ana.20417
   ROY S, 1969, J PATHOL, V99, P39, DOI 10.1002/path.1710990106
   SCHAPIRA AHV, 1989, LANCET, V1, P1269, DOI 10.1016/S0140-6736(89)92366-0
   SCIACCO M, 1994, HUM MOL GENET, V3, P13, DOI 10.1093/hmg/3.1.13
   Smigrodzki R, 2004, NEUROBIOL AGING, V25, P1273, DOI 10.1016/j.neurobiolaging.2004.02.020
   Song DD, 2004, EXP NEUROL, V186, P158, DOI 10.1016/S0014-4886(03)00342-X
   Stichel CC, 2007, HUM MOL GENET, V16, P2377, DOI 10.1093/hmg/ddm083
   Swerdlow RH, 1997, NEUROLOGY, V49, P918, DOI 10.1212/WNL.49.4.918
   Taylor RW, 2003, J CLIN INVEST, V112, P1351, DOI 10.1172/JCI200319435
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Tiangyou W, 2006, NEUROLOGY, V67, P1698, DOI 10.1212/01.wnl.0000238963.07425.d5
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Trimmer PA, 2004, J NEUROCHEM, V88, P800, DOI 10.1046/j.1471-4159.2003.02168.x
   van der Walt JM, 2003, AM J HUM GENET, V72, P804, DOI 10.1086/373937
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Wanrooij S, 2004, NUCLEIC ACIDS RES, V32, P3053, DOI 10.1093/nar/gkh634
NR 48
TC 8
Z9 8
U1 1
U2 6
PU PORTLAND PRESS LTD
PI LONDON
PA THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND
SN 0300-5127
EI 
J9 BIOCHEM SOC T
JI Biochem. Soc. Trans.
PD NOV 15
PY 2007
VL 35
IS 
BP 1232
EP 1235
DI 10.1042/BST0351232
PG 4
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 236CE
UT WOS:000251279800092
PM 17956320
DA 2024-11-01
ER

PT J
AU Mkaouar-Rebai, E
   Tlili, A
   Masmoudi, S
   Belguith, N
   Charfeddine, I
   Mnif, M
   Triki, C
   Fakhfakh, F
AF Mkaouar-Rebai, Emna
   Tlili, Abdelaziz
   Masmoudi, Saber
   Belguith, Neila
   Charfeddine, Ilhem
   Mnif, Mouna
   Triki, Chahnez
   Fakhfakh, Faiza
TI Mutational analysis of the mitochondrial tRNA<SUP>Leu(UUR)</SUP> gene in Tunisian patients with mitochondrial diseases
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE A3243G mutation; tRNA(Leu(UUR)) gene; mitochondrial ND1 gene; diabetes; hearing loss; MIDD; T3396C
ID dna a3243g mutation; diabetes-mellitus; clinical-features; melas mutation; insulin sensitivity; lactic-acidosis; hearing-loss; g-transition; rna; prevalence
AB The mitochondrial tRNA(Leu(UUR)) gene (MTTL) is a hot spot for pathogenic mutations that are associated with mitochondrial diseases with various clinical features. Among these mutations, the A3243G mutation was associated with various types of mitochondrial multisystem disorders, such as MIDD, MELAS, MERRF, PEO, hypertrophic cardiomyopathy, and a subtype of Leigh syndrome. We screened 128 Tunisian patients for the A3243G mutation in the mitochondrial tRNA(Leu(UUR)) gene. This screening was carried out using PCR-RFLP with the restriction endonuclease ApaI. None of the 128 patients or the 100 controls tested were found to carry the mitochondrial A3243G mutation in the tRNA(Leu(UUR)) gene in homoplasmic or heteroplasmic form. After direct sequencing of the entire mitochondrial tRNA(Leu(UUR)) gene and a part of the mitochondrial NADH dehydrogenase 1, we found neither mutations nor polymorphisms in the MTTL1 gene in the tested patients and controls, and we confirmed the absence of the A3243G mutation in this gene. We also found a T3396C transition in the ND1 gene in one family with NSHL which was absent in the other patients and in 100 controls. Neither polymorphisms nor other mutations were found in the mitochondrial tRNA(Leu(UUR)) gene in the tested patients. (c) 2007 Elsevier Inc. All rights reserved.
C1 Fac Med, Lab Genet Mol Humaine, Sfax 3029, Tunisia.
   CHU Habib Bourguiba, Serv ORL, Sfax 3029, Tunisia.
   CHU Habib Bourguiba, Serv Neurol, Sfax 3029, Tunisia.
   CHU Habib Bourguiba, Serv Endocrinol, Sfax 3029, Tunisia.
C3 Universite de Sfax; Universite de Sfax; Hopital Habib Bourguiba; Universite de Sfax; Hopital Habib Bourguiba; Universite de Sfax; Hopital Hedi Chaker; Hopital Habib Bourguiba
RP Mkaouar-Rebai, E (corresponding author), Fac Med, Lab Genet Mol Humaine, Sfax 3029, Tunisia.
EM emna_mkaouar@mail2world.com; faiza.fakhfakh@gnet.tn
CR Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Chae JH, 2004, BRAIN DEV-JPN, V26, P459, DOI 10.1016/j.braindev.2004.01.002
   CIAFALONI E, 1992, ANN NEUROL, V31, P391, DOI 10.1002/ana.410310408
   De Kremer RD, 2001, AM J MED GENET, V99, P83, DOI 10.1002/1096-8628(2001)9999:9999<::AID-AJMG1136>3.0.CO;2-X
   Deschauer M, 2001, ARCH NEUROL-CHICAGO, V58, P1885, DOI 10.1001/archneur.58.11.1885
   Deschauer M, 1999, NEUROMUSCULAR DISORD, V9, P305, DOI 10.1016/S0960-8966(99)00019-X
   DEVRIES D, 1994, J NEUROL SCI, V124, P77, DOI 10.1016/0022-510X(94)90014-0
   Fabrizi GM, 1996, J NEUROL NEUROSUR PS, V61, P47, DOI 10.1136/jnnp.61.1.47
   Flierl A, 1997, J BIOL CHEM, V272, P27189, DOI 10.1074/jbc.272.43.27189
   GERBITZ KD, 1995, BBA-MOL BASIS DIS, V1271, P253, DOI 10.1016/0925-4439(95)00036-4
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Helm M, 1999, NUCLEIC ACIDS RES, V27, P756, DOI 10.1093/nar/27.3.756
   Holmes-Walker DJ, 2001, DIABETIC MED, V18, P381, DOI 10.1046/j.1464-5491.2001.00472.x
   Kanaumi T, 2006, PEDIATR NEUROL, V34, P235, DOI 10.1016/j.pediatrneurol.2005.08.024
   Koga Y, 2000, ACTA NEUROPATHOL, V99, P186, DOI 10.1007/PL00007423
   Lee HC, 1997, J CLIN ENDOCR METAB, V82, P372, DOI 10.1210/jc.82.2.372
   Lehto M, 1999, DIABETOLOGIA, V42, P1131, DOI 10.1007/s001250051281
   LEWIN HA, 1992, BIOTECHNIQUES, V13, P522
   Majamaa K, 1998, AM J HUM GENET, V63, P447, DOI 10.1086/301959
   Mkaouar-Rebai E, 2006, BIOCHEM BIOPH RES CO, V340, P1251, DOI 10.1016/j.bbrc.2005.12.123
   MORAES CT, 1993, NEUROMUSCULAR DISORD, V3, P43, DOI 10.1016/0960-8966(93)90040-Q
   Nagata H, 2001, J HUM GENET, V46, P595, DOI 10.1007/s100380170027
   Newkirk JE, 1997, DIABETIC MED, V14, P457, DOI 10.1002/(SICI)1096-9136(199706)14:6<457::AID-DIA372>3.3.CO;2-N
   Ng MCY, 2000, CLIN ENDOCRINOL, V52, P557, DOI 10.1046/j.1365-2265.2000.00989.x
   ODAWARA M, 1995, J CLIN ENDOCR METAB, V80, P1290, DOI 10.1210/jc.80.4.1290
   OTABE S, 1994, J CLIN ENDOCR METAB, V79, P768, DOI 10.1210/jc.79.3.768
   Pang CY, 1999, J FORMOS MED ASSOC, V98, P326
   Park H, 2003, BIOCHEMISTRY-US, V42, P958, DOI 10.1021/bi026882r
   Rossmanith W, 1998, FEBS LETT, V433, P269, DOI 10.1016/S0014-5793(98)00928-4
   Sue CM, 1997, NEUROLOGY, V49, P1013, DOI 10.1212/WNL.49.4.1013
   Suzuki Y, 2003, DIABETES CARE, V26, P1315, DOI 10.2337/diacare.26.4.1315
   Thomas AW, 1996, J MED GENET, V33, P253, DOI 10.1136/jmg.33.3.253
   Uchigata Y, 1996, DIABETOLOGIA, V39, P245, DOI 10.1007/BF00403970
   Ueki I, 2006, MITOCHONDRION, V6, P29, DOI 10.1016/j.mito.2005.10.003
   VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368
   Velho G, 1996, DIABETES, V45, P478, DOI 10.2337/diabetes.45.4.478
   Vilarinho L, 1997, J MED GENET, V34, P607, DOI 10.1136/jmg.34.7.607
   YANG YL, 2006, CHIN MED J, V5, P373
   Yorifuji T, 1996, J MED GENET, V33, P621, DOI 10.1136/jmg.33.7.621
NR 39
TC 19
Z9 21
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD APR 20
PY 2007
VL 355
IS 4
BP 1031
EP 1037
DI 10.1016/j.bbrc.2007.02.083
PG 7
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 148ZD
UT WOS:000245115000030
PM 17336924
DA 2024-11-01
ER

PT J
AU Maeso, E
   Rueda, A
   Jiménez, S
   del Hoyo, P
   Martín, R
   Cabello, A
   Mendoza, LM
   Arenas, J
   Campos, Y
AF Maeso, E.
   Rueda, A.
   Jimenez, S.
   del Hoyo, P.
   Martin, R.
   Cabello, A.
   Mendoza, L. M.
   Arenas, J.
   Campos, Y.
TI A novel mutation in the mitochondrial DNA tRNA Leu (UUR) gene associated with late-onset ocular myopathy
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE mitochondrial diseases; mitochondrial DNA; transfer RNA Leu (UUR); ocular myopathy; mitochondria
ID point mutation; muscle; melas
AB We identified a novel G3283A transition in the mitochondrial DNA tRNA(Leu (UUR)) gene in a patient with ptosis, ophthalmoparesis and hyporeftexia. Muscle biopsy showed cytochrome oxidase positive ragged-red fibers, and defects of complexes I, III and IV of the mitochondrial respiratory chain. The mutation was heteroplasmic in muscle of the proband, being absent in her blood. Ragged-red fibers harbored greater levels of mutant genomes than normal fibers. The G3283A mutation affects a strictly conserved base pair in the T Psi C stem of the gene and was not found in controls, thus satisfying the accepted criteria for pathogenicity. (c) 2007 Elsevier B.V. All rights reserved.
C1 Hosp 12 Octubre, Ctr Invest, E-28041 Madrid, Spain.
   Hosp Univ Getafe, Serv Neurol, Madrid, Spain.
   Hosp 12 Octubre, Serv Anat Patol, E-28041 Madrid, Spain.
C3 Hospital Universitario 12 de Octubre; Hospital Universitario de Getafe; Hospital Universitario 12 de Octubre
RP Campos, Y (corresponding author), Hosp 12 Octubre, Ctr Invest, Avda Cordoba Km 5-4, E-28041 Madrid, Spain.
EM ycamposg@yahoo.es
CR Campos Y, 1998, NEUROMUSCULAR DISORD, V8, P568, DOI 10.1016/S0960-8966(98)00080-7
   Carnpos Y, 2003, NEUROMUSCULAR DISORD, V13, P416, DOI 10.1016/S0960-8966(03)00039-7
   DiMauro S, 1997, MOL GENETIC BASIS NE, V0, P201
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   MORAES CT, 1992, AM J HUM GENET, V50, P934
   PETRUZZELLA V, 1994, HUM MOL GENET, V3, P449, DOI 10.1093/hmg/3.3.449
   Rieder MJ, 1998, NUCLEIC ACIDS RES, V26, P967, DOI 10.1093/nar/26.4.967
   Sciacco M, 1996, METHODS ENZYMOL, V264, P509, DOI 10.1016/S0076-6879(96)64045-2
   Servidei Serenella, 2004, NEUROMUSCUL DISORD, V14, P107
   TIRANTI V, 1995, HUM MOL GENET, V4, P1421, DOI 10.1093/hmg/4.8.1421
NR 10
TC 4
Z9 5
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD MAY 15
PY 2007
VL 17
IS 5
BP 415
EP 418
DI 10.1016/j.nmd.2007.01.015
PG 4
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 175VB
UT WOS:000247041000009
PM 17363246
DA 2024-11-01
ER

PT J
AU Maassen, JA
   't Hart, LM
   Ouwens, DM
AF Maassen, Johannes A.
   't Hart, Leen M.
   Ouwens, D. Margriet
TI Lessons that can be learned from patients with diabetogenic mutations in mitochondrial DNA: Implications for common type 2 diabetes
SO CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE
LA English
DT Article
DE fatty acids; antiretroviral therapy; highly active; mitochondria; diabetes mellitus; type 2
ID insulin-resistance; adipose-tissue; molecular-mechanisms; fatty-acids; oxidative-phosphorylation; potential links; inflammation; obesity; diseases; involvement
AB These observations suggest a pathogenic model for obesity associated type 2 diabetes, in which mitochondrial activity in peripheral adipocytes is essential to keep triabylglycerol stored within these cells. Mitochondria protect the organism against fatty acid-induced insulin, resistance and lipotoxicity to the pancreas. In adipocytes,e fatty acids through uncoupled beta oxidation, whereas in muscle fatty acids, removal is largely driven by adenosine dip hate, production through physical activity.
C1 Leiden Univ, Med Ctr, Dept Mol Cell Biol, NL-2300 RC Leiden, Netherlands.
C3 Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC
RP Maassen, JA (corresponding author), Leiden Univ, Med Ctr, Dept Mol Cell Biol, Albinusdreef 2, NL-2300 RC Leiden, Netherlands.
EM j.a.maassen@lumc.nl
CR Beck V, 2007, FASEB J, V21, P1137, DOI 10.1096/fj.06-7489com
   Blaak EE, 2007, OBESITY, V15, P653, DOI 10.1038/oby.2007.606
   Bogacka I, 2005, DIABETES, V54, P1392, DOI 10.2337/diabetes.54.5.1392
   BORST P, 1962, BIOCHIM BIOPHYS ACTA, V62, P509, DOI 10.1016/0006-3002(62)90232-9
   Boudina S, 2005, CIRCULATION, V112, P2686, DOI 10.1161/CIRCULATIONAHA.105.554360
   Capeau J, 2005, BIOCHEM SOC T, V33, P1073, DOI 10.1042/BST0331073
   Choo HJ, 2006, DIABETOLOGIA, V49, P784, DOI 10.1007/s00125-006-0170-2
   Coenen MJH, 2004, NEW ENGL J MED, V351, P2080, DOI 10.1056/NEJMoa041878
   Guillausseau PJ, 2001, ANN INTERN MED, V134, P721, DOI 10.7326/0003-4819-134-9_Part_1-200105010-00008
   Hirabara SM, 2006, BBA-BIOENERGETICS, V1757, P57, DOI 10.1016/j.bbabio.2005.11.007
   Hosogai N, 2007, DIABETES, V56, P901, DOI 10.2337/db06-0911
   Hotamisligil GS, 2005, DIABETES, V54, PS73, DOI 10.2337/diabetes.54.suppl_2.S73
   HOTAMISLIGIL GS, 1994, DIABETES, V43, P1271, DOI 10.2337/diabetes.43.11.1271
   Kahn SE, 2003, DIABETOLOGIA, V46, P3, DOI 10.1007/s00125-002-1009-0
   Kahn SE, 2006, NEW ENGL J MED, V355, P2427, DOI 10.1056/NEJMoa066224
   Kim JK, 2006, CELL METAB, V4, P417, DOI 10.1016/j.cmet.2006.11.008
   Knouff C, 2004, ENDOCR REV, V25, P899, DOI 10.1210/er.2003-0036
   Koonen DPY, 2005, BBA-MOL CELL BIOL L, V1736, P163, DOI 10.1016/j.bbalip.2005.08.018
   Laaksonen DE, 2005, DIABETES, V54, P158, DOI 10.2337/diabetes.54.1.158
   Maassen JA, 2006, BIOCHEM SOC T, V34, P819, DOI 10.1042/BST0340819
   Maassen JA, 2005, ANN MED, V37, P213, DOI 10.1080/07853890510007188
   Maassen JA, 2004, DIABETES, V53, PS103, DOI 10.2337/diabetes.53.2007.S103
   Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180
   Morino K, 2006, DIABETES, V55, PS9, DOI 10.2337/db06-S002
   Nicholls DG, 2006, BBA-BIOENERGETICS, V1757, P459, DOI 10.1016/j.bbabio.2006.02.005
   Perseghin G, 2003, INT J OBESITY, V27, PS6, DOI 10.1038/sj.ijo.0802491
   Rajala MW, 2003, ENDOCRINOLOGY, V144, P3765, DOI 10.1210/en.2003-0580
   Roden M, 2005, INT J OBESITY, V29, PS111, DOI 10.1038/sj.ijo.0803102
   Rydén M, 2002, J BIOL CHEM, V277, P1085, DOI 10.1074/jbc.M109498200
   Scheper GC, 2007, NAT GENET, V39, P534, DOI 10.1038/ng2013
   Suzuki S, 2003, DIABETES RES CLIN PR, V59, P207, DOI 10.1016/S0168-8227(02)00246-2
   Suzuki Y, 2004, DIABETES RES CLIN PR, V63, P225, DOI 10.1016/j.diabres.2003.10.024
   t Hart LM, 2005, DIABETES, V54, P1892, DOI 10.2337/diabetes.54.6.1892
   TAKEDA S, 1990, ACTA NEUROPATHOL, V80, P118, DOI 10.1007/BF00308913
   Trayhurn P, 2004, BRIT J NUTR, V92, P347, DOI 10.1079/BJN20041213
   VAARTJES WJ, 1978, BIOCHIM BIOPHYS ACTA, V503, P437, DOI 10.1016/0005-2728(78)90143-3
   van der Valk M, 2004, ANTIVIR THER, V9, P385
   VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368
   Vianna CR, 2006, CELL METAB, V4, P453, DOI 10.1016/j.cmet.2006.11.003
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523
   Weinberg JM, 2006, KIDNEY INT, V70, P1560, DOI 10.1038/sj.ki.5001834
   Wellen KE, 2007, CELL, V129, P537, DOI 10.1016/j.cell.2007.02.049
   Wilson-Fritch L, 2004, J CLIN INVEST, V114, P1281, DOI 10.1172/JCI200421752
   Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451
   Zierath JR, 2007, CELL METAB, V5, P161, DOI 10.1016/j.cmet.2007.02.005
NR 46
TC 16
Z9 17
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1363-1950
EI 1473-6519
J9 CURR OPIN CLIN NUTR
JI Curr. Opin. Clin. Nutr. Metab. Care
PD NOV 15
PY 2007
VL 10
IS 6
BP 693
EP 697
DI 10.1097/MCO.0b013e3282f0b774
PG 5
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA 226EA
UT WOS:000250569100006
PM 18089949
DA 2024-11-01
ER

PT J
AU Vergani, L
   Malena, A
   Sabatelli, P
   Loro, E
   Cavallini, L
   Magalhaes, P
   Valente, L
   Bragantini, F
   Carrara, F
   Leger, B
   Poulton, J
   Russell, AP
   Holt, IJ
AF Vergani, Lodovica
   Malena, Adriana
   Sabatelli, Patrizia
   Loro, Emanuele
   Cavallini, Lucia
   Magalhaes, Paolo
   Valente, Lucia
   Bragantini, Federica
   Carrara, Franco
   Leger, Bertrand
   Poulton, Joanna
   Russell, Aaron P.
   Holt, Ian J.
TI Cultured muscle cells display defects of mitochondrial myopathy ameliorated by anti-oxidants
SO BRAIN
LA English
DT Article
DE cybrids; MELAS; differentiation; ROS
ID stroke-like episodes; oxidative stress; lactic-acidosis; transcription termination; tissue-specificity; skeletal-muscle; melas subgroup; mutation; mtdna; deficiency
AB The mitochondrial DNA A3243G mutation causes neuromuscular disease. To investigate the muscle-specific pathophysiology of mitochondrial disease, rhabdomyosarcoma transmitochondrial hybrid cells (cybrids) were generated that retain the capacity to differentiate to myotubes. In some cases, striated muscle-like fibres were formed after innervation with rat embryonic spinal cord. Myotubes carrying A3243G mtDNA produced more reactive oxygen species than controls, and had altered glutathione homeostasis. Moreover, A3243G mutant myotubes showed evidence of abnormal mitochondrial distribution, which was associated with down-regulation of three genes involved in mitochondrial morphology, Mfn1, Mfn2 and DRP1. Electron microscopy revealed mitochondria with ultrastructural abnormalities and paracrystalline inclusions. All these features were ameliorated by anti-oxidant treatment, with the exception of the paracrystalline inclusions. These data suggest that rhabdomyosarcoma cybrids are a valid cellular model for studying muscle-specific features of mitochondrial disease and that excess reactive oxygen species production is a significant contributor to mitochondrial dysfunction, which is amenable to anti-oxidant therapy.
C1 Univ Padua, Dept Neurol Sci, I-35129 Padua, Italy.
   CNR, ITOI, IOP, I-40136 Bologna, Italy.
   Univ Padua, Dept Biochem, I-35121 Padua, Italy.
   Univ Padua, Dept Biomed Sci, I-35121 Padua, Italy.
   Natl Neurol Inst C Besta, Dept Mol Neurogenet, I-20126 Milan, Italy.
   Clin Romande Readaptat, CH-1951 Sion, Switzerland.
   John Radcliffe Hosp, Dept Obstet & Gynaecol, Oxford OX3 9DU, England.
   Deakin Univ, Sch Exercise & Nutr Sci, Geelong, Vic 3125, Australia.
   Univ Cambridge, MRC, Dunn Human Nutr Unit, Cambridge CB2 OXY, England.
C3 University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua; University of Padua; Fondazione IRCCS Istituto Neurologico Carlo Besta; University of Oxford; Deakin University; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research; University of Cambridge
RP Vergani, L (corresponding author), Venetian Inst Mol Med, Via Orus,2, I-35129 Padua, Italy.
EM lodovica.vergani@unipd.it
FU MRC [G0500695, MC_U105663140] Funding Source: UKRI; Medical Research Council [G0500695, MC_U105663140] Funding Source: Medline; Telethon [1252] Funding Source: Medline
CR Antonicka H, 2006, HUM MOL GENET, V15, P1835, DOI 10.1093/hmg/ddl106
   Bach D, 2003, J BIOL CHEM, V278, P17190, DOI 10.1074/jbc.M212754200
   Brookes PS, 2004, AM J PHYSIOL-CELL PH, V287, PC817, DOI 10.1152/ajpcell.00139.2004
   Chan DC, 2006, CELL, V125, P1241, DOI 10.1016/j.cell.2006.06.010
   Chomyn A, 2000, J BIOL CHEM, V275, P19198, DOI 10.1074/jbc.M908734199
   CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221
   DUNBAR DR, 1995, P NATL ACAD SCI USA, V92, P6562, DOI 10.1073/pnas.92.14.6562
   Dunbar DR, 1996, HUM MOL GENET, V5, P123, DOI 10.1093/hmg/5.1.123
   Filosto M, 2002, ACTA NEUROPATHOL, V103, P215, DOI 10.1007/s004010100455
   Finkel T, 2003, CURR OPIN CELL BIOL, V15, P247, DOI 10.1016/S0955-0674(03)00002-4
   Frieden M, 2004, J BIOL CHEM, V279, P22704, DOI 10.1074/jbc.M312366200
   Gonzalo R, 2005, FEBS LETT, V579, P6909, DOI 10.1016/j.febslet.2005.11.034
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Halliwell B, 2003, FEBS LETT, V540, P3, DOI 10.1016/S0014-5793(03)00235-7
   HAMMANS SR, 1992, BRAIN, V115, P343, DOI 10.1093/brain/115.2.343
   Hargreaves IP, 2005, J INHERIT METAB DIS, V28, P81, DOI 10.1007/s10545-005-4160-1
   HESS JF, 1991, NATURE, V351, P236, DOI 10.1038/351236a0
   Inoue K, 2000, NAT GENET, V26, P176, DOI 10.1038/82826
   Jacobs HT, 2003, AGING CELL, V2, P11, DOI 10.1046/j.1474-9728.2003.00032.x
   Kamei S, 2005, INVEST OPHTH VIS SCI, V46, P4288, DOI 10.1167/iovs.03-1407
   Kelly G S, 1998, ALTERN MED REV, V3, P114
   KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477
   Kirkinezos IG, 2001, SEMIN CELL DEV BIOL, V12, P449, DOI 10.1006/scdb.2001.0282
   KOBAYASHI T, 1987, J NEUROSCI, V7, P3131
   Kraft CS, 2006, AM J PHYSIOL-CELL PH, V290, PC1119, DOI 10.1152/ajpcell.00463.2005
   Leary SC, 1998, BBA-BIOENERGETICS, V1365, P522, DOI 10.1016/S0005-2728(98)00105-4
   Léger B, 2006, FASEB J, V20, P583, DOI 10.1096/fj.05-5249fje
   Lyons CN, 2004, BIOCHEM CELL BIOL, V82, P391, DOI 10.1139/O04-040
   Mattiazzi M, 2004, HUM MOL GENET, V13, P869, DOI 10.1093/hmg/ddh103
   MORAES CT, 1992, AM J HUM GENET, V50, P934
   MORGANHUGHES JA, 1995, BBA-MOL BASIS DIS, V1271, P135, DOI 10.1016/0925-4439(95)00020-5
   OHKOSHI N, 1995, MUSCLE NERVE, V18, P1265, DOI 10.1002/mus.880181108
   PANG CY, 2001, ENHANCED OXIDATIVE D, V0, PS45
   Pletjushkina OY, 2006, BBA-BIOENERGETICS, V1757, P518, DOI 10.1016/j.bbabio.2006.03.018
   Rojo M, 2002, J CELL SCI, V115, P1663
   Saada A, 2003, MOL GENET METAB, V79, P1, DOI 10.1016/S1096-7192(03)00063-5
   Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4
   Shin KS, 1996, DEV BIOL, V175, P14, DOI 10.1006/dbio.1996.0091
   Smirnova E, 1998, J CELL BIOL, V143, P351, DOI 10.1083/jcb.143.2.351
   Tanaka Y, 1998, CELL, V93, P1147, DOI 10.1016/S0092-8674(00)81459-2
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   TIRANTI V, 1995, HUM MOL GENET, V4, P2017, DOI 10.1093/hmg/4.11.2017
   Tsatmali M, 2005, BRAIN RES, V1040, P137, DOI 10.1016/j.brainres.2005.01.087
   Tsatmali M, 2006, MOL CELL NEUROSCI, V33, P345, DOI 10.1016/j.mcn.2006.08.005
   Van Heerebeek L, 2002, J CLIN PATHOL, V55, P561, DOI 10.1136/jcp.55.8.561
   VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368
   Vergani L, 2004, EUR J BIOCHEM, V271, P3646, DOI 10.1111/j.1432-1033.2004.04298.x
   Vergani L, 2000, NEUROMUSCULAR DISORD, V10, P454, DOI 10.1016/S0960-8966(00)00096-1
   Wittenhagen LM, 2002, NAT STRUCT BIOL, V9, P586, DOI 10.1038/nsb820
   Wong A, 2002, HUM MOL GENET, V11, P431, DOI 10.1093/hmg/11.4.431
   Wong A, 1997, BIOCHEM BIOPH RES CO, V239, P139, DOI 10.1006/bbrc.1997.7443
   Yasukawa T, 2005, FEBS LETT, V579, P2948, DOI 10.1016/j.febslet.2005.04.038
   Yasukawa T, 2000, J BIOL CHEM, V275, P4251, DOI 10.1074/jbc.275.6.4251
NR 53
TC 13
Z9 14
U1 0
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
EI 
J9 BRAIN
JI Brain
PD OCT 15
PY 2007
VL 130
IS 
BP 2715
EP 2724
DI 10.1093/brain/awm151
PG 10
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 218UC
UT WOS:000250039500022
PM 17626036
DA 2024-11-01
ER

PT J
AU Mancuso, M
   Filosto, M
   Choub, A
   Tentorio, M
   Broglio, L
   Padovani, A
   Siciliano, G
AF Mancuso, Michelangelo
   Filosto, Massimiliano
   Choub, Anna
   Tentorio, Marta
   Broglio, Laura
   Padovani, Alessandro
   Siciliano, Gabriele
TI Mitochondrial DNA-related disorders
SO BIOSCIENCE REPORTS
LA English
DT Article; Proceedings Paper
DE mitochondrial disease; mitochondrial DNA; MELAS; MERRF; PEO; Leber
ID external ophthalmoplegia; paternal inheritance; mutation; gene; deletions
AB Mitochondrial diseases are a group of disorders due to a mitochondrial respiratory chain deficiency. They may depend on mitochondrial genome (mtDNA-related disorders) as well as on a nuclear genome defect (nDNA-related disorders). mtDNA-related disorders encompass an increasing number of clinical pictures associated with more than 250 different provisional or confirmed pathogenic changes in mtDNA. Although some clinical syndromes are nosologically defined, most of the cases present with polymorphous phenotypes ranging from pure myopathy to multi-system involvement. Complexity of mitochondrial genetics is in part responsible for the extreme clinical intra- and inter-familial heterogeneity of this group of diseases. In this review, we briefly report an updated classification and overview the main clinical pictures of this class of diseases.
C1 Univ Pisa, Dept Neurosci, I-56126 Pisa, Italy.
   Univ Hosp, Spedali Civili, Sect Neuromuscular Dis & Neuropathies, Brescia, Italy.
   Univ Verona, Dept Neurol Sci & Vis, Sect Clin Neurol, I-37100 Verona, Italy.
C3 University of Pisa; Hospital Spedali Civili Brescia; University of Verona
RP Mancuso, M (corresponding author), Univ Pisa, Dept Neurosci, Via Roma 67, I-56126 Pisa, Italy.
EM mmancuso@inwind.it
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Andreu AL, 1999, NEW ENGL J MED, V341, P1037, DOI 10.1056/NEJM199909303411404
   Carelli V, 2004, PROG RETIN EYE RES, V23, P53, DOI 10.1016/j.preteyeres.2003.10.003
   Chakrapani A, 1998, J INHERIT METAB DIS, V21, P685, DOI 10.1023/A:1005401121344
   Cock HR, 1998, ANN NEUROL, V44, P187, DOI 10.1002/ana.410440208
   DEVRIES DD, 1993, ANN NEUROL, V34, P410, DOI 10.1002/ana.410340319
   DiMauro S, 1999, J CHILD NEUROL, V14, PS23, DOI 10.1177/0883073899014001051
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   DiMauro S, 2002, ADV NEUROL, V89, P217
   DiMauro S, 2001, SEMIN NEUROL, V21, P251, DOI 10.1055/s-2001-17942
   Filosto M, 2003, ANN NEUROL, V54, P524, DOI 10.1002/ana.10709
   FILOSTO M, 2007, ACTA NEUROLO SCAND, V0, P0
   Gillis L, 2002, PEDIATR CLIN N AM, V49, P203, DOI 10.1016/S0031-3955(03)00115-9
   HIRANO M, 1992, NEUROMUSCULAR DISORD, V2, P125, DOI 10.1016/0960-8966(92)90045-8
   Hirano M, 1996, HANDBOOK OF MUSCLE DISEASE, V0, P479
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   KEARNS TP, 1958, ARCH OPHTHALMOL-CHIC, V60, P280, DOI 10.1001/archopht.1958.00940080296016
   LYONS G, 1996, NEUROLOGY HEREDITARY, V0, P92
   Mancuso M, 2004, NEUROLOGY, V62, P2119, DOI 10.1212/01.WNL.0000127608.48406.F1
   *MIT, 2006, HUM MIT GEN DAT, V0, P0
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   NAKASE H, 1990, AM J HUM GENET, V46, P418
   ROTIG A, 1992, AM J HUM GENET, V50, P364
   SCHON EA, 1989, SCIENCE, V244, P346, DOI 10.1126/science.2711184
   SCHON EA, 1991, MOL GENETIC APPROACH, V0, P57
   SCHON EA, 2001, MITOCHONDRIA PATHOGE, V0, P53
   Schwartz M, 2002, NEW ENGL J MED, V347, P576, DOI 10.1056/NEJMoa020350
   Servidei Serenella, 2003, NEUROMUSCUL DISORD, V13, P848
   Shanske S, 2002, AM J HUM GENET, V71, P679, DOI 10.1086/342482
   Spagnolo M, 2001, NEUROMUSCULAR DISORD, V11, P481, DOI 10.1016/S0960-8966(01)00195-X
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
NR 31
TC 23
Z9 28
U1 0
U2 2
PU PORTLAND PRESS LTD
PI LONDON
PA 5TH FLR, 90 HIGH HOLBORN, LONDON WC1V 6LJ, ENGLAND
SN 0144-8463
EI 1573-4935
J9 BIOSCIENCE REP
JI Biosci. Rep.
PD JUN 15
PY 2007
VL 27
IS 1-3
BP 31
EP 37
DI 10.1007/s10540-007-9035-2
PG 7
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 178YM
UT WOS:000247256300005
PM 17484046
DA 2024-11-01
ER

PT J
AU Surmeier, DJ
AF Surmeier, D. James
TI Calcium, ageing, and neuronal vulnerability in Parkinson's disease
SO LANCET NEUROLOGY
LA English
DT Article
ID nigral dopamine neurons; mitochondrial-dna deletions; substantia-nigra; firing pattern; human-brain; functional consequences; channel blockers; ca2+ channels; risk; mechanisms
AB Parkinson's disease is a common neurodegenerative disorder of unknown cause. There is no cure or proven strategy for slowing the progression of the disease. Although there are signs of pathology in many brain regions, the core symptoms of Parkinson's disease are attributable to the selective degeneration of dopaminergic neurons in the substantia nigra pars compacta. A potential clue to the vulnerability of these neurons is their increasing reliance on Ca2+ channels to maintain autonomous activity with age. This reliance could pose a sustained metabolic stress on mitochondria, accelerating cellular ageing and death. The Ca2+ channels underlying autonomous activity in dopaminergic neurons are closely related to the L-type channels found in the heart and smooth muscle. Systemic administration of isradipine, a dihydropyridine blocker of L-type channels, forces dopaminergic neurons in rodents to revert to a juvenile, Ca2+-independent mechanism to generate autonomous activity. More importantly, reversion confers protection against toxins that produce experimental parkinsonism, pointing to a potential neuroprotective strategy for Parkinson's disease with a drug class that has been used safely in human beings for decades. These studies also suggest that, although genetic and environmental factors can hasten its onset, Parkinson's disease stems from a distinctive neuronal design common to all human beings, making its appearance simply a matter of time.
C1 Northwestern Univ, Feinburg Sch Med, Dept Physiol, Chicago, IL 60611 USA.
C3 Northwestern University; Feinberg School of Medicine
RP Surmeier, DJ (corresponding author), Northwestern Univ, Feinburg Sch Med, Dept Physiol, 303 E Chicago Ave, Chicago, IL 60611 USA.
EM j-surmeier@northwestern.edu
CR Abou-Sleiman PM, 2006, NAT REV NEUROSCI, V7, P207, DOI 10.1038/nrn1868
   Arbuthnott GW, 2007, TRENDS NEUROSCI, V30, P62, DOI 10.1016/j.tins.2006.12.003
   Bäckman L, 2000, AM J PSYCHIAT, V157, P635
   BEAN BP, 1991, AM J HYPERTENS, V4, PS406, DOI 10.1093/ajh/4.7.406S
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3
   Betarbet R, 2006, NEUROBIOL DIS, V22, P404, DOI 10.1016/j.nbd.2005.12.003
   Bonci A, 1998, J NEUROSCI, V18, P6693
   Braak H, 2004, CELL TISSUE RES, V318, P121, DOI 10.1007/s00441-004-0956-9
   BRUCKE T, 1995, J CEREBR BLOOD F MET, V15, P513
   CALABRESI P, 1994, J NEUROSCI, V14, P4871
   Chan CS, 2007, NATURE, V447, P1081, DOI 10.1038/nature05865
   Damier P, 1999, BRAIN, V122, P1437, DOI 10.1093/brain/122.8.1437
   Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3
   Duke DC, 2006, NEUROGENETICS, V7, P139, DOI 10.1007/s10048-006-0033-5
   Eisenberg MJ, 2004, AM J MED, V116, P35, DOI 10.1016/j.amjmed.2003.08.027
   Fahn S, 2005, J NEUROL, V252, P37, DOI 10.1007/s00415-005-4008-5
   Fahn Stanley, 2004, NEURORX, V1, P139, DOI 10.1602/neurorx.1.1.139
   FITTON A, 1990, DRUGS, V40, P31, DOI 10.2165/00003495-199040010-00004
   GERMAN DC, 1992, ANN NEUROL, V32, P667, DOI 10.1002/ana.410320510
   GERMAN DC, 1992, ANN NY ACAD SCI, V648, P42, DOI 10.1111/j.1749-6632.1992.tb24523.x
   Ghezzi D, 2005, EUR J HUM GENET, V13, P748, DOI 10.1038/sj.ejhg.5201425
   GRACE AA, 1984, J NEUROSCI, V4, P2866
   Greenamyre JT, 2004, SCIENCE, V304, P1120, DOI 10.1126/science.1098966
   Grobaski KC, 1997, BRIT J PHARMACOL, V120, P575, DOI 10.1038/sj.bjp.0700938
   HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x
   Helton TD, 2005, J NEUROSCI, V25, P10247, DOI 10.1523/JNEUROSCI.1089-05.2005
   HOEHN MM, 1967, NEUROLOGY, V17, P427, DOI 10.1212/WNL.17.5.427
   HORNYKIEWICZ O, 1966, PHARMACOL REV, V18, P925
   Huerta C, 2005, J NEUROL SCI, V236, P49, DOI 10.1016/j.jns.2005.04.016
   Hung AY, 2007, CURR OPIN NEUROL, V20, P477, DOI 10.1097/WCO.0b013e32826388d6
   Ishikawa T, 1996, J NUCL MED, V37, P1760
   ITO H, 1992, ANN NEUROL, V32, P543, DOI 10.1002/ana.410320410
   KISH SJ, 1988, NEW ENGL J MED, V318, P876, DOI 10.1056/NEJM198804073181402
   Koschak A, 2001, J BIOL CHEM, V276, P22100, DOI 10.1074/jbc.M101469200
   Kraytsberg Y, 2006, NAT GENET, V38, P518, DOI 10.1038/ng1778
   Kupsch A, 1996, BRAIN RES, V741, P185, DOI 10.1016/S0006-8993(96)00917-1
   Liang CL, 2007, EXP NEUROL, V203, P370, DOI 10.1016/j.expneurol.2006.08.015
   MATZUK MM, 1985, ANN NEUROL, V18, P552, DOI 10.1002/ana.410180507
   McMahon A, 1998, MOL BRAIN RES, V54, P56, DOI 10.1016/S0169-328X(97)00305-7
   Moore DJ, 2005, ANNU REV NEUROSCI, V28, P57, DOI 10.1146/annurev.neuro.28.061604.135718
   MOORE RY, 1979, ANNU REV NEUROSCI, V2, P113, DOI 10.1146/annurev.ne.02.030179.000553
   Oka H, 2007, BRAIN, V130, P2425, DOI 10.1093/brain/awm174
   Olson PA, 2005, J NEUROSCI, V25, P1050, DOI 10.1523/JNEUROSCI.3327-04.2005
   Paladini CA, 2003, P NATL ACAD SCI USA, V100, P2866, DOI 10.1073/pnas.0138018100
   Ping HX, 1999, J NEUROPHYSIOL, V81, P977, DOI 10.1152/jn.1999.81.3.977
   Ping HX, 1996, NEUROREPORT, V7, P809, DOI 10.1097/00001756-199602290-00031
   Puopolo M, 2007, J NEUROSCI, V27, P645, DOI 10.1523/JNEUROSCI.4341-06.2007
   Pyle A, 2005, ANN NEUROL, V57, P564, DOI 10.1002/ana.20417
   RIEDERER P, 1976, J NEURAL TRANSM, V38, P277, DOI 10.1007/BF01249445
   Rizzuto R, 2006, PHYSIOL REV, V86, P369, DOI 10.1152/physrev.00004.2005
   Rodnitzky RL, 1999, DRUGS, V57, P845, DOI 10.2165/00003495-199957060-00001
   SAPER CB, 1991, ANN NEUROL, V29, P577, DOI 10.1002/ana.410290602
   Scholze A, 2001, MOL ENDOCRINOL, V15, P1211, DOI 10.1210/me.15.7.1211
   SHOFFNER JM, 1993, GENOMICS, V17, P171, DOI 10.1006/geno.1993.1299
   Stark AK, 2004, CELL TISSUE RES, V318, P81, DOI 10.1007/s00441-004-0972-9
   Striessnig J, 2006, BIOCHEM SOC T, V34, P903, DOI 10.1042/BST0340903
   Sulzer D, 2007, TRENDS NEUROSCI, V30, P244, DOI 10.1016/j.tins.2007.03.009
   Swerdlow RH, 1996, ANN NEUROL, V40, P663, DOI 10.1002/ana.410400417
   Tepper J M, 1998, ADV PHARMACOL, V42, P694
   Ton TGN, 2007, PARKINSONISM RELAT D, V13, P165, DOI 10.1016/j.parkreldis.2006.08.011
   van der Walt JM, 2003, AM J HUM GENET, V72, P804, DOI 10.1086/373937
   Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751
   Whitton PS, 2007, BRIT J PHARMACOL, V150, P963, DOI 10.1038/sj.bjp.0707167
   WILLIAMS JT, 1984, NEUROSCIENCE, V13, P137, DOI 10.1016/0306-4522(84)90265-3
   Wilson CJ, 2000, J NEUROPHYSIOL, V83, P3084, DOI 10.1152/jn.2000.83.5.3084
   Xu WF, 2001, J NEUROSCI, V21, P5944, DOI 10.1523/JNEUROSCI.21-16-05944.2001
   Zhang L, 2005, HUM MOL GENET, V14, P2063, DOI 10.1093/hmg/ddi211
   ZIGMOND MJ, 1990, TRENDS NEUROSCI, V13, P290, DOI 10.1016/0166-2236(90)90112-N
NR 69
TC 225
Z9 260
U1 1
U2 23
PU LANCET LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 1474-4422
EI 
J9 LANCET NEUROL
JI Lancet Neurol.
PD OCT 15
PY 2007
VL 6
IS 10
BP 933
EP 938
DI 10.1016/S1474-4422(07)70246-6
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA 218SQ
UT WOS:000250035600023
PM 17884683
DA 2024-11-01
ER

PT J
AU Castro, MG
   Terrados, N
   Reguero, JR
   Alvarez, V
   Coto, E
AF Castro, Monica G.
   Terrados, Nicolas
   Reguero, Julian R.
   Alvarez, Victoria
   Coto, Eliecer
TI Mitochondrial haplogroup T is negatively associated with the status of elite endurance athlete
SO MITOCHONDRION
LA English
DT Article
DE mitochondrial DNA; endurance capacity; mitochondrial haplogroups; genetic association
ID familial resemblance; risk; polymorphisms; performance; capacity; disease; vo2max; muscle
AB Mitochondrial function is absolutely necessary to supply the energy required for muscles, and germ line mutations in mitochondrial genes have been related with impaired cardiac function and exercise intolerance. In addition, alleles at several polymorphic sites in mtDNA define nine common haplogroups, and some of these haplogroups have been implicated in the risk of developing several diseases. In this study, we analysed the association between mtHaplogroups and the capacity to reach the status of elite endurance athlete. DNA was obtained from blood leukocytes of 95 Spanish elite endurance athletes and 250 healthy male population controls. We analysed eight mitochondrial polymorphisms and the frequencies were statistically compared between elite athletes and controls. Haplogroup T, specifically defined by 13368A, was significantly less frequent among elite endurance athletes (p = 0.012, Fisher's exact test). Our study suggests that allele 13368A and mitochondrial haplogroup T might be a marker negatively associated with the status of elite endurance athlete. This mitochondrial variant could be related with a lower capacity to respond to endurance training, through unknown mechanisms involving a less efficient mitochondrial workload. (c) 2007 Elsevier B.V. and Mitochondria Research Society. All rights reserved.
C1 Univ Oviedo, Hosp Cent Asturias, Inst Mol Genet Estudios Nefrol, E-33080 Oviedo, Spain.
   Funt Univ, Dept Biol, Oviedo, Spain.
   Fdn Dep Municipal Aviles, Aviles, Spain.
   Univ Oviedo, Hosp Cent Asturias, E-33080 Oviedo, Spain.
C3 University of Oviedo; Central University Hospital Asturias; University of Oviedo; Central University Hospital Asturias
RP Coto, E (corresponding author), Univ Oviedo, Hosp Cent Asturias, Inst Mol Genet Estudios Nefrol, E-33080 Oviedo, Spain.
EM eliecer.coto@sespa.princast.es
CR Alvarez R, 2000, EUR J APPL PHYSIOL, V82, P117, DOI 10.1007/s004210050660
   Bouchard C, 1998, MED SCI SPORT EXER, V30, P252, DOI 10.1097/00005768-199802000-00013
   BOUCHARD C, 1986, MED SCI SPORT EXER, V18, P639
   Castro MG, 2006, INT J CARDIOL, V112, P202, DOI 10.1016/j.ijcard.2005.09.008
   di Prampero PE, 2003, EUR J APPL PHYSIOL, V90, P420, DOI 10.1007/s00421-003-0926-z
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   DIONNE FT, 1991, MED SCI SPORT EXER, V23, P177
   HAMEL P, 1986, MED SCI SPORT EXER, V18, P690
   HOLLOSZY JO, 1984, J APPL PHYSIOL, V56, P831, DOI 10.1152/jappl.1984.56.4.831
   Hoppeler H, 1998, J EXP BIOL, V201, P1051
   HOPPELER H, 1985, J APPL PHYSIOL, V59, P320, DOI 10.1152/jappl.1985.59.2.320
   LESAGE R, 1985, HUM HERED, V35, P182, DOI 10.1159/000153540
   LORTIE G, 1984, INT J SPORTS MED, V5, P232, DOI 10.1055/s-2008-1025911
   Montgomery HE, 1998, NATURE, V393, P221, DOI 10.1038/30374
   Murakami H, 2001, JPN J PHYSIOL, V51, P563, DOI 10.2170/jjphysiol.51.563
   Niemi AK, 2005, EUR J HUM GENET, V13, P166, DOI 10.1038/sj.ejhg.5201308
   Nishigaki Y, 2007, MITOCHONDRION, V7, P72, DOI 10.1016/j.mito.2006.11.002
   Rankinen T, 2004, MED SCI SPORT EXER, V36, P1451, DOI 10.1249/01.MSS.0000139902.42385.5F
   Rivera MA, 1998, MED SCI SPORT EXER, V30, P687, DOI 10.1097/00005768-199805000-00007
   Ross OA, 2003, EXP GERONTOL, V38, P397, DOI 10.1016/S0531-5565(02)00266-8
   Ruiz-Pesini E, 2004, SCIENCE, V303, P223, DOI 10.1126/science.1088434
   Ruiz-Pesini E, 2000, AM J HUM GENET, V67, P682, DOI 10.1086/303040
   Scott RA, 2005, COMP BIOCHEM PHYS B, V140, P497, DOI 10.1016/j.cbpc.2004.11.014
   Torroni A, 1996, GENETICS, V144, P1835
   van der Walt JM, 2003, AM J HUM GENET, V72, P804, DOI 10.1086/373937
   Zoll J, 2002, J PHYSIOL-LONDON, V543, P191, DOI 10.1113/jphysiol.2002.019661
NR 26
TC 43
Z9 47
U1 0
U2 11
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
EI 1872-8278
J9 MITOCHONDRION
JI Mitochondrion
PD SEP 15
PY 2007
VL 7
IS 5
BP 354
EP 357
DI 10.1016/j.mito.2007.06.002
PG 4
WC Cell Biology; Genetics & Heredity
SC Cell Biology; Genetics & Heredity
GA 217RG
UT WOS:000249964400008
PM 17660050
DA 2024-11-01
ER

PT J
AU Semba, RD
   Lauretani, F
   Ferrucci, L
AF Semba, Richard D.
   Lauretani, Fulvio
   Ferrucci, Luigi
TI Carotenoids as protection against sarcopenia in older adults
SO ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
LA English
DT Review
DE aging; carotene; carotenoids; cryptoxanthin; inflammation; lutein; lycopene; muscle; sarcopenia; zeaxanthin
ID dna deletion mutations; mitochondrial-dna; oxidative stress; cardiovascular-disease; skeletal-muscle; handgrip strength; blood-pressure; vegetable consumption; plasma-concentrations; atherosclerosis risk
AB Sarcopenia, or loss of muscle mass and strength, plays a major role in the disablement process in older adults and increases the risk of impaired physical performance, falls, physical disability, frailty, and death. Oxidative stress is a major mechanism implicated in the pathogenesis of sarcopenia; aging muscle shows increased oxidative damage to DNA, protein, and lipids. Carotenoids quench free radicals, reduce damage from reactive oxygen species, and appear to modulate redox-sensitive transcription factors such as NF-kappa B that are involved in the upregulation of IL-6 and other proinflammatory cytokines. Recent epidemiological studies in community-dwelling older adults show that low serum/plasma carotenoids are independently associated with low skeletal muscle strength and the development of walking disability. These observations are consistent with a growing number of studies showing that a diet with high intake of fruits and vegetables is associated with a reduced risk of inflammation, hypertension, diabetes, cardiovascular disease, and mortality. (c) 2007 Published by Elsevier Inc.
C1 Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA.
   Tuscany Reg Agcy, Florence, Italy.
   NIA, Longitudinal Studies Sect, Clin Res Branch, Baltimore, MD 21224 USA.
C3 Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)
RP Semba, RD (corresponding author), Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA.
EM rdsemba@jhmi.edu
FU Intramural NIH HHS [Z99 AG999999] Funding Source: Medline; NIA NIH HHS [N01-AG-821336, R01 AG027012, N01-AG-916413, N01-AG-5-0002] Funding Source: Medline
CR [Anonymous], 2001, DIETARY REFERENCE IN, V0, P0, DOI DOI 10.1016/S0899-9007(00)00596-7
   Appel LJ, 1997, NEW ENGL J MED, V336, P1117, DOI 10.1056/NEJM199704173361601
   Baumgartner RN, 1998, AM J EPIDEMIOL, V147, P755, DOI 10.1093/oxfordjournals.aje.a009520
   Bazzano LA, 2002, AM J CLIN NUTR, V76, P93
   Bua EA, 2002, J APPL PHYSIOL, V92, P2617, DOI 10.1152/japplphysiol.01102.2001
   Çakatay U, 2003, CLIN BIOCHEM, V36, P51, DOI 10.1016/S0009-9120(02)00407-1
   Carmeli E, 2002, EXP GERONTOL, V37, P477, DOI 10.1016/S0531-5565(01)00220-0
   Carmelli D, 2000, J APPL PHYSIOL, V89, P1879, DOI 10.1152/jappl.2000.89.5.1879
   Ceriello A, 2004, ARTERIOSCL THROM VAS, V24, P816, DOI 10.1161/01.ATV.0000122852.22604.78
   Cesari M, 2004, J GERONTOL A-BIOL, V59, P242
   Cesari M, 2004, AM J CLIN NUTR, V79, P289
   Chrysohoou C, 2004, J AM COLL CARDIOL, V44, P152, DOI 10.1016/j.jacc.2004.03.039
   Delsite RL, 2003, MUTAGENESIS, V18, P497, DOI 10.1093/mutage/geg027
   Doherty TJ, 2003, J APPL PHYSIOL, V95, P1717, DOI 10.1152/japplphysiol.00347.2003
   Ershler WB, 2000, ANNU REV MED, V51, P245, DOI 10.1146/annurev.med.51.1.245
   Esposito K, 2004, JAMA-J AM MED ASSOC, V292, P1440, DOI 10.1001/jama.292.12.1440
   Facchini FS, 2000, AM J CLIN NUTR, V72, P776
   Fayet G, 2002, NEUROMUSCULAR DISORD, V12, P484, DOI 10.1016/S0960-8966(01)00332-7
   Ferrando AA, 2002, AM J PHYSIOL-ENDOC M, V282, PE601, DOI 10.1152/ajpendo.00362.2001
   Ferrucci L, 2005, BLOOD, V105, P2294, DOI 10.1182/blood-2004-07-2599
   Ferrucci L, 2002, J AM GERIATR SOC, V50, P1947, DOI 10.1046/j.1532-5415.2002.50605.x
   FIATARONE MA, 1994, NEW ENGL J MED, V330, P1769, DOI 10.1056/NEJM199406233302501
   Genkinger JM, 2004, AM J EPIDEMIOL, V160, P1223, DOI 10.1093/aje/kwh339
   Giampaoli S, 1999, AGE AGEING, V28, P283, DOI 10.1093/ageing/28.3.283
   Gianni P, 2004, EXP GERONTOL, V39, P1391, DOI 10.1016/j.exger.2004.06.002
   Hamilton ML, 2001, P NATL ACAD SCI USA, V98, P10469, DOI 10.1073/pnas.171202698
   HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298
   Houston DK, 2005, AM J CLIN NUTR, V81, P515
   Hozawa A, 2006, AM J EPIDEMIOL, V163, P929, DOI 10.1093/aje/kwj136
   Janssen I, 2004, AM J EPIDEMIOL, V159, P413, DOI 10.1093/aje/kwh058
   Janssen I, 2004, J AM GERIATR SOC, V52, P80, DOI 10.1111/j.1532-5415.2004.52014.x
   Janssen I, 2002, J AM GERIATR SOC, V50, P889, DOI 10.1046/j.1532-5415.2002.50216.x
   Janssen-Heininger YMW, 2000, FREE RADICAL BIO MED, V28, P1317, DOI 10.1016/S0891-5849(00)00218-5
   John JH, 2002, LANCET, V359, P1969, DOI 10.1016/S0140-6736(02)98858-6
   Jozsi AC, 1999, J GERONTOL A-BIOL, V54, PM591, DOI 10.1093/gerona/54.11.M591
   Kabe Y, 2005, ANTIOXID REDOX SIGN, V7, P395, DOI 10.1089/ars.2005.7.395
   Karin M, 2001, BIOFACTORS, V15, P87, DOI 10.1002/biof.5520150207
   Kovalenko SA, 1997, BIOCHEM BIOPH RES CO, V232, P147, DOI 10.1006/bbrc.1997.6251
   Krabbe KS, 2004, EXP GERONTOL, V39, P687, DOI 10.1016/j.exger.2004.01.009
   Kuh D, 2002, AM J EPIDEMIOL, V156, P627, DOI 10.1093/aje/kwf099
   Lauretani F, 2003, J APPL PHYSIOL, V95, P1851, DOI 10.1152/japplphysiol.00246.2003
   Lim PS, 2002, FREE RADICAL RES, V36, P295, DOI 10.1080/10715760290019318
   Liu S, 2000, AM J CLIN NUTR, V72, P922
   Lopes HF, 2003, HYPERTENSION, V41, P422, DOI 10.1161/01.HYP.0000053450.19998.11
   Lopez-Garcia E, 2004, AM J CLIN NUTR, V80, P1029, DOI 10.1093/ajcn/80.4.1029
   McKenzie D, 2002, EUR J BIOCHEM, V269, P2010, DOI 10.1046/j.1432-1033.2002.02867.x
   Mecocci P, 1999, FREE RADICAL BIO MED, V26, P303, DOI 10.1016/S0891-5849(98)00208-1
   MELOV S, 1995, NUCLEIC ACIDS RES, V23, P4122, DOI 10.1093/nar/23.20.4122
   Melton LJ, 2000, J AM GERIATR SOC, V48, P625
   Morley JE, 2004, J GERONTOL A-BIOL, V59, P924
   Morley JE, 2001, NUTRITION, V17, P660, DOI 10.1016/S0899-9007(01)00574-3
   Morley JE, 2001, J LAB CLIN MED, V137, P231, DOI 10.1067/mlc.2001.113504
   NELSON ME, 1994, JAMA-J AM MED ASSOC, V272, P1909, DOI 10.1001/jama.272.24.1909
   Newman AB, 2006, J GERONTOL A-BIOL, V61, P72, DOI 10.1093/gerona/61.1.72
   Newman AB, 2003, J AM GERIATR SOC, V51, P1602, DOI 10.1046/j.1532-5415.2003.51534.x
   Pansarasa O, 1999, FREE RADICAL BIO MED, V27, P617, DOI 10.1016/S0891-5849(99)00108-2
   Rantanen T, 2003, J AM GERIATR SOC, V51, P636, DOI 10.1034/j.1600-0579.2003.00207.x
   Rantanen T, 1999, JAMA-J AM MED ASSOC, V281, P558, DOI 10.1001/jama.281.6.558
   Reddy P, 2004, CURR OPIN HEMATOL, V11, P405, DOI 10.1097/01.moh.0000141926.95319.42
   Roubenoff R, 2000, J GERONTOL A-BIOL, V55, PM716, DOI 10.1093/gerona/55.12.M716
   Sacks FM, 2001, NEW ENGL J MED, V344, P3, DOI 10.1056/NEJM200101043440101
   Sayer AA, 2004, J GERONTOL A-BIOL, V59, P930, DOI 10.1093/gerona/59.9.M930
   Schaap LA, 2006, AM J MED, V119, P0, DOI 10.1016/j.amjmed.2005.10.049
   Semba RD, 2003, AGING CLIN EXP RES, V15, P482, DOI 10.1007/BF03327377
   Shaulian E, 2002, NAT CELL BIOL, V4, PE131, DOI 10.1038/ncb0502-e131
   Steffen LM, 2003, AM J CLIN NUTR, V78, P383, DOI 10.1093/ajcn/78.3.383
   Sumbayev VV, 2005, ARCH BIOCHEM BIOPHYS, V436, P406, DOI 10.1016/j.abb.2005.02.021
   Tinetti ME, 1997, NEW ENGL J MED, V337, P1279, DOI 10.1056/NEJM199710303371806
   Vanltallie TB, 2003, METABOLISM, V52, P22, DOI 10.1053/S0026-0495(03)00297-X
   Visser M, 2002, J AM GERIATR SOC, V50, P897, DOI 10.1046/j.1532-5415.2002.50217.x
   Walston J, 2006, AM J EPIDEMIOL, V163, P18, DOI 10.1093/aje/kwj007
   Wanagat J, 2001, FASEB J, V15, P322, DOI 10.1096/fj.00-0320com
   Watkins LR, 1999, LIFE SCI, V65, P449, DOI 10.1016/S0024-3205(99)00095-8
   WEINDRUCH R, 1995, J GERONTOL A-BIOL, V50, P157
   WOLFSON L, 1995, J GERONTOL A-BIOL, V50, P64
   Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514
   Yarovaya NO, 2002, BIOGERONTOLOGY, V3, P25, DOI 10.1023/A:1015295011131
   Young AJ, 2004, OXIDAT STRESS DIS, V13, P105
   Zhang CF, 1998, HUM MUTAT, V11, P360
   Zhao XF, 2006, AM J CLIN NUTR, V83, P163
NR 81
TC 112
Z9 135
U1 2
U2 24
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0003-9861
EI 1096-0384
J9 ARCH BIOCHEM BIOPHYS
JI Arch. Biochem. Biophys.
PD FEB 15
PY 2007
VL 458
IS 2
BP 141
EP 145
DI 10.1016/j.abb.2006.11.025
PG 5
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 138TI
UT WOS:000244385000007
PM 17196927
DA 2024-11-01
ER

PT J
AU Jeppesen, TD
   Quistorff, B
   Wibrand, F
   Vissing, J
AF Jeppesen, Tina Dysgaard
   Quistorff, Bjorn
   Wibrand, Flemming
   Vissing, John
TI <SUP>31</SUP>P-MRS of skeletal muscle is not a sensitive diagnostic test for mitochondrial myopathy
SO JOURNAL OF NEUROLOGY
LA English
DT Article
DE 31-phosphorous magnetic resonance spectroscopy muscle disorders; mitochondrial myopathy; diagnostic procedures; mtDNA mutations
ID magnetic-resonance spectroscopy; tibialis anterior muscle; encephalomyopathy merrf; mr spectroscopy; heart-failure; human calf; exercise; recovery; disease; dna
AB Clinical phenotypes of persons with mitochondrial DNA (mtDNA) mutations vary considerably. Therefore, diagnosing mitochondrial myopathy (MM) patients can be challenging and warrants diagnostic guidelines. (31)phosphorous magnetic resonance spectroscopy (P-31-MRS) have been included as a minor diagnostic criterion for MM but the diagnostic strength of this test has not been compared with that of other commonly used diagnostic procedures for MM. To investigate this, we studied seven patients with single, large-scale deletions-, nine with point mutations of mtDNA and 14 healthy subjects, who were investigated for the following: 1) P-31-MRS of lower arm and leg muscles before and after exercise, 2) resting and peak-exercise induced increases of plasma lactate, 3) muscle morphology and -mitochondrial enzyme activity, 4) maximal oxygen uptake (VO2max), 5) venous oxygen desaturation during handgrip exercise and 6) a neurological examination. All MM patients had clinical symptoms of MM, > 2% ragged red fibers in muscle, and impaired oxygen desaturation during handgrip. Fourteen of 16 patients had impaired VO2max, 10/16 had elevated resting plasma lactate, and 10/11 that were investigated had impaired citrate synthase-corrected complex I activity. Resting PCr/P-i ratio and leg P-i recovery were lower in MM patients vs. healthy subjects. PCr and ATP production after exercise were similar in patients and healthy subjects. Although the specificity for MM of some P-31-MRS variables was as high as 100%, the sensitivity was low (0-63%) and the diagnostic strength of P-31-MRS was inferior to the other diagnostic tests for MM. Thus, P-31-MRS should not be a routine test for MM, but may be an important research tool.
C1 Natl Univ Hosp, Rigshosp, Neuromuscular Res Unit, Sect 7611, DK-2100 Copenhagen, Denmark.
   Univ Copenhagen, Panum Inst, NMR Ctr, DK-2200 Copenhagen, Denmark.
   John F Kennedy Inst, DK-2600 Glostrup, Denmark.
C3 Rigshospitalet; University of Copenhagen; University of Copenhagen
RP Jeppesen, TD (corresponding author), Natl Univ Hosp, Rigshosp, Neuromuscular Res Unit, Sect 7611, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.
EM dysgaard@rh.dk
CR ARGOV Z, 1991, ANN NEUROL, V30, P90, DOI 10.1002/ana.410300116
   ARGOV Z, 1987, NEUROLOGY, V37, P257, DOI 10.1212/WNL.37.2.257
   Argov Z, 1996, NMR BIOMED, V9, P165, DOI 10.1002/(SICI)1099-1492(199606)9:4<165::AID-NBM408>3.0.CO;2-X
   ARNOLD DL, 1985, ANN NEUROL, V18, P189, DOI 10.1002/ana.410180205
   BANGSBO J, 1993, J APPL PHYSIOL, V74, P2034, DOI 10.1152/jappl.1993.74.4.2034
   Bernier FP, 2002, NEUROLOGY, V59, P1406, DOI 10.1212/01.WNL.0000033795.17156.00
   Chen JT, 2001, MAGNET RESON MED, V46, P870, DOI 10.1002/mrm.1271
   CIAFALONI E, 1992, ANN NEUROL, V31, P391, DOI 10.1002/ana.410310408
   Dimauro S, 2004, ANN NY ACAD SCI, V1011, P217, DOI 10.1196/annals.1293.022
   HOCH JC, 1995, NMR DATA PROCESSING, V0, P0
   Janssen AJM, 2003, ANN CLIN BIOCHEM, V40, P3, DOI 10.1258/000456303321016114
   Jensen TD, 2002, NEUROLOGY, V58, P1533, DOI 10.1212/WNL.58.10.1533
   Jeppesen TD, 2003, J NEUROL, V250, P293, DOI 10.1007/s00415-003-0993-4
   JOHNSTON W, 1995, ANN NEUROL, V37, P16, DOI 10.1002/ana.410370106
   KATZ SD, 1993, J APPL PHYSIOL, V75, P1974, DOI 10.1152/jappl.1993.75.5.1974
   KEMP GJ, 1993, NMR BIOMED, V6, P302, DOI 10.1002/nbm.1940060504
   KRAUSE KH, 1985, ANN NY ACAD SCI, V447, P297, DOI 10.1111/j.1749-6632.1985.tb18447.x
   KRENTZ AJ, 1990, METABOLISM, V39, P938, DOI 10.1016/0026-0495(90)90304-U
   KUHL CK, 1994, RADIOLOGY, V192, P223, DOI 10.1148/radiology.192.1.8208943
   Laguno M, 2005, ANTIVIR THER, V10, P423
   Larsen AI, 2001, EUR HEART J, V22, P684, DOI 10.1053/euhj.2000.2286
   Larson-Meyer DE, 2000, NMR BIOMED, V13, P14, DOI 10.1002/(SICI)1099-1492(200002)13:1<14::AID-NBM605>3.0.CO;2-0
   MARIOTTI C, 1995, J NEUROL, V242, P547, DOI 10.1007/BF00868806
   MATTHEWS PM, 1991, ANN NEUROL, V29, P435, DOI 10.1002/ana.410290416
   MATTHEWS PM, 1991, NEUROLOGY, V41, P114, DOI 10.1212/WNL.41.1.114
   MCCULLY KK, 1988, MUSCLE NERVE, V11, P212, DOI 10.1002/mus.880110304
   MIZUNO M, 1994, J APPL PHYSIOL, V76, P531, DOI 10.1152/jappl.1994.76.2.531
   Nakagawa Y, 2005, MED SCI SPORT EXER, V37, P937, DOI 10.1249/01.mss.0000166946.94871.9b
   PARK JH, 1990, RADIOLOGY, V177, P473, DOI 10.1148/radiology.177.2.2217788
   POLAGR J, 1973, J NEUROL SCI, V19, P307
   QUISTORFF B, 1993, BIOCHEM J, V291, P681, DOI 10.1042/bj2910681
   Ratkevicius A, 2002, MUSCLE NERVE, V25, P419, DOI 10.1002/mus.10064
   Schwartz M, 2002, NEW ENGL J MED, V347, P576, DOI 10.1056/NEJMoa020350
   Tarnopolsky MA, 1999, MUSCLE NERVE, V22, P1228, DOI 10.1002/(SICI)1097-4598(199909)22:9<1228::AID-MUS9>3.3.CO;2-Y
   TAYLOR DJ, 1994, J NEUROL SCI, V127, P198, DOI 10.1016/0022-510X(94)90073-6
   Vissing J, 1998, NEUROLOGY, V50, P1875, DOI 10.1212/WNL.50.6.1875
   VISSING J, 2002, SKELETAL MUSCLE PATH, V0, P153
   Walker UA, 1996, EUR NEUROL, V36, P260, DOI 10.1159/000117269
   WALLACE DC, 1988, CELL, V55, P601, DOI 10.1016/0092-8674(88)90218-8
   Wibrand F, 2001, ANN NEUROL, V50, P540, DOI 10.1002/ana.1224
   YOUNKIN DP, 1987, NEUROLOGY, V37, P165, DOI 10.1212/WNL.37.1.165
NR 41
TC 32
Z9 34
U1 0
U2 3
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0340-5354
EI 1432-1459
J9 J NEUROL
JI J. Neurol.
PD JAN 15
PY 2007
VL 254
IS 1
BP 29
EP 37
DI 10.1007/s00415-006-0229-5
PG 9
WC Clinical Neurology
SC Neurosciences & Neurology
GA 137NV
UT WOS:000244300200005
PM 17278044
DA 2024-11-01
ER

PT J
AU Auré, K
   de Baulny, HO
   Laforêt, P
   Jardel, C
   Eymard, B
   Lombès, A
AF Aure, Karine
   de Baulny, Helene Ogier
   Laforet, Pascal
   Jardel, Claude
   Eymard, Bruno
   Lombes, Anne
TI Chronic progressive ophthalmoplegia with large-scale mtDNA rearrangement:: can we predict progression?
SO BRAIN
LA English
DT Article
DE mitochondrial disease; deletion; Kearns-Sayre syndrome; CPEO; natural history
ID kearns-sayre syndrome; mitochondrial-dna deletions; marrow-pancreas syndrome; external ophthalmoplegia; pearson-syndrome; tissue distribution; muscle-fibers; myopathy; duplications; plus
AB The prognosis of chronic progressive ophthalmoplegia with large-scale mitochondrial DNA (mtDNA) may strikingly vary from mild slowly progressive myopathy to severe multi-organ involvement. Evaluation of the disease course at the beginning of the disease is reputed impossible. To address the existence of predictive prognostic clues of these diseases, we classified 69 patients with chronic progressive ophthalmoplegia and large size mtDNA deletion into two groups according to the presence of manifestations from brain, inner ear or retina. These manifestations were present in 29 patients (CPEO/+N group) and absent in 40 patients (CPEO/-N group). We retrospectively established the clinical history of the patients and characterized their genetic alteration (amount of residual normal mtDNA molecules, site, size and percentage of the mtDNA deletion in 116 DNA samples from muscle, blood, urinary and buccal cells). In both clinical groups, the disease was progressive and heart conduction defects were frequent. We show that the CPEO/+N phenotype segregated with severe prognosis in term of rate of progression, multi-organs involvement and rate of survival. Age at onset appeared a predictive factor. The risk to develop a CPEO/+N phenotype was high when onset was before 9 years of age and low when onset was after 20 years of age. The presence and proportion of the mtDNA deletion in blood was also significantly associated with the CPEO/ +N phenotype. This study is the first to establish the natural history of chronic ophthalmoplegia with mtDNA deletion in a large series of patients and to look for parameters potentially predictive of the patients'clinical course.
C1 INSERM, U582, F-75013 Paris, France.
   Univ Paris 06, IFRI4, F-75013 Paris, France.
   Hop Robert Debre, Ctr Reference Maladies Hereditaires Metab, F-75020 Paris, France.
   Hop La Pitie Salpetriere, Inst Myol, F-75013 Paris, France.
   Hop La Pitie Salpetriere, F-75013 Paris, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm); Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite; Hopital Universitaire Robert-Debre - APHP; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP
RP Lombes, A (corresponding author), INSERM, U582, Inst Myol, Grp Hosp Pitie Salpetriere, 47-83 Blvd De LHop, F-75013 Paris, France.
EM a.lombes@myologie.chups.jussieu.fr
CR Auré K, 2006, BRAIN, V129, P1249, DOI 10.1093/brain/awl061
   BASTIAENSEN LAK, 1978, ACTA NEUROL SCAND, V58, P9
   BERENBERG RA, 1977, ANN NEUROL, V1, P37, DOI 10.1002/ana.410010104
   BERNES SM, 1993, J PEDIATR-US, V123, P598, DOI 10.1016/S0022-3476(05)80962-X
   BROCKINGTON M, 1995, J NEUROL SCI, V131, P78, DOI 10.1016/0022-510X(95)00091-F
   BUTLER IJ, 1976, ARCH INTERN MED, V136, P1290
   Cheng G, 1999, DEVELOPMENT, V126, P5041
   Chinnery PF, 2000, ANN NEUROL, V48, P188, DOI 10.1002/1531-8249(200008)48:2<188::AID-ANA8>3.3.CO;2-G
   DRACHMAN DA, 1968, ARCH NEUROL-CHICAGO, V18, P654, DOI 10.1001/archneur.1968.00470360076008
   GERBITZ KD, 1990, J NEUROL, V237, P5, DOI 10.1007/BF00319660
   HAMMANS SR, 1992, BRAIN, V115, P343, DOI 10.1093/brain/115.2.343
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   HOLT IJ, 1989, ANN NEUROL, V26, P699, DOI 10.1002/ana.410260603
   HURKO O, 1990, PEDIATR RES, V28, P542, DOI 10.1203/00006450-199011000-00026
   KEARNS TP, 1958, ARCH OPHTHALMOL-CHIC, V60, P280, DOI 10.1001/archopht.1958.00940080296016
   Lacbawan F, 2000, AM J MED GENET, V95, P266, DOI 10.1002/1096-8628(20001127)95:3<266::AID-AJMG13>3.3.CO;2-S
   LARSSON NG, 1990, PEDIATR RES, V28, P131, DOI 10.1203/00006450-199028020-00011
   Manfredi G, 1997, ANN NEUROL, V42, P180, DOI 10.1002/ana.410420208
   MCSHANE MA, 1991, AM J HUM GENET, V48, P39
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   Odoardi F, 2003, AM J MED GENET A, V118A, P247, DOI 10.1002/ajmg.a.20006
   OLDFORS A, 1992, J NEUROL SCI, V110, P169, DOI 10.1016/0022-510X(92)90025-G
   PEARSON HA, 1979, J PEDIATR-US, V95, P976, DOI 10.1016/S0022-3476(79)80286-3
   POULTON J, 1991, AM J HUM GENET, V48, P649
   POULTON J, 1994, HUM MOL GENET, V3, P947, DOI 10.1093/hmg/3.6.947
   Remes AM, 2005, NEUROLOGY, V64, P976, DOI 10.1212/01.WNL.0000154518.31302.ED
   ROTIG A, 1995, HUM MOL GENET, V4, P1327, DOI 10.1093/hmg/4.8.1327
   SCIACCO M, 1994, HUM MOL GENET, V3, P13, DOI 10.1093/hmg/3.1.13
   SHANSKE S, 1990, NEUROLOGY, V40, P24, DOI 10.1212/WNL.40.1.24
   Shanske S, 2002, AM J HUM GENET, V71, P679, DOI 10.1086/342482
   SHY GM, 1967, AM J MED, V42, P163, DOI 10.1016/0002-9343(67)90015-0
   YAMAMOTO M, 1991, NEUROLOGY, V41, P1822, DOI 10.1212/WNL.41.11.1822
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
   ZEVIANI M, 1990, ANN NEUROL, V28, P94, DOI 10.1002/ana.410280118
NR 34
TC 48
Z9 52
U1 0
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
EI 
J9 BRAIN
JI Brain
PD JUN 15
PY 2007
VL 130
IS 
BP 1516
EP 1524
DI 10.1093/brain/awm067
PG 9
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 183IA
UT WOS:000247565300009
PM 17439982
DA 2024-11-01
ER

PT J
AU Lewis, W
   Day, BJ
   Kohler, JJ
   Hosseini, SH
   Chan, SSL
   Green, EC
   Haase, CP
   Keebaugh, ES
   Long, R
   Ludaway, T
   Russ, R
   Steltzer, J
   Tioleco, N
   Santoianni, R
   Copeland, WC
AF Lewis, William
   Day, Brian J.
   Kohler, James J.
   Hosseini, Seyed H.
   Chan, Sherine S. L.
   Green, Elgin C.
   Haase, Chad P.
   Keebaugh, Erin S.
   Long, Robert
   Ludaway, Tomika
   Russ, Rodney
   Steltzer, Jeffrey
   Tioleco, Nina
   Santoianni, Robert
   Copeland, William C.
TI Decreased mtDNA, oxidative stress, cardiomyopathy, and death from transgenic cardiac targeted human mutant polymerase γ
SO LABORATORY INVESTIGATION
LA English
DT Article
DE mitochondria; Pol gamma; oxidative stress; cardiomyopathy; transgenic
ID mitochondrial-dna polymerase; progressive external ophthalmoplegia; manganese superoxide-dismutase; p55 accessory subunit; autosomal-dominant; deoxynucleotide carrier; dilated cardiomyopathy; multiple deletions; nuclear-dna; mouse heart
AB POLG is the human gene that encodes the catalytic subunit of DNA polymerase gamma (Pol gamma), the replicase for human mitochondrial DNA (mtDNA). A POLG Y955C point mutation causes human chronic progressive external ophthalmoplegia (CPEO), a mitochondrial disease with eye muscle weakness and mtDNA defects. Y955C POLG was targeted transgenically (TG) to the murine heart. Survival was determined in four TG (+/-) lines and wild- type (WT) littermates (-/-). Left ventricle (LV) performance (echocardiography and MRI), heart rate (electrocardiography), mtDNA abundance ( real time PCR), oxidation of mtDNA (8-OHdG), histopathology and electron microscopy defined the phenotype. Cardiac targeted Y955C POLG yielded a molecular signature of CPEO in the heart with cardiomyopathy (CM), mitochondrial oxidative stress, and premature death. Increased LV cavity size and LV mass, bradycardia, decreased mtDNA, increased 8- OHdG, and cardiac histopathological and mitochondrial EM defects supported and defined the phenotype. This study underscores the pathogenetic role of human mutant POLG and its gene product in mtDNA depletion, mitochondrial oxidative stress, and CM as it relates to the genetic defect in CPEO. The transgenic model pathophysiologically links human mutant Pol gamma, mtDNA depletion, and mitochondrial oxidative stress to the mtDNA replication apparatus and to CM.
C1 Emory Univ, Sch Med, Dept Pathol, Atlanta, GA USA.
   Natl Jewish Med Ctr, Denver, CO USA.
   Natl Inst Environm Hlth Sci, Lab Mol Genet, NIH, Res Triangle Pk, NC USA.
   Emory Univ, Sch Med, Dept Radiol, Atlanta, GA USA.
C3 Emory University; National Jewish Health; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Emory University
RP Lewis, W (corresponding author), Emory Univ, Sch Med, Dept Pathol, Atlanta, GA USA.
EM wlewis@emory.edu
FU Intramural NIH HHS Funding Source: Medline; NHLBI NIH HHS [HL072707, R01 HL072707, R01 HL059798] Funding Source: Medline; NIEHS NIH HHS [Z01 ES065080-11, Z01 ES065078-12] Funding Source: Medline
CR Bohlega S, 1996, NEUROLOGY, V46, P1329, DOI 10.1212/WNL.46.5.1329
   Chan SSL, 2005, DNA REPAIR, V4, P1381, DOI 10.1016/j.dnarep.2005.08.010
   Copeland WC, 2003, ACTA BIOCHIM POL, V50, P155
   Côté HCF, 2003, J INFECT DIS, V187, P1972, DOI 10.1086/375353
   DALAKAS MC, 1990, NEW ENGL J MED, V322, P1098, DOI 10.1056/NEJM199004193221602
   Davani EY, 2003, CRIT CARE, V7, PR176, DOI 10.1186/cc2375
   DIVI RL, 2006, IN PRESS ENV MOL MUT, V0, P0
   Elpeleg O, 2003, PEDIATR RES, V54, P153, DOI 10.1203/01.PDR.0000072796.25097.A5
   Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805
   Graziewicz MA, 2006, CHEM REV, V106, P383, DOI 10.1021/cr040463d
   Hirano M, 2001, SEMIN CELL DEV BIOL, V12, P417, DOI 10.1006/scdb.2001.0279
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Kaguni LS, 2004, ANNU REV BIOCHEM, V73, P293, DOI 10.1146/annurev.biochem.72.121801.161455
   Kajander OA, 2002, HUM MOL GENET, V11, P317, DOI 10.1093/hmg/11.3.317
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Lewis W, 2006, AIDS, V20, P675, DOI 10.1097/01.aids.0000216367.23325.58
   Lewis W, 2005, ANTIVIR THER, V10, P0
   Lewis W, 2005, LAB INVEST, V85, P972, DOI 10.1038/labinvest.3700301
   Lewis W, 2005, LAB INVEST, V85, P182, DOI 10.1038/labinvest.3700222
   Lewis W, 2003, NAT REV DRUG DISCOV, V2, P812, DOI 10.1038/nrd1201
   Lewis W, 2003, AIDS, V17, PS36, DOI 10.1097/00002030-200304001-00006
   Lewis W, 2000, LAB INVEST, V80, P187, DOI 10.1038/labinvest.3780022
   Lewis W, 2001, LAB INVEST, V81, P1527, DOI 10.1038/labinvest.3780366
   LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376
   Lim SE, 1999, J BIOL CHEM, V274, P38197, DOI 10.1074/jbc.274.53.38197
   Loeb LA, 2005, P NATL ACAD SCI USA, V102, P18769, DOI 10.1073/pnas.0509776102
   Longley DB, 2006, ONCOGENE, V25, P838, DOI 10.1038/sj.onc.1209122
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Longley MJ, 2001, J BIOL CHEM, V276, P38555, DOI 10.1074/jbc.M105230200
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Mott JL, 2001, MUTAT RES-FUND MOL M, V474, P35, DOI 10.1016/S0027-5107(00)00159-7
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Pagnamenta AT, 2006, HUM REPROD, V21, P2467, DOI 10.1093/humrep/del076
   Ponamarev MV, 2002, J BIOL CHEM, V15, P15
   Raidel SM, 2002, AM J PHYSIOL-HEART C, V282, PH1672, DOI 10.1152/ajpheart.00955.2001
   Rampazzo C, 2004, J BIOL CHEM, V279, P17019, DOI 10.1074/jbc.M313957200
   RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465
   Robbins J, 2000, ANNU REV PHYSIOL, V62, P261, DOI 10.1146/annurev.physiol.62.1.261
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Velsor LW, 2004, TOXICOL APPL PHARM, V199, P10, DOI 10.1016/j.taap.2004.03.005
   Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751
   Williams MD, 1998, J BIOL CHEM, V273, P28510, DOI 10.1074/jbc.273.43.28510
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
   Zhang D, 2005, AM J PHYSIOL-HEART C, V288, PH2476, DOI 10.1152/ajpheart.00670.2004
   Zhang D, 2005, CARDIOVASC PATHOL, V14, P61, DOI 10.1016/j.carpath.2005.01.006
NR 50
TC 101
Z9 113
U1 0
U2 10
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 
J9 LAB INVEST
JI Lab. Invest.
PD APR 15
PY 2007
VL 87
IS 4
BP 326
EP 335
DI 10.1038/labinvest.3700523
PG 10
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 148UY
UT WOS:000245103200002
PM 17310215
DA 2024-11-01
ER

PT J
AU Brinckmann, A
   Rüther, K
   Williamson, K
   Lorenz, B
   Lucke, B
   Nuernberg, P
   Trijbels, F
   Janssen, A
   Schuelke, M
AF Brinckmann, Anja
   Ruether, Klaus
   Williamson, Kathleen
   Lorenz, Birgit
   Lucke, Barbara
   Nuernberg, Peter
   Trijbels, Frans
   Janssen, Antoon
   Schuelke, Markus
TI De novo double mutation in <i>PAX6</i> and mtDNA <i>tRNA<SUP>Lys</SUP></i> associated with atypical aniridia and mitochondrial disease
SO JOURNAL OF MOLECULAR MEDICINE-JMM
LA English
DT Article
DE mtDNA; heteroplasmy; PAX6; ptosis; nystagmus; pyrosequencing
ID dna; polymorphism; humans; gene
AB We report on the clinical, molecular and biochemical findings of a patient with the rare event (< 4.02 x 10(-9) per generation) of coinciding de novo mutations in the nuclear PAX6 ( c. 1252 - 1267del16) and the mitochondrial mt.RNA(Lys) (8347A -> G) genes. The boy suffers from exercise intolerance, ptosis, nystagmus, macular hypoplasia and anterior segment abnormalities evocative of Axenfeld-Rieger anomaly. The PAX6 mutation is predicted to cause haploinsufficiency. The novel mt.RNA(Lys) mutation is located close to the classic myoclonic epilepsy with ragged-red-fibers mutation, but the patient exhibits neither myoclonic epilepsy nor ragged-red-fibers. The degree of mutant mtDNA heteroplasmy, as determined by a very accurate pyrosequencing assay, varies between 31% ( muscle) and 38% ( fibroblasts). We discuss a potential effect of the PAX6 mutation on the mtDNA mutation rate.
C1 Charite Univ Med Berlin, Dept Neuropediat, D-13353 Berlin, Germany.
   Charite Univ Med Berlin, Neurosci Res Ctr, D-13353 Berlin, Germany.
   Free Univ Berlin, Dept Biol Chem & Pharm, Berlin, Germany.
   Charite Univ Med Berlin, Dept Ophthalmol, D-13353 Berlin, Germany.
   Western Gen Hosp, MRC, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland.
   Klinikum Univ Regensburg, Dept Pediat Ophthalmol Strabismol & Ophthalmogene, Regensburg, Germany.
   Univ Cologne, Cologne Ctr Genome, D-5000 Cologne 41, Germany.
   Univ Cologne, Inst Genet, D-5000 Cologne 41, Germany.
   Univ Med Ctr St Radboud, Nijmegen Ctr Mitochondrial Disorders, Dept Pediat, Nijmegen, Netherlands.
C3 Berlin Institute of Health; Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Berlin Institute of Health; Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Berlin Institute of Health; Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Edinburgh; University of Regensburg; University of Cologne; University of Cologne; Radboud University Nijmegen
RP Schuelke, M (corresponding author), Charite Univ Med Berlin, Dept Neuropediat, Augustenburger Pl 1, D-13353 Berlin, Germany.
EM markus.schuelke@charite.de
FU PHS HHS [01GR0416] Funding Source: Medline
CR Arsenijevic D, 2000, NAT GENET, V26, P435, DOI 10.1038/82565
   Brandon MC, 2005, NUCLEIC ACIDS RES, V33, P0
   CORONA P, 2001, ANN NEUROL, V51, P122
   Dimauro S, 2001, AM J MED GENET, V106, P18, DOI 10.1002/ajmg.1392
   ERNST BP, 1994, MOL CELL PROBE, V8, P45, DOI 10.1006/mcpr.1994.1006
   GLASER T, 1992, NAT GENET, V2, P232, DOI 10.1038/ng1192-232
   Hensey C, 1998, DEV BIOL, V203, P36, DOI 10.1006/dbio.1998.9028
   Krempler F, 2002, DIABETES, V51, P3331, DOI 10.2337/diabetes.51.11.3331
   Levitt NC, 2002, TRENDS MOL MED, V8, P179, DOI 10.1016/S1471-4914(02)02298-0
   Malandrini A, 2001, CLIN GENET, V60, P151, DOI 10.1034/j.1399-0004.2001.600210.x
   Morrison D, 2002, J MED GENET, V39, P16, DOI 10.1136/jmg.39.1.16
   Santos C, 2005, MOL BIOL EVOL, V22, P1490, DOI 10.1093/molbev/msi141
   Schuelke M, 2002, ANN NEUROL, V51, P388, DOI 10.1002/ana.10151
   Sisodiya SM, 2001, NAT GENET, V28, P214, DOI 10.1038/90042
   SPENCER Herbert, 1901, ENCY LIFE SCI, V0, P1
   Tzoulaki I, 2005, BMC GENET, V6, P0, DOI 10.1186/1471-2156-6-27
   Uhlmann K, 2002, ELECTROPHORESIS, V23, P4072, DOI 10.1002/elps.200290023
   van Heyningen V, 2002, HUM MOL GENET, V11, P1161, DOI 10.1093/hmg/11.10.1161
   Wei YH, 2002, EXP BIOL MED, V227, P671, DOI 10.1177/153537020222700901
   Wong LJC, 1997, CLIN CHEM, V43, P1241
   Yasukawa T, 2001, EMBO J, V20, P4794, DOI 10.1093/emboj/20.17.4794
NR 22
TC 8
Z9 10
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013 USA
SN 0946-2716
EI 
J9 J MOL MED-JMM
JI J. Mol. Med.
PD FEB 15
PY 2007
VL 85
IS 2
BP 163
EP 168
DI 10.1007/s00109-006-0112-y
PG 6
WC Genetics & Heredity; Medicine, Research & Experimental
SC Genetics & Heredity; Research & Experimental Medicine
GA 137NS
UT WOS:000244299900008
PM 17031679
DA 2024-11-01
ER

PT J
AU Wong, LJC
AF Wong, Lee-Jun C.
TI Pathogenic mitochondrial DNA mutations in protein-coding genes
SO MUSCLE & NERVE
LA English
DT Review
DE mitochondrial mRNA mutations; mtDNA mutations; mtDNA mutations; in protein coding regions; pathogenic mtDNA mutations
ID cytochrome-c-oxidase; hereditary optic neuropathy; complex-iii deficiency; stop-codon mutation; lhon/melas overlap syndrome; missense mutation; nonsense mutation; leigh-syndrome; b gene; subunit-iii
AB More than 200 disease-related mitochondrial DNA (mtDNA) point mutations have been reported in the Mitomap (http://www.mitomap. org) database. These mutations can be divided into two groups: mutations affecting mitochondrial protein synthesis, including mutations in tRNA and rRNA genes; and mutations in protein-encoding genes (mRNAs). This review focuses on mutations in mitochondrial genes that encode proteins. These mutations are involved in a broad spectrum of human diseases, including a variety of multisystem disorders as well as more tissue-specific diseases such as isolated myopathy and Leber hereditary optic neuropathy (LHON). Because the mitochondrial genome contains a large number of apparently neutral polymorphisms that have little pathogenic significance, along with secondary homoplasmic mutations that do not have primary disease-causing effect, the pathogenic role of all newly discovered mutations must be rigorously established. A scoring system has been applied to evaluate the pathogenicity of the mutations in mtDNA protein-encoding genes and to review the predominant clinical features and the molecular characteristics of mutations in each mtDNA-encoded respiratory chain complex.
C1 Baylor Coll Med, Dept Human Mol Genet, Houston, TX 77030 USA.
C3 Baylor College of Medicine
RP Wong, LJC (corresponding author), Baylor Coll Med, Dept Human Mol Genet, 1 Baylor Pl,NAB2015, Houston, TX 77030 USA.
EM ljwong@bcm.edu
CR Abu-Amero KK, 2006, INVEST OPHTH VIS SCI, V47, P4211, DOI 10.1167/iovs.06-0295
   Abu-Amero Khaled K, 2005, OPHTHALMIC GENET, V26, P31, DOI 10.1080/13816810590918235
   Andreu AL, 1999, MOL GENET METAB, V67, P49, DOI 10.1006/mgme.1999.2843
   Andreu AL, 2000, PEDIATR RES, V48, P311, DOI 10.1203/00006450-200009000-00008
   Andreu AL, 1999, ANN NEUROL, V45, P820, DOI 10.1002/1531-8249(199906)45:6<820::AID-ANA22>3.0.CO;2-W
   Andreu AL, 1998, NEUROLOGY, V51, P1444, DOI 10.1212/WNL.51.5.1444
   Andreu AL, 1999, ANN NEUROL, V45, P127, DOI 10.1002/1531-8249(199901)45:1<127::AID-ART20>3.0.CO;2-Y
   Andreu AL, 1999, NEW ENGL J MED, V341, P1037, DOI 10.1056/NEJM199909303411404
   Blakely EL, 2005, FEBS J, V272, P3583, DOI 10.1111/j.1742-4658.2005.04779.x
   Blakely EL, 2005, EUR J HUM GENET, V13, P623, DOI 10.1038/sj.ejhg.5201363
   Bouzidi MF, 1996, BBA-MOL BASIS DIS, V1317, P199, DOI 10.1016/S0925-4439(96)00055-5
   Brown MD, 1996, AM J MED GENET, V61, P283, DOI 10.1002/(SICI)1096-8628(19960122)61:3<283::AID-AJMG15>3.0.CO;2-P
   Brown MD, 2002, HUM GENET, V110, P130, DOI 10.1007/s00439-001-0660-8
   BROWN MD, 1995, HUM MUTAT, V6, P311, DOI 10.1002/humu.1380060405
   Bruno C, 1999, AM J HUM GENET, V65, P611, DOI 10.1086/302546
   Campos Y, 2001, ANN NEUROL, V50, P409, DOI 10.1002/ana.1141
   CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033
   Carrozzo R, 2000, FEBS LETT, V486, P297, DOI 10.1016/S0014-5793(00)02244-4
   Chinnery PF, 2001, BRAIN, V124, P209, DOI 10.1093/brain/124.1.209
   Chol M, 2003, J MED GENET, V40, P188, DOI 10.1136/jmg.40.3.188
   Clark KM, 1999, AM J HUM GENET, V64, P1330, DOI 10.1086/302361
   Comi GP, 1998, ANN NEUROL, V43, P110, DOI 10.1002/ana.410430119
   Corona P, 2001, ANN NEUROL, V49, P106, DOI 10.1002/1531-8249(200101)49:1<106::AID-ANA16>3.0.CO;2-T
   Crimi M, 2003, NEUROLOGY, V60, P1857, DOI 10.1212/01.WNL.0000066048.72780.69
   De Coo IFM, 1999, ANN NEUROL, V45, P130, DOI 10.1002/1531-8249(199901)45:1<130::AID-ART21>3.0.CO;2-Z
   DEMEIRLEIR L, 1995, PEDIATR NEUROL, V13, P242, DOI 10.1016/0887-8994(95)00184-H
   Deschauer M, 2003, NEUROLOGY, V60, P1357, DOI 10.1212/01.WNL.0000055869.99975.4B
   DeVries DD, 1996, AM J HUM GENET, V58, P703
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   DiMauro S, 1998, NAT GENET, V19, P214, DOI 10.1038/883
   Dionisi-Vici C, 1998, J INHERIT METAB DIS, V21, P2, DOI 10.1023/A:1005397227996
   Dumoulin R, 1996, MOL CELL PROBE, V10, P389, DOI 10.1006/mcpr.1996.0053
   Enns GM, 2006, MOL GENET METAB, V88, P364, DOI 10.1016/j.ymgme.2006.02.001
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Filosto M, 2003, ANN NEUROL, V54, P524, DOI 10.1002/ana.10709
   Gattermann N, 1997, BLOOD, V90, P4961, DOI 10.1182/blood.V90.12.4961.4961_4961_4972
   Gropman A, 2004, AM J MED GENET A, V124A, P377, DOI 10.1002/ajmg.a.20456
   HALTIA T, 1991, EMBO J, V10, P2015, DOI 10.1002/j.1460-2075.1991.tb07731.x
   HALTIA T, 1989, EMBO J, V8, P3571, DOI 10.1002/j.1460-2075.1989.tb08529.x
   Hanna MG, 1998, AM J HUM GENET, V63, P29, DOI 10.1086/301910
   Horváth R, 2005, NEUROMUSCULAR DISORD, V15, P851, DOI 10.1016/j.nmd.2005.09.005
   Horváth R, 2002, J MED GENET, V39, P812, DOI 10.1136/jmg.39.11.812
   IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0
   JOHNS DR, 1994, J NEURO-OPHTHALMOL, V14, P135
   JUN AS, 1994, P NATL ACAD SCI USA, V91, P6206, DOI 10.1073/pnas.91.13.6206
   Karadimas CL, 2000, NEUROLOGY, V55, P644, DOI 10.1212/WNL.55.5.644
   Keightley JA, 2000, AM J HUM GENET, V67, P1400, DOI 10.1086/316900
   Keightley JA, 1996, NAT GENET, V12, P410, DOI 10.1038/ng0496-410
   Kim JY, 2002, ANN NEUROL, V51, P630, DOI 10.1002/ana.10177
   Kirby DM, 2004, J MED GENET, V41, P784, DOI 10.1136/jmg.2004.020537
   Kollberg G, 2005, J NEUROPATH EXP NEUR, V64, P123, DOI 10.1093/jnen/64.2.123
   Lebon S, 2003, J MED GENET, V40, P896, DOI 10.1136/jmg.40.12.896
   Legros F, 2001, EUR J HUM GENET, V9, P510, DOI 10.1038/sj.ejhg.5200678
   LeoKottler B, 1996, GER J OPHTHALMOL, V5, P233
   Li XM, 2005, BIOCHEM BIOPH RES CO, V328, P491, DOI 10.1016/j.bbrc.2005.01.006
   Liang MH, 1998, AM J MED GENET, V77, P395, DOI 10.1002/(SICI)1096-8628(19980605)77:5<395::AID-AJMG8>3.0.CO;2-M
   Liolitsa D, 2003, ANN NEUROL, V53, P128, DOI 10.1002/ana.10435
   Luberichs J, 2002, GRAEF ARCH CLIN EXP, V240, P96, DOI 10.1007/s00417-001-0423-1
   Makino M, 1998, NEUROMUSCULAR DISORD, V8, P149, DOI 10.1016/S0960-8966(98)00017-0
   Mancuso M, 2003, J NEUROL SCI, V209, P61, DOI 10.1016/S0022-510X(02)00462-8
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   MANFREDI G, 1995, NEUROMUSCULAR DISORD, V5, P391, DOI 10.1016/0960-8966(94)00079-O
   Matsumoto M, 1999, OPHTHALMIC GENET, V20, P153, DOI 10.1076/opge.20.3.153.2281
   Mayorov V, 2005, ANN NEUROL, V58, P807, DOI 10.1002/ana.20669
   McFarland R, 2004, NEUROMUSCULAR DISORD, V14, P162, DOI 10.1016/j.nmd.2003.10.011
   McFarland R, 2004, ANN NEUROL, V55, P58, DOI 10.1002/ana.10787
   Mitchell AL, 2006, J MED GENET, V43, P175, DOI 10.1136/jmg.2005.032474
   Moslemi AR, 2005, NEUROPEDIATRICS, V36, P314, DOI 10.1055/s-2005-872845
   Munakata K, 2004, GENOMICS, V84, P1041, DOI 10.1016/j.ygeno.2004.08.015
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   NEWMAN NJ, 1994, AM J OPHTHALMOL, V118, P158, DOI 10.1016/S0002-9394(14)72895-8
   Opdal SH, 2002, PEDIATR NEUROL, V27, P23, DOI 10.1016/S0887-8994(02)00384-3
   Pandya A, 1999, AM J HUM GENET, V65, P1803, DOI 10.1086/302658
   Papadopoulou LC, 1999, NAT GENET, V23, P333
   Penisson-Besnier I, 2000, NEUROLOGY, V55, P317, DOI 10.1212/WNL.55.2.317
   Péquignot MO, 2001, HUM MUTAT, V17, P374, DOI 10.1002/humu.1112.abs
   PROCHASKA LJ, 1987, J BIOENERG BIOMEMBR, V19, P143, DOI 10.1007/BF00762722
   Pulkes T, 1999, ANN NEUROL, V46, P916, DOI 10.1002/1531-8249(199912)46:6<916::AID-ANA16>3.0.CO;2-R
   Rahman S, 1999, AM J HUM GENET, V65, P1030, DOI 10.1086/302590
   Rani DS, 2006, FERTIL STERIL, V86, P1783, DOI 10.1016/j.fertnstert.2006.04.044
   Ravn K, 2001, EUR J HUM GENET, V9, P805, DOI 10.1038/sj.ejhg.5200712
   Rocha H, 1999, AM J HUM GENET, V65, P1457, DOI 10.1086/302641
   Rubio-Gozalbo ME, 2000, HUM MUTAT, V15, P522, DOI 10.1002/1098-1004(200006)15:6<522::AID-HUMU4>3.0.CO;2-Y
   Ruiter EM, 2007, EUR J HUM GENET, V15, P155, DOI 10.1038/sj.ejhg.5201735
   Santorelli FM, 1997, BIOCHEM BIOPH RES CO, V238, P326, DOI 10.1006/bbrc.1997.7167
   Sarzi E, 2007, AM J MED GENET A, V143A, P33, DOI 10.1002/ajmg.a.31565
   Schagger H, 1995, METHOD ENZYMOL, V260, P82, DOI 10.1016/0076-6879(95)60132-5
   Schnopp NM, 1996, CLIN NEUROPATHOL, V15, P348
   Schuelke M, 2002, ANN NEUROL, V51, P388, DOI 10.1002/ana.10151
   SHOFFNER JM, 1993, GENOMICS, V17, P171, DOI 10.1006/geno.1993.1299
   SHOFFNER JM, 2001, METABOLIC MOL BASES, V2, P2367
   Shoubridge EA, 2001, AM J MED GENET, V106, P46, DOI 10.1002/ajmg.1378
   Simon DK, 2003, NEUROGENETICS, V4, P199, DOI 10.1007/s10048-003-0150-3
   Smeitink J, 2001, NAT REV GENET, V2, P342, DOI 10.1038/35072063
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Spinazzola A, 2005, GENE, V354, P162, DOI 10.1016/j.gene.2005.03.025
   Sudo A, 2004, J HUM GENET, V49, P92, DOI 10.1007/s10038-003-0116-1
   Sue CM, 1999, J PEDIATR-US, V134, P696, DOI 10.1016/S0022-3476(99)70283-0
   Tarnopolsky MA, 2004, MUSCLE NERVE, V29, P537, DOI 10.1002/mus.20020
   Tarnopolsky MA, 2004, AM J MED GENET A, V124A, P372, DOI 10.1002/ajmg.a.20449
   Temperley RJ, 2003, HUM MOL GENET, V12, P2341, DOI 10.1093/hmg/ddg238
   Tiranti V, 2000, HUM MOL GENET, V9, P2733, DOI 10.1093/hmg/9.18.2733
   Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136
   Ugalde C, 2007, MOL GENET METAB, V90, P10, DOI 10.1016/j.ymgme.2006.08.003
   Uusimaa J, 2003, PEDIATRICS, V111, P0, DOI 10.1542/peds.111.3.e262
   Valentino ML, 2006, J MED GENET, V43, P0, DOI 10.1136/jmg.2005.037507
   Valentino ML, 2004, ANN NEUROL, V56, P631, DOI 10.1002/ana.20236
   Valentino ML, 2002, ANN NEUROL, V51, P774, DOI 10.1002/ana.10193
   Valnot I, 1999, HUM GENET, V104, P460, DOI 10.1007/s004390050988
   Varlamov DA, 2002, HUM MOL GENET, V11, P1797, DOI 10.1093/hmg/11.16.1797
   Wallace DC, 2001, THE METABOLIC AND MOLECULAR BASIS OF INHERITED DISEASE, V0, P2425
   WALLACE DC, 2006, MITOMAP HUMAN MITOCH, V0, P0
   Wibrand F, 2001, ANN NEUROL, V50, P540, DOI 10.1002/ana.1224
   Wong LJC, 2001, AM J MED GENET, V102, P95, DOI 10.1002/1096-8628(20010722)102:1<95::AID-AJMG1412>3.0.CO;2-U
   Yan H, 2006, J BIOL CHEM, V281, P3926, DOI 10.1074/jbc.M509822200
   Yuan HJ, 2005, AM J MED GENET A, V138A, P133, DOI 10.1002/ajmg.a.30952
   Zhou XT, 2006, BIOCHEM BIOPH RES CO, V340, P69, DOI 10.1016/j.bbrc.2005.11.150
NR 117
TC 89
Z9 100
U1 0
U2 22
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0148-639X
EI 1097-4598
J9 MUSCLE NERVE
JI Muscle Nerve
PD SEP 15
PY 2007
VL 36
IS 3
BP 279
EP 293
DI 10.1002/mus.20807
PG 15
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 202IO
UT WOS:000248895400001
PM 17503499
DA 2024-11-01
ER

PT J
AU Chen, YM
   Lin, CM
   Thajeb, P
AF Chen, Yi-Min
   Lin, Chih-Ming
   Thajeb, Peterus
TI Paradoxical effect of sodium valproate that aggravates epilepsy of MELAS in a patient with A3243G mutation of the mitochondrial DNA
SO CENTRAL EUROPEAN JOURNAL OF MEDICINE
LA English
DT Article
DE acidosis; epilepsy; MELAS; mitochondrial disease; paradoxical effect; sodium valproate
ID c-oxidase deficiency; lactic-acidosis; encephalopathy; myopathy; diseases; episodes
AB Epilepsy is an associated feature of patients with the syndrome of mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS). A substitution at nucleotide position 3243 A>G of the mitochondrial DNA is the most common mutation encountered both in Caucasians and in Chinese/Taiwanese. We herein report a 38-year-old man with A3243G mutation of the mitochondrial DNA whom developed MELAS. The manifestation of his focal motor epilepsy was aggravated by use of sodium valproate (VPA). The mechanism of this paradoxical effect is proposed. (C) Versita Warsaw and Springer-Verlag Berlin Heidelberg. All rights reserved.
C1 [Chen, Yi-Min; Lin, Chih-Ming; Thajeb, Peterus] Mackay Mem Hosp, Dept Neurol & Med Res, Taipei, Taiwan.
   [Thajeb, Peterus] Natl Yang Ming Univ, Sch Med, Taipei 112, Taiwan.
   [Thajeb, Peterus] Taipei Med Univ, Taipei, Taiwan.
C3 Mackay Memorial Hospital; National Yang Ming Chiao Tung University; Taipei Medical University
RP Thajeb, P (corresponding author), Mackay Mem Hosp, Dept Neurol & Med Res, Taipei, Taiwan.
EM thajebp@hotmail.com
CR ALTRUP U, 1992, EPILEPSIA, V33, P753, DOI 10.1111/j.1528-1157.1992.tb02357.x
   CHABROL B, 1994, EUR J PEDIATR, V153, P133, DOI 10.1007/BF01959226
   Chinnery PF, 1997, BRAIN, V120, P1713, DOI 10.1093/brain/120.10.1713
   DiMauro S, 2004, BBA-BIOENERGETICS, V1658, P80, DOI 10.1016/j.bbabio.2004.03.014
   Dimauro S, 2005, ANN MED, V37, P222, DOI 10.1080/07853890510007368
   FANG W, 1993, ARCH NEUROL-CHICAGO, V50, P977, DOI 10.1001/archneur.1993.00540090074013
   HUANG CC, 1994, J NEUROL NEUROSUR PS, V57, P586, DOI 10.1136/jnnp.57.5.586
   Lam CW, 1997, EUR J PEDIATR, V156, P562, DOI 10.1007/s004310050663
   LIOU CW, 1994, ACTA NEUROL SCAND, V90, P354
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   PONCHAUT S, 1995, EUR J PEDIATR, V154, P79, DOI 10.1007/BF01972980
   PONCHAUT S, 1992, BIOCHEM PHARMACOL, V43, P644, DOI 10.1016/0006-2952(92)90590-F
   Shoffner JM, 1996, LANCET, V348, P1283, DOI 10.1016/S0140-6736(96)09138-6
   Thajeb P, 2005, ANN NY ACAD SCI, V1042, P48, DOI 10.1196/annals.1338.005
   Thajeb Peterus, 2006, TAIWAN J OBSTET GYNECOL, V45, P201
   Tzen CY, 2003, MUSCLE NERVE, V28, P575, DOI 10.1002/mus.10473
   ZHANG Y, 2001, CHIN MED J BEIJING, V114, P129
NR 17
TC 4
Z9 4
U1 0
U2 1
PU VERSITA
PI WARSAW 41
PA 9 DRUGA POPRZECNA ST, 04-604 WARSAW 41, POLAND
SN 1895-1058
EI 
J9 CENT EUR J MED
JI Cent. Eur. J. Med.
PD MAR 15
PY 2007
VL 2
IS 1
BP 103
EP 107
DI 10.2478/s11536-007-0007-5
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA 273OH
UT WOS:000253940300009
DA 2024-11-01
ER

PT J
AU McKiernan, SH
   Tuen, VC
   Baldwin, K
   Wanagat, J
   Djamali, A
   Aiken, JM
AF McKiernan, Susan H.
   Tuen, Victoria C.
   Baldwin, Katherine
   Wanagat, Jonathan
   Djamali, Arjang
   Aiken, Judd M.
TI Adult-onset calorie restriction delays the accumulation of mitochondrial enzyme abnormalities in aging rat kidney tubular epithelial cells
SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY
LA English
DT Article
DE dietary restriction; cytochrome c oxidase; mtDNA deletion mutations
ID dna-deletion mutations; skeletal-muscle; gene-expression; genomic damage; renal-failure; disease; nephropathy; progression; products; fibers
AB Adult-onset calorie restriction (A-CR) is an experimental model of life extension and healthy aging less explored, compared with calorie restriction begun at early ages, but one more realistic for human application. We examined the effect of A-CR on the aging rat kidney with respect to common structural age-dependent changes and the accumulation of mitochondrial enzyme abnormalities in tubular epithelial cells. A 40% calorie restriction was initiated in middle-aged rats, before the onset of significant age-related changes in the Fischer x Brown Norway rat kidney. This dietary intervention effectively reduced glomerulosclerosis and tubular atrophy within 6 mo and changed the rate of interstitial fibrosis formation within 1 yr and vascular wall thickening and the expression cytochrome c oxidase (COX)-deficient tubular epithelial cells in 18 mo compared with age-matched ad libitum-fed rats. Our histological approach (histochemical staining for mitochondrial enzyme activity and laser capture microdissection) coupled with mitochondrial DNA (mtDNA) PCR analyses demonstrated that COX-deficient renal tubular epithelial cells accumulated mtDNA deletion mutations and that these cells contained unique, clonally expanded mtDNA deletion mutations. Renal tubular epithelial cells with mitochondrial abnormalities presented cellular characteristics indicative of physiological dysfunction.
C1 Univ Wisconsin, Dept Anim Hlth & Biomed Sci, Madison, WI 53706 USA.
   Univ Wisconsin, Dept Med, Madison, WI 53706 USA.
   Univ Washington, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA.
C3 University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Washington; University of Washington Seattle
RP McKiernan, SH (corresponding author), Univ Wisconsin, Dept Anim Hlth & Biomed Sci, 1656 Linden Dr, Madison, WI 53706 USA.
EM mckiernan@svm.vetmed.wisc.edu
FU NIA NIH HHS [AG-17543, AG-11604] Funding Source: Medline; NIDDK NIH HHS [DK-067981] Funding Source: Medline
CR Alexeyev MF, 2004, CLIN SCI, V107, P355, DOI 10.1042/CS20040148
   ANDERSON S, 1986, AM J MED, V80, P435, DOI 10.1016/0002-9343(86)90718-7
   Baker DJ, 2006, J GERONTOL A-BIOL, V61, P675, DOI 10.1093/gerona/61.7.675
   Bua E, 2006, AM J HUM GENET, V79, P469, DOI 10.1086/507132
   Cao ZJ, 2001, NUCLEIC ACIDS RES, V29, P4502, DOI 10.1093/nar/29.21.4502
   CHOUDHURY D, 2004, KIDNEY, V0, P0
   Coresh J, 2003, AM J KIDNEY DIS, V41, P1, DOI 10.1053/ajkd.2003.50007
   DiMauro S, 2002, MUSCLE NERVE, V26, P597, DOI 10.1002/mus.10194
   DUBOWITZ V, 1985, HISTOLOGICAL HISTOCH, V0, P0
   Gokey NG, 2004, AGING CELL, V3, P319, DOI 10.1111/j.1474-9728.2004.00122.x
   Hard GC, 2004, TOXICOL PATHOL, V32, P171, DOI 10.1080/01926230490422574
   HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298
   Holthöfer H, 1999, FASEB J, V13, P523, DOI 10.1096/fasebj.13.3.523
   Hütter E, 2006, EXP GERONTOL, V41, P103, DOI 10.1016/j.exger.2005.09.011
   Jiang T, 2005, J AM SOC NEPHROL, V16, P2385, DOI 10.1681/ASN.2004080701
   JOHNSON BC, 1986, P NATL ACAD SCI USA, V83, P5659, DOI 10.1073/pnas.83.15.5659
   Julian D, 2004, AM J PHYSIOL-REG I, V286, PR20, DOI 10.1152/ajpregu.00522.2003
   Kakimoto M, 2002, DIABETES, V51, P1588, DOI 10.2337/diabetes.51.5.1588
   Kim HJ, 2002, EXP GERONTOL, V37, P1041, DOI 10.1016/S0531-5565(02)00082-7
   Lane MA, 2004, J GERONTOL A-BIOL, V59, P405
   Lebrecht D, 2004, NEPHROL DIAL TRANSPL, V19, P329, DOI 10.1093/ndt/gfg564
   Lee JH, 2004, EXP GERONTOL, V39, P1361, DOI 10.1016/j.exger.2004.06.015
   Lim PS, 2000, FREE RADICAL BIO MED, V29, P454, DOI 10.1016/S0891-5849(00)00334-8
   Liu CS, 2001, NEPHROL DIAL TRANSPL, V16, P561, DOI 10.1093/ndt/16.3.561
   López-Lluch G, 2006, P NATL ACAD SCI USA, V103, P1768, DOI 10.1073/pnas.0510452103
   Mager DE, 2006, FASEB J, V20, P631, DOI 10.1096/fj.05-5263com
   Mandarim-De-Lacerda CA, 2003, AN ACAD BRAS CIENC, V75, P469, DOI 10.1590/S0001-37652003000400006
   Martin William F, 2005, NUTR METAB (LOND), V2, P25, DOI 10.1186/1743-7075-2-25
   Masoro EJ, 2006, J GERONTOL A-BIOL, V61, P14, DOI 10.1093/gerona/61.1.14
   Nicoletti VG, 2005, NEUROCHEM RES, V30, P737, DOI 10.1007/s11064-005-6867-7
   PREISIG PA, 1995, SEMIN NEPHROL, V15, P327
   Rao GN, 2002, TOXICOL PATHOL, V30, P651, DOI 10.1080/01926230290166733
   Razzaque M S, 1999, MOL CELL BIOL RES COMMUN, V1, P82, DOI 10.1006/mcbr.1999.0104
   Remuzzi G, 2006, J CLIN INVEST, V116, P288, DOI 10.1172/JCI27699
   Ruiz-Torres MP, 1998, J AM SOC NEPHROL, V9, P782
   Sanders PW, 2006, CURR OPIN NEPHROL HY, V15, P54, DOI 10.1097/01.mnh.0000186853.23512.a5
   SAS, 1989, SAS US GUID, V0, P0
   SELIGMAN AM, 1968, J CELL BIOL, V38, P1, DOI 10.1083/jcb.38.1.1
   Sheehan DC, 1980, THEORY AND PRACTICE OF HISTOTECHNOLOGY, Vsecond, P0
   Solin ML, 2000, LAB INVEST, V80, P1227, DOI 10.1038/labinvest.3780130
   Stern JS, 2001, J NUTR, V131, P913S, DOI 10.1093/jn/131.3.913S
   Stopper H, 2005, J RENAL NUTR, V15, P81, DOI 10.1053/j.jrn.2004.09.017
   Stopper H, 2004, SEMIN NEPHROL, V24, P474, DOI 10.1016/j.semnephrol.2004.06.025
   Takaki A, 2004, ANN NY ACAD SCI, V1011, P332, DOI 10.1196/annals.1293.033
   Taylor RW, 2003, J CLIN INVEST, V112, P1351, DOI 10.1172/JCI200319435
   VANLIEW JB, 1992, AM J PHYSIOL, V263, PF554, DOI 10.1152/ajprenal.1992.263.3.F554
   Wanagat J, 2001, FASEB J, V15, P322, DOI 10.1096/fj.00-0320com
   WEINDRUCH R, 1988, RETARDATION AGING DI, V0, P73
   Yamagata K, 2002, J AM SOC NEPHROL, V13, P0, DOI 10.1097/01.ASN.0000019772.17954.F8
   Yowe DL, 1998, GENE, V209, P23, DOI 10.1016/S0378-1119(97)00628-8
NR 53
TC 51
Z9 51
U1 0
U2 3
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1931-857X
EI 1522-1466
J9 AM J PHYSIOL-RENAL
JI Am. J. Physiol.-Renal Physiol.
PD JUN 15
PY 2007
VL 292
IS 6
BP F1751
EP F1760
DI 10.1152/ajprenal.00307.2006
PG 10
WC Physiology; Urology & Nephrology
SC Physiology; Urology & Nephrology
GA 188TK
UT WOS:000247942000011
PM 17344189
DA 2024-11-01
ER

PT J
AU Graziewicz, MA
   Bienstock, RJ
   Copeland, WC
AF Graziewicz, Maria A.
   Bienstock, Rachelle J.
   Copeland, William C.
TI The DNA polymerase γ Y955C disease variant associated with PEO and parkinsonism mediates the incorporation and translesion synthesis opposite 7,8-dihydro-8-oxo-2'-deoxyguanosine
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID progressive external ophthalmoplegia; mitochondrial-dna; oxidative damage; saccharomyces-cerevisiae; reverse-transcriptase; nucleotide insertion; autosomal-dominant; dopamine neurons; nucleic-acids; steady-state
AB Mitochondrial DNA is replicated and repaired by DNA polymerase gamma (pol gamma), encoded by the POLG gene. The Y955C substitution in POLG leads to autosomal dominant progressive external ophthalmoplegia (PEO) with other severe phenotypes. PEO patients with this mutation can further develop parkinsonism or premature ovarian failure. Mouse and yeast models with this mutation show enhanced amounts of oxidative lesions and increased mtDNA damage. In DNA pol gamma, Tyr955 plays a critical role in catalysis and high fidelity DNA synthesis. 7,8-dihydro-8-oxo-2 '-deoxyguanosine (8-oxo-dG) is one of the most common oxidative lesions in DNA and can promote transversion mutations. Mitochondria are thought to be a major source of endogenous reactive oxygen species that can react with dG to form 8-oxo-dG as one of the more common products. DNA polymerases can mitigate mutagenesis by 8-oxo-dG through allosteric interactions from amino acid side chains, which limit the anti-conformation of the 8-oxo-dG template base during translesion DNA synthesis. Here, we show that the Y955C pol g displays relaxed discrimination when either incorporating 8-oxo-dGTP or translesion synthesis opposite 8-oxo-dG. Molecular modeling and biochemical analysis suggest that this residue, Tyr955, in conjunction with Phe961 helps attenuate the anti-conformation in human pol g for error free bypass of 8-oxo-dG and substitution to Cys allows the mutagenic syn conformation. Collectively, these results offer a biochemical link between the observed oxidative stress in model systems and parkinsonism in patients, suggesting that patients harboring the Y955C POLG mutation may undergo enhanced oxidative stress and DNA mutagenesis.
C1 Natl Inst Environm Hlth Sci, Mol Genet Lab, Natl Inst Hlth, Res Triangle Pk, NC 27709 USA.
   Natl Inst Environm Hlth Sci, Comp Sci Lab, Natl Inst Hlth, Res Triangle Pk, NC 27709 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)
RP Copeland, WC (corresponding author), Natl Inst Environm Hlth Sci, Mol Genet Lab, Natl Inst Hlth, POB 12233, Res Triangle Pk, NC 27709 USA.
EM copelan1@niehs.nih.gov
FU Intramural NIH HHS [Z01 ES065078-14] Funding Source: Medline
CR Alam ZI, 1997, J NEUROCHEM, V69, P1196, DOI 10.1046/j.1471-4159.1997.69031196.x
   Baruffini E, 2006, HUM MOL GENET, V15, P2846, DOI 10.1093/hmg/ddl219
   Beckman KB, 2000, FREE RADICAL BIO MED, V29, P357, DOI 10.1016/S0891-5849(00)00316-6
   Beckman KB, 1999, MUTAT RES-FUND MOL M, V424, P51, DOI 10.1016/S0027-5107(99)00007-X
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Bohr VA, 2002, FREE RADICAL BIO MED, V32, P804, DOI 10.1016/S0891-5849(02)00787-6
   BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689
   Brieba LG, 2005, STRUCTURE, V13, P1653, DOI 10.1016/j.str.2005.07.020
   Brieba LG, 2004, EMBO J, V23, P3452, DOI 10.1038/sj.emboj.7600354
   Croteau DL, 1999, MUTAT RES-DNA REPAIR, V434, P137, DOI 10.1016/S0921-8777(99)00025-7
   Davidzon G, 2006, ANN NEUROL, V59, P859, DOI 10.1002/ana.20831
   de Souza-Pinto NC, 2001, CANCER RES, V61, P5378
   DIMAURO S, 1993, NEUROLOGY, V43, P2170, DOI 10.1212/WNL.43.11.2170
   DiMauro S, 2006, BRAIN, V129, P1637, DOI 10.1093/brain/awl169
   Doudican NA, 2005, MOL CELL BIOL, V25, P5196, DOI 10.1128/MCB.25.12.5196-5204.2005
   Fukae J, 2007, MITOCHONDRION, V7, P58, DOI 10.1016/j.mito.2006.12.002
   Furge LL, 1998, BIOCHEMISTRY-US, V37, P3567, DOI 10.1021/bi9722094
   Furge LL, 1997, BIOCHEMISTRY-US, V36, P6475, DOI 10.1021/bi9627267
   Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805
   Graziewicz MA, 2006, CHEM REV, V106, P383, DOI 10.1021/cr040463d
   Graziewicz MA, 2004, NUCLEIC ACIDS RES, V32, P397, DOI 10.1093/nar/gkh213
   Greene JG, 2005, NEUROBIOL DIS, V18, P19, DOI 10.1016/j.nbd.2004.10.003
   Hanes JW, 2006, J BIOL CHEM, V281, P36241, DOI 10.1074/jbc.M607965200
   HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489
   Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0
   Hsu GW, 2004, NATURE, V431, P217, DOI 10.1038/nature02908
   Hudson G, 2006, HUM MOL GENET, V15, PR244, DOI 10.1093/hmg/ddl233
   Johnson AA, 2001, J BIOL CHEM, V276, P40847, DOI 10.1074/jbc.M106743200
   Kaguni LS, 2004, ANNU REV BIOCHEM, V73, P293, DOI 10.1146/annurev.biochem.72.121801.161455
   KANG D, 1995, J BIOL CHEM, V270, P14659, DOI 10.1074/jbc.270.24.14659
   Karagiozova D, 2003, IMP DAM STRUCT, V1, P1
   Krahn JM, 2003, STRUCTURE, V11, P121, DOI 10.1016/S0969-2126(02)00930-9
   Kraytsberg Y, 2006, NAT GENET, V38, P518, DOI 10.1038/ng1778
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Lewis W, 2007, LAB INVEST, V87, P326, DOI 10.1038/labinvest.3700523
   Lim SE, 2003, J MOL BIOL, V329, P45, DOI 10.1016/S0022-2836(03)00405-4
   Lim SE, 2001, J BIOL CHEM, V276, P23616, DOI 10.1074/jbc.M101114200
   Lim SE, 1999, J BIOL CHEM, V274, P38197, DOI 10.1074/jbc.274.53.38197
   Longley MJ, 2005, GENE, V354, P125, DOI 10.1016/j.gene.2005.03.029
   Longley MJ, 1998, BIOCHEMISTRY-US, V37, P10529, DOI 10.1021/bi980772w
   Longley MJ, 2001, J BIOL CHEM, V276, P38555, DOI 10.1074/jbc.M105230200
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0
   Mancuso M, 2004, ARCH NEUROL-CHICAGO, V61, P1777, DOI 10.1001/archneur.61.11.1777
   Nakabeppu Y, 2006, BIOL CHEM, V387, P373, DOI 10.1515/BC.2006.050
   Nakabeppu Y, 2007, J NEUROSCI RES, V85, P919, DOI 10.1002/jnr.21191
   Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042
   ORourke TW, 2002, MOL CELL BIOL, V22, P4086, DOI 10.1128/MCB.22.12.4086-4093.2002
   Pagnamenta AT, 2006, HUM REPROD, V21, P2467, DOI 10.1093/humrep/del076
   PAVLOV YI, 1994, BIOCHEMISTRY-US, V33, P4695, DOI 10.1021/bi00181a029
   PINZ KG, 1995, J BIOL CHEM, V270, P9202, DOI 10.1074/jbc.270.16.9202
   Ponamarev MV, 2002, J BIOL CHEM, V277, P15225, DOI 10.1074/jbc.C200100200
   REARDON JE, 1990, J BIOL CHEM, V265, P20302
   Rodriguez R, 1998, BIOINFORMATICS, V14, P523, DOI 10.1093/bioinformatics/14.6.523
   SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626
   Shen MY, 2006, PROTEIN SCI, V15, P2507, DOI 10.1110/ps.062416606
   SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0
   Shimura-Miura H, 1999, ANN NEUROL, V46, P920, DOI 10.1002/1531-8249(199912)46:6<920::AID-ANA17>3.0.CO;2-R
   Shults CW, 2002, ARCH NEUROL-CHICAGO, V59, P1541, DOI 10.1001/archneur.59.10.1541
   Stuart GR, 2006, HUM MOL GENET, V15, P363, DOI 10.1093/hmg/ddi454
   Tiangyou W, 2006, NEUROLOGY, V67, P1698, DOI 10.1212/01.wnl.0000238963.07425.d5
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   VYAS I, 1986, J NEUROCHEM, V46, P1501, DOI 10.1111/j.1471-4159.1986.tb01768.x
   Wang YL, 2007, BIOPHYS J, V92, P3063, DOI 10.1529/biophysj.106.092106
   Wanrooij S, 2004, NUCLEIC ACIDS RES, V32, P3053, DOI 10.1093/nar/gkh634
   Yamaguchi H, 2006, CELL DEATH DIFFER, V13, P551, DOI 10.1038/sj.cdd.4401788
   Zhang J, 1999, AM J PATHOL, V154, P1423, DOI 10.1016/S0002-9440(10)65396-5
   Zheng WM, 2006, MUTAT RES-FUND MOL M, V599, P11, DOI 10.1016/j.mrfmmm.2005.12.012
NR 68
TC 79
Z9 86
U1 0
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD NOV 15
PY 2007
VL 16
IS 22
BP 2729
EP 2739
DI 10.1093/hmg/ddm227
PG 11
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 227SZ
UT WOS:000250679400009
PM 17725985
DA 2024-11-01
ER

PT J
AU Yao, YG
   Ellison, FM
   McCoy, JP
   Chen, JC
   Young, NS
AF Yao, Yong-Gang
   Ellison, Felicia M.
   McCoy, J. Philip
   Chen, Jichun
   Young, Neal S.
TI Age-dependent accumulation of mtDNA mutations in murine hematopoietic stem cells is modulated by the nuclear genetic background
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID mitochondrial-dna mutations; point mutations; degenerative diseases; oxidative stress; skeletal-muscle; control region; mice; replication; sequence; senescence
AB Alterations in mitochondrial DNA (mtDNA) and consequent loss of mitochondrial function underlie the mitochondrial theory of aging. In this study, we systematically analyzed the mtDNA control region somatic mutation pattern in 2864 single hematopoietic stem cells (HSCs) and progenitors, isolated by flow cytometry sorting on Lin(-)Kit(+)CD34(-) parameters from young and old C57BL/6 (B6) and BALB/cBy (BALB) mice, to test the hypothesis that the accumulated mtDNA mutations in HSCs were strain-correlated and associated with HSC functional senescence during aging. An increased level of mtDNA mutations in single HSCs was observed in old B6 when compared with young B6 mice (P=0.003); in contrast, no significant age-dependent accumulation of mutations was observed in BALB mice (old versus young, P=0.202) and the level of mutations in both young and old BALB mice was close to that of old B6 mice (P > 0.280). Cellular reactive oxygen species (ROS) in mouse HSCs could not be correlated with the level of mtDNA mutations in these cells, although B6 mice had a higher proportion of ROS- cells when compared with the BALB mice. Propagation assays of single HSCs showed B6 cells form larger colonies compared with cells from BALB mice, irrespective of age and mtDNA mutation load. We infer from our data that age-related mtDNA somatic mutation accumulation in mouse HSCs is influenced by the nuclear genetic background and that these mutations may not obviously correlate to either cellular ROS content or HSC senescence.
C1 NHLBI, Hematol Branch, NIH, Bethesda, MD 20892 USA.
   NHLBI, Flow Cytometry Core Facil, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)
RP Yao, YG (corresponding author), NHLBI, Hematol Branch, NIH, Bldg 10 CRC,Rm 3E-5140,10 Ctr Dr, Bethesda, MD 20892 USA.
EM yaoy3@nhlbi.nih.gov
CR Bayona-Bafaluy MP, 2003, NUCLEIC ACIDS RES, V31, P5349, DOI 10.1093/nar/gkg739
   Berkahn Leanne, 2004, HEMATOLOGY, V9, P159, DOI 10.1080/10245330410001701468
   Bua E, 2006, AM J HUM GENET, V79, P469, DOI 10.1086/507132
   Camargo FD, 2006, BLOOD, V107, P501, DOI 10.1182/blood-2005-02-0655
   Chen JC, 1999, EXP HEMATOL, V27, P928, DOI 10.1016/S0301-472X(99)00018-1
   Chen JC, 2000, EXP HEMATOL, V28, P442, DOI 10.1016/S0301-472X(99)00157-5
   Chinnery PF, 2002, LANCET, V360, P1323, DOI 10.1016/S0140-6736(02)11310-9
   de Grey ADNJ, 2004, REJUV RES, V7, P171, DOI 10.1089/rej.2004.7.171
   Dick JE, 2005, INT J HEMATOL, V82, P389, DOI 10.1532/IJH97.05144
   Driver C, 2004, BIOESSAYS, V26, P1160, DOI 10.1002/bies.20149
   Dröge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001
   Finkel T, 2005, NAT REV MOL CELL BIO, V6, P971, DOI 10.1038/nrm1763
   HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x
   Harman D, 2006, ANN NY ACAD SCI, V1067, P10, DOI 10.1196/annals.1354.003
   HARRISON DE, 1989, J IMMUNOL, V142, P3833
   Howes RM, 2006, ANN NY ACAD SCI, V1067, P22, DOI 10.1196/annals.1354.004
   Jacobs HT, 2003, AGING CELL, V2, P11, DOI 10.1046/j.1474-9728.2003.00032.x
   Khaidakov M, 2003, MUTAT RES-FUND MOL M, V526, P1, DOI 10.1016/S0027-5107(03)00010-1
   Khrapko K, 2006, AGING CELL, V5, P279, DOI 10.1111/j.1474-9726.2006.00209.x
   Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125
   Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285
   Liang Y, 2005, BLOOD, V106, P1479, DOI 10.1182/blood-2004-11-4282
   Lin PH, 2003, FREE RADICAL BIO MED, V35, P1310, DOI 10.1016/j.freeradbiomed.2003.07.002
   LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4
   Loeb LA, 2005, P NATL ACAD SCI USA, V102, P18769, DOI 10.1073/pnas.0509776102
   Michikawa Y, 1999, SCIENCE, V286, P774, DOI 10.1126/science.286.5440.774
   Morrison SJ, 1996, NAT MED, V2, P1011, DOI 10.1038/nm0996-1011
   Mott JL, 2001, MUTAT RES-FUND MOL M, V474, P35, DOI 10.1016/S0027-5107(00)00159-7
   Nagley P, 1998, TRENDS GENET, V14, P513, DOI 10.1016/S0168-9525(98)01580-7
   Ogasawara Y, 2005, BLOOD, V106, P3271, DOI 10.1182/blood-2005-01-0150
   Osawa M, 1996, SCIENCE, V273, P242, DOI 10.1126/science.273.5272.242
   Pak JW, 2003, AGING CELL, V2, P1, DOI 10.1046/j.1474-9728.2003.00034.x
   Pallotti F, 1996, AM J HUM GENET, V59, P591
   Shin MG, 2004, BLOOD, V103, P553, DOI 10.1182/blood-2003-05-1724
   Song XF, 2005, GENE, V350, P193, DOI 10.1016/j.gene.2005.02.008
   Sudo K, 2000, J EXP MED, V192, P1273, DOI 10.1084/jem.192.9.1273
   Trifunovic A, 2005, P NATL ACAD SCI USA, V102, P17993, DOI 10.1073/pnas.0508886102
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Trifunovic A, 2006, BBA-BIOENERGETICS, V1757, P611, DOI 10.1016/j.bbabio.2006.03.003
   Van Zant G, 2003, INT J HEMATOL, V77, P29, DOI 10.1007/BF02982600
   Vogel H, 1999, P NATL ACAD SCI USA, V96, P10770, DOI 10.1073/pnas.96.19.10770
   Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751
   Wang Y, 2001, P NATL ACAD SCI USA, V98, P4022, DOI 10.1073/pnas.061013598
   Yao YG, 2007, BLOOD, V109, P756, DOI 10.1182/blood-2006-01-011007
   Zhang D, 2003, CARDIOVASC RES, V57, P147, DOI 10.1016/S0008-6363(02)00695-8
   Zhang DK, 2000, GENOMICS, V69, P151, DOI 10.1006/geno.2000.6333
   Zhang J, 2003, P NATL ACAD SCI USA, V100, P1116, DOI 10.1073/pnas.242719399
NR 47
TC 26
Z9 33
U1 0
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD FEB 1
PY 2007
VL 16
IS 3
BP 286
EP 294
DI 10.1093/hmg/ddl457
PG 9
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 135AK
UT WOS:000244126000005
PM 17185390
DA 2024-11-01
ER

PT J
AU Bonnet, C
   Kaltimbacher, V
   Ellouze, S
   Augustin, S
   Bénit, P
   Forster, V
   Rustin, P
   Sahel, JA
   Corral-Debrinski, M
AF Bonnet, Crystel
   Kaltimbacher, Valerie
   Ellouze, Sami
   Augustin, Sebastien
   Benit, Paule
   Forster, Valerie
   Rustin, Pierre
   Sahel, Jose-Alain
   Corral-Debrinski, Marisol
TI Allotopic mRNA localization to the mitochondrial surface rescues respiratory chain defects in fibroblasts harboring mitochondrial DNA mutations affecting complex I or V subunits
SO REJUVENATION RESEARCH
LA English
DT Article
ID hereditary optic neuropathy; cultured skin fibroblasts; hydrophobic proteins; yeast mitochondria; atp synthesis; human-cells; gene; deficiency; disorders; import
AB The possibility of synthesizing mitochondrial DNA (mtDNA)-coded proteins in the cytosolic compartment, called allotopic expression, provides an attractive option for genetic treatment of human diseases caused by mutations of the corresponding genes. However, it is now appreciated that the high hydrophobicity of proteins encoded by the mitochondrial genome represents a strong limitation on their mitochondrial import when translated in the cytosol. Recently, we optimized the allotopic expression of a recoded ATP6 gene in human cells, by forcing its mRNA to localize to the mitochondrial surface. In this study, we show that this approach leads to a long-lasting and complete rescue of mitochondrial dysfunction of fibroblasts harboring the neurogenic muscle weakness, ataxia and retinitis Pigmentosa T8993G ATP6 mutation or the Leber hereditary optic neuropathy G11778A ND4 mutation. The recoded ATP6 gene was associated with the cis-acting elements of SOD2, while the ND4 gene was associated with the cis-acting elements of COX10. Both ATP6 and ND4 gene products were efficiently translocated into the mitochondria and functional within their respective respiratory chain complexes. Indeed, the abilities to grow in galactose and to produce adenosine triphosphate (ATP) in vitro were both completely restored in fibroblasts allotopically expressing either ATP6 or ND4. Notably, in fibroblasts harboring the ATP6 mutation, allotopic expression of ATP6 led to the recovery of complex V enzymatic activity. Therefore, mRNA sorting to the mitochondrial surface represents a powerful strategy that could ultimately be applied in human therapy and become available for an array of devastating disorders caused by mtDNA mutations.
C1 Univ Paris 06, Hop St Antoine, INSERM, U592,Lab Physiopathol Cellulaire & Mol Retine, F-75571 Paris 12, France.
   Hop Robert Debre 48, INSERM, U676, F-75019 Paris, France.
C3 Assistance Publique Hopitaux Paris (APHP); Sorbonne Universite; Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite; Hopital Universitaire Robert-Debre - APHP
RP Corral-Debrinski, M (corresponding author), Univ Paris 06, Hop St Antoine, INSERM, U592,Lab Physiopathol Cellulaire & Mol Retine, Bat Kourilsky 184,Rue Fbg St Antoine, F-75571 Paris 12, France.
EM corral@st-antoine.inserm.fr
CR Benit P, 2006, CLIN CHIM ACTA, V374, P81, DOI 10.1016/j.cca.2006.05.034
   Bokori-Brown M, 2006, REJUV RES, V9, P455, DOI 10.1089/rej.2006.9.455
   Carelli V, 2004, PROG RETIN EYE RES, V23, P53, DOI 10.1016/j.preteyeres.2003.10.003
   Chretien D, 2003, BIOCHEM BIOPH RES CO, V301, P222, DOI 10.1016/S0006-291X(02)03016-4
   Claros M G, 1996, METHODS ENZYMOL, V264, P389, DOI 10.1016/S0076-6879(96)64036-1
   CLAROS MG, 1995, EUR J BIOCHEM, V228, P762, DOI 10.1111/j.1432-1033.1995.0762m.x
   Cock HR, 1999, J NEUROL SCI, V165, P10, DOI 10.1016/S0022-510X(99)00088-X
   Corral-Debrinski M, 1999, MOL MICROBIOL, V31, P1499, DOI 10.1046/j.1365-2958.1999.01295.x
   Corral-Debrinski M, 2000, MOL CELL BIOL, V20, P7881, DOI 10.1128/MCB.20.21.7881-7892.2000
   DAurelio M, 2006, HUM MOL GENET, V15, P2157, DOI 10.1093/hmg/ddl141
   Diaz F, 2005, HUM MOL GENET, V14, P2737, DOI 10.1093/hmg/ddi307
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Dudkina NV, 2005, P NATL ACAD SCI USA, V102, P3225, DOI 10.1073/pnas.0408870102
   Fünfschilling U, 1999, MOL BIOL CELL, V10, P3289, DOI 10.1091/mbc.10.10.3289
   George R, 2002, FEBS LETT, V516, P213, DOI 10.1016/S0014-5793(02)02528-0
   Geromel V, 1997, BIOCHEM BIOPH RES CO, V236, P643, DOI 10.1006/bbrc.1997.7024
   Geromel V, 2001, HUM MOL GENET, V10, P1221, DOI 10.1093/hmg/10.11.1221
   Ghelli A, 2003, J BIOL CHEM, V278, P4145, DOI 10.1074/jbc.M210285200
   Ginsberg MD, 2003, J MOL BIOL, V327, P885, DOI 10.1016/S0022-2836(03)00173-6
   Guy J, 2002, ANN NEUROL, V52, P534, DOI 10.1002/ana.10354
   Hakkaart GAJ, 2006, EMBO REP, V7, P341, DOI 10.1038/sj.embor.7400601
   Hofhaus G, 1996, J BIOL CHEM, V271, P13155, DOI 10.1074/jbc.271.22.13155
   Kaltimbacher V, 2006, RNA, V12, P1408, DOI 10.1261/rna.18206
   Kasahara A, 2006, HUM MOL GENET, V15, P871, DOI 10.1093/hmg/ddl005
   Manfred G, 1999, J BIOL CHEM, V274, P9386, DOI 10.1074/jbc.274.14.9386
   Manfredi G, 2002, NAT GENET, V30, P394, DOI 10.1038/ng851
   Margeot A, 2002, EMBO J, V21, P6893, DOI 10.1093/emboj/cdf690
   Oca-Cossio J, 2003, GENETICS, V165, P707
   Ojaimi J, 2002, MOL BIOL CELL, V13, P3836, DOI 10.1091/mbc.E02-05-0306
   Ouhabi R, 1998, ANAL BIOCHEM, V263, P169, DOI 10.1006/abio.1998.2776
   Pallotti F, 2004, BIOCHEM J, V384, P287, DOI 10.1042/BJ20040561
   Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006
   Rötig A, 2003, J AM SOC NEPHROL, V14, P2995, DOI 10.1097/01.ASN.0000095481.24091.C9
   Schaefer AM, 2004, BBA-BIOENERGETICS, V1659, P115, DOI 10.1016/j.bbabio.2004.09.005
   Smith PM, 2004, BBA-BIOENERGETICS, V1659, P232, DOI 10.1016/j.bbabio.2004.09.003
   Surace EM, 2003, PROG RETIN EYE RES, V22, P705, DOI 10.1016/S1350-9462(03)00052-1
   Sylvestre J, 2003, MOL BIOL CELL, V14, P3848, DOI 10.1091/mbc.E03-02-0074
   Ugalde C, 2004, HUM MOL GENET, V13, P659, DOI 10.1093/hmg/ddh071
   Yen MY, 2006, PROG RETIN EYE RES, V25, P381, DOI 10.1016/j.preteyeres.2006.05.002
   Zeviani M, 2003, CURR OPIN NEUROL, V16, P585, DOI 10.1097/00019052-200310000-00004
   Zullo SJ, 2005, REJUV RES, V8, P18, DOI 10.1089/rej.2005.8.18
NR 41
TC 75
Z9 84
U1 0
U2 9
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1549-1684
EI 1557-8577
J9 REJUV RES
JI Rejuv. Res.
PD JUN 15
PY 2007
VL 10
IS 2
BP 127
EP 143
DI 10.1089/rej.2006.0526
PG 17
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA 180IS
UT WOS:000247357000002
PM 17518546
DA 2024-11-01
ER

PT J
AU Herbst, A
   Pak, JW
   McKenzie, D
   Bua, E
   Bassiouni, M
   Aiken, JM
AF Herbst, Allen
   Pak, Jeong W.
   McKenzie, Debbie
   Bua, Entela
   Bassiouni, Marwa
   Aiken, Judd M.
TI Accumulation of mitochondrial DNA deletion mutations in aged muscle fibers: Evidence for a causal role in muscle fiber loss
SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES
LA English
DT Article
ID skeletal-muscle; rhesus-monkeys; abnormality; diseases; sarcopenia; atrophy; number; pcr; pathology; genm
AB Although mitochondrial mutation abundance has been recognized to increase in an age-dependent manner, the impact of mutation has been more difficult to establish. Using quantitative polymerase chain reaction, we measured the intracellular abundance of mutant and wild-type mitochondrial genomes along the length of individual laser-captured microdissected muscle fibers from aged rat quadriceps. Aged muscle fibers possessed segmental, clonal intracellular expansions of unique somatically derived mitochondrial DNA (mtDNA) deletion mutations. When the mutation abundance surpassed 90% of the total mitochondrial genomes, the fiber lost cytochrome c oxidase activity and exhibited an increase in succinate dehydrogenase activity. In addition to the mitochondrial enzymatic abnormalities, some fibers displayed abnornal morphology such as fiber splitting, atrophy, and breakage. Deletion mutation accumulation was linked to these aberrant morphologies with more severe cellular pathologies resulting from higher deletion mutation abundance. In summary, our measurements indicate that age-induced mtDNA deletion mutations expand within individual muscle fibers, eliciting fiber dysfunction and breakage.
C1 Univ Wisconsin, Dept Anim Hlth & Biomed Sci, Madison, WI 53706 USA.
C3 University of Wisconsin System; University of Wisconsin Madison
RP Aiken, JM (corresponding author), Univ Wisconsin, Dept Anim Hlth & Biomed Sci, 1656 Linden Dr, Madison, WI 53706 USA.
EM aiken@svm.vetmed.wisc.edu
FU NIA NIH HHS [AG011604, R01 AG011604, R01 AG030423, R01 AG011604-04A1] Funding Source: Medline; NIEHS NIH HHS [ES09090] Funding Source: Medline
CR Bua EA, 2002, J APPL PHYSIOL, V92, P2617, DOI 10.1152/japplphysiol.01102.2001
   Cao ZJ, 2001, NUCLEIC ACIDS RES, V29, P4502, DOI 10.1093/nar/29.21.4502
   CHUNG SS, 1994, AGING-CLIN EXP RES, V6, P193, DOI 10.1007/BF03324239
   CORTOPASSI GA, 1990, NUCLEIC ACIDS RES, V18, P6927, DOI 10.1093/nar/18.23.6927
   deGrey ADNJ, 1997, BIOESSAYS, V19, P161, DOI 10.1002/bies.950190211
   Dimauro Salvatore, 1998, BIOFACTORS, V7, P277
   EDRIS W, 1994, MUTAT RES-DNAGING G, V316, P69, DOI 10.1016/0921-8734(94)90009-4
   Elson JL, 2001, AM J HUM GENET, V68, P802, DOI 10.1086/318801
   Evans W, 1997, J NUTR, V127, P998S, DOI 10.1093/jn/127.5.998S
   Gokey NG, 2004, AGING CELL, V3, P319, DOI 10.1111/j.1474-9728.2004.00122.x
   HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x
   HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614
   He LP, 2002, NUCLEIC ACIDS RES, V30, P0, DOI 10.1093/nar/gnf067
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125
   Lee CM, 1998, FREE RADICAL BIO MED, V25, P964, DOI 10.1016/S0891-5849(98)00185-3
   LEE CM, 1993, J GERONTOL, V48, P201
   LEXELL J, 1988, J NEUROL SCI, V84, P275, DOI 10.1016/0022-510X(88)90132-3
   LINNANE AW, 1990, BIOCHEM INT, V22, P1067
   Lopez ME, 2000, MUTAT RES-FUND MOL M, V452, P123, DOI 10.1016/S0027-5107(00)00059-2
   McKiernan S, 2004, FASEB J, V18, P580, DOI 10.1096/fj.03-0667fje
   MELOV S, 1994, NUCLEIC ACIDS RES, V22, P1075, DOI 10.1093/nar/22.6.1075
   MIQUEL J, 1980, EXP GERONTOL, V15, P575, DOI 10.1016/0531-5565(80)90010-8
   MITA S, 1989, P NATL ACAD SCI USA, V86, P9509, DOI 10.1073/pnas.86.23.9509
   MORAES CT, 1992, NAT GENET, V1, P359, DOI 10.1038/ng0892-359
   MULLERHOCKER J, 1993, VIRCHOWS ARCH A, V422, P7, DOI 10.1007/BF01605127
   OLDFORS A, 1992, J NEUROL SCI, V110, P169, DOI 10.1016/0022-510X(92)90025-G
   Rosenberg IH, 1997, J NUTR, V127, PS990, DOI 10.1093/jn/127.5.990S
   Rossignol R, 2003, BIOCHEM J, V370, P751, DOI 10.1042/BJ20021594
   SATO T, 1984, MECH AGEING DEV, V28, P99, DOI 10.1016/0047-6374(84)90156-8
   SCHWARZE SR, 1995, MECH AGEING DEV, V83, P91, DOI 10.1016/0047-6374(95)01611-3
   SHOUBRIDGE EA, 1990, CELL, V62, P43, DOI 10.1016/0092-8674(90)90238-A
   SHOUBRIDGE EA, 1994, J BIOENERG BIOMEMBR, V26, P301, DOI 10.1007/BF00763101
   SIMONETTI S, 1992, BIOCHIM BIOPHYS ACTA, V1180, P113, DOI 10.1016/0925-4439(92)90059-V
   Smeitink J, 2001, NAT REV GENET, V2, P342, DOI 10.1038/35072063
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523
   Wanagat J, 2001, FASEB J, V15, P322, DOI 10.1096/fj.00-0320com
NR 39
TC 142
Z9 163
U1 0
U2 11
PU GERONTOLOGICAL SOC AMER
PI WASHINGTON
PA 1030 15TH ST NW, STE 250, WASHINGTON, DC 20005202-842 USA
SN 1079-5006
EI 
J9 J GERONTOL A-BIOL
JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci.
PD MAR 15
PY 2007
VL 62
IS 3
BP 235
EP 245
DI 10.1093/gerona/62.3.235
PG 11
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 228WM
UT WOS:000250763300002
PM 17389720
DA 2024-11-01
ER

PT J
AU Bourdon, A
   Minai, L
   Serre, V
   Jais, JP
   Sarzi, E
   Aubert, S
   Chrétien, D
   de Lonlay, P
   Paquis-Flucklinger, V
   Arakawa, H
   Nakamura, Y
   Munnich, A
   Rötig, A
AF Bourdon, Alice
   Minai, Limor
   Serre, Valerie
   Jais, Jean-Philippe
   Sarzi, Emmanuelle
   Aubert, Sophie
   Chretien, Dominique
   de Lonlay, Pascale
   Paquis-Flucklinger, Veronique
   Arakawa, Hirofumi
   Nakamura, Yusuke
   Munnich, Arnold
   Rotig, Agnes
TI Mutation of <i>RRM2B</i>, encoding p53-controlled ribonucleotide reductase (p53R2), causes severe mitochondrial DNA depletion
SO NATURE GENETICS
LA English
DT Article
ID swiss-model; r2 protein; dntp pools; gene; encephalomyopathy; cluspro; docking; kinase; damage; cells
AB Mitochondrial DNA (mtDNA) depletion syndrome (MDS; MIM 251880) is a prevalent cause of oxidative phosphorylation disorders characterized by a reduction in mtDNA copy number. The hitherto recognized disease mechanisms alter either mtDNA replication (POLG (ref. 1)) or the salvage pathway of mitochondrial deoxyribonucleosides 5'- triphosphates (dNTPs) for mtDNA synthesis (DGUOK (ref. 2), TK2 (ref. 3) and SUCLA2 (ref. 4)). A last gene, MPV17 ( ref. 5), has no known function. Yet the majority of cases remain unexplained. Studying seven cases of profound mtDNA depletion (1-2% residual mtDNA in muscle) in four unrelated families, we have found nonsense, missense and splice-site mutations and in-frame deletions of the RRM2B gene, encoding the cytosolic p53-inducible ribonucleotide reductase small subunit. Accordingly, severe mtDNA depletion was found in various tissues of the Rrm2b(-/-) mouse. The mtDNA depletion triggered by p53R2 alterations in both human and mouse implies that p53R2 has a crucial role in dNTP supply for mtDNA synthesis.
C1 Hop Necker Enfants Malad, INSERM, U781, F-75015 Paris, France.
   Hop Necker Enfants Malad, Serv Genet, F-75015 Paris, France.
   Univ Paris 07, F-75005 Paris, France.
   Univ Paris 05, Hop Necker Enfants Malad, Fac Med, Serv Biostat & Informat, F-75015 Paris, France.
   Archet 2 Hosp, Dept Med Genet, F-06107 Nice, France.
   Univ Tokyo, Inst Med Sci, Human Genome Ctr, Minato Ku, Tokyo 1088639, Japan.
C3 Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite; Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite; Hopital Universitaire Necker-Enfants Malades - APHP; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite; Hopital Universitaire Necker-Enfants Malades - APHP; CHU Nice; University of Tokyo
RP Rötig, A (corresponding author), Hop Necker Enfants Malad, INSERM, U781, 149 Rue Sevres, F-75015 Paris, France.
EM roetig@necker.fr
CR Abecasis GR, 2002, NAT GENET, V30, P97, DOI 10.1038/ng786
   Butow RA, 2004, MOL CELL, V14, P1, DOI 10.1016/S1097-2765(04)00179-0
   Chabes AL, 2003, P NATL ACAD SCI USA, V100, P3925, DOI 10.1073/pnas.0330774100
   Comeau SR, 2004, BIOINFORMATICS, V20, P45, DOI 10.1093/bioinformatics/btg371
   Comeau SR, 2004, NUCLEIC ACIDS RES, V32, PW96, DOI 10.1093/nar/gkh354
   Eklund H, 2001, PROG BIOPHYS MOL BIO, V77, P177, DOI 10.1016/S0079-6107(01)00014-1
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505
   Håkansson P, 2006, J BIOL CHEM, V281, P7834, DOI 10.1074/jbc.M512894200
   Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0
   Kimura T, 2003, NAT GENET, V34, P440, DOI 10.1038/ng1212
   Kolberg M, 2004, BBA-PROTEINS PROTEOM, V1699, P1, DOI 10.1016/j.bbapap.2004.02.007
   Liu ZC, 2006, ANNU REV GENET, V40, P159, DOI 10.1146/annurev.genet.40.110405.090613
   LYCKSELL PO, 1994, BIOCHEMISTRY-US, V33, P2838, DOI 10.1021/bi00176a013
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Matoba S, 2006, SCIENCE, V312, P1650, DOI 10.1126/science.1126863
   Nordlund N, 2006, ANNU REV BIOCHEM, V75, P681, DOI 10.1146/annurev.biochem.75.103004.142443
   PAQUISFLUCKLINGER V, 1995, EUR J PEDIATR, V154, P557, DOI 10.1007/s004310050342
   RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506
   Zhou BS, 2003, CANCER RES, V63, P6583
NR 26
TC 429
Z9 476
U1 1
U2 39
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1061-4036
EI 1546-1718
J9 NAT GENET
JI Nature Genet.
PD JUN 15
PY 2007
VL 39
IS 6
BP 776
EP 780
DI 10.1038/ng2040
PG 5
WC Genetics & Heredity
SC Genetics & Heredity
GA 173FO
UT WOS:000246859100022
PM 17486094
DA 2024-11-01
ER

PT J
AU Luoma, PT
   Eerola, J
   Ahola, S
   Hakonen, AH
   Hellström, O
   Kivistö, KT
   Tienari, PJ
   Suomalainen, A
AF Luoma, P. T.
   Eerola, J.
   Ahola, S.
   Hakonen, A. H.
   Hellstroem, O.
   Kivistoe, K. T.
   Tienari, P. J.
   Suomalainen, A.
TI Mitochondrial DNA polymerase gamma variants in idiopathic sporadic Parkinson disease
SO NEUROLOGY
LA English
DT Article
ID substantia-nigra neurons; trinucleotide cag repeat; polg mutations; gene; deletions; family; ataxia; ophthalmoplegia; disorders; brain
AB Objective: Dysfunction of mitochondrial DNA polymerase gamma ( POLG) has been recently recognized as an important cause of inherited neurodegenerative diseases. We have reported dominant and recessive inheritance of parkinsonism, mitochondrial myopathy, and premature amenorrhea in five ethnically distinct families with POLG1 mutations. This prompted us to carry out a detailed analysis of the coding region and intron- exon boundaries of POLG1 in Finnish patients with idiopathic sporadic Parkinson disease ( PD) and in nonparkinsonian controls. Methods: The coding region of POLG1 was analyzed in 140 Finnish patients with PD and their 127 spouses as age- and ethnically matched controls. Further, we analyzed the intragenic CAGrepeat region of POLG1 in 126 additional patients with nonparkinsonian neurologic disorders and in 516 Finnish population controls. Results: We found clustering of rare variants of the POLG1 CAG- repeat, encoding a polyglutamine tract, in Finnish patients with idiopathic PD as compared to their spouses ( p = 0.003; OR 3.01, 95% CI 1.35 to 6.71), population controls ( p = 0.001; OR 2.45, 95% CI 1.45 to 4.14), and patients with nonparkinsonian neurologic disorders ( p = 0.05, OR 1.98, 95% CI 0.97 to 4.05). We found several amino acid substitutions, none of them associating with PD. These included a previously parkinsonism- associated POLG variant Y831C, found in one patient with PD, but also in five controls, suggesting that it is a neutral amino acid polymorphism. Conclusions: Our results suggest that POLG polyglutamine tract variants should be considered as a predisposing genetic factor in idiopathic sporadic Parkinson disease.
C1 Univ Helsinki, Biomedicum Helsinki, Res Program Mol Neurol, Helsinki 00290, Finland.
   Univ Helsinki, Cent Hosp, Dept Neurol, FIN-00014 Helsinki, Finland.
   Seinajoki Cent Hosp, Seinajoki, Finland.
   Tampere Univ, Dept Pharmacol Sci, FIN-33101 Tampere, Finland.
C3 University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Seinajoki Central Hospital; Tampere University
RP Suomalainen, A (corresponding author), Univ Helsinki, Biomedicum Helsinki, Res Program Mol Neurol, Room C523B,Haartmaninkatu 8, Helsinki 00290, Finland.
EM anu.wartiovaara@helsinki.fi
CR Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209
   CHAN SS, 2006, HUM MOL GENET, V0, P0
   CLARIMON J, 2005, NEUROBIOL AGING, V0, P0
   Darios F, 2003, HUM MOL GENET, V12, P517, DOI 10.1093/hmg/ddg044
   Davidzon G, 2006, ANN NEUROL, V59, P859, DOI 10.1002/ana.20831
   Eerola J, 2005, J NEUROL NEUROSUR PS, V76, P1211, DOI 10.1136/jnnp.2004.045237
   Greene JC, 2003, P NATL ACAD SCI USA, V100, P4078, DOI 10.1073/pnas.0737556100
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   HAWLEY ME, 1995, J HERED, V86, P409, DOI 10.1093/oxfordjournals.jhered.a111613
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Ide M, 2005, HUM GENET, V117, P520, DOI 10.1007/s00439-005-1342-8
   Kaguni LS, 2004, ANNU REV BIOCHEM, V73, P293, DOI 10.1146/annurev.biochem.72.121801.161455
   Krausz C, 2004, J CLIN ENDOCR METAB, V89, P4292, DOI 10.1210/jc.2004-0008
   Kraytsberg Y, 2006, NAT GENET, V38, P518, DOI 10.1038/ng1778
   Lamantea E, 2004, ANN NEUROL, V56, P454, DOI 10.1002/ana.20219
   LANGSTON JW, 1984, BRAIN RES, V292, P390
   Lecrenier N, 1997, GENE, V185, P147, DOI 10.1016/S0378-1119(96)00663-4
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Luoma PT, 2005, HUM MOL GENET, V14, P1907, DOI 10.1093/hmg/ddi196
   Malyarchuk BA, 2005, HUM BIOL, V77, P355, DOI 10.1353/hub.2005.0050
   Mancuso M, 2004, ARCH NEUROL-CHICAGO, V61, P1777, DOI 10.1001/archneur.61.11.1777
   MIZUNO Y, 1987, J NEUROCHEM, V48, P1787, DOI 10.1111/j.1471-4159.1987.tb05737.x
   Myllykangas L, 2005, J NEUROL SCI, V236, P17, DOI 10.1016/j.jns.2005.04.008
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   NICKLAS WJ, 1985, LIFE SCI, V36, P2503, DOI 10.1016/0024-3205(85)90146-8
   Palacino JJ, 2004, J BIOL CHEM, V279, P18614, DOI 10.1074/jbc.M401135200
   Payami H, 2003, MOVEMENT DISORD, V18, P425, DOI 10.1002/mds.10375
   Rovio A, 1999, EUR J HUM GENET, V7, P140, DOI 10.1038/sj.ejhg.5200244
   Rovio AT, 2001, NAT GENET, V29, P261, DOI 10.1038/ng759
   Rovio AT, 2004, MAMM GENOME, V15, P492, DOI 10.1007/s00335-004-3049-x
   Taanman JW, 2005, NEUROSCI LETT, V376, P56, DOI 10.1016/j.neulet.2004.11.023
   TIANGYOU W, 2006, IDIOPATHIC PARKINSON, V0, P0
   Valente EM, 2004, SCIENCE, V304, P1158, DOI 10.1126/science.1096284
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
NR 36
TC 106
Z9 124
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD SEP 11
PY 2007
VL 69
IS 11
BP 1152
EP 1159
DI 10.1212/01.wnl.0000276955.23735.eb
PG 8
WC Clinical Neurology
SC Neurosciences & Neurology
GA 208VA
UT WOS:000249346100012
PM 17846414
DA 2024-11-01
ER

PT J
AU Yu, Q
   Zhang, Y
   Wang, ZX
   Yang, YL
   Yuan, Y
   Niu, SL
   Pei, P
   Wang, ST
   Ma, YA
   Bu, DF
   Zou, LP
   Fang, F
   Xiao, J
   Sun, F
   Zhang, Y
   Wu, Y
   Wang, S
   Xiong, H
   Wu, XR
AF Yu, Qi
   Zhang, Ying
   Wang, Zhaoxia
   Yang, Yanling
   Yuan, Yun
   Niu, Shulan
   Pei, Pei
   Wang, Songtao
   Ma, Yinan
   Bu, Dingfang
   Zou, Liping
   Fang, Fang
   Xiao, Jing
   Sun, Fang
   Zhang, Yao
   Wu, Ye
   Wang, Shuang
   Xiong, Hui
   Wu, Xiru
TI Screening of common mitochondrial mutations in Chinese patients with mitochondrial encephalomyopathies
SO MITOCHONDRION
LA English
DT Article
DE mitochondrial encephalomyopathy; MELAS; MERRF; Leigh's syndrome; mitochondrial DNA (mtDNA); mutation
ID stroke-like episodes; lactic-acidosis; mtdna mutation; dna; melas; disease; gene; encephalopathy; myopathy; deafness
AB To investigate the spectrum of common mitochondrial mutations in Northern China during the years of 2000-2005, 552 patients of mitochondrial encephalomyopathies clinically diagnosed as MELAS, MERRF or Leigh's syndrome, 14 cases of LHON and 46 cases of aminoglycoside induced deafness along with their family members, accepted routine point mutation tests at nucleotide positions 3243, 8344, 8993, 11778 or 1555 in mitochondrial genome. PCR-RFLP analysis, site-specific PCR and PCR-sequencing methods were used to identify the mutations. Fifty-seven cases with A3243G mutation, 4 cases with A8344G, 2 cases with T8993C and 1 case with T8993G were identified from the 552 encephalomyopathy patients. In addition, one case with G11778A was found from the 14 cases of LHON, and 5 cases with A1555G from the 46 cases of aminoglycoside ototoxicity patients. Additional screening for T8356G and T3271C merely had limited significance for the diagnosis of MERRF and MELAS. Differential diagnosis among mitochondrial encephalomyopathies was often complicated due to many similar clinical manifestations. For A3243G mutation, the proportion of mutant mtDNA was not related to severity of the disease but to the age of onset. (c) 2006 Elsevier B.V. and Mitochondria Research Society. All rights reserved.
C1 Peking Univ, Hosp 1, Cent Lab, Beijing, Peoples R China.
   Peking Univ, Hosp 1, Dept Neurol, Beijing, Peoples R China.
   Peking Univ, Hosp 1, Dept Pediat, Beijing, Peoples R China.
   Beijing Childrens Hosp, Dept Neurol, Beijing, Peoples R China.
C3 Peking University; Peking University; Peking University; Capital Medical University
RP Yu, Q (corresponding author), Peking Univ, Hosp 1, Cent Lab, Beijing, Peoples R China.
EM qiyu0724@yahoo.com
CR FANG W, 1994, MUSCLE NERVE, V17, P52, DOI 10.1002/mus.880170107
   Goto Y, 1995, RINSHO SHINKEIGAKU, V35, P1425
   GOTO Y, 1991, BIOCHIM BIOPHYS ACTA, V1097, P238, DOI 10.1016/0925-4439(91)90042-8
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Guo YP, 1997, CHINESE MED J-PEKING, V110, P851
   HOLT IJ, 1990, AM J HUM GENET, V46, P428
   HUANG CC, 1994, J NEUROL NEUROSUR PS, V57, P586, DOI 10.1136/jnnp.57.5.586
   LOTT MT, 1990, AM J OPHTHALMOL, V109, P625, DOI 10.1016/S0002-9394(14)72429-8
   MATTHEWS PM, 1994, J MED GENET, V31, P41, DOI 10.1136/jmg.31.1.41
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   Niu Shu-lan, 2003, ZHONGGUO YI XUE KE XUE YUAN XUE BAO, V25, P153
   PREZANT TR, 1993, NAT GENET, V4, P289, DOI 10.1038/ng0793-289
   SANTORELLI FM, 1994, NEUROLOGY, V44, P972, DOI 10.1212/WNL.44.5.972
   Song DL, 2001, CHINESE MED J-PEKING, V114, P1273
   Tarnopolsky MA, 1998, MUSCLE NERVE, V21, P25, DOI 10.1002/(SICI)1097-4598(199801)21:1<25::AID-MUS4>3.0.CO;2-I
   Thajeb P, 2000, ZHONGHUA YI XUE ZA ZHI (TAIPEI), V63, P71
   Ueki I, 2006, MITOCHONDRION, V6, P29, DOI 10.1016/j.mito.2005.10.003
   van den Ouweland JMW, 1999, DIABETOLOGIA, V42, P485, DOI 10.1007/s001250051183
   WALLACE DC, 1988, CELL, V55, P601, DOI 10.1016/0092-8674(88)90218-8
   Zhang Ying, 2005, ZHONGGUO YI XUE KE XUE YUAN XUE BAO, V27, P77
NR 20
TC 19
Z9 24
U1 2
U2 11
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
EI 1872-8278
J9 MITOCHONDRION
JI Mitochondrion
PD FEB-APR 15
PY 2007
VL 7
IS 1-2
BP 147
EP 150
DI 10.1016/j.mito.2006.11.019
PG 4
WC Cell Biology; Genetics & Heredity
SC Cell Biology; Genetics & Heredity
GA 157EM
UT WOS:000245701400022
PM 17276742
DA 2024-11-01
ER

PT J
AU Hudson, G
   Schaefer, AM
   Taylor, RW
   Tiangyou, W
   Gibson, A
   Venables, G
   Griffiths, P
   Burn, DJ
   Turnbull, DM
   Chinnery, PF
AF Hudson, Gavin
   Schaefer, Andrew M.
   Taylor, Robert W.
   Tiangyou, Watcharee
   Gibson, Andrew
   Venables, Graham
   Griffiths, Philip
   Burn, David J.
   Turnbull, Douglass M.
   Chinnery, Patrick F.
TI Mutation of the linker region of the polymerase γ-1 (<i>POLG1</i>) gene associated with progressive external ophthalmoplegia and parkinsonism
SO ARCHIVES OF NEUROLOGY
LA English
DT Article
ID mitochondrial-dna polymerase; gamma mutations; alpers-syndrome; neuropathy; defects; family
AB Objective: To define the molecular basis of the autosomal dominant progressive external ophthalmoplegia and parkinsonism in a large family with a dominantly transmitted multiple mitochondrial DNA deletion disorder. Design: Microsatellite analysis and screening of the progressive external ophthalmoplegia 1 (PEO1), adenine nucleotide translocator 1 (ANT1), and polymerase gamma-1 (POLG1) genes. Results: We identified 3 novel heterozygous POLG1 substitutions in the same family. Autosomal dominant progressive external ophthalmoplegia segregated with 1532G > A in exon 8 and an intronic variant c. 2070 + 158G > A in cis. The one patient with parkinsonism had an additional heterozygous substitution in exon 7 in trans (1389G > T). Both coding region mutations were predicted to alter conserved amino acids in the linker region of polymerase gamma. None of the substitutions were found in 192 ethnically matched control chromosomes, 108 patients with progressive external ophthalmoplegia, nor 140 cases of sporadic idiopathic Parkinson disease. Conclusion: Both autosomal dominant progressive external ophthalmoplegia and parkinsonism can because caused by mutations that directly affect the polymerase domain of polymerase gamma.
C1 Univ Newcastle Upon Tyne, Sch Med, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   Univ Newcastle Upon Tyne, Inst Human Genet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   Newcastle Upon Tyne Hosp NHS Fdn Trust, Dept Neurol, Newcastle Upon Tyne, Tyne & Wear, England.
   Newcastle Upon Tyne Hosp NHS Fdn Trust, Dept Ophthalmol, Newcastle Upon Tyne, Tyne & Wear, England.
   Sheffield Teaching Hosp NHS Fdn, Dept Neurol, Sheffield, S Yorkshire, England.
C3 Newcastle University - UK; Newcastle University - UK; Newcastle Upon Tyne Hospitals NHS Foundation Trust; Newcastle Upon Tyne Hospitals NHS Foundation Trust
RP Chinnery, PF (corresponding author), Univ Newcastle Upon Tyne, Sch Med, Mitochondrial Res Grp, M41014,Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM p.f.chinnery@ncl.ac.uk
FU Wellcome Trust Funding Source: Medline
CR Chan SSL, 2005, J BIOL CHEM, V280, P31341, DOI 10.1074/jbc.M506762200
   Davidzon G, 2006, ANN NEUROL, V59, P859, DOI 10.1002/ana.20831
   Davidzon G, 2005, ANN NEUROL, V57, P921, DOI 10.1002/ana.20498
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   GIBB WRG, 1988, J NEUROL NEUROSUR PS, V51, P745, DOI 10.1136/jnnp.51.6.745
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Kaguni LS, 2004, ANNU REV BIOCHEM, V73, P293, DOI 10.1146/annurev.biochem.72.121801.161455
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Luoma PT, 2005, HUM MOL GENET, V14, P1907, DOI 10.1093/hmg/ddi196
   Mancuso M, 2004, ARCH NEUROL-CHICAGO, V61, P1777, DOI 10.1001/archneur.61.11.1777
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Stuart GR, 2006, HUM MOL GENET, V15, P363, DOI 10.1093/hmg/ddi454
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
NR 17
TC 66
Z9 72
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0003-9942
EI 
J9 ARCH NEUROL-CHICAGO
JI Arch. Neurol.
PD APR 15
PY 2007
VL 64
IS 4
BP 553
EP 557
DI 10.1001/archneur.64.4.553
PG 5
WC Clinical Neurology
SC Neurosciences & Neurology
GA 155AG
UT WOS:000245549300013
PM 17420318
DA 2024-11-01
ER

PT J
AU Lebedeva, MA
   Shadel, GS
AF Lebedeva, Maria A.
   Shadel, Gerald S.
TI Cell cycle- and ribonucleotide reductase-driven changes in mtDNA copy number influence mtDNA inheritance without compromising mitochondrial gene expression
SO CELL CYCLE
LA English
DT Article
DE mitochondria; mtDNA; respiration; cell cycle; ribonucleotide reductase; Rad53p; Abf2p
ID mobility group protein; transcription factor-a; dna-replication; skeletal-muscle; yeast; nuclear; biogenesis; damage; maintenance; inhibition
AB Most eukaryotes maintain multiple copies of mtDNA, ranging from 20-50 in yeast to as many as 10,000 in mammalian cells. The mitochondrial genome encodes essential subunits of the respiratory chain, but the number of mtDNA molecules is apparently in excess of that needed to sustain adequate respiration, as evidenced by the "threshold effect" in mitochondrial diseases. Thus, other selective pressures apparently have contributed to the universal maintenance of multiple mtDNA molecules/cell. Here we analyzed the interplay between the two pathways proposed to regulate mtDNA copy number in Saccharomyces cerevisiae, and the requirement of normal mtDNA copy number for mitochondrial gene expression, respiration, and inheritance. We provide the first direct evidence that upregulation of mtDNA can be achieved by increasing ribonucleotide reductase (RNR) activity via derepression of nuclear RNR gene transcription or elimination of allosteric-feedback regulation. Analysis of rad53 mutant strains also revealed upregulation of mtDNA copy number independent of that resulting from elevated RNR activity. We present evidence that a prolonged cell cycle allows accumulation of mtDNA in these strains. Analysis of multiple strains with increased or decreased mtDNA revealed that mechanisms are in place to prevent significant changes in mitochondrial gene expression and respiration in the face of similar to two-fold alterations in mtDNA copy number. However, depletion of mtDNA in abf2 null strains leads to defective mtDNA inheritance that is partially rescued by replenishing mtDNA via overexpression of RNR1. These results indicate that one role for multiple mtDNA copies is to ensure optimal inheritance of mtDNA during cell division.
C1 Yale Univ, Dept Pathol, Sch Med, New Haven, CT 06520 USA.
   Yale Univ, Grad Program Genet, Sch Med, New Haven, CT 06520 USA.
C3 Yale University; Yale University
RP Shadel, GS (corresponding author), Yale Univ, Dept Pathol, Sch Med, 310 Cedar St,POB 208023, New Haven, CT 06520 USA.
EM gerald.shadel@yale.edu
FU NIEHS NIH HHS [P01 ES011163, P01 ES011163-01A10001] Funding Source: Medline; NIGMS NIH HHS [T32GM007223, T32 GM007223] Funding Source: Medline
CR Bonawitz ND, 2006, MOL CELL, V24, P813, DOI 10.1016/j.molcel.2006.11.024
   Bonawitz ND, 2006, MOL CELL BIOL, V26, P4818, DOI 10.1128/MCB.02360-05
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Brewer LR, 2003, BIOPHYS J, V85, P2519, DOI 10.1016/S0006-3495(03)74674-8
   Cha RS, 2002, SCIENCE, V297, P602, DOI 10.1126/science.1071398
   Chabes A, 2003, CELL, V112, P391, DOI 10.1016/S0092-8674(03)00075-8
   Chen XJ, 2005, SCIENCE, V307, P714, DOI 10.1126/science.1106391
   DIFFLEY JFX, 1991, P NATL ACAD SCI USA, V88, P7864, DOI 10.1073/pnas.88.17.7864
   EATON JS, 2007, IN PRESS J CLIN INVE, V0, P0
   Ekstrand MI, 2004, HUM MOL GENET, V13, P935, DOI 10.1093/hmg/ddh109
   Elpeleg O, 2002, J MOL MED-JMM, V80, P389, DOI 10.1007/s00109-002-0343-5
   FORTUNA MM, 2000, CURRENT PROTOCOLS CY, V11, P1
   FOX TD, 1991, METHOD ENZYMOL, V194, P149
   Friddle RW, 2004, BIOPHYS J, V86, P1632, DOI 10.1016/S0006-3495(04)74231-9
   GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408
   HALL RM, 1976, MOL GEN GENET, V145, P169, DOI 10.1007/BF00269590
   HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4
   Huang MX, 1998, CELL, V94, P595, DOI 10.1016/S0092-8674(00)81601-3
   Ivessa AS, 2003, MOL CELL, V12, P1525, DOI 10.1016/S1097-2765(03)00456-8
   Kanki T, 2004, MOL CELL BIOL, V24, P9823, DOI 10.1128/MCB.24.22.9823-9834.2004
   LARSSON NG, 1994, BIOCHEM BIOPH RES CO, V200, P1374, DOI 10.1006/bbrc.1994.1603
   LECRENIER N, 1995, MOL GEN GENET, V249, P1, DOI 10.1007/BF00290229
   Lisowsky T, 2002, MOL BIOL CELL, V13, P2245, DOI 10.1091/mbc.01-07-0359
   MacAlpine DM, 2000, EMBO J, V19, P767, DOI 10.1093/emboj/19.4.767
   MacAlpine DM, 1998, P NATL ACAD SCI USA, V95, P6739, DOI 10.1073/pnas.95.12.6739
   Mandal S, 2005, DEV CELL, V9, P843, DOI 10.1016/j.devcel.2005.11.006
   Matsushima Y, 2004, J BIOL CHEM, V279, P26900, DOI 10.1074/jbc.M401643200
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   NAGLEY P, 1972, J MOL BIOL, V66, P181, DOI 10.1016/S0022-2836(72)80015-9
   NEWLON CS, 1975, CELL, V5, P423
   ORourke TW, 2005, GENE, V354, P86, DOI 10.1016/j.gene.2005.03.031
   ORourke TW, 2002, MOL CELL BIOL, V22, P4086, DOI 10.1128/MCB.22.12.4086-4093.2002
   POULTON J, 1994, HUM MOL GENET, V3, P1763, DOI 10.1093/hmg/3.10.1763
   REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025
   Rodeheffer MS, 2003, J BIOL CHEM, V278, P18695, DOI 10.1074/jbc.M301399200
   Rodeheffer MS, 2001, J BIOL CHEM, V276, P8616, DOI 10.1074/jbc.M009901200
   Sambrook J, 1989, MOLECULAR CLONING, V0, P0
   SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091
   Seidel-Rogol BL, 2002, NUCLEIC ACIDS RES, V30, P1929, DOI 10.1093/nar/30.9.1929
   SENA EP, 1975, J BACTERIOL, V123, P497, DOI 10.1128/JB.123.2.497-504.1975
   Shadel GS, 1999, AM J HUM GENET, V65, P1230, DOI 10.1086/302630
   Shen EL, 2001, NUCLEIC ACIDS RES, V29, P2822, DOI 10.1093/nar/29.13.2822
   SHERMAN F, 1991, METHOD ENZYMOL, V194, P3
   Taylor SD, 2005, MOL BIOL CELL, V16, P3010, DOI 10.1091/mbc.E05-01-0053
   THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025
   TRUEBLOOD CE, 1987, MOL CELL BIOL, V7, P3520, DOI 10.1128/MCB.7.10.3520
   Tyynismaa H, 2004, HUM MOL GENET, V13, P3219, DOI 10.1093/hmg/ddh342
   ULERY TL, 1994, MOL CELL BIOL, V14, P1160, DOI 10.1128/MCB.14.2.1160
   VELTRI KL, 1990, J CELL PHYSIOL, V143, P160, DOI 10.1002/jcp.1041430122
   Weinstein S M, 1994, ONCOLOGY (WILLISTON PARK), V8, P65
   WILLIAMS RS, 1986, J BIOL CHEM, V261, P376
   WILLIAMSON DH, 1971, BIOCHEM BIOPH RES CO, V42, P195, DOI 10.1016/0006-291X(71)90087-8
   Wu H, 2002, SCIENCE, V296, P349, DOI 10.1126/science.1071163
   YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819
   Yao RJ, 2003, P NATL ACAD SCI USA, V100, P6628, DOI 10.1073/pnas.1131932100
   Zelenaya-Troitskaya O, 1998, GENETICS, V148, P1763
   Zhao XL, 2001, EMBO J, V20, P3544, DOI 10.1093/emboj/20.13.3544
   Zhao XL, 1998, MOL CELL, V2, P329, DOI 10.1016/S1097-2765(00)80277-4
   Zong HH, 2002, P NATL ACAD SCI USA, V99, P15983, DOI 10.1073/pnas.252625599
NR 59
TC 34
Z9 46
U1 0
U2 6
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538-4101
EI 1551-4005
J9 CELL CYCLE
JI Cell Cycle
PD AUG 15
PY 2007
VL 6
IS 16
BP 2048
EP 2057
DI 10.4161/cc.6.16.4572
PG 10
WC Cell Biology
SC Cell Biology
GA 208LL
UT WOS:000249320700015
PM 17721079
DA 2024-11-01
ER

PT J
AU Mortiboys, HJ
   Schaefer, J
   Reichmann, H
   Jackson, S
AF Mortiboys, Heather Jane
   Schaefer, Jochen
   Reichmann, Heinz
   Jackson, Sandra
TI Mitochondrial dysfunction in Parkinson's disease - revisited
SO NEUROLOGIA I NEUROCHIRURGIA POLSKA
LA English
DT Review
DE mitochondria; Parkinson's disease; complex I; rotenone
ID electron-transport chain; complex-i deficiency; synuclein transgenic mice; substantia-nigra neurons; transfer-rna genes; alpha-synuclein; respiratory-chain; skeletal-muscle; oxidative stress; dna mutations
AB In recent years much of the research conducted in the field of Parkinson's disease (PD) has been aimed at trying to elucidate the molecular mechanisms involved in the development of the rare familial forms of the disease, with the hope that an understanding of these mechanisms will shed some light into the pathogenesis of the more prevalent idiopathic form of the disease. These studies have implicated mitochondrial dysfunction in the pathogenesis of familial PD, either as a primary event, with disease causing mutations identified in genes encoding mitochondrial proteins, or as a secondary event. Thus, the role played by mitochondrial respiratory chain function in the pathogeneis of idiopathic PD, an area of research that was a main focus some 15-20 years ago, has come back to the forefront of the field. A number of studies have directly investigated respiratory chain function in a variety of tissues from idiopathic PD patients. Although abundant in number, these studies have provided contradictory results, which still require clarification. In this review we will examine the data indicating the presence of a respiratory chain defect in patients with idiopathic PD and attempt to link it with the pathways that have been implicated by familial studies.
C1 [Mortiboys, Heather Jane] Univ Sheffield, Sch Med, Acad Neurol Unit, Sheffield, S Yorkshire, England.
   [Mortiboys, Heather Jane; Schaefer, Jochen; Reichmann, Heinz; Jackson, Sandra] Tech Univ, Dept Neurol, Dresden, Germany.
C3 University of Sheffield; Technische Universitat Dresden
RP Mortiboys, HJ (corresponding author), Univ Sheffield, Sch Med, Acad Neurol Unit, Sheffield, S Yorkshire, England.
EM H.Mortiboys@sheffield.ac.uk
CR Adam-Vizi V, 2005, ANTIOXID REDOX SIGN, V7, P1140, DOI 10.1089/ars.2005.7.1140
   ANDERSON JJ, 1993, J NEUROL NEUROSUR PS, V56, P477, DOI 10.1136/jnnp.56.5.477
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Aomi Y, 2001, BIOCHEM BIOPH RES CO, V280, P265, DOI 10.1006/bbrc.2000.4113
   Autere J, 2004, HUM GENET, V115, P29, DOI 10.1007/s00439-004-1123-9
   BARROSO N, 1993, CLIN CHEM, V39, P667
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   BENECKE R, 1993, BRAIN, V116, P1451, DOI 10.1093/brain/116.6.1451
   Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834
   BINDOFF LA, 1991, J NEUROL SCI, V104, P203, DOI 10.1016/0022-510X(91)90311-T
   Blake CI, 1997, MOVEMENT DISORD, V12, P3, DOI 10.1002/mds.870120103
   BLIN O, 1994, J NEUROL SCI, V125, P95, DOI 10.1016/0022-510X(94)90248-8
   Blum D, 2001, PROG NEUROBIOL, V65, P135, DOI 10.1016/S0301-0082(01)00003-X
   Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209
   Boveris A, 1977, ADV EXP MED BIOL, V78, P67
   Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9
   BRAVI D, 1992, MOVEMENT DISORD, V7, P228, DOI 10.1002/mds.870070307
   Brown MD, 1996, AM J MED GENET, V61, P283, DOI 10.1002/(SICI)1096-8628(19960122)61:3<283::AID-AJMG15>3.0.CO;2-P
   CARDELLACH F, 1993, NEUROLOGY, V43, P2258, DOI 10.1212/WNL.43.11.2258
   Chen Q, 2003, J BIOL CHEM, V278, P36027, DOI 10.1074/jbc.M304854200
   Clark IE, 2006, NATURE, V441, P1162, DOI 10.1038/nature04779
   COLLINS MA, 1985, NEUROSCI LETT, V55, P179, DOI 10.1016/0304-3940(85)90016-3
   DAMATO RJ, 1986, SCIENCE, V231, P987, DOI 10.1126/science.3080808
   Darios F, 2003, HUM MOL GENET, V12, P517, DOI 10.1093/hmg/ddg044
   Dauer W, 2002, P NATL ACAD SCI USA, V99, P14524, DOI 10.1073/pnas.172514599
   DAVIS GC, 1979, PSYCHIAT RES, V1, P249, DOI 10.1016/0165-1781(79)90006-4
   DIDONATO S, 1993, NEUROLOGY, V43, P2262, DOI 10.1212/WNL.43.11.2262
   Eriksen JL, 2005, ARCH NEUROL-CHICAGO, V62, P353, DOI 10.1001/archneur.62.3.353
   FORNO LS, 1986, ANN NEUROL, V20, P449, DOI 10.1002/ana.410200403
   Gandhi S, 2006, BRAIN, V129, P1720, DOI 10.1093/brain/awl114
   García-Lozano JR, 2002, EUR NEUROL, V48, P34, DOI 10.1159/000064955
   Grasbon-Frodl EM, 1999, NEUROGENETICS, V2, P121, DOI 10.1007/s100480050063
   Greene JC, 2005, HUM MOL GENET, V14, P799, DOI 10.1093/hmg/ddi074
   Greene JC, 2003, P NATL ACAD SCI USA, V100, P4078, DOI 10.1073/pnas.0737556100
   Gu GY, 2002, J NEUROPATH EXP NEUR, V61, P634, DOI 10.1093/jnen/61.7.634
   Gu M, 1998, ANN NEUROL, V44, P177, DOI 10.1002/ana.410440207
   HAAS RH, 1995, ANN NEUROL, V37, P714, DOI 10.1002/ana.410370604
   Hanagasi HA, 2005, INT J NEUROSCI, V115, P479, DOI 10.1080/00207450590523017
   HATTORI N, 1993, ADV NEUROL, V60, P292
   Hsu LJ, 2000, AM J PATHOL, V157, P401, DOI 10.1016/S0002-9440(10)64553-1
   IKEBE S, 1995, MOL BRAIN RES, V28, P281, DOI 10.1016/0169-328X(94)00209-W
   Itoh K, 1997, MOVEMENT DISORD, V12, P9, DOI 10.1002/mds.870120104
   JANETZKY B, 1994, NEUROSCI LETT, V169, P126, DOI 10.1016/0304-3940(94)90372-7
   Kapsa RMI, 1996, J NEUROL SCI, V144, P204, DOI 10.1016/S0022-510X(96)00247-X
   Kim RH, 2005, P NATL ACAD SCI USA, V102, P5215, DOI 10.1073/pnas.0501282102
   KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477
   Kosel S, 1998, NEUROGENETICS, V1, P197, DOI 10.1007/s100480050029
   Kosel S, 1996, J NEUROSCI RES, V44, P174
   Kraytsberg Y, 2006, NAT GENET, V38, P518, DOI 10.1038/ng1778
   KRIGE D, 1992, ANN NEUROL, V32, P782, DOI 10.1002/ana.410320612
   Kuroda Y, 2006, HUM MOL GENET, V15, P883, DOI 10.1093/hmg/ddl006
   LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561
   Langston JW, 1999, ANN NEUROL, V46, P598, DOI 10.1002/1531-8249(199910)46:4<598::AID-ANA7>3.0.CO;2-F
   LESTIENNE P, 1990, J NEUROCHEM, V55, P1810, DOI 10.1111/j.1471-4159.1990.tb04973.x
   Limongelli A, 2004, J MED GENET, V41, P342, DOI 10.1136/jmg.2003.016048
   Liu YB, 2002, J NEUROCHEM, V80, P780, DOI 10.1046/j.0022-3042.2002.00744.x
   MANN VM, 1992, BRAIN, V115, P333, DOI 10.1093/brain/115.2.333
   Martin LJ, 2006, J NEUROSCI, V26, P41, DOI 10.1523/JNEUROSCI.4308-05.2006
   Martin MA, 1996, NEUROLOGY, V46, P1343, DOI 10.1212/WNL.46.5.1343
   Martins LM, 2004, MOL CELL BIOL, V24, P9848, DOI 10.1128/MCB.24.22.9848-9862.2004
   Mawrin C, 2004, NEUROSCI LETT, V357, P111, DOI 10.1016/j.neulet.2003.11.073
   Mayr-Wohlfart U, 1997, EUR J MED RES, V2, P111
   Miller DW, 2004, NEUROLOGY, V62, P1835, DOI 10.1212/01.WNL.0000127517.33208.F4
   Mitsumoto A, 2001, FREE RADICAL RES, V35, P885, DOI 10.1080/10715760100301381
   MIZUNO Y, 1990, J NEUROL SCI, V96, P49, DOI 10.1016/0022-510X(90)90056-S
   MIZUNO Y, 1989, BIOCHEM BIOPH RES CO, V163, P1450, DOI 10.1016/0006-291X(89)91141-8
   Müftüoglu M, 2004, MOVEMENT DISORD, V19, P544, DOI 10.1002/mds.10695
   Muller FL, 2004, J BIOL CHEM, V279, P49064, DOI 10.1074/jbc.M407715200
   MYTILINEOU C, 1994, J NEURAL TRANSM-PARK, V8, P223, DOI 10.1007/BF02260943
   NICKLAS WJ, 1985, LIFE SCI, V36, P2503, DOI 10.1016/0024-3205(85)90146-8
   Orth M, 2003, NEUROSCI LETT, V351, P29, DOI 10.1016/S0304-3940(03)00941-8
   OZAWA T, 1990, BIOCHEM BIOPH RES CO, V172, P483, DOI 10.1016/0006-291X(90)90698-M
   Palacino JJ, 2004, J BIOL CHEM, V279, P18614, DOI 10.1074/jbc.M401135200
   Park J, 2006, NATURE, V441, P1157, DOI 10.1038/nature04788
   Parker WD, 2005, BIOCHEM BIOPH RES CO, V326, P667, DOI 10.1016/j.bbrc.2004.11.093
   PARKER WD, 1989, ANN NEUROL, V26, P719, DOI 10.1002/ana.410260606
   Pesah Y, 2004, DEVELOPMENT, V131, P2183, DOI 10.1242/dev.01095
   Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045
   Pyle A, 2005, ANN NEUROL, V57, P564, DOI 10.1002/ana.20417
   REICHMANN H, 1994, EUR NEUROL, V34, P263, DOI 10.1159/000117053
   Richter G, 2002, J NEURAL TRANSM, V109, P721, DOI 10.1007/s007020200060
   Ross OA, 2003, EXP GERONTOL, V38, P397, DOI 10.1016/S0531-5565(02)00266-8
   SANDY MS, 1993, MOVEMENT DISORD, V8, P74, DOI 10.1002/mds.870080114
   SCHAPIRA AHV, 1989, LANCET, V1, P1269, DOI 10.1016/S0140-6736(89)92366-0
   SCHAPIRA AHV, 1990, J NEUROCHEM, V55, P2142, DOI 10.1111/j.1471-4159.1990.tb05809.x
   SCHAPIRA AHV, 1990, J NEUROCHEM, V54, P823, DOI 10.1111/j.1471-4159.1990.tb02325.x
   SCHAPIRA AHV, 1990, MOVEMENT DISORD, V5, P294, DOI 10.1002/mds.870050406
   SHAN DE, 1995, ACTA NEUROL SCAND, V91, P149
   Sherer TB, 2003, EXP NEUROL, V179, P9, DOI 10.1006/exnr.2002.8072
   Sherer TB, 2003, J NEUROSCI, V23, P10756, DOI 10.1523/jneurosci.23-34-10756.2003
   Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060
   SHOFFNER JM, 1991, ANN NEUROL, V30, P332, DOI 10.1002/ana.410300304
   SHOFFNER JM, 1993, GENOMICS, V17, P171, DOI 10.1006/geno.1993.1299
   Simon DK, 2004, NEUROBIOL AGING, V25, P71, DOI 10.1016/S0197-4580(03)00037-X
   Simon DK, 2000, NEUROLOGY, V54, P703, DOI 10.1212/WNL.54.3.703
   Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278
   Smigrodzki R, 2004, NEUROBIOL AGING, V25, P1273, DOI 10.1016/j.neurobiolaging.2004.02.020
   Song DD, 2004, EXP NEUROL, V186, P158, DOI 10.1016/S0014-4886(03)00342-X
   Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166
   St-Pierre J, 2002, J BIOL CHEM, V277, P44784, DOI 10.1074/jbc.M207217200
   Strauss KM, 2005, HUM MOL GENET, V14, P2099, DOI 10.1093/hmg/ddi215
   Swerdlow RH, 1997, NEUROLOGY, V49, P918, DOI 10.1212/WNL.49.4.918
   Tan EK, 2000, NEUROLOGY, V55, P533, DOI 10.1212/WNL.55.4.533
   TAYLOR DJ, 1994, J NEUROL SCI, V125, P77, DOI 10.1016/0022-510X(94)90245-3
   Taylor SW, 2003, NAT BIOTECHNOL, V21, P281, DOI 10.1038/nbt793
   Taylor SW, 2003, TRENDS BIOTECHNOL, V21, P82, DOI 10.1016/S0167-7799(02)00037-9
   Trimmer PA, 2004, J NEUROCHEM, V88, P800, DOI 10.1046/j.1471-4159.2003.02168.x
   Valente EM, 2004, SCIENCE, V304, P1158, DOI 10.1126/science.1096284
   Vanderford ML, 2003, J HEALTH COMMUN, V8, P11, DOI 10.1080/10810730390224820
   Vives-Bauza C, 2002, BIOCHEM BIOPH RES CO, V290, P1593, DOI 10.1006/bbrc.2002.6388
   Wakabayashi K, 1997, MUTAT RES-FUND MOL M, V376, P253, DOI 10.1016/S0027-5107(97)00050-X
   West AB, 2005, P NATL ACAD SCI USA, V102, P16842, DOI 10.1073/pnas.0507360102
   Wiedemann FR, 1999, ANN NY ACAD SCI, V893, P426, DOI 10.1111/j.1749-6632.1999.tb07870.x
   Winkler-Stuck K, 2004, J NEUROL SCI, V220, P41, DOI 10.1016/j.jns.2004.02.003
   YOSHINO H, 1992, J NEURAL TRANSM-PARK, V4, P27, DOI 10.1007/BF02257619
   Zhang J, 2002, PARKINSONISM RELAT D, V8, P165, DOI 10.1016/S1353-8020(01)00041-4
   Zhang L, 2005, HUM MOL GENET, V14, P2063, DOI 10.1093/hmg/ddi211
   Zimprich A, 2004, NEURON, V44, P601, DOI 10.1016/j.neuron.2004.11.005
NR 118
TC 7
Z9 8
U1 1
U2 5
PU VIA MEDICA
PI GDANSK
PA UL SWIETOKRZYSKA 73, 80-180 GDANSK, POLAND
SN 0028-3843
EI 1897-4260
J9 NEUROL NEUROCHIR POL
JI Neurol. Neurochir. Pol.
PD JUN 15
PY 2007
VL 41
IS 2
BP 150
EP 159
DI 
PG 10
WC Clinical Neurology
SC Neurosciences & Neurology
GA 281TW
UT WOS:000254522800008
PM 17530578
DA 2024-11-01
ER

PT J
AU Matsushima, Y
   Kaguni, LS
AF Matsushima, Yuichi
   Kaguni, Laurie S.
TI Differential phenotypes of active site and human autosomal dominant progressive external ophthalmoplegia mutations in <i>Drosophila</i> mitochondrial DNA helicase expressed in Schneider cells
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID transcription factor; copy number; multiple deletions; crystal-structure; mtdna maintenance; primase-helicase; bacteriophage t7; binding protein; linker region; twinkle
AB We report the cloning and molecular analysis of Drosophila mitochondrial DNA helicase (d-mtDNA helicase) homologous to human TWINKLE, which encodes one of the genes responsible for autosomal dominant progressive external ophthalmoplegia. An RNA interference construct was designed that reduces expression of d-mtDNA helicase to an undetectable level in Schneider cells. RNA interference knockdown of d-mtDNA helicase decreases the copy number of mitochondrial DNA (mtDNA) similar to 5-fold. In a corollary manner, overexpression of d-mtDNA helicase increases mtDNA levels 1.4-fold. Overexpression of helicase active site mutants K388A and D483A results in a severe depletion of mtDNA and a dominant negative lethal phenotype. Overexpression of mutants analogous to human autosomal dominant progressive external ophthalmoplegia mutations shows differential effects. Overexpression of 1334T and A442P mutants yields a dominant negative effect as for the active site mutants. In contrast, overexpression of A326T, R341Q, and W441C mutants results in increased mtDNA copy number, as observed with wild-type overexpression. Our dominant negative analysis of d-mtDNA helicase in cultured cells provides a tractable model for understanding human autosomal dominant progressive external ophthalmoplegia mutations.
C1 Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA.
C3 Michigan State University
RP Kaguni, LS (corresponding author), Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA.
EM lskaguni@msu.edu
FU NIGMS NIH HHS [GM45295, R01 GM045295] Funding Source: Medline
CR ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2
   Arenas J, 2003, ANN NEUROL, V53, P278, DOI 10.1002/ana.10430
   Baulcombe DC, 1999, CURR BIOL, V9, PR599, DOI 10.1016/S0960-9822(99)80383-2
   BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043
   Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x
   Farr CL, 2004, J BIOL CHEM, V279, P17047, DOI 10.1074/jbc.M400283200
   Goto A, 2001, BIOCHEM J, V354, P243, DOI 10.1042/0264-6021:3540243
   Guo SY, 1999, J BIOL CHEM, V274, P30303, DOI 10.1074/jbc.274.42.30303
   Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107
   Horton P, 1997, ISMB-97 - FIFTH INTERNATIONAL CONFERENCE ON INTELLIGENT SYSTEMS FOR MOLECULAR BIOLOGY, V0, P147
   Kaguni LS, 2004, ANNU REV BIOCHEM, V73, P293, DOI 10.1146/annurev.biochem.72.121801.161455
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0
   Kiechl S, 2004, J NEUROL NEUROSUR PS, V75, P1125, DOI 10.1136/jnnp.2003.025890
   Korhonen JA, 2004, EMBO J, V23, P2423, DOI 10.1038/sj.emboj.7600257
   Korhonen JA, 2003, J BIOL CHEM, V278, P48627, DOI 10.1074/jbc.M306981200
   Lee SJ, 2004, J BIOL CHEM, V279, P23384, DOI 10.1074/jbc.M400857200
   Lewis S, 2002, J NEUROL SCI, V201, P39, DOI 10.1016/S0022-510X(02)00190-9
   Matsushima Y, 2005, J BIOL CHEM, V280, P16815, DOI 10.1074/jbc.M500569200
   Matsushima Y, 2004, J BIOL CHEM, V279, P26900, DOI 10.1074/jbc.M401643200
   Matsushima Y, 2003, J BIOL CHEM, V278, P31149, DOI 10.1074/jbc.M303842200
   PATEL SS, 1994, BIOCHEMISTRY-US, V33, P7857, DOI 10.1021/bi00191a013
   Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651
   Sawaya MR, 1999, CELL, V99, P167, DOI 10.1016/S0092-8674(00)81648-7
   Singleton MR, 2000, CELL, V101, P589, DOI 10.1016/S0092-8674(00)80871-5
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spinazzola A, 2005, GENE, V354, P162, DOI 10.1016/j.gene.2005.03.025
   Suomalainen A, 1997, NEUROLOGY, V48, P1244, DOI 10.1212/WNL.48.5.1244
   SUOMALAINEN A, 1992, J CLIN INVEST, V90, P61, DOI 10.1172/JCI115856
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   Toth EA, 2003, MOL CELL, V12, P1113, DOI 10.1016/S1097-2765(03)00442-8
   Tyynismaa H, 2005, P NATL ACAD SCI USA, V102, P17687, DOI 10.1073/pnas.0505551102
   Tyynismaa H, 2004, HUM MOL GENET, V13, P3219, DOI 10.1093/hmg/ddh342
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2003, HUM MUTAT, V22, P175, DOI 10.1002/humu.10246
   Washington MT, 1996, J BIOL CHEM, V271, P26825, DOI 10.1074/jbc.271.43.26825
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
NR 37
TC 37
Z9 40
U1 1
U2 2
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAR 30
PY 2007
VL 282
IS 13
BP 9436
EP 9444
DI 10.1074/jbc.M610550200
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 153HA
UT WOS:000245421700016
PM 17272269
DA 2024-11-01
ER

PT J
AU Verity, MA
AF Verity, M. Anthony
TI Diagnostic uncertainty in the inflammatory myopathies
SO BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY
LA English
DT Article
DE dermatomyositis; eosinophilic myositis; inflammatory dysferlinopathy; inflammatory myopathy with abundant macrophages; membrane attack complex; MHC-I complex; myopathic polyarteritis nodosa; necrotizing myopathy; pipe stem capillaries; polymyositis
ID inclusion-body myositis; minimal cellular infiltration; mitochondrial-dna deletions; macrophagic myofasciitis; hemophagocytic syndrome; eosinophilic polymyositis; angiolymphoid hyperplasia; dysferlin deficiency; pipestem capillary; polyarteritis-nodosa
AB A group of case histories with appropriate muscle biopsy findings is presented to demonstrate some atypical presentations of the inflammatory myopathies. Differential diagnostic possibilities are considered in presentations of idiopathic polymyositis, statin myotoxicity, the inflammatory component with the dysferlinopathies, treated dermatomyositis, a necrotizing myopathy with pipe-stem microvascular change, an inflammatory myopathy with abundant macrophages, inclusion-body myositis, and the differential diagnosis of problems with eosinophilic infiltration in the muscle biopsy. Attention is given to the role of membrane attack complex deposition in the microvasculature and the role of major histiocompatibility complex-I-expressing muscle fibers indicating activation of the endoplasmic reticulum stress response.
C1 Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
C3 University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA
RP Verity, MA (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.
EM mverity@mednet.ucla.edu
CR Argov Z, 2000, BRAIN, V123, P1229, DOI 10.1093/brain/123.6.1229
   Authier FJ, 1996, NEUROLOGY, V46, P1448, DOI 10.1212/WNL.46.5.1448
   Bassez G, 2003, J NEUROPATH EXP NEUR, V62, P464, DOI 10.1093/jnen/62.5.464
   BJELLE A, 1980, EUR NEUROL, V19, P128, DOI 10.1159/000115137
   BUCHANAN R, 1980, HISTOPATHOLOGY, V4, P197, DOI 10.1111/j.1365-2559.1980.tb02912.x
   CARPENTER S, 1978, NEUROLOGY, V28, P8, DOI 10.1212/WNL.28.1.8
   DEVERE R, 1975, BRAIN, V98, P637, DOI 10.1093/brain/98.4.637
   EISEN A, 1983, NEUROLOGY, V33, P1109, DOI 10.1212/WNL.33.9.1109
   EMSLIESMITH AM, 1991, NEUROLOGY, V41, P936
   FANG MA, 1988, J RHEUMATOL, V15, P1291
   Fanin M, 2002, NEUROPATH APPL NEURO, V28, P461, DOI 10.1046/j.1365-2990.2002.00417.x
   FAUCI AS, 1982, ANN INTERN MED, V97, P78, DOI 10.7326/0003-4819-97-1-78
   Gallardo E, 2001, NEUROLOGY, V57, P2136, DOI 10.1212/WNL.57.11.2136
   Gherardi RK, 1998, LANCET, V352, P347, DOI 10.1016/S0140-6736(98)02326-5
   Gherardi RK, 2001, BRAIN, V124, P1821, DOI 10.1093/brain/124.9.1821
   Giordano N, 1997, LANCET, V349, P1600, DOI 10.1016/S0140-6736(05)61628-5
   Hall C, 2001, J RHEUMATOL, V28, P871
   HALL FC, 1995, QJM-MON J ASSOC PHYS, V88, P581
   Han R, 2007, J CLIN INVEST, V117, P1805, DOI 10.1172/JCI30848
   HOHLFELD R, 1991, NEW ENGL J MED, V324, P877, DOI 10.1056/NEJM199103283241303
   KAMM MA, 1987, J RHEUMATOL, V14, P831
   LAKHANPAL S, 1988, SEMIN ARTHRITIS RHEU, V17, P221, DOI 10.1016/0049-0172(88)90008-X
   LAYZER RB, 1977, ANN NEUROL, V1, P65, DOI 10.1002/ana.410010106
   Madaule S, 2000, RHEUMATOLOGY, V39, P1157, DOI 10.1093/rheumatology/39.10.1157
   Mastaglia FL, 2003, MUSCLE NERVE, V27, P407, DOI 10.1002/mus.10313
   Moslemi AR, 1997, HUM MUTAT, V10, P381, DOI 10.1002/(SICI)1098-1004(1997)10:5<381::AID-HUMU8>3.0.CO;2-I
   Nagaraju K, 2005, ARTHRITIS RHEUM, V52, P1824, DOI 10.1002/art.21103
   Nakamura T, 2003, CLIN RHEUMATOL, V22, P149, DOI 10.1007/s10067-002-0688-8
   Needham M, 2007, NEUROMUSCULAR DISORD, V17, P194, DOI 10.1016/j.nmd.2006.10.007
   OLDFORS A, 1995, J NEUROPATH EXP NEUR, V54, P581, DOI 10.1097/00005072-199507000-00012
   Papo T, 1999, J RHEUMATOL, V26, P927
   Piccolo F, 2000, ANN NEUROL, V48, P902, DOI 10.1002/1531-8249(200012)48:6<902::AID-ANA11>3.0.CO;2-Z
   Rowin J, 1999, NEUROMUSCULAR DISORD, V9, P417, DOI 10.1016/S0960-8966(99)00041-3
   SERRATRICE G, 1980, J RHEUMATOL, V7, P199
   STARK RJ, 1979, ARCH NEUROL-CHICAGO, V36, P721, DOI 10.1001/archneur.1979.00500470091022
   Tager RE, 1999, RHEUMATOLOGY, V38, P397, DOI 10.1093/rheumatology/38.5.397
   van der Pas J, 2004, J NEUROL NEUROSUR PS, V75, P136
   VERITY MA, 1992, J NEUROPATH EXP NEUR, V51, P356
   WINCHESTER RJ, 1971, ARTHRITIS RHEUM-US, V14, P650, DOI 10.1002/art.1780140513
   Yasuda S, 1998, BRIT J RHEUMATOL, V37, P1357
NR 40
TC 6
Z9 6
U1 0
U2 2
PU BAILLIERE TINDALL
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1521-6942
EI 
J9 BEST PRACT RES CL RH
JI Best Pract. Res. Clin. Rheumatol.
PD DEC 15
PY 2007
VL 21
IS 6
BP 1051
EP 1070
DI 10.1016/j.berh.2007.10.004
PG 20
WC Rheumatology
SC Rheumatology
GA 247QH
UT WOS:000252093900007
PM 18068861
DA 2024-11-01
ER

PT J
AU Carter, CS
   Hofer, T
   Seo, AY
   Leeuwenburgh, C
AF Carter, Christy S.
   Hofer, Tim
   Seo, Arnold Y.
   Leeuwenburgh, Christian
TI Molecular mechanisms of life- and health-span extension: role of calorie restriction and exercise intervention
SO APPLIED PHYSIOLOGY NUTRITION AND METABOLISM
LA English
DT Article; Proceedings Paper
DE aging; human; dysfunction; muscle; frailty; apoptosis; inflammation; oxidative stress; intervention
ID dna deletion mutations; ubiquitin gene-expression; necrosis-factor-alpha; human skeletal-muscle; mitochondrial-dna; oxidative stress; dietary restriction; contractile property; physical performance; glucose-tolerance
AB The aging process results in a gradual and progressive structural deterioration of biomolecular and cellular compartments and is associated with many pathological conditions, including cardiovascular disease, stroke, Alzheimer's disease, osteoporosis, sarcopenia, and liver dysfunction. Concomitantly, each of these conditions is associated with progressive functional decline, loss of independence, and ultimately disability. Because disabled individuals require care in outpatient or home care settings, and in light of the social, emotional, and fiscal burden associated with caring for an ever-increasing elderly population, research in geriatric medicine has recently focused on the biological mechanisms that are involved in the progression towards functional decline and disability to better design treatment and intervention strategies. Although not completely understood, the mechanisms underlying the aging process may partly involve inflammatory processes, oxidative damage, mitochondrial dysfunction, and apoptotic tissue degeneration. These hypotheses are based on epidemiological evidence and data from animal models of aging, as well as interventional studies. Findings from these studies have identified possible strategies to decrease the incidence of age-related diseases and delay the aging process. For example, lifelong exercise is known to extend mean life-span, whereas calorie restriction (CR) increases both mean and maximum life-span in a variety of species. Optimal application of these intervention strategies in the elderly may positively affect health-related outcomes and possibly longevity. Therefore, the scope of this article is to (i) provide an interpretation of various theories of aging from a "health-span" perspective; (ii) describe interventional testing in animals (CR and exercise); and (iii) provide a translational interpretation of these data.
C1 Univ Florida, Coll Med, Div Biol Aging, Dept Aging & Geriatr Res, Gainesville, FL 32610 USA.
   Malcom Randall Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Gainesville, FL 32608 USA.
   Inst Aging, Gainesville, FL 32610 USA.
C3 State University System of Florida; University of Florida; Geriatric Research Education & Clinical Center
RP Carter, CS (corresponding author), Univ Florida, Coll Med, Div Biol Aging, Dept Aging & Geriatr Res, Gainesville, FL 32610 USA.
EM ccarter@aging.ufl.edu
FU NIA NIH HHS [AG17994, R01 AG021042, R01 AG017994, AG21042, 1 P30 AG028740, AG024526, R01 AG024526] Funding Source: Medline
CR ALNAQEEB MA, 1987, J ANAT, V153, P31
   Anglade P, 1997, HISTOL HISTOPATHOL, V12, P603
   Anson RM, 2003, P NATL ACAD SCI USA, V100, P6216, DOI 10.1073/pnas.1035720100
   ANSVED T, 1989, J NEUROL SCI, V93, P105, DOI 10.1016/0022-510X(89)90165-2
   Aspnes LE, 1997, FASEB J, V11, P573, DOI 10.1096/fasebj.11.7.9212081
   ATTAIX D, 1998, ADV MOL CELL, V0, P27235
   Baron AD, 2001, AM J CARDIOL, V88, P16H, DOI 10.1016/S0002-9149(01)01832-X
   Baumgartner RN, 2000, ANN NY ACAD SCI, V904, P437
   Bodyak ND, 2001, HUM MOL GENET, V10, P17, DOI 10.1093/hmg/10.1.17
   Cao ZJ, 2001, NUCLEIC ACIDS RES, V29, P4502, DOI 10.1093/nar/29.21.4502
   Carter CS, 2002, J GERONTOL A-BIOL, V57, PB193, DOI 10.1093/gerona/57.5.B193
   Cassano P, 2004, ANN NY ACAD SCI, V1019, P269, DOI 10.1196/annals.1297.045
   Cesari M, 2004, AM J CLIN NUTR, V79, P289
   Chang HR, 1998, NUTRITION, V14, P853, DOI 10.1016/S0899-9007(98)00108-7
   Chomyn A, 2003, BIOCHEM BIOPH RES CO, V304, P519, DOI 10.1016/S0006-291X(03)00625-9
   Chung HY, 2002, MICROSC RES TECHNIQ, V59, P264, DOI 10.1002/jemt.10203
   CORTOPASSI GA, 1992, P NATL ACAD SCI USA, V89, P7370, DOI 10.1073/pnas.89.16.7370
   Cortopassi GA, 1999, BBA-BIOENERGETICS, V1410, P183, DOI 10.1016/S0005-2728(98)00166-2
   Coskun PE, 2003, P NATL ACAD SCI USA, V100, P2174, DOI 10.1073/pnas.0630589100
   Davì G, 2004, CHEM PHYS LIPIDS, V128, P149, DOI 10.1016/j.chemphyslip.2003.10.001
   Davì G, 2002, JAMA-J AM MED ASSOC, V288, P2008, DOI 10.1001/jama.288.16.2008
   De la Fuente M, 2002, EUR J CLIN NUTR, V56, PS5, DOI 10.1038/sj.ejcn.1601476
   Del Bo R, 2002, J NEUROL SCI, V202, P85, DOI 10.1016/S0022-510X(02)00247-2
   Dirks A, 2002, AM J PHYSIOL-REG I, V282, PR519, DOI 10.1152/ajpregu.00458.2001
   Dirks AJ, 2006, MECH AGEING DEV, V127, P1, DOI 10.1016/j.mad.2005.09.001
   Dirks AJ, 2005, SPORTS MED, V35, P473, DOI 10.2165/00007256-200535060-00002
   Dirks AJ, 2004, FREE RADICAL BIO MED, V36, P27, DOI 10.1016/j.freeradbiomed.2003.10.003
   Dröge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001
   Duke RC, 1996, SCI AM, V275, P80, DOI 10.1038/scientificamerican1296-80
   EBISUI C, 1995, CLIN SCI, V89, P431, DOI 10.1042/cs0890431
   Edström E, 2005, AGING CELL, V4, P65, DOI 10.1111/j.1474-9728.2005.00145.x
   Fanò G, 2001, J MUSCLE RES CELL M, V22, P345, DOI 10.1023/A:1013122805060
   Ferrucci L, 1999, J AM GERIATR SOC, V47, P639, DOI 10.1111/j.1532-5415.1999.tb01583.x
   Ferrucci L, 2002, J AM GERIATR SOC, V50, P1947, DOI 10.1046/j.1532-5415.2002.50605.x
   FOURY F, 1992, EMBO J, V11, P2717, DOI 10.1002/j.1460-2075.1992.tb05337.x
   Fujita J, 1996, INT J CANCER, V68, P637, DOI 10.1002/(SICI)1097-0215(19961127)68:5<637::AID-IJC14>3.0.CO;2-Z
   Gadaleta MN, 1998, BIOCHIMIE, V80, P863, DOI 10.1016/S0300-9084(00)88881-1
   GARCIAMARTINEZ C, 1993, MOL CELL BIOCHEM, V125, P11, DOI 10.1007/BF00926829
   Genova ML, 1997, FEBS LETT, V410, P467
   Gokey NG, 2004, AGING CELL, V3, P319, DOI 10.1111/j.1474-9728.2004.00122.x
   GOODRICK CL, 1983, EXP AGING RES, V9, P203, DOI 10.1080/03610738308258453
   GOODRICK CL, 1982, GERONTOLOGY, V28, P233, DOI 10.1159/000212538
   GURALNIK JM, 1994, J GERONTOL, V49, PM85, DOI 10.1093/geronj/49.2.M85
   Heilbronn LK, 2006, JAMA-J AM MED ASSOC, V295, P1539, DOI 10.1001/jama.295.13.1539
   Hepple RT, 2004, J GERONTOL A-BIOL, V59, P108
   Higami Y, 1997, CELL TISSUE RES, V288, P69, DOI 10.1007/s004410050793
   Higami Y, 2000, CELL TISSUE RES, V301, P125, DOI 10.1007/s004419900156
   Hofer T, 2006, FREE RADICAL RES, V40, P0
   HOLLOSZY JO, 1988, J GERONTOL, V43, PB149, DOI 10.1093/geronj/43.6.B149
   HOLLOSZY JO, 1991, MECH AGEING DEV, V60, P199, DOI 10.1016/0047-6374(91)90131-I
   Holloszy JO, 1997, J APPL PHYSIOL, V82, P399, DOI 10.1152/jappl.1997.82.2.399
   HOLLOSZY JO, 1993, J GERONTOL, V48, PB97, DOI 10.1093/geronj/48.3.B97
   HOLLOSZY JO, 1985, J APPL PHYSIOL, V59, P826, DOI 10.1152/jappl.1985.59.3.826
   HOLLOSZY JO, 1987, FASEB J, V46, P1850
   HOLLOSZY JO, 1992, J NUTR, V122, P774, DOI 10.1093/jn/122.suppl_3.774
   Howes RM, 2006, ANN NY ACAD SCI, V1067, P22, DOI 10.1196/annals.1354.004
   Ingram DK, 2004, ANN NY ACAD SCI, V1019, P412, DOI 10.1196/annals.1297.074
   Janssen I, 2002, J AM GERIATR SOC, V50, P889, DOI 10.1046/j.1532-5415.2002.50216.x
   Kalain R, 2006, J GERONTOL A-BIOL, V61, P211, DOI 10.1093/gerona/61.3.211
   Khrapko K, 1999, NUCLEIC ACIDS RES, V27, P2434, DOI 10.1093/nar/27.11.2434
   Kowald A, 2005, AGING CELL, V4, P273, DOI 10.1111/j.1474-9726.2005.00169.x
   Kraytsberg Y, 2003, MECH AGEING DEV, V124, P49, DOI 10.1016/S0047-6374(02)00169-0
   Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125
   LARSSON L, 1978, ACTA PHYSIOL SCAND, V103, P31, DOI 10.1111/j.1748-1716.1978.tb06187.x
   Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390
   Leeuwenburgh C, 2005, AM J PHYSIOL-REG I, V288, PR1288, DOI 10.1152/ajpregu.00576.2004
   LEXELL J, 1995, J GERONTOL A-BIOL, V50, P11
   Li YP, 1998, FASEB J, V12, P871, DOI 10.1096/fasebj.12.10.871
   Lim PS, 2002, BLOOD PURIFICAT, V20, P537, DOI 10.1159/000066962
   LIPMAN RD, 1995, AGING-CLIN EXP RES, V7, P136, DOI 10.1007/BF03324303
   Llovera M, 1998, CANCER LETT, V133, P83, DOI 10.1016/S0304-3835(98)00216-X
   Llovera M, 1996, BIOCHEM BIOPH RES CO, V221, P653, DOI 10.1006/bbrc.1996.0651
   Llovera M, 1997, BIOCHEM BIOPH RES CO, V230, P238, DOI 10.1006/bbrc.1996.5827
   LLOVERA M, 1993, J NATL CANCER I, V85, P1334, DOI 10.1093/jnci/85.16.1334
   Mazat JP, 2001, BBA-BIOENERGETICS, V1504, P20, DOI 10.1016/S0005-2728(00)00236-X
   McCarter RJM, 1997, AGING-CLIN EXP RES, V9, P73, DOI 10.1007/BF03340130
   McCay CM, 1935, J NUTR, V10, P63, DOI 10.1093/jn/10.1.63
   McKenzie D, 2002, EUR J BIOCHEM, V269, P2010, DOI 10.1046/j.1432-1033.2002.02867.x
   Mecocci P, 1999, FREE RADICAL BIO MED, V26, P303, DOI 10.1016/S0891-5849(98)00208-1
   Miller GD, 2003, CONTROL CLIN TRIALS, V24, P462, DOI 10.1016/S0197-2456(03)00063-1
   Morley JE, 2005, NES NUTR WS, V10, P167, DOI 10.1159/000083304
   Morley JE, 2001, J LAB CLIN MED, V137, P231, DOI 10.1067/mlc.2001.113504
   Nekhaeva E, 2002, MECH AGEING DEV, V123, P891, DOI 10.1016/S0047-6374(02)00026-X
   Nekhaeva E, 2002, P NATL ACAD SCI USA, V99, P5521, DOI 10.1073/pnas.072670199
   Newman AB, 2001, J AM GERIATR SOC, V49, P1309, DOI 10.1046/j.1532-5415.2001.49258.x
   Nicklas BJ, 2004, AM J EPIDEMIOL, V160, P741, DOI 10.1093/aje/kwh281
   Pansarasa O, 2000, FREE RADICAL RES, V33, P287, DOI 10.1080/10715760000301451
   Phaneuf S, 2001, MED SCI SPORT EXER, V33, P393, DOI 10.1097/00005768-200103000-00010
   Phillips T, 2005, FASEB J, V19, P668, DOI 10.1096/fj.04-2870fje
   Phillips T, 2004, REJUV RES, V7, P243, DOI 10.1089/rej.2004.7.243
   Pollack M, 2002, ANN NY ACAD SCI, V959, P93, DOI 10.1111/j.1749-6632.2002.tb02086.x
   Racette SB, 2006, J GERONTOL A-BIOL, V61, P943, DOI 10.1093/gerona/61.9.943
   Radák Z, 2002, EXP GERONTOL, V37, P1423, DOI 10.1016/S0531-5565(02)00116-X
   Ramakrishna R, 2001, AM J PHYSIOL-REG I, V280, PR695, DOI 10.1152/ajpregu.2001.280.3.R695
   Rice KM, 2005, BIOGERONTOLOGY, V6, P335, DOI 10.1007/s10522-005-4808-0
   ROUBENOFF R, 1994, J CLIN INVEST, V93, P2379, DOI 10.1172/JCI117244
   Sánchez-Moreno C, 2004, STROKE, V35, P163, DOI 10.1161/01.STR.0000105391.62306.2E
   Seo AY, 2006, ANTIOXID REDOX SIGN, V8, P529, DOI 10.1089/ars.2006.8.529
   Snow LM, 2005, ANAT REC PART A, V286A, P866, DOI 10.1002/ar.a.20218
   Spittle MA, 2001, AM J KIDNEY DIS, V38, P1408, DOI 10.1053/ajkd.2001.29280
   Sprott RL, 1997, EXP GERONTOL, V32, P205, DOI 10.1016/S0531-5565(96)00065-4
   STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Tsujinaka T, 1996, J CLIN INVEST, V97, P244, DOI 10.1172/JCI118398
   Vescovo G, 2002, INT J CARDIOL, V83, P33, DOI 10.1016/S0167-5273(02)00015-3
   Wallace DC, 2000, AM HEART J, V139, PS70, DOI 10.1067/mhj.2000.103934
   Wanagat J, 2001, FASEB J, V15, P322, DOI 10.1096/fj.00-0320com
   Wang ED, 1997, MUTAT RES-FUND MOL M, V377, P157, DOI 10.1016/S0027-5107(97)00091-2
   Wang Y, 2001, P NATL ACAD SCI USA, V98, P4022, DOI 10.1073/pnas.061013598
   Wannamethee SG, 2005, ARCH INTERN MED, V165, P1035, DOI 10.1001/archinte.165.9.1035
   Warner HR, 1999, ANTICANCER RES, V19, P2837
   Warner HR, 1997, CURR TOP CELL REGUL, V35, P107, DOI 10.1016/S0070-2137(97)80004-0
   WEINDRUCH R, 1986, J NUTR, V116, P641, DOI 10.1093/jn/116.4.641
   Weiss EP, 2006, AM J CLIN NUTR, V84, P1033
   YEN TC, 1991, BIOCHEM BIOPH RES CO, V178, P124, DOI 10.1016/0006-291X(91)91788-E
   YOU T, 2005, CR BODY COMPOSITION, V0, P0
   Yu BP, 1996, ANN NY ACAD SCI, V786, P1, DOI 10.1111/j.1749-6632.1996.tb39047.x
   Yu BP, 1996, FREE RADICAL BIO MED, V21, P651, DOI 10.1016/0891-5849(96)00162-1
   YU BP, 1985, J GERONTOL, V40, P657, DOI 10.1093/geronj/40.6.657
   Zarzhevsky N, 2001, ANN NY ACAD SCI, V928, P212
   Zhang Y, 2000, AM J PHYSIOL-ENDOC M, V279, PE196, DOI 10.1152/ajpendo.2000.279.1.E196
NR 121
TC 55
Z9 70
U1 0
U2 15
PU CANADIAN SCIENCE PUBLISHING
PI OTTAWA
PA 65 AURIGA DR, SUITE 203, OTTAWA, ON K2E 7W6, CANADA
SN 1715-5312
EI 1715-5320
J9 APPL PHYSIOL NUTR ME
JI Appl. Physiol. Nutr. Metab.
PD OCT 15
PY 2007
VL 32
IS 5
BP 954
EP 966
DI 10.1139/H07-085
PG 13
WC Nutrition & Dietetics; Physiology; Sport Sciences
SC Nutrition & Dietetics; Physiology; Sport Sciences
GA 229QB
UT WOS:000250818000017
PM 18059622
DA 2024-11-01
ER

PT J
AU Annunen-Rasila, J
   Kärppä, M
   Finnilä, S
   Ylä-Outinen, H
   Veijola, J
   Tuominen, H
   Peltonen, J
   Majamaa, K
AF Annunen-Rasila, Johanna
   Karppa, Mikko
   Finnila, Saara
   Yla-Outinen, Heli
   Veijola, Johanna
   Tuominen, Hannu
   Peltonen, Juha
   Majamaa, Karl
TI Cytoskeletal structure in cells harboring two mutations:: R133C in <i>NOTCH3</i> and 5650G&gt;A in mitochondrial DNA
SO MITOCHONDRION
LA English
DT Article
DE CADASIL; immunocytochemistry; histochemistry; mitochondria; muscle fibres
ID muscle-fibers; cadasil; microtubules; patient; neurons; gene
AB We have previously described a patient with cerebral autosomal-dominant arteriopathy with subcortical infarcts and leucoencephalopathy (CADASIL) caused by R133C mutation in NOTCH3 and with a concomitant myopathy caused by a G to A point mutation at base pair 5650 (5650G>A) in the gene encoding tRNA(Ala) in mitochondrial DNA (mtDNA). In the present study, we have examined the morphology of the cytoskeletal components in fibroblasts and myoblasts of this patient. Immunolabeling revealed that tubulin network was sparse and formed asters in these cells, whereas no changes were found in actin and vimentin networks in comparison to the control cell lines. Furthermore, mitochondria were less abundant and the branches of the mitochondrial network were reduced in number. Muscle histochemical analysis showed ragged red fibres (RRFs) and cytochrome c oxidase (COX)-negative fibres. The mean proportion of mtDNA with 5650G>A was lower in histologically normal muscle fibres than in the COX-negative fibres and in the RRFs. These findings suggest that 5650G>A is a pathogenic mtDNA mutation. However, the changes in tubulin network and mitochondrial distribution in patient fibroblasts and myoblasts cannot solely be explained by this mutation. (c) 2007 Elsevier B.V. and Mitochondria Research Society. All rights reserved.
C1 Univ Oulu, Dept Neurol, FIN-90014 Oulu, Finland.
   Oulu Univ Hosp, Clin Res Ctr, FIN-90014 Oulu, Finland.
   Univ Turku, Dept Anat, FIN-20014 Turku, Finland.
   Oulu Univ Hosp, Dept Pathol, FIN-90029 Oulu, Finland.
   Univ Oulu, Dept Anat & Cell Biol, FIN-90014 Oulu, Finland.
   Univ Oulu, Dept Dermatol, FIN-90014 Oulu, Finland.
   Univ Turku, Dept Dermatol, FIN-20014 Turku, Finland.
   Univ Turku, Dept Neurol, FIN-20014 Turku, Finland.
C3 University of Oulu; University of Oulu; University of Turku; University of Oulu; University of Oulu; University of Oulu; University of Turku; University of Turku
RP Majamaa, K (corresponding author), Univ Oulu, Dept Neurol, FIN-90014 Oulu, Finland.
EM Kari.Majamaa@utu.fi
CR Allani PK, 2004, TOXICOL APPL PHARM, V196, P29, DOI 10.1016/j.taap.2003.12.010
   Barrientos A, 1999, J BIOL CHEM, V274, P16188, DOI 10.1074/jbc.274.23.16188
   Bernier FP, 2002, NEUROLOGY, V59, P1406, DOI 10.1212/01.WNL.0000033795.17156.00
   de la Peña P, 2001, NEUROLOGY, V57, P1235, DOI 10.1212/WNL.57.7.1235
   Dotti MT, 2004, ARCH NEUROL-CHICAGO, V61, P942, DOI 10.1001/archneur.61.6.942
   Finnilä S, 2001, J MOL MED, V79, P641, DOI 10.1007/s001090100268
   Honore S, 2005, CELL MOL LIFE SCI, V62, P3039, DOI 10.1007/s00018-005-5330-x
   Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0
   Kärppä M, 2005, BRAIN, V128, P1861, DOI 10.1093/brain/awh515
   LI K, 1995, AM J PHYSIOL-CELL PH, V269, PC1265, DOI 10.1152/ajpcell.1995.269.5.C1265
   Malandrini A, 2002, NEUROLOGY, V59, P617, DOI 10.1212/WNL.59.4.617
   MORRIS RL, 1995, J CELL BIOL, V131, P1315, DOI 10.1083/jcb.131.5.1315
   Moslemi AR, 1998, NEUROMUSCULAR DISORD, V8, P345, DOI 10.1016/S0960-8966(98)00029-7
   OLDFORS A, 1995, J NEUROPATH EXP NEUR, V54, P581, DOI 10.1097/00005072-199507000-00012
   OSBORN M, 1976, P NATL ACAD SCI USA, V73, P867, DOI 10.1073/pnas.73.3.867
   Rosenblatt J, 2005, NAT CELL BIOL, V7, P219, DOI 10.1038/ncb0305-219
   Ruchoux MM, 2003, AM J PATHOL, V162, P329, DOI 10.1016/S0002-9440(10)63824-2
   Rusanen H, 2002, CELL MOTIL CYTOSKEL, V53, P231, DOI 10.1002/cm.10066
   Schröder JM, 2005, ACTA NEUROPATHOL, V110, P587, DOI 10.1007/s00401-005-1082-9
   Sciacco M, 1996, METHODS ENZYMOL, V264, P509, DOI 10.1016/S0076-6879(96)64045-2
   THORIG GEW, 1981, GENETICS, V99, P65
   Yaffe MP, 1999, SCIENCE, V283, P1493, DOI 10.1126/science.283.5407.1493
NR 22
TC 5
Z9 6
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
EI 
J9 MITOCHONDRION
JI Mitochondrion
PD FEB-APR 15
PY 2007
VL 7
IS 1-2
BP 96
EP 100
DI 10.1016/j.mito.2006.11.004
PG 5
WC Cell Biology; Genetics & Heredity
SC Cell Biology; Genetics & Heredity
GA 157EM
UT WOS:000245701400015
PM 17276737
DA 2024-11-01
ER

PT J
AU deBruyn, JC
   Chan, AK
   Bhargava, R
   Idikio, H
   Huynh, HQ
AF deBruyn, Jennifer C.
   Chan, Alicia K.
   Bhargava, Ravi
   Idikio, Halliday
   Huynh, Hien Q.
TI Liver failure in mitochondrial DNA depletion syndrome: The importance of serial neuroimaging in liver transplantation evaluation
SO JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
LA English
DT Article
ID mtdna depletion; myopathy; muscle; involvement
C1 Univ Alberta, Div Pediat Gastroenterol & Nutr, Dept Pediat, Edmonton, AB T6G 2J3, Canada.
   Univ Alberta, Dept Med Genet, Edmonton, AB T6G 2J3, Canada.
   Univ Alberta, Div Pediat Radiol, Dept Pediat, Edmonton, AB T6G 2J3, Canada.
   Univ Alberta, Dept Lab Med & Pathol, Edmonton, AB T6G 2J3, Canada.
C3 University of Alberta; University of Alberta; University of Alberta; University of Alberta
RP Huynh, HQ (corresponding author), Univ Alberta, Stollery Childrens Hosp, Dept Pediat, Div Pediat Gastroenterol & Nutr, 8213 Aberhart Ctr 1,11402 Univ Ave, Edmonton, AB T6G 2J3, Canada.
EM hien.huynh@ualberta.ca
CR Barthélémy C, 2001, ANN NEUROL, V49, P607, DOI 10.1002/ana.1002.abs
   Campos Y, 1998, NEUROMUSCULAR DISORD, V8, P568, DOI 10.1016/S0960-8966(98)00080-7
   Carrozzo R, 2003, HUM MUTAT, V21, P0, DOI 10.1002/humu.9135
   Dubern B, 2001, TRANSPLANTATION, V71, P633, DOI 10.1097/00007890-200103150-00009
   Ducluzeau PH, 1999, J HEPATOL, V30, P149, DOI 10.1016/S0168-8278(99)80019-1
   FIGARELLABRANGER D, 1992, J NEUROL SCI, V108, P105, DOI 10.1016/0022-510X(92)90195-Q
   Mandel H, 2001, HEPATOLOGY, V34, P776, DOI 10.1053/jhep.2001.27664
   MARIOTTI C, 1995, J NEUROL, V242, P547, DOI 10.1007/BF00868806
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Morris AAM, 1998, J HEPATOL, V28, P556, DOI 10.1016/S0168-8278(98)80278-X
   POULTON J, 1995, J INHERIT METAB DIS, V18, P4, DOI 10.1007/BF00711367
   POULTON J, 1994, HUM MOL GENET, V3, P1763, DOI 10.1093/hmg/3.10.1763
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   TELERMANTOPPET N, 1992, J INHERIT METAB DIS, V15, P323, DOI 10.1007/BF02435967
   Thomson M, 1998, J PEDIATR GASTR NUTR, V26, P478, DOI 10.1097/00005176-199804000-00024
   TRITSCHLER HJ, 1980, NEUROLOGY, V30, P795
   Vu TH, 1998, NEUROLOGY, V50, P1783, DOI 10.1212/WNL.50.6.1783
NR 17
TC 9
Z9 9
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0277-2116
EI 
J9 J PEDIATR GASTR NUTR
JI J. Pediatr. Gastroenterol. Nutr.
PD AUG 15
PY 2007
VL 45
IS 2
BP 252
EP 256
DI 10.1097/MPG.0b013e318048838f
PG 5
WC Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics
SC Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics
GA 194BH
UT WOS:000248318400019
PM 17667724
DA 2024-11-01
ER

PT J
AU Valdivieso, AG
   Marcucci, F
   Taminelli, G
   Guerrico, AG
   Alvarez, S
   Teiber, ML
   Dankert, MA
   Santa-Coloma, TA
AF Valdivieso, Angel G.
   Marcucci, Florencia
   Taminelli, Guillermo
   Guerrico, Anatilde Gonzalez
   Alvarez, Sergio
   Teiber, Maria Luz
   Dankert, Marcelo A.
   Santa-Coloma, Tomas A.
TI The expression of the mitochondrial gene <i>MT-ND4</i> is downregulated in cystic fibrosis
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE mitochondria; mitochondrial expressed genes; cystic fibrosis; CFTR; MT-ND4; CFDE; glibenclamide; CFTR(inh)-172
ID differential display; nadh dehydrogenase; messenger-rna; cells; identification; skeletal; cloning; muscle; chain; dna
AB Cystic fibrosis (CF) is a disease produced by mutations in the CFTR channel. We have previously reported that the CFTR chloride transport activity indirectly regulates the differential expression of several genes, including SRC and MUCI. Here we report that MTND4, a mitochondrial gene encoding a subunit of the mitochondrial Complex I (mtCx-1), is also a CFTR-dependent gene. A reduced expression of MT-ND4 was observed in CFDE cells (derived from a CF patient) when compared to CFDE cells ectopically expressing wild-type CFTR. The differential expression of MT-ND4 in CF was confirmed by RT-PCR. In situ hybridizations of deparaffinized human lung tissue slices derived from wt-CFTR or CF patients also showed downregulation of ND4 in CF. In addition, the CFTR chloride transport inhibitors glibenclamide and CFTR(inh)-172 also reduced MT-ND4 expression in CFDE cells ectopically expressing wt CFTR. These results suggest that the CFTR chloride transport activity indirectly up-regulates MT-ND4 expression. (c) 2007 Elsevier Inc. All rights reserved.
C1 Univ Buenos Aires, Fac Ciencias Exactas & Nat, RA-1053 Buenos Aires, DF, Argentina.
   Consejo Nacl Invest Cient & Tecn, Inst Invest Bioquim Buenos Aires, RA-1033 Buenos Aires, DF, Argentina.
   IIB Fdn Campomar, Buenos Aires, DF, Argentina.
   Pontificia Univ Catolica Argentina, Fac Ciencias Med, Programa Invest Biomed, Buenos Aires, DF, Argentina.
C3 University of Buenos Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Leloir Institute; Pontificia Universidad Catolica Argentina
RP Santa-Coloma, TA (corresponding author), Univ Buenos Aires, Fac Ciencias Exactas & Nat, RA-1053 Buenos Aires, DF, Argentina.
EM tsantacoloma@gmail.com
CR Cafferata EG, 1996, CELL MOL BIOL, V42, P797
   DECHECCHI MC, 1988, ENZYME, V40, P45, DOI 10.1159/000469141
   DEMEER K, 1995, THORAX, V50, P980, DOI 10.1136/thx.50.9.980
   DiMauro S, 1999, ITAL J NEUROL SCI, V20, P387
   ESPOSTI MD, 1994, FEBS LETT, V352, P375, DOI 10.1016/0014-5793(94)00971-6
   Gattermann N, 2004, NUCLEOS NUCLEOT NUCL, V23, P1275, DOI 10.1081/NCN-200027545
   González-Guerrico AM, 2002, J BIOL CHEM, V277, P17239, DOI 10.1074/jbc.M112456200
   Hirst J, 2003, BBA-BIOENERGETICS, V1604, P135, DOI 10.1016/S0005-2728(03)00059-8
   Lei DC, 1996, GENE THER, V3, P427
   LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393
   LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269
   Ma TH, 2002, J CLIN INVEST, V110, P1651, DOI 10.1172/JCI200216112
   Miller FJ, 2003, NUCLEIC ACIDS RES, V31, P0, DOI 10.1093/nar/gng060
   RIORDAN JR, 1989, SCIENCE, V245, P1066
   SHAPIRO BL, 1982, AM J HUM GENET, V34, P846
   SHAPIRO BL, 1989, LIFE SCI, V44, P1327, DOI 10.1016/0024-3205(89)90389-5
   SHAPIRO BL, 1988, LANCET, V2, P290
   SHAPIRO BL, 1979, P NATL ACAD SCI USA, V76, P2979, DOI 10.1073/pnas.76.6.2979
NR 18
TC 37
Z9 38
U1 0
U2 12
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD MAY 11
PY 2007
VL 356
IS 3
BP 805
EP 809
DI 10.1016/j.bbrc.2007.03.057
PG 5
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 157SJ
UT WOS:000245740900047
PM 17382898
DA 2024-11-01
ER

PT J
AU Pénisson-Besnier, I
   Biancalana, V
   Reynier, P
   Cossée, M
   Dubas, F
AF Penisson-Besnier, Isabelle
   Biancalana, Valerie
   Reynier, Pascal
   Cossee, Mireille
   Dubas, Frederic
TI Diagnosis of myotubular myopathy in the oldest known manifesting female carrier:: A clinical and genetic study
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE X-linked myotubular myopathy; female carrier; symptomatic heterozygote; x-inactivation; diaphragmatic paresis
ID skewed x-inactivation; methylation; chromosome; mutations
AB X-linked myotubular myopathy is a congenital myopathy due to mutation in the MTM1 gene, encoding myotubularin. Most of the affected male neonates die early of respiratory failure. The female carriers are usually asymptomatic. The authors report a novel MTM1 mutation in a 77-year-old woman. She presented with progressive ptosis since childhood, proximal limb weakness, and a severe restrictive respiratory dysfunction with a hemidiaphragmatic paresis, leading to death at 84 years of age. The muscle biopsy showed centrally nucleated fibers and mitochondrial abnormalities. A stop mutation Leu498X in MTM1 gene was identified in the proband and in her two healthy daughters. The X-inactivation pattern was random in the proband's blood and muscle DNA, and in blood DNA from her two unaffected MTM1 mutation carrier daughters. Two large heteroplasmic deletions were also detected in the muscle mitochondrial DNA of the propositus, raising the question of their putative impact on the phenotype. (C) 2006 Elsevier B.V. All rights reserved.
C1 CHU Angers, Ctr Reference Malad Neuromusculaires Rares Nantes, F-49033 Angers, France.
   Dept Neurol, F-49033 Angers, France.
   CHU Angers, Dept Pathol Cellulaire & Tissulaire Neuropathol, F-49033 Angers, France.
   CHRU, Lab Diagnost Genet, F-67085 Strasbourg, France.
   Univ Strasbourg 1, Fac Med, F-67085 Strasbourg, France.
   CHU Angers, Lab Biochim & Biol Mol, F-49033 Angers, France.
C3 Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; CHU Strasbourg; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Universite d'Angers; Centre Hospitalier Universitaire d'Angers
RP Pénisson-Besnier, I (corresponding author), CHU Angers, Ctr Reference Malad Neuromusculaires Rares Nantes, 4 Rue Larrey, F-49033 Angers, France.
EM ispenisson-besnier@chu-angers.fr
CR ALLEN RC, 1992, AM J HUM GENET, V51, P1229
   Bitoun M, 2005, NAT GENET, V37, P1207, DOI 10.1038/ng1657
   Carrel L, 1996, AM J MED GENET, V64, P27, DOI 10.1002/(SICI)1096-8628(19960712)64:1<27::AID-AJMG3>3.0.CO;2-O
   Grogan PM, 2005, NEUROLOGY, V64, P1638, DOI 10.1212/01.WNL.0000160393.99621.D0
   Hammans SR, 2000, NEUROMUSCULAR DISORD, V10, P133, DOI 10.1016/S0960-8966(99)00073-5
   Jungbluth H, 2003, NEUROMUSCULAR DISORD, V13, P55, DOI 10.1016/S0960-8966(02)00194-3
   Kristiansen M, 2003, NEUROMUSCULAR DISORD, V13, P468, DOI 10.1016/S0960-8966(03)00067-1
   Laporte J, 1996, NAT GENET, V13, P175, DOI 10.1038/ng0696-175
   Martínez F, 1998, J MED GENET, V35, P284, DOI 10.1136/jmg.35.4.284
   REYNIER P, 1999, MITOCHONDRIAL DIS, V0, P379
   Schara U, 2003, NEUROLOGY, V60, P1363, DOI 10.1212/01.WNL.0000058763.90924.FA
   Sutton IJ, 2001, NEUROLOGY, V57, P900, DOI 10.1212/WNL.57.5.900
   Tanner SM, 1999, HUM GENET, V104, P249, DOI 10.1007/s004390050943
NR 13
TC 21
Z9 22
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD FEB 15
PY 2007
VL 17
IS 2
BP 180
EP 185
DI 10.1016/j.nmd.2006.10.008
PG 6
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 148AG
UT WOS:000245046300009
PM 17251023
DA 2024-11-01
ER

PT J
AU Baloh, RH
   Salavaggione, E
   Milbrandt, J
   Pestronk, A
AF Baloh, Robert H.
   Salavaggione, Ezequiel
   Milbrandt, Jeffrey
   Pestronk, Alan
TI Familial parkinsonism and ophthalmoplegia from a mutation in the mitochondrial DNA helicase twinkle
SO ARCHIVES OF NEUROLOGY
LA English
DT Article
ID substantia-nigra neurons; deletions; disease; neuropathy; polg
AB Objective: To describe the clinical phenotype and genetic basis of a family with autosomal dominant progressive external ophthalmoplegia and parkinsonism from a Twinkle mutation. Design: All coding exons of POLG1, Twinkle ( aka C10ORF2, PEO1), and ANT1 ( SLC25A4) were sequenced in the proband with targeted sequencing of the Twinkle gene in all additional subjects. Subjects: Members of a 3-generation family followed up in a neuromuscular disease center for dominantly inherited progressive external ophthalmoplegia. Results: We identified a heterozygous G1121A mutation ( R374Q) in exon 1 of Twinkle that segregated with the disease phenotype in all affected family members. No pathogenic mutations were present in POLG1 or ANT1. Conclusion: This finding broadens the clinical spectrum of Twinkle gene mutations and further implicates loss of mitochondrial DNA integrity in the pathogenesis of Parkinson disease.
C1 Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA.
   Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA.
   Washington Univ, Sch Med, Hope Ctr Neurol Dis, St Louis, MO 63110 USA.
C3 Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)
RP Baloh, RH (corresponding author), Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA.
EM balohb@neuro.wustl.edu
FU NCRR NIH HHS [1K12RR023249-01] Funding Source: Medline
CR Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Davidzon G, 2006, ANN NEUROL, V59, P859, DOI 10.1002/ana.20831
   Hudson G, 2005, NEUROLOGY, V64, P371, DOI 10.1212/01.WNL.0000149767.51152.83
   Kraytsberg Y, 2006, NAT GENET, V38, P518, DOI 10.1038/ng1778
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Mancuso M, 2004, ARCH NEUROL-CHICAGO, V61, P1777, DOI 10.1001/archneur.61.11.1777
   SCHAPIRA AHV, 1989, LANCET, V1, P1269, DOI 10.1016/S0140-6736(89)92366-0
   Schapira AHV, 2006, NEUROLOGY, V66, PS10, DOI 10.1212/WNL.66.10_suppl_4.S10
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Van Goethem G, 2003, HUM MUTAT, V22, P175, DOI 10.1002/humu.10246
   VYAS I, 1986, J NEUROCHEM, V46, P1501, DOI 10.1111/j.1471-4159.1986.tb01768.x
NR 11
TC 81
Z9 84
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0003-9942
EI 
J9 ARCH NEUROL-CHICAGO
JI Arch. Neurol.
PD JUL 15
PY 2007
VL 64
IS 7
BP 998
EP 1000
DI 10.1001/archneur.64.7.998
PG 3
WC Clinical Neurology
SC Neurosciences & Neurology
GA 188AZ
UT WOS:000247892100011
PM 17620490
DA 2024-11-01
ER

PT J
AU Kato, T
AF Kato, Tadafumi
TI Mitochondrial dysfunction as the molecular basis of bipolar disorder - Therapeutic implications
SO CNS DRUGS
LA English
DT Review
ID progressive external ophthalmoplegia; magnetic-resonance-spectroscopy; subunit gene ndufv2; expression analysis; mood stabilizers; invivo p-31; i disorder; quantitative-analysis; dna polymorphisms; mtdna deletions
AB Multiple lines of evidence, such as impaired energy metabolism in the brain detected by magnetic resonance spectroscopy, a possible role of maternal inheritance, co-morbidity with mitoctiondrial diseases, the effects of mood stabilisers on mitochondria, increased mitochondrial DNA (mtDNA) deletion in the brain, and association with mtDNA mutations/polymorphisms or nuclear-encoded mitochondrial genes, suggest that mitochondrial dysfunction is an important component of bipolar disorder. Global reduction of mitochondria-related gene expression in the postmortem brains of patients with bipolar disorder may also be an indicator, but such findings are affected by sample pH and thus need to be interpreted with caution. A recently developed animal model carrying rntDNA deletion in neurons suggested that accumulation of mtDNA deletions causes bipolar disorder-like phenotypes. The next step in the study of mitochondrial dysfunction in bipolar disorder should be clarification of how mitochondrial dysfunction, a nonspecific risk factor, can cause specific symptoms of bipolar disorder. Two hypothetical mechanisms are rntDNA neuroplasticity and nonvisual photoreception impairment. Further study of mitochondrial dysfunction in bipolar disorder is expected to be useful for the development of new mood stabilisers.
C1 RIKEN, Brain Sci Inst, Lab Mol Dynam Mental Disorders, Wako, Saitama 3510198, Japan.
C3 RIKEN
RP Kato, T (corresponding author), RIKEN, Brain Sci Inst, Lab Mol Dynam Mental Disorders, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.
EM kato@brain.riken.go.jp
CR Bachmann RF, 2005, MOL NEUROBIOL, V32, P173, DOI 10.1385/MN:32:2:173
   Barbini B, 2005, BIPOLAR DISORD, V7, P98, DOI 10.1111/j.1399-5618.2004.00166.x
   BARBIROLI B, 1993, J CEREBR BLOOD F MET, V13, P469, DOI 10.1038/jcbfm.1993.61
   Benes FM, 2006, MOL PSYCHIATR, V11, P241, DOI 10.1038/sj.mp.4001758
   Boles RG, 2005, AM J MED GENET B, V137B, P20, DOI 10.1002/ajmg.b.30199
   Bowden CL, 2003, ARCH GEN PSYCHIAT, V60, P392, DOI 10.1001/archpsyc.60.4.392
   Bown CD, 2002, BIPOLAR DISORD, V4, P145, DOI 10.1034/j.1399-5618.2002.t01-1-40201.x
   Burnett BB, 2005, J AFFECT DISORDERS, V88, P109, DOI 10.1016/j.jad.2005.05.009
   Carlezon WA, 2005, BIOL PSYCHIAT, V57, P343, DOI 10.1016/j.biopsych.2004.11.038
   Chen G, 1999, J NEUROCHEM, V72, P879, DOI 10.1046/j.1471-4159.1999.720879.x
   Chen G, 1999, J NEUROCHEM, V72, P1327, DOI 10.1046/j.1471-4159.2000.0721327.x
   CHOU JC, 2000, ARCH GEN PSYCHIAT, V57, P481
   Chuang DM, 2005, ANN NY ACAD SCI, V1053, P195, DOI 10.1196/annals.1344.018
   Dager SR, 2004, ARCH GEN PSYCHIAT, V61, P450, DOI 10.1001/archpsyc.61.5.450
   Deschauer M, 2005, NEUROMUSCULAR DISORD, V15, P311, DOI 10.1016/j.nmd.2004.12.004
   Di Fonzo A, 2003, HUM MUTAT, V22, P0, DOI 10.1002/humu.9203
   Diaz F, 2002, NUCLEIC ACIDS RES, V30, P4626, DOI 10.1093/nar/gkf602
   Dokucu ME, 2005, NEUROPSYCHOPHARMACOL, V30, P2216, DOI 10.1038/sj.npp.1300764
   Einat H, 2005, BEHAV BRAIN RES, V165, P172, DOI 10.1016/j.bbr.2005.06.012
   Einat Haim, 2003, PSYCHOPHARMACOL BULL, V37, P47
   Fattal O, 2006, PSYCHOSOMATICS, V47, P1, DOI 10.1176/appi.psy.47.1.1
   Geddes JR, 2004, AM J PSYCHIAT, V161, P217, DOI 10.1176/appi.ajp.161.2.217
   Glantz LA, 2006, SCHIZOPHR RES, V81, P47, DOI 10.1016/j.schres.2005.08.014
   Goodwin FK, 1990, MANIC DEPRESSIVE ILL, V36, P0
   Gould TD, 2006, GENES BRAIN BEHAV, V5, P113, DOI 10.1111/j.1601-183X.2005.00186.x
   Hajek T, 2005, BIPOLAR DISORD, V7, P393, DOI 10.1111/j.1399-5618.2005.00238.x
   Haldane M, 2004, PROG NEURO-PSYCHOPH, V28, P943, DOI 10.1016/j.pnpbp.2004.05.040
   Hashimoto H, 2006, ANN NY ACAD SCI, V1070, P75, DOI 10.1196/annals.1317.038
   Hernández F, 2002, J NEUROCHEM, V83, P1529, DOI 10.1046/j.1471-4159.2002.01269.x
   Iwamoto K, 2005, HUM MOL GENET, V14, P241, DOI 10.1093/hmg/ddi022
   Kakiuchi C, 2005, INT J NEUROPSYCHOPH, V8, P515, DOI 10.1017/S1461145705005213
   Kakiuchi C, 2003, NAT GENET, V35, P171, DOI 10.1038/ng1235
   Karry R, 2004, BIOL PSYCHIAT, V55, P676, DOI 10.1016/j.biopsych.2003.12.012
   Kasahara T, 2006, MOL PSYCHIATR, V11, P577, DOI 10.1038/sj.mp.4001824
   KATO T, 1995, PSYCHOL MED, V25, P557, DOI 10.1017/S003329170003347X
   Kato T, 1996, J AFFECT DISORDERS, V37, P67, DOI 10.1016/0165-0327(95)00050-X
   Kato T, 1997, BIOL PSYCHIAT, V42, P871, DOI 10.1016/S0006-3223(97)00012-7
   Kato T, 2005, DRUG TODAY, V41, P335, DOI 10.1358/dot.2005.41.5.893616
   Kato T, 1998, J NEUROPSYCH CLIN N, V10, P133, DOI 10.1176/jnp.10.2.133
   Kato T, 1998, EUR ARCH PSY CLIN N, V248, P301, DOI 10.1007/s004060050054
   Kato T, 2001, J AFFECT DISORDERS, V62, P151, DOI 10.1016/S0165-0327(99)00173-1
   KATO T, 1994, J AFFECT DISORDERS, V31, P125, DOI 10.1016/0165-0327(94)90116-3
   KATO T, 1993, J AFFECT DISORDERS, V27, P53, DOI 10.1016/0165-0327(93)90097-4
   KATO T, 1991, J AFFECT DISORDERS, V22, P185, DOI 10.1016/0165-0327(91)90064-Y
   Kato T, 1997, BIOL PSYCHIAT, V42, P311, DOI 10.1016/S0006-3223(96)00377-0
   Kato T, 2000, BIPOLAR DISORD, V2, P180, DOI 10.1034/j.1399-5618.2000.020305.x
   Kato T, 2001, MOL PSYCHIATR, V6, P625, DOI 10.1038/sj.mp.4000926
   Kato T, 2000, AM J MED GENET, V96, P182, DOI 10.1002/(SICI)1096-8628(20000403)96:2<182::AID-AJMG12>3.0.CO;2-Q
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kazuno AA, 2005, PSYCHIAT CLIN NEUROS, V59, P497, DOI 10.1111/j.1440-1819.2005.01404.x
   Kazuno AA, 2006, PLOS GENET, V2, P1167, DOI 10.1371/journal.pgen.0020128
   Kirk R, 1999, AM J HUM GENET, V65, P508, DOI 10.1086/302507
   Klivenyi P, 2004, NEUROMOL MED, V6, P87, DOI 10.1385/NMM:6:2-3:087
   Konradi C, 2004, ARCH GEN PSYCHIAT, V61, P300, DOI 10.1001/archpsyc.61.3.300
   Kramer A, 2001, SCIENCE, V294, P2511, DOI 10.1126/science.1067716
   Lenox RH, 2002, AM J MED GENET, V114, P391, DOI 10.1002/ajmg.10360
   LEWY AJ, 1981, LANCET, V1, P383
   Li JZ, 2004, HUM MOL GENET, V13, P609, DOI 10.1093/hmg/ddh065
   Linseman DA, 2004, J NEUROSCI, V24, P9993, DOI 10.1523/JNEUROSCI.2057-04.2004
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Machado-Vieira R, 2004, PROG NEURO-PSYCHOPH, V28, P209, DOI 10.1016/j.pnpbp.2003.10.015
   Magariños AM, 1999, EUR J PHARMACOL, V371, P113, DOI 10.1016/S0014-2999(99)00163-6
   Magnusson J, 2003, EXP CELL RES, V289, P133, DOI 10.1016/S0014-4827(03)00249-0
   Mancuso M, 2004, NEUROLOGY, V62, P316, DOI 10.1212/WNL.62.2.316
   Manji H K, 2001, PSYCHOPHARMACOL BULL, V35, P5
   MCMAHON FJ, 1995, AM J HUM GENET, V56, P1277
   McMahon FJ, 2000, AM J PSYCHIAT, V157, P1058, DOI 10.1176/appi.ajp.157.7.1058
   Meesters Y, 1998, AM J PSYCHIAT, V155, P306
   Mott JL, 2005, REJUV RES, V8, P216, DOI 10.1089/rej.2005.8.216
   Mrosovsky N, 2003, CHRONOBIOL INT, V20, P989, DOI 10.1081/CBI-120026043
   Munakata K, 2005, BIOL PSYCHIAT, V57, P525, DOI 10.1016/j.biopsych.2004.11.041
   Munakata K, 2004, GENOMICS, V84, P1041, DOI 10.1016/j.ygeno.2004.08.015
   NAKAMURA S, 1991, PROG BRAIN RES, V88, P587
   Nakatani N, 2004, PHARMACOGENOMICS J, V4, P114, DOI 10.1038/sj.tpj.6500234
   Nakatani N, 2006, HUM MOL GENET, V15, P1949, DOI 10.1093/hmg/ddl118
   OKUMA T, 1981, PSYCHOPHARMACOLOGY, V73, P95, DOI 10.1007/BF00431111
   Peng TI, 2006, BBA-MOL BASIS DIS, V1762, P241, DOI 10.1016/j.bbadis.2005.10.008
   Post RM, 1996, MOL NEUROBIOL, V13, P33, DOI 10.1007/BF02740751
   RENSHAW PF, 1987, MAGN RESON MED, V4, P221, DOI 10.1002/mrm.1910040303
   Roubertoux PL, 2003, NAT GENET, V35, P65, DOI 10.1038/ng1230
   Ryan MM, 2006, MOL PSYCHIATR, V11, P965, DOI 10.1038/sj.mp.4001875
   Saydoff JA, 2003, BRAIN RES, V994, P44, DOI 10.1016/j.brainres.2003.09.049
   Siciliano G, 2003, NEUROMUSCULAR DISORD, V13, P162, DOI 10.1016/S0960-8966(02)00221-3
   Silverstone PH, 2002, HUM PSYCHOPHARM CLIN, V17, P425, DOI 10.1002/hup.434
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   STINE OC, 1993, BIOL PSYCHIAT, V42, P311
   Stork C, 2005, MOL PSYCHIATR, V10, P900, DOI 10.1038/sj.mp.4001711
   Sun XJ, 2006, J PSYCHIATR NEUROSCI, V31, P189
   SUOMALAINEN A, 1992, J CLIN INVEST, V90, P61, DOI 10.1172/JCI115856
   Takao M, 2000, NEUROSCIENCE, V97, P779, DOI 10.1016/S0306-4522(00)00053-1
   Tohen M, 2006, AM J PSYCHIAT, V163, P247, DOI 10.1176/appi.ajp.163.2.247
   Tomita H, 2004, BIOL PSYCHIAT, V55, P346, DOI 10.1016/j.biopsych.2003.10.013
   Tyynismaa H, 2005, P NATL ACAD SCI USA, V102, P17687, DOI 10.1073/pnas.0505551102
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Vawter MP, 2006, MOL PSYCHIATR, V11, P663, DOI 10.1038/sj.mp.4001830
   Washizuka S, 2006, AM J MED GENET B, V141B, P301, DOI 10.1002/ajmg.b.30285
   Washizuka S, 2005, BIPOLAR DISORD, V7, P146, DOI 10.1111/j.1399-5618.2005.00184.x
   Washizuka S, 2004, BIOL PSYCHIAT, V56, P483, DOI 10.1016/j.biopsych.2004.07.004
   Washizuka S, 2003, AM J MED GENET B, V120B, P72, DOI 10.1002/ajmg.b.20041
   Wehr TA, 1998, BIOL PSYCHIAT, V43, P822, DOI 10.1016/S0006-3223(97)00542-8
   Yamawaki S, 1998, LIFE SCI, V62, P1665, DOI 10.1016/S0024-3205(98)00125-8
   Zhou R, 2005, J NEUROSCI, V25, P4493, DOI 10.1523/JNEUROSCI.4530-04.2005
NR 104
TC 69
Z9 76
U1 0
U2 5
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1172-7047
EI 1179-1934
J9 CNS DRUGS
JI CNS Drugs
PD JUN 15
PY 2007
VL 21
IS 1
BP 1
EP 11
DI 10.2165/00023210-200721010-00001
PG 11
WC Clinical Neurology; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA 135PO
UT WOS:000244165700001
PM 17190525
DA 2024-11-01
ER

PT J
AU Bykhovskaya, Y
   Mengesha, E
   Fischel-Ghodsian, N
AF Bykhovskaya, Yelena
   Mengesha, Emebet
   Fischel-Ghodsian, Nathan
TI Pleiotropic effects and compensation mechanisms determine tissue specificity in mitochondrial myopathy and sideroblastic anemia (MLASA)
SO MOLECULAR GENETICS AND METABOLISM
LA English
DT Article
DE oxidative phosphorylation disorder; pseudouridylation; expression; microarray; sideroblastic anemia; myopathy
ID erythroid 5-aminolevulinate synthase; pseudouridine-synthase; gene-expression; iron-metabolism; messenger-rna; cell-lines; dyskeratosis-congenita; missense mutation; u2 snrna; erythropoietin
AB The tissue specificity of mitochondrial diseases is poorly understood. Recently, tissue-specific quantitative differences of the components of the mitochondrial translation system have been found to correlate with disease presentation in fatal hepatopathy caused by mutations in mitochondrial translation factor EFGI. MLASA is an autosomal recessive inherited progressive oxidative phosphorylation disorder that affects muscle and erythroid cells. The disease is caused by the homozygous point mutation C656T (R116W) in the catalytic domain of the pseudouridylate synthase 1 (PUS1) gene, which leads to a complete lack of pseudouridylation at the expected sites in mitochondrial and cytoplasmic tRNAs. Despite the presence of these altered tRNAs, most tissues are unaffected, and even in muscle and erythroid cells the disease phenotype only slowly emerges over the course of years. In order to elucidate intracellular pathways through which the homozygous mutation leads to tissue-restricted phenotype, we performed microarray expression analysis of EBV-transformed lymphoblasts from MLASA patients, heterozygous parents, and controls using human Beadchip microarray with 47,296 transcripts. Genes coding for proteins involved in DNA transcription and its regulation, and metal binding proteins, demonstrated major differences in expression between patients and all other individuals with normal phenotype. Genes coding for ribosomal proteins differed significantly between individual with at least one copy of the mutated PUS1 gene and controls. These findings indicate that the lack of tRNA pseudouridylation can be overcome by compensatory changes in levels of ribosomal proteins, and that the disease phenotype in affected tissues is likely due to pleiotropic effects of PUS1p on non-tRNA molecules involved in DNA transcription and iron metabolism. Similar combinations of mechanisms may play a role in the tissue specificity of other mitochondrial disorders. (c) 2007 Elsevier Inc. All rights reserved.
C1 Cedars Sinai Med Ctr, Steven Spielberg Pediat Res Ctr, Inst Med Genet, Ahmanson Dept Pediat, Los Angeles, CA 90048 USA.
   Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90048 USA.
C3 Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA
RP Fischel-Ghodsian, N (corresponding author), Cedars Sinai Med Ctr, Steven Spielberg Pediat Res Ctr, Inst Med Genet, Ahmanson Dept Pediat, 8700 Beverly Blvd,Suite SSB378, Los Angeles, CA 90048 USA.
EM nathan.fischel@cshs.org
FU NCRR NIH HHS [M01-RR00425, M01 RR000425] Funding Source: Medline; NIDDK NIH HHS [R01 DK074368-02, R01 DK074368-01A2, R01-DK74368, R01 DK074368] Funding Source: Medline
CR Antonicka H, 2006, HUM MOL GENET, V15, P1835, DOI 10.1093/hmg/ddl106
   Baron CA, 2006, J AUTISM DEV DISORD, V36, P973, DOI 10.1007/s10803-006-0134-x
   Behm-Ansmant I, 2003, RNA, V9, P1371, DOI 10.1261/rna.5520403
   Behm-Ansmant I, 2006, RNA, V12, P1583, DOI 10.1261/rna.100806
   Busfield SJ, 1997, EUR J BIOCHEM, V249, P77, DOI 10.1111/j.1432-1033.1997.t01-1-00077.x
   Bykhovskaya Y, 2004, AM J HUM GENET, V74, P1303, DOI 10.1086/421530
   Casas KA, 2004, AM J MED GENET A, V125A, P201, DOI 10.1002/ajmg.a.20368
   CASEY JL, 1989, EMBO J, V8, P3693, DOI 10.1002/j.1460-2075.1989.tb08544.x
   Charette M, 2000, IUBMB LIFE, V49, P341
   Chen JG, 2000, BIOCHEM J, V352, P465, DOI 10.1042/0264-6021:3520465
   Dennis G, 2003, GENOME BIOL, V4, P0, DOI 10.1186/gb-2003-4-9-r60
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   DiMauro S, 2004, MITOCHONDRION, V4, P799, DOI 10.1016/j.mito.2004.07.032
   Dokal I, 2000, BRIT J HAEMATOL, V110, P768, DOI 10.1046/j.1365-2141.2000.02109.x
   Gunderson KL, 2004, GENOME RES, V14, P870, DOI 10.1101/gr.2255804
   Haas CS, 2006, ARTHRITIS RHEUM-US, V54, P2047, DOI 10.1002/art.21953
   HANSON ES, 2002, MOL CELLULAR IRON TR, V0, P207
   Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175
   Hosack DA, 2003, GENOME BIOL, V4, P0, DOI 10.1186/gb-2003-4-10-r70
   Hube F, 2006, DNA CELL BIOL, V25, P418, DOI 10.1089/dna.2006.25.418
   KLAUSNER RD, 1993, MOL BIOL CELL, V4, P1
   Koonin EV, 1996, NUCLEIC ACIDS RES, V24, P2411, DOI 10.1093/nar/24.12.2411
   Kuhn K, 2004, GENOME RES, V14, P2347, DOI 10.1101/gr.2739104
   Makita T, 2001, GENE DEV, V15, P889, DOI 10.1101/gad.871601
   Massenet S, 1999, MOL CELL BIOL, V19, P2142
   Massenet S, 1998, MODIFICATION EDITING, V0, P201
   Mitchell JR, 1999, NATURE, V402, P551, DOI 10.1038/990141
   Mochizuki Y, 2004, P NATL ACAD SCI USA, V101, P10756, DOI 10.1073/pnas.0402560101
   Morello F, 2004, ARTERIOSCL THROM VAS, V24, P2149, DOI 10.1161/01.ATV.0000145978.70872.63
   Motorin Y, 1998, RNA, V4, P856, DOI 10.1017/S1355838298980396
   Ofengand J, 2002, FEBS LETT, V514, P17, DOI 10.1016/S0014-5793(02)02305-0
   Patton JR, 2005, J BIOL CHEM, V280, P19823, DOI 10.1074/jbc.M500216200
   PATTON JR, 1994, BIOCHIMIE, V76, P1129, DOI 10.1016/0300-9084(94)90041-8
   Ponka P, 1997, BLOOD, V89, P1
   PRESSMAN S, 1991, AM J HUM GENET, V49, P467
   Ruggero D, 2003, SCIENCE, V299, P259, DOI 10.1126/science.1079447
   Sadlon TJ, 1999, INT J BIOCHEM CELL B, V31, P1153, DOI 10.1016/S1357-2725(99)00073-4
   THEIL EC, 1990, J BIOL CHEM, V265, P4771
   Watts JA, 2002, AM J HUM GENET, V71, P791, DOI 10.1086/342974
   Weiss G, 1997, BLOOD, V89, P680, DOI 10.1182/blood.V89.2.680
   Yoon A, 2006, SCIENCE, V312, P902, DOI 10.1126/science.1123835
   Zhao XS, 2004, MOL CELL, V15, P549, DOI 10.1016/j.molcel.2004.06.044
   Zoller H, 2002, BRIT J HAEMATOL, V118, P619, DOI 10.1046/j.1365-2141.2002.03626.x
NR 43
TC 13
Z9 13
U1 0
U2 2
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1096-7192
EI 1096-7206
J9 MOL GENET METAB
JI Mol. Genet. Metab.
PD JUN 15
PY 2007
VL 91
IS 2
BP 148
EP 156
DI 10.1016/j.ymgme.2007.02.006
PG 9
WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research & Experimental
SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental Medicine
GA 181AE
UT WOS:000247408300005
PM 17374500
DA 2024-11-01
ER

PT J
AU Wong, A
   Cortopassi, G
AF Wong, Alice
   Cortopassi, Gino
TI Mitochondrial Genetic Diseases
SO NEUROBIOLOGY OF DISEASE
LA English
DT Article; Book Chapter
DE Dominant Optic Atrophy; Friedreich's ataxia; Kearns-Sayre syndrome/chronic progressive external ophthalmoplegia, Leber's hereditary optic neuropathy; Mitochondrial Encephalomyopathy, Lactic Acidosis, and Strokelike episodes; Myoclonic Epilepsy and Ragged Red Fibers; mitochondria; Neuropathy, Ataxia, and Retinitis pigmentosa
ID hereditary optic neuropathy; oxidative stress; transfer-rna; complex-i; mutations; cells; mtdna; aminoacylation; merrf; dna
C1 [Wong, Alice; Cortopassi, Gino] Univ Calif Davis, Sch Vet Med, Dept Mol Biosci, Davis, CA 95616 USA.
C3 University of California System; University of California Davis
RP Wong, A (corresponding author), Univ Calif Davis, Sch Vet Med, Dept Mol Biosci, Davis, CA 95616 USA.
CR Baracca A, 2005, ARCH NEUROL-CHICAGO, V62, P730, DOI 10.1001/archneur.62.5.730
   Börner GV, 2000, HUM MOL GENET, V9, P467, DOI 10.1093/hmg/9.4.467
   Calabrese V, 2005, J NEUROL SCI, V233, P145, DOI 10.1016/j.jns.2005.03.012
   Carelli V, 2004, BBA-BIOENERGETICS, V1658, P172, DOI 10.1016/j.bbabio.2004.05.009
   Chomyn A, 1998, AM J HUM GENET, V62, P745, DOI 10.1086/301813
   Chomyn A, 2000, J BIOL CHEM, V275, P19198, DOI 10.1074/jbc.M908734199
   Danielson SR, 2002, J BIOL CHEM, V277, P5810, DOI 10.1074/jbc.M110119200
   DiMauro S, 2004, BBA-BIOENERGETICS, V1658, P80, DOI 10.1016/j.bbabio.2004.03.014
   ENRIQUEZ JA, 1995, NAT GENET, V10, P47, DOI 10.1038/ng0595-47
   Genova ML, 2001, FEBS LETT, V505, P364, DOI 10.1016/S0014-5793(01)02850-2
   Ghelli A, 2003, J BIOL CHEM, V278, P4145, DOI 10.1074/jbc.M210285200
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Jacobs HT, 2005, TRENDS GENET, V21, P312, DOI 10.1016/j.tig.2005.04.003
   Kamei S, 2005, INVEST OPHTH VIS SCI, V46, P4288, DOI 10.1167/iovs.03-1407
   Lenaz G, 2004, BBA-BIOENERGETICS, V1658, P89, DOI 10.1016/j.bbabio.2004.03.013
   Lodi R, 2004, ANN NEUROL, V56, P719, DOI 10.1002/ana.20278
   LUFT R, 1962, J CLIN INVEST, V41, P1776, DOI 10.1172/JCI104637
   Mattiazzi M, 2004, HUM MOL GENET, V13, P869, DOI 10.1093/hmg/ddh103
   McKenzie M, 2004, NEUROCHEM RES, V29, P589, DOI 10.1023/B:NERE.0000014829.42364.dd
   MORAES CT, 1995, MUSCLE NERVE, V0, PS150
   Schon EA, 2001, SEMIN CELL DEV BIOL, V12, P441, DOI 10.1006/scdb.2001.0281
   SHOFFNER JM, 1992, AM J HUM GENET, V51, P1179
   Vives-Bauza C, 2006, NEUROSCI LETT, V391, P136, DOI 10.1016/j.neulet.2005.08.049
   WALLACE DC, 1988, CELL, V55, P601, DOI 10.1016/0092-8674(88)90218-8
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   Wei YH, 2001, CHINESE J PHYSIOL, V44, P1
   Wittenhagen LM, 2002, NAT STRUCT BIOL, V9, P586, DOI 10.1038/nsb820
   Wong A, 2002, HUM MOL GENET, V11, P431, DOI 10.1093/hmg/11.4.431
   Yasukawa T, 2001, EMBO J, V20, P4794, DOI 10.1093/emboj/20.17.4794
   Zeviani M, 2003, CURR OPIN NEUROL, V16, P585, DOI 10.1097/00019052-200310000-00004
NR 30
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA
SN 
EI 
J9 
PD JUN 15
PY 2007
VL 0
IS 
BP 157
EP 161
DI 10.1016/B978-012088592-3/50016-5
PG 5
WC Neurosciences
SC Neurosciences & Neurology
GA BCO40
UT WOS:000310853000015
DA 2024-11-01
ER

PT J
AU Wilcox, RA
   Churchyard, A
   Dahl, HH
   Hutchison, WM
   Kirby, DM
   Thyagarajan, D
AF Wilcox, Robert A.
   Churchyard, Andrew
   Dahl, Henrik H.
   Hutchison, Wendy M.
   Kirby, Denise M.
   Thyagarajan, Dominic
TI Levodopa response in parkinsonism with multiple mitochondrial DNA deletions
SO MOVEMENT DISORDERS
LA English
DT Article
DE mitochondrial disease; Parkinson's disease; parkinsonism; chronic progressive external ophthalmoplegia; neuropathy
ID disease
AB We report a patient with an autosomal dominant chronic progressive external ophthalmoplegia phenotype associated with multiple mtDNA deletions in muscle from a family in which linkage analysis excluded mutations in DNA polymerase gamma (POLG), adenine nucleotide translocase (ANT-1) or C10orf2 (Twinkle). She presented with prominent Parkinsonism characterized by prolonged benefit from levodopa (L-dopa) and the later development Of L-dopa induced dyskinesias and motor fluctuations. Thus L-dopa responsiveness, L-dopa induced dyskinesias and motor fluctuations may also occur in atypical Parkinsonism of mitochondrial disease, just as they may in multiple system atrophy. (C) 2007 Movement Disorder Society.
C1 Flinders Med Ctr, Dept Neurol, Bedford Pk, SA, Australia.
   Cabini Med Ctr, Malvern, Vic, Australia.
   Murdoch Childrens Res Inst, Dept Paediat, Melbourne, Vic, Australia.
   Univ Melbourne, Royal Childrens Hosp, Melbourne, Vic, Australia.
C3 Flinders Medical Centre; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of Melbourne
RP Wilcox, RA (corresponding author), Univ Queensland, Royal Brisbane Hosp, Dept Neurol, Herston, Qld 4029, Australia.
EM robert_wilcox@health.qld.gov.au
CR Abou-Sleiman PM, 2006, NAT REV NEUROSCI, V7, P207, DOI 10.1038/nrn1868
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Berciano J, 2002, MOVEMENT DISORD, V17, P812, DOI 10.1002/mds.10190
   Chalmers RM, 1996, J NEUROL SCI, V143, P41, DOI 10.1016/S0022-510X(96)00032-9
   Chinnery PF, 2003, J NEUROL NEUROSUR PS, V74, P1188, DOI 10.1136/jnnp.74.9.1188
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Kirby DM, 1999, NEUROLOGY, V52, P1255, DOI 10.1212/WNL.52.6.1255
   Kraytsberg Y, 2006, NAT GENET, V38, P518, DOI 10.1038/ng1778
   Lewis S, 2002, J NEUROL SCI, V201, P39, DOI 10.1016/S0022-510X(02)00190-9
   Rana M, 2000, ANN NEUROL, V48, P774, DOI 10.1002/1531-8249(200011)48:5<774::AID-ANA11>3.3.CO;2-9
   Spinazzola A, 2005, GENE, V354, P162, DOI 10.1016/j.gene.2005.03.025
   Thyagarajan D, 2000, ANN NEUROL, V48, P730, DOI 10.1002/1531-8249(200011)48:5<730::AID-ANA6>3.0.CO;2-0
   THYAGARAJAN D, 2006, NEUROLOGICAL THERAPE, V0, P1743
NR 13
TC 10
Z9 10
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0885-3185
EI 1531-8257
J9 MOVEMENT DISORD
JI Mov. Disord.
PD MAY 15
PY 2007
VL 22
IS 7
BP 1020
EP 1023
DI 10.1002/mds.21416
PG 4
WC Clinical Neurology
SC Neurosciences & Neurology
GA 174BU
UT WOS:000246917000019
PM 17357142
DA 2024-11-01
ER

PT J
AU De Flora, S
   Izzotti, A
AF De Flora, Silvio
   Izzotti, Alberto
TI Mutagenesis and cardiovascular diseases Molecular mechanisms, risk factors, and protective factors
SO MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS
LA English
DT Article
DE atherosclerosis; mutation; DNA adducts; oxidative DNA damage; genetic polymorphisms; prevention
ID human atherosclerotic lesions; coronary-artery-disease; smooth-muscle-cells; oxidative dna-damage; smoke-exposed rats; s-transferase m1; cigarette-smoke; chemopreventive agents; gene polymorphisms; mitochondrial-dna
AB Although no generalization can be made, it is of interest that cancer, cardiovascular diseases, and other chronic conditions often share common risk factors and common protective factors as well as common pathogenetic determinants, such as DNA damage, oxidative stress, and chronic inflammation. Atherosclerosis is the most important cause of vascular forms representing the major cause of death in the population of many geographical areas. A great deal of studies support the "response-to-injury" theory. A variety of experimental and epidemiological findings are also in favor of the somatic mutation theory, which maintains that the earliest event in the atherogenic process is represented by mutations in arterial smooth muscle cells, akin to formation of a benign tumor. These two theories can be harmonized, also taking into account the highly diversified nature of atherosclerotic lesions. Molecular epidemiology studies performed in our laboratory and other laboratories have shown that DNA adducts are systematically present in arterial smooth muscle cells, and their levels are correlated with atherogenic risk factors known from traditional epidemiology. Oxidative DNA damage was also consistently detected in these cells. The role of glutathione S-transferase polymorphisms on the frequency of the above molecular alterations and of arterial diseases is rather controversial. Prevention of both cancer and atherosclerosis is based on avoidance of exposure to risk factors and on fortification of the host defense mechanisms by means of dietary principles and chemopreventive drugs. (C) 2007 Elsevier B.V. All rights reserved.
C1 Univ Genoa, Dept Hlth Sci, I-16132 Genoa, Italy.
C3 University of Genoa
RP De Flora, S (corresponding author), Univ Genoa, Dept Hlth Sci, Via A Pastore 1, I-16132 Genoa, Italy.
EM sdf@unige.it
CR AMES BN, 1995, P NATL ACAD SCI USA, V92, P5258, DOI 10.1073/pnas.92.12.5258
   Andreassi MG, 2000, ENVIRON MOL MUTAGEN, V35, P265, DOI 10.1002/1098-2280(2000)35:4<265::AID-EM1>3.0.CO;2-M
   Andreassi MG, 1999, J HYPERTENS, V17, P843, DOI 10.1097/00004872-199917060-00017
   Andreassi MG, 2003, MUTAT RES-REV MUTAT, V543, P67, DOI 10.1016/S1383-5742(02)00089-3
   [Anonymous], 1985, WHO TECH REP SERV, V143, P1
   Balansky R, 1996, CANCER RES, V56, P1642
   BENDITT EP, 1973, P NATL ACAD SCI USA, V70, P1753, DOI 10.1073/pnas.70.6.1753
   Binková B, 2002, MUTAT RES-FUND MOL M, V501, P115, DOI 10.1016/S0027-5107(02)00019-2
   Bogliolo M, 1999, MUTAGENESIS, V14, P77, DOI 10.1093/mutage/14.1.77
   Bogliolo M, 1996, CHEM-BIOL INTERACT, V102, P55, DOI 10.1016/0009-2797(96)03731-3
   Botto N, 2005, MUTAT RES-FUND MOL M, V570, P81, DOI 10.1016/j.mrfmmm.2004.10.003
   BRIDGES B A, 1990, MUTATION RESEARCH, V239, P143, DOI 10.1016/0165-1110(90)90002-S
   BUSBEE DL, 1982, CARCINOGENESIS, V3, P1107, DOI 10.1093/carcin/3.10.1107
   CASALONE R, 1991, HUM GENET, V87, P139, DOI 10.1007/BF00204169
   Collins AR, 1998, FASEB J, V12, P1397, DOI 10.1096/fasebj.12.13.1397
   CRAWFORD DW, 1991, ATHEROSCLEROSIS, V89, P97, DOI 10.1016/0021-9150(91)90049-9
   DAGOSTINI F, 1995, CANCER EPIDEM BIOMAR, V4, P111
   De Flora S, 2005, FASEB J, V19, P892, DOI 10.1096/fj.04-3541rev
   de Nigris F, 2003, CELL CYCLE, V2, P325, DOI 10.4161/cc.2.4.414
   DeFlora S, 1997, FASEB J, V11, P1021, DOI 10.1096/fasebj.11.12.9337155
   DeFlora S, 1996, MUTAT RES-REV GENET, V366, P197, DOI 10.1016/S0165-1110(96)00043-7
   DEFLORA S, 1991, MUTAT RES, V258, P285, DOI 10.1016/0165-1110(91)90013-L
   Duthie G G, 1989, NUTR RES REV, V2, P51, DOI 10.1079/NRR19890007
   GAIROLA CG, 1991, ENVIRON MOL MUTAGEN, V17, P253, DOI 10.1002/em.2850170406
   GAUBATZ JW, 1986, J MOL CELL CARDIOL, V18, P1317, DOI 10.1016/S0022-2828(86)80435-7
   Godschalk R, 2003, FREE RADICAL RES, V37, P1299, DOI 10.1080/10715760310001621333
   GORDON D, 1990, P NATL ACAD SCI USA, V87, P4600, DOI 10.1073/pnas.87.12.4600
   GRAINGER DJ, 1993, SCIENCE, V260, P1655, DOI 10.1126/science.8503012
   HOGG SI, 1982, COMP BIOCHEM PHYS B, V73, P669, DOI 10.1016/0305-0491(82)90094-3
   Howard G, 1998, JAMA-J AM MED ASSOC, V279, P119, DOI 10.1001/jama.279.2.119
   IMAI H, 1980, SCIENCE, V207, P651, DOI 10.1126/science.7352277
   INDOLFI C, 1995, NAT MED, V1, P541, DOI 10.1038/nm0695-541
   IZZOTTI A, 1991, CARCINOGENESIS, V12, P1281, DOI 10.1093/carcin/12.7.1281
   Izzotti A, 2003, FASEB J, V17, P1127, DOI 10.1096/fj.02-0967fje
   Izzotti A, 1999, CARCINOGENESIS, V20, P1499, DOI 10.1093/carcin/20.8.1499
   Izzotti A, 1998, FASEB J, V12, P753, DOI 10.1096/fasebj.12.9.753
   Izzotti A, 2001, MUTAT RES-GEN TOX EN, V494, P97, DOI 10.1016/S1383-5718(01)00183-8
   Izzotti A, 2001, FASEB J, V15, P752, DOI 10.1096/fj.00-0312com
   Izzotti A, 2001, CANCER RES, V61, P2472
   IZZOTTI A, 1995, CANCER EPIDEM BIOMAR, V4, P105
   Izzotti A, 2007, MUTAT RES-FUND MOL M, V621, P119, DOI 10.1016/j.mrfmmm.2006.12.012
   Johnson CD, 2003, PHYSIOL GENOMICS, V13, P263, DOI 10.1152/physiolgenomics.00006.2003
   KANNEL WB, 1981, AM HEART J, V101, P319, DOI 10.1016/0002-8703(81)90197-6
   KENDALL CW, 1992, CANCER LETT, V66, P241, DOI 10.1016/0304-3835(92)90253-R
   Knaapen AM, 2007, MUTAT RES-FUND MOL M, V621, P31, DOI 10.1016/j.mrfmmm.2006.12.010
   Kris-Etherton PM, 2002, AM J MED, V113, P71, DOI 10.1016/S0002-9343(01)00995-0
   Lapenna D, 1998, CIRCULATION, V97, P1930, DOI 10.1161/01.CIR.97.19.1930
   LEWTAS J, 1993, ENV HLTH PERSPECT, V99, P88
   Li RL, 2001, ATHEROSCLEROSIS, V154, P729, DOI 10.1016/S0021-9150(00)00582-7
   Loeb LA, 2005, P NATL ACAD SCI USA, V102, P18769, DOI 10.1073/pnas.0509776102
   Lopez AD, 2000, ENCYCLOPEDIA OF EPIDEMIOLOGIC METHODS, V0, P617
   MAJESKY MW, 1985, P NATL ACAD SCI USA, V82, P3450, DOI 10.1073/pnas.82.10.3450
   Manfredi S, 2002, ENVIRON MOL MUTAGEN, V40, P110, DOI 10.1002/em.10098
   Manfredi S, 2007, MUTAT RES-FUND MOL M, V621, P106, DOI 10.1016/j.mrfmmm.2007.02.014
   Martinet W, 2002, CIRCULATION, V106, P927, DOI 10.1161/01.CIR.0000026393.47805.21
   Matturri L, 1997, CARDIOLOGIA, V42, P833
   MCMANUS BM, 1987, LAB INVEST, V57, P78
   Mercer J, 2007, MUTAT RES-FUND MOL M, V621, P75, DOI 10.1016/j.mrfmmm.2007.02.011
   Naira J, 2007, MUTAT RES-FUND MOL M, V621, P95, DOI 10.1016/j.mrfmmm.2007.02.013
   PAIGEN B, 1986, CANCER RES, V46, P3321
   PENG SK, 1978, ARCH PATHOL LAB MED, V102, P57
   PENN A, 1986, P NATL ACAD SCI USA, V83, P7951, DOI 10.1073/pnas.83.20.7951
   PENN A, 1988, CARCINOGENESIS, V9, P2185, DOI 10.1093/carcin/9.12.2185
   Peto R, 1997, BRIT MED J, V315, P1030, DOI 10.1136/bmj.315.7115.1030
   PUTNAM JB, 1991, ANN THORAC SURG, V51, P906, DOI 10.1016/0003-4975(91)91003-E
   RAMOS KS, 1996, CASARETT DOULLS TOXI, V0, P487
   RANDERATH E, 1989, JNCI-J NATL CANCER I, V81, P341, DOI 10.1093/jnci/81.5.341
   RANDERATH E, 1988, CARCINOGENESIS, V9, P75, DOI 10.1093/carcin/9.1.75
   RANDERATH E, 1986, CANCER RES, V46, P5869
   ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806
   ROSS R, 1993, AM J PATHOL, V143, P987
   Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207
   SADHU D, 1993, ANTIMUTAGENESIS ANTI, V0, P263
   Salama SA, 2002, ENVIRON MOL MUTAGEN, V40, P153, DOI 10.1002/em.10106
   SEVANIAN A, 1986, FOOD CHEM TOXICOL, V24, P1103, DOI 10.1016/0278-6915(86)90295-4
   Sorensen M, 2003, MUTAT RES-REV MUTAT, V544, P255, DOI 10.1016/j.mrrev.2003.06.010
   SPEIR E, 1994, SCIENCE, V265, P391, DOI 10.1126/science.8023160
   SUGIMURA T, 1986, SCIENCE, V233, P312, DOI 10.1126/science.3088728
   Thuillez C, 2005, J HUM HYPERTENS, V19, PS21, DOI 10.1038/sj.jhh.1001889
   TROSKO JE, 1980, MED HYPOTHESES, V6, P455, DOI 10.1016/0306-9877(80)90098-5
   VAN SF, 1998, FASEB J, V12, P1409
   VANNI R, 1991, DIS MARKERS, V9, P81
   Wilson MH, 2003, BIOMARKERS, V8, P43, DOI 10.1080/1354750021000042439
   Wilson MH, 2000, FASEB J, V14, P791, DOI 10.1096/fasebj.14.5.791
   YOSHIDA Y, 1990, ANN NY ACAD SCI, V598, P256, DOI 10.1111/j.1749-6632.1990.tb42298.x
   Zhang YJ, 1998, ATHEROSCLEROSIS, V140, P325, DOI 10.1016/S0021-9150(98)00136-1
   ZWIJSEN RML, 1990, ATHEROSCLEROSIS, V85, P71, DOI 10.1016/0021-9150(90)90184-K
   ZWIJSEN RML, 1992, CARCINOGENESIS, V13, P1913, DOI 10.1093/carcin/13.10.1913
NR 89
TC 56
Z9 65
U1 0
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0027-5107
EI 1873-135X
J9 MUTAT RES-FUND MOL M
JI Mutat. Res.-Fundam. Mol. Mech. Mutagen.
PD AUG 1
PY 2007
VL 621
IS 1-2
BP 5
EP 17
DI 10.1016/j.mrfmmm.2006.12.008
PG 13
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology
GA 199SA
UT WOS:000248714300002
PM 17383689
DA 2024-11-01
ER

PT J
AU Baruffini, E
   Ferrero, I
   Foury, F
AF Baruffini, Enrico
   Ferrero, Iliana
   Foury, Francoise
TI Mitochondrial DNA defects in <i>Saccharomyces cerevisiae</i> caused by functional interactions between DNA polymerase gamma mutations associated with disease in human
SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
LA English
DT Article
DE POLG; mutation; disease; yeast; mip1 mutant; mtDNA
ID progressive external ophthalmoplegia; polg mutations; alpers-syndrome; gene; mtdna; disorders; mutants; family; ataxia; chain
AB The yeast mitochondrial DNA (mtDNA) replicase Mip1 has been used as a model to generate five mutations equivalent to POLG mutations associated with a broad spectrum of diseases in human. All mip1 mutations, alone or in combination in cis or in trans, increase mtDNA instability as measured by petite frequency and Ery(R) mutant accumulation. This phenotype is associated with decreased Mip1 levels in mitochondrial extracts and/or decreased polymerase activity. We have demonstrated that (1) in the mip1(G651S) (hG848S) mutant the high mtDNA instability and increased frequency of point Ery(R) mutations is associated with low Mip1 levels and polymerase activity; (2) in the mip1(A692T-E900G) (hA889T-hE1143G) mutant, A692T is the major contributor to mtDNA instability by decreasing polymerase activity, and E900G acts synergistically by decreasing Mip1 levels; (3) in the mip1(H734Y)/mip1(G807R) (hH932Y/hG1051R) mutant, H734Y is the most deleterious mutation and acts synergistically with G807R as a result of its dominant character; (4) the mip1(E900G) (h1143G) mutation is not neutral but results in a temperature-sensitive phenotype associated with decreased Mip1 levels, a property explaining its synergistic effect with mutations impairing the polymerase activity. Thus, the human E1143G mutation is not a true polymorphism. (c) 2007 Elsevier B.V. All rights reserved.
C1 [Baruffini, Enrico; Foury, Francoise] Catholic Univ Louvain, Inst Sci Vie, B-1348 Louvain, Belgium.
   [Baruffini, Enrico; Ferrero, Iliana] Univ Parma, Dept Genet, I-43100 Parma, Italy.
C3 Universite Catholique Louvain; University of Parma
RP Foury, F (corresponding author), Catholic Univ Louvain, Inst Sci Vie, B-1348 Louvain, Belgium.
EM foury@fysa.ucl.ac.be
CR Baruffini E, 2007, GENETICS, V177, P1227, DOI 10.1534/genetics.107.079293
   Baruffini E, 2006, HUM MOL GENET, V15, P2846, DOI 10.1093/hmg/ddl219
   BONNEAUD N, 1991, YEAST, V7, P609, DOI 10.1002/yea.320070609
   Chan SSL, 2006, HUM MOL GENET, V15, P3473, DOI 10.1093/hmg/ddl424
   Davidzon G, 2005, ANN NEUROL, V57, P921, DOI 10.1002/ana.20498
   Di Fonzo A, 2003, HUM MUTAT, V22, P0, DOI 10.1002/humu.9203
   DUJON B, 1900, P505, V0, P0
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279
   FOURY F, 1992, EMBO J, V11, P2717, DOI 10.1002/j.1460-2075.1992.tb05337.x
   Hisama FM, 2005, AM J MED GENET A, V135A, P217, DOI 10.1002/ajmg.a.30672
   HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Hudson G, 2006, HUM MOL GENET, V15, PR244, DOI 10.1093/hmg/ddl233
   Kaguni LS, 2004, ANNU REV BIOCHEM, V73, P293, DOI 10.1146/annurev.biochem.72.121801.161455
   Kaiser C, 1994, METHODS YEAST GENETI, V0, P0
   Kollberg G, 2005, EUR J HUM GENET, V13, P463, DOI 10.1038/sj.ejhg.5201341
   Kollberg G, 2006, J NEUROPATH EXP NEUR, V65, P758, DOI 10.1097/01.jnen.0000229987.17548.6e
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   LECRENIER N, 1995, MOL GEN GENET, V249, P1, DOI 10.1007/BF00290229
   Longley MJ, 2005, GENE, V354, P125, DOI 10.1016/j.gene.2005.03.029
   Mancuso M, 2004, NEUROLOGY, V62, P316, DOI 10.1212/WNL.62.2.316
   MATHEWS S, 1977, PREFERENTIAL LOSS RE, V0, P133
   Nguyen KV, 2005, NEUROLOGY, V65, P1493, DOI 10.1212/01.wnl.0000182814.55361.70
   Ponamarev MV, 2002, J BIOL CHEM, V277, P15225, DOI 10.1074/jbc.C200100200
   SLONIMSKI PP, 1976, EUR J BIOCHEM, V61, P27, DOI 10.1111/j.1432-1033.1976.tb09994.x
   SOR F, 1984, NUCLEIC ACIDS RES, V12, P8313, DOI 10.1093/nar/12.22.8313
   Stuart GR, 2006, HUM MOL GENET, V15, P363, DOI 10.1093/hmg/ddi454
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   TZAGOLOFF A, 1975, J BIOL CHEM, V250, P8236
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Wanrooij S, 2004, NUCLEIC ACIDS RES, V32, P3053, DOI 10.1093/nar/gkh634
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
   Yakubovskaya E, 2006, J BIOL CHEM, V281, P374, DOI 10.1074/jbc.M509730200
NR 35
TC 43
Z9 51
U1 0
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0925-4439
EI 
J9 BBA-MOL BASIS DIS
JI Biochim. Biophys. Acta-Mol. Basis Dis.
PD DEC 15
PY 2007
VL 1772
IS 11-12
BP 1225
EP 1235
DI 10.1016/j.bbadis.2007.10.002
PG 11
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 249OR
UT WOS:000252238800005
PM 17980715
DA 2024-11-01
ER

PT J
AU Cardaioli, E
   Da Pozzo, P
   Gallus, GN
   Malandrini, A
   Gambelli, S
   Gaudiano, C
   Malfatti, E
   Viscomi, C
   Zicari, E
   Berti, G
   Serni, G
   Dotti, MT
   Federico, A
AF Cardaioli, Elena
   Da Pozzo, Paola
   Gallus, Gian Nicola
   Malandrini, Alessandro
   Gambelli, Simona
   Gaudiano, Carnien
   Malfatti, Edoardo
   Viscomi, Carlo
   Zicari, Enza
   Berti, Gianna
   Serni, Giovanni
   Dotti, Maria Teresa
   Federico, Antonio
TI A novel heteroplasmic tRNA<SUP>Ser(UCN)</SUP> mtDNA point mutation associated with progressive external ophthalmoplegia and hearing loss
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE progressive external ophthalmoplegia; mitochondrial DNA; tRNA(Ser(UCN))
ID a3243g mutation; mitochondrial; deletions; gene
AB We sequenced all mitochondrial tRNA genes from a patient with sporadic external ophthalmoplegia (PEO) and 5% COX-negative fibers in muscle biopsy, who had no detectable large mtDNA deletions. Direct sequencing showed a heteroplasmic mutation at nucleotide 7506 in the dihydrouridine stem of the tRNA(Ser(UCN)) gene. RFLP analysis confirmed that 30% of muscle and 20% of urinary epithelium mtDNA harbored the mutation, which was absent in other tissues of the proband as well as in mtDNA of his mother and 100 patients with various encephalomyopathies. Several point mutations on mitochondrial tRNA genes have been reported in PEO patients without large-scale rearrangements of mtDNA but no point mutations have hitherto been found in the gene coding for tRNA(Ser(UCN)) . (C) 2007 Elsevier B.V. All rights reserved.
C1 [Cardaioli, Elena; Da Pozzo, Paola; Gallus, Gian Nicola; Malandrini, Alessandro; Gambelli, Simona; Gaudiano, Carnien; Malfatti, Edoardo; Zicari, Enza; Berti, Gianna; Serni, Giovanni; Dotti, Maria Teresa; Federico, Antonio] Univ Siena, Dept Neurol & Behav Sci, I-53100 Siena, Italy.
   [Viscomi, Carlo] Natl Inst Neurol C Besta, Unit Mol Neurogenet, I-20126 Milan, Italy.
C3 University of Siena
RP Federico, A (corresponding author), Univ Siena, Dept Neurol & Behav Sci, Via Bracci 2, I-53100 Siena, Italy.
EM federico@unisi.it
CR Bidooki S, 2004, NEUROMUSCULAR DISORD, V14, P417, DOI 10.1016/j.nmd.2004.03.004
   Cardaioli E, 2005, BIOCHEM BIOPH RES CO, V327, P675, DOI 10.1016/j.bbrc.2004.11.170
   Chinnery PF, 2000, ANN NEUROL, V47, P381, DOI 10.1002/1531-8249(200003)47:3<381::AID-ANA17>3.0.CO;2-2
   EDQVIST J, 1993, NUCLEIC ACIDS RES, V21, P413, DOI 10.1093/nar/21.3.413
   Koga Y, 2000, ARCH DIS CHILD, V82, P407, DOI 10.1136/adc.82.5.407
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   PUGLISI JD, 1993, NUCLEIC ACIDS RES, V21, P41, DOI 10.1093/nar/21.1.41
   ZEVIANI M, 1990, AM J HUM GENET, V47, P904
NR 8
TC 13
Z9 15
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD OCT 15
PY 2007
VL 17
IS 9-10
BP 681
EP 683
DI 10.1016/j.nmd.2007.05.001
PG 3
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 221WL
UT WOS:000250258000005
PM 17614276
DA 2024-11-01
ER

PT J
AU Prigione, A
   Cortopassi, G
AF Prigione, Alessandro
   Cortopassi, Gino
TI Mitochondrial DNA deletions induce the adenosine monophosphate-activated protein kinase energy stress pathway and result in decreased secretion of some proteins
SO AGING CELL
LA English
DT Article
DE AMPK; ATP synthesis; deletions; mitochondria; secretion
ID substantia-nigra neurons; adp-ribosylation factor; human skeletal-muscle; kearns-sayre syndrome; gene-expression; human brain; disease; cells; age; differentiation
AB Mitochondrial DNA (mtDNA) deletions occur sporadically in zygotic and somatic tissues and reach their highest concentration in substantia nigra. Previously, we noted the increase of the adenosine monophosphate (AMP)-activated protein kinase (AMPK) transcript by microarray in multiple cells and tissues bearing deletions. In this work, we demonstrate that the induction of AMPK transcript is dependent on deletions by quantitative polymerase chain reaction, and also demonstrate a deficiency in adenosine triphosphate (ATP) synthesis in the same cells. Consistent with AMPK induction, its known targets SREBF1 (sterol regulatory element binding protein-1) and ATG12 were inhibited and induced, respectively. AMPK induction is known to decrease secretory processes in some cells, and the secretion of both osteoprotegerin (OPG) and fibronectin (FN) proteins to the extracellular space was significantly deficient. Deletions caused a defect in the adenosine diphosphate (ADP)-ribosylation factor-like 2 (ARL2) transcript, which is known to be important in secretion and interacts with protein phosphatase 2A (PP2A) and thus AMPK. The deletion-dependent dysfunctions occurred even in cells bearing less than 30% deletions, suggesting that the concept of a high biological 'threshold' for deletions should be further revised downward. The defects in ATP synthesis, induction of the AMPK and SREBF1 transcripts, and decreased expression of ARL2 and secretion of OPG and FN were recapitulated by low doses of rotenone, demonstrating that they were a specific consequence of electron transport chain inhibition. Thus, mtDNA deletions result in cellular energy depletion, which causes the induction of AMPK and its regulated targets, and inhibit secretion of some proteins. We integrate these observations into a pathophysiological model for how mitochondrial deletions cause disease.
C1 Univ Calif Davis, Dept Mol Biosci, Davis, CA 95616 USA.
   Univ Milano Bicocca, Dept Neurosci & Biomed Technol, Monza, Italy.
C3 University of California System; University of California Davis; University of Milano-Bicocca
RP Cortopassi, G (corresponding author), Univ Calif Davis, Dept Mol Biosci, 1311 Haring Hall, Davis, CA 95616 USA.
EM gcortopassi@ucdavis.edu
FU NEI NIH HHS [EY12245] Funding Source: Medline; NIA NIH HHS [AG16719, AG11967] Funding Source: Medline; NIEHS NIH HHS [5P30ES005707] Funding Source: Medline
CR Alemi M, 2007, FREE RADICAL BIO MED, V42, P32, DOI 10.1016/j.freeradbiomed.2006.09.014
   BALCH WE, 1992, J BIOL CHEM, V267, P13053
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Bolster DR, 2002, J BIOL CHEM, V277, P23977, DOI 10.1074/jbc.C200171200
   Bua E, 2006, AM J HUM GENET, V79, P469, DOI 10.1086/507132
   CARLING D, 1987, FEBS LETT, V223, P217, DOI 10.1016/0014-5793(87)80292-2
   CORMIER V, 1990, J PEDIATR-US, V117, P599, DOI 10.1016/S0022-3476(05)80698-5
   CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324
   CORTOPASSI GA, 1992, P NATL ACAD SCI USA, V89, P7370, DOI 10.1073/pnas.89.16.7370
   CORTOPASSI GA, 1990, NUCLEIC ACIDS RES, V18, P6927, DOI 10.1093/nar/18.23.6927
   Cortopassi G, 2006, MITOCHONDRION, V6, P161, DOI 10.1016/j.mito.2006.05.002
   Danielson SR, 2002, J BIOL CHEM, V277, P5810, DOI 10.1074/jbc.M110119200
   Daval M, 2006, J PHYSIOL-LONDON, V574, P55, DOI 10.1113/jphysiol.2006.111484
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Gimeno-Alcañiz JV, 2003, J MOL BIOL, V333, P201, DOI 10.1016/j.jmb.2003.08.022
   Hardie DG, 2004, J CELL SCI, V117, P5479, DOI 10.1242/jcs.01540
   HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   John CE, 2006, NEUROCHEM INT, V49, P737, DOI 10.1016/j.neuint.2006.06.004
   Jou MJ, 2005, ANN NY ACAD SCI, V1042, P221, DOI 10.1196/annals.1338.024
   Kopsidas G, 1998, MUTAT RES-FUND MOL M, V421, P27, DOI 10.1016/S0027-5107(98)00150-X
   Kraytsberg Y, 2006, NAT GENET, V38, P518, DOI 10.1038/ng1778
   Lindsley JE, 2004, COMP BIOCHEM PHYS B, V139, P543, DOI 10.1016/j.cbpc.2004.06.014
   Long YC, 2006, J CLIN INVEST, V116, P1776, DOI 10.1172/JCI29044
   Lu CY, 1999, MUTAT RES-FUND MOL M, V423, P11, DOI 10.1016/S0027-5107(98)00220-6
   McFarland R, 2002, LANCET NEUROL, V1, P343, DOI 10.1016/S1474-4422(02)00159-X
   MITA S, 1989, P NATL ACAD SCI USA, V86, P9509, DOI 10.1073/pnas.86.23.9509
   Mizushima N, 2003, INT J BIOCHEM CELL B, V35, P553, DOI 10.1016/S1357-2725(02)00343-6
   MORAES CT, 1995, MUSCLE NERVE, V0, PS150
   Nakamura MT, 2004, LIPIDS, V39, P1077, DOI 10.1007/s11745-004-1333-0
   NAKASE H, 1990, AM J HUM GENET, V46, P418
   Papiha SS, 1998, J CLIN PATHOL, V51, P117, DOI 10.1136/jcp.51.2.117
   Porteous WK, 1998, EUR J BIOCHEM, V257, P192, DOI 10.1046/j.1432-1327.1998.2570192.x
   Roodman GD, 2006, ANN NY ACAD SCI, V1068, P100, DOI 10.1196/annals.1346.013
   Schapira AHV, 2006, LANCET, V368, P70, DOI 10.1016/S0140-6736(06)68970-8
   Schoeler S, 2005, BIOCHEM BIOPH RES CO, V332, P43, DOI 10.1016/j.bbrc.2005.04.086
   SCHON EA, 1989, SCIENCE, V244, P346, DOI 10.1126/science.2711184
   Sharer JD, 2002, MOL BIOL CELL, V13, P71, DOI 10.1091/mbc.01-05-0245
   Shern JF, 2003, J BIOL CHEM, V278, P40829, DOI 10.1074/jbc.M308678200
   Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408
   SOONG NW, 1992, NAT GENET, V2, P318
   Tsuboi T, 2003, J BIOL CHEM, V278, P52042, DOI 10.1074/jbc.M307800200
   Vitale N, 2002, J CELL BIOL, V159, P79, DOI 10.1083/jcb.200203027
   Wierzbicka-Patynowski I, 2003, J CELL SCI, V116, P3269, DOI 10.1242/jcs.00670
   Wong A, 2002, HUM MOL GENET, V11, P431, DOI 10.1093/hmg/11.4.431
   Xavier GD, 2003, BIOCHEM J, V371, P761
NR 46
TC 19
Z9 19
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1474-9726
EI 
J9 AGING CELL
JI Aging Cell
PD OCT 15
PY 2007
VL 6
IS 5
BP 619
EP 630
DI 10.1111/j.1474-9726.2007.00323.x
PG 12
WC Cell Biology; Geriatrics & Gerontology
SC Cell Biology; Geriatrics & Gerontology
GA 210TZ
UT WOS:000249479800004
PM 17651460
DA 2024-11-01
ER

PT J
AU Alberio, S
   Mineri, R
   Tiranti, V
   Zeviani, M
AF Alberio, Simona
   Mineri, Rossana
   Tiranti, Valeria
   Zeviani, Massimo
TI Depletion of mtDNA: Syndromes and genes
SO MITOCHONDRION
LA English
DT Review
DE mtDNA depletion; OXPHOS; tissue specificity
ID mitochondrial-dna depletion; nucleoside-diphosphate kinase; thymidine kinase; polg mutations; deoxyguanosine kinase; myopathy; localization; disorders
AB Maintenance of mitochondrial DNA (mtDNA) requires the concerted activity of several nuclear-encoded factors that participate in its replication, being part of the mitochondrial replisome or ensuring the balanced supply of dNTPs to mitochondria. In the past decade, a growing number of syndromes associated with dysfunction due to tissue-specific depletion of mtDNA (MDS) have been reported. This article reviews the current knowledge of the genes responsible for these disorders, the impact of different mutations in the epidemiology of MDS and their role in the pathogenic mechanisms underlying the different clinical presentations. (c) 2006 Elsevier B.V. and Mitochondria Research Society. All rights reserved.
EM zeviani@fastwebnet.it
FU Telethon [GGP030039] Funding Source: Medline
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   BOGENHAGEN D, 1976, J BIOL CHEM, V251, P2938
   Calvo S, 2006, NAT GENET, V38, P576, DOI 10.1038/ng1776
   Carrozzo R, 2003, HUM MUTAT, V21, P0, DOI 10.1002/humu.9135
   Chan SSL, 2005, J BIOL CHEM, V280, P31341, DOI 10.1074/jbc.M506762200
   Davidzon G, 2005, ANN NEUROL, V57, P921, DOI 10.1002/ana.20498
   Ducluzeau PH, 1999, J HEPATOL, V30, P149, DOI 10.1016/S0168-8278(99)80019-1
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Elpeleg O, 2003, PEDIATR RES, V54, P153, DOI 10.1203/01.PDR.0000072796.25097.A5
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Galbiati S, 2006, PEDIATR NEUROL, V34, P177, DOI 10.1016/j.pediatrneurol.2005.07.013
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Johansson M, 1997, J BIOL CHEM, V272, P8454, DOI 10.1074/jbc.272.13.8454
   KADRMAS EF, 1991, BIOCHIM BIOPHYS ACTA, V1074, P339, DOI 10.1016/0304-4165(91)90083-S
   KAVANAUGHBLACK A, 1994, P NATL ACAD SCI USA, V91, P5883, DOI 10.1073/pnas.91.13.5883
   Kowluru A, 2002, ARCH BIOCHEM BIOPHYS, V398, P160, DOI 10.1006/abbi.2001.2710
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Mancuso M, 2003, ARCH NEUROL-CHICAGO, V60, P1007, DOI 10.1001/archneur.60.7.1007
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   MAZZIOTTA MRM, 1992, J PEDIATR-US, V121, P896, DOI 10.1016/S0022-3476(05)80335-X
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Naviaux RK, 2005, ANN NEUROL, V58, P491, DOI 10.1002/ana.20544
   Nguyen KV, 2005, NEUROLOGY, V65, P1493, DOI 10.1212/01.wnl.0000182814.55361.70
   NGUYEN KV, 2006, J HEPATOL, V0, P0
   PARKS RE, 1973, COMP BIOCHEM PHYSIOL, V45, P355, DOI 10.1016/0305-0491(73)90070-9
   Saada A, 2004, DNA CELL BIOL, V23, P797
   Saada A, 2003, MOL GENET METAB, V79, P1, DOI 10.1016/S1096-7192(03)00063-5
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Salviati L, 2002, ANN NEUROL, V52, P311, DOI 10.1002/ana.10284
   Slama A, 2005, MOL GENET METAB, V86, P462, DOI 10.1016/j.ymgme.2005.09.006
   Taanman JW, 2002, ANN NEUROL, V52, P237, DOI 10.1002/ana.10247
   Tadiboyina VT, 2005, AM J MED GENET A, V135A, P289, DOI 10.1002/ajmg.a.30748
   TRITSCHLER HJ, 1992, NEUROLOGY, V42, P209, DOI 10.1212/WNL.42.1.209
   Tzoulis C, 2006, BRAIN, V129, P1685, DOI 10.1093/brain/awl097
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Vilà MR, 2003, NEUROLOGY, V60, P1203, DOI 10.1212/01.WNL.0000055928.58122.47
   Vu TH, 1998, NEUROLOGY, V50, P1783, DOI 10.1212/WNL.50.6.1783
   Wang LY, 2005, MOL GENET METAB, V84, P75, DOI 10.1016/j.ymgme.2004.09.005
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
   Yang MY, 2002, CELL, V111, P495, DOI 10.1016/S0092-8674(02)01075-9
   ZWACKA RM, 1994, EMBO J, V13, P5129, DOI 10.1002/j.1460-2075.1994.tb06842.x
NR 45
TC 76
Z9 84
U1 1
U2 9
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
EI 1872-8278
J9 MITOCHONDRION
JI Mitochondrion
PD FEB-APR 15
PY 2007
VL 7
IS 1-2
BP 6
EP 12
DI 10.1016/j.mito.2006.11.010
PG 7
WC Cell Biology; Genetics & Heredity
SC Cell Biology; Genetics & Heredity
GA 157EM
UT WOS:000245701400002
PM 17280874
DA 2024-11-01
ER

PT J
AU Coté, HC
   Day, AG
   Heyland, DK
AF Coté, Hélène C. F.
   Day, Andrew G.
   Heyland, Daren K.
TI Longitudinal increases in mitochondrial DNA levels in blood cells are associated with survival in critically ill patients
SO CRITICAL CARE
LA English
DT Article
ID systemic inflammation; damage; dysfunction; severity; muscle; toll-like-receptor-4; depletion; skeletal; insulin; sepsis
AB Background Mitochondrial dysfunction may be causally related to the pathogenesis of organ failure in critically ill patients. Decreased mitochondrial DNA (mtDNA) levels have been associated with mitochondrial dysfunction and were investigated here in relation to short-term (31-day) survival. Methods This was a prospective longitudinal cohort study of 28 mechanically ventilated critically ill adults admitted to a single center tertiary care intensive care unit (ICU) with hypotension secondary to cardiogenic (N = 13), septic (N = 14) or hypovolemic (N = 1) disease processes. Clinical data and blood were collected at baseline and patients were followed until they expired or left the ICU. Blood was collected every Monday, Wednesday and Friday, and the buffycoat relative mtDNA/ nuclear DNA (nDNA) ratio was determined. An archived pool of healthy controls was also studied. Results At baseline, the patients' mtDNA/nDNA ratio was 30% lower than a pool of 24 healthy controls (0.76 versus 1.09) and was not different between short-term survivors and non-survivors (0.74 +/- 0.05 (N = 16) versus 0.79 +/- 0.06 (N = 12), p = 0.49). By day 4, the percent mtDNA/nDNA change from baseline in survivors was significantly different from that in non-survivors (+ 29.5% versus -5.7%, p = 0.03). It also tended to be higher in survivors at last measurement (+ 38.4% versus + 7.1%, p = 0.06). There was a weak correlation between within patient mtDNA/nDNA and platelet count (r = 0.20, p = 0.03) but not with Sequential Organ Failure Assessment (SOFA) scores (r = 0.12, p = 0.23). The mtDNA associations remained after adjustment for platelet. Conclusion Blood mtDNA levels appeared initially low, increased over time in patients who ultimately survived, and remained low in those who did not. This is consistent with mitochondrial recovery being associated with survival and warrants further investigation as a marker of mitochondrial alterations and outcome in critical illness.
C1 Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V6T 2B5, Canada.
   Kingston Gen Hosp, Clin Res Ctr, Crit Care Program, Kingston, ON K7L 2V7, Canada.
   Queens Univ, Dept Med, Kingston, ON K7L 2V7, Canada.
C3 University of British Columbia; Queens University - Canada; Queens University - Canada
RP Coté, HC (corresponding author), Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V6T 2B5, Canada.
EM helene.cote@ubc.ca
CR Banas B, 2004, EUR J MED RES, V9, P371
   Brealey David, 2002, LANCET (NORTH AMERICAN EDITION), V360, P219, DOI 10.1016/S0140-6736(02)09459-X
   Brealey David, 2003, CURR INFECT DIS REP, V5, P365, DOI 10.1007/s11908-003-0015-9
   BRODER G, 1964, SCIENCE, V143, P1457, DOI 10.1126/science.143.3613.1457
   Calvano SE, 2005, NATURE, V437, P1032, DOI 10.1038/nature03985
   Côté HCF, 2003, J INFECT DIS, V187, P1972, DOI 10.1086/375353
   Coté HCF, 2002, NEW ENGL J MED, V346, P811, DOI 10.1056/NEJMoa012035
   Crouser ED, 2004, MITOCHONDRION, V4, P729, DOI 10.1016/j.mito.2004.07.023
   Crouser ED, 2002, CRIT CARE MED, V30, P276, DOI 10.1097/00003246-200202000-00002
   Crouser ED, 1999, AM J RESP CRIT CARE, V160, P1347, DOI 10.1164/ajrccm.160.4.9810116
   Crouser ED, 2006, CRIT CARE MED, V34, P2439, DOI 10.1097/01.CCM.0000230240.02216.21
   Davies NA, 2003, ADV EXP MED BIOL, V530, P725
   Fink MP, 2002, CRIT CARE CLIN, V18, P165, DOI 10.1016/S0749-0704(03)00071-X
   Fredriksson K, 2006, AM J PHYSIOL-ENDOC M, V291, PE1044, DOI 10.1152/ajpendo.00218.2006
   Gonzalez PK, 1996, SHOCK, V6, PS23, DOI 10.1097/00024382-199610001-00006
   Hang Tao, 2006, ZHONGGUO WEI ZHONG BING JI JIU YI XUE, V18, P554
   HAYES MA, 1994, NEW ENGL J MED, V330, P1717, DOI 10.1056/NEJM199406163302404
   Heyland DK, 2007, JPEN-PARENTER ENTER, V31, P109, DOI 10.1177/0148607107031002109
   Heyland DK, 2005, INTENS CARE MED, V31, P327, DOI 10.1007/s00134-004-2522-z
   Hsieh YC, 2007, J CELL PHYSIOL, V211, P364, DOI 10.1002/jcp.20943
   KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009
   Lyamzaev KG, 2004, BIOCHEM SOC T, V32, P1070, DOI 10.1042/BST0321070
   Miller FJ, 2003, NUCLEIC ACIDS RES, V31, P0, DOI 10.1093/nar/gng060
   Mollen KP, 2006, SHOCK, V26, P430, DOI 10.1097/01.shk.0000228797.41044.08
   Moreno R, 1999, INTENS CARE MED, V25, P686, DOI 10.1007/s001340050931
   Prince JM, 2006, J AM COLL SURGEONS, V202, P407, DOI 10.1016/j.jamcollsurg.2005.11.021
   *SAS I INC, 1999, SAS STAT US GUID VER, V0, P2083
   Short KR, 2005, P NATL ACAD SCI USA, V102, P5618, DOI 10.1073/pnas.0501559102
   SHUSTER RC, 1988, BIOCHEM BIOPH RES CO, V155, P1360, DOI 10.1016/S0006-291X(88)81291-9
   Skulachev VP, 2002, ANN NY ACAD SCI, V959, P214, DOI 10.1111/j.1749-6632.2002.tb02095.x
   Suliman HB, 2005, FASEB J, V19, P1531, DOI 10.1096/fj.04-3500fje
   Suliman HB, 2003, AM J RESP CRIT CARE, V167, P570, DOI 10.1164/rccm.200206-518OC
   Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300
   Vanhorebeek I, 2005, LANCET, V365, P53, DOI 10.1016/S0140-6736(04)17665-4
   Watts JA, 2004, J MOL CELL CARDIOL, V36, P141, DOI 10.1016/j.yjmcc.2003.10.015
   Xue L, 2001, CURR BIOL, V11, P361, DOI 10.1016/S0960-9822(01)00100-2
NR 36
TC 20
Z9 20
U1 0
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1364-8535
EI 1466-609X
J9 CRIT CARE
JI Crit. Care
PD JUN 15
PY 2007
VL 11
IS 4
BP 
EP 
DI 10.1186/cc6096
PG 8
WC Critical Care Medicine
SC General & Internal Medicine
GA 224TJ
UT WOS:000250469000017
PM 17697385
DA 2024-11-01
ER

PT J
AU Sproule, DM
   Kaufmann, P
   Engelstad, K
   Starc, TJ
   Hordof, AJ
   De Vivo, DC
AF Sproule, Douglas M.
   Kaufmann, Petra
   Engelstad, Kristen
   Starc, Thomas J.
   Hordof, Allan J.
   De Vivo, Darryl C.
TI Wolff-Parkinson-White syndrome in patients with MELAS
SO ARCHIVES OF NEUROLOGY
LA English
DT Article
ID stroke-like episodes; lactic-acidosis; mitochondrial myopathy; encephalopathy; encephalomyopathy; gene
AB Background: Tissues with high energy demands, such as the heart, are susceptible to the effects of mitochondrial DNA point mutations. Objective: To investigate the frequency of Wolff-Parkinson-White (WPW) syndrome among a phenotypically and genotypically homogeneous cohort of patients with MELAS (mitochondrial encephalopathy, lactic acidosis, and strokelike episodes) and the A3243G mutation most commonly associated with MELAS syndrome. Design: Survey. Setting: The Pediatric Neuromuscular Disease Center at Columbia University. Patients: Thirty patients with the A3243G mutation and MELAS syndrome enrolled in a clinical trial to assess the effect of dichloroacetate on neurologic symptoms. Interventions: Medical histories and electrocardiograms were reviewed and DNA samples from fibroblasts, urine and cheek epithelial cells, leukocytes, and hair were analyzed to determine mitochondrial mutation abundance and estimate total mutation burden. Results: Four of 30 patients (13%) had a clinical history of, or electrocardiographic findings consistent with, WPW syndrome. In 2 patients, WPW syndrome preceded MELAS syndrome by 15 and 21 years. The tissue burden of mutant mitochondria was similar in patients with (49.4%) and without (39.1%) WPW syndrome. Conclusions: The prevalence of WPW syndrome among patients with MELAS syndrome and the A3243G mutation appears much higher than in the normal population and may become manifest earlier than neurologic symptoms. Patients with WPW syndrome and neurologic abnormalities consistent with MELAS syndrome, such as seizures, deafness, short stature, and stroke, should be screened for the A3243G mutation. Moreover, patients with MELAS syndrome should be monitored for cardiac anomalies including cardiomyopathy and WPW syndrome.
C1 Columbia Univ, Dept Neurol, Div Pediat Neurol, New York, NY USA.
   Columbia Univ, Dept Pediat, New York, NY 10027 USA.
   Childrens Hosp New York, Dept Pediat, Div Pediat Cardiol, New York, NY USA.
C3 Columbia University; Columbia University
RP De Vivo, DC (corresponding author), Neurol Inst, 710 W 168th St,Room 2-201, New York, NY 10032 USA.
FU NCRR NIH HHS [K12 RR017648] Funding Source: Medline; NICHD NIH HHS [P01-HD32062] Funding Source: Medline
CR Gollob MH, 2001, NEW ENGL J MED, V344, P1823, DOI 10.1056/NEJM200106143442403
   Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x
   HIRANO M, 1992, NEUROMUSCULAR DISORD, V2, P125, DOI 10.1016/0960-8966(92)90045-8
   Kaufmann P, 2006, NEUROLOGY, V66, P324, DOI 10.1212/01.wnl.0000196641.05913.27
   Kaufmann P, 1996, ANN NEUROL, V40, P172, DOI 10.1002/ana.410400208
   KOBAYASHI Y, 1991, AM J HUM GENET, V49, P590
   Okajima Y, 1998, HEART, V80, P292, DOI 10.1136/hrt.80.3.292
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   SATO W, 1994, AM HEART J, V128, P733, DOI 10.1016/0002-8703(94)90272-0
   YONEDA M, 1989, J NEUROL SCI, V92, P143, DOI 10.1016/0022-510X(89)90132-9
NR 10
TC 49
Z9 61
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0003-9942
EI 
J9 ARCH NEUROL-CHICAGO
JI Arch. Neurol.
PD NOV 15
PY 2007
VL 64
IS 11
BP 1625
EP 1627
DI 10.1001/archneur.64.11.1625
PG 3
WC Clinical Neurology
SC Neurosciences & Neurology
GA 229YZ
UT WOS:000250843800009
PM 17998445
DA 2024-11-01
ER

PT J
AU Meulemans, A
   De Paepe, B
   De Bleecker, J
   Smet, J
   Lissens, W
   Van Coster, R
   De Meirleir, L
   Seneca, S
AF Meulemans, Ann
   De Paepe, Boel
   De Bleecker, Jan
   Smet, Joel
   Lissens, Willy
   Van Coster, Rudy
   De Meirleir, Linda
   Seneca, Sara
TI Two novel mitochondrial DNA mutations in muscle tissue of a patient with limb-girdle myopathy
SO ARCHIVES OF NEUROLOGY
LA English
DT Article
ID trna(tyr) gene; complex-i; sequence; deletion
AB Background: Defects in the oxidative phosphorylation system can cause a broad spectrum of clinical symptoms ranging from an isolated myopathy to a multisystemic disorder. Objective: To study and identify the underlying molecular defect in a patient with limb-girdle myopathy. Design: Biochemical, histochemical, and immunocytochemical analyses were performed in combination with polymerase chain reaction-single-strand conformation polymorphism and restriction fragment length polymorphism-polymerase chain reaction techniques. Setting: University hospital. Patient: A48-year-old woman with limb-girdle myopathy. Main Outcome Measures: The pathogenic characteristics of the identified nucleotide alterations were defined using single-muscle fiber analysis. Results: A complex III deficiency was detected using blue native-polyacrylamide gel electrophoresis, while immunocytochemical results showed a mosaic staining pattern for complexes I and IV. After molecular analyses, 2 novel heteroplasmic mitochondrial DNA ( mtDNA) nucleotide aberrations, m. 5888insA and m. 14639A > G, were identified in muscle tissue. Single-muscle fiber analyses demonstrated that cytochrome c oxidase-deficient fibers, compared with cytochrome c oxidase-positive fibers, harbored statistically significantly higher levels of both mtDNA mutations ( P < .001, t test). Conclusions: These results, together with previously defined canonical criteria determining the pathogenic characteristics of mtDNA mutations, suggest that both nucleotide changes are pathogenic mutations. To our knowledge, this is only the third report of the coexistence of 2 pathogenic mtDNA mutations present in different genes within individual skeletal muscle fibers of a patient.
C1 Vrije Univ Brussels, Ctr Med Genet, B-1090 Brussels, Belgium.
   Vrije Univ Brussels, Univ Ziekenhous Brussel, Dept Pediat Neurol, B-1090 Brussels, Belgium.
   State Univ Ghent Hosp, Dept Neurol, B-9000 Ghent, Belgium.
   State Univ Ghent Hosp, Dept Pediat Neurol, B-9000 Ghent, Belgium.
   State Univ Ghent Hosp, Metab Serv, B-9000 Ghent, Belgium.
C3 Vrije Universiteit Brussel; University Hospital Brussels; Vrije Universiteit Brussel; Ghent University; Ghent University Hospital; Ghent University; Ghent University Hospital; Ghent University; Ghent University Hospital
RP Seneca, S (corresponding author), Vrije Univ Brussels, Ctr Med Genet, Laarbeeklaan 101, B-1090 Brussels, Belgium.
EM lgensas@az.vub.ac.be
CR Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Cao ZJ, 2001, NUCLEIC ACIDS RES, V29, P4502, DOI 10.1093/nar/29.21.4502
   Carrozzo R, 2006, ANN NEUROL, V59, P265, DOI 10.1002/ana.20729
   Dimauro S, 2001, AM J MED GENET, V106, P18, DOI 10.1002/ajmg.1392
   El Meziane A, 1998, NAT GENET, V18, P350
   HOLLAND VR, 1974, TETRAHEDRON, V30, P3299, DOI 10.1016/S0040-4020(01)97504-0
   Janssen RJRJ, 2006, J INHERIT METAB DIS, V29, P499, DOI 10.1007/s10545-006-0362-4
   McFarland R, 2004, TRENDS GENET, V20, P591, DOI 10.1016/j.tig.2004.09.014
   Meulemans A, 2007, EUR J PAEDIATR NEURO, V11, P17, DOI 10.1016/j.ejpn.2006.10.004
   Mitchell AL, 2006, J MED GENET, V43, P175, DOI 10.1136/jmg.2005.032474
   *MITOMAP, 2006, HUM MIT GEN DAT, V0, P0
   Moraes C T, 1996, METHODS ENZYMOL, V264, P522, DOI 10.1016/S0076-6879(96)64046-4
   Ohno K, 1996, ANN NEUROL, V40, P480
   Ohno K, 1996, ANN NEUROL, V39, P761, DOI 10.1002/ana.410390612
   Pulkes T, 2000, NEUROLOGY, V55, P1210, DOI 10.1212/WNL.55.8.1210
   Raffelsberger T, 2001, NEUROLOGY, V57, P2298, DOI 10.1212/WNL.57.12.2298
   Van Coster R, 2001, PEDIATR RES, V50, P658, DOI 10.1203/00006450-200111000-00020
NR 17
TC 11
Z9 12
U1 0
U2 5
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9942
EI 1538-3687
J9 ARCH NEUROL-CHICAGO
JI Arch. Neurol.
PD SEP 15
PY 2007
VL 64
IS 9
BP 1339
EP 1343
DI 10.1001/archneur.64.9.1339
PG 5
WC Clinical Neurology
SC Neurosciences & Neurology
GA 208TP
UT WOS:000249342400018
PM 17846276
DA 2024-11-01
ER

PT J
AU Shinmei, Y
   Kase, M
   Suzuki, Y
   Nitta, T
   Chin, S
   Yoshida, K
   Goto, Y
   Nagashima, T
   Ohno, S
AF Shinmei, Yasuhiro
   Kase, Manahu
   Suzuki, Yasuo
   Nitta, Takuya
   Chin, Shinki
   Yoshida, Kazuhiko
   Goto, Yu-ichi
   Nagashima, Toshiko
   Ohno, Shigeaki
TI Ocular motor disorders in mitochondrial encephalopathy with lactic acid and stroke-like episodes with the 3271 (T-C) point mutation in mitochondrial DNA
SO JOURNAL OF NEURO-OPHTHALMOLOGY
LA English
DT Article
ID 3-dimensional eye position; downbeat nystagmus; disease; encephalomyopathy; myopathy; melas
AB Background: Ocular motor function can provide insights into areas of dysfunction within the nervous system. There are no published eye movement recordings in patients with mitochondrial encephalopathy with lactic acid and stroke-like episodes (MELAS). Our purpose in this study was to analyze the ocular motor features of a family with MELAS with a (T-C) mutation at nucleotide position 3271 in the mitochondrial tRNA-Leu gene. Methods: The search coil method was used to record visually-guided saccades, antisaccades, and triangular pursuit tasks in the horizontal and vertical planes in three patients in a Japanese family with MELAS. Results: The patients showed saccadic dysmetria and prolonged saccadic reaction times, deficits in the ability to suppress reflex eye movements, and increased reaction time during antisaccades, downbeat nystagmus, square wave jerks, and impairment in pursuit. Conclusions: On the basis of eye movement recordings, patients with MELAS have frontal cortex as well as cerebellar dysfunction.
C1 Hokkaido Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sapporo, Hokkaido 0608638, Japan.
   Teine Keijinkai Hosp, Dept Ophthalmol, Sapporo, Hokkaido, Japan.
   Teine Keijinkai Hosp, Dept Neurol, Sapporo, Hokkaido, Japan.
   Sapporo Med Univ, Sch Med, Dept Ophthalmol, Sapporo, Hokkaido, Japan.
   Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Mental Retardat & Birth Defect Res, Tokyo, Japan.
C3 Hokkaido University; Teine Keijinkai Hospital; Teine Keijinkai Hospital; Sapporo Medical University; National Center for Neurology & Psychiatry - Japan
RP Shinmei, Y (corresponding author), Hokkaido Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, West 7,North 15, Sapporo, Hokkaido 0608638, Japan.
EM yshinmei@med.hokudai.ac.jp
CR Amador N, 2004, J NEUROPHYSIOL, V91, P1672, DOI 10.1152/jn.00138.2003
   Barash S, 1999, J NEUROSCI, V19, P10931, DOI 10.1523/JNEUROSCI.19-24-10931.1999
   BLASS JP, 1988, REV NEUROL, V144, P543
   FLETCHER WA, 1986, ANN NEUROL, V20, P464, DOI 10.1002/ana.410200405
   FUKUHARA N, 1980, J NEUROL SCI, V47, P117, DOI 10.1016/0022-510X(80)90031-3
   FUKUSHIMA J, 1988, BIOL PSYCHIAT, V23, P670, DOI 10.1016/0006-3223(88)90050-9
   Glasauer S, 2003, J NEUROPHYSIOL, V89, P338, DOI 10.1152/jn.00297.2002
   GOTO Y, 1991, BIOCHIM BIOPHYS ACTA, V1097, P238, DOI 10.1016/0925-4439(91)90042-8
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   GOTO Y, 1995, MUSCLE NERVE, V0, PS107
   HALMAGYI GM, 1983, ARCH NEUROL-CHICAGO, V40, P777
   HESS BJM, 1992, VISION RES, V32, P1647, DOI 10.1016/0042-6989(92)90157-E
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   KEARNS TP, 1958, ARCH OPHTHALMOL-CHIC, V60, P280, DOI 10.1001/archopht.1958.00940080296016
   KITAGAWA M, 1994, NEUROLOGY, V44, P2285, DOI 10.1212/WNL.44.12.2285
   LASKER AG, 1987, NEUROLOGY, V37, P364, DOI 10.1212/WNL.37.3.364
   MARIE SKN, 1994, BIOCHEM MED METAB B, V52, P136, DOI 10.1006/bmmb.1994.1045
   Marti S, 2005, INVEST OPHTH VIS SCI, V46, P143, DOI 10.1167/iovs.04-0235
   Mojon D, 2001, THER UMSCH, V58, P49, DOI 10.1024/0040-5930.58.1.49
   Nagashima T, 2001, NEUROMUSCULAR DISORD, V11, P470, DOI 10.1016/S0960-8966(01)00190-0
   Ohno, 2000, JPN J OPHTHALMOL, V44, P695, DOI 10.1016/S0021-5155(00)00263-X
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   Rivaud-Péchoux S, 2000, NEUROLOGY, V54, P1029, DOI 10.1212/WNL.54.5.1029
   Sue CM, 1997, NEUROLOGY, V49, P1013, DOI 10.1212/WNL.49.4.1013
   Suzuki Y, 2000, INVEST OPHTH VIS SCI, V41, P2954
   ZEE DS, 1974, ARCH NEUROL-CHICAGO, V30, P227, DOI 10.1001/archneur.1974.00490330035006
NR 26
TC 11
Z9 11
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1070-8022
EI 1536-5166
J9 J NEURO-OPHTHALMOL
JI J. Neuro-Ophthal.
PD MAR 15
PY 2007
VL 27
IS 1
BP 22
EP 28
DI 10.1097/WNO.0b013e3180334cb0
PG 7
WC Clinical Neurology; Ophthalmology
SC Neurosciences & Neurology; Ophthalmology
GA 148JN
UT WOS:000245070800005
PM 17414868
DA 2024-11-01
ER

PT J
AU Ashley, N
   Adams, S
   Slama, A
   Zeviani, M
   Suomalainen, A
   Andreu, AL
   Naviaux, RK
   Poulton, J
AF Ashley, Neil
   Adams, Susan
   Slama, Abdelhamid
   Zeviani, Massimo
   Suomalainen, Anu
   Andreu, Antonio L.
   Naviaux, Robert K.
   Poulton, Joanna
TI Defects in maintenance of mitochondrial DNA are associated with intramitochondrial nucleotide imbalances
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID progressive external ophthalmoplegia; thymidine phosphorylase-deficiency; mtdna depletion; neurogastrointestinal encephalomyopathy; polymerase-gamma; alpers-syndrome; helicase activity; tk2 deficiency; gene-mutations; human-cells
AB Defects in mtDNA maintenance range from fatal multisystem childhood diseases, such as Alpers syndrome, to milder diseases in adults, including mtDNA depletion syndromes (MDS) and familial progressive external ophthalmoplegia (AdPEO). Most are associated with defects in genes involved in mitochondrial deoxynucleotide metabolism or utilization, such as mutations in thymidine kinase 2 (TK2) as well as the mtDNA replicative helicase, Twinkle and gamma polymerase (POLG). We have developed an in vitro system to measure incorporation of radiolabelled dNTPs into mitochondria of saponin permeabilized cells. We used this to compare the rates of mtDNA synthesis in cells from 12 patients with diseases of mtDNA maintenance. We observed reduced incorporation of exogenous alpha P-32-dTTP in fibroblasts from a patient with Alpers syndrome associated with the A467T substitution in POLG, a patient with dGK mutations, and a patient with mtDNA depletion of unknown origin compared to controls. However, incorporation of alpha P-32-dTTP relative to either cell doubling time or alpha P-32-dCTP incorporation was increased in patients with thymidine kinase deficiency or PEO as the result of TWINKLE mutations compared with controls. The specific activity of newly synthesized mtDNA depends on the size of the endogenous pool diluting the exogenous labelled nucleotide. Our result is consistent with a deficiency in the intramitochondrial pool of dTTP relative to dCTP in cells from patients with TK2 deficiency and TWINKLE mutations. Such DNA precursor asymmetry could cause pausing of the replication complex and hence exacerbate the propensity for age-related mtDNA mutations. Because deviations from the normal concentrations of dNTPs are known to be mutagenic, we suggest that intramitochondrial nucleoticle imbalance could underlie the multiple mtDNA mutations observed in these patients.
C1 Hop Bicetre, Lab Biochim 1, APHP, Le Kremlin Bicetre, France.
   Natl Neurol Inst C Besta, Div Mol Neurogenet, I-20126 Milan, Italy.
   Biomedicum, Programme Neurosci, Helsinki, Finland.
   Univ Calif San Diego, Mitochondrial & Metab Dis Ctr, San Diego, CA 92103 USA.
C3 Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Universite Paris Saclay; Hopital Universitaire Bicetre - APHP; Hopital Universitaire Antoine-Beclere - APHP; Fondazione IRCCS Istituto Neurologico Carlo Besta; University of Helsinki; University of California System; University of California San Diego
RP Poulton, J (corresponding author), John Radcliffe Hosp, Nuffield Dept Obstet & Gynaecol, Mitochondrial Genet Grp, Level 3,Womens Ctr, Oxford OX3 9DU, England.
EM joanna.poulton@obs-gyn.ox.ac.uk
FU MRC [G0500695] Funding Source: UKRI; Medical Research Council [G0500695] Funding Source: Medline
CR Ashley N, 2005, EXP CELL RES, V303, P432, DOI 10.1016/j.yexcr.2004.10.013
   Baruffini E, 2006, HUM MOL GENET, V15, P2846, DOI 10.1093/hmg/ddl219
   BOGENHAGEN D, 1977, CELL, V11, P719, DOI 10.1016/0092-8674(77)90286-0
   Bradshaw PC, 2005, AM J PHYSIOL-CELL PH, V288, PC989, DOI 10.1152/ajpcell.00530.2004
   Chan SSL, 2005, DNA REPAIR, V4, P1381, DOI 10.1016/j.dnarep.2005.08.010
   Chan SSL, 2005, J BIOL CHEM, V280, P31341, DOI 10.1074/jbc.M506762200
   CHENG S, 1994, NAT GENET, V7, P350, DOI 10.1038/ng0794-350
   Chinnery PF, 1999, AM J HUM GENET, V64, P1158, DOI 10.1086/302311
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Emmerson CF, 2001, NUCLEIC ACIDS RES, V29, P0, DOI 10.1093/nar/29.2.e1
   Fairbanks LD, 2002, J INHERIT METAB DIS, V25, P603, DOI 10.1023/A:1022007827133
   Ferraro P, 2005, J BIOL CHEM, V280, P24472, DOI 10.1074/jbc.M502869200
   GRAHAM J, 1997, SUBCELLULAR FRACTION, V0, P135
   Iida R, 2006, BIOCHEM BIOPH RES CO, V344, P948, DOI 10.1016/j.bbrc.2006.04.008
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Korhonen JA, 2004, EMBO J, V23, P2423, DOI 10.1038/sj.emboj.7600257
   Korhonen JA, 2003, J BIOL CHEM, V278, P48627, DOI 10.1074/jbc.M306981200
   KUNKEL TA, 1988, BIOCHIM BIOPHYS ACTA, V951, P1, DOI 10.1016/0167-4781(88)90020-6
   KUNZ BA, 1991, ANNU REV GENET, V25, P339, DOI 10.1146/annurev.ge.25.120191.002011
   Lindhurst MJ, 2006, P NATL ACAD SCI USA, V103, P15927, DOI 10.1073/pnas.0607661103
   Longley MJ, 2005, GENE, V354, P125, DOI 10.1016/j.gene.2005.03.029
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Martí R, 2003, BIOCHEM BIOPH RES CO, V303, P14, DOI 10.1016/S0006-291X(03)00294-8
   MATSON SW, 1983, J BIOL CHEM, V258, P4017
   Minamikawa T, 1999, J CELL SCI, V112, P2419
   Morten KJ, 1996, J INHERIT METAB DIS, V19, P123, DOI 10.1007/BF01799409
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Naviaux RK, 1999, ANN NEUROL, V45, P54, DOI 10.1002/1531-8249(199901)45:1<54::AID-ART10>3.0.CO;2-B
   Nishigaki Y, 2003, J CLIN INVEST, V111, P1913, DOI 10.1172/JCI200317828
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Petronilli V, 1999, BIOPHYS J, V76, P725, DOI 10.1016/S0006-3495(99)77239-5
   Pombo A, 1999, EMBO J, V18, P2241, DOI 10.1093/emboj/18.8.2241
   Ponamarev MV, 2002, J BIOL CHEM, V277, P15225, DOI 10.1074/jbc.C200100200
   Pontarin G, 2006, J BIOL CHEM, V281, P22720, DOI 10.1074/jbc.M604498200
   Rampazzo C, 2004, J BIOL CHEM, V279, P17019, DOI 10.1074/jbc.M313957200
   Saada A, 2003, BIOCHEM BIOPH RES CO, V310, P963, DOI 10.1016/j.bbrc.2003.09.104
   Saada A, 2003, MOL GENET METAB, V79, P1, DOI 10.1016/S1096-7192(03)00063-5
   Saks VA, 1998, MOL CELL BIOCHEM, V184, P1, DOI 10.1023/A:1006894531396
   Slama A, 2005, MOL GENET METAB, V84, P326, DOI 10.1016/j.ymgme.2004.12.004
   Song SW, 2005, P NATL ACAD SCI USA, V102, P4990, DOI 10.1073/pnas.0500253102
   Song SW, 2003, J BIOL CHEM, V278, P43893, DOI 10.1074/jbc.C300401200
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Spinazzola A, 2002, J BIOL CHEM, V277, P4128, DOI 10.1074/jbc.M111028200
   Taanman JW, 1997, HUM MOL GENET, V6, P935, DOI 10.1093/hmg/6.6.935
   Taanman JW, 2003, HUM MOL GENET, V12, P1839, DOI 10.1093/hmg/ddg192
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Viguera E, 2001, EMBO J, V20, P2587, DOI 10.1093/emboj/20.10.2587
   Vilà MR, 2003, NEUROLOGY, V60, P1203, DOI 10.1212/01.WNL.0000055928.58122.47
   Wang LY, 2000, BIOCHEM J, V351, P469, DOI 10.1042/0264-6021:3510469
   Wanrooij S, 2004, NUCLEIC ACIDS RES, V32, P3053, DOI 10.1093/nar/gkh634
   Washington MT, 1996, J BIOL CHEM, V271, P26825, DOI 10.1074/jbc.271.43.26825
   WERNETTE CM, 1988, BIOCHEMISTRY-US, V27, P6046, DOI 10.1021/bi00416a033
NR 53
TC 40
Z9 43
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD JUN 15
PY 2007
VL 16
IS 12
BP 1400
EP 1411
DI 10.1093/hmg/ddm090
PG 12
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 190UA
UT WOS:000248084900002
PM 17483096
DA 2024-11-01
ER

PT J
AU Rivera, H
   Blázquez, A
   Carretero, J
   Alvarez-Cermeño, JC
   Campos, Y
   Cabello, A
   Gonzalez-Vioque, E
   Borstein, B
   Garesse, R
   Arenas, J
   Martín, MA
AF Rivera, Henry
   Blazquez, Alberto
   Carretero, Julian
   Alvarez-Cermeno, Jose C.
   Campos, Y.
   Cabello, Ana
   Gonzalez-Vioque, Emiliano
   Borstein, Belen
   Garesse, Rafael
   Arenas, Joaquin
   Martin, Miguel A.
TI Mild ocular myopathy associated with a novel mutation in mitochondrial twinkle helicase
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE PEO1; twinkle; adPEO; mitochondrial disorders; mtDNA multiple deletions
ID external ophthalmoplegia; dna deletions; polg; ant1
AB Autosomal dominant PEO is associated with mutations in a number of nuclear genes affecting the intergenomic communication with mitochondrial DNA. We report a Spanish family showing a mild phenotype characterized by autosomal dominant ocular myopathy and morphological signs of mitochondrial dysfunction, that harboured a novel c.1071G > C (p.R357P) mutation in the hot-spot linker region of the twinkle protein. (C) 2007 Published by Elsevier B.V.
C1 [Rivera, Henry; Blazquez, Alberto; Carretero, Julian; Campos, Y.; Arenas, Joaquin; Martin, Miguel A.] Hosp Univ 12 Octubre, Ctr Invest, Madrid, Spain.
   [Alvarez-Cermeno, Jose C.] Hosp Ramon & Cajal, Serv Neurol, Madrid, Spain.
   [Cabello, Ana] Hosp Univ 12 Octubre, Serv Neurol, Madrid, Spain.
   [Rivera, Henry; Blazquez, Alberto; Campos, Y.; Cabello, Ana; Gonzalez-Vioque, Emiliano; Borstein, Belen; Garesse, Rafael; Arenas, Joaquin; Martin, Miguel A.] Ctr Biomed Res Rare Disorders, Madrid, Spain.
   [Gonzalez-Vioque, Emiliano; Borstein, Belen; Garesse, Rafael] Univ Autonoma Madrid, Biomed Res Ctr Rare Disorder, Fac Med, Inst Invest Biomed Albert Sols,CSIC,UAM, E-28049 Madrid, Spain.
C3 Hospital Universitario 12 de Octubre; Hospital Universitario Ramon y Cajal; Hospital Universitario 12 de Octubre; CIBER - Centro de Investigacion Biomedica en Red; CIBERER; CIBER - Centro de Investigacion Biomedica en Red; CIBERER; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)
RP Martín, MA (corresponding author), Hosp Univ 12 Octubre, Ctr Invest, Av Cordoba S-N, Madrid, Spain.
EM mamcasanueva@h12o.es
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   Brierley EJ, 1998, ANN NEUROL, V43, P217, DOI 10.1002/ana.410430212
   Deschauer M, 2003, NEUROMUSCULAR DISORD, V13, P568, DOI 10.1016/S0960-8966(03)00071-3
   DiMauro S, 1997, MOL GENETIC BASIS NE, V0, P201
   González-Vioque E, 2006, ARCH NEUROL-CHICAGO, V63, P107, DOI 10.1001/archneur.63.1.107
   Hirano M, 2001, NEUROLOGY, V57, P2163, DOI 10.1212/WNL.57.12.2163
   Hudson G, 2005, NEUROLOGY, V64, P371, DOI 10.1212/01.WNL.0000149767.51152.83
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Tyynismaa H, 2005, P NATL ACAD SCI USA, V102, P17687, DOI 10.1073/pnas.0505551102
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
NR 10
TC 13
Z9 14
U1 0
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD OCT 15
PY 2007
VL 17
IS 9-10
BP 677
EP 680
DI 10.1016/j.nmd.2007.05.006
PG 4
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 221WL
UT WOS:000250258000004
PM 17614277
DA 2024-11-01
ER

PT J
AU Childs, AM
   Hutchin, T
   Pysden, K
   Highet, L
   Bamford, J
   Livingston, J
   Crow, YJ
AF Childs, A. -M.
   Hutchin, T.
   Pysden, K.
   Highet, L.
   Bamford, J.
   Livingston, J.
   Crow, Y. -J.
TI Variable phenotype including Leigh syndrome with a 9185T&gt;C mutation in the <i>MTATP6</i> gene
SO NEUROPEDIATRICS
LA English
DT Article
DE mitochondrial disease; Leigh syndrome; NARP; MTATP6; 9185T > C
ID mitochondrial-dna; disease
AB We describe 15 members of a Caucasian family with an apparently homoplasmic T -> C mutation at nucleotide position 9185 (9185T>C) in the mtDNA encoded MTATP6 (ATPase 6) gene. The clinical phenotype is extremely variable and includes late-onset Leigh syndrome (LS), isolated demyelinating peripheral neuropathy and neurogenic muscle weakness, ataxia and retinitis pigmentosa (NARP). Following recent reports of this same mutation in a single case and in a family with late-onset LS and NARP-like features, our paper emphasises the role of MTATP6 in LS and expands the associated clinical phenotype further.
C1 [Childs, A. -M.; Pysden, K.; Highet, L.; Livingston, J.] Leeds Teaching Hosp Trust, Gen Infirm Leeds Belmont Grove, Dept Paediat Neurol, Leeds LS2 9NS, W Yorkshire, England.
   [Hutchin, T.; Crow, Y. -J.] Univ Leeds, Leeds Inst Mol Med, Leeds, W Yorkshire, England.
   [Bamford, J.] Leeds Teaching Hosp Trust, Dept Neurol, Leeds Gen Infirm, Leeds, W Yorkshire, England.
C3 University of Leeds; Leeds General Infirmary; University of Leeds; University of Leeds; Leeds General Infirmary
RP Childs, AM (corresponding author), Leeds Teaching Hosp Trust, Gen Infirm Leeds Belmont Grove, Dept Paediat Neurol, B Floor,Clarendon Wing, Leeds LS2 9NS, W Yorkshire, England.
EM anne-marie.childs@leedsth.nhs.uk
CR Castagna AE, 2007, AM J MED GENET A, V143A, P808, DOI 10.1002/ajmg.a.31637
   DAVIS PC, 1987, AM J NEURORADIOL, V8, P71
   LEIGH D, 1951, J NEUROL NEUROSUR PS, V14, P216, DOI 10.1136/jnnp.14.3.216
   LYONS G, 1996, EARLY INFANTILE PROG, V0, P0
   Makino M, 2000, J HUM GENET, V45, P69, DOI 10.1007/s100380050014
   Moslemi AR, 2005, NEUROPEDIATRICS, V36, P314, DOI 10.1055/s-2005-872845
   Ogilvie I, 1999, FEBS LETT, V453, P179, DOI 10.1016/S0014-5793(99)00605-5
   Rahman S, 1996, ANN NEUROL, V39, P343, DOI 10.1002/ana.410390311
   Santorelli FM, 1996, PEDIATR RES, V39, P914, DOI 10.1203/00006450-199605000-00028
   TATUCH Y, 1992, AM J HUM GENET, V50, P852
NR 10
TC 40
Z9 43
U1 1
U2 10
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0174-304X
EI 
J9 NEUROPEDIATRICS
JI Neuropediatrics
PD DEC 15
PY 2007
VL 38
IS 6
BP 313
EP 316
DI 10.1055/s-2008-1065355
PG 4
WC Clinical Neurology; Pediatrics
SC Neurosciences & Neurology; Pediatrics
GA 306HF
UT WOS:000256238200009
PM 18461509
DA 2024-11-01
ER

PT J
AU Pessayre, D
AF Pessayre, Dominique
TI Role of mitochondria in non-alcoholic fatty liver disease
SO JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
LA English
DT Article; Proceedings Paper
DE diabetes; mitochondria; obesity; steatohepatitis; steatosis
ID receptor-gamma coactivator-1; human skeletal-muscle; uncoupling protein-2 expression; type-2 diabetic-patients; cytochrome-c-oxidase; insulin-resistance; beta-cell; hepatic mitochondrial; oxidative-phosphorylation; common polymorphism
AB Mitochondrial dysfunction is involved in the three stages of the transition from lack of exercise and excessive food intake to insulin resistance, diabetes and non-alcoholic steatohepatitis (NASH). In muscle, lack of exercise, a fat-rich diet, a polymorphism in peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1), and possibly age-related mitochondrial DNA (mtDNA) mutations may variously combine their effects to decrease PGC-1 expression, mitochondrial biogenesis and fat oxidation. Together with excessive food intake, insufficient fat oxidation causes fat accumulation and cellular stress in myocytes. The activation of Jun N-terminal kinase and protein kinase C-theta triggers the serine phosphorylation and inactivation of the insulin receptor substrate, and hampers the insulin-mediated translocation of glucose transporter-4 to the plasma membrane. Initially, the trend for increased blood glucose increases insulin secretion by pancreatic beta-cells. High plasma insulin levels compensate for insulin resistance in muscle and maintain normal blood glucose levels. Eventually, however, increased uncoupling protein-2 expression and possibly acquired mtDNA mutations in pancreatic beta-cells can blunt glucose-mediated adenosine triphosphate (ATP) formation and insulin secretion, to cause diabetes in some patients. High plasma glucose and/or insulin levels induce hepatic lipogenesis and cause hepatic steatosis. In fat-engorged hepatocytes, several vicious cycles involving tumor necrosis factor-alpha, reactive oxygen species (ROS), peroxynitrite, and lipid peroxidation products alter respiratory chain polypeptides and mtDNA, thus partially blocking the flow of electrons in the respiratory chain. The overreduction of upstream respiratory chain complexes increases mitochondrial ROS and peroxynitrite formation. Oxidative stress increases the release of lipid peroxidation products and cytokines, which together trigger the liver lesions of NASH.
C1 French Natl Inst Hlth & Med Res, INSERM, Bichat Beaujon Ctr Biomed Res, Unit 773, Paris, France.
   Univ Paris 07, Fac Med Xavier Bichat, Paris, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Cite
RP Pessayre, D (corresponding author), INSERM, Fac Med Xavier Bichat, U773, BP 416, F-75018 Paris, France.
EM pessayre@bichat.inserm.fr
CR ADIELS M, 2005, ARTERIOSCLER THROMB, V25, P16967
   Anello M, 2005, DIABETOLOGIA, V48, P282, DOI 10.1007/s00125-004-1627-9
   BALLINGER SW, 1992, NAT GENET, V1, P11, DOI 10.1038/ng0492-11
   BRADY LJ, 1985, BIOCHEM J, V231, P439, DOI 10.1042/bj2310439
   Browning JD, 2004, J CLIN INVEST, V114, P147, DOI 10.1172/JCI200422422
   Caldwell SH, 1999, J HEPATOL, V31, P430, DOI 10.1016/S0168-8278(99)80033-6
   Canbay A, 2003, LAB INVEST, V83, P655, DOI 10.1097/01.LAB.0000069036.63405.5C
   Chalasani N, 2003, HEPATOLOGY, V37, P544, DOI 10.1053/jhep.2003.50095
   Charlton N, 2002, HEPATOLOGY, V35, P898, DOI 10.1053/jhep.2002.32527
   Chen JJ, 1998, BBA-GEN SUBJECTS, V1380, P336, DOI 10.1016/S0304-4165(98)00002-6
   Chen JJ, 2000, ALCOHOL CLIN EXP RES, V24, P544, DOI 10.1111/j.1530-0277.2000.tb02023.x
   COLBERG SR, 1995, J CLIN INVEST, V95, P1846, DOI 10.1172/JCI117864
   COOK GA, 1987, J BIOL CHEM, V262, P2050
   Cortez-Pinto H, 1999, JAMA-J AM MED ASSOC, V282, P1659, DOI 10.1001/jama.282.17.1659
   Cortez-Pinto H, 1999, GASTROENTEROLOGY, V116, P1184, DOI 10.1016/S0016-5085(99)70022-3
   Diraison F, 2002, AM J PHYSIOL-ENDOC M, V282, PE46, DOI 10.1152/ajpendo.2002.282.1.E46
   Ek J, 2001, DIABETOLOGIA, V44, P2220, DOI 10.1007/s001250100032
   El-Assaad W, 2003, ENDOCRINOLOGY, V144, P4154, DOI 10.1210/en.2003-0410
   Esterbauer H, 2001, NAT GENET, V28, P178, DOI 10.1038/88911
   Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112
   Feldstein AE, 2003, GASTROENTEROLOGY, V125, P437, DOI 10.1016/S0016-5085(03)00907-7
   Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376
   FROMENTY B, 1995, PHARMACOL THERAPEUT, V67, P101, DOI 10.1016/0163-7258(95)00012-6
   Frosig C, 2004, AM J PHYSIOL-ENDOC M, V286, PE411, DOI 10.1152/ajpendo.00317.2003
   FUKUDA K, 1993, HEPATOLOGY, V18, P945, DOI 10.1002/hep.1840180428
   Gao DQ, 2004, AM J PHYSIOL-GASTR L, V287, PG1070, DOI 10.1152/ajpgi.00228.2004
   GORDON ES, 1960, AM J CLIN NUTR, V8, P740, DOI 10.1093/ajcn/8.5.740
   Haque M, 2002, HEPATOLOGY, V36, P0
   Hara K, 2002, DIABETOLOGIA, V45, P740, DOI 10.1007/s00125-002-0803-z
   Hensley K, 2000, CARCINOGENESIS, V21, P983, DOI 10.1093/carcin/21.5.983
   Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137
   Iizuka K, 2004, P NATL ACAD SCI USA, V101, P7281, DOI 10.1073/pnas.0401516101
   Ikejima K, 2002, GASTROENTEROLOGY, V122, P1399, DOI 10.1053/gast.2002.32995
   Joseph JW, 2004, J BIOL CHEM, V279, P51049, DOI 10.1074/jbc.M409189200
   Kelley DE, 2002, DIABETES, V51, P2944, DOI 10.2337/diabetes.51.10.2944
   Kim JK, 2004, J CLIN INVEST, V114, P823, DOI 10.1172/JCI200422230
   Krauss S, 2003, J CLIN INVEST, V112, P1831, DOI 10.1172/JCI200319774
   Lameloise N, 2001, DIABETES, V50, P803, DOI 10.2337/diabetes.50.4.803
   Lehman JJ, 2000, J CLIN INVEST, V106, P847, DOI 10.1172/JCI10268
   Leonarduzzi G, 1997, FASEB J, V11, P851, DOI 10.1096/fasebj.11.11.9285483
   Maechler P, 2001, NATURE, V414, P807, DOI 10.1038/414807a
   Miele L, 2003, AM J GASTROENTEROL, V98, P2335, DOI 10.1111/j.1572-0241.2003.07725.x
   Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180
   Mourier T, 2001, MOL BIOL EVOL, V18, P1833, DOI 10.1093/oxfordjournals.molbev.a003971
   Muller YL, 2003, DIABETES, V52, P895, DOI 10.2337/diabetes.52.3.895
   Özcan U, 2004, SCIENCE, V306, P457, DOI 10.1126/science.1103160
   PAROLA M, 1993, BIOCHEM BIOPH RES CO, V194, P1044, DOI 10.1006/bbrc.1993.1927
   Patti ME, 2003, P NATL ACAD SCI USA, V100, P8466, DOI 10.1073/pnas.1032913100
   Pérez-Carreras M, 2003, HEPATOLOGY, V38, P999, DOI 10.1053/jhep.2003.50398
   Perseghin G, 1999, DIABETES, V48, P1600, DOI 10.2337/diabetes.48.8.1600
   Pessayre D, 2005, J HEPATOL, V42, P928, DOI 10.1016/j.jhep.2005.03.004
   Pessayre D, 2004, EUR J GASTROEN HEPAT, V16, P1095, DOI 10.1097/00042737-200411000-00003
   Pessayre D, 2002, AM J PHYSIOL-GASTR L, V282, PG193, DOI 10.1152/ajpgi.00426.2001
   Pessayre D, 2001, SEMIN LIVER DIS, V21, P57, DOI 10.1055/s-2001-12929
   Petersen KF, 2004, NEW ENGL J MED, V350, P664, DOI 10.1056/NEJMoa031314
   Petersen KF, 2003, SCIENCE, V300, P1140, DOI 10.1126/science.1082889
   Polonsky KS, 1996, NEW ENGL J MED, V334, P777, DOI 10.1056/NEJM199603213341207
   Rimbert Virginie, 2004, FASEB J, V18, P737
   Sanyal AJ, 2001, GASTROENTEROLOGY, V120, P1183, DOI 10.1053/gast.2001.23256
   Sasahara M, 2004, DIABETES, V53, P482, DOI 10.2337/diabetes.53.2.482
   Saxena NK, 2002, HEPATOLOGY, V35, P762, DOI 10.1053/jhep.2002.32029
   Sesti G, 2003, DIABETES, V52, P1280, DOI 10.2337/diabetes.52.5.1280
   Shepherd PR, 1999, NEW ENGL J MED, V341, P248, DOI 10.1056/NEJM199907223410406
   Shimomura I, 1999, J BIOL CHEM, V274, P30028, DOI 10.1074/jbc.274.42.30028
   Simoneau JA, 1999, FASEB J, V13, P2051, DOI 10.1096/fasebj.13.14.2051
   SPARKS JD, 1994, BIOCHEM BIOPH RES CO, V205, P417, DOI 10.1006/bbrc.1994.2681
   Sparks LM, 2005, DIABETES, V54, P1926, DOI 10.2337/diabetes.54.7.1926
   STEFAN Y, 1982, DIABETES, V31, P694, DOI 10.2337/diabetes.31.8.694
   Taanman JW, 1999, BBA-BIOENERGETICS, V1410, P103, DOI 10.1016/S0005-2728(98)00161-3
   VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368
   Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000
   Wang Y, 2001, P NATL ACAD SCI USA, V98, P4022, DOI 10.1073/pnas.061013598
   WIS I, 2005, SCIENCE, V307, P418
   Wu H, 2002, SCIENCE, V296, P349, DOI 10.1126/science.1071163
   Yamashita H, 2001, P NATL ACAD SCI USA, V98, P9116, DOI 10.1073/pnas.161284298
   YANG D, 1985, P NATL ACAD SCI USA, V82, P4443, DOI 10.1073/pnas.82.13.4443
   Yang SQ, 2000, ARCH BIOCHEM BIOPHYS, V378, P259, DOI 10.1006/abbi.2000.1829
NR 77
TC 226
Z9 256
U1 0
U2 17
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0815-9319
EI 1440-1746
J9 J GASTROEN HEPATOL
JI J. Gastroenterol. Hepatol.
PD JUN 15
PY 2007
VL 22
IS 
BP S20
EP S27
DI 10.1111/j.1440-1746.2006.04640.x
PG 8
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 178FB
UT WOS:000247205500006
PM 17567459
DA 2024-11-01
ER

PT J
AU Wabbels, B
   Schroeder, JA
   Voll, B
   Siegmund, H
   Lorenz, B
AF Wabbels, Bettina
   Schroeder, Josef A.
   Voll, Beate
   Siegmund, Heiko
   Lorenz, Birgit
TI Electron microscopic findings in levator muscle biopsies of patients with isolated congenital or acquired ptosis
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE mitochondria; electron microscopy; ptosis; congenital; acquired; child; CPEO
ID progressive external ophthalmoplegia; mitochondrial-dna deletion; extraocular-muscles; diagnostic-value; ocular myopathy; diseases; expression; encephalomyopathy; population; disorders
AB Objective Systemic mitochondriopathies as chronic progressive external ophthalmoplegia (CPEO) are frequently associated with ptosis. We investigated whether mitochondrial abnormalities in the levator muscle are also found in patients with isolated congenital or acquired ptosis showing no other signs of mitochondrial cytopathy. Methods Biopsies of levator muscle were taken during surgery from 24 patients with isolated congenital (group 1) or early-onset acquired ptosis (group 2). All patients were given a thorough clinical examination before and after surgery. Ultrathin muscle sections were examined by transmission electron microscopy. The findings were compared with biopsies from five patients with CPEO (positive control) and two patients with traumatic ptosis or pseudoptosis (negative control). Results The mean levator function equalled 7.3 mm (range 4-10 mm) in group 1 and 12.8 mm (range 9-15 mm) in group 2. Eight out of 11 patients in group 1 and eight out of 13 patients in group 2 were found to have mitochondrial alterations such as megamitochondria, mitochondrial matrix alterations and abnormal cristae, similar to CPEO. Within group 1 and 2, no significant clinical differences were found between patients with and without mitochondrial abnormalities. Conclusion Mitochondrial alterations were found in a surprisingly large proportion of levator biopsies from patients with isolated congenital or early-onset acquired ptosis. There was no statistically significant correlation between mitochondrial alterations and levator function. Our findings suggest that the ultrastructural assessment of mitochondria in the eyelid muscle is a valuable tool, and may guide further biochemical and mutation screening tests that will help to understand the etiopathology of this disease.
C1 Univ Regensburg, Dept Pediat Ophthalmol Strabismol & Opthalmogenet, D-93042 Regensburg, Germany.
   Univ Regensburg, Inst Pathol, Cent EM Lab, D-93053 Regensburg, Germany.
   Univ Bonn, Dept Ophthalmol, D-53127 Bonn, Germany.
C3 University of Regensburg; University of Regensburg; University of Bonn
RP Lorenz, B (corresponding author), Univ Regensburg, Dept Pediat Ophthalmol Strabismol & Opthalmogenet, Franz Josef Str Allee 11, D-93042 Regensburg, Germany.
EM birgit.lorenz@klinik.uni-regensburg.de
CR AASLY J, 1990, EUR NEUROL, V30, P314, DOI 10.1159/000117363
   Ben Yaou R, 2006, REV NEUROL-FRANCE, V162, P339, DOI 10.1016/S0035-3787(06)75020-2
   Biousse V, 2003, CURR OPIN NEUROL, V16, P35, DOI 10.1097/00019052-200302000-00005
   BUTLER IJ, 1976, ARCH INTERN MED, V136, P1290
   Carta A, 2005, BRIT J OPHTHALMOL, V89, P825, DOI 10.1136/bjo.2004.060590
   Carta A, 2000, ARCH OPHTHALMOL-CHIC, V118, P1441
   Challa S, 2004, NEUROL INDIA, V52, P353
   Chinnery PF, 2004, LANCET, V364, P592, DOI 10.1016/S0140-6736(04)16851-7
   CHOU SM, 1968, ACTA NEUROPATHOL BER, V12, P68
   Chow C W, 2000, HUM REPROD, V15 Suppl 2, P68
   CULLEN MJ, 1975, J NEUROL SCI, V24, P179, DOI 10.1016/0022-510X(75)90232-4
   Deschauer M, 2004, GENET TEST, V8, P395, DOI 10.1089/gte.2004.8.395
   DEVIVO DC, 1993, BRAIN DEV-JPN, V15, P1, DOI 10.1016/0387-7604(93)90002-P
   Fischer MD, 2005, PHYSIOL GENOMICS, V22, P283, DOI 10.1152/physiolgenomics.00158.2004
   Fischer MD, 2002, PHYSIOL GENOMICS, V9, P71, DOI 10.1152/physiolgenomics.00115.2001
   GHADIALLY FN, 1997, ULTRASTRUCT PATHOL, V0, P195
   Greenamyre JT, 1999, BIOCHEM SOC SYMP, V66, P85, DOI 10.1042/bss0660085
   Caballero PEJ, 2007, NEUROLOGIST, V13, P33, DOI 10.1097/01.nrl.0000252953.49721.f5
   KACZMARSKI F, 1979, FOL HISTOCH CYTOCHEM, V17, P85
   KAMINSKI HJ, 1992, ANN NEUROL, V32, P586, DOI 10.1002/ana.410320418
   Kornblum C, 2004, KLIN MONATSBL AUGENH, V221, P1057, DOI 10.1055/s-2004-813830
   KRETSCHMANN U, 2000, OPHTHALMOLOGE, V97, P115
   Lee Andrew G, 2002, CURR NEUROL NEUROSCI REP, V2, P413, DOI 10.1007/s11910-002-0067-5
   Lee V, 2002, BRIT J OPHTHALMOL, V86, P1282, DOI 10.1136/bjo.86.11.1282
   LINDAL S, 1992, ULTRASTRUCT PATHOL, V16, P263, DOI 10.3109/01913129209061355
   Lucas CA, 1997, INVEST OPHTH VIS SCI, V38, P2817
   Mierau GW, 2004, PEDIATR DEVEL PATHOL, V7, P637, DOI 10.1007/s10024-004-5048-z
   Miles L, 2006, HUM PATHOL, V37, P173, DOI 10.1016/j.humpath.2005.10.008
   Mojon D, 2001, THER UMSCH, V58, P49, DOI 10.1024/0040-5930.58.1.49
   NORRIS FH, 1966, ARCH NEUROL-CHICAGO, V14, P574, DOI 10.1001/archneur.1966.00470120006002
   Okulla T, 2005, GRAEF ARCH CLIN EXP, V243, P380, DOI 10.1007/s00417-004-1000-1
   Piccolo G, 1982, SCHWEIZ ARCH NEUROL NEUROCHIR PSYCHIATR, V131, P161
   SADEH M, 2004, MYOLOGY BASIC CLIN, V0, P119
   Sarnat HB, 2005, CAN J NEUROL SCI, V32, P152, DOI 10.1017/S0317167100003929
   Schoser BGH, 2006, STRABISMUS, V14, P107, DOI 10.1080/09273970600701218
   Sciacco M, 2001, J NEUROL, V248, P778, DOI 10.1007/s004150170094
   Sewry CA, 1985, MUSCLE BIOPSY PRACTI, V0, P129
   SHAFIQ SA, 1967, ARCH NEUROL-CHICAGO, V17, P666, DOI 10.1001/archneur.1967.00470300108018
   SHAPIRA Y, 1975, NEUROLOGY, V25, P614, DOI 10.1212/WNL.25.7.614
   Shoubridge EA, 2002, STRUCTURAL MOL BASIS, V0, P202
   SICILIANO G, 1992, CLIN NEUROL NEUROSUR, V94, P133, DOI 10.1016/0303-8467(92)90070-J
   Speeg-Schatz C, 2001, BINOCUL VIS STRABISMUS Q, V16, P187
   Uusimaa J, 2000, PEDIATRICS, V105, P598, DOI 10.1542/peds.105.3.598
   Van Goethem G, 2003, NEUROMOL MED, V3, P129, DOI 10.1385/NMM:3:3:129
   Van Huyen JPD, 2003, AM J CLIN PATHOL, V119, P546, DOI 10.1309/8B8BJ6AP5KGV7C1H
   Vogel H, 2001, J NEUROPATH EXP NEUR, V60, P217, DOI 10.1093/jnen/60.3.217
   Wakabayashi T, 2002, J CELL MOL MED, V6, P497, DOI 10.1111/j.1582-4934.2002.tb00452.x
   Wright RA, 1997, J NEURO-OPHTHALMOL, V17, P39
NR 48
TC 15
Z9 18
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013 USA
SN 0721-832X
EI 
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD OCT 15
PY 2007
VL 245
IS 10
BP 1533
EP 1541
DI 10.1007/s00417-007-0603-8
PG 9
WC Ophthalmology
SC Ophthalmology
GA 209RJ
UT WOS:000249405400016
PM 17522883
DA 2024-11-01
ER

PT J
AU Sanaker, PS
   Husebye, ES
   Fondenes, O
   Bindoff, LA
AF Sanaker, P. S.
   Husebye, E. S.
   Fondenes, O.
   Bindoff, L. A.
TI Clinical evolution of Kearns-Sayre syndrome with polyendocrinopathy and respiratory failure
SO ACTA NEUROLOGICA SCANDINAVICA
LA English
DT Article; Proceedings Paper
DE endocrine disease; Kearns Sayre syndrome; mitochondrial disease; respiratory failure
ID mitochondrial-dna deletion; ventilatory response; mutation; disease; encephalomyopathy; thyroiditis; myopathy; sleep; melas; gene
AB Background- The triad of progressive external ophthalmoplegia, atypical retinal pigmentation and cardiac conduction defects characterizes Kearns-Sayre syndrome (KSS), which is most often caused by a single, large deletion of mitochondrial DNA. Endocrine disease appears to be more common in KSS than in other mitochondrial diseases. Materials, methods and results- A patient presenting with KSS developed Addison's disease, hypothyroidism and glucose intolerance. Thyroid peroxidase antibodies and adrenal 21-hydroxylase antibodies were identified. She developed acute respiratory failure requiring invasive ventilatory support, but improved and currently requires only non-invasive, nocturnal BiPAP treatment. Discussion and conclusion- This case confirms the association of KSS and endocrine dysfunction. Our finding of autoantibodies to thyroid and adrenal glands distinguishes this patient from most other published cases and suggests a potential synergy between the two disease mechanisms. In addition, we demonstrate that respiratory failure can be a treatable event in this disease.
C1 Haukeland Hosp, Dept Neurol, N-5021 Bergen, Norway.
   Univ Bergen, Inst Clin Med, Bergen, Norway.
   Univ Bergen, Inst Med, Bergen, Norway.
   Haukeland Hosp, Dept Med, N-5021 Bergen, Norway.
   Haukeland Hosp, Dept Pulmonol, Norwegian Ctr Home Mech Ventilat, N-5021 Bergen, Norway.
C3 University of Bergen; Haukeland University Hospital; University of Bergen; University of Bergen; University of Bergen; Haukeland University Hospital; University of Bergen; Haukeland University Hospital
RP Sanaker, PS (corresponding author), Haukeland Hosp, Dept Neurol, N-5021 Bergen, Norway.
EM petter.schandl.sanaker@helse-bergen.no
CR Artuch R, 1998, HORM RES, V50, P99, DOI 10.1159/000023243
   BAROHN RJ, 1990, NEUROLOGY, V40, P103, DOI 10.1212/WNL.40.1.103
   Berio A, 2002, PANMINERVA MED, V44, P265
   Boles RG, 1998, EUR J PEDIATR, V157, P643, DOI 10.1007/s004310050902
   CARROLL JE, 1976, NEUROLOGY, V26, P140, DOI 10.1212/WNL.26.2.140
   Chinnery PF, 2004, LANCET, V364, P592, DOI 10.1016/S0140-6736(04)16851-7
   CUMMISKEY J, 1987, NEUROLOGY, V37, P1876, DOI 10.1212/WNL.37.12.1876
   de Andrade PBM, 2006, DIABETOLOGIA, V49, P1816, DOI 10.1007/s00125-006-0301-9
   HARVEY JN, 1992, CLIN ENDOCRINOL, V37, P97, DOI 10.1111/j.1365-2265.1992.tb02289.x
   Isotani H, 1996, CLIN ENDOCRINOL, V45, P637, DOI 10.1046/j.1365-2265.1996.00856.x
   KEARNS TP, 1958, ARCH OPHTHALMOL-CHIC, V60, P280, DOI 10.1001/archopht.1958.00940080296016
   Kobayashi T, 1996, DIABETOLOGIA, V39, P1196, DOI 10.1007/BF02658506
   Ohno K, 1996, ANN NEUROL, V39, P761, DOI 10.1002/ana.410390612
   OKA Y, 1993, LANCET, V342, P527, DOI 10.1016/0140-6736(93)91649-7
   Osanai S, 2001, RESPIROLOGY, V6, P163, DOI 10.1046/j.1440-1843.2001.00318.x
   Schoffner JMWallaceDC, 1995, METABOLIC MOL BASES, V0, P1535
   Simon DK, 1999, ANNU REV MED, V50, P111
   SUZUKI S, 1994, DIABETOLOGIA, V37, P818, DOI 10.1007/s001250050183
   TANDON N, 1991, CLIN ENDOCRINOL, V34, P383
   TATSUMI C, 1988, EUR NEUROL, V28, P64, DOI 10.1159/000116231
   Vaidya B, 2000, CLIN ENDOCRINOL, V53, P403, DOI 10.1046/j.1365-2265.2000.01116.x
   WENG TR, 1985, CHEST, V88, P488, DOI 10.1378/chest.88.4.488
NR 22
TC 22
Z9 22
U1 0
U2 2
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 0001-6314
EI 
J9 ACTA NEUROL SCAND
JI Acta Neurol. Scand.
PD JUN 15
PY 2007
VL 115
IS 
BP 64
EP 67
DI 10.1111/j.1600-0404.2007.00850.x
PG 4
WC Clinical Neurology
SC Neurosciences & Neurology
GA 152AK
UT WOS:000245332300012
PM 17419832
DA 2024-11-01
ER

PT J
AU Bacman, SR
   Williams, SL
   Hernandez, D
   Moraes, CT
AF Bacman, S. R.
   Williams, S. L.
   Hernandez, D.
   Moraes, C. T.
TI Modulating mtDNA heteroplasmy by mitochondria-targeted restriction endonucleases in a 'differential multiple cleavage-site' model
SO GENE THERAPY
LA English
DT Article
DE mitochondria; mtDNA heteroplasmy; mitochondrial diseases; restriction endonuclease; adenovirus
ID gene-therapy; adenoviral vectors; dna heteroplasmy; skeletal-muscle; transgene expression; point mutation; ragged-red; in-vivo; mice; transduction
AB The ability to manipulate mitochondrial DNA ( mtDNA) heteroplasmy would provide a powerful tool to treat mitochondrial diseases. Recent studies showed that mitochondria-targeted restriction endonucleases can modify mtDNA heteroplasmy in a predictable and efficient manner if it recognizes a single site in the mutant mtDNA. However, the applicability of such model is limited to mutations that create a novel cleavage site, not present in the wild-type mtDNA. We attempted to extend this approach to a 'differential multiple cleavage site' model, where an mtDNA mutation creates an extra restriction site to the ones normally present in the wild-type mtDNA. Taking advantage of a heteroplasmic mouse model harboring two haplotypes of mtDNA (NZB/BALB) and using adenovirus as a gene vector, we delivered a mitochondria-targeted Scal restriction endonuclease to different mouse tissues. Scal recognizes five sites in the NZB mtDNA but only three in BALB mtDNA. Our results showed that changes in mtDNA heteroplasmy were obtained by the expression of mitochondria-targeted ScaI in both liver, after intravenous injection, and in skeletal muscle, after intramuscular injection. Although mtDNA depletion was an undesirable side effect, our data suggest that under a regulated expression system, mtDNA depletion could be minimized and restriction endonucleases recognizing multiple sites could have a potential for therapeutic use.
C1 Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA.
   Univ Miami, Miller Sch Med, Dept Cell Biol & Anat, Miami, FL 33136 USA.
C3 University of Miami; University of Miami
RP Moraes, CT (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol, 1095 NW 14th Terrace, Miami, FL 33136 USA.
EM cmoraes@med.miami.edu
FU NCI NIH HHS [R01 CA085700-08, R01 CA085700-07, R01 CA085700] Funding Source: Medline; NEI NIH HHS [R01 EY010804, R01 EY010804-11S1, R01 EY010804-13, EY10804, R01 EY010804-14A1] Funding Source: Medline; NINDS NIH HHS [R01 NS041777, R56 NS041777, R01 NS041777-07, NS041777, R01 NS041777-08] Funding Source: Medline
CR Allamand V, 2000, GENE THER, V7, P1385, DOI 10.1038/sj.gt.3301247
   Bangari DS, 2006, CURR GENE THER, V6, P215, DOI 10.2174/156652306776359478
   Barrientos A, 2002, METHODS, V26, P307, DOI 10.1016/S1046-2023(02)00036-1
   Battersby BJ, 2001, HUM MOL GENET, V10, P2469, DOI 10.1093/hmg/10.22.2469
   Bayona-Bafaluy MP, 2005, P NATL ACAD SCI USA, V102, P14392, DOI 10.1073/pnas.0502896102
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Cao HB, 2004, VIRAL IMMUNOL, V17, P327, DOI 10.1089/vim.2004.17.327
   Cazzalini O, 2001, BIOCHEM PHARMACOL, V62, P893, DOI 10.1016/S0006-2952(01)00713-4
   Chinnery PF, 2000, ANN NEUROL, V48, P188, DOI 10.1002/1531-8249(200008)48:2<188::AID-ANA8>3.3.CO;2-G
   Chinnery PF, 1999, GENE THER, V6, P1919, DOI 10.1038/sj.gt.3301061
   CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221
   Clark KM, 1997, NAT GENET, V16, P222, DOI 10.1038/ng0797-222
   DSouza GGM, 2004, CURR GENE THER, V4, P317
   De Giorgi F, 1999, METHOD CELL BIOL, V58, P75
   Diaz F, 2005, HUM MOL GENET, V14, P2737, DOI 10.1093/hmg/ddi307
   DiMauro S, 2006, CURR OPIN RHEUMATOL, V18, P636, DOI 10.1097/01.bor.0000245729.17759.f2
   Dudley RWR, 2004, HUM GENE THER, V15, P145, DOI 10.1089/104303404772679959
   Everett RS, 2003, HUM GENE THER, V14, P1715, DOI 10.1089/104303403322611737
   Gonzalez-Nicolini V, 2006, J GENE MED, V8, P1208, DOI 10.1002/jgm.960
   Gregorevic P, 2006, NAT MED, V12, P787, DOI 10.1038/nm1439
   HANNA MG, 1995, J NEUROL SCI, V130, P154, DOI 10.1016/0022-510X(95)00022-T
   HUARD J, 1995, GENE THER, V2, P107
   Jazayeri M, 2003, J BIOL CHEM, V278, P9823, DOI 10.1074/jbc.M211730200
   Jenuth JP, 1997, NAT GENET, V16, P93, DOI 10.1038/ng0597-93
   Manfred G, 1999, J BIOL CHEM, V274, P9386, DOI 10.1074/jbc.274.14.9386
   Martin-Touaux E, 2002, HUM MOL GENET, V11, P1637, DOI 10.1093/hmg/11.14.1637
   Menezes KM, 2006, HUM GENE THER, V17, P314, DOI 10.1089/hum.2006.17.314
   Mitsuoka T, 1998, NO TO SHINKEI, V50, P1089
   MORAES CT, 1992, NAT GENET, V1, P359, DOI 10.1038/ng0892-359
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Moreno-Loshuertos R, 2006, NAT GENET, V38, P1261, DOI 10.1038/ng1897
   Nicklin SA, 2005, MOL THER, V12, P384, DOI 10.1016/j.ymthe.2005.05.008
   OHara AJ, 2001, MUSCLE NERVE, V24, P488, DOI 10.1002/mus.1031
   PETRUZZELLA V, 1994, HUM MOL GENET, V3, P449, DOI 10.1093/hmg/3.3.449
   Ragot Thierry, 1996, COMPTES RENDUS DES SEANCES DE LA SOCIETE DE BIOLOGIE ET DE SES FILIALES, V190, P13
   REICHMANN H, 1992, HISTOCHEMISTRY, V98, P131, DOI 10.1007/BF00717004
   Schaefer AM, 2004, BBA-BIOENERGETICS, V1659, P115, DOI 10.1016/j.bbabio.2004.09.005
   Shayakhmetov DM, 2004, J VIROL, V78, P5368, DOI 10.1128/JVI.78.10.5368-5381.2004
   Shoubridge EA, 1997, HUM MOL GENET, V6, P2239, DOI 10.1093/hmg/6.13.2239
   SOLIGNAC M, 1983, P NATL ACAD SCI-BIOL, V80, P6942, DOI 10.1073/pnas.80.22.6942
   Srivastava S, 2001, HUM MOL GENET, V10, P3093, DOI 10.1093/hmg/10.26.3093
   Sullivan DE, 1997, HUM GENE THER, V8, P1195, DOI 10.1089/hum.1997.8.10-1195
   Taivassalo T, 1999, HUM MOL GENET, V8, P1047, DOI 10.1093/hmg/8.6.1047
   Tanaka M, 2002, J BIOMED SCI, V9, P534, DOI 10.1007/BF02254980
   Tang YY, 2000, MOL BIOL CELL, V11, P1471, DOI 10.1091/mbc.11.4.1471
   Taylor RW, 1997, NAT GENET, V15, P212, DOI 10.1038/ng0297-212
   Walther W, 2007, MOL CANCER THER, V6, P236, DOI 10.1158/1535-7163.MCT-06-0070
   Xu ZL, 2005, ADV DRUG DELIVER REV, V57, P781, DOI 10.1016/j.addr.2004.12.010
NR 48
TC 72
Z9 86
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0969-7128
EI 1476-5462
J9 GENE THER
JI Gene Ther.
PD SEP 15
PY 2007
VL 14
IS 18
BP 1309
EP 1318
DI 10.1038/sj.gt.3302981
PG 10
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine
GA 207GP
UT WOS:000249239900001
PM 17597792
DA 2024-11-01
ER

PT J
AU Nogueira, C
   Nunes, J
   Evangelista, T
   Fattori, F
   Tessa, A
   Pereira, C
   Santorelli, FM
   Vilarinho, L
AF Nogueira, Celia
   Nunes, Joao
   Evangelista, Teresinha
   Fattori, Fabiana
   Tessa, Alessandra
   Pereira, Cristina
   Santorelli, Filippo M.
   Vilarinho, Laura
TI A new mtDNA-tRNA<SUP>Glu</SUP> mutation (14728T &gt; C) presenting a late-onset mitochondrial encephalomyopathy
SO MITOCHONDRION
LA English
DT Article
DE mtDNA; late-onset myopathy; ataxia
ID transfer-rnas; dna; deficiency; features; disease
AB We identified a new mutation in the mtDNA-encoded transfer RNA glutamate gene (tRNAGlu) in a patient presenting with late-onset myopathy. The mutation was nearly homoplasmic in muscle but hardly detectable in peripheral blood. Adding to the list of disease-related mtDNA variants, our findings propose to consider screening of tRNAGlu in cases of late-onset neuromuscular disorders. (c) 2007 Elsevier B.V. and Mitochondria Research Society. All rights reserved.
C1 [Nogueira, Celia; Pereira, Cristina; Vilarinho, Laura] Inst Med Genet, P-4099028 Oporto, Portugal.
   [Nunes, Joao] Inst Portugues Oncol Francisco Gentil, P-1099023 Lisbon, Portugal.
   [Evangelista, Teresinha] Neuropathol Unit, P-1649035 Lisbon, Portugal.
   [Fattori, Fabiana; Tessa, Alessandra; Santorelli, Filippo M.] Childrens Hosp Bambino Gesu, IRCCS, I-00165 Rome, Italy.
C3 Portuguese Institute of Oncology; IRCCS Bambino Gesu
RP Vilarinho, L (corresponding author), Inst Med Genet, Praca Pedro Nunes 88, P-4099028 Oporto, Portugal.
EM laura.vilarinho@igm.min-saude.pt
CR CORMIERDAIRE V, 1994, J PEDIATR-US, V124, P63, DOI 10.1016/S0022-3476(94)70255-1
   DiMauro S, 2005, NEUROMUSCULAR DISORD, V15, P276, DOI 10.1016/j.nmd.2004.12.008
   DIMAURO S, 1987, ANN NEUROL, V22, P498, DOI 10.1002/ana.410220409
   Helm M, 2000, RNA, V6, P1356, DOI 10.1017/S1355838200001047
   Kirino Y, 2005, P NATL ACAD SCI USA, V102, P7127, DOI 10.1073/pnas.0500563102
   Melone MAB, 2004, ARCH NEUROL-CHICAGO, V61, P269, DOI 10.1001/archneur.61.2.269
   MORAES CT, 1993, MITOCHONDRIAL DNA HU, V8, P7
   Pistilli D, 2003, HUM PATHOL, V34, P1058, DOI 10.1053/S0046-8177(03)00344-7
   Sciacco M, 1996, METHODS ENZYMOL, V264, P509, DOI 10.1016/S0076-6879(96)64045-2
   Taylor RW, 1998, BIOCHEM BIOPH RES CO, V251, P883, DOI 10.1006/bbrc.1998.9553
   Vilarinho L, 1999, J NEUROL SCI, V163, P168, DOI 10.1016/S0022-510X(99)00030-1
NR 11
TC 7
Z9 7
U1 1
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
EI 
J9 MITOCHONDRION
JI Mitochondrion
PD DEC 15
PY 2007
VL 7
IS 6
BP 396
EP 398
DI 10.1016/j.mito.2007.08.002
PG 3
WC Cell Biology; Genetics & Heredity
SC Cell Biology; Genetics & Heredity
GA 242TU
UT WOS:000251749900005
PM 17897888
DA 2024-11-01
ER

PT J
AU Li, JY
   Hsieh, RH
   Peng, NJ
   Lai, PH
   Lee, CF
   Lo, YK
   Wei, YH
AF Li, Jie-Yuan
   Hsieh, Rong-Hong
   Peng, Nan-Jing
   Lai, Ping-Hong
   Lee, Cheng-Feng
   Lo, Yuk-Keung
   Wei, Yau-Huei
TI A follow-up study in a Taiwanese family with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes syndrome
SO JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
LA English
DT Article
DE follow-up study; MELAS; mitochondrial disease; mitochondrial DNA; mutation
ID transfer rnaleu(uur) gene; melas syndrome; clinical presentations; diabetes-mellitus; mutation; dna; encephalomyopathy; diseases; patient; involvement
AB Background/Purpose: MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes) syndrome is often associated with A3243G point mutation of mitochondrial DNA (mtDNA). We previously described a MELAS family characterized by harboring an additional similar to 260 bp tandem duplication in the D-loop and a novel C3093G point mutation in the 16S rRNA gene of mtDNA in the proband. We studied the clinical progression and fluctuation of mtDNA mutations in this Taiwanese MELAS family. Methods: We followed up the clinical course in all members of this family (I proband, her mother and 3 sons) for 12 years. Mutations of mtDNA in serial muscle biopsies of the proband and blood samples and hair follicles taken at different time points from the members of this family were analyzed. Results: The proband developed repeated stroke-like episodes, chronic intestinal pseudo-obstruction, polyneuropathy, progressive renal failure and dilated cardiomyopathy with heart failure. During the follow-up period, the mother and one of the siblings of the proband developed stroke-like episodes at age 62 and 12, respectively. There was no significant difference in the proportions of mtDNA with A3243G mutation among five serial muscle biopsies of the proband. In one carrier (1-2), the proportion of A3243G mutated mtDNA in blood cells was slightly increased with disease progression. Conclusion: This study underlines the importance of early detection of extraneuromuscular symptoms in the members of a family with MELAS syndrome by adequate follow-up. The age of onset of stroke-like episode in MELAS syndrome may be as late as 62 years. We suggest that the manifestations of MELAS syndrome in this family might be associated with the additional similar to 260 bp tandem duplication in the D-loop region and the coexistence of C3093G mutation in the 16S rRNA gene with the A3243G mutation of mtDNA.
C1 Natl Yang Ming Univ, Sch Life Sci, Dept Biochem Mol Biol, Taipei 112, Taiwan.
   Kaohsiung & Natl Yang Ming Univ, Div Neurol, Taipei, Taiwan.
   Kaohsiung & Natl Yang Ming Univ, Dept Nucl Med, Taipei, Taiwan.
   Kaohsiung & Natl Yang Ming Univ, Kaohsiung Vet Gen Hosp, Dept Radiol, Taipei, Taiwan.
   Taipei Med Univ, Sch Nutr & Hlth Sci, Taipei, Taiwan.
   Natl Yang Ming Univ, Sch Life Sci, Dept Biochem Mol Biol, Taipei, Taiwan.
C3 National Yang Ming Chiao Tung University; Kaohsiung Veterans General Hospital; Taipei Medical University; National Yang Ming Chiao Tung University
RP Wei, YH (corresponding author), Natl Yang Ming Univ, Sch Life Sci, Dept Biochem Mol Biol, 155 Li Nong St,Sect 2,Shih-Pai, Taipei 112, Taiwan.
EM joeman@ym.edu.tw
CR Arenas J, 1999, NEUROLOGY, V52, P377, DOI 10.1212/WNL.52.2.377
   Bidooki SK, 1997, AM J HUM GENET, V60, P1430, DOI 10.1086/515460
   Chang TM, 2004, PEDIATR NEUROL, V31, P374, DOI 10.1016/j.pediatrneurol.2004.05.009
   Chinnery PF, 1997, BRAIN, V120, P1713, DOI 10.1093/brain/120.10.1713
   CIAFALONI E, 1992, ANN NEUROL, V31, P391, DOI 10.1002/ana.410310408
   DAMIAN MS, 1995, ACTA NEUROL SCAND, V92, P409
   DiMauro S, 2004, BBA-BIOENERGETICS, V1658, P80, DOI 10.1016/j.bbabio.2004.03.014
   Dimauro S, 2005, ANN MED, V37, P222, DOI 10.1080/07853890510007368
   DiMauro S, 2006, MUSCLE NERVE, V34, P265, DOI 10.1002/mus.20598
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Hiel JAP, 1998, NETH J MED, V53, P27, DOI 10.1016/S0300-2977(98)00018-7
   Hsieh RH, 2001, J BIOMED SCI, V8, P328, DOI 10.1159/000054051
   KADOWAKI T, 1994, NEW ENGL J MED, V330, P962, DOI 10.1056/NEJM199404073301403
   KAWAKAMI Y, 1994, ANN NEUROL, V35, P370, DOI 10.1002/ana.410350322
   KOBAYASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P816, DOI 10.1016/S0006-291X(05)80860-5
   LARSSON NG, 1990, PEDIATR RES, V28, P131, DOI 10.1203/00006450-199028020-00011
   Lev D, 2004, PEDIATR CARDIOL, V25, P443, DOI 10.1007/s00246-003-0490-7
   Li JY, 1996, ACTA NEUROL SCAND, V93, P450
   Lien LM, 2001, ACTA NEUROL SCAND, V103, P159, DOI 10.1034/j.1600-0404.2001.103003159.x
   Miyamoto A, 1997, NEURORADIOLOGY, V39, P427, DOI 10.1007/s002340050438
   MORAES CT, 1993, NEUROMUSCULAR DISORD, V3, P43, DOI 10.1016/0960-8966(93)90040-Q
   Nardin RA, 2001, MUSCLE NERVE, V24, P170, DOI 10.1002/1097-4598(200102)24:2<170::AID-MUS30>3.0.CO;2-0
   Ohno K, 1996, ANN NEUROL, V39, P761, DOI 10.1002/ana.410390612
   Okajima Y, 1998, HEART, V80, P292, DOI 10.1136/hrt.80.3.292
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   ROSEN L, 1990, NEURORADIOLOGY, V32, P168, DOI 10.1007/BF00588572
   Sano M, 1995, ACTA NEUROL SCAND, V92, P497
   Valanne L, 1998, AM J NEURORADIOL, V19, P369
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   Watanabe Y, 1998, J NUCL MED, V39, P961
NR 30
TC 13
Z9 17
U1 0
U2 2
PU ELSEVIER TAIWAN
PI TAIPEI
PA RM N-412, 4F, CHIA HSIN BUILDING 11, NO 96, ZHONG SHAN N ROAD SEC 2, TAIPEI, 10449, TAIWAN
SN 0929-6646
EI 1876-0821
J9 J FORMOS MED ASSOC
JI J. Formos. Med. Assoc.
PD JUL 15
PY 2007
VL 106
IS 7
BP 528
EP 536
DI 10.1016/S0929-6646(07)60003-5
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 197UT
UT WOS:000248582700003
PM 17660142
DA 2024-11-01
ER

PT J
AU Finsterer, J
AF Finsterer, J.
TI Genetic, pathogenetic, and phenotypic implications of the mitochondrial A3243G tRNALeu(UUR) mutation
SO ACTA NEUROLOGICA SCANDINAVICA
LA English
DT Review
DE mitochondrial; metabolic myopathy; genotype; phenotype; ribonucleic acid; mutation; genetics
ID stroke-like episodes; wobble modification deficiency; peptide nucleic-acid; mutant transfer-rnas; lactic-acidosis; point mutation; dna mutation; leigh-syndrome; diabetes-mellitus; melas mutation
AB Mitochondrial disorders are frequently caused by mutations in mitochondrial genes and usually present as multisystem disease. One of the most frequent mitochondrial mutations is the A3243G transition in the tRNALeu(UUR) gene. The phenotypic expression of the mutation is variable and comprises syndromic or non-syndromic mitochondrial disorders. Among the syndromic manifestations the mitochondrial encephalopathy, lactacidosis, and stroke-like episode (MELAS) syndrome is the most frequent. In single cases the A3243G mutation may be associated with maternally inherited diabetes and deafness syndrome, myoclonic epilepsy and ragged-red fibers (MERRF) syndrome, MELAS/MERRF overlap syndrome, maternally inherited Leigh syndrome, chronic external ophthalmoplegia, or Kearns-Sayre syndrome. The wide phenotypic variability of the mutation is explained by the peculiarities of the mitochondrial DNA, such as heteroplasmy and mitotic segregation, resulting in different mutation loads in different tissues and family members. Moreover, there is some evidence that additional mtDNA sequence variations (polymorphisms, haplotypes) influence the phenotype of the A3243G mutation. This review aims to give an overview on the actual knowledge about the genetic, pathogenetic, and phenotypic implications of the A3243G mtDNA mutation.
C1 Krankenanstalt Rudolfstiftung Wien, Vienna, Austria.
C3 Rudolfstiftung Hospital
RP Finsterer, J (corresponding author), Postfach 20, A-1180 Vienna, Austria.
EM duarte@aonmail.at
CR Abe K, 2004, NEUROLOGY, V63, P2458, DOI 10.1212/WNL.63.12.2458
   Abu-Amero Khaled K, 2005, OPHTHALMIC GENET, V26, P31, DOI 10.1080/13816810590918235
   AGAFITOS E, 1997, GEN DIAGN PATHOL, V142, P335
   Akbari M, 2004, SCAND J CLIN LAB INV, V64, P86, DOI 10.1080/00365510410004209
   Akman CI, 2004, J CHILD NEUROL, V19, P258, DOI 10.1177/088307380401900403
   ANAN R, 1995, CIRCULATION, V91, P955, DOI 10.1161/01.CIR.91.4.955
   Aoki Y, 2002, ANN INTERN MED, V137, P703, DOI 10.7326/0003-4819-137-8-200210150-00031
   Apostolova LG, 2005, ARCH NEUROL-CHICAGO, V62, P1154, DOI 10.1001/archneur.62.7.1154
   Arii J, 2000, AM J NEURORADIOL, V21, P1502
   Bai RK, 2004, CLIN CHEM, V50, P996, DOI 10.1373/clinchem.2004.031153
   Bellmann C, 2004, INVEST OPHTH VIS SCI, V45, P2355, DOI 10.1167/iovs.03-1090
   Blanco-Barca O, 2004, REV NEUROLOGIA, V39, P618
   Börner GV, 2000, HUM MOL GENET, V9, P467, DOI 10.1093/hmg/9.4.467
   Bosbach S, 2003, BRAIN, V126, P1231, DOI 10.1093/brain/awg101
   Brière JJ, 2004, BIOCHEM BIOPH RES CO, V316, P1138, DOI 10.1016/j.bbrc.2004.03.002
   Brown DT, 2001, AM J HUM GENET, V68, P533, DOI 10.1086/318190
   Bruno C, 2002, J CHILD NEUROL, V17, P233, DOI 10.1177/088307380201700318
   Campos Y, 1996, MUSCLE NERVE, V19, P187, DOI 10.1002/(SICI)1097-4598(199602)19:2<187::AID-MUS10>3.0.CO;2-S
   Carmi E, 2001, ANN DERMATOL VENER, V128, P1031
   Casademont J, 2004, MED SCI MONITOR, V10, P0
   Chae JH, 2004, BRAIN DEV-JPN, V26, P459, DOI 10.1016/j.braindev.2004.01.002
   Chalmers RM, 1997, NEUROLOGY, V49, P589, DOI 10.1212/WNL.49.2.589
   Chen Yung-Nien, 2004, CHANG GUNG MED J, V27, P66
   Chinnery PE, 1998, BRAIN, V121, P1889, DOI 10.1093/brain/121.10.1889
   Chinnery PF, 2001, NEUROLOGY, V56, P1101, DOI 10.1212/WNL.56.8.1101
   Chinnery PF, 1997, BRAIN, V120, P1713, DOI 10.1093/brain/120.10.1713
   Chol M, 2003, J MED GENET, V40, P188, DOI 10.1136/jmg.40.3.188
   Chomyn A, 2000, J BIOL CHEM, V275, P19198, DOI 10.1074/jbc.M908734199
   CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221
   Cooper JM, 2003, BIOFACTORS, V18, P163, DOI 10.1002/biof.5520180219
   Crimi M, 2005, FASEB J, V19, P866, DOI 10.1096/fj.04-3045fje
   de Andrade PBM, 2006, DIABETOLOGIA, V49, P1816, DOI 10.1007/s00125-006-0301-9
   De Coo IFM, 1999, ANN NEUROL, V45, P130, DOI 10.1002/1531-8249(199901)45:1<130::AID-ART21>3.0.CO;2-Z
   Deschauer M, 2004, J NEUROL NEUROSUR PS, V75, P1204, DOI 10.1136/jnnp.2003.026278
   Deschauer M, 2001, ARCH NEUROL-CHICAGO, V58, P1885, DOI 10.1001/archneur.58.11.1885
   Desguerre I, 2003, NEUROPEDIATRICS, V34, P265
   Doleris LM, 2000, KIDNEY INT, V58, P1851, DOI 10.1046/j.1523-1755.2000.00356.x
   Durand-Dubief F, 2004, REV NEUROL-FRANCE, V160, P824, DOI 10.1016/S0035-3787(04)71038-3
   El Meziane A, 1998, HUM MOL GENET, V7, P2141, DOI 10.1093/hmg/7.13.2141
   Fabrizi GM, 1996, J NEUROL NEUROSUR PS, V61, P47, DOI 10.1136/jnnp.61.1.47
   Farina L, 2002, AM J NEURORADIOL, V23, P1095
   Finsterer J, 2006, ACTA NEUROL SCAND, V114, P217, DOI 10.1111/j.1600-0404.2006.00671.x
   Finsterer J, 2005, CLIN NEUROL NEUROSUR, V107, P181, DOI 10.1016/j.clineuro.2004.07.001
   Finsterer J, 2004, CARDIOLOGY, V102, P228, DOI 10.1159/000081015
   Finsterer J, 2003, EUR NEUROL, V49, P186, DOI 10.1159/000069078
   Flierl A, 1997, J BIOL CHEM, V272, P27189, DOI 10.1074/jbc.272.43.27189
   Florentz C, 2002, BIOSCIENCE REP, V22, P81, DOI 10.1023/A:1016065107165
   Fujii A, 2004, INTERNAL MED, V43, P1126, DOI 10.2169/internalmedicine.43.1126
   GERBITZ KD, 1995, BBA-MOL BASIS DIS, V1271, P253, DOI 10.1016/0925-4439(95)00036-4
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Hancock DK, 2002, CLIN CHEM, V48, P2155
   Hao R, 2004, FEBS LETT, V578, P135, DOI 10.1016/j.febslet.2004.11.004
   Helm M, 1999, NUCLEIC ACIDS RES, V27, P756, DOI 10.1093/nar/27.3.756
   Huang CC, 2002, J BIOMED SCI, V9, P527, DOI 10.1007/BF02254979
   Huntsman RJ, 2005, PEDIATR NEUROL, V32, P334, DOI 10.1016/j.pediatrneurol.2004.12.009
   Iizuka T, 2003, NEUROLOGY, V61, P577, DOI 10.1212/01.WNL.0000078931.87815.B3
   Iizuka T, 2002, NEUROLOGY, V59, P816, DOI 10.1212/WNL.59.6.816
   Jacobs HT, 2000, HUM MOL GENET, V9, P463, DOI 10.1093/hmg/9.4.463
   Janssen GMC, 1999, J BIOL CHEM, V274, P29744, DOI 10.1074/jbc.274.42.29744
   Jeppesen TD, 2003, J NEUROL SCI, V214, P17, DOI 10.1016/S0022-510X(03)00168-0
   Jiang YW, 2002, J CHILD NEUROL, V17, P450, DOI 10.1177/088307380201700611
   Jones M, 2004, AM J OPHTHALMOL, V138, P1051, DOI 10.1016/j.ajo.2004.06.026
   Kanaumi T, 2006, PEDIATR NEUROL, V34, P235, DOI 10.1016/j.pediatrneurol.2005.08.024
   Kang JH, 2005, J NEUROL, V252, P103, DOI 10.1007/s00415-005-0600-y
   Kariya S, 2005, NEUROPEPTIDES, V39, P97, DOI 10.1016/j.npep.2004.11.004
   Kaufmann P, 2004, NEUROLOGY, V62, P1297, DOI 10.1212/01.WNL.0000120557.83907.A8
   Kaufmann P, 2006, ARCH NEUROL-CHICAGO, V63, P746, DOI 10.1001/archneur.63.5.746
   Keng WT, 2003, DEV MED CHILD NEUROL, V45, P704
   Kharasch ED, 2006, ANESTHESIOLOGY, V105, P737, DOI 10.1097/00000542-200610000-00020
   KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480
   Kirby DM, 2003, ANN NEUROL, V54, P473, DOI 10.1002/ana.10687
   Kirino Y, 2006, HUM MOL GENET, V15, P897, DOI 10.1093/hmg/ddl007
   Kirino Y, 2004, P NATL ACAD SCI USA, V101, P15070, DOI 10.1073/pnas.0405173101
   Kishnani PS, 1996, EUR J PEDIATR, V155, P898
   Klemm T, 2001, EXP CLIN ENDOCR DIAB, V109, P283, DOI 10.1055/s-2001-16348
   Koga A, 2003, NEUROMUSCULAR DISORD, V13, P259, DOI 10.1016/S0960-8966(02)00267-5
   Koga Y, 2006, NEUROLOGY, V66, P1766, DOI 10.1212/01.wnl.0000220197.36849.1e
   Koga Y, 2005, NEUROLOGY, V64, P710, DOI 10.1212/01.WNL.0000151976.60624.01
   Koga Y, 2000, ARCH DIS CHILD, V82, P407, DOI 10.1136/adc.82.5.407
   Köller H, 2003, J NEUROL, V250, P1501, DOI 10.1007/s00415-003-0260-8
   Leonard JV, 2000, LANCET, V355, P389, DOI 10.1016/S0140-6736(99)05226-5
   Lerman-Sagie T, 2005, MOL GENET METAB, V84, P127, DOI 10.1016/j.ymgme.2004.09.008
   Levinger L, 2004, J MOL BIOL, V337, P535, DOI 10.1016/j.jmb.2004.02.008
   Lien LM, 2001, ACTA NEUROL SCAND, V103, P159, DOI 10.1034/j.1600-0404.2001.103003159.x
   Liou CW, 2001, DIABETES RES CLIN PR, V54, PS39, DOI 10.1016/S0168-8227(01)00334-5
   Liu CS, 2006, ACTA NEUROL SCAND, V113, P334, DOI 10.1111/j.1600-0404.2006.00586.x
   Lodi R, 2004, BBA-BIOENERGETICS, V1657, P146, DOI 10.1016/j.bbabio.2004.05.003
   Lorenc A, 2003, MITOCHONDRION, V3, P119, DOI 10.1016/S1567-7249(03)00106-5
   Löwik MM, 2005, NEPHROL DIAL TRANSPL, V20, P336, DOI 10.1093/ndt/gfh546
   Lynn S, 2003, DIABETOLOGIA, V46, P296, DOI 10.1007/s00125-002-1018-z
   Maassen JA, 2005, ANN MED, V37, P213, DOI 10.1080/07853890510007188
   Maassen JA, 2001, EXP CLIN ENDOCR DIAB, V109, P127, DOI 10.1055/s-2001-14834
   Majamaa-Voltti KAM, 2006, NEUROLOGY, V66, P1470, DOI 10.1212/01.wnl.0000216136.61640.79
   Mancuso M, 2004, NEUROLOGY, V62, P2119, DOI 10.1212/01.WNL.0000127608.48406.F1
   Mancuso M, 2004, ACTA NEUROL SCAND, V110, P72, DOI 10.1111/j.1600-0404.2004.00254.x
   MarinGarcia J, 1996, PEDIATR CARDIOL, V17, P387, DOI 10.1007/s002469900084
   Masucci JP, 1996, MOL BIOL REP, V22, P187, DOI 10.1007/BF00988727
   McFarland R, 2002, LANCET NEUROL, V1, P343, DOI 10.1016/S1474-4422(02)00159-X
   Meierhofer D, 2006, BRIT J CANCER, V94, P268, DOI 10.1038/sj.bjc.6602929
   Mikol J, 2005, ANN PATHOL, V25, P292, DOI 10.1016/S0242-6498(05)80133-6
   Mori M, 2004, BRAIN DEV-JPN, V26, P453, DOI 10.1016/j.braindev.2003.12.009
   Moslemi AR, 2003, NEUROLOGY, V61, P991, DOI 10.1212/01.WNL.0000082391.98672.0A
   Nagata H, 2001, J HUM GENET, V46, P595, DOI 10.1007/s100380170027
   Nakano K, 2005, MITOCHONDRION, V5, P426, DOI 10.1016/j.mito.2005.10.002
   Nan DN, 2002, POSTGRAD MED J, V78, P298, DOI 10.1136/pmj.78.919.298
   Narbonne H, 2004, DIABETES METAB, V30, P61, DOI 10.1016/S1262-3636(07)70090-3
   Narbonne H, 2001, EUR J ENDOCRINOL, V145, P541, DOI 10.1530/eje.0.1450541
   Nomiyama T, 2004, ANN NY ACAD SCI, V1011, P193, DOI 10.1196/annals.1293.020
   Ohkubo K, 2001, CLIN CHEM, V47, P1641
   Oishi Kenichi, 2003, RINSHO SHINKEIGAKU, V43, P154
   Okhuijsen-Kroes EJ, 2001, NEUROPEDIATRICS, V32, P183, DOI 10.1055/s-2001-17372
   Otsuki T, 2005, ARCH NEUROL-CHICAGO, V62, P485, DOI 10.1001/archneur.62.3.485
   Pang CY, 1999, J FORMOS MED ASSOC, V98, P326
   Park H, 2003, BIOCHEMISTRY-US, V42, P958, DOI 10.1021/bi026882r
   Patel MN, 2002, FREE RADICAL RES, V36, P1139, DOI 10.1080/1071576021000016391
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   Pons R, 2004, J PEDIATR-US, V144, P81, DOI 10.1016/j.jpeds.2003.10.023
   Pronicki Maciej, 2002, MED SCI MONIT, V8, P0
   Pulkes T, 2000, LANCET, V356, P2068, DOI 10.1016/S0140-6736(00)03408-5
   Rahman S, 2001, AM J HUM GENET, V68, P238, DOI 10.1086/316930
   Rossi A, 2003, AM J NEURORADIOL, V24, P1188
   Rossmanith W, 1998, FEBS LETT, V433, P269, DOI 10.1016/S0014-5793(98)00928-4
   Roy MD, 2005, RNA, V11, P254, DOI 10.1261/rna.7143305
   Rustin P, 2003, EXPERT OPIN INV DRUG, V12, P569, DOI 10.1517/eoid.12.4.569.23756
   Sakuta R, 2002, PEDIATR NEUROL, V27, P397, DOI 10.1016/S0887-8994(02)00456-3
   Saneto RP, 2006, J CHILD NEUROL, V21, P77, DOI 10.1177/08830738060210010601
   Sangkhathat S, 2005, PEDIATR SURG INT, V21, P745, DOI 10.1007/s00383-005-1471-0
   Santorelli FM, 1998, MUSCLE NERVE, V21, P681
   Schapira AHV, 1999, EUR J CLIN INVEST, V29, P886
   Schöls L, 2004, J NEURAL TRANSM-SUPP, V0, P135
   SCHON EA, 1992, BIOCHIM BIOPHYS ACTA, V1101, P206, DOI 10.1016/0005-2728(92)90226-R
   Schulte-Mattler WJ, 2003, ARCH NEUROL-CHICAGO, V60, P50, DOI 10.1001/archneur.60.1.50
   Sciacco M, 2003, J NEUROL, V250, P1498, DOI 10.1007/s00415-003-0246-6
   Seneca S, 2001, ARCH NEUROL-CHICAGO, V58, P1113, DOI 10.1001/archneur.58.7.1113
   Servidei Serenella, 2004, NEUROMUSCUL DISORD, V14, P107
   Shanske S, 2004, AM J MED GENET A, V130A, P134, DOI 10.1002/ajmg.a.30220
   SHIMOMURA T, 1994, LANCET, V344, P625, DOI 10.1016/S0140-6736(94)92015-X
   Sohm B, 2003, J MOL BIOL, V328, P995, DOI 10.1016/S0022-2836(03)00373-5
   Sparaco M, 2003, ACTA NEUROPATHOL, V106, P202, DOI 10.1007/s00401-003-0716-z
   Strachan J, 2001, J INHERIT METAB DIS, V24, P409, DOI 10.1023/A:1010573122748
   Sue CM, 1998, J NEUROL SCI, V161, P36, DOI 10.1016/S0022-510X(98)00179-8
   Suzuki Y, 2004, DIABETES RES CLIN PR, V63, P225, DOI 10.1016/j.diabres.2003.10.024
   Tafrechi RSJ, 2005, MUTAT RES-FUND MOL M, V578, P43, DOI 10.1016/j.mrfmmm.2005.02.002
   Tanaka K, 2000, INTERNAL MED, V39, P249, DOI 10.2169/internalmedicine.39.249
   Tay SHK, 2006, ARCH NEUROL-CHICAGO, V63, P281, DOI 10.1001/archneur.63.2.281
   Tay SKH, 2005, J CHILD NEUROL, V20, P142, DOI 10.1177/08830738050200022301
   Thauvin-Robinet C, 2006, EUR J MED GENET, V49, P71, DOI 10.1016/j.ejmg.2005.04.001
   Thorns C, 1998, EXP CLIN ENDOCR DIAB, V106, P384, DOI 10.1055/s-0029-1212003
   Torroni A, 2003, AM J HUM GENET, V72, P1005, DOI 10.1086/373936
   TRA J, 1995, ACTA NEUROL SCAND, V92, P394
   Tsao CY, 2003, J CHILD NEUROL, V18, P62, DOI 10.1177/08830738030180011401
   Tsuji M, 2003, BRAIN DEV-JPN, V25, P245, DOI 10.1016/S0387-7604(02)00220-6
   Tzen CY, 2003, MUSCLE NERVE, V28, P575, DOI 10.1002/mus.10473
   Ueki I, 2006, MITOCHONDRION, V6, P29, DOI 10.1016/j.mito.2005.10.003
   Urata M, 2004, CLIN CHEM, V50, P2045, DOI 10.1373/clinchem.2004.033761
   Van Goethem G, 2003, NEUROLOGY, V61, P1811, DOI 10.1212/01.WNL.0000098997.23471.65
   VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368
   Vielhaber S, 2002, J NEUROPATH EXP NEUR, V61, P885, DOI 10.1093/jnen/61.10.885
   WALLACE DC, 1994, P NATL ACAD SCI USA, V91, P8739, DOI 10.1073/pnas.91.19.8739
   Wang Zhen-Cheng, 2003, YICHUAN, V25, P383
   White HE, 2005, GENET TEST, V9, P190, DOI 10.1089/gte.2005.9.190
   Wilichowski E, 1998, J NEUROL SCI, V157, P206, DOI 10.1016/S0022-510X(98)00068-9
   Wilson CJ, 2000, J CHILD NEUROL, V15, P830, DOI 10.1177/088307380001501218
   Wittenhagen LM, 2003, NUCLEIC ACIDS RES, V31, P596, DOI 10.1093/nar/gkg131
   Wittenhagen LM, 2002, NAT STRUCT BIOL, V9, P586, DOI 10.1038/nsb820
   Wong LJC, 2004, MUSCLE NERVE, V30, P118, DOI 10.1002/mus.20045
   Yang YL, 2006, CHINESE MED J-PEKING, V119, P373, DOI 10.1097/00029330-200603010-00004
   Yasukawa T, 2005, FEBS LETT, V579, P2948, DOI 10.1016/j.febslet.2005.04.038
   Yasukawa T, 2000, J BIOL CHEM, V275, P4251, DOI 10.1074/jbc.275.6.4251
   Younes-Mhenni S, 2002, REV MED INTERNE, V23, P1027, DOI 10.1016/S0248-8663(02)00730-0
   Zeviani M, 2003, CURR OPIN NEUROL, V16, P585, DOI 10.1097/00019052-200310000-00004
   Zhang Ying, 2005, ZHONGGUO YI XUE KE XUE YUAN XUE BAO, V27, P77
NR 172
TC 88
Z9 113
U1 0
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0001-6314
EI 1600-0404
J9 ACTA NEUROL SCAND
JI Acta Neurol. Scand.
PD JUL 15
PY 2007
VL 116
IS 1
BP 1
EP 14
DI 10.1111/j.1600-0404.2007.00836.x
PG 14
WC Clinical Neurology
SC Neurosciences & Neurology
GA 181ZS
UT WOS:000247475500001
PM 17587249
DA 2024-11-01
ER

PT J
AU Prigione, A
   Cortopassi, G
AF Prigione, Alessandro
   Cortopassi, Gino
TI Mitochondrial DNA deletions and chloramphenicol treatment stimulate the autophagic transcript ATG12
SO AUTOPHAGY
LA English
DT Article
DE mitochondria; mtDNA deletions; autophagy; ATG12; chloramphenicol; tRNAs deletion; mitochondrial protein synthesis
ID substantia-nigra neurons; parkinsons-disease; human brain; proteasome; muscle; neurodegeneration; translation; degradation; pathways; proteins
AB Deletion mutations of mitochondrial DNA (mtDNA) accumulate somatically on a cell-by-cell basis with age, resulting in decreased cell function in muscle and substantia nigra. In osteosarcoma cells deletions incapacitate mitochondria and induce the autophagic transcript ATG12, which is involved in an early step of the mammalian autophagy pathway. We discuss here which consequences of mtDNA deletions could induce ATG12, and provide two new pieces of data. Our previous studies demonstrated that mtDNA deletions decreased mitochondrial ATP production and proteasomal function, induced the AMPK transcript (likely as a consequence of bioenergetic depletion), and decreased the intracellular concentration of 20 amino acids (possibly as a consequence of decreased proteasomal activity). Deletions eliminate essential tRNAs for mitochondrial protein synthesis, as well as essential components of mitochondrial multisubunit enzymes; therefore, the increased level of ATG12 could result from decreased bioenergetic function, increased oxidative damage, or decreased mitochondrial protein synthesis. However, the bioenergetic inhibitor rotenone does not induce ATG12. We show here that chloramphenicol, which inhibits mitochondrial protein synthesis, induces ATG12, and that mtDNA deletions result in an increased burden of oxidatively damaged protein. Thus, mtDNA deletions could induce ATG12 through a mechanism such as the following: deletions > mitochondrial protein synthesis inhibition or ROS > proteasome inhibition > amino acid depletion > ATG12.
C1 Univ Calif Davis, Dept Mol Biosci, Davis, CA 95616 USA.
   Univ Milano Bicocca, Dept Neurosci & Biomed Technol, Monza, Italy.
C3 University of California System; University of California Davis; University of Milano-Bicocca
RP Cortopassi, G (corresponding author), Univ Calif Davis, Dept Mol Biosci, 1311 Haring Hall, Davis, CA 95616 USA.
EM gcortopossi@ucdavis.edu
CR Alemi M, 2007, FREE RADICAL BIO MED, V42, P32, DOI 10.1016/j.freeradbiomed.2006.09.014
   Anglade P, 1997, HISTOL HISTOPATHOL, V12, P25
   Anthony JC, 2000, J NUTR, V130, P2413
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Betarbet R, 2006, NEUROBIOL DIS, V22, P404, DOI 10.1016/j.nbd.2005.12.003
   Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834
   CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324
   CORTOPASSI GA, 1992, P NATL ACAD SCI USA, V89, P7370, DOI 10.1073/pnas.89.16.7370
   Darsow T, 1997, J CELL BIOL, V138, P517, DOI 10.1083/jcb.138.3.517
   Davies KJA, 2006, NEUROLOGY, V66, PS93, DOI 10.1212/01.wnl.0000192308.43151.63
   Hanada T, 2005, AUTOPHAGY, V1, P110, DOI 10.4161/auto.1.2.1858
   Hardy J, 2006, ANN NEUROL, V60, P389, DOI 10.1002/ana.21022
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Ishihara N, 2001, MOL BIOL CELL, V12, P3690, DOI 10.1091/mbc.12.11.3690
   Jefferson LS, 2003, J NUTR, V133, P2046S, DOI 10.1093/jn/133.6.2046S
   Jou MJ, 2005, ANN NY ACAD SCI, V1042, P221, DOI 10.1196/annals.1338.024
   Kraytsberg Y, 2006, NAT GENET, V38, P518, DOI 10.1038/ng1778
   Lindsley JE, 2004, COMP BIOCHEM PHYS B, V139, P543, DOI 10.1016/j.cbpc.2004.06.014
   MITA S, 1989, P NATL ACAD SCI USA, V86, P9509, DOI 10.1073/pnas.86.23.9509
   Muqit MMK, 2006, ARCH NEUROL-CHICAGO, V63, P649, DOI 10.1001/archneur.63.5.649
   PRIGIONE A, 2007, UNPUB AGING CELL, V0, P0
   Reggiori F, 2004, MOL BIOL CELL, V15, P2189, DOI 10.1091/mbc.E03-07-0479
   Rubinsztein DC, 2006, NATURE, V443, P780, DOI 10.1038/nature05291
   SOONG NW, 1992, NAT GENET, V2, P318
   Sullivan PG, 2004, J BIOL CHEM, V279, P20699, DOI 10.1074/jbc.M313579200
   Zhu JH, 2003, BRAIN PATHOL, V13, P473
   Zhu JH, 2007, AM J PATHOL, V170, P75, DOI 10.2353/ajpath.2007.060524
NR 27
TC 23
Z9 25
U1 0
U2 6
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1554-8627
EI 1554-8635
J9 AUTOPHAGY
JI Autophagy
PD JUL-AUG 15
PY 2007
VL 3
IS 4
BP 377
EP 380
DI 10.4161/auto.4239
PG 4
WC Cell Biology
SC Cell Biology
GA 183DY
UT WOS:000247554100017
PM 17457038
DA 2024-11-01
ER

PT J
AU Pereira, C
   Nogueira, C
   Barbot, C
   Tessa, A
   Soares, C
   Fattori, F
   Guimaraes, A
   Santorelli, FM
   Vilarinho, L
AF Pereira, Cristina
   Nogueira, Celia
   Barbot, Clara
   Tessa, Alessandra
   Soares, Carla
   Fattori, Fabiana
   Guimaraes, Antonio
   Santorelli, Filippo M.
   Vilarinho, Laura
TI Identification of a new mtDNA mutation (14724G&gt;A) associated with mitochondrial leukoencephalopathy
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE mtDNA; mutation; transfer RNA
ID white-matter involvement; c-oxidase deficiency; point mutation; leigh-syndrome; dna; diagnosis; disorders; trna(glu); children; diseases
AB We report a novel 14724G > A mutation in the mitochondrial tRNA glutamic acid gene in a 4-year-old boy with myopathy and leukoencephalopathy. A muscle biopsy showed cytochrome c oxidase-negative ragged-red fibers and biochemical analysis of the respiratory chain enzymes in muscle homogenate revealed partial complex I and complex IV deficiencies. The mutation, which affects the dihydrouridine arm at a conserved site, was nearly homoplasmic in muscle and heteroplasmic in blood DNA of the proband, but it was absent in peripheral leukocytes from the asymptomatic mother, sister, and two maternal aunts, suggesting that it arose de novo. This report proposes to look for variants in the mitochondrial genome when dealing with otherwise undetermined leukodystrophies of childhood. (c) 2007 Elsevier Inc. All rights reserved.
C1 Childrens Hosp Bambino Gesu, IRCCS, I-00165 Rome, Italy.
   Inst Genet Med Jacinto de Magalhaes, P-4099028 Oporto, Portugal.
   Hosp Maria Pia, Neuropediat Dept, Oporto, Portugal.
   Hosp S Sebastiao, Dept Pediat, Oporto, Portugal.
   HGSA, Neuropathol Unit, Oporto, Portugal.
C3 IRCCS Bambino Gesu
RP Vilarinho, L (corresponding author), Childrens Hosp Bambino Gesu, IRCCS, Piazza S Onofrio, I-00165 Rome, Italy.
EM fms3@na.flashnet.it; laura.vilarinho@igm.min-saude.pt
CR Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Bruno C, 2003, J CHILD NEUROL, V18, P300, DOI 10.1177/08830738030180040401
   Di Rocco M, 2004, AM J MED GENET B, V129B, P85, DOI 10.1002/ajmg.b.30029
   DiMauro S, 2005, NEUROMUSCULAR DISORD, V15, P276, DOI 10.1016/j.nmd.2004.12.008
   DiMauro S, 2004, BBA-BIOENERGETICS, V1658, P80, DOI 10.1016/j.bbabio.2004.03.014
   DIMAURO S, 1987, ANN NEUROL, V22, P498, DOI 10.1002/ana.410220409
   Hao HL, 1996, J BIOL CHEM, V271, P2347, DOI 10.1074/jbc.271.4.2347
   Harpey JP, 1998, J INHERIT METAB DIS, V21, P748, DOI 10.1023/A:1005497116398
   Helm M, 2000, RNA, V6, P1356, DOI 10.1017/S1355838200001047
   Lerman-Sagie T, 2005, MOL GENET METAB, V84, P127, DOI 10.1016/j.ymgme.2004.09.008
   Mayr JA, 2006, NEUROMUSCULAR DISORD, V16, P874, DOI 10.1016/j.nmd.2006.08.010
   McFarland R, 2004, TRENDS GENET, V20, P591, DOI 10.1016/j.tig.2004.09.014
   Melone MAB, 2004, ARCH NEUROL-CHICAGO, V61, P269, DOI 10.1001/archneur.61.2.269
   Meulemans A, 2006, ARCH NEUROL-CHICAGO, V63, P1194, DOI 10.1001/archneur.63.8.1194
   Moroni I, 2002, NEUROPEDIATRICS, V33, P79, DOI 10.1055/s-2002-32372
   Munnich A, 2001, AM J MED GENET, V106, P4, DOI 10.1002/ajmg.1391
   Perucca-Lostanlen D, 2002, BBA-MOL BASIS DIS, V1588, P210, DOI 10.1016/S0925-4439(02)00167-9
   Pistilli D, 2003, HUM PATHOL, V34, P1058, DOI 10.1053/S0046-8177(03)00344-7
   Rossi A, 2003, AM J NEURORADIOL, V24, P1188
   Schapira AHV, 2006, LANCET, V368, P70, DOI 10.1016/S0140-6736(06)68970-8
   Schiffmann R, 2004, CURR OPIN NEUROL, V17, P187, DOI 10.1097/00019052-200404000-00017
   Sciacco M, 1996, METHODS ENZYMOL, V264, P509, DOI 10.1016/S0076-6879(96)64045-2
   Stewart Victoria C, 1998, BIOCHEMICAL SOCIETY TRANSACTIONS, V26, P0
   Taylor RW, 1998, BIOCHEM BIOPH RES CO, V251, P883, DOI 10.1006/bbrc.1998.9553
   Tzen CY, 2003, MUSCLE NERVE, V28, P575, DOI 10.1002/mus.10473
   vanderKnaap MS, 1995, NEURORADIOLOGY, V37, P679, DOI 10.1007/BF00593394
   Vilarinho L, 1999, J NEUROL SCI, V163, P168, DOI 10.1016/S0022-510X(99)00030-1
NR 27
TC 12
Z9 13
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD MAR 23
PY 2007
VL 354
IS 4
BP 937
EP 941
DI 10.1016/j.bbrc.2007.01.068
PG 5
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 139DF
UT WOS:000244411800016
PM 17266923
DA 2024-11-01
ER

PT J
AU Conforto, AB
   Yamamoto, FL
   Oba-Shinjo, SM
   Pinto, JGC
   Hoshino, M
   Scaff, M
   Marie, SKN
AF Conforto, Adriana Bastos
   Yamamoto, Fabio luji
   Oba-Shinjo, Sueli Mieko
   Pinto, Julio Guy C.
   Hoshino, Mauricio
   Scaff, Milberto
   Marie, Suely Kazue Nagahashi
TI Screening for MELAS mutations in young patients with stroke of undetermined origin
SO ARQUIVOS DE NEURO-PSIQUIATRIA
LA English
DT Article
DE cerebrovascular disease; diagnostic methods; mitochondrial disease; myopathy; cryptogenic stroke
ID mitochondrial-dna a3243g; lactic-acidosis; ischemic-stroke; arterial territory; episodes melas; human brain; myopathy; encephalopathy; encephalomyopathy; diagnosis
AB Purpose: It has been suggested that mitochondrial disease may be responsible for a substantial proportion of strokes of indetermined origin. We have preliminarily screened for MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes) mutations in young patients with cryptogenic strokes. Method: The mitochondrial mutations A3243G and T3271C were investigated in 38 subjects 14 aged less than 46 years. Group 1: 15 patients with cryptogenic strokes; Group 2: 3 patients with diagnosis of MELAS syndrome, including stroke-like episodes; Group 3: 20 healthy subjects. Results: The A3243G mutation was absent in all subjects in Groups 1 and 3 but was present in all subjects in Group 2. Conclusion: Our results do not support screening for these mutations to diagnose oligosymptomatic forms of MELAS in cryptogenic strokes in the absence of other features of the syndrome. We suggest that clinical findings should guide mitochondrial genetic testing.
C1 Univ Sao Paulo, Div Neurol, Hosp Clin, HC,FMUSP, Sao Paulo, Brazil.
C3 Universidade de Sao Paulo
RP Conforto, AB (corresponding author), FMUSP, Dept Neurol, HC, Ave Dr Eneas Carvalho Aguiar 255-5084, BR-05403000 Sao Paulo, Brazil.
EM abconf@yahoo.com
CR ADAMS HP, 1995, ARCH NEUROL-CHICAGO, V52, P491, DOI 10.1001/archneur.1995.00540290081021
   ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35
   Di Gennaro G, 2000, HEADACHE, V40, P568, DOI 10.1046/j.1526-4610.2000.00088.x
   Dickerson BC, 2005, NEW ENGL J MED, V353, P2271, DOI 10.1056/NEJMcpc059032
   Dubowitz V, 1985, MUSCLE BIOPSY-A PRACTICAL APPROACH, VSecond, P19
   FANG W, 1993, ARCH NEUROL-CHICAGO, V50, P977, DOI 10.1001/archneur.1993.00540090074013
   GOTO Y, 1992, NEUROLOGY, V42, P545, DOI 10.1212/WNL.42.3.545
   Iizuka T, 2003, NEUROLOGY, V61, P1238, DOI 10.1212/01.WNL.0000091888.26232.FE
   Jacobs BS, 2002, STROKE, V33, P2789, DOI 10.1161/01.STR.0000038988.64376.3A
   Kaufmann P, 2004, NEUROLOGY, V62, P1297, DOI 10.1212/01.WNL.0000120557.83907.A8
   Koga Y, 2005, NEUROLOGY, V64, P710, DOI 10.1212/01.WNL.0000151976.60624.01
   Kristensen B, 1997, STROKE, V28, P1702, DOI 10.1161/01.STR.28.9.1702
   Majamaa K, 1997, NEUROLOGY, V49, P1331, DOI 10.1212/WNL.49.5.1331
   MARIE SKN, 1994, BIOCHEM MED METAB B, V52, P136, DOI 10.1006/bmmb.1994.1045
   Martínez-Fernández E, 2001, STROKE, V32, P2507, DOI 10.1161/hs1101.098328
   Melberg A, 1996, ACTA NEUROL SCAND, V94, P233, DOI 10.1111/j.1600-0404.1996.tb07058.x
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   Musolino R, 2003, CEREBROVASC DIS, V15, P121, DOI 10.1159/000067139
   OHAMA E, 1987, ACTA NEUROPATHOL, V74, P226, DOI 10.1007/BF00688185
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   Pulkes T, 2000, LANCET, V356, P2068, DOI 10.1016/S0140-6736(00)03408-5
   Rozen TD, 2004, HEADACHE, V44, P674, DOI 10.1111/j.1526-4610.2004.04126.x
   Sciacco M, 2001, J NEUROL, V248, P778, DOI 10.1007/s004150170094
   Shanske S, 2004, AM J MED GENET A, V130A, P134, DOI 10.1002/ajmg.a.30220
   Shoffner JM, 2000, NEUROL CLIN, V18, P105, DOI 10.1016/S0733-8619(05)70180-8
   Siqueira JI, 1996, STROKE, V27, P2016
   Tatu L, 1998, NEUROLOGY, V50, P1699, DOI 10.1212/WNL.50.6.1699
   Tatu L, 1996, NEUROLOGY, V47, P1125, DOI 10.1212/WNL.47.5.1125
   Thompson VA, 1997, ANESTH ANALG, V85, P1404, DOI 10.1097/00000539-199712000-00041
   Torelli P, 2004, CEPHALALGIA, V24, P29, DOI 10.1111/j.1468-2982.2004.00633.x
   VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368
   Werneck L C, 1987, ARQ NEUROPSIQUIATR, V45, P288
   Yonemura K, 2001, AM J NEURORADIOL, V22, P269
NR 33
TC 6
Z9 6
U1 0
U2 1
PU ASSOC ARQUIVOS NEURO- PSIQUIATRIA
PI SAO PAULO SP
PA PR AMADEU AMARAL 47/33, 01327-010 SAO PAULO SP, BRAZIL
SN 0004-282X
EI 1678-4227
J9 ARQ NEURO-PSIQUIAT
JI Arq. Neuro-Psiquiatr.
PD JUN 15
PY 2007
VL 65
IS 2B
BP 371
EP 376
DI 10.1590/S0004-282X2007000300001
PG 6
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 192TD
UT WOS:000248225000001
PM 17664998
DA 2024-11-01
ER

PT J
AU Carelli, V
   Franceschini, F
   Venturi, S
   Barboni, P
   Savini, G
   Barbieri, G
   Pirro, E
   La Morgia, C
   Valentino, ML
   Zanardi, F
   Violante, FS
   Mattioli, S
AF Carelli, Valerio
   Franceschini, Flavia
   Venturi, Silvia
   Barboni, Piero
   Savini, Giacomo
   Barbieri, Giuseppe
   Pirro, Ettore
   La Morgia, Chiara
   Valentino, Maria L.
   Zanardi, Francesca
   Violante, Francesco S.
   Mattioli, Stefano
TI Grand rounds:: Could occupational exposure to <i>n</i>-hexane and other solvents precipitate visual failure in Leber hereditary optic neuropathy?
SO ENVIRONMENTAL HEALTH PERSPECTIVES
LA English
DT Article
DE environmental trigger; Leber hereditary optic neuropathy; mitochondrial DNA; neurotoxin; n-hexane; occupational exposure; solvents
ID hearing-loss; mitochondria; expression; mutation; workers
AB CONTEXT: Leber hereditary optic neuropathy (LHON) is a maternally inherited loss of central vision related to pathogenic mutations in the mitochondrial genome, which are a necessary but not sufficient condition to develop the disease. Investigation of precipitating environmental/occupational (and additional genetic) factors could be relevant for prevention. CASE PRESENTATION: After a 6-month period of occupational exposure to n-hexane and other organic solvents, a 27-year-old man (a moderate smoker) developed an optic neuropathy. The patient had a full oplithalmologic and neurologic investigation, including standardized cycloergometer test for serum lactic acid levels and a skeletal muscle biopsy. His exposure history was also detailed, and he underwent genetic testing for LHON mitochondrial DNA mutations. The patient suffered a sequential optic neuropathy with the hallmarks of LHON and tested positive for the homoplasmic 11778G -> A/ND4 mutation. Routine laboratory monitoring revealed increased concentrations of urinary 2.5 hexandione (n-hexane metabolite) and hippuric acid (toluene metabolite) in the period immediately preceding the visual loss. DISCUSSION: In a subject carrying an LHON mutation, the strict temporal sequence of prolonged appreciable occupational exposure followed by sudden onset of visual loss must raise a suspicion of causality (with a possible further interaction with tobacco smoke). RELEVANCE: In this article, we add to the candidate occupational/environmental triggers of LHON and highlight the need for appropriate case-control (and laboratory) studies to validate the causal effect of mixed toxic exposures.
C1 Univ Bologna, Lab Epidemiol, UO Med Lavoro, Policlin S Orsola Malphighi,Alma Mater Studiorum, I-40138 Bologna, Italy.
   Univ Bologna, Dipartimento Sci Neurol, Alma Mater Studiorum, I-40138 Bologna, Italy.
   Azienda USL Bologna, Dipartimento Sanita Pubbl, Bologna, Italy.
   Ctr Oftalmol Salus, Bologna, Italy.
C3 University of Bologna; University of Bologna; AUSL di Bologna
RP Mattioli, S (corresponding author), Univ Bologna, Lab Epidemiol, UO Med Lavoro, Policlin S Orsola Malphighi,Alma Mater Studiorum, Via Pelagio Palagi 9, I-40138 Bologna, Italy.
EM s.mattioli@unibo.it
CR *ACGIH, 2005, TLVS BEIS, V0, P0
   Barboni P, 2005, OPHTHALMOLOGY, V112, P120, DOI 10.1016/j.ophtha.2004.06.034
   Canton M, 1996, BBA-BIOENERGETICS, V1274, P39, DOI 10.1016/0005-2728(96)00008-4
   Carelli V, 2003, TRENDS GENET, V19, P257, DOI 10.1016/S0168-9525(03)00072-6
   Carelli V, 2004, PROG RETIN EYE RES, V23, P53, DOI 10.1016/j.preteyeres.2003.10.003
   Daré E, 2004, TOXICOLOGY, V201, P125, DOI 10.1016/j.tox.2004.04.010
   EHYAI A, 1983, J NEUROL NEUROSUR PS, V46, P349, DOI 10.1136/jnnp.46.4.349
   Gobba F, 2003, NEUROTOXICOLOGY, V24, P693, DOI 10.1016/S0161-813X(03)00037-8
   JOHNS DR, 1992, ARCH OPHTHALMOL-CHIC, V110, P1577, DOI 10.1001/archopht.1992.01080230077025
   Kerrison JB, 2000, AM J OPHTHALMOL, V130, P803, DOI 10.1016/S0002-9394(00)00603-6
   Kiyokawa M, 1999, JPN J OPHTHALMOL, V43, P438, DOI 10.1016/S0021-5155(99)00102-1
   Lachmund U, 2006, KLIN MONATSBL AUGENH, V223, P393, DOI 10.1055/s-2006-926559
   Man PYW, 2002, J MED GENET, V39, P162, DOI 10.1136/jmg.39.3.162
   Maruff P, 1998, BRAIN, V121, P1903, DOI 10.1093/brain/121.10.1903
   Mashima Y, 2000, J NEURO-OPHTHALMOL, V20, P166, DOI 10.1097/00041327-200020030-00006
   Meadows R, 1996, SOUTHERN MED J, V89, P455, DOI 10.1097/00007611-199605000-00001
   MONTAGNA P, 1995, J NEUROL NEUROSUR PS, V58, P640, DOI 10.1136/jnnp.58.5.640
   Moshe S, 2002, ARCH ENVIRON HEALTH, V57, P127, DOI 10.1080/00039890209602927
   Newman NJ, 2005, AM J OPHTHALMOL, V140, P407, DOI 10.1016/j.ajo.2005.03.058
   Noraberg J, 2000, NEUROTOXICOLOGY, V21, P409
   OGAWA Y, 1998, IND HLTH, V26, P239
   RAITTA C, 1978, A GRAEF ARCH KLIN EX, V209, P99, DOI 10.1007/BF00407843
   Rufa A, 2005, EUR NEUROL, V53, P32, DOI 10.1159/000083927
   Sadun AA, 2003, AM J OPHTHALMOL, V136, P231, DOI 10.1016/S0002-9394(03)00099-0
   SCHAUMBURG HH, 1978, SCIENCE, V199, P199, DOI 10.1126/science.413192
   SICKLES DW, 1990, BRAIN RES, V528, P25, DOI 10.1016/0006-8993(90)90190-M
   SPENCER PS, 1985, SCAN J WORK ENV H S1, V11, P0
   Torroni A, 1997, AM J HUM GENET, V60, P1107
   WILLIAMS DML, 1988, J OTOLARYNGOL, V17, P321
   ZAHLSEN K, 1984, ARCH TOXICOL, V0, P268
NR 30
TC 41
Z9 43
U1 0
U2 8
PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE
PI RES TRIANGLE PK
PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA
SN 0091-6765
EI 1552-9924
J9 ENVIRON HEALTH PERSP
JI Environ. Health Perspect.
PD JAN 15
PY 2007
VL 115
IS 1
BP 113
EP 115
DI 10.1289/ehp.9245
PG 3
WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology
SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology
GA 123ME
UT WOS:000243299200042
PM 17366829
DA 2024-11-01
ER

PT J
AU Filosto, M
   Tomelleri, G
   Tonin, P
   Scarpelli, M
   Vattemi, G
   Rizzuto, N
   Padovani, A
   Simonati, A
AF Filosto, Massimiliano
   Tomelleri, Giuliano
   Tonin, Paola
   Scarpelli, Mauro
   Vattemi, Gaetano
   Rizzuto, Nicolo
   Padovani, Alessandro
   Simonati, Alessandro
TI Neuropathology of mitochondrial diseases
SO BIOSCIENCE REPORTS
LA English
DT Article; Proceedings Paper
DE mitochondrial diseases; neuropathology; muscle pathology
ID stroke-like episodes; lactic-acidosis; encephalomyopathy; myopathy; features; melas; encephalopathy; mutations
AB The term "mitochondrial diseases" (MD) refers to a group of disorders related to respiratory chain dysfunction. Clinical features are usually extremely heterogeneous because MD may involve several tissues with different degrees of severity. Muscle and brain are mostly affected, probably because of their high dependence on oxidative metabolism. Muscle can be the only affected tissue or involved as a part of a multi-system disease; ragged red fibers, accumulation of structurally altered mitochondria and cytochrome-c-oxidase (COX) negative fibers are the main pathological features. In mitochondrial encephalopathies, central nervous system (CNS) structures are affected according to different patterns of distribution and severity. Characteristic lesions are neuronal loss, vasculo-necrotic changes, gliosis, demyelination and spongy degeneration. In accordance with either grey matter or white matter involvement two main groups of diseases may be distinguished. Neuronal loss and vasculo-necrotic multifocal lesions are the common features of grey matter involvement; demyelination and spongy degeneration occur when white matter is affected, often associated with less severe lesions of the grey structures. Grey matter lesions are prevalent in MERRF, MELAS, Alpers and Leigh syndromes. White matter involvement is always seen in Kearns-Sayre syndrome and was recently described in mtDNA depletion syndrome linked to dGK mutations and in the rare conditions associated with complex I and II deficiency. In this review we describe the main histopathological features of muscle and CNS lesions in mitochondrial diseases.
C1 Univ Hosp, Spedali Civili, Sect Neuromuscular Dis & Neuropathies, I-25100 Brescia, Italy.
   Univ Verona, Dept Neurol Sci & Vis, Sect Clin Neurol, I-37100 Verona, Italy.
C3 Hospital Spedali Civili Brescia; University of Verona
RP Filosto, M (corresponding author), Univ Hosp, Spedali Civili, Sect Neuromuscular Dis & Neuropathies, P Spedali Civili 1, I-25100 Brescia, Italy.
EM filosto@med.unibs.it
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Betts J, 2006, NEUROPATH APPL NEURO, V32, P359, DOI 10.1111/j.1365-2990.2006.00731.x
   Betts J, 2004, NEUROCHEM RES, V29, P505, DOI 10.1023/B:NERE.0000014821.07269.8d
   Brown GK, 1996, J INHERIT METAB DIS, V19, P553, DOI 10.1007/BF01799116
   Burgeois M, 1992, BRAIN DEV, V14, P404
   Clark JM, 1996, NEUROLOGY, V46, P223, DOI 10.1212/WNL.46.1.223
   DIDONATO S, 2002, MITOCHONDRIAL DISORD, V0, P5
   Dimauro S, 2001, AM J MED GENET, V106, P18, DOI 10.1002/ajmg.1392
   DIMAURO S, 1993, ARCH NEUROL-CHICAGO, V50, P1197, DOI 10.1001/archneur.1993.00540110075008
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Filosto M, 2004, ACTA NEUROPATHOL, V108, P168, DOI 10.1007/s00401-004-0872-9
   FILOSTO M, 2007, ACTA NEUROLO SCAND, V0, P0
   GOTO Y, 1992, NEUROLOGY, V42, P545, DOI 10.1212/WNL.42.3.545
   HASEGAWA H, 1991, ANN NEUROL, V29, P601, DOI 10.1002/ana.410290606
   MONTPETIT VJ, 1971, BRAIN, V94, P1, DOI 10.1093/brain/94.1.1
   Sarnat HB, 2005, CAN J NEUROL SCI, V32, P152, DOI 10.1017/S0317167100003929
   Schuelke M, 1999, NAT GENET, V21, P260, DOI 10.1038/6772
   SHAPIRA Y, 1975, NEUROLOGY, V25, P614, DOI 10.1212/WNL.25.7.614
   Simonati A, 2003, ACTA NEUROPATHOL, V106, P57, DOI 10.1007/s00401-003-0698-x
   SPARACO M, 1993, J NEUROPATH EXP NEUR, V52, P1, DOI 10.1097/00005072-199301000-00001
   Tanji K, 2001, SEMIN CELL DEV BIOL, V12, P429, DOI 10.1006/scdb.2001.0280
   Vu TH, 2002, NEUROL CLIN, V20, P809, DOI 10.1016/S0733-8619(01)00017-2
NR 22
TC 75
Z9 91
U1 0
U2 6
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0144-8463
EI 
J9 BIOSCIENCE REP
JI Biosci. Rep.
PD JUN 15
PY 2007
VL 27
IS 1-3
BP 23
EP 30
DI 10.1007/s10540-007-9034-3
PG 8
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 178YM
UT WOS:000247256300004
PM 17541738
DA 2024-11-01
ER

PT J
AU Pancrudo, J
   Shanske, S
   Cau, J
   Lu, J
   Mardach, R
   Akinan, O
   Krishna, S
   Bonilla, E
   DiNlauro, S
AF Pancrudo, Jacklyn
   Shanske, Sara
   Cau, Jorida
   Lu, J.
   Mardach, Rebecca
   Akinan, Orhan
   Krishna, Sindu
   Bonilla, Eduardo
   DiNlauro, Salvatore
TI Mitochondrial myopathy associated with a novel mutation in mtDNA
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE mtDNA mutation; tRNA-arginine; mitochondrial encephalomyopathy
ID dna; abnormality; genes
AB A 6-year-old boy had progressive muscle weakness since age 4 and emotional problems diagnosed as Asperger syndrome. His mother and two older siblings are in good health and there is no family history of neuromuscular disorders. Muscle biopsy showed ragged-red and cytochrome c oxidase (COX)-negative fibers. Respiratory chain activities were reduced for all enzymes containing mtDNA-encoded subunits, especially COX. Sequence analysis of the 22 tRNA genes revealed a novel G10406A base substitution, which was heteroplasmic in multiple tissues of the patient by RFLP analysis (muscle, 96%; urinary sediment, 94%; cheek mucosa, 36%; blood, 29%). The mutation was not detected in any accessible tissues from his mother or siblings. It appears that this mutation arose de novo in the proband, probably early in embryogenesis. (C) 2007 Elsevier B.V. All rights reserved.
C1 Columbia Univ, Coll Phys & Surg 4 420, Med Ctr,Dept Neurol, H Houston Merritt Clin Res Ctr Muscular Dystrophy, New York, NY 10032 USA.
   Kaiser Permanente Med Ctr, Div Med Genet, Los Angeles, CA 90034 USA.
C3 Columbia University; Kaiser Permanente
RP DiNlauro, S (corresponding author), Columbia Univ, Coll Phys & Surg 4 420, Med Ctr,Dept Neurol, H Houston Merritt Clin Res Ctr Muscular Dystrophy, 630 W 168th St, New York, NY 10032 USA.
EM sd12@columbia.edu
FU NICHD NIH HHS [P01 HD032062, P01 HD032062-049001, HD 32062] Funding Source: Medline
CR DIMAURO S, 1987, ANN NEUROL, V22, P498, DOI 10.1002/ana.410220409
   HAYASHI JI, 1994, J BIOL CHEM, V269, P19060
   Pons R, 2004, J PEDIATR-US, V144, P81, DOI 10.1016/j.jpeds.2003.10.023
   SCHON EA, 2006, MITOCHONDRIAL MED, V0, P329
   Shanske S, 2004, AM J MED GENET A, V130A, P134, DOI 10.1002/ajmg.a.30220
   Tanji K, 2001, METHOD CELL BIOL, V65, P311, DOI 10.1016/S0091-679X(01)65019-2
   Uusimaa J, 2004, PEDIATRICS, V114, P443, DOI 10.1542/peds.114.2.443
NR 7
TC 15
Z9 19
U1 0
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD AUG 15
PY 2007
VL 17
IS 8
BP 651
EP 654
DI 10.1016/j.nmd.2007.04.005
PG 4
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 202BJ
UT WOS:000248876200008
PM 17588757
DA 2024-11-01
ER

PT J
AU Arnestad, M
   Opdal, SH
   Vege, Å
   Rognum, TO
AF Arnestad, Marianne
   Opdal, Siri Hauge
   Vege, Ashild
   Rognum, Torleiv Ole
TI A mitochondrial DNA polymorphism associated with cardiac arrhythmia investigated in sudden infant death syndrome
SO ACTA PAEDIATRICA
LA English
DT Article
DE cardiac arrhythmia; LQTS; mitochondrial myopathy; mtDNA; SIDS
ID hereditary optic neuropathy; long-qt syndrome; sleeping infants; mtdna; cardiomyopathy; mutation; diseases; heart
AB Aim: Long QT syndrome (LQTS) has been shown to be the cause of death in some cases originally diagnosed as sudden infant death syndrome (SIDS). Such cardiac arrhythmias have also been noted in families with mitochondrial disease, and studies indicate that mitochondrial disease could be involved in SIDS. This makes the mtDNA polymorphism T3394C interesting, as a previous study has shown it to be associated with electrocardiographic (ECG) changes after exercise in a family with LQTS, where some members harboured a KCNH2 mutation. Subjects: A total of 245 SIDS cases and 176 control cases. Methods: DNA was prepared from blood/tissue samples. Polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) were performed to search for the mtDNA polymorphism and KCNH2 mutation. Differences were confirmed by sequencing. Results: The T3394C polymorphism was found in 3 pure SIDS cases (1.5%), 2 borderline SIDS cases (4.4%), 1 case of explained death (1.6%) and 2 living control cases (1.8%) (p = 0.62). The KCNH2 mutation was not found in cases or controls. Conclusion: The mtDNA polymorphism studied was found in a small number of SIDS cases and the frequency did not differ statistically from control subjects, making an association with increased SIDS risk unlikely.
C1 Univ Oslo, Inst Forens Med, Oslo, Norway.
C3 University of Oslo
RP Arnestad, M (corresponding author), Natl Hosp Norway, Inst Forens Med, N-0027 Oslo, Norway.
EM marianne.arnestad@medisin.ui.no
CR Ackerman MJ, 2001, JAMA-J AM MED ASSOC, V286, P2264, DOI 10.1001/jama.286.18.2264
   Ackerman MJ, 1998, MAYO CLIN PROC, V73, P250, DOI 10.4065/73.3.250
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Arnestad M, 2002, ACTA PAEDIATR, V91, P1060, DOI 10.1080/080352502760311557
   Arnestad M, 2001, ARCH DIS CHILD, V85, P108, DOI 10.1136/adc.85.2.108
   ARNESTAD M, 2005, HEART RHYTHM, V2, P0
   Brown MD, 1997, AM J HUM GENET, V60, P381
   BROWN MD, 1992, FASEB J, V6, P2791, DOI 10.1096/fasebj.6.10.1634041
   Crotti L, 2005, CIRCULATION, V112, P1251, DOI 10.1161/CIRCULATIONAHA.105.549071
   Gregersen M, 1995, P50, V0, P0
   Hauck F R, 2000, CURR PROBL PEDIATR, V30, P237
   Hlaing T, 2005, ANN NONINVAS ELECTRO, V10, P211, DOI 10.1111/j.1542-474X.2005.05588.x
   JOHNS DR, 1992, BIOCHEM BIOPH RES CO, V187, P1551, DOI 10.1016/0006-291X(92)90479-5
   Matsuoka R, 1999, BIOCHEM BIOPH RES CO, V257, P228, DOI 10.1006/bbrc.1999.0443
   NIKOSKELAINEN E, 1985, LANCET, V1, P696
   OBAYASHI T, 1992, AM HEART J, V124, P1263, DOI 10.1016/0002-8703(92)90410-W
   Opdal SH, 2002, PEDIATR NEUROL, V27, P23, DOI 10.1016/S0887-8994(02)00384-3
   Passarino G, 2002, EUR J HUM GENET, V10, P521, DOI 10.1038/sj.ejhg.5200834
   ROGNUM TO, 1991, PEDIATRICS, V87, P306
   ROGNUM TO, 2004, SCAND J FORENS SCI, V0, P10
   Schwartz PJ, 1998, NEW ENGL J MED, V338, P1709, DOI 10.1056/NEJM199806113382401
   Schwartz PJ, 2001, SUDDEN INFANT DEATH SYNDROME, V0, P83
   SILVESTRI G, 1994, HUM MUTAT, V3, P37, DOI 10.1002/humu.1380030107
   Tester DJ, 2005, CARDIOVASC RES, V67, P388, DOI 10.1016/j.cardiores.2005.02.013
   Thomas AW, 1996, J MED GENET, V33, P253, DOI 10.1136/jmg.33.3.253
   Tuffnell CS, 1996, ARCH DIS CHILD, V75, P249, DOI 10.1136/adc.75.3.249
   Tuffnell CS, 1995, EARLY HUM DEV, V43, P109, DOI 10.1016/0378-3782(95)01659-7
   Wallace DC, 1999, GENE, V238, P211, DOI 10.1016/S0378-1119(99)00295-4
   Wallington TJ, 2002, HANDB ENVIRON CHEM, V3, P85
   Wang JM, 1999, NAT GENET, V21, P133, DOI 10.1038/5089
NR 30
TC 11
Z9 13
U1 0
U2 2
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 0803-5253
EI 
J9 ACTA PAEDIATR
JI Acta Paediatr.
PD FEB 15
PY 2007
VL 96
IS 2
BP 206
EP 210
DI 10.1111/j.1651-2227.2007.00022.x
PG 5
WC Pediatrics
SC Pediatrics
GA 133DZ
UT WOS:000243993800014
PM 17429906
DA 2024-11-01
ER

PT J
AU Durham, SE
   Samuels, DC
   Cree, LM
   Chinnery, PF
AF Durham, Steve E.
   Samuels, David C.
   Cree, Lynsey M.
   Chinnery, Patrick F.
TI Normal levels of wild-type mitochondrial DNA maintain cytochrome <i>c</i> oxidase activity for two pathogenic mitochondrial DNA mutations but not for m.3243A→G
SO AMERICAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID deficient muscle-fibers; stroke-like episodes; wobble modification; protein-synthesis; skeletal-muscle; lactic-acidosis; mtdna mutation; point mutation; transfer-rnas; melas
AB Mitochondrial DNA (mtDNA) mutations are a common cause of human disease and accumulate as part of normal ageing and in common neurodegenerative disorders. Cells express a biochemical defect only when the proportion of mutated mtDNA exceeds a critical threshold, but it is not clear whether the actual cause of this defect is a loss of wild-type mtDNA, an excess of mutated mtDNA, or a combination of the two. Here, we show that segments of human skeletal muscle fibers harboring two pathogenic mtDNA mutations retain normal cytochrome c oxidase (COX) activity by maintaining a minimum amount of wild- type mtDNA. For these mutations, direct measurements of mutated and wild- type mtDNA molecules within the same skeletal muscle fiber are consistent with the "maintenance of wild type" hypothesis, which predicts that there is nonselective proliferation of mutated and wild- type mtDNA in response to the molecular defect. However, for the m. 3243A -> G mutation, a superabundance of wild-type mtDNA was found in many muscle-fiber sections with negligible COX activity, indicating that the pathogenic mechanism for this particular mutation involves interference with the function of the wild- type mtDNA or wild-type gene products.
C1 Newcastle Univ, Mitochondrial Res Grp, Newcastle Upon Tyne, Tyne & Wear, England.
   Newcastle Univ, Inst Human Genet, Newcastle Upon Tyne, Tyne & Wear, England.
   Virginia Polytech Inst & State Univ, Virginia Bioinformat Inst, Blacksburg, VA 24061 USA.
C3 Newcastle University - UK; Newcastle University - UK; Virginia Polytechnic Institute & State University
RP Chinnery, PF (corresponding author), Med Sch Newcastle Upon Tyne, M4014, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM P.F.Chinnery@ncl.ac.uk
FU Wellcome Trust Funding Source: Medline
CR ATTARDI G, 1995, BBA-MOL BASIS DIS, V1271, P241, DOI 10.1016/0925-4439(95)00034-2
   Auré K, 2006, BRAIN, V129, P1249, DOI 10.1093/brain/awl061
   Bidooki SK, 1997, AM J HUM GENET, V60, P1430, DOI 10.1086/515460
   BOULET L, 1992, AM J HUM GENET, V51, P1187
   Capps GJ, 2003, J THEOR BIOL, V221, P565, DOI 10.1006/jtbi.2003.3207
   Chinnery PF, 1999, AM J HUM GENET, V64, P1158, DOI 10.1086/302311
   CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221
   Clark KM, 1999, AM J HUM GENET, V64, P1330, DOI 10.1086/302361
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Dubeau F, 2000, ANN NEUROL, V47, P179, DOI 10.1002/1531-8249(200002)47:2<179::AID-ANA7>3.0.CO;2-Z
   Dunbar DR, 1996, HUM MOL GENET, V5, P123, DOI 10.1093/hmg/5.1.123
   Durham SE, 2005, NEUROLOGY, V65, P453, DOI 10.1212/01.wnl.0000171861.30277.88
   Elson JL, 2002, NEUROMUSCULAR DISORD, V12, P858, DOI 10.1016/S0960-8966(02)00047-0
   Florentz C, 2003, CELL MOL LIFE SCI, V60, P1356, DOI 10.1007/s00018-003-2343-1
   HAMMANS SR, 1992, J NEUROL SCI, V107, P87, DOI 10.1016/0022-510X(92)90213-5
   Hao R, 2004, FEBS LETT, V578, P135, DOI 10.1016/j.febslet.2004.11.004
   HAYASHI JI, 1993, BIOCHEM BIOPH RES CO, V197, P1049, DOI 10.1006/bbrc.1993.2584
   He LP, 2002, NUCLEIC ACIDS RES, V30, P0, DOI 10.1093/nar/gnf067
   Kim JY, 2005, NEUROLOGY, V64, P966, DOI 10.1212/01.WNL.0000157282.76715.B1
   KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480
   Kirino Y, 2006, HUM MOL GENET, V15, P897, DOI 10.1093/hmg/ddl007
   KOGA Y, 1995, MUSCLE NERVE, V0, PS119
   MITA S, 1989, P NATL ACAD SCI USA, V86, P9509, DOI 10.1073/pnas.86.23.9509
   OLDFORS A, 1992, J NEUROL SCI, V110, P169, DOI 10.1016/0022-510X(92)90025-G
   Pyle A, 2007, J MED GENET, V44, P69, DOI 10.1136/jmg.2006.043109
   SCIACCO M, 1994, HUM MOL GENET, V3, P13, DOI 10.1093/hmg/3.1.13
   SHOUBRIDGE EA, 1990, CELL, V62, P43, DOI 10.1016/0092-8674(90)90238-A
   SUOMALAINEN A, 1993, HUM MOL GENET, V2, P525, DOI 10.1093/hmg/2.5.525
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   TOKUNAGA M, 1994, ANN NEUROL, V35, P413, DOI 10.1002/ana.410350407
   Villani G, 1997, P NATL ACAD SCI USA, V94, P1166, DOI 10.1073/pnas.94.4.1166
   Yasukawa T, 2005, FEBS LETT, V579, P2948, DOI 10.1016/j.febslet.2005.04.038
   YONEDA M, 1992, P NATL ACAD SCI USA, V89, P11164, DOI 10.1073/pnas.89.23.11164
   YONEDA M, 1994, MOL CELL BIOL, V14, P2699, DOI 10.1128/MCB.14.4.2699
NR 34
TC 64
Z9 72
U1 0
U2 8
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0002-9297
EI 1537-6605
J9 AM J HUM GENET
JI Am. J. Hum. Genet.
PD JUL 15
PY 2007
VL 81
IS 1
BP 189
EP 195
DI 10.1086/518901
PG 7
WC Genetics & Heredity
SC Genetics & Heredity
GA 175UO
UT WOS:000247039700018
PM 17564976
DA 2024-11-01
ER

PT J
AU Vydt, TCG
   de Coo, RFM
   Soliman, OII
   ten Cate, FJ
   van Geuns, RJM
   Vletter, WB
   Schoonderwoerd, K
   van den Bosch, BJC
   Smeets, HJM
   Geleijnse, ML
AF Vydt, Tom C. G.
   de Coo, Ren F. M.
   Soliman, Osama I. I.
   ten Cate, Folkert J.
   van Geuns, Robert-Jan M.
   Vletter, Wim B.
   Schoonderwoerd, Kees
   van den Bosch, Bianca J. C.
   Smeets, Hubert J. M.
   Geleijnse, Marcel L.
TI Cardiac involvement in adults with m.3243A&gt;G MELAS gene mutation
SO AMERICAN JOURNAL OF CARDIOLOGY
LA English
DT Article
ID transfer rnaleu(uur) gene; lactic-acidosis; mitochondrial myopathy; point mutation; encephalopathy; episodes; dna
AB Cardiac data in adults with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS syndrome) or asymptomatic gene carriers with the mitochondrial deoxyribonucleic acid adenine-to-guanine point mutation at nucleotide pair 3243 are scarce. Twelve subjects (mean-age 35 +/- 13 years), 8 with MELAS syndrome (patients) and 4 asymptomatic gene carriers (carriers), were enrolled in the study. Each subject underwent electrocardiography, exercise testing, Holter monitoring, echocardiography, and genetic and biochemical analysis for respiratory chain enzyme activity (complex I rest activity) in skeletal muscle. On electrocardiography and Hotter monitoring, none of the subjects had evidence of preexcitation, cardiac arrhythmias, or conduction abnormalities. Patients had significantly lower (42 +/- 17% from normal vs 103 +/- 14%, p < 0.02) exercise tolerance. All but 1 of the patients and none of the gene carriers had ragged red fibers on muscle biopsy. The mean percentage of gene mutation in skeletal muscle tended to be higher in patients (53 +/- 19%, range 19% to 73%) compared with carriers (33 +/- 20%, range 15% to 62%). Mean complex I rest activity in patients (36 +/- 18%, range 10% to 58%) was significantly (p < 0.01) lower compared with carriers (120 +/- 60%, range 72% to 205%). Left ventricular (LV) abnormalities were confined to patients with MELAS syndrome. Two patients had LV hypertrophy, 5 had LV systolic abnormalities, and 5 had LV diastolic dysfunction. Apart from 1 patient with an isolated LV diastolic abnormality, all patients with LV abnormalities had ragged red fibers. Patients with abnormal systolic LV function had a trend toward a higher percentage of mutated skeletal muscle (59.7 +/- 10.7% vs 35.8 +/- 21.3%, p < 0.10) and significantly lower complex I rest activity (26.7 +/- 14.0% vs 97.8% +/- 57.9, p < 0.01). In conclusion, none of the MELAS gene carriers had cardiac abnormalities, whereas most patients with the MELAS phenotype, particularly those with ragged red fibers, had LV involvement. (c) 2007 Elsevier Inc. All rights reserved.
C1 Erasmus MC, Dept Cardiol, Thoraxctr, Rotterdam, Netherlands.
   Erasmus MC, Dept Neurol, Rotterdam, Netherlands.
   Erasmus MC, Dept Clin Genet, Rotterdam, Netherlands.
   Univ Maastricht, Dept Genet & Cell Biol, Res Inst GROW, Maastricht, Netherlands.
C3 Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Maastricht University
RP Geleijnse, ML (corresponding author), Erasmus MC, Dept Cardiol, Thoraxctr, Rotterdam, Netherlands.
EM m.geleijnse@erasmusmc.nl
CR ANAN R, 1995, CIRCULATION, V91, P955, DOI 10.1161/01.CIR.91.4.955
   CIAFALONI E, 1992, ANN NEUROL, V31, P391, DOI 10.1002/ana.410310408
   DiMauro S, 1998, CURR OPIN CARDIOL, V13, P190
   GOTO Y, 1991, BIOCHIM BIOPHYS ACTA, V1097, P238, DOI 10.1016/0925-4439(91)90042-8
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   HIRANO M, 1994, J CHILD NEUROL, V9, P4, DOI 10.1177/088307389400900102
   JOHNS DR, 1995, NEW ENGL J MED, V333, P638, DOI 10.1056/NEJM199509073331007
   KELLY DP, 1994, NEW ENGL J MED, V330, P913
   Khouri SJ, 2004, J AM SOC ECHOCARDIOG, V17, P290, DOI 10.1016/j.echo.2003.08.012
   KOBAYASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P816, DOI 10.1016/S0006-291X(05)80860-5
   Leonard JV, 2000, LANCET, V355, P299, DOI 10.1016/S0140-6736(99)05225-3
   Lev D, 2004, PEDIATR CARDIOL, V25, P443, DOI 10.1007/s00246-003-0490-7
   Lodi R, 2004, BBA-BIOENERGETICS, V1657, P146, DOI 10.1016/j.bbabio.2004.05.003
   Marwick TH, 2004, CURR OPIN CARDIOL, V19, P442, DOI 10.1097/01.hco.0000131535.32657.87
   MORTEN KJ, 1993, HUM MOL GENET, V2, P2081, DOI 10.1093/hmg/2.12.2081
   Munagala VK, 2003, J AM SOC ECHOCARDIOG, V16, P1049, DOI 10.1016/S0894-7317(03)00516-9
   Nagueh SF, 1997, J AM COLL CARDIOL, V30, P1527, DOI 10.1016/S0735-1097(97)00344-6
   Nikitin NP, 2003, J AM SOC ECHOCARDIOG, V16, P906, DOI 10.1016/S0894-7317(03)00279-7
   Okajima Y, 1998, HEART, V80, P292, DOI 10.1136/hrt.80.3.292
   Okhuijsen-Kroes EJ, 2001, NEUROPEDIATRICS, V32, P183, DOI 10.1055/s-2001-17372
   Ommen SR, 2000, CIRCULATION, V102, P1788
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   Poulsen SH, 2003, J AM SOC ECHOCARDIOG, V16, P724, DOI 10.1016/S0894-7317(03)00403-6
   Schiller N B, 1989, J AM SOC ECHOCARDIOGR, V2, P358
   Silvestri G, 1997, MUSCLE NERVE, V20, P221
   Wallace DC, 2000, AM HEART J, V139, PS70, DOI 10.1067/mhj.2000.103934
NR 26
TC 55
Z9 60
U1 0
U2 0
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 0002-9149
EI 1879-1913
J9 AM J CARDIOL
JI Am. J. Cardiol.
PD JAN 15
PY 2007
VL 99
IS 2
BP 264
EP 269
DI 10.1016/j.amjcard.2006.07.089
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 126WJ
UT WOS:000243545900023
PM 17223431
DA 2024-11-01
ER

PT J
AU Pancrudo, J
   Shanske, S
   Bonilla, E
   Daras, M
   Akman, HO
   Krishna, S
   Malkin, E
   DiMauro, S
AF Pancrudo, Jacklyn
   Shanske, Sara
   Bonilla, Eduardo
   Daras, Mariza
   Akman, Hasan O.
   Krishna, Sindu
   Malkin, Elfrida
   DiMauro, Salvatore
TI Mitochondrial encephalomyopathy due to a novel mutation in the tRNA<SUP>Glu</SUP> of mitochondrial DNA
SO JOURNAL OF CHILD NEUROLOGY
LA English
DT Article
DE mtDNA mutation; tRNA glutamic acid; mitochondrial encephalomyopathy
ID glutamic-acid gene; diabetes-mellitus; onset myopathy
AB A 14-year-old boy had exercise intolerance, weakness, ataxia, and lactic acidosis. Because his muscle biopsy showed a mosaic pattern of fibers staining intensely with the succinate dehydrogenase reaction but not at all with the cytochrome c oxidase reaction, we sequenced his mitochondrial DNA and found a novel mutation (C14680A) in the gene for tRNA(Glu). The mutation was present in accessible tissues from the asymptomatic mother but not from a brother with Asperger syndrome. These data expand the clinical heterogeneity of mutations in this mitochondrial gene.
C1 Columbia Univ, Med Ctr, Dept Neurol, H Houston Merrit Clin Res Ctr Muscular Dystrophy, New York, NY 10027 USA.
   Columbia Presbyterian Med Ctr, Dept Neurol, Columbia, NY USA.
C3 Columbia University; NewYork-Presbyterian Hospital; Columbia University
RP DiMauro, S (corresponding author), Columbia Univ Coll Phys & Surg, Dept Neurol, 4-420,630 W 168th St, New York, NY 10032 USA.
EM sdl2@columbia.edu
CR Anitori R, 2005, MOL GENET METAB, V84, P176, DOI 10.1016/j.ymgme.2004.10.003
   Bruno C, 2003, J CHILD NEUROL, V18, P300, DOI 10.1177/08830738030180040401
   Damore ME, 1999, J PEDIATR ENDOCR MET, V12, P207
   DIMAURO S, 1987, ANN NEUROL, V22, P498, DOI 10.1002/ana.410220409
   Dimauro S, 2005, ANN MED, V37, P222, DOI 10.1080/07853890510007368
   HANNA MG, 1995, AM J HUM GENET, V56, P1026
   HAO HL, 1995, AM J HUM GENET, V56, P1017
   Mancuso M, 2005, J NEUROL SCI, V228, P93, DOI 10.1016/j.jns.2004.10.018
   McFarland R, 2004, ANN NEUROL, V55, P478, DOI 10.1002/ana.20004
   Pons R, 2004, J PEDIATR-US, V144, P81, DOI 10.1016/j.jpeds.2003.10.023
   SCHON EA, 2006, MITOCHONDRIAL MED, V0, P329
   Shanske S, 2004, AM J MED GENET A, V130A, P134, DOI 10.1002/ajmg.a.30220
   Tanji K, 2001, METHOD CELL BIOL, V65, P311, DOI 10.1016/S0091-679X(01)65019-2
   VILARINHO L, 2001, P 5 EUR M MIT PATH V, V0, P297
NR 14
TC 5
Z9 5
U1 1
U2 3
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0883-0738
EI 1708-8283
J9 J CHILD NEUROL
JI J. Child Neurol.
PD JUL 15
PY 2007
VL 22
IS 7
BP 858
EP 862
DI 10.1177/0883073807304199
PG 5
WC Clinical Neurology; Pediatrics
SC Neurosciences & Neurology; Pediatrics
GA 201LG
UT WOS:000248832300012
PM 17715279
DA 2024-11-01
ER

PT J
AU Sarzi, E
   Bourdon, A
   Chrétien, D
   Zarhrate, M
   Corcos, J
   Slama, A
   Cormier-Daire, V
   de Lonlay, P
   Munnich, A
   Rötig, A
AF Sarzi, Emmanuelle
   Bourdon, Alice
   Chretien, Dominique
   Zarhrate, Mohamed
   Corcos, Johanna
   Slama, Abdelhamid
   Cormier-Daire, Valerie
   de Lonlay, Pascale
   Munnich, Arnold
   Rotig, Agnes
TI Mitochondrial DNA depletion is a prevalent cause of multiple respiratory chain deficiency in childhood
SO JOURNAL OF PEDIATRICS
LA English
DT Article
ID progressive external ophthalmoplegia; leigh-syndrome; mutations; polg; kinase; mtdna; gene; deletions
AB Objective To determine the actual incidence of mitochondrial DNA (mtDNA) depletion syndrome in multiple respiratory chain deficiency. Study design We carried out a real-time polymerase chain reaction quantification of mtDNA in liver or muscle tissue of 100 children with unexplained multiple oxidative phosphorylation enzyme deficiency. Results A reduction of mtDNA copy number to < 35% of control values was found in liver and/or muscle in half of the children (50/100). Most of these patients (32/50; 64%) presented with severe neonatal onset liver involvement; 7 (1.4%) had Alpers syndrome, and 11 (22%) exhibited various forms of neurologic involvement. Deoxyguanosine kinase or polymerase gamma (POLG) mutations could be identified in 11 of 32 patients with liver involvement, and POLG imitations were consistently found in all 7 patients with Alpers syndrome. Homozygous thymidine kinase 2 and MPV17 gene mutations were found in 2 patients. Conclusions Our findings show that mtDNA depletion is a prevalent cause of multiple respiratory chain deficiency ill infancy.
C1 Hop Necker Enfants Malad, INSERM U781, F-75015 Paris, France.
   Hop Necker Enfants Malad, Genet Unit, F-75015 Paris, France.
   Hop Necker Enfants Malad, Metab Unit, F-75015 Paris, France.
   Hop Bicetre, Biochem Unit, Le Kremlin Bicetre, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite; Hopital Universitaire Necker-Enfants Malades - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite; Hopital Universitaire Necker-Enfants Malades - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite; Hopital Universitaire Necker-Enfants Malades - APHP; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP; Hopital Universitaire Bicetre - APHP
RP Rötig, A (corresponding author), Hop Necker Enfants Malad, INSERM U781, 149 Rue Sevres, F-75015 Paris, France.
EM roetig@necker.fr
CR Absalon MJ, 2001, PEDIATR NEUROL, V24, P60, DOI 10.1016/S0887-8994(00)00226-5
   CormierDaire V, 1997, J PEDIATR-US, V130, P817, DOI 10.1016/S0022-3476(97)80027-3
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Filiano JJ, 2002, PEDIATR NEUROL, V26, P239, DOI 10.1016/S0887-8994(01)00377-0
   Freisinger P, 2006, ARCH NEUROL-CHICAGO, V63, P1129, DOI 10.1001/archneur.63.8.1129
   Gellerich FN, 2002, BBA-BIOENERGETICS, V1556, P41, DOI 10.1016/S0005-2728(02)00305-5
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Labarthe F, 2005, J HEPATOL, V43, P333, DOI 10.1016/j.jhep.2005.03.023
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Naïmi M, 2006, EUR J HUM GENET, V14, P917, DOI 10.1038/sj.ejhg.5201627
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Petit C, 2003, JAIDS-J ACQ IMM DEF, V33, P461, DOI 10.1097/00126334-200308010-00006
   Rovio AT, 2001, NAT GENET, V29, P261, DOI 10.1038/ng759
   RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Salviati L, 2002, ANN NEUROL, V52, P311, DOI 10.1002/ana.10284
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
NR 23
TC 125
Z9 134
U1 0
U2 7
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-3476
EI 1097-6833
J9 J PEDIATR-US
JI J. Pediatr.
PD MAY 15
PY 2007
VL 150
IS 5
BP 531
EP 534
DI 10.1016/j.jpeds.2007.01.044
PG 4
WC Pediatrics
SC Pediatrics
GA 164PH
UT WOS:000246245600022
PM 17452231
DA 2024-11-01
ER

PT J
AU Fernandez-Vizarra, E
   Berardinelli, A
   Valente, L
   Tiranti, V
   Zeviani, M
AF Fernandez-Vizarra, Erika
   Berardinelli, Angela
   Valente, Lucia
   Tiranti, Valeria
   Zeviani, Massimo
TI Nonsense mutation in pseudouridylate synthase 1 (PUS1) in two brothers affected by myopathy, lactic acidosis and sideroblastic anaemia (MLASA)
SO JOURNAL OF MEDICAL GENETICS
LA English
DT Article
ID transfer-rna; mitochondrial myopathy; pseudouridine synthase-1; missense mutation; yeast; gene; protein; biogenesis; disease; import
AB Introduction: Myopathy, lactic acidosis and sideroblastic anaemia (MLASA) is a rare condition that combines early-onset myopathy with lactic acidosis and sideroblastic anaemia. MLASA has been associated with a missense mutation in pseudouridylate synthase 1 (PUS1), an enzyme located in both nucleus and mitochondria, which converts uridine into pseudouridine in several cytosolic and mitochondrial tRNA positions and increases the efficiency of protein synthesis in both compartments. Subjects and methods: We have identified two Italian brothers, offspring of distantly related parents, both of whom are affected by MLASA. The six exons of the PUS1 gene were analysed by automated sequencing. Results: We found combined defects in mitochondrial respiratory chain complexes in muscle and fibroblast homogenates of both patients, and low levels of mtDNA translation products in fibroblast mitochondria. A novel, homozygous stop mutation was present in PUS1 (E220X). We have investigated the structural and mechanistic aspects of the double localisation of PUS1, demonstrating that the isoform located in the nucleus contains an N-terminal extension which is absent in the mature mitochondrial isoform. Conclusions: The stop mutation in PUS1 is likely to determine the loss of function of the protein, since it predicts the synthesis of a protein missing 208/427 amino acid residues on the C terminus, and was associated with low mtDNA translation. The structural differences in nuclear versus mitochondrial isoforms of PUS1 may be implicated in the variability of the clinical presentations in MLASA.
C1 Natl Inst Neurol C Besta, Pierfranco & Luisa Mariani Ctr Study Mitochrondri, Div Mol Neurogenet, I-20126 Milan, Italy.
   IRCCS C Mondino Fdn, Dept Child Neurol & Psychiat, Pavia, Italy.
C3 IRCCS Fondazione Casimiro Mondino
RP Zeviani, M (corresponding author), Natl Inst Neurol C Besta, Pierfranco & Luisa Mariani Ctr Study Mitochrondri, Div Mol Neurogenet, Via Temolo 4, I-20126 Milan, Italy.
EM zeviani@istituto-besta.it
FU Telethon [GGP030039] Funding Source: Medline
CR Bugiani M, 2004, BBA-BIOENERGETICS, V1659, P136, DOI 10.1016/j.bbabio.2004.09.006
   Bykhovskaya Y, 2004, AM J HUM GENET, V74, P1303, DOI 10.1086/421530
   Casas KA, 2004, AM J MED GENET A, V125A, P201, DOI 10.1002/ajmg.a.20368
   Chen JG, 1999, RNA, V5, P409, DOI 10.1017/S1355838299981591
   Chen JG, 2000, BIOCHEM J, V352, P465, DOI 10.1042/0264-6021:3520465
   DiMauro S, 2005, NEUROMUSCULAR DISORD, V15, P276, DOI 10.1016/j.nmd.2004.12.008
   Fernández-Vizarra E, 2002, METHODS, V26, P292, DOI 10.1016/S1046-2023(02)00034-8
   Grosshans H, 2001, J BIOL CHEM, V276, P46333, DOI 10.1074/jbc.M107141200
   INBAL A, 1995, AM J MED GENET, V55, P372, DOI 10.1002/ajmg.1320550325
   Jacobs HT, 2005, TRENDS GENET, V21, P312, DOI 10.1016/j.tig.2005.04.003
   Lecointe F, 2002, J BIOL CHEM, V277, P30445, DOI 10.1074/jbc.M203456200
   Lecointe F, 1998, J BIOL CHEM, V273, P1316, DOI 10.1074/jbc.273.3.1316
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Patton JR, 2005, J BIOL CHEM, V280, P19823, DOI 10.1074/jbc.M500216200
   Petruzzella V, 1998, GENOMICS, V54, P494, DOI 10.1006/geno.1998.5580
   Simos G, 1996, EMBO J, V15, P2270, DOI 10.1002/j.1460-2075.1996.tb00580.x
   Singh B, 2006, BIOCHEM BIOPH RES CO, V346, P911, DOI 10.1016/j.bbrc.2006.05.188
   Spinazzola A, 2005, GENE, V354, P162, DOI 10.1016/j.gene.2005.03.025
   Tiranti V, 1999, HUM MOL GENET, V8, P2533, DOI 10.1093/hmg/8.13.2533
   Tiranti V, 2004, AM J HUM GENET, V74, P239, DOI 10.1086/381653
   Wiedemann N, 2004, J BIOL CHEM, V279, P14473, DOI 10.1074/jbc.R400003200
   Zeharia A, 2005, J CHILD NEUROL, V20, P449, DOI 10.1177/08830738050200051301
   Zhao XS, 2004, MOL CELL, V15, P549, DOI 10.1016/j.molcel.2004.06.044
NR 23
TC 107
Z9 119
U1 1
U2 8
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-2593
EI 1468-6244
J9 J MED GENET
JI J. Med. Genet.
PD MAR 15
PY 2007
VL 44
IS 3
BP 173
EP 180
DI 10.1136/jmg.2006.045252
PG 8
WC Genetics & Heredity
SC Genetics & Heredity
GA 146GF
UT WOS:000244921800003
PM 17056637
DA 2024-11-01
ER

PT J
AU Morten, KJ
   Ashley, N
   Wijburg, F
   Hadzic, N
   Parr, J
   Jayawant, S
   Adams, S
   Bindoff, L
   Bakker, HD
   Mieli-Vergani, G
   Zeviani, M
   Poulton, J
AF Morten, Karl J.
   Ashley, Neil
   Wijburg, Frits
   Hadzic, Nedim
   Parr, Jeremy
   Jayawant, Sandeep
   Adams, Susan
   Bindoff, Laurence
   Bakker, Henk D.
   Mieli-Vergani, Giorgina
   Zeviani, Massimo
   Poulton, Joanna
TI Liver mtDNA content increases during development: A comparison of methods and the importance of age- and tissue-specific controls for the diagnosis of mtDNA depletion
SO MITOCHONDRION
LA English
DT Article
DE mtDNA depletion syndrome; mitochondrial DNA; PicoGreen; movement disorder; hepatocerebral syndrome
ID mitochondrial-dna depletion; deoxyguanosine kinase; alpers-syndrome; gene-mutations; human-cells; deficiency; disorders; reversion; myopathy; diseases
AB Background: The quantitative loss of mitochondrial DNA (mtDNA) known as mtDNA depletion, often gives rise to liver disease. The diagnosis of mtDNA depletion syndrome is frequently imprecise, both for technical reasons and because of the lack of established age-adjusted normal ranges. We aimed to refine quantitative methods for diagnosing the hepatic type of mtDNA depletion syndrome, firstly by establishing an age-matched reference range for mitochondrial to nuclear DNA ratio (henceforth "mtDNA content") and secondly by investigating mtDNA in fibroblasts. Methods: By comparing realtime PCR with an established method for quantifying mtDNA content we established a reference range for young children using biopsy and post-mortem material from patients < 15 years. In addition, we investigated the arrangement of mtDNA in nucleoids from fibroblasts using fluorescence microscopy. Results: Both methods showed that the mtDNA content of liver increases rapidly over the perinatal period. In a patient whose liver mtDNA content fell, but remained within the reference range, early investigation and age-matched controls were essential, as we found a progressive increase in muscle mtDNA copy number, respiratory chain activity and muscle power with age. In three further patients, fluorescence microscopy of the fibroblasts proved diagnostic. In one case a movement disorder was an important pointer. Conclusions: These cases highlight the (i) need for comparing mtDNA copy number data generated from patients to DNA isolated from an age-matched normal range from the tissue of interest and (ii) the utility of mtDNA staining with PicoGreen as a method to detect aberrant nucleoid morphology in mtDNA depletion patient fibroblast lines when affected tissues are not available for measuring mtDNA copy number. (c) 2007 Elsevier B.V. and Mitochondria Research Society. All rights reserved.
C1 [Morten, Karl J.; Ashley, Neil; Adams, Susan; Poulton, Joanna] Univ Oxford, Womens Ctr, John Radcliffe Hosp, Nuffield Dept Obstet & Gynaecol, Oxford OX3 9DU, England.
   [Parr, Jeremy; Jayawant, Sandeep] John Radcliffe Hosp, Dept Paediat, Oxford OX3 9DU, England.
   [Wijburg, Frits; Bakker, Henk D.] Univ Hosp Amsterdam, Dept Paediat, Div Metab Disorders, Acad Med Ctr G8 205, NL-1105 AZ Amsterdam, Netherlands.
   [Hadzic, Nedim; Mieli-Vergani, Giorgina] Kings Coll Hosp London, Univ London Kings Coll, Sch Med, Inst Liver Studies, London SE5 9RJ, England.
   [Bindoff, Laurence] Haukeland Hosp, Dept Neurol, Inst Clin Med, N-5021 Bergen, Norway.
   [Zeviani, Massimo] Natl Neurol Inst C Besta, Div Mol Neurogenet, I-20126 Milan, Italy.
C3 University of Oxford; University of Oxford; University of Amsterdam; Academic Medical Center Amsterdam; University of London; King's College London; King's College Hospital NHS Foundation Trust; King's College Hospital; University of Bergen; Haukeland University Hospital; Fondazione IRCCS Istituto Neurologico Carlo Besta
RP Poulton, J (corresponding author), Univ Oxford, Womens Ctr, John Radcliffe Hosp, Nuffield Dept Obstet & Gynaecol, Oxford OX3 9DU, England.
EM Joanna.poulton@obs-gyn.ox.ac.uk
FU MRC [G0500695] Funding Source: UKRI; Medical Research Council [G0500695] Funding Source: Medline
CR ANTI M, 1994, CANCER, V73, P281, DOI 10.1002/1097-0142(19940115)73:2<281::AID-CNCR2820730208>3.0.CO;2-6
   Antonicka H, 2006, HUM MOL GENET, V15, P1835, DOI 10.1093/hmg/ddl106
   Ashley N, 2005, EXP CELL RES, V303, P432, DOI 10.1016/j.yexcr.2004.10.013
   Bai RK, 2004, ANN NY ACAD SCI, V1011, P304, DOI 10.1196/annals.1293.029
   Barthélémy C, 2002, HUM GENET, V110, P479, DOI 10.1007/s00439-002-0708-4
   Barthélémy C, 2001, ANN NEUROL, V49, P607, DOI 10.1002/ana.1002.abs
   Chabi B, 2003, CLIN CHEM, V49, P1309, DOI 10.1373/49.8.1309
   Chinnery PF, 2005, J HEPATOL, V43, P207, DOI 10.1016/j.jhep.2005.05.012
   Chiu RWK, 2003, CLIN CHEM, V49, P719, DOI 10.1373/49.5.719
   DIMAURO S, 1983, ANN NEUROL, V14, P226, DOI 10.1002/ana.410140209
   Ducluzeau PH, 2002, J HEPATOL, V36, P698, DOI 10.1016/S0168-8278(02)00021-1
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   EPSTEIN CJ, 1967, NATURE, V214, P1050, DOI 10.1038/2141050a0
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Guidotti JE, 2003, J BIOL CHEM, V278, P19095, DOI 10.1074/jbc.M300982200
   Hargreaves IP, 2002, J INHERIT METAB DIS, V25, P7, DOI 10.1023/A:1015104910239
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Iborra FJ, 2004, BMC BIOL, V2, P0, DOI 10.1186/1741-7007-2-9
   Labarthe F, 2005, J HEPATOL, V43, P333, DOI 10.1016/j.jhep.2005.03.023
   Legros F, 2004, J CELL SCI, V117, P2653, DOI 10.1242/jcs.01134
   Macmillan CJ, 1996, PEDIATR NEUROL, V14, P203, DOI 10.1016/0887-8994(96)00018-5
   Macsween RNM, 2002, PATHOLOGY LIVER, V4th, P0
   Magnusson J, 2003, EXP CELL RES, V289, P133, DOI 10.1016/S0014-4827(03)00249-0
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   MORITZ C, 1987, P NATL ACAD SCI USA, V84, P7183, DOI 10.1073/pnas.84.20.7183
   Morris AAM, 1998, J HEPATOL, V28, P556, DOI 10.1016/S0168-8278(98)80278-X
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Naviaux RK, 1999, ANN NEUROL, V45, P54, DOI 10.1002/1531-8249(199901)45:1<54::AID-ART10>3.0.CO;2-B
   Nguyen KV, 2006, J HEPATOL, V45, P108, DOI 10.1016/j.jhep.2005.12.026
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   POULTON J, 1995, J INHERIT METAB DIS, V18, P4, DOI 10.1007/BF00711367
   RICCI E, 1992, BRAIN PATHOL, V2, P141, DOI 10.1111/j.1750-3639.1992.tb00682.x
   Roubertoux PL, 2003, NAT GENET, V35, P65, DOI 10.1038/ng1230
   Salviati L, 2002, ANN NEUROL, V52, P311, DOI 10.1002/ana.10284
   SPERL W, 1992, ANN CLIN BIOCHEM, V29, P638, DOI 10.1177/000456329202900604
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Spinazzola A, 2005, GENE, V354, P162, DOI 10.1016/j.gene.2005.03.025
   Taanman JW, 1997, HUM MOL GENET, V6, P935, DOI 10.1093/hmg/6.6.935
   Vilà MR, 2003, NEUROLOGY, V60, P1203, DOI 10.1212/01.WNL.0000055928.58122.47
   Vilarinho L, 1999, J INHERIT METAB DIS, V22, P90, DOI 10.1023/A:1005471904710
   Vu TH, 1998, NEUROLOGY, V50, P1783, DOI 10.1212/WNL.50.6.1783
   Wang LY, 2005, MOL GENET METAB, V84, P75, DOI 10.1016/j.ymgme.2004.09.005
   WATMOUGH NJ, 1989, BIOCHEM BIOPH RES CO, V160, P623, DOI 10.1016/0006-291X(89)92478-9
NR 45
TC 51
Z9 60
U1 0
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
EI 
J9 MITOCHONDRION
JI Mitochondrion
PD DEC 15
PY 2007
VL 7
IS 6
BP 386
EP 395
DI 10.1016/j.mito.2007.09.001
PG 10
WC Cell Biology; Genetics & Heredity
SC Cell Biology; Genetics & Heredity
GA 242TU
UT WOS:000251749900004
PM 17981517
DA 2024-11-01
ER

PT J
AU Farge, G
   Pham, XH
   Holmlund, T
   Khorostov, I
   Falkenberg, M
AF Farge, Geraldine
   Pham, Xuan Hoi
   Holmlund, Teresa
   Khorostov, Ivan
   Falkenberg, Maria
TI The accessory subunit B of DNA polymerase γ is required for mitochondrial replisome function
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID deoxyribonucleic-acid; escherichia-coli; phage t7; binding; replication; helicase; twinkle; processivity; protein; primase
AB The mitochondrial replication machinery in human cells includes the DNA polymerase gamma holoenzyme and the TWINKLE helicase. Together, these two factors form a processive replication machinery, a replisome, which can use duplex DNA as template to synthesize long stretches of single-stranded DNA. We here address the importance of the smaller, accessory B subunit of DNA polymerase gamma and demonstrate that this subunit is absolutely required for replisome function. The duplex DNA binding activity of the B subunit is needed for coordination of POL gamma holoenzyme and TWINKLE helicase activities at the mtDNA replication fork. In the absence of proof for direct physical interactions between the components of the mitochondrial replisome, these functional interactions may explain the strict interdependence of TWINKLE and DNA polymerase gamma for mitochondrial DNA synthesis. Furthermore, mutations in TWINKLE as well as in the catalytic A and accessory B subunits of the POL gamma holoenzyme, may cause autosomal dominant progressive external ophthalmoplegia, a disorder associated with deletions in mitochondrial DNA. The crucial importance of the B subunit for replisome function may help to explain why mutations in these three proteins cause an identical syndrome.
C1 Karolinska Inst, Div Metab Dis, SE-14186 Stockholm, Sweden.
C3 Karolinska Institutet
RP Falkenberg, M (corresponding author), Karolinska Inst, Div Metab Dis, SE-14186 Stockholm, Sweden.
EM maria.falkenberg@ki.se
CR Carrodeguas JA, 2002, J BIOL CHEM, V277, P50008, DOI 10.1074/jbc.M207030200
   Carrodeguas JA, 1999, MOL CELL BIOL, V19, P4039
   Carrodeguas JA, 2001, MOL CELL, V7, P43, DOI 10.1016/S1097-2765(01)00153-8
   Falkenberg M, 2000, P NATL ACAD SCI USA, V97, P3896, DOI 10.1073/pnas.97.8.3896
   Fan L, 2006, J MOL BIOL, V358, P1229, DOI 10.1016/j.jmb.2006.02.073
   Gaspari M, 2004, EMBO J, V23, P4606, DOI 10.1038/sj.emboj.7600465
   Hamdan SM, 2005, P NATL ACAD SCI USA, V102, P5096, DOI 10.1073/pnas.0501637102
   HUBER HE, 1986, J BIOL CHEM, V261, P5006
   Johnson AA, 2001, J BIOL CHEM, V276, P38097
   Kaguni LS, 2004, ANNU REV BIOCHEM, V73, P293, DOI 10.1146/annurev.biochem.72.121801.161455
   Korhonen JA, 2004, EMBO J, V23, P2423, DOI 10.1038/sj.emboj.7600257
   Korhonen JA, 2003, J BIOL CHEM, V278, P48627, DOI 10.1074/jbc.M306981200
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   NAKAI H, 1988, J BIOL CHEM, V263, P9831
   Notarnicola SM, 1997, J BIOL CHEM, V272, P18425, DOI 10.1074/jbc.272.29.18425
   Shadel GS, 1997, ANNU REV BIOCHEM, V66, P409, DOI 10.1146/annurev.biochem.66.1.409
   Shutt TE, 2006, TRENDS GENET, V22, P90, DOI 10.1016/j.tig.2005.11.007
   Shutt TE, 2006, J MOL EVOL, V62, P588, DOI 10.1007/s00239-005-0162-8
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767
   Wang YX, 1997, J BIOL CHEM, V272, P13640, DOI 10.1074/jbc.272.21.13640
   Yakubovskaya E, 2006, J BIOL CHEM, V281, P374, DOI 10.1074/jbc.M509730200
   Zhang HL, 2001, P NATL ACAD SCI USA, V98, P10608, DOI 10.1073/pnas.191321998
   Zhu YL, 2003, J VIROL, V77, P10147, DOI 10.1128/JVI.77.18.10147-10153.2003
NR 24
TC 42
Z9 50
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 1362-4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD FEB 15
PY 2007
VL 35
IS 3
BP 902
EP 911
DI 10.1093/nar/gkl1116
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 139KD
UT WOS:000244429800024
PM 17251196
DA 2024-11-01
ER

PT J
AU Hakonen, AH
   Davidzon, G
   Salemi, R
   Bindoff, LA
   Van Goethem, G
   DiMauro, S
   Thorburn, DR
   Suomalainen, A
AF Hakonen, Anna H.
   Davidzon, Guido
   Salemi, Renato
   Bindoff, Laurence A.
   Van Goethem, Gert
   DiMauro, Salvatore
   Thorburn, David R.
   Suomalainen, Anu
TI Abundance of the POLG disease mutations in Europe, Australia, New Zealand, and the United States explained by single ancient European founders
SO EUROPEAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
DE polymerase gamma; POLG; POLG1; ataxia; MIRAS; Alpers
ID mitochondrial-dna polymerase; progressive external ophthalmoplegia; autosomal recessive ataxia; alpers-syndrome; gamma-a; depletion; spectrum; origin; a467t
AB We reported previously that the DNA polymerase gamma (POLG) W748S mutation, a common cause of mitochondrial recessive ataxia syndrome (MIRAS), has a common ancient founder for all the disease chromosomes in Finland, Norway, United Kingdom, and Belgium. Here, we present results showing that the same ancestral chromosome underlies MIRAS and Alpers syndrome in Australia and New Zealand. Furthermore, we show that a second common POLG mutation, A467T, also shows common European ancestry: patients from Australia, New Zealand, and the United States share a common haplotype with the previously reported European patients. These data of ancestral haplotypes indicate that the POLG locus is quite stable and that the recessive W748S and A467T mutations, and probably also G848S, have occurred once in history. They have effectively spread to populations of European descent with carrier frequencies up to 1% in several populations. Our data predict that these mutations are common causes of ataxia and Alpers disease in the Western world.
C1 Univ Helsinki, Res Program Mol Neurol, FIN-00290 Helsinki, Finland.
C3 University of Helsinki
RP Suomalainen, A (corresponding author), Univ Helsinki, Res Program Mol Neurol, R C523B,Haartmaninkatu 8, FIN-00290 Helsinki, Finland.
EM anu.wartiovaara@helsinki.fi
CR [Anonymous], 1987, AUSTR HIST STAT, V0, P0
   Chan SSL, 2005, J BIOL CHEM, V280, P31341, DOI 10.1074/jbc.M506762200
   Cossee M, 1997, P NATL ACAD SCI USA, V94, P7452, DOI 10.1073/pnas.94.14.7452
   Davidzon G, 2005, ANN NEUROL, V57, P921, DOI 10.1002/ana.20498
   Domínguez BM, 2002, ARCH LATINOAM NUTR, V52, P219
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   *GEOGRAPHICA, 2000, SUUR MAAILM MAAN MAA, V0, P0
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Kaguni LS, 2004, ANNU REV BIOCHEM, V73, P293, DOI 10.1146/annurev.biochem.72.121801.161455
   KHOO S, 2004, 20540 AUSTR BUR STAT, V0, P11
   Kollberg G, 2006, J NEUROPATH EXP NEUR, V65, P758, DOI 10.1097/01.jnen.0000229987.17548.6e
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Longley MJ, 1998, P NATL ACAD SCI USA, V95, P12244, DOI 10.1073/pnas.95.21.12244
   Luoma PT, 2005, HUM MOL GENET, V14, P1907, DOI 10.1093/hmg/ddi196
   Naviaux RK, 2005, ANN NEUROL, V58, P491, DOI 10.1002/ana.20544
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Nguyen KV, 2006, J HEPATOL, V45, P108, DOI 10.1016/j.jhep.2005.12.026
   Nguyen KV, 2005, NEUROLOGY, V65, P1493, DOI 10.1212/01.wnl.0000182814.55361.70
   RAMUS SJ, 1995, AM J HUM GENET, V56, P1034
   Rantamäki M, 2001, NEUROLOGY, V57, P1043, DOI 10.1212/WNL.57.6.1043
   Tzoulis C, 2006, BRAIN, V129, P1685, DOI 10.1093/brain/awl097
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Van Goethem G, 2003, HUM MUTAT, V22, P175, DOI 10.1002/humu.10246
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Varilo T, 1999, THESIS NATL PUBLIC H, V0, P0
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
NR 29
TC 61
Z9 63
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1018-4813
EI 1476-5438
J9 EUR J HUM GENET
JI Eur. J. Hum. Genet.
PD JUL 15
PY 2007
VL 15
IS 7
BP 779
EP 783
DI 10.1038/sj.ejhg.5201831
PG 5
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 181KT
UT WOS:000247436300011
PM 17426723
DA 2024-11-01
ER

PT J
AU Tanji, K
   Bonilla, E
AF Tanji, Kurenai
   Bonilla, Eduardo
TI Optical Imaging techniques (histochemical, immunohistochemical, and <i>in situ</i> hybridization staining methods) to visualize mitochondria
SO MITOCHONDRIA, 2ND EDITION
LA English
DT Review; Book Chapter
ID cytochrome-c-oxidase; progressive external ophthalmoplegia; kearns-sayre-syndrome; stroke-like episodes; red fibers merrf; myoclonic epilepsy; skeletal-muscle; dna deletions; respiratory-chain; mtdna mutation
C1 Columbia Univ, Dept Pathol, New York, NY 10032 USA.
   Columbia Univ, Dept Neurol, New York, NY 10032 USA.
C3 Columbia University; Columbia University
RP Tanji, K (corresponding author), Columbia Univ, Dept Pathol, New York, NY 10032 USA.
FU NICHD NIH HHS [P01 HD 32062] Funding Source: Medline; NINDS NIH HHS [NS 11766] Funding Source: Medline
CR Ackrell BAC, 2002, MOL ASPECTS MED, V23, P369, DOI 10.1016/S0098-2997(02)00012-2
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   ANDREETTA F, 1991, J NEUROL SCI, V105, P88, DOI 10.1016/0022-510X(91)90123-O
   ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cb.04.110188.001445
   BEDETTI CD, 1985, J HISTOCHEM CYTOCHEM, V33, P446, DOI 10.1177/33.5.2580882
   BOGENHAGEN D, 1974, J BIOL CHEM, V249, P7991
   Bonilla E, 1999, BBA-BIOENERGETICS, V1410, P171, DOI 10.1016/S0005-2728(98)00165-0
   BONILLA E, 1992, BRAIN PATHOL, V2, P113, DOI 10.1111/j.1750-3639.1992.tb00679.x
   BONILLA E, 1975, J ULTRA MOL STRUCT R, V51, P404, DOI 10.1016/S0022-5320(75)80103-1
   CAPALDI RA, 1990, ARCH BIOCHEM BIOPHYS, V280, P252, DOI 10.1016/0003-9861(90)90327-U
   COOPER CE, 1991, BIOCH CELL BIOL, V69, P596
   Di Mauro S, 2004, MYOLOGY PHILADELPHIA, V0, P1623
   DIMAURO S, 1994, MITOCHONDRIAL DISORD, V0, P91
   ENGEL WK, 1963, NEUROLOGY, V13, P919, DOI 10.1212/WNL.13.11.919
   GILES RE, 1980, P NATL ACAD SCI-BIOL, V77, P6715, DOI 10.1073/pnas.77.11.6715
   GOTO Y, 1991, BIOCHIM BIOPHYS ACTA, V1097, P238, DOI 10.1016/0925-4439(91)90042-8
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   HALLER RG, 1991, J CLIN INVEST, V88, P1197, DOI 10.1172/JCI115422
   HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.biochem.54.1.1015
   HATTORI N, 1991, ANN NEUROL, V30, P563, DOI 10.1002/ana.410300409
   HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614
   HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661
   JOHNSON MA, 1983, J NEUROL SCI, V60, P31, DOI 10.1016/0022-510X(83)90125-9
   JOHNSON MA, 1988, J NEUROL SCI, V87, P75, DOI 10.1016/0022-510X(88)90056-1
   KADENBACH B, 1987, CURR TOP BIOENERG, V15, P113
   KLOECKENERGRUISSEM B, 1987, CURR GENET, V12, P311, DOI 10.1007/BF00405753
   Manfredi G, 1997, ANN NEUROL, V42, P180, DOI 10.1002/ana.410420208
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   MORAES CT, 1992, NAT GENET, V1, P359, DOI 10.1038/ng0892-359
   Moslemi AR, 1996, ANN NEUROL, V40, P707, DOI 10.1002/ana.410400506
   NAKASE H, 1990, AM J HUM GENET, V46, P418
   Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863
   Papadopoulou LC, 1999, NAT GENET, V23, P333
   PEL HJ, 1992, CURR GENET, V21, P139, DOI 10.1007/BF00318473
   PETTE D, 1981, HISTOCHEM J, V13, P319, DOI 10.1007/BF01006885
   SATOH M, 1991, EXP CELL RES, V196, P137, DOI 10.1016/0014-4827(91)90467-9
   SELIGMAN AM, 1951, SCIENCE, V113, P317, DOI 10.1126/science.113.2934.317-a
   SELIGMAN AM, 1968, J CELL BIOL, V38, P1, DOI 10.1083/jcb.38.1.1
   SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N
   Shoubridge EA, 2001, HUM MOL GENET, V10, P2277, DOI 10.1093/hmg/10.20.2277
   Shoubridge Eric A, 1993, P109, V0, P0
   SILVESTRI G, 1992, AM J HUM GENET, V51, P1213
   SPARACO M, 1995, BRAIN PATHOL, V5, P125, DOI 10.1111/j.1750-3639.1995.tb00586.x
   SZABOLCS MJ, 1994, KIDNEY INT, V45, P1388, DOI 10.1038/ki.1994.181
   Taanman JW, 1997, J BIOENERG BIOMEMBR, V29, P151, DOI 10.1023/A:1022638013825
   Taanman JW, 1996, BBA-MOL BASIS DIS, V1315, P199, DOI 10.1016/0925-4439(95)00127-1
   Tanji K, 1999, ANN NEUROL, V45, P377, DOI 10.1002/1531-8249(199903)45:3<377::AID-ANA14>3.0.CO;2-M
   Tanji K, 2003, ACTA NEUROPATHOL, V105, P69, DOI 10.1007/s00401-002-0604-y
   Taylor RW, 1996, ANN NEUROL, V39, P224, DOI 10.1002/ana.410390212
   Tiranti V, 1998, AM J HUM GENET, V63, P1609, DOI 10.1086/302150
   TRITSCHLER HJ, 1992, NEUROLOGY, V42, P209, DOI 10.1212/WNL.42.1.209
   Vu TH, 1998, NEUROLOGY, V51, P1190, DOI 10.1212/WNL.51.4.1190
   Vu TH, 2000, MUSCLE NERVE, V23, P80, DOI 10.1002/(SICI)1097-4598(200001)23:1<80::AID-MUS10>3.0.CO;2-V
   WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523
   WONGRILEY MTT, 1989, TRENDS NEUROSCI, V12, P94, DOI 10.1016/0166-2236(89)90165-3
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
   Zhu ZQ, 1998, NAT GENET, V20, P337, DOI 10.1038/3804
NR 57
TC 11
Z9 11
U1 0
U2 5
PU ELSEVIER ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0091-679X
EI 
J9 METHOD CELL BIOL
JI Methods Cell Biol.
PD JUN 15
PY 2007
VL 80
IS 
BP 135
EP +
DI 10.1016/S0091-679X(06)80006-3
PG 22
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA BGB65
UT WOS:000245920700006
PM 17445692
DA 2024-11-01
ER

PT J
AU da Costa, CK
   Kiyomoto, BH
   Schmidt, B
   Oliveira, ASB
   Gabbai, AA
   Tengan, CH
AF da Costa, Carina K.
   Kiyomoto, Beatriz H.
   Schmidt, Beny
   Oliveira, Acary S. B.
   Gabbai, Alberto A.
   Tengan, Celia H.
TI Age-related mitochondrial DNA point mutations in patients with mitochondrial myopathy
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Article
DE mitochondrial DNA; aging; mitochondrial diseases; mitochondria
ID mtdna control region; d-loop; skeletal-muscle; healthy-subjects; accumulation; deletions; duplications; replication; increase; disease
AB Mutations in the control region (D-loop) of mitochondrial DNA (mtDNA) have been described in normal old individuals and it is suggested that they originated from oxidative damage. Respiratory chain defects may lead to increased free radical generation, increased susceptibility to oxidative damage and further increased accumulation of age-related mutations. The objective of this study was to verify whether patients with a mitochondrial disease are more predisposed to accumulate the A189G and T408A mutations in the D-loop and confirm their age-associated nature. We evaluated the presence and levels of heteroplasmy of these two mutations in muscle DNA of 52 individuals with different ages (21 age-matched controls and 31 patients with single or multiple mtDNA deletions). The frequency of both mutations was significantly increased with age, but no differences were observed comparing the group of patients with their age-matched controls. We could not observe correlation of levels of heteroplasmy with age. Our results confirm the age-related nature of the A189G and T408A mutations in the D-loop in controls and patients with mitochondrial disease, but do not suggest that patients are more predisposed to the development of age-related point mutations. (c) 2007 Elsevier B.V. All rights reserved.
C1 [da Costa, Carina K.; Kiyomoto, Beatriz H.; Oliveira, Acary S. B.; Gabbai, Alberto A.; Tengan, Celia H.] Univ Fed Sao Paulo, Escola Paulista Med, Dept Neurol, Sao Paulo, Brazil.
   [Schmidt, Beny] Univ Fed Sao Paulo, Escola Paulista Med, Dept Pathol, Sao Paulo, Brazil.
C3 Universidade Federal de Sao Paulo (UNIFESP); Universidade Federal de Sao Paulo (UNIFESP)
RP Tengan, CH (corresponding author), R Pedro Toledo 781, BR-0403932 Sao Paulo, Brazil.
EM chtengan@neuro.epm.br
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Bouzidi MF, 1998, HUM MOL GENET, V7, P385, DOI 10.1093/hmg/7.3.385
   Chinnery PF, 2002, LANCET, V360, P1323, DOI 10.1016/S0140-6736(02)11310-9
   COLLINS S, 1995, ACTA NEUROL SCAND, V91, P287, DOI 10.1111/j.1600-0404.1995.tb07007.x
   Cormio A, 2005, NEUROBIOL AGING, V26, P655, DOI 10.1016/j.neurobiolaging.2004.06.014
   CORTOPASSI GA, 1990, NUCLEIC ACIDS RES, V18, P6927, DOI 10.1093/nar/18.23.6927
   Del Bo R, 2003, NEUROBIOL AGING, V24, P829, DOI 10.1016/S0197-4580(02)00233-6
   Del Bo R, 2002, J NEUROL SCI, V202, P85, DOI 10.1016/S0022-510X(02)00247-2
   HARMAN D, 1992, MUTAT RES, V275, P257, DOI 10.1016/0921-8734(92)90030-S
   KATSUMATA K, 1994, BIOCHEM BIOPH RES CO, V202, P102, DOI 10.1006/bbrc.1994.1899
   Kovalenko SA, 1996, BIOCHEM BIOPH RES CO, V222, P201, DOI 10.1006/bbrc.1996.0722
   LEE HC, 1994, FEBS LETT, V354, P79, DOI 10.1016/0014-5793(94)01063-3
   LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4
   MELOV S, 1995, NUCLEIC ACIDS RES, V23, P4122, DOI 10.1093/nar/23.20.4122
   Michikawa Y, 1999, SCIENCE, V286, P774, DOI 10.1126/science.286.5440.774
   RIFAI Z, 1995, ANN NEUROL, V37, P24, DOI 10.1002/ana.410370107
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Tengan CH, 2002, BBA-MOL BASIS DIS, V1588, P65, DOI 10.1016/S0925-4439(02)00140-0
   Tengan CH, 1997, MUTAT RES-FUND MOL M, V379, P1, DOI 10.1016/S0027-5107(97)00076-6
   Trifunovic A, 2005, P NATL ACAD SCI USA, V102, P17993, DOI 10.1073/pnas.0508886102
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Wang Y, 2001, P NATL ACAD SCI USA, V98, P4022, DOI 10.1073/pnas.061013598
   Wiesner RJ, 2006, FREE RADICAL RES, V40, P1284, DOI 10.1080/10715760600913168
   Yowe DL, 1998, GENE, V209, P23, DOI 10.1016/S0378-1119(97)00628-8
NR 24
TC 7
Z9 9
U1 1
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-510X
EI 
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD DEC 15
PY 2007
VL 263
IS 1-2
BP 139
EP 144
DI 10.1016/j.jns.2007.07.006
PG 6
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 269SY
UT WOS:000253671700023
PM 17698085
DA 2024-11-01
ER

PT J
AU de Vries, MC
   Rodenburg, RJ
   Morava, E
   van Kaauwen, EPM
   ter Laak, H
   Mullaart, RA
   Snoeck, IN
   van Hasselt, PM
   Harding, P
   van den Heuvel, LPW
   Smeitink, JAM
AF de Vries, Maaike C.
   Rodenburg, Richard J.
   Morava, Eva
   van Kaauwen, Edwin P. M.
   ter Laak, Henk
   Mullaart, Reinier A.
   Snoeck, Irina N.
   van Hasselt, Peter M.
   Harding, Peter
   van den Heuvel, Lambert P. W.
   Smeitink, Jan A. M.
TI Multiple oxidative phosphorylation deficiencies in severe childhood multi-system disorders due to polymerase gamma (<i>POLG1</i>) mutations
SO EUROPEAN JOURNAL OF PEDIATRICS
LA English
DT Article
DE POLG1; combined OXPHOS deficiencies; mitochondrial medicine
ID mitochondrial-dna polymerase; progressive external ophthalmoplegia; alpers-syndrome; autosomal-dominant; gene; depletion; defects; ataxia; valproate; deletions
AB Failure to thrive, feeding difficulties, variable forms of infantile epilepsy or psychomotor developmental delay and hypotonia were the most frequent clinical disease presentations in eight.children with combined oxidative phosphorylation enzyme complex deficiencies carrying mutations in the polymerase gamma (POLGI) gene. Five out of eight patients developed severe liver dysfunction during the course of the disease. Three of these patients fulfilled the disease criteria for Alpers syndrome. Most children showed deficiencies of respiratory chain enzyme complexes I and III, in combination with complex II, complex IV and/or PDHc in muscle, whereas in fibroblasts normal enzyme activities were measured. All children carried homozygous or compound heterozygous mutations in the POLGI gene, including two novel mutations in association with mtDNA depletion. Conclusion We suggest performing POLGI mutation analysis in children with combined oxidative phosphorylation deficiencies in muscle, even if the clinical picture is not Alpers syndrome.
C1 Radboud Univ Nijmegen, Nijmegen Med Ctr, Dept Pediat, NL-6500 HB Nijmegen, Netherlands.
   Radboud Univ Nijmegen, Nijmegen Med Ctr, Dept Child Neurol, NL-6500 HB Nijmegen, Netherlands.
   Radboud Univ Nijmegen, Nijmegen Med Ctr, Ctr Mitochondrail Disorders, Dept Pediat,Lab Pediat & Neurol, NL-6500 HB Nijmegen, Netherlands.
   Radboud Univ Nijmegen, Nijmegen Med Ctr, Dept Pathol, NL-6500 HB Nijmegen, Netherlands.
   Juliana Childrens Hosp, Dept Neurol, The Hague, Netherlands.
   Acad Med Ctr, Dept Pediat, Utrecht, Netherlands.
   Klinikum Oldenburg, Dept Pediat, Oldenburg, Germany.
C3 Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; Klinikum Oldenburg
RP de Vries, MC (corresponding author), Radboud Univ Nijmegen, Nijmegen Med Ctr, Dept Pediat, POB 9101, NL-6500 HB Nijmegen, Netherlands.
EM m.devries@cukz.umcn.nl
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   Alpers BJ, 1931, ARCH NEURO PSYCHIATR, V25, P469, DOI 10.1001/archneurpsyc.1931.02230030027002
   CHABROL B, 1994, EUR J PEDIATR, V153, P133, DOI 10.1007/BF01959226
   Davidzon G, 2005, ANN NEUROL, V57, P921, DOI 10.1002/ana.20498
   Di Fonzo A, 2003, HUM MUTAT, V22, P0, DOI 10.1002/humu.9203
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   GONZALEZ E, 2004, POLG TWINKLE MUTATIO, V0, P59
   González-Vioque E, 2006, ARCH NEUROL-CHICAGO, V63, P107, DOI 10.1001/archneur.63.1.107
   Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805
   Graziewicz MA, 2006, CHEM REV, V106, P383, DOI 10.1021/cr040463d
   HAAS R, 1981, NEUROLOGY, V31, P1473, DOI 10.1212/WNL.31.11.1473
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Janssen AJM, 2003, ANN CLIN BIOCHEM, V40, P3, DOI 10.1258/000456303321016114
   Lamantea E, 2004, ANN NEUROL, V56, P454, DOI 10.1002/ana.20219
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Loeffen JLCM, 2000, HUM MUTAT, V15, P123, DOI 10.1002/(SICI)1098-1004(200002)15:2<123::AID-HUMU1>3.3.CO;2-G
   Longley MJ, 2005, GENE, V354, P125, DOI 10.1016/j.gene.2005.03.029
   Luoma PT, 2005, HUM MOL GENET, V14, P1907, DOI 10.1093/hmg/ddi196
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Naviaux RK, 1999, ANN NEUROL, V45, P54, DOI 10.1002/1531-8249(199901)45:1<54::AID-ART10>3.0.CO;2-B
   Nguyen KV, 2005, NEUROLOGY, V65, P1493, DOI 10.1212/01.wnl.0000182814.55361.70
   Salviati L, 2002, ANN NEUROL, V52, P311, DOI 10.1002/ana.10284
   Smeitink J, 2001, J BIOENERG BIOMEMBR, V33, P259, DOI 10.1023/A:1010743321800
   Taanman JW, 2005, NEUROSCI LETT, V376, P56, DOI 10.1016/j.neulet.2004.11.023
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Van Goethem G, 2003, NEUROLOGY, V61, P1811, DOI 10.1212/01.WNL.0000098997.23471.65
   Van Goethem G, 2003, EUR J HUM GENET, V11, P547, DOI 10.1038/sj.ejhg.5201002
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
   Wolf NI, 2002, NEUROLOGY, V59, P1402, DOI 10.1212/01.WNL.0000031795.91814.D8
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
NR 32
TC 58
Z9 58
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013 USA
SN 0340-6199
EI 
J9 EUR J PEDIATR
JI Eur. J. Pediatr.
PD MAR 15
PY 2007
VL 166
IS 3
BP 229
EP 234
DI 10.1007/s00431-006-0234-9
PG 6
WC Pediatrics
SC Pediatrics
GA 142JH
UT WOS:000244645100008
PM 16957900
DA 2024-11-01
ER

PT J
AU Saada, A
   Shaag, A
   Amon, S
   Dolfin, T
   Miller, C
   Fuchs-Telem, D
   Lombes, A
   Elpeleg, O
AF Saada, A.
   Shaag, A.
   Amon, S.
   Dolfin, T.
   Miller, C.
   Fuchs-Telem, D.
   Lombes, A.
   Elpeleg, O.
TI Antenatal mitochondrial disease caused by mitochondrial ribosomal protein (<i>MRPS22</i>) mutation
SO JOURNAL OF MEDICAL GENETICS
LA English
DT Article
ID dna depletion; translation; deficiency
AB Three patients born to the same set of consanguineous parents presented with antenatal skin oedema, hypotonia, cardiomyopathy and tubulopathy. The enzymatic activities of multiple mitochondrial respiratory chain complexes were reduced in muscle. Marked reduction of 12s rRNA, the core of the mitochondrial small ribosomal subunit, was found in fibroblasts. Homozygosity mapping led to the identification of a mutation in the MRPS22 gene, which encodes a mitochondrial ribosomal protein. Transfection of the patient cells with wildtype MRPS22 cDNA increased the 12s rRNA content and normalised the enzymatic activities. Quantification of mitochondrial transcripts is advisable in patients with multiple defects of the mitochondrial respiratory chain.
C1 Hebrew Univ Jerusalem, Med Ctr, Metab Dis Unit, IL-91120 Jerusalem, Israel.
   Meir Med Ctr, Dept Neonatol, Kefar Sava, Israel.
   Hop La Pitie Salpetriere, INSERM 582, Paris, France.
C3 Hebrew University of Jerusalem; Tel Aviv University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm)
RP Elpeleg, O (corresponding author), Hebrew Univ Jerusalem, Med Ctr, Metab Dis Unit, IL-91120 Jerusalem, Israel.
EM elpeleg@cc.huji.ac.il
CR Arnon S, 2002, PRENATAL DIAG, V22, P34, DOI 10.1002/pd.232
   Coenen MJH, 2004, NEW ENGL J MED, V351, P2080, DOI 10.1056/NEJMoa041878
   DENNIS PP, 1975, J BACTERIOL, V121, P994, DOI 10.1128/JB.121.3.994-999.1975
   Edvardson S, 2007, AM J HUM GENET, V81, P857, DOI 10.1086/521227
   Koc EC, 2001, J BIOL CHEM, V276, P19363, DOI 10.1074/jbc.M100727200
   Miller C, 2004, ANN NEUROL, V56, P734, DOI 10.1002/ana.20282
   Sarzi E, 2007, J PEDIATR-US, V150, P531, DOI 10.1016/j.jpeds.2007.01.044
   Smeitink JAM, 2006, AM J HUM GENET, V79, P869, DOI 10.1086/508434
   Valente L, 2007, AM J HUM GENET, V80, P44, DOI 10.1086/510559
NR 9
TC 127
Z9 138
U1 0
U2 3
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-2593
EI 
J9 J MED GENET
JI J. Med. Genet.
PD DEC 15
PY 2007
VL 44
IS 12
BP 784
EP 786
DI 10.1136/jmg.2007.053116
PG 3
WC Genetics & Heredity
SC Genetics & Heredity
GA 236QE
UT WOS:000251317700006
PM 17873122
DA 2024-11-01
ER

PT J
AU Ugalde, C
   Hinttala, R
   Timal, S
   Smeets, R
   Rodenburg, RJT
   Uusimaa, J
   van Heuvel, LP
   Nijtmans, LGJ
   Majamaa, K
   Smeitink, JAM
AF Ugalde, Cristina
   Hinttala, Reetta
   Timal, Sharita
   Smeets, Roel
   Rodenburg, Richard J. T.
   Uusimaa, Johanna
   van Heuvel, Lambert P.
   Nijtmans, Leo G. J.
   Majamaa, Karl
   Smeitink, Jan A. M.
TI Mutated <i>ND2</i> impairs mitochondrial complex I assembly and leads to Leigh syndrome
SO MOLECULAR GENETICS AND METABOLISM
LA English
DT Article
DE NADH ubiquinone oxidorreductase deficiency; assembly; mtDNA; mitochondrial disorders; Leigh syndrome
ID hereditary optic neuropathy; dna; deficiency; sequence
AB We describe a novel mitochondrial ND2 mutation (T4681C) in a patient presenting with Leigh Syndrome. Biochemical analyses revealed a low isolated complex I activity in patient's fibroblasts, blood and skeletal muscle. Mutant transmitochondrial cybrid clones retained the specific complex I defect, demonstrating the mitochondrial genetic origin of the disease. The mutation leads to a L71P substitution at an evolutionary conserved amino acid stretch. By two-dimensional blue native electrophoresis (2D-BN-SDS-PAGE), decreased complex I levels were observed together with an accumulation of specific assembly intermediates, suggesting that the mutation disturbs the complex I assembly pathway. (c) 2006 Elsevier Inc. All rights reserved.
C1 Radboud Univ Nijmegen, Med Ctr, Dept Pediat, Nijmegen Ctr Mitochondrial Disorders, NL-6500 HB Nijmegen, Netherlands.
   Univ Madrid, Hosp 12 Octubre, Ctr Invest, Madrid, Spain.
   Oulu Univ Hosp, Clin Res Ctr, Oulu, Finland.
   Univ Oulu, Dept Neurol, Oulu, Finland.
   Univ Oulu, Dept Pediat, SF-90100 Oulu, Finland.
   Univ Turku, Dept Neurol, FIN-20520 Turku, Finland.
C3 Radboud University Nijmegen; Hospital Universitario 12 de Octubre; University of Oulu; University of Oulu; University of Oulu; University of Turku
RP Smeitink, JAM (corresponding author), Radboud Univ Nijmegen, Med Ctr, Dept Pediat, Nijmegen Ctr Mitochondrial Disorders, Geerst Grootepl 10, NL-6500 HB Nijmegen, Netherlands.
EM j.smeitink@cukz.umcn.nl
CR Andreu AL, 1999, ANN NEUROL, V45, P820, DOI 10.1002/1531-8249(199906)45:6<820::AID-ANA22>3.0.CO;2-W
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   BROWN MD, 1992, GENETICS, V130, P163
   Carelli V, 2004, BBA-BIOENERGETICS, V1658, P172, DOI 10.1016/j.bbabio.2004.05.009
   Carroll J, 2003, MOL CELL PROTEOMICS, V2, P117, DOI 10.1074/mcp.M300014-MCP200
   DeVries DD, 1996, AM J HUM GENET, V58, P703
   Finnilä S, 2000, AM J HUM GENET, V66, P1017, DOI 10.1086/302802
   HINTTALA R, 2006, J MED GENET, V0, P0
   King M P, 1996, METHODS ENZYMOL, V264, P313, DOI 10.1016/S0076-6879(96)64030-0
   Kirby DM, 2000, ANN NEUROL, V48, P102, DOI 10.1002/1531-8249(200007)48:1<102::AID-ANA15>3.3.CO;2-D
   Pulkes T, 1999, ANN NEUROL, V46, P916, DOI 10.1002/1531-8249(199912)46:6<916::AID-ANA16>3.0.CO;2-R
   Schwartz M, 2002, NEW ENGL J MED, V347, P576, DOI 10.1056/NEJMoa020350
   Triepels RH, 2001, AM J MED GENET, V106, P37, DOI 10.1002/ajmg.1397
   Ugalde C, 2004, HUM MOL GENET, V13, P2461, DOI 10.1093/hmg/ddh262
   Ugalde C, 2004, HUM MOL GENET, V13, P659, DOI 10.1093/hmg/ddh071
NR 15
TC 63
Z9 72
U1 0
U2 5
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1096-7192
EI 
J9 MOL GENET METAB
JI Mol. Genet. Metab.
PD JAN 15
PY 2007
VL 90
IS 1
BP 10
EP 14
DI 10.1016/j.ymgme.2006.08.003
PG 5
WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research & Experimental
SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental Medicine
GA 125XK
UT WOS:000243476600002
PM 16996290
DA 2024-11-01
ER

PT J
AU Castagna, AE
   Addis, J
   McInnes, RR
   Clarke, JTR
   Ashby, P
   Blaser, S
   Robinson, BH
AF Castagna, Avril E.
   Addis, Jane
   McInnes, Roderick R.
   Clarke, Joe T. R.
   Ashby, Peter
   Blaser, Susan
   Robinson, Brian H.
TI Late onset Leigh syndrome and ataxia due to a T to C mutation at bp 9,185 of mitochondrial DNA
SO AMERICAN JOURNAL OF MEDICAL GENETICS PART A
LA English
DT Article
DE Leigh syndrome; ataxia; mitochondrial DNA mutation
ID atpase 6 gene; respiratory-chain defects; clinical-features; point mutation; mtdna; transition; synthase; disease
AB A T-to-C missense mutation at nucleotide position 9,185 in the protein-coding ATP6 gene of the mitochondrial genome was present at high heteroplasmy in members of a Canadian family with Leigh syndrome with predominant ataxia and peripheral neuropathy. This mutation results in the substitution of a proline residue for an evolutionary-conserved leucine at position of amino acid 220 near the carboxyl terminus of the mitochondrial protein. The index patient and brother, who had an identical clinical presentation, had > 90% mutant mtDNA in Cultured skin fibroblasts, lymphocytes, and whole blood. Their mother and a maternal uncle, symptomatic with a peripheral neuropathy alone, had 86% and 85% heteroplasmy, respectively. Symptomatic maternal cousins with early onset revealed 90% and 91% mutant mtDNA in all tissues analyzed. Studies of lymphoblasts from the asymptomatic maternal grandmother and eldest brother of the proband were heteroplasmic for Mutant mtDNA with 56% and 17%, respectively. Biochemical analysis demonstrated normal respiratory chain enzyme activity in muscle and fibroblasts, normal ATP synthesis, but reduced oligomycin-sensitive H(+)ATPase in cultured lymphoblast mitochondria. We propose that the 9,185T > C mtDNA Mutation is pathogenic even though the initial phenotype is mild and the biochemical phenotype not easily detectable. (c) 2007 Wiley-Liss, Inc.
C1 Hosp Sick Children, Metab Res Programme, Inst Res, Toronto, ON M5G 1X8, Canada.
   Hosp Sick Children, Dev Biol Programme, Inst Res, Toronto, ON M5G 1X8, Canada.
   Hosp Sick Children, Scarborough Gen Hosp, Toronto, ON M5G 1X8, Canada.
   Hosp Sick Children, Dept Diagnost Imaging, Toronto, ON M5G 1X8, Canada.
   Univ Hlth Network, Toronto Western Hosp, Toronto, ON, Canada.
   Univ Toronto, Dept Biochem & Paediat, Toronto, ON, Canada.
C3 University of Toronto; Hospital for Sick Children (SickKids); University of Toronto; Hospital for Sick Children (SickKids); University of Toronto; Hospital for Sick Children (SickKids); Scarborough Hospital; University of Toronto; Hospital for Sick Children (SickKids); University of Toronto; University Health Network Toronto; University of Toronto
RP Robinson, BH (corresponding author), Hosp Sick Children, Metab Res Programme, Inst Res, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.
EM bhr@sickkids.ca
CR Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   BARTLETT GR, 1959, J BIOL CHEM, V234, P466
   BERKOVIC SF, 1991, LANCET, V338, P457, DOI 10.1016/0140-6736(91)91090-H
   BOURGERON T, 1992, BIOCHEM BIOPH RES CO, V186, P16, DOI 10.1016/S0006-291X(05)80769-7
   BOYER PD, 1989, FASEB J, V3, P2164, DOI 10.1096/fasebj.3.10.2526771
   Campos Y, 1997, NEUROLOGY, V49, P595, DOI 10.1212/WNL.49.2.595
   Carrozzo R, 2001, NEUROLOGY, V56, P687, DOI 10.1212/WNL.56.5.687
   DAS AM, 1990, AM J PHYSIOL, V259, PH1264, DOI 10.1152/ajpheart.1990.259.4.H1264
   DEMEIRLEIR L, 1995, PEDIATR NEUROL, V13, P242, DOI 10.1016/0887-8994(95)00184-H
   DEVRIES DD, 1993, ANN NEUROL, V34, P410, DOI 10.1002/ana.410340319
   HOLT IJ, 1990, AM J HUM GENET, V46, P428
   Jesina P, 2004, BIOCHEM J, V383, P561, DOI 10.1042/BJ20040407
   KANEKO M, 1993, GENET RES, V61, P195, DOI 10.1017/S0016672300031360
   LEIGH D, 1951, J NEUROL NEUROSUR PS, V14, P216, DOI 10.1136/jnnp.14.3.216
   MERANTE F, 1994, AM J HUM GENET, V55, P437
   Merante F, 1996, HUM MUTAT, V8, P216, DOI 10.1002/(SICI)1098-1004(1996)8:3<216::AID-HUMU4>3.0.CO;2-7
   Merante F, 1996, METHODS MOL BIOL, V58, P3
   Moslemi AR, 2005, NEUROPEDIATRICS, V36, P314, DOI 10.1055/s-2005-872845
   Ogilvie I, 1999, FEBS LETT, V453, P179, DOI 10.1016/S0014-5793(99)00605-5
   Rahman S, 1996, ANN NEUROL, V39, P343, DOI 10.1002/ana.410390311
   ROBINSON BH, 1986, J CLIN INVEST, V77, P1422, DOI 10.1172/JCI112453
   ROBINSON BH, 1990, PEDIATR RES, V28, P549, DOI 10.1203/00006450-199011000-00027
   SANTORELLI FM, 1994, NEUROLOGY, V44, P972, DOI 10.1212/WNL.44.5.972
   SILVESTRI G, 1993, NEUROLOGY, V43, P1200, DOI 10.1212/WNL.43.6.1200
   TATUCH Y, 1993, BIOCHEM BIOPH RES CO, V192, P124, DOI 10.1006/bbrc.1993.1390
   TATUCH Y, 1992, AM J HUM GENET, V50, P852
   Tatuch Yuriy, 1994, EUROPEAN JOURNAL OF HUMAN GENETICS, V2, P35
   THYAGARAJAN D, 1995, ANN NEUROL, V38, P468, DOI 10.1002/ana.410380321
NR 28
TC 51
Z9 57
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1552-4825
EI 1552-4833
J9 AM J MED GENET A
JI Am. J. Med. Genet. A
PD APR 15
PY 2007
VL 143A
IS 8
BP 808
EP 816
DI 10.1002/ajmg.a.31637
PG 9
WC Genetics & Heredity
SC Genetics & Heredity
GA 156PP
UT WOS:000245661800005
PM 17352390
DA 2024-11-01
ER

PT J
AU Wanrooij, S
   Goffart, S
   Pohjoismäki, JLO
   Yasukawa, T
   Spelbrink, JN
AF Wanrooij, Sjoerd
   Goffart, Steffi
   Pohjoismaki, Jaakko L. O.
   Yasukawa, Takehiro
   Spelbrink, Johannes N.
TI Expression of catalytic mutants of the mtDNA helicase Twinkle and polymerase POLG causes distinct replication stalling phenotypes
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID human mitochondrial-dna; progressive external ophthalmoplegia; agarose-gel electrophoresis; escherichia-coli; binding protein; saccharomyces-cerevisiae; crystal-structure; bacteriophage t7; lagging-strand; mutations
AB The mechanism of mitochondrial DNA replication is a subject of intense debate. One model proposes a strand-asynchronous replication in which both strands of the circular genome are replicated semi-independently while the other model proposes both a bidirectional coupled leading- and lagging-strand synthesis mode and a unidirectional mode in which the lagging-strand is initially laid-down as RNA by an unknown mechanism (RITOLS mode). Both the strand-asynchronous and RITOLS model have in common a delayed synthesis of the DNA-lagging strand. Mitochondrial DNA is replicated by a limited set of proteins including DNA polymerase gamma (POLG) and the helicase Twinkle. Here, we report the effects of expression of various catalytically deficient mutants of POLG1 and Twinkle in human cell culture. Both groups of mutants reduced mitochondrial DNA copy number by severe replication stalling. However, the analysis showed that while induction of POLG1 mutants still displayed delayed lagging-strand synthesis, Twinkle- induced stalling resulted in maturated, essentially fully double-stranded DNA intermediates. In the latter case, limited inhibition of POLG with dideoxycytidine restored the delay between leading- and lagging-strand synthesis. The observed cause-effect relationship suggests that Twinkle- induced stalling increases lagging- strand initiation events and/or maturation mimicking conventional strand-coupled replication.
C1 Inst Med Technol, Tampere, Finland.
   Tampere Univ Hosp, Tampere, Finland.
   MRC, Dunn Human Nutr Unit, Cambridge, England.
C3 Tampere University; Tampere University Hospital; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research
RP Spelbrink, JN (corresponding author), Inst Med Technol, Tampere, Finland.
EM hans.spelbrink@uta.fi
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Belanger KG, 1996, NUCLEIC ACIDS RES, V24, P2166, DOI 10.1093/nar/24.11.2166
   Bowmaker M, 2003, J BIOL CHEM, V278, P50961, DOI 10.1074/jbc.M308028200
   BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8
   BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X
   Brown TA, 2005, GENE DEV, V19, P2466, DOI 10.1101/gad.1352105
   CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6
   Crampton DJ, 2006, MOL CELL, V21, P165, DOI 10.1016/j.molcel.2005.11.027
   FOURY F, 1992, EMBO J, V11, P2717, DOI 10.1002/j.1460-2075.1992.tb05337.x
   Friedman KL, 1995, METHOD ENZYMOL, V262, P613
   Garrido N, 2003, MOL BIOL CELL, V14, P1583, DOI 10.1091/mbc.E02-07-0399
   Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805
   Guo SY, 1999, J BIOL CHEM, V274, P30303, DOI 10.1074/jbc.274.42.30303
   Holt IJ, 2000, CELL, V100, P515, DOI 10.1016/S0092-8674(00)80688-1
   HU JP, 1995, GENE, V160, P105, DOI 10.1016/0378-1119(95)00215-R
   Jazayeri M, 2003, J BIOL CHEM, V278, P9823, DOI 10.1074/jbc.M211730200
   Kaguni LS, 2004, ANNU REV BIOCHEM, V73, P293, DOI 10.1146/annurev.biochem.72.121801.161455
   Korhonen JA, 2004, EMBO J, V23, P2423, DOI 10.1038/sj.emboj.7600257
   Korhonen JA, 2003, J BIOL CHEM, V278, P48627, DOI 10.1074/jbc.M306981200
   Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125
   Legros F, 2004, J CELL SCI, V117, P2653, DOI 10.1242/jcs.01134
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Longley MJ, 2005, GENE, V354, P125, DOI 10.1016/j.gene.2005.03.029
   MEYER RR, 1990, MICROBIOL REV, V54, P342, DOI 10.1128/MMBR.54.4.342-380.1990
   Murakami E, 2003, J BIOL CHEM, V278, P36403, DOI 10.1074/jbc.M306236200
   Nikali K, 2005, HUM MOL GENET, V14, P2981, DOI 10.1093/hmg/ddi328
   POLESKY AH, 1992, J BIOL CHEM, V267, P8417
   POLESKY AH, 1990, J BIOL CHEM, V265, P14579
   ROBBERSON DL, 1972, P NATL ACAD SCI USA, V69, P737, DOI 10.1073/pnas.69.3.737
   Sawaya MR, 1999, CELL, V99, P167, DOI 10.1016/S0092-8674(00)81648-7
   Shutt TE, 2006, TRENDS GENET, V22, P90, DOI 10.1016/j.tig.2005.11.007
   Shutt TE, 2006, J MOL EVOL, V62, P588, DOI 10.1007/s00239-005-0162-8
   Singleton MR, 2000, CELL, V101, P589, DOI 10.1016/S0092-8674(00)80871-5
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spelbrink JN, 2000, J BIOL CHEM, V275, P24818, DOI 10.1074/jbc.M000559200
   SPELBRINK JN, 2003, GENETICS MITOCHONDRI, V0, P0
   TAKAMATSU C, 2002, EMBO REP, V18, P18
   TIRANTI V, 1993, GENE, V126, P219, DOI 10.1016/0378-1119(93)90370-I
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Tyynismaa H, 2005, P NATL ACAD SCI USA, V102, P17687, DOI 10.1073/pnas.0505551102
   Tyynismaa H, 2004, HUM MOL GENET, V13, P3219, DOI 10.1093/hmg/ddh342
   Vanderstraeten S, 1998, J BIOL CHEM, V273, P23690, DOI 10.1074/jbc.273.37.23690
   Viguera E, 1998, GENE, V217, P41, DOI 10.1016/S0378-1119(98)00375-8
   Wanrooij S, 2004, NUCLEIC ACIDS RES, V32, P3053, DOI 10.1093/nar/gkh634
   Washington MT, 1996, J BIOL CHEM, V271, P26825, DOI 10.1074/jbc.271.43.26825
   Yang MY, 2002, CELL, V111, P495, DOI 10.1016/S0092-8674(02)01075-9
   Yasukawa T, 2005, MOL CELL, V18, P651, DOI 10.1016/j.molcel.2005.05.002
   Yasukawa T, 2006, EMBO J, V25, P5358, DOI 10.1038/sj.emboj.7601392
NR 49
TC 116
Z9 128
U1 0
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD MAY 15
PY 2007
VL 35
IS 10
BP 3238
EP 3251
DI 10.1093/nar/gkm215
PG 14
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 186ZO
UT WOS:000247817300007
PM 17452351
DA 2024-11-01
ER

PT J
AU Siciliano, G
   Volpi, L
   Piazza, S
   Ricci, G
   Mancuso, M
   Murri, L
AF Siciliano, Gabriele
   Volpi, Leda
   Piazza, Selina
   Ricci, Giulia
   Mancuso, Michelangelo
   Murri, Luigi
TI Functional diagnostics in mitochondrial diseases
SO BIOSCIENCE REPORTS
LA English
DT Article; Proceedings Paper
DE mitochondrial myopathy; exercise; muscle fatigue
ID cytochrome-c-oxidase; progressive external ophthalmoplegia; magnetic-resonance-spectroscopy; coenzyme q(10) deficiency; skeletal-muscle; cerebellar-ataxia; dna depletion; anaerobic threshold; endurance exercise; sperm mitochondria
AB Mitochondrial diseases (MD) with respiratory chain defects are caused by genetic mutations that determine an impairment of the electron transport chain functioning. Diagnosis often requires a complex approach with measurements of serum lactate, magnetic resonance spectroscopy (MRS), muscle histology and ultrastructure, enzymology, genetic analysis, and exercise testing. The ubiquitous distribution of the mitochondria in the human body explains the multiple organ involvement. Exercise intolerance is a common symptom of MD, due to increased dependence of skeletal muscle on anaerobic metabolism, with an excess lactate generation, phosphocreatine depletion, enhanced free radical production, reduced oxygen extraction and electron flux through the respiratory chain. MD treatment has included antioxidants (vitamin E, alpha lipoic acid), coenzyme Q10, riboflavin, creatine monohydrate, dichloroacetate and exercise training. Exercise is a particularly important tool in diagnosis as well as in the management of these diseases.
C1 Univ Pisa, Dept Neurosci, Neurol Sect, I-56126 Pisa, Italy.
C3 University of Pisa
RP Siciliano, G (corresponding author), Univ Pisa, Dept Neurosci, Neurol Sect, Cia Roma 67, I-56126 Pisa, Italy.
EM g.siciliano@med.unipi.it
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   Agostino A, 2003, HUM MOL GENET, V12, P399, DOI 10.1093/hmg/ddg038
   ANDERSEN P, 1977, ACTA PHYSIOL SCAND, V99, P123, DOI 10.1111/j.1748-1716.1977.tb10361.x
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Antonicka H, 2003, AM J HUM GENET, V72, P101, DOI 10.1086/345489
   Antonicka H, 2006, HUM MOL GENET, V15, P1835, DOI 10.1093/hmg/ddl106
   Argov Z, 2000, MUSCLE NERVE, V23, P1316, DOI 10.1002/1097-4598(200009)23:9<1316::AID-MUS2>3.3.CO;2-9
   ARGOV Z, 1987, NEUROLOGY, V37, P257, DOI 10.1212/WNL.37.2.257
   Auré K, 2004, NEUROLOGY, V63, P727, DOI 10.1212/01.WNL.0000134607.76780.B2
   Bai RK, 2005, J MOL DIAGN, V7, P613, DOI 10.1016/S1525-1578(10)60595-8
   Barrientos A, 2002, EMBO J, V21, P43, DOI 10.1093/emboj/21.1.43
   Battersby BJ, 2003, NAT GENET, V33, P183, DOI 10.1038/ng1073
   BIGLANDRITCHIE B, 1984, MUSCLE NERVE, V7, P691, DOI 10.1002/mus.880070902
   Bohr VA, 2002, GENE, V286, P127, DOI 10.1016/S0378-1119(01)00813-7
   BONNE G, 1993, EUR J BIOCHEM, V217, P1099, DOI 10.1111/j.1432-1033.1993.tb18342.x
   BOULET L, 1992, AM J HUM GENET, V51, P1187
   Cao ZJ, 2001, NUCLEIC ACIDS RES, V29, P4502, DOI 10.1093/nar/29.21.4502
   Cejudo P, 2005, MUSCLE NERVE, V32, P342, DOI 10.1002/mus.20368
   CLAYTON DA, 1991, ANNU REV CELL BIOL, V7, P453, DOI 10.1146/annurev.cb.07.110191.002321
   Di Giovanni S, 2001, NEUROLOGY, V57, P515, DOI 10.1212/WNL.57.3.515
   DiMauro S, 1996, J INHERIT METAB DIS, V19, P489, DOI 10.1007/BF01799110
   DIMAURO S, 1993, ARCH NEUROL-CHICAGO, V50, P1197, DOI 10.1001/archneur.1993.00540110075008
   DIMAURO S, 1985, ANN NEUROL, V17, P521, DOI 10.1002/ana.410170602
   Edwards R H, 1981, CIBA FOUND SYMP, V82, P1
   Fadic R, 1996, SEMIN NEUROL, V16, P11, DOI 10.1055/s-2008-1040954
   Finsterer J, 2000, METAB BRAIN DIS, V15, P163
   Gillis L, 2002, PEDIATR CLIN N AM, V49, P203, DOI 10.1016/S0031-3955(03)00115-9
   Gimenez-Roqueplo AP, 2002, J CLIN ENDOCR METAB, V87, P4771, DOI 10.1210/jc.2002-020525
   Gironi M, 2004, NEUROLOGY, V62, P818, DOI 10.1212/01.WNL.0000113719.67643.B7
   Irrcher I, 2003, SPORTS MED, V33, P783, DOI 10.2165/00007256-200333110-00001
   Jeppesen TD, 2003, J NEUROL, V250, P293, DOI 10.1007/s00415-003-0993-4
   KEMP GJ, 1993, NMR BIOMED, V6, P302, DOI 10.1002/nbm.1940060504
   KEMP GJ, 1993, J NEUROL SCI, V116, P201, DOI 10.1016/0022-510X(93)90326-T
   KLAUSEN K, 1981, ACTA PHYSIOL SCAND, V113, P9, DOI 10.1111/j.1748-1716.1981.tb06854.x
   Kornblum C, 2005, EUR J NEUROL, V12, P300, DOI 10.1111/j.1468-1331.2004.00970.x
   Lalani SR, 2005, ARCH NEUROL-CHICAGO, V62, P317, DOI 10.1001/archneur.62.2.317
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Lamperti C, 2003, NEUROLOGY, V60, P1206, DOI 10.1212/01.WNL.0000055089.39373.FC
   Leonard JV, 2000, LANCET, V355, P299, DOI 10.1016/S0140-6736(99)05225-3
   MACRAE HSH, 1995, EUR J APPL PHYSIOL O, V71, P523, DOI 10.1007/BF00238555
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   McFarland R, 2002, LANCET NEUROL, V1, P343, DOI 10.1016/S1474-4422(02)00159-X
   McKenzie S, 2000, AM J PHYSIOL-ENDOC M, V278, PE580, DOI 10.1152/ajpendo.2000.278.4.E580
   Musumeci O, 2001, NEUROLOGY, V56, P849, DOI 10.1212/WNL.56.7.849
   Naccarati A, 2000, NEUROL SCI, V21, PS963, DOI 10.1007/s100720070010
   Neumann HPH, 2002, NEW ENGL J MED, V346, P1459, DOI 10.1056/NEJMoa020152
   Olsen DB, 2005, NEUROLOGY, V64, P1064, DOI 10.1212/01.WNL.0000150584.45055.27
   Orngreen MC, 2005, ANN NEUROL, V57, P754, DOI 10.1002/ana.20460
   Rollins S, 2001, AM J CLIN PATHOL, V116, P326
   Rötig A, 2000, LANCET, V356, P391, DOI 10.1016/S0140-6736(00)02531-9
   Rustin P, 2002, BBA-BIOENERGETICS, V1553, P117, DOI 10.1016/S0005-2728(01)00228-6
   Salviati L, 2005, NEUROLOGY, V65, P606, DOI 10.1212/01.wnl.0000172859.55579.a7
   Salviati L, 2002, ANN NEUROL, V52, P311, DOI 10.1002/ana.10284
   Salviati L, 2002, BIOCHEM J, V363, P321, DOI 10.1042/0264-6021:3630321
   Salviati L, 2002, ARCH NEUROL-CHICAGO, V59, P862, DOI 10.1001/archneur.59.5.862
   SCHAGGER H, 1995, EUR J BIOCHEM, V230, P235, DOI 10.1111/j.1432-1033.1995.0235i.x
   Schlame M, 2002, ANN NEUROL, V51, P634, DOI 10.1002/ana.10176
   Sciacco M, 1998, MUSCLE NERVE, V21, P1374, DOI 10.1002/(SICI)1097-4598(199811)21:11<1374::AID-MUS3>3.0.CO;2-6
   Shitara H, 2001, FEBS LETT, V500, P7, DOI 10.1016/S0014-5793(01)02574-1
   SHOFFNER JM, 1990, ADV HUM GENET, V19, P267
   SHOUBRIDGE EA, 1990, CELL, V62, P43, DOI 10.1016/0092-8674(90)90238-A
   Shoubridge EA, 1997, HUM MOL GENET, V6, P2239, DOI 10.1093/hmg/6.13.2239
   Siciliano G, 2000, NEUROMUSCULAR DISORD, V10, P40, DOI 10.1016/S0960-8966(99)00068-1
   Siciliano G, 1999, NEUROMUSCULAR DISORD, V9, P411, DOI 10.1016/S0960-8966(99)00047-4
   SJODIN B, 1976, ACTA PHYSIOL SCAND, V97, P150, DOI 10.1111/j.1748-1716.1976.tb10247.x
   Sobreira C, 1997, NEUROLOGY, V48, P1238, DOI 10.1212/WNL.48.5.1238
   Sperl W, 1997, WIEN KLIN WOCHENSCHR, V109, P93
   Sutovsky P, 2000, BIOL REPROD, V63, P582, DOI 10.1095/biolreprod63.2.582
   TAANMAN JW, 1992, BIOCHIM BIOPHYS ACTA, V1139, P155, DOI 10.1016/0925-4439(92)90095-5
   Taivassalo T, 1998, NEUROLOGY, V50, P1055, DOI 10.1212/WNL.50.4.1055
   Taivassalo T, 1996, NEUROLOGY, V47, P529, DOI 10.1212/WNL.47.2.529
   Taivassalo T, 2001, ANN NEUROL, V50, P133, DOI 10.1002/ana.1050
   Taivassalo T, 2003, BRAIN, V126, P413, DOI 10.1093/brain/awg028
   Taivassalo T, 2006, BRAIN, V129, P3391, DOI 10.1093/brain/awl282
   Takahashi Y, 2002, MOL CELL BIOL, V22, P7614, DOI 10.1128/MCB.22.21.7614-7621.2002
   Tarnopolsky M, 2004, MITOCHONDRION, V4, P529, DOI 10.1016/j.mito.2004.07.011
   Tarnopolsky MA, 2005, MED SCI SPORT EXER, V37, P2086, DOI 10.1249/01.mss.0000177341.89478.06
   Tarnopolsky MA, 2001, ANN NEUROL, V49, P561, DOI 10.1002/ana.1028.abs
   Tomasetti M, 1999, FREE RADICAL BIO MED, V27, P1027, DOI 10.1016/S0891-5849(99)00132-X
   Triepels RH, 2001, AM J MED GENET, V106, P37, DOI 10.1002/ajmg.1397
   TZAGOLOFF A, 1986, ANNU REV BIOCHEM, V55, P249, DOI 10.1146/annurev.biochem.55.1.249
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Van Maldergem L, 2002, ANN NEUROL, V52, P750, DOI 10.1002/ana.10371
   Visapää I, 2002, AM J HUM GENET, V71, P863, DOI 10.1086/342773
   Vissing J, 2003, ANN NEUROL, V54, P539, DOI 10.1002/ana.10725
   Walker UA, 1996, EUR NEUROL, V36, P260, DOI 10.1159/000117269
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   Wang Y, 2001, P NATL ACAD SCI USA, V98, P4022, DOI 10.1073/pnas.061013598
   WASSERMAN K, 1973, J APPL PHYSIOL, V35, P236, DOI 10.1152/jappl.1973.35.2.236
   Weltman A, 1997, MED SCI SPORT EXER, V29, P669, DOI 10.1097/00005768-199705000-00013
   Zeviani M, 2003, CURR OPIN NEUROL, V16, P585, DOI 10.1097/00019052-200310000-00004
NR 91
TC 38
Z9 42
U1 0
U2 7
PU PORTLAND PRESS LTD
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER STREET, LONDON WC1N 2JU, ENGLAND
SN 0144-8463
EI 1573-4935
J9 BIOSCIENCE REP
JI Biosci. Rep.
PD JUN 15
PY 2007
VL 27
IS 1-3
BP 53
EP 67
DI 10.1007/s10540-007-9037-0
PG 15
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 178YM
UT WOS:000247256300007
PM 17492503
DA 2024-11-01
ER

PT J
AU Meissner, C
AF Meissner, C.
TI Mutations of mitochondrial DNA - cause or consequence of the ageing process?
SO ZEITSCHRIFT FUR GERONTOLOGIE UND GERIATRIE
LA English
DT Article
DE ageing; mitochondria; oxidative damage; point mutations; deletions
ID human skeletal-muscle; manganese superoxide-dismutase; oxidative damage; deletion mutations; mtdna mutations; life-span; increase; disease; brain; neurodegeneration
AB Ageing is a stochastic process which leads to a gradual decline in cellular, tissue and even organ function, especially in energy dependent postmitotic tissues like skeletal muscle, brain and heart. The mitochondrial theory of ageing is based on the assumption that reactive oxygen species (ROS) and free radicals generated in the immediate vicinity of the electron transport chain during the lifespan of an organism damage proteins, lipids and mitochondrial DNA (mtDNA). Whereas it was generally believed that mitochondria are among the important players regarding the ageing process, two recent important approaches shed new light on the complex interactions. It has been shown by single cell experiments and computer simulation models that mitochondrial mutations are generated stochastically in childhood or early adolescence and accumulate clonally in a cell or muscle fibre, leading to a local age related impairment of cellular energy supply. Other important observations come from mitochondrial mutator mice, harbouring mitochondrial mutations due to a deficient repair enzyme (POLG). These mice reveal a premature senescence but do not exhibit a vicious cycle of increased oxidative damage or ROS production as has been postulated by the mitochondrial theory of ageing. At the moment it is hard to decide, if mitochondrial mutations are the cause or consequence of human ageing, but it is suggested that mitochondrial point mutations are just the consequence, while deletions seem to play a causal role.
C1 Univ Hosp Schleswig Holstein, Dept Forens Med, D-23562 Lubeck, Germany.
C3 University of Kiel; Schleswig Holstein University Hospital
RP Meissner, C (corresponding author), Univ Hosp Schleswig Holstein, Dept Forens Med, Kahlhorststr 31-35, D-23562 Lubeck, Germany.
EM meissner@rmed.mu-luebeck.de
CR Ballard JWO, 2001, CURR OPIN GENET DEV, V11, P667, DOI 10.1016/S0959-437X(00)00251-3
   Bank C, 2000, BIOCHEM BIOPH RES CO, V279, P595, DOI 10.1006/bbrc.2000.3951
   Barja G, 2000, AGING CLIN EXP RES, V12, P342, DOI 10.1007/BF03339859
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Berdanier CD, 2001, MUTAT RES-FUND MOL M, V475, P169, DOI 10.1016/S0027-5107(01)00068-9
   Bodyak ND, 2001, HUM MOL GENET, V10, P17, DOI 10.1093/hmg/10.1.17
   Bowmaker M, 2003, J BIOL CHEM, V278, P50961, DOI 10.1074/jbc.M308028200
   Bua E, 2006, AM J HUM GENET, V79, P469, DOI 10.1086/507132
   Cassano P, 2004, ANN NY ACAD SCI, V1019, P269, DOI 10.1196/annals.1297.045
   Chabi B, 2005, BIOCHEM BIOPH RES CO, V332, P542, DOI 10.1016/j.bbrc.2005.04.153
   CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324
   CORTOPASSI GA, 1992, P NATL ACAD SCI USA, V89, P7370, DOI 10.1073/pnas.89.16.7370
   Elson JL, 2001, AM J HUM GENET, V68, P802, DOI 10.1086/318801
   Fiskum G, 1999, J CEREBR BLOOD F MET, V19, P351, DOI 10.1097/00004647-199904000-00001
   Gokey NG, 2004, AGING CELL, V3, P319, DOI 10.1111/j.1474-9728.2004.00122.x
   Graeber MB, 1998, J NEUROSCI RES, V52, P1
   HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x
   Hasty P, 2005, MECH AGEING DEV, V126, P71, DOI 10.1016/j.mad.2004.09.036
   Hayakawa M, 1996, BIOCHEM BIOPH RES CO, V226, P369, DOI 10.1006/bbrc.1996.1363
   Jacobs HT, 2003, AGING CELL, V2, P11, DOI 10.1046/j.1474-9728.2003.00032.x
   KADENBACH B, 1995, MUTAT RES-DNAGING G, V338, P161, DOI 10.1016/0921-8734(95)00021-W
   Kajander OA, 2000, HUM MOL GENET, V9, P2821, DOI 10.1093/hmg/9.19.2821
   KEUTZER DA, 1998, P NATL ACAD SCI USA, V95, P3578
   Khrapko K, 2003, MUTAT RES-FUND MOL M, V522, P13, DOI 10.1016/S0027-5107(02)00306-8
   Khrapko K, 2007, NAT GENET, V39, P445, DOI 10.1038/ng0407-445
   Khrapko K, 2006, AGING CELL, V5, P279, DOI 10.1111/j.1474-9726.2006.00209.x
   Korr H, 1998, BRAZ J MED BIOL RES, V31, P289, DOI 10.1590/S0100-879X1998000200012
   Kovalenko SA, 1997, BIOCHEM BIOPH RES CO, V232, P147, DOI 10.1006/bbrc.1997.6251
   Kowald A, 1999, EXP GERONTOL, V34, P605, DOI 10.1016/S0531-5565(99)00011-X
   Kraytsberg Y, 2006, NAT GENET, V38, P518, DOI 10.1038/ng1778
   Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125
   Kujoth GC, 2007, PLOS GENET, V3, P161, DOI 10.1371/journal.pgen.0030024
   Lezza AMS, 1999, FASEB J, V13, P1083, DOI 10.1096/fasebj.13.9.1083
   Mandavilli BS, 2002, MUTAT RES-FUND MOL M, V509, P127, DOI 10.1016/S0027-5107(02)00220-8
   Melov S, 1999, P NATL ACAD SCI USA, V96, P846, DOI 10.1073/pnas.96.3.846
   MELOV S, 1995, NUCLEIC ACIDS RES, V23, P4122, DOI 10.1093/nar/23.20.4122
   MIQUEL J, 1980, EXP GERONTOL, V15, P575, DOI 10.1016/0531-5565(80)90010-8
   MO JQ, 1995, MECH AGEING DEV, V81, P73, DOI 10.1016/0047-6374(95)01586-O
   Mohamed SA, 2006, EXP GERONTOL, V41, P508, DOI 10.1016/j.exger.2006.03.014
   Passos JF, 2007, PLOS BIOL, V5, P1138, DOI 10.1371/journal.pbio.0050110
   Phadnis N, 2005, GENETICS, V171, P1549, DOI 10.1534/genetics.105.047092
   Raha S, 2000, TRENDS BIOCHEM SCI, V25, P502, DOI 10.1016/S0968-0004(00)01674-1
   Rasmussen UF, 2003, EXP GERONTOL, V38, P877, DOI 10.1016/S0531-5565(03)00092-5
   Sato A, 2005, P NATL ACAD SCI USA, V102, P16765, DOI 10.1073/pnas.0506197102
   Schriner SE, 2005, SCIENCE, V308, P1909, DOI 10.1126/science.1106653
   SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771
   SIMONETTI S, 1992, BIOCHIM BIOPHYS ACTA, V1180, P113, DOI 10.1016/0925-4439(92)90059-V
   SOONG NW, 1992, NAT GENET, V2, P318
   Srivastava S, 2005, HUM MOL GENET, V14, P893, DOI 10.1093/hmg/ddi082
   St-Pierre J, 2002, J BIOL CHEM, V277, P44784, DOI 10.1074/jbc.M207217200
   Storm T, 2002, EXP GERONTOL, V37, P1389, DOI 10.1016/S0531-5565(02)00121-3
   Streit WJ, 2002, GLIA, V40, P133, DOI 10.1002/glia.10154
   Sun JT, 1999, MOL CELL BIOL, V19, P216
   Taylor RW, 2003, J CLIN INVEST, V112, P1351, DOI 10.1172/JCI200319435
   Trifunovic A, 2005, P NATL ACAD SCI USA, V102, P17993, DOI 10.1073/pnas.0508886102
   VEMULST M, 2007, NAT GENET, V39, P540
   Wiesner RJ, 2006, FREE RADICAL RES, V40, P1284, DOI 10.1080/10715760600913168
   Yen HC, 1996, J CLIN INVEST, V98, P1253, DOI 10.1172/JCI118909
   YEN TC, 1994, FREE RADICAL BIO MED, V16, P207, DOI 10.1016/0891-5849(94)90145-7
   Zeviani M, 2003, CURR OPIN GENET DEV, V13, P262, DOI 10.1016/S0959-437X(03)00052-2
   Zhang CF, 1998, HUM MUTAT, V11, P360
   Zhong WX, 1996, CELL GROWTH DIFFER, V7, P1175
NR 62
TC 24
Z9 28
U1 0
U2 12
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0948-6704
EI 1435-1269
J9 Z GERONTOL GERIATR
JI Z. Gerontol. Geriatr.
PD OCT 15
PY 2007
VL 40
IS 5
BP 325
EP 333
DI 10.1007/s00391-007-0481-z
PG 9
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 221QV
UT WOS:000250243300003
PM 17943235
DA 2024-11-01
ER

PT J
AU Sarzi, E
   Brown, MD
   Lebon, S
   Chretien, D
   Munnich, A
   Rotig, A
   Procaccio, V
AF Sarzi, Emmanuelle
   Brown, Michael D.
   Lebon, Sophie
   Chretien, Dominique
   Munnich, Arnold
   Rotig, Agnes
   Procaccio, Vincent
TI A novel recurrent mitochondrial DNA mutation in <i>ND3</i> gene is associated with isolated complex I deficiency causing Leigh syndrome and dystonia
SO AMERICAN JOURNAL OF MEDICAL GENETICS PART A
LA English
DT Article
DE Leigh syndrome; dystonia; complex I; mitochondrial genome; mtDNA; ND3
ID missense mutation; ubiquinone oxidoreductase; heart-mitochondria; g13513a mutation; point mutation; human mtdna; disease; nadh; melas; strategy
AB Defects in NADH:ubiquinone oxidoreductase (complex I), the largest complex of the mitochondrial respiratory chain, account for most cases of respiratory chain deficiency in human. Complex I contains at least 45 subunits, 7 of which are encoded by mitochondrial DNA (mtDNA). Here we report a novel 10197G > A mutation of the ND3 gene in three unrelated families with Leigh syndrome (LS) or dystonia. Variable degrees of heteroplasmy were found in all tissues tested and a high percentage of mutant mtDNA was observed in muscle. The 10197G > A mutation modifies a hydrophobic alanine residue into a hydrophilic threonine (A47T) in a highly conserved domain of ND3 subunit. Furthermore, this defect could be transferred along with the mutant mtDNAs to rho degrees lymphoblastoid cells in cybrid experiments. However, nuclear modifier genes may also play a role in the phenotypic expression and severity of 10197G > A mutation. The association of the 10197G > A ND3 mutation with an isolated biochemical defect involving complex I and the discovery of the 10197G > A mutation with a similar phenotype in three unrelated families establish its pathogenicity and demonstrate that the amino acid position A47 is important for the function of complex I. These results show that the 10197G > A mutation in the mitochondrial ND3 gene should be considered as a common mtDNA mutation responsible for LS and dystonia. (c) 2006 Wiley-Liss, Inc.
C1 Univ Calif Irvine, Ctr Mol & Mitochondrial Med & Genet, Irvine, CA 92697 USA.
   Hop Necker Enfants Malad, INSERM, Dept Genet, U781, F-75730 Paris, France.
   Mercer Univ, Sch Med, Div Basic Med Sci, Macon, GA 31207 USA.
   Univ Calif Irvine, Dept Pediat, Irvine, CA 92717 USA.
C3 University of California System; University of California Irvine; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite; Hopital Universitaire Necker-Enfants Malades - APHP; Mercer University; University of California System; University of California Irvine
RP Procaccio, V (corresponding author), Univ Calif Irvine, Ctr Mol & Mitochondrial Med & Genet, Irvine, CA 92697 USA.
EM vproca@uci.edu
FU NIA NIH HHS [AG24373] Funding Source: Medline; NINDS NIH HHS [NS41850, R01 NS21328] Funding Source: Medline
CR Alves PC, 1998, BIOCHEM CELL BIOL, V76, P139, DOI 10.1139/bcb-76-1-139
   Bannwarth S, 2005, HUM MUTAT, V25, P575, DOI 10.1002/humu.20177
   Brandon MC, 2005, NUCLEIC ACIDS RES, V33, P0
   BRINK J, 1987, EUR J BIOCHEM, V166, P287, DOI 10.1111/j.1432-1033.1987.tb13513.x
   Bykhovskaya Y, 2004, MOL GENET METAB, V83, P199, DOI 10.1016/j.ymgme.2004.07.009
   Chol M, 2003, J MED GENET, V40, P188, DOI 10.1136/jmg.40.3.188
   CHOMYN A, 1986, SCIENCE, V234, P614, DOI 10.1126/science.3764430
   Crimi M, 2004, PEDIATR RES, V55, P842, DOI 10.1203/01.PDR.0000117844.73436.68
   Fischel-Ghodsian N, 2004, MITOCHONDRION, V4, P675, DOI 10.1016/j.mito.2004.07.040
   Gigarel N, 2005, MOL GENET METAB, V84, P289, DOI 10.1016/j.ymgme.2004.10.008
   Guénebaut V, 1998, J MOL BIOL, V276, P105, DOI 10.1006/jmbi.1997.1518
   Hirst J, 2003, BBA-BIOENERGETICS, V1604, P135, DOI 10.1016/S0005-2728(03)00059-8
   Kirby DM, 2000, ANN NEUROL, V48, P102, DOI 10.1002/1531-8249(200007)48:1<102::AID-ANA15>3.3.CO;2-D
   Kirby DM, 2004, J MED GENET, V41, P784, DOI 10.1136/jmg.2004.020537
   Kirby DM, 2004, J CLIN INVEST, V114, P837, DOI 10.1172/JCI200420683
   Kirby DM, 2003, ANN NEUROL, V54, P473, DOI 10.1002/ana.10687
   Lebon S, 2003, J MED GENET, V40, P896, DOI 10.1136/jmg.40.12.896
   Leshinsky-Silver E, 2005, BIOCHEM BIOPH RES CO, V334, P582, DOI 10.1016/j.bbrc.2005.06.134
   LETELLIER T, 1994, BIOCHEM J, V302, P171, DOI 10.1042/bj3020171
   Loeffen J, 2001, ANN NEUROL, V49, P195, DOI 10.1002/1531-8249(20010201)49:2<195::AID-ANA39>3.0.CO;2-M
   Malgat Monique, 1995, JOURNAL OF BIOLOGICAL SYSTEMS, V3, P165, DOI 10.1142/S0218339095000162
   McFarland R, 2004, ANN NEUROL, V55, P58, DOI 10.1002/ana.10787
   Mitchell AL, 2006, J MED GENET, V43, P175, DOI 10.1136/jmg.2005.032474
   Rahman S, 2001, AM J HUM GENET, V68, P238, DOI 10.1086/316930
   Rubio-Gozalbo ME, 2000, NEUROPEDIATRICS, V31, P114, DOI 10.1055/s-2000-7491
   Ruiz-Pesini E, 2004, SCIENCE, V303, P223, DOI 10.1126/science.1088434
   RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8
   SHOFFNER JM, 1995, ANN NEUROL, V38, P163, DOI 10.1002/ana.410380207
   Sudo A, 2004, J HUM GENET, V49, P92, DOI 10.1007/s10038-003-0116-1
   Taylor RW, 2002, EUR J HUM GENET, V10, P141, DOI 10.1038/sj.ejhg.5200773
   Taylor RW, 2001, ANN NEUROL, V50, P104, DOI 10.1002/ana.1084
   Triepels RH, 2001, AM J MED GENET, V106, P37, DOI 10.1002/ajmg.1397
   TROUNCE I, 1994, P NATL ACAD SCI USA, V91, P8334, DOI 10.1073/pnas.91.18.8334
   Trounce I A, 1996, METHODS ENZYMOL, V264, P484, DOI 10.1016/S0076-6879(96)64044-0
   Ugalde C, 2003, ANN NEUROL, V54, P665, DOI 10.1002/ana.10734
   von Kleist-Retzow JC, 1998, AM J HUM GENET, V63, P428, DOI 10.1086/301957
   WALLACE DC, 2006, IN PRESS EMERY RIMOI, V0, P0
NR 37
TC 85
Z9 99
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1552-4825
EI 1552-4833
J9 AM J MED GENET A
JI Am. J. Med. Genet. A
PD JAN 1
PY 2007
VL 143A
IS 1
BP 33
EP 41
DI 10.1002/ajmg.a.31565
PG 9
WC Genetics & Heredity
SC Genetics & Heredity
GA 124GY
UT WOS:000243357500004
PM 17152068
DA 2024-11-01
ER

PT J
AU Murray, J
   Schilling, B
   Row, RH
   Yoo, CB
   Gibson, BW
   Marusich, MF
   Capaldi, RA
AF Murray, James
   Schilling, Birgit
   Row, Richard H.
   Yoo, Chris B.
   Gibson, Bradford W.
   Marusich, Michael F.
   Capaldi, Roderick A.
TI Small-scale immunopurification of cytochrome c oxidase for a high-throughput multiplexing analysis of enzyme activity and amount
SO BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY
LA English
DT Article
ID mitochondrial respiratory-chain; complex-i deficiency; alzheimers-disease; parkinsons-disease; pyruvate-dehydrogenase; zidovudine myopathy; encoded subunits; neck-cancer; dna content; expression
AB COX (cytochrome c oxidase) deficiency is one of the main causes of genetic mitochondrial disease and presents with multiple phenotypes, depending on whether the causative mutation exists in a mitochondrial or nuclear gene and on whether it involves an altered catalytic or structural component or an assembly factor for this membrane-em bedded 13-subunit enzyme complex. COX deficiency is routinely observed in AD (Alzheimer's disease), although there is continuing debate about whether this is a causative or a secondary consequence of the condition. Altered levels of COX and reduced oxidative phosphorylation capacity have been reported in other common diseases, including cancer, and are seen as unwanted side effects in a number of drug treatments, particularly with antiretroviral and antibiotic treatments. Here, we introduce a simple, rapid, high-throughput 96-well plate protocol that uses a multiplex approach to determine the amount and activity of COX, which should find widespread use in evaluating the above diseases and in drug safety studies. Importantly, the method uses very small amounts of cell material or tissue and does not require the isolation of mitochondria. We show the utility of this approach by example of the analysis of fibroblasts from patients with COX activity deficiency and the effect of the antiretroviral drug ddC (2',3'-dideoxycytidine) on the biogenesis of the enzyme.
C1 [Murray, James; Marusich, Michael F.; Capaldi, Roderick A.] Mitosci Inc, Eugene, OR 97403 USA.
   [Schilling, Birgit; Row, Richard H.; Yoo, Chris B.; Gibson, Bradford W.] Buck Inst Age Res, Novato, CA 94945 USA.
   [Gibson, Bradford W.] Univ Calif San Francisco, Dept Pharmaceut Sci, San Francisco, CA 94143 USA.
   [Marusich, Michael F.] Univ Oregon, Inst Neurosci, Eugene, OR 97403 USA.
   [Capaldi, Roderick A.] Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA.
C3 Buck Institute for Research on Aging; University of California System; University of California San Francisco; University of Oregon; University of Oregon
RP Capaldi, RA (corresponding author), Mitosci Inc, Eugene, OR 97403 USA.
EM rcapaldi@mitosciences.com
FU NIGMS NIH HHS [2R42GM071052-02] Funding Source: Medline
CR Aggeler R, 2002, J BIOL CHEM, V277, P33906, DOI 10.1074/jbc.M204538200
   ANTHONY G, 1990, FEBS LETT, V277, P97, DOI 10.1016/0014-5793(90)80817-3
   Bénit P, 2001, AM J HUM GENET, V68, P1344, DOI 10.1086/320603
   Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834
   Bosetti F, 2002, NEUROBIOL AGING, V23, P371, DOI 10.1016/S0197-4580(01)00314-1
   Bringsjord S, 2001, PSYCOLOQUY, V12, P1
   CAPALDI RA, 1988, J BIOENERG BIOMEMBR, V20, P291, DOI 10.1007/BF00769634
   Cardoso SM, 2004, NEUROBIOL AGING, V25, P105, DOI 10.1016/S0197-4580(03)00033-2
   Chandrasekaran K, 1996, EXP NEUROL, V142, P80, DOI 10.1006/exnr.1996.0180
   CHARIOT P, 1993, ANN NEUROL, V34, P561, DOI 10.1002/ana.410340409
   Coenen MJH, 2006, J CHILD NEUROL, V21, P508, DOI 10.1177/08830738060210062501
   Collins ML, 2004, JAIDS-J ACQ IMM DEF, V37, P1132, DOI 10.1097/01.qai.0000131585.77530.64
   Cruciat CM, 2000, J BIOL CHEM, V275, P18093, DOI 10.1074/jbc.M001901200
   Finsterer J, 2004, EUR J NEUROL, V11, P163, DOI 10.1046/j.1351-5101.2003.00728.x
   Genova ML, 2004, ANN NY ACAD SCI, V1011, P86, DOI 10.1196/annals.1293.010
   Grandjean F, 2002, BIOCHEM PHARMACOL, V63, P823, DOI 10.1016/S0006-2952(01)00865-6
   Hanson BJ, 2001, J BIOL CHEM, V276, P16296, DOI 10.1074/jbc.M011162200
   Herrmann PC, 2003, PROTEOMICS, V3, P1801, DOI 10.1002/pmic.200300461
   Jiang WW, 2006, CLIN CANCER RES, V12, P1564, DOI 10.1158/1078-0432.CCR-05-1471
   Jiang WW, 2005, CLIN CANCER RES, V11, P2486, DOI 10.1158/1078-0432.CCR-04-2147
   Jové M, 2004, J LIPID RES, V45, P113, DOI 10.1194/jlr.M300208-JLR200
   Krieg RC, 2004, PROTEOMICS, V4, P2789, DOI 10.1002/pmic.200300796
   Lib M, 2003, ANAL BIOCHEM, V314, P121, DOI 10.1016/S0003-2697(02)00645-0
   Mancuso M, 2003, EXP NEUROL, V182, P421, DOI 10.1016/S0014-4886(03)00092-X
   Marusich MF, 1997, BBA-MOL BASIS DIS, V1362, P145, DOI 10.1016/S0925-4439(97)00061-6
   Matoba S, 2006, SCIENCE, V312, P1650, DOI 10.1126/science.1126863
   Maurer I, 2000, NEUROBIOL AGING, V21, P455, DOI 10.1016/S0197-4580(00)00112-3
   McKee EE, 2006, ANTIMICROB AGENTS CH, V50, P2042, DOI 10.1128/AAC.01411-05
   MIZUNO Y, 1989, BIOCHEM BIOPH RES CO, V163, P1450, DOI 10.1016/0006-291X(89)91141-8
   Murray J, 2003, J BIOL CHEM, V278, P13619, DOI 10.1074/jbc.C300064200
   Murray J, 2002, FEBS LETT, V529, P173, DOI 10.1016/S0014-5793(02)03278-7
   Musatov A, 2002, BIOCHEMISTRY-US, V41, P8212, DOI 10.1021/bi025896u
   Payne CM, 2005, CANCER EPIDEM BIOMAR, V14, P2066, DOI 10.1158/1055-9965.EPI-05-0180
   Perkins AC, 1999, NUCL MED COMMUN, V20, P1, DOI 10.1097/00006231-199901000-00001
   Rossignol R, 2004, CANCER RES, V64, P985, DOI 10.1158/0008-5472.CAN-03-1101
   Schägger H, 2000, EMBO J, V19, P1777, DOI 10.1093/emboj/19.8.1777
   Schapira AHV, 2002, J INHERIT METAB DIS, V25, P207, DOI 10.1023/A:1015629912477
   SCHAPIRA AHV, 1990, J NEUROCHEM, V54, P823, DOI 10.1111/j.1471-4159.1990.tb02325.x
   Schilling B, 2006, BBA-MOL BASIS DIS, V1762, P213, DOI 10.1016/j.bbadis.2005.07.003
   Shoubridge EA, 2001, AM J MED GENET, V106, P46, DOI 10.1002/ajmg.1378
   SIMONIAN NA, 1994, J NEUROPATH EXP NEUR, V53, P508, DOI 10.1097/00005072-199409000-00010
   Smith AL, 1967, METHODS IN ENZYMOLOGY, V0, PP81, DOI 10.1016/0076-6879(67)10016-5
   TAANMAN JW, 1993, BIOCHIM BIOPHYS ACTA, V1225, P95, DOI 10.1016/0925-4439(93)90128-N
   Tschischka K, 2000, J EXP BIOL, V203, P3355
   van der Walt JM, 2003, AM J HUM GENET, V72, P804, DOI 10.1086/373937
   von Kleist-Retzow JC, 2003, EXP PHYSIOL, V88, P155, DOI 10.1113/eph8802509
   Yerroum M, 2000, ACTA NEUROPATHOL, V100, P82, DOI 10.1007/s004010051196
NR 47
TC 10
Z9 12
U1 0
U2 3
PU PORTLAND PRESS LTD
PI LONDON
PA THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND
SN 0885-4513
EI 
J9 BIOTECHNOL APPL BIOC
JI Biotechnol. Appl. Biochem.
PD DEC 15
PY 2007
VL 48
IS 
BP 167
EP 178
DI 10.1042/BA20060223
PG 12
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
GA 244RM
UT WOS:000251883000006
PM 17508937
DA 2024-11-01
ER

PT J
AU Finsterer, J
   Stöllberger, C
   Steger, C
   Cozzarini, W
AF Finsterer, Josef
   Stollberger, Claudia
   Steger, Christine
   Cozzarini, Wolfgang
TI Complete heart block associated with noncompaction, nail-patella syndrome, and mitochondrial myopathy
SO JOURNAL OF ELECTROCARDIOLOGY
LA English
DT Article
DE respiratory chain; neuromuscular disorder; rhythm abnormality; hypertrophic cardiomyopathy
ID complete atrioventricular-block; ventricular myocardium
AB Objectives: Complete heart block has not been reported in association with left ventricular hypertrabeculation (LVHT)/noncompaction, nail-patella syndrome (NPS), and mitochondrial myopathy (MMP). Case Report: A 47-year-old man with congenital NPS from a 17-bp deletion in exon 5 of the LMX1B gene, MMP from the A3243G mitochondrial DNA transition, and LVHT was acutely admitted after a syncope followed by dizziness. Cardiological examinations revealed bradycardia. Blood pressure was 70/30 mm Hg. Blood work revealed a creatine kinase of 389 U/L (normal, < 175 U/L), renal insufficiency, anemia, and reduced calcium, phosphorus, and magnesium. Electrocardiogram showed complete heart block with an escape rhythm of 30/min. A temporary pacemaker was inserted. During the procedure, the patient became asystole but was successfully resuscitated. One day later, he received a permanent pacemaker. Echocardiograpby showed normal systolic function and LVHT. The patient recovered without sequelae. Conclusion: In single cases, LVHT may be associated with complete heart block. Most likely, complete heart block was due to MMP. Patients with NPS and MMP require multidisciplinary surveillance, including regular electrocardiograms, for indicating anticipatory intervention in time. (c) 2007 Elsevier Inc. All rights reserved.
C1 Krankenanstalt Rudolfstiftung Wien, Dept Med, Vienna, Austria.
   Krankenanstalt Stockerauftung, Dept Med, Stockerau, Austria.
C3 Rudolfstiftung Hospital
RP Finsterer, J (corresponding author), Univ Doz DDR J Finsterer, A-1180 Vienna, Austria.
EM duarte@aomail.at
CR Dagdeviren B, 2002, ACTA CARDIOL, V57, P221, DOI 10.2143/AC.57.3.2005392
   Dogan R, 2005, HEART SURG FORUM, V8, PE110, DOI 10.1532/HSF98.20041142
   Finsterer J, 2001, EUR NEUROL, V46, P92, DOI 10.1159/000050770
   FISNTERER J, 2004, CIRCULATION, V109, P0
   Goshen E, 2000, CLIN NUCL MED, V25, P476, DOI 10.1097/00003072-200006000-00020
   Hamlington J D, 2001, HUM MUTAT, V18, P458, DOI 10.1002/humu.1217
   Özkutlu S, 2002, J AM SOC ECHOCARDIOG, V15, P1523, DOI 10.1067/mje.2002.128212
   Stöllberger C, 2004, J AM SOC ECHOCARDIOG, V17, P91, DOI 10.1016/S0894-7317(03)00514-5
   Taniguchi M, 2004, CIRC J, V68, P873, DOI 10.1253/circj.68.873
   Zeviani M, 2004, BRAIN, V127, P2153, DOI 10.1093/brain/awh259
NR 10
TC 14
Z9 15
U1 0
U2 2
PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS
PI PHILADELPHIA
PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA
SN 0022-0736
EI 1532-8430
J9 J ELECTROCARDIOL
JI J. Electrocardiol.
PD JUL-AUG 15
PY 2007
VL 40
IS 4
BP 352
EP 354
DI 10.1016/j.jelectrocard.2006.11.008
PG 3
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 189XP
UT WOS:000248022200007
PM 17291523
DA 2024-11-01
ER

PT J
AU Filosto, M
   Mancuso, M
AF Filosto, M.
   Mancuso, M.
TI Mitochondrial diseases: a nosological update
SO ACTA NEUROLOGICA SCANDINAVICA
LA English
DT Review
DE mitochondrial diseases; mtDNA; respiratory chain defects
ID cytochrome-c-oxidase; progressive external ophthalmoplegia; adenine-nucleotide translocator; large-scale deletion; complex-ii gene; autosomal-dominant; sideroblastic anemia; polg mutations; dna depletion; paternal inheritance
AB Mitochondrial diseases are disorders caused by impairment of the mitochondrial respiratory chain, characterized by clinical-genetic heterogeneity and frequent multisystemic involvement. It is difficult to establish a precise genotype/phenotype correlation and obtain a definitive nosology. Today's genetic classification distinguishes disorders caused by defects in the mitochondrial genome (sporadic or maternally-inherited) from disorders caused by defects in the nuclear genome (autosomally-inherited). We report an updated classification, briefly review the main clinical syndromes and describe the most recent genetic knowledge.
C1 Univ Hosp Spedali Civili Brescia, Neurol Clin, Sect Neuromuscular Dis & Neuropathies, Brescia, Italy.
   Univ Pisa, Dept Neurosci, Pisa, Italy.
C3 Hospital Spedali Civili Brescia; University of Pisa
RP Filosto, M (corresponding author), Univ Hosp Spedali Civili Brescia, Neurol Clin, Sect Neuromuscular Dis & Neuropathies, Ple Spedali Civili 1, Brescia, Italy.
EM filosto@med.unibs.it
CR Allikmets R, 1999, HUM MOL GENET, V8, P743, DOI 10.1093/hmg/8.5.743
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Andreu AL, 1999, NEW ENGL J MED, V341, P1037, DOI 10.1056/NEJM199909303411404
   Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Bénit P, 2003, HUM MUTAT, V21, P582, DOI 10.1002/humu.10225
   Bénit P, 2001, AM J HUM GENET, V68, P1344, DOI 10.1086/320603
   Bernier FP, 2002, NEUROLOGY, V59, P1406, DOI 10.1212/01.WNL.0000033795.17156.00
   Birch-Machin MA, 2000, ANN NEUROL, V48, P330, DOI 10.1002/1531-8249(200009)48:3<330::AID-ANA7>3.0.CO;2-A
   Borthwick GM, 1999, ANN NEUROL, V46, P787, DOI 10.1002/1531-8249(199911)46:5<787::AID-ANA17>3.0.CO;2-8
   Bosetti F, 2002, NEUROBIOL AGING, V23, P371, DOI 10.1016/S0197-4580(01)00314-1
   BOURGERON T, 1995, NAT GENET, V11, P144, DOI 10.1038/ng1095-144
   Brandner K, 2005, MOL BIOL CELL, V16, P5202, DOI 10.1091/mbc.E05-03-0256
   Budde SMS, 2000, BIOCHEM BIOPH RES CO, V275, P63, DOI 10.1006/bbrc.2000.3257
   Bugiani M, 2005, J MED GENET, V42, P0, DOI 10.1136/jmg.2004.029926
   Bykhovskaya Y, 2004, AM J HUM GENET, V74, P1303, DOI 10.1086/421530
   Casari G, 1998, CELL, V93, P973, DOI 10.1016/S0092-8674(00)81203-9
   Chen HC, 2005, J BIOL CHEM, V280, P26185, DOI 10.1074/jbc.M503062200
   Chinnery PF, 2003, J NEUROL NEUROSUR PS, V74, P1188, DOI 10.1136/jnnp.74.9.1188
   Comi GP, 1998, ANN NEUROL, V43, P110, DOI 10.1002/ana.410430119
   Coskun PE, 2004, P NATL ACAD SCI USA, V101, P10726, DOI 10.1073/pnas.0403649101
   Davidzon G, 2006, ANN NEUROL, V59, P859, DOI 10.1002/ana.20831
   Davidzon G, 2005, ANN NEUROL, V57, P921, DOI 10.1002/ana.20498
   De Meirleir L, 2004, J MED GENET, V41, P120, DOI 10.1136/jmg.2003.012047
   Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936
   Deschauer M, 2003, NEUROMUSCULAR DISORD, V13, P568, DOI 10.1016/S0960-8966(03)00071-3
   DIDONATO S, 2002, MITOCHONDRIAL DISORD, V0, P5
   DiMauro S, 1999, J CHILD NEUROL, V14, PS23, DOI 10.1177/0883073899014001051
   Dimauro S, 2001, AM J MED GENET, V106, P18, DOI 10.1002/ajmg.1392
   DIMAURO S, 1993, ARCH NEUROL-CHICAGO, V50, P1197, DOI 10.1001/archneur.1993.00540110075008
   DiMauro S, 2003, BASIC APPL MYOL, V13, P145
   Dipchand AI, 2001, PEDIATR CARDIOL, V22, P14, DOI 10.1007/s002460010145
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Filosto M, 2004, ACTA NEUROPATHOL, V108, P168, DOI 10.1007/s00401-004-0872-9
   Filosto M, 2003, ANN NEUROL, V54, P524, DOI 10.1002/ana.10709
   Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279
   Fu K, 1996, HUM MOL GENET, V5, P1835, DOI 10.1093/hmg/5.11.1835
   Gillis L, 2002, PEDIATR CLIN N AM, V49, P203, DOI 10.1016/S0031-3955(03)00115-9
   Gimm O, 2000, CANCER RES, V60, P6822
   Hirano M, 2001, SEMIN CELL DEV BIOL, V12, P417, DOI 10.1006/scdb.2001.0279
   HOLT IJ, 1990, AM J HUM GENET, V46, P428
   Jacobs HT, 2005, TRENDS GENET, V21, P312, DOI 10.1016/j.tig.2005.04.003
   Jin H, 1996, NAT GENET, V14, P177, DOI 10.1038/ng1096-177
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Koutnikova H, 1997, NAT GENET, V16, P345, DOI 10.1038/ng0897-345
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Lev D, 2004, PEDIATR CARDIOL, V25, P443, DOI 10.1007/s00246-003-0490-7
   Lewis S, 2002, J NEUROL SCI, V201, P39, DOI 10.1016/S0022-510X(02)00190-9
   Limongelli A, 2004, J MED GENET, V41, P342, DOI 10.1136/jmg.2003.016048
   LOEEN J, 1998, AM J HUM GENET, V63, P1598
   LOEEN J, 2001, ANN NEUROL, V49, P195
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Mancuso M, 2004, ARCH NEUROL-CHICAGO, V61, P1777, DOI 10.1001/archneur.61.11.1777
   Mancuso M, 2004, NEUROLOGY, V62, P2119, DOI 10.1212/01.WNL.0000127608.48406.F1
   Mancuso M, 2004, ACTA NEUROL SCAND, V110, P72, DOI 10.1111/j.1600-0404.2004.00254.x
   Mancuso M, 2004, NEUROLOGY, V62, P316, DOI 10.1212/WNL.62.2.316
   Mancuso M, 2003, ARCH NEUROL-CHICAGO, V60, P1445, DOI 10.1001/archneur.60.10.1445
   Mancuso M, 2003, EXP NEUROL, V182, P421, DOI 10.1016/S0014-4886(03)00092-X
   Mancuso M, 2003, ARCH NEUROL-CHICAGO, V60, P1007, DOI 10.1001/archneur.60.7.1007
   Mancuso M, 2003, J NEUROL SCI, V209, P61, DOI 10.1016/S0022-510X(02)00462-8
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   Mancuso M, 2004, NEUROSCI LETT, V371, P158, DOI 10.1016/j.neulet.2004.08.060
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   MANFREDI G, 1995, NEUROMUSCULAR DISORD, V5, P391, DOI 10.1016/0960-8966(94)00079-O
   Miller C, 2004, ANN NEUROL, V56, P734, DOI 10.1002/ana.20282
   MITA S, 1990, NUCLEIC ACIDS RES, V18, P561, DOI 10.1093/nar/18.3.561
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Musumeci O, 2001, NEUROLOGY, V56, P849, DOI 10.1212/WNL.56.7.849
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Niemann S, 2000, NAT GENET, V26, P268, DOI 10.1038/81551
   Nikali K, 2005, HUM MOL GENET, V14, P2981, DOI 10.1093/hmg/ddi328
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Orth M, 2001, AM J MED GENET, V106, P27, DOI 10.1002/ajmg.1425
   Palmieri L, 2005, HUM MOL GENET, V14, P3079, DOI 10.1093/hmg/ddi341
   Papadopoulou LC, 1999, NAT GENET, V23, P333
   Patton JR, 2005, J BIOL CHEM, V280, P19823, DOI 10.1074/jbc.M500216200
   Petruzzella V, 1998, GENOMICS, V54, P494, DOI 10.1006/geno.1998.5580
   Petruzzella V, 2001, HUM MOL GENET, V10, P529, DOI 10.1093/hmg/10.5.529
   Quinzii C, 2006, AM J HUM GENET, V78, P345, DOI 10.1086/500092
   Ravn K, 2001, EUR J HUM GENET, V9, P805, DOI 10.1038/sj.ejhg.5200712
   ROTIG A, 1992, AM J HUM GENET, V50, P364
   Rowland LP, 1997, NEUROMUSCULAR DISORD, V7, PS15, DOI 10.1016/S0960-8966(97)00076-X
   Saada A, 2003, BIOCHEM BIOPH RES CO, V310, P963, DOI 10.1016/j.bbrc.2003.09.104
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Salviati L, 2002, ANN NEUROL, V52, P311, DOI 10.1002/ana.10284
   Santorelli FM, 1997, BIOCHEM BIOPH RES CO, V238, P326, DOI 10.1006/bbrc.1997.7167
   SCHON EA, 1989, SCIENCE, V244, P346, DOI 10.1126/science.2711184
   SCHON EA, 2001, MITOCHONDRIA PATHOGE, V0, P53
   Schuelke M, 1999, NAT GENET, V21, P260, DOI 10.1038/6772
   Schwartz M, 2002, NEW ENGL J MED, V347, P576, DOI 10.1056/NEJMoa020350
   Servidei Serenella, 2003, NEUROMUSCUL DISORD, V13, P848
   Shanske S, 2002, AM J HUM GENET, V71, P679, DOI 10.1086/342482
   Siciliano G, 2003, NEUROMUSCULAR DISORD, V13, P162, DOI 10.1016/S0960-8966(02)00221-3
   Simon DK, 2000, NEUROLOGY, V54, P703, DOI 10.1212/WNL.54.3.703
   Simonati A, 2003, J NEUROL, V250, P702, DOI 10.1007/s00415-003-1065-5
   Spagnolo M, 2001, NEUROMUSCULAR DISORD, V11, P481, DOI 10.1016/S0960-8966(01)00195-X
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spencer CT, 2005, PEDIATR CARDIOL, V26, P632, DOI 10.1007/s00246-005-0873-z
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Spinazzola A, 2005, GENE, V354, P162, DOI 10.1016/j.gene.2005.03.025
   STRYER L, 1989, BIOCHIMICA, V0, P458
   Taylor RW, 2003, ANN NEUROL, V54, P521, DOI 10.1002/ana.10673
   Triepels RH, 1999, ANN NEUROL, V45, P787, DOI 10.1002/1531-8249(199906)45:6<787::AID-ANA13>3.0.CO;2-6
   Tzen CY, 2001, KIDNEY INT, V59, P846, DOI 10.1046/j.1523-1755.2001.00567.x
   Valnot I, 2000, AM J HUM GENET, V67, P1104
   Valnot I, 2000, HUM MOL GENET, V9, P1245, DOI 10.1093/hmg/9.8.1245
   van den Heuvel L, 1998, AM J HUM GENET, V62, P262, DOI 10.1086/301716
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Vu TH, 2002, NEUROL CLIN, V20, P809, DOI 10.1016/S0733-8619(01)00017-2
   Witherell GW, 2001, J MED VIROL, V63, P8, DOI 10.1002/1096-9071(200101)63:1<8::AID-JMV1001>3.0.CO;2-K
   Xu FH, 2004, BIOCHEM J, V382, P331, DOI 10.1042/BJ20040469
   Zeharia A, 2005, J CHILD NEUROL, V20, P449, DOI 10.1177/08830738050200051301
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
   Zhu ZQ, 1998, NAT GENET, V20, P337, DOI 10.1038/3804
NR 117
TC 38
Z9 42
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0001-6314
EI 1600-0404
J9 ACTA NEUROL SCAND
JI Acta Neurol. Scand.
PD APR 15
PY 2007
VL 115
IS 4
BP 211
EP 221
DI 10.1111/j.1600-0404.2006.00777.x
PG 11
WC Clinical Neurology
SC Neurosciences & Neurology
GA 148DN
UT WOS:000245054800001
PM 17376118
DA 2024-11-01
ER

PT J
AU Kawahara, H
   Fukura, M
   Tsuchishima, M
   Takase, S
AF Kawahara, Hiromu
   Fukura, Masayuki
   Tsuchishima, Mutsumi
   Takase, Shujiro
TI Mutation of mitochondrial DNA in livers from patients with alcoholic hepatitis and nonalcoholic steatohepatitis
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Article; Proceedings Paper
DE alcoholic hepatitis; nonalcoholic steatohepatitis; mitochondrial DNA; transition
ID microsatellite instability; colorectal carcinomas; oxidative stress; skeletal-muscle; human tissue; repair; dysfunction; oxygen; damage; 8-oxoguanine
AB Background: In alcoholic hepatitis (Al-Hep) and nonalcoholic steatohepatitis (NASH), triglycerides accumulate in hepatocytes. We examined the hypothesis that mutations in mitochondrial DNA may take place by mitochondrial overwork, resulting in dysfunction of mitochondria. Subjects and Methods: Subjects of this research were 8 cases each of Al-Hep, NASH, and fatty liver (FL). Total DNA was extracted from the biopsied liver samples. DNA fragments were amplified by PCR and DNA sequences determined in the control and coding regions of mitochondrion. Results: When the numbers of mutations per 1,000 bases of mitochondrial DNA were compared between each group, no significant differences were found among D-loop, HV1, and HV2 mitochondrial DNA regions. However, there were significantly more mutations in ND1 and COII of Al-Hep and NASH than in FL, and mutations were comparatively at random. Neither a region in which mutations were focused nor differences among the groups were recognized. When details of the base mutation in a control region were investigated by group, the transition type of mutation between T:A <<->> C:G occurred in at least 70%. Also, a transition-type mutation was found mostly in a coding region, which was similar to the mutation pattern in the control region, except for the ND1 and COII regions where there were hardly any mutations. Conclusions: As gene mutations of mitochondrial DNA appeared frequently in Al-Hep, and also in NASH, mitochondrial dysfunction caused by mutation in mitochondrial DNA may be involved in the pathogenesis of both diseases.
C1 Kanazawa Med Univ, Dept Gastroenterol, Uchinada, Ishikawa, Japan.
C3 Kanazawa Medical University
RP Kawahara, H (corresponding author), Kanazawa Med Univ, Dept Gastroenterol, 1-1 Daigaku, Uchinada, Ishikawa, Japan.
EM hiromu@kanazawa-med.ac.jp
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Anson RM, 1998, NUCLEIC ACIDS RES, V26, P662, DOI 10.1093/nar/26.2.662
   BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707
   BROWN WM, 1979, P NATL ACAD SCI USA, V76, P1967, DOI 10.1073/pnas.76.4.1967
   Browning JD, 2004, J CLIN INVEST, V114, P147, DOI 10.1172/JCI200422422
   Brunt EM, 2004, SEMIN LIVER DIS, V24, P3
   Caulfield JL, 1998, J BIOL CHEM, V273, P12689, DOI 10.1074/jbc.273.21.12689
   Chomyn A, 2003, BIOCHEM BIOPH RES CO, V304, P519, DOI 10.1016/S0006-291X(03)00625-9
   CORTOPASSI GA, 1992, P NATL ACAD SCI USA, V89, P7370, DOI 10.1073/pnas.89.16.7370
   de Souza-Pinto NC, 2001, CANCER RES, V61, P5378
   Dianov G, 1998, J BIOL CHEM, V273, P33811, DOI 10.1074/jbc.273.50.33811
   GARCIARUIZ C, 1995, MOL PHARMACOL, V48, P825
   Habano W, 1998, ONCOGENE, V17, P1931, DOI 10.1038/sj.onc.1202112
   Habano W, 1999, INT J CANCER, V83, P625, DOI 10.1002/(SICI)1097-0215(19991126)83:5<625::AID-IJC10>3.0.CO;2-N
   Hensley K, 2000, CARCINOGENESIS, V21, P983, DOI 10.1093/carcin/21.5.983
   Hoek JB, 2002, GASTROENTEROLOGY, V122, P2049, DOI 10.1053/gast.2002.33613
   Khrapko K, 1997, P NATL ACAD SCI USA, V94, P13798, DOI 10.1073/pnas.94.25.13798
   Kreutzer DA, 1998, P NATL ACAD SCI USA, V95, P3578, DOI 10.1073/pnas.95.7.3578
   Lee HC, 1999, ARCH BIOCHEM BIOPHYS, V362, P309, DOI 10.1006/abbi.1998.1036
   Liu VWS, 1998, NUCLEIC ACIDS RES, V26, P1268, DOI 10.1093/nar/26.5.1268
   Medina J, 2004, DIABETES CARE, V27, P2057, DOI 10.2337/diacare.27.8.2057
   MELOV S, 1995, NUCLEIC ACIDS RES, V23, P4122, DOI 10.1093/nar/23.20.4122
   Moraes CT, 2003, J MOL DIAGN, V5, P197, DOI 10.1016/S1525-1578(10)60474-6
   Neuschwander-Tetri BA, 2003, HEPATOLOGY, V38, P1008, DOI 10.1053/jhep.2003.50420
   ORourke TW, 2002, MOL CELL BIOL, V22, P4086, DOI 10.1128/MCB.22.12.4086-4093.2002
   Pallotti F, 1996, AM J HUM GENET, V59, P591
   Pessayre D, 2002, AM J PHYSIOL-GASTR L, V282, PG193, DOI 10.1152/ajpgi.00426.2001
   Pessayre D, 2001, SEMIN LIVER DIS, V21, P57, DOI 10.1055/s-2001-12929
   Raha S, 2000, TRENDS BIOCHEM SCI, V25, P502, DOI 10.1016/S0968-0004(00)01674-1
   Rossignol R, 2003, BIOCHEM J, V370, P751, DOI 10.1042/BJ20021594
   Tamura G, 1999, EUR J CANCER, V35, P316, DOI 10.1016/S0959-8049(98)00360-8
   ZHANG CF, 1993, BIOCHEM BIOPH RES CO, V195, P1104, DOI 10.1006/bbrc.1993.2158
NR 32
TC 28
Z9 29
U1 0
U2 4
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 0145-6008
EI 
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JAN 15
PY 2007
VL 31
IS 
BP 54S
EP 60S
DI 10.1111/j.1530-0277.2006.00287.x
PG 7
WC Substance Abuse
SC Substance Abuse
GA 128YY
UT WOS:000243696800010
PM 17331167
DA 2024-11-01
ER

PT J
AU Yamanaka, H
   Gatanaga, H
   Kosalaraksa, P
   Matsuoka-Aizawa, S
   Takahashi, T
   Kimura, S
   Oka, S
AF Yamanaka, Hikaru
   Gatanaga, Hiroyuki
   Kosalaraksa, Pope
   Matsuoka-Aizawa, Saori
   Takahashi, Takao
   Kimura, Satoshi
   Oka, Shinichi
TI Novel mutation of human DNA polymerase γ associated with mitochondrial toxicity induced by anti-HIV treatment
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article; Proceedings Paper
ID progressive external ophthalmoplegia; human-immunodeficiency-virus; infected patients; antiretroviral therapy; nucleoside; polg; aids; depletion; deletions; analogs
AB Mitochondrial toxicity is a major adverse effect of the nucleoside reverse-transcriptase inhibitors (NRTIs) used for treatment of human immunodeficiency virus type 1 (HIV-1) infection and can result in life-threatening lactic acidosis. The toxicity is due to inhibition of polymerase gamma (Pol gamma), which is required for replication of mitochondrial DNA (mtDNA). Genetic factors could be involved in this process, given that not all NRTI treated patients experience the toxicity. In 1 patient with lactic acidosis, a novel homozygous Pol gamma mutation (arginine to cysteine at codon 964 [R964C]) was identified at a site close to polymerase motif B, which is highly conserved among family A polymerases. Recombinant R964C Pol gamma showed only 14% activity, compared with that of wild-type Pol gamma. Culture with stavudine significantly reduced mtDNA levels in patient-derived lymphoblastoid cell lines (LCLs) harboring R964C Pol gamma, compared with those in LCLs harboring wild-type Pol gamma. The novel Pol gamma mutation could be associated with the severe lactic acidosis induced by long-term NRTI use.
C1 Int Med Ctr Japan, AIDS Clin Ctr, Shinjuku Ku, Tokyo 1628655, Japan.
   Keio Univ, Sch Med, Dept Pediat, Keio, Japan.
   Tokyo Teishin Hosp, Tokyo, Japan.
   Khon Kaen Univ, Fac Med, Dept Pediat, Khon Kaen, Thailand.
C3 National Center for Global Health & Medicine - Japan; Keio University; Khon Kaen University
RP Gatanaga, H (corresponding author), Int Med Ctr Japan, AIDS Clin Ctr, Shinjuku Ku, 1-21-1 Toyama, Tokyo 1628655, Japan.
EM higatana@imcj.acc.go.jp
CR Boubaker K, 2001, CLIN INFECT DIS, V33, P1931, DOI 10.1086/324353
   Cohen J, 2003, SCIENCE, V301, P1662, DOI 10.1126/science.301.5640.1662
   Copeland WC, 2003, ACTA BIOCHIM POL, V50, P155
   Cossarizza A, 2004, AIDS, V18, P137, DOI 10.1097/00002030-200401230-00002
   Coté HCF, 2002, NEW ENGL J MED, V346, P811, DOI 10.1056/NEJMoa012035
   DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461
   Doublié S, 1998, NATURE, V391, P251, DOI 10.1038/34593
   DUDLEY MN, 1992, J INFECT DIS, V166, P480, DOI 10.1093/infdis/166.3.480
   Fang GW, 1999, NAT MED, V5, P239, DOI 10.1038/5607
   Feng JY, 2001, J BIOL CHEM, V276, P23832, DOI 10.1074/jbc.M101156200
   Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279
   Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805
   He LP, 2002, NUCLEIC ACIDS RES, V30, P0, DOI 10.1093/nar/gnf067
   Johnson AA, 2001, J BIOL CHEM, V276, P40847, DOI 10.1074/jbc.M106743200
   Kaguni LS, 2004, ANNU REV BIOCHEM, V73, P293, DOI 10.1146/annurev.biochem.72.121801.161455
   Lewis W, 2003, NAT REV DRUG DISCOV, V2, P812, DOI 10.1038/nrd1201
   Lim SE, 2001, J BIOL CHEM, V276, P23616, DOI 10.1074/jbc.M101114200
   Longley MJ, 2005, GENE, V354, P125, DOI 10.1016/j.gene.2005.03.029
   Miró O, 2004, CLIN INFECT DIS, V39, P710, DOI 10.1086/423176
   Montaner JSG, 2003, JAIDS-J ACQ IMM DEF, V34, PS85, DOI 10.1097/00126334-200309011-00013
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Odawara F, 2002, J VIROL METHODS, V106, P115, DOI 10.1016/S0166-0934(02)00142-8
   Penzak SR, 2003, JAMA-J AM MED ASSOC, V289, P2648, DOI 10.1001/jama.289.20.2648-c
   Petit C, 2003, JAIDS-J ACQ IMM DEF, V33, P461, DOI 10.1097/00126334-200308010-00006
   Ponamarev MV, 2002, J BIOL CHEM, V277, P15225, DOI 10.1074/jbc.C200100200
   Rovio AT, 2001, NAT GENET, V29, P261, DOI 10.1038/ng759
   Suzuki T, 1997, J GEN VIROL, V78, P3073, DOI 10.1099/0022-1317-78-12-3073
   Suzuki T, 2002, JPN J PHARMACOL, V90, P210, DOI 10.1254/jjp.90.210
   UENO T, 1995, J BIOL CHEM, V270, P23605, DOI 10.1074/jbc.270.40.23605
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Yeni PG, 2004, JAMA-J AM MED ASSOC, V292, P251, DOI 10.1001/jama.292.2.251
NR 32
TC 67
Z9 75
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD MAY 15
PY 2007
VL 195
IS 10
BP 1419
EP 1425
DI 10.1086/513872
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 158HG
UT WOS:000245781800006
PM 17436221
DA 2024-11-01
ER

PT J
AU Mathews, CK
   Song, SW
AF Mathews, Christopher K.
   Song, Shiwei
TI Maintaining precursor pools for mitochondrial DNA replication
SO FASEB JOURNAL
LA English
DT Review
DE mitochondria; DNA precursors; deoxyribonucleotides; nucleotide pools
ID progressive external ophthalmoplegia; mouse l-cells; deoxynucleotide carrier; thymidine phosphorylase; nucleoside analogs; polymerase-gamma; neurogastrointestinal encephalomyopathy; 3'-azido-3'-deoxythymidine azt; ribonucleotide reductase; computational model
AB Among the human diseases that result from abnormalities in mitochondrial genome stability or maintenance are several that result from mutations affecting enzymes of deoxyribonucleoside triphosphate ( dNTP) metabolism. In addition, it is evident that the toxicity of antiviral nucleoside analogs is determined in part by the extent to which their intracellular conversion to dNTP analogs occurs within the mitochondrion. Finally, recent work from this laboratory has shown considerable variation among different mammalian tissues with respect to mitochondrial dNTP pool sizes and has suggested that natural asymmetries in mitochondrial dNTP concentrations may contribute to the high rates at which the mitochondrial genome undergoes mutation. These factors suggest that much more information is needed about maintenance and regulation of dNTP pools within mammalian mitochondria. This review summarizes our current understanding and suggests directions for future research.
C1 Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA.
C3 Oregon State University
RP Mathews, CK (corresponding author), Oregon State Univ, Dept Biochem & Biophys, 2011 Agr & Life Sci Bldg, Corvallis, OR 97331 USA.
EM mathewsc@onid.orst.edu
CR ARNER ESJ, 1995, PHARMACOL THERAPEUT, V67, P155, DOI 10.1016/0163-7258(95)00015-9
   Baruffini E, 2006, HUM MOL GENET, V15, P2846, DOI 10.1093/hmg/ddl219
   BESTWICK RK, 1982, J BIOL CHEM, V257, P9305
   BESTWICK RK, 1982, J BIOL CHEM, V257, P9300
   BOGENHAGEN D, 1976, J BIOL CHEM, V251, P2938
   Bradshaw PC, 2005, BIOCHEM J, V392, P363, DOI 10.1042/BJ20050749
   Bradshaw PC, 2005, AM J PHYSIOL-CELL PH, V288, PC989, DOI 10.1152/ajpcell.00530.2004
   Bridges EG, 1999, J BIOL CHEM, V274, P4620, DOI 10.1074/jbc.274.8.4620
   Desler C, 2006, NUCLEOS NUCLEOT NUCL, V25, P1171, DOI 10.1080/15257770600894501
   Dolce V, 2001, P NATL ACAD SCI USA, V98, P2284, DOI 10.1073/pnas.031430998
   ENRIQUEZ JA, 1994, NUCLEIC ACIDS RES, V22, P1861, DOI 10.1093/nar/22.10.1861
   Ferraro P, 2005, J BIOL CHEM, V280, P24472, DOI 10.1074/jbc.M502869200
   Ferraro P, 2006, P NATL ACAD SCI USA, V103, P18586, DOI 10.1073/pnas.0609020103
   Hirano M, 2001, SEMIN CELL DEV BIOL, V12, P417, DOI 10.1006/scdb.2001.0279
   Johnson AA, 2001, J BIOL CHEM, V276, P40847, DOI 10.1074/jbc.M106743200
   KANG D, 1995, J BIOL CHEM, V270, P14659, DOI 10.1074/jbc.270.24.14659
   KAROL MH, 1968, SCIENCE, V162, P470, DOI 10.1126/science.162.3852.470
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kumagai Y, 2006, INTERNAL MED, V45, P443, DOI 10.2169/internalmedicine.45.1371
   Lacombe ML, 2000, J BIOENERG BIOMEMBR, V32, P247, DOI 10.1023/A:1005584929050
   Ladner RD, 1997, J BIOL CHEM, V272, P19072, DOI 10.1074/jbc.272.30.19072
   Lam W, 2005, MOL PHARMACOL, V67, P408, DOI 10.1124/mol.104.007120
   Lara MC, 2006, NEUROLOGY, V67, P1461, DOI 10.1212/01.wnl.0000239824.95411.52
   Lee H, 2003, BIOCHEMISTRY-US, V42, P14711, DOI 10.1021/bi035596s
   LEEDS JM, 1987, MOL CELL BIOL, V7, P532, DOI 10.1128/MCB.7.1.532
   Lewis W, 2005, LAB INVEST, V85, P972, DOI 10.1038/labinvest.3700301
   Lim SE, 2003, J MOL BIOL, V329, P45, DOI 10.1016/S0022-2836(03)00405-4
   Lim SE, 2001, J BIOL CHEM, V276, P23616, DOI 10.1074/jbc.M101114200
   Lindhurst MJ, 2006, P NATL ACAD SCI USA, V103, P15927, DOI 10.1073/pnas.0607661103
   Lynx MD, 2006, BIOCHEM PHARMACOL, V72, P239, DOI 10.1016/j.bcp.2006.04.004
   Lynx MD, 2006, BIOCHEM PHARMACOL, V71, P1342, DOI 10.1016/j.bcp.2006.01.003
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Marcelino LA, 1999, MUTAT RES-DNA REPAIR, V434, P177, DOI 10.1016/S0921-8777(99)00028-2
   Mathews CK, 2006, FASEB J, V20, P1300, DOI 10.1096/fj.06-5730rev
   MATHEWS CK, 1986, EXP CELL RES, V162, P285, DOI 10.1016/0014-4827(86)90335-6
   McKee Edward E, 2004, CARDIOVASC TOXICOL, V4, P155, DOI 10.1385/CT:4:2:155
   Mootha VK, 2003, CELL, V115, P629, DOI 10.1016/S0092-8674(03)00926-7
   Nishigaki Y, 2003, J CLIN INVEST, V111, P1913, DOI 10.1172/JCI200317828
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Parker WB, 1994, J. NATL. INST. HEALTH RES, V6, P57
   Ponamarev MV, 2002, J BIOL CHEM, V277, P15225, DOI 10.1074/jbc.C200100200
   Pontarin G, 2003, P NATL ACAD SCI USA, V100, P12159, DOI 10.1073/pnas.1635259100
   Pontarin G, 2006, J BIOL CHEM, V281, P22720, DOI 10.1074/jbc.M604498200
   Rampazzo C, 2004, J BIOL CHEM, V279, P17019, DOI 10.1074/jbc.M313957200
   Rampazzo C, 2000, P NATL ACAD SCI USA, V97, P8239, DOI 10.1073/pnas.97.15.8239
   Rosenberg MJ, 2002, NAT GENET, V32, P175, DOI 10.1038/ng948
   Saada A, 2003, BIOCHEM BIOPH RES CO, V310, P963, DOI 10.1016/j.bbrc.2003.09.104
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Schapira AHV, 2006, LANCET, V368, P70, DOI 10.1016/S0140-6736(06)68970-8
   Song SW, 2005, P NATL ACAD SCI USA, V102, P4990, DOI 10.1073/pnas.0500253102
   Song SW, 2003, J BIOL CHEM, V278, P43893, DOI 10.1074/jbc.C300401200
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spinazzola A, 2002, J BIOL CHEM, V277, P4128, DOI 10.1074/jbc.M111028200
   Suh JH, 2003, FREE RADICAL BIO MED, V35, P1064, DOI 10.1016/S0891-5849(03)00468-4
   Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361
   Tyynismaa H, 2005, P NATL ACAD SCI USA, V102, P17687, DOI 10.1073/pnas.0505551102
   Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751
   Wang LY, 2003, FEBS LETT, V554, P319, DOI 10.1016/S0014-5793(03)01181-5
   Wang LY, 2003, J BIOL CHEM, V278, P6963, DOI 10.1074/jbc.M206143200
   YOUNG P, 1994, BIOCHEM BIOPH RES CO, V203, P46, DOI 10.1006/bbrc.1994.2146
NR 62
TC 33
Z9 40
U1 0
U2 6
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 
J9 FASEB J
JI Faseb J.
PD AUG 15
PY 2007
VL 21
IS 10
BP 2294
EP 2303
DI 10.1096/fj.06-7977rev
PG 10
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology
GA 196AS
UT WOS:000248454400004
PM 17403938
DA 2024-11-01
ER

PT J
AU Mömke, S
   Distl, O
AF Moemke, Stefanie
   Distl, Ottmar
TI Bilateral convergent strabismus with exophthalmus (BCSE) in cattle:: An overview of clinical signs and genetic traits
SO VETERINARY JOURNAL
LA English
DT Review
DE cattle; strabismus; inheritance; candidate gene; comparative genomics
ID progressive external ophthalmoplegia; nucleotide translocator-1 gene; dairy-cattle; mitochondrial-dna; mtdna deletions; mutation; mngie
AB Bilateral convergent strabismus with exophthalmus (BCSE) is a heritable eye defect prevalent in many cattle breeds and known worldwide. BCSE shows a progressive course often terminating in complete blindness. The onset of the defect can sometimes be slowly progressing (late in life) and, as the first signs of the defect are frequently not noticed prior to first breeding, prevention cannot be achieved only by exclusion of affected animals from the breeding program. This paper provides an overview of the clinical signs, histopathology and genetics of BCSE, its distribution in different cattle breeds and analyses the association between milk production traits and US Brown Swiss. There were different modes of inheritance proposed for BCSE, but although an autosomal dominant major gene is considered most likely in German Brown cattle, an association with milk production traits could not be found. Comparative molecular genetic approaches could help to characterize the responsible genes for this ocular disease in cattle. (c) 2005 Elsevier Ltd. All rights reserved.
C1 Univ Vet Med Hannover, Inst Genet & Anim Breeding, D-30559 Hannover, Germany.
C3 University of Veterinary Medicine Hannover
RP Distl, O (corresponding author), Univ Vet Med Hannover, Inst Genet & Anim Breeding, Bunteweg 17P, D-30559 Hannover, Germany.
EM ottmar.distl@tiho-hannover.de
CR BARRIER M, 1885, B SOC CENTRALE MED V, V29, P303
   Deschauer M, 2001, NERVENARZT, V72, P122, DOI 10.1007/s001150050724
   DISTL O, 1994, DEUT TIERARZTL WOCH, V101, P202
   DISTL O, 1993, J ANIM BREED GENET, V110, P393, DOI 10.1111/j.1439-0388.1993.tb00752.x
   Distl O, 2000, J VET MED A, V47, P31, DOI 10.1046/j.1439-0442.2000.00259.x
   DISTL O, 1991, DEUT TIERARZTL WOCH, V98, P354
   Gerst M, 1997, ARCH TIERZUCHT, V40, P401
   Gerst M, 1998, TIERARZTL UMSCHAU, V53, P6
   GERST M, 1996, THESIS L MAXIMILIANS, V0, P0
   HAUKE G, 2003, THESIS TIERARZTLICHE, V0, P0
   Holmes JR, 1957, VETERINARY RECORD, V69, P148
   JAKOB H, 1920, TIERARZTLICHE AUGENH, V0, P71
   JUBB TF, 1988, AUST VET J, V65, P353, DOI 10.1111/j.1751-0813.1988.tb14263.x
   JULIAN RJ, 1975, VET MED SMALL ANIMAL, V0, P1151
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   KOCH, 1875, LEHRBUCH AUGENHEILKU, V0, P400
   Komaki H, 2002, ANN NEUROL, V51, P645, DOI 10.1002/ana.10172
   Magnusson RA, 1983, BOVINE PRACTITIONER, V18, P195
   MILES KA, 1932, VET REC, V12, P759
   MINTSCHEV P, 1965, RIND MONATSHEFTE VET, V20, P41
   Mojon D, 2001, THER UMSCH, V58, P49, DOI 10.1024/0040-5930.58.1.49
   Napoli L, 2001, NEUROLOGY, V57, P2295, DOI 10.1212/WNL.57.12.2295
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   POWER EP, 1987, IRISH VET J, V41, P357
   Regan WM, 1944, J HERED, V35, P233, DOI 10.1093/oxfordjournals.jhered.a105391
   SCHUTZHANKE W, 1979, DEUT TIERARZTL WOCH, V86, P185
   SISSON S, 1953, ANATOMY DOMESTIC ANI, V0, P860
   Sorkin JA, 1997, AM J OPHTHALMOL, V123, P235, DOI 10.1016/S0002-9394(14)71041-4
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Suomalainen A, 2001, AM J MED GENET, V106, P53, DOI 10.1002/ajmg.1379
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   VEENENDAL H, 1958, TIJDSCHRIFT DIERGEEN, V83, P337
   Vissing J, 2002, NEUROLOGY, V59, P926, DOI 10.1212/WNL.59.6.926
   Vogt C, 2002, TIERARZTLICHE PRAXIS. AUSGABE G, V0, P0
   VOGT C, 2000, THESIS TIERARZLTLICH, V0, P0
NR 35
TC 7
Z9 7
U1 0
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1090-0233
EI 
J9 VET J
JI Vet. J.
PD MAR 15
PY 2007
VL 173
IS 2
BP 272
EP 277
DI 10.1016/j.tvjl.2005.11.020
PG 6
WC Veterinary Sciences
SC Veterinary Sciences
GA 145IQ
UT WOS:000244858900012
PM 16434218
DA 2024-11-01
ER

PT J
AU von Kleist-Retzow, JC
   Hornig-Do, HT
   Schauen, M
   Eckertz, S
   Dinh, TAD
   Stassen, F
   Lottmann, N
   Bust, M
   Galunska, B
   Wielckens, K
   Hein, W
   Beuth, J
   Braun, JM
   Fischer, JH
   Ganitkevich, VY
   Maniura-Weber, K
   Wiesner, RJ
AF von Kleist-Retzow, Juergen-Christoph
   Hornig-Do, Hue-Tran
   Schauen, Matthias
   Eckertz, Sabrina
   Dinh, Tuan Anh Duong
   Stassen, Frank
   Lottmann, Nadine
   Bust, Maria
   Galunska, Bistra
   Wielckens, Klaus
   Hein, Wolfgang
   Beuth, Joseph
   Braun, Jan-Matthias
   Fischer, Juergen H.
   Ganitkevich, Vladimir Y.
   Maniura-Weber, Katharina
   Wiesner, Rudolf J.
TI Impaired mitochondrial Ca<SUP>2+</SUP> homeostasis in respiratory chain-deficient cells but efficient compensation of energetic disadvantage by enhanced anaerobic glycolysis due to low ATP steady state levels
SO EXPERIMENTAL CELL RESEARCH
LA English
DT Article
DE mitochondria; cell culture; tRNALeu(UUR)
ID modification defect; a3302g mutation; lactic-acidosis; dna; mtdna; rna; myopathy; encephalopathy; pathogenesis; dysfunction
AB Energy-producing pathways, adenine nucleotide levels, oxidative stress response and Ca2+ homeostasis were investigated in cybrid cells incorporating two pathogenic mitochondrial DNA point mutations, 3243A>G and 3302A>G in tRNA(Leu(UUR)), as well as Rho(o) cells and compared to their parental 143B osteosarcoma cell line. All cells suffering from a severe respiratory chain deficiency were able to proliferate as fast as controls. The major defect in oxidative phosphorylation was efficiently compensated by a rise in anaerobic glycolysis, so that the total ATP production rate was preserved. This enhancement of glycolysis was enabled by a considerable decrease of cellular total adenine nucleotide pools and a concomitant shift in the AMP+ADP/ATP ratios, while the energy charge potential was still in the normal range. Further important consequences were an increased production of superoxide which, however, was neither escorted by major changes in the antioxidative defence systems nor was it leading to substantial oxidative damage. Most interestingly, the lowered mitochondrial membrane potential led to a disturbed intramitochondrial calcium homeostasis, which most likely is a major pathomechanism in mitochondrial diseases. (c) 2007 Elsevier Inc. All rights reserved.
C1 Univ Cologne, Inst Vegetat Physiol, D-50931 Cologne, Germany.
   Univ Cologne, Ctr Mol Med Cologne, D-50931 Cologne, Germany.
   Univ Cologne, Dept Pediat, D-50924 Cologne, Germany.
   Univ Med Varna, Dept Preclin, Clin Pharmacol & Biochem, Varna 9002, Bulgaria.
   Univ Cologne, Inst Clin Chem, D-50924 Cologne, Germany.
   Univ Cologne, Inst Naturopathy, D-50924 Cologne, Germany.
   Univ Cologne, Inst Expt Med, D-50931 Cologne, Germany.
   Univ Jena, Inst Physiol 2, D-07743 Jena, Germany.
C3 University of Cologne; University of Cologne; University of Cologne; Medical University Varna; University of Cologne; University of Cologne; University of Cologne; Friedrich Schiller University of Jena
RP von Kleist-Retzow, JC (corresponding author), Univ Cologne, Inst Vegetat Physiol, Robert Koch Str 39, D-50931 Cologne, Germany.
EM juergen-christoph.vonkleist@uk-koeln.de
CR Alberts B, 2007, MOL BIOL CELL, V0, P0
   Appleby RD, 1999, EUR J BIOCHEM, V262, P108, DOI 10.1046/j.1432-1327.1999.00350.x
   BINDOFF LA, 1993, J BIOL CHEM, V268, P19559
   Brini M, 1999, NAT MED, V5, P951, DOI 10.1038/11396
   Campanella M, 2004, BIOL RES, V37, P653
   Chomyn A, 2000, J BIOL CHEM, V275, P19198, DOI 10.1074/jbc.M908734199
   Dunbar DR, 1996, HUM MOL GENET, V5, P123, DOI 10.1093/hmg/5.1.123
   El Meziane A, 1998, HUM MOL GENET, V7, P2141, DOI 10.1093/hmg/7.13.2141
   Fischer J, 1995, LC-GC INT., V8, P254
   Hansson A, 2004, P NATL ACAD SCI USA, V101, P3136, DOI 10.1073/pnas.0308710100
   HISSIN PJ, 1976, ANAL BIOCHEM, V74, P214, DOI 10.1016/0003-2697(76)90326-2
   Hutchison WM, 2005, ARCH NEUROL-CHICAGO, V62, P1920, DOI 10.1001/archneur.62.12.1920
   KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477
   LEVINE RL, 1994, METHOD ENZYMOL, V233, P346
   Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292
   Maniura-Weber K, 2004, NUCLEIC ACIDS RES, V32, P6015, DOI 10.1093/nar/gkh921
   Maniura-Weber K, 2006, NUCLEIC ACIDS RES, V34, P6404, DOI 10.1093/nar/gkl727
   *MITOMAP, 2003, HUM MIT GEN DAT, V0, P0
   Möllers M, 2005, NUCLEIC ACIDS RES, V33, P5647, DOI 10.1093/nar/gki876
   MOUDY AM, 1995, P NATL ACAD SCI USA, V92, P729, DOI 10.1073/pnas.92.3.729
   Munnich A, 2001, AM J MED GENET, V106, P4, DOI 10.1002/ajmg.1391
   Piva TJ, 1998, J CELL BIOCHEM, V68, P213, DOI 10.1002/(SICI)1097-4644(19980201)68:2<213::AID-JCB8>3.0.CO;2-Y
   Porteous WK, 1998, EUR J BIOCHEM, V257, P192, DOI 10.1046/j.1432-1327.1998.2570192.x
   PORTER NA, 1995, LIPIDS, V30, P277, DOI 10.1007/BF02536034
   RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0
   RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8
   Schauen M, 2006, J CELL PHYSIOL, V209, P103, DOI 10.1002/jcp.20711
   SELLEVOLD OFM, 1986, J MOL CELL CARDIOL, V18, P517, DOI 10.1016/S0022-2828(86)80917-8
   Tavi P, 2005, HUM MOL GENET, V14, P1069, DOI 10.1093/hmg/ddi119
   Toompuu M, 2004, BIOCHEM BIOPH RES CO, V322, P803, DOI 10.1016/j.bbrc.2004.07.181
   van den Bosch BJC, 2004, NEUROMUSCULAR DISORD, V14, P683, DOI 10.1016/j.nmd.2004.06.004
   Vives-Bauza C, 2006, NEUROSCI LETT, V391, P136, DOI 10.1016/j.neulet.2005.08.049
   von Kleist-Retzow JC, 2003, EXP PHYSIOL, V88, P155, DOI 10.1113/eph8802509
   WIESNER RJ, 2003, EUR J PHYSL, V445, P0
   Wredenberg A, 2002, P NATL ACAD SCI USA, V99, P15066, DOI 10.1073/pnas.232591499
   Yasukawa T, 2000, J BIOL CHEM, V275, P4251, DOI 10.1074/jbc.275.6.4251
   Yasukawa T, 2001, EMBO J, V20, P4794, DOI 10.1093/emboj/20.17.4794
NR 37
TC 51
Z9 53
U1 0
U2 4
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4827
EI 1090-2422
J9 EXP CELL RES
JI Exp. Cell Res.
PD AUG 15
PY 2007
VL 313
IS 14
BP 3076
EP 3089
DI 10.1016/j.yexcr.2007.04.015
PG 14
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA 199EU
UT WOS:000248679800011
PM 17509565
DA 2024-11-01
ER

PT J
AU Meulemans, A
   Gerlo, E
   Seneca, S
   Lissens, W
   Smet, J
   Van Coster, R
   De Meirleir, L
AF Meulemans, Ann
   Gerlo, Erik
   Seneca, Sara
   Lissens, Willy
   Smet, Joel
   Van Coster, Rudy
   De Meirleir, Linda
TI The aerobic forearm exercise test, a non-invasive tool to screen for mitochondrial disorders
SO ACTA NEUROLOGICA BELGICA
LA English
DT Article
DE aerobic forearm exercise; diagnosis; mitochondrial; disease; muscle; oxygen extraction
ID myopathy; muscle; metabolism; mutations; workload; lactate; dna
AB The diagnosis of a mitochondrial disorder is often difficult. Therefore, new approaches and diagnostic criteria are being developed. One of these tests is the aerobic forearm exercise test, a screening tool that can contribute to assess whether or not the patient suffers from a mitochondrial myopathy. With this simple, non-invasive test, the oxidative metabolism of muscle can be evaluated in rest and during exercise. We performed the aerobic forearm exercise test in patients with a mitochondrial disorder and an identified pathogenic gene mutation, in patients with a suspected mitochondrial disorder based on their clinical presentation and biochemical results, but without a molecular diagnosis, and in patients with atypical fatigue and no characteristics of a mitochondrial myopathy. In the first two groups, abnormal oxygen extraction from the blood during exercise was observed in four out of twelve patients. In the third group no abnormalities were found. The number of patients that we could test so far was limited, but all the patients experienced the aerobic forearm exercise as an easy test. We would like to stimulate clinicians to perform this test whenever a mitochondrial myopathy is suspected, as it can be a valuable diagnostic screening tool.
C1 UZ Brussels, B-1090 Brussels, Belgium.
   Vrije Univ Brussels, Ctr Genet Med, Brussels, Belgium.
   Vrije Univ Brussels, Dept Clin Chem & Radioimmunol, Brussels, Belgium.
   Vrije Univ Brussels, Dept Pediat Neurol, Brussels, Belgium.
   Ghent Univ Hosp, Ghent, Belgium.
C3 Vrije Universiteit Brussel; Vrije Universiteit Brussel; Vrije Universiteit Brussel; Ghent University; Ghent University Hospital
RP Meulemans, A (corresponding author), UZ Brussels, Laarbeeklaan 101, B-1090 Brussels, Belgium.
CR Andreu AL, 1999, NEW ENGL J MED, V341, P1037, DOI 10.1056/NEJM199909303411404
   BARBIROLI B, 1995, NEUROLOGY, V45, P1364, DOI 10.1212/WNL.45.7.1364
   Chance B, 1998, BIOFACTORS, V7, P237
   DiMauro S, 2001, ANN MED, V33, P472, DOI 10.3109/07853890109002096
   Finsterer J, 2004, EUR J NEUROL, V11, P811, DOI 10.1111/j.1468-1331.2004.00859.x
   Hammarén E, 2004, EUR NEUROL, V51, P38, DOI 10.1159/000074981
   Hanisch F, 2006, J NEUROL, V253, P417, DOI 10.1007/s00415-006-0987-0
   Jensen TD, 2002, NEUROLOGY, V58, P1533, DOI 10.1212/WNL.58.10.1533
   Jeppesen TD, 2007, J NEUROL, V254, P29, DOI 10.1007/s00415-006-0229-5
   Kazemi-Esfarjani P, 2002, ANN NEUROL, V52, P153, DOI 10.1002/ana.10263
   Seneca S, 2000, J INHERIT METAB DIS, V23, P853, DOI 10.1023/A:1026729223050
   Taivassalo T, 2002, ANN NEUROL, V51, P38, DOI 10.1002/ana.10027
   Van Coster R, 2001, PEDIATR RES, V50, P658, DOI 10.1203/00006450-200111000-00020
   van den Bosch BJC, 2000, NUCLEIC ACIDS RES, V28, P0, DOI 10.1093/nar/28.20.e89
NR 14
TC 14
Z9 15
U1 0
U2 2
PU ACTA MEDICA BELGICA
PI BRUSSELS
PA AVENUE CIRCULAIRE 138-A, B-1180 BRUSSELS, BELGIUM
SN 0300-9009
EI 
J9 ACTA NEUROL BELG
JI Acta Neurol. Belg.
PD SEP 15
PY 2007
VL 107
IS 3
BP 78
EP 83
DI 
PG 6
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 232XY
UT WOS:000251056200004
PM 18072335
DA 2024-11-01
ER

PT J
AU Sarzi, E
   Goffart, S
   Serre, V
   Chrétein, D
   Slama, A
   Munnich, A
   Spelbrink, JN
   Rötig, A
AF Sarzi, Emmanuelle
   Goffart, Steffi
   Serre, Valerie
   Chretein, Dominique
   Slama, Abdethamid
   Munnich, Arnold
   Spelbrink, Johannes N.
   Roetig, Agnes
TI Twinkle helicase (<i>PEO1</i>) gene mutation causes mitochondrial DNA depletion
SO ANNALS OF NEUROLOGY
LA English
DT Article
ID progressive external ophthalmoplegia; mtdna maintenance; swiss-model; protein; deletions; polg; replication; deficiency; kinase
AB Objective: Mitochondrial DNA (mtDNA) depletion syndrome (MDS) is a clinically and genetically heterogeneous group of autosomal recessive diseases characterized by a reduction in mtDNA copy number. Several nuclear genes have been shown to account for these severe oxidative phosphorylation disorders, but the disease-causing mutations remain largely unknown. Methods: By virtue of homozygosity mapping, we tested candidate genes involved in mtDNA maintenance in patients born to consanguineous parents. Results: We found homozygosity for microsatellite markers flanking the PEO1 gene, encoding the mitochondrial Twinkle helicase, in two sibs presenting a hepatocerebral form of MDS. Sequencing the PEO1 gene showed a homozygous mutation at a conserved position of the protein in the two patients (T457I). The modeling of the Twinkle protein showed that T457 is located in the interface between two monomers of the hexameric enzyme. Finally, using purified recombinant protein, we demonstrated that the T457I mutant Twinkle has a defective helicase activity. Interpretation: Although dominant Twinkle mutations have been previously reported in patients with autosomal dominant progressive external ophthalmoplegia and multiple mtDNA deletions, we report here the first recessive Twinkle mutation in patients with hepatocerebral form of MDS. Identifying other Twinkle mutations in MDS and/or autosomal dominant progressive external ophthalmoplegia and studying their impact on the isolated proteins should help in understanding why some mutations are recessive and others are dominant.
C1 [Sarzi, Emmanuelle; Serre, Valerie; Chretein, Dominique; Munnich, Arnold; Roetig, Agnes] Hop Necker Enfants Malad, INSERM, U781, F-75015 Paris, France.
   [Sarzi, Emmanuelle; Serre, Valerie; Chretein, Dominique; Munnich, Arnold; Roetig, Agnes] Hop Necker Enfants Malad, Serv Genet, F-75015 Paris, France.
   [Goffart, Steffi; Spelbrink, Johannes N.] Tampere Univ Hosp, Tampere, Finland.
   [Goffart, Steffi; Spelbrink, Johannes N.] Inst Med Technol, Tampere, Finland.
   [Slama, Abdethamid] Hop Kremlin Bicetre, Biochim Lab, Le Kremlin Bicetre, France.
C3 Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite; Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite; Hopital Universitaire Necker-Enfants Malades - APHP; Tampere University; Tampere University Hospital; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Universite Paris Saclay
RP Rötig, A (corresponding author), Hop Necker Enfants Malad, INSERM, U781, 149 Rue Sevres, F-75015 Paris, France.
EM roetig@necker.fr
CR Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Crampton DJ, 2006, MOL CELL, V21, P165, DOI 10.1016/j.molcel.2005.11.027
   Crampton DJ, 2004, P NATL ACAD SCI USA, V101, P4373, DOI 10.1073/pnas.0400968101
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505
   Guo SY, 1999, J BIOL CHEM, V274, P30303, DOI 10.1074/jbc.274.42.30303
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Korhonen JA, 2003, J BIOL CHEM, V278, P48627, DOI 10.1074/jbc.M306981200
   Liao JC, 2005, J MOL BIOL, V350, P452, DOI 10.1016/j.jmb.2005.04.051
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Nikali K, 2005, HUM MOL GENET, V14, P2981, DOI 10.1093/hmg/ddi328
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Sarzi E, 2007, J PEDIATR-US, V150, P531, DOI 10.1016/j.jpeds.2007.01.044
   Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spelbrink JN, 2000, J BIOL CHEM, V275, P24818, DOI 10.1074/jbc.M000559200
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Tyynismaa H, 2005, P NATL ACAD SCI USA, V102, P17687, DOI 10.1073/pnas.0505551102
   Tyynismaa H, 2004, HUM MOL GENET, V13, P3219, DOI 10.1093/hmg/ddh342
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Wanrooij S, 2007, NUCLEIC ACIDS RES, V35, P3238, DOI 10.1093/nar/gkm215
   Yasukawa T, 2006, EMBO J, V25, P5358, DOI 10.1038/sj.emboj.7601392
   Ziegelin G, 2003, NUCLEIC ACIDS RES, V31, P5917, DOI 10.1093/nar/gkg790
NR 27
TC 129
Z9 143
U1 0
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0364-5134
EI 1531-8249
J9 ANN NEUROL
JI Ann. Neurol.
PD DEC 15
PY 2007
VL 62
IS 6
BP 579
EP 587
DI 10.1002/ana.21207
PG 9
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 248AM
UT WOS:000252123700007
PM 17722119
DA 2024-11-01
ER

PT J
AU Raule, N
   Sevini, F
   Santoro, A
   Altilia, S
   Franceschi, C
AF Raule, Nicola
   Sevini, Federica
   Santoro, Aurelia
   Altilia, Serena
   Franceschi, Claudio
TI Association studies on human mitochondrial DNA: Methodological aspects and results in the most common age-related diseases
SO MITOCHONDRION
LA English
DT Review
DE mitochondrial DNA; longevity; mtDNA mutations; mtDNA haplogroups; centenarians; mtDNA resequencing
ID parkinsons-disease; human mtdna; alzheimer-disease; control-region; population-genetics; replication origin; oxidative stress; island melanesia; skeletal-muscle; human-evolution
AB Mitochondrial DNA (mtDNA) follows direct maternal inheritance and, as such, can be used in phylogenetic studies to determine a human lineage tree. The presence of common polymorphisms allows a classification of mtDNA in haplogroups and sub-haplogroups, according to the branch they belong to. Thanks to the rapidly growing number of mtDNA sequences available, this classification is being corrected and redefined to be more accurate. In parallel with this process, several studies are trying to identify an association between common mtDNA polymorphisms and common complex traits, as hypothesized by the common disease-common variant theory. Here we review the associations already reported with the main age-related complex diseases and we identify the critical points (sample size, size of the recruiting area, careful matching between cases and controls regarding geographical origin and ethnicity, data quality checking) to be taken in account in planning such studies. On the whole, this research area is opening a new perspective as an important component of "mitochondrial medicine", capable of identifying new molecular targets for the diagnosis, prevention and treatment of common complex diseases. (c) 2007 Elsevier B.V. and Mitochondria Research Society. All rights reserved.
C1 Ctr Interdipartimentale L Galvani, I-40126 Bologna, Italy.
   Univ Bologna, Dept Expt Pathol, I-40126 Bologna, Italy.
   INRCA Ancona, Dept Gerontol Sci, I-60121 Ancona, Italy.
C3 University of Bologna; IRCCS INRCA
RP Raule, N (corresponding author), Ctr Interdipartimentale L Galvani, Via S Giacomo 12, I-40126 Bologna, Italy.
EM nicola.raule@unibo.it
CR Achilli A, 2004, AM J HUM GENET, V75, P910, DOI 10.1086/425590
   Alcolado JC, 2002, DIABETIC MED, V19, P89, DOI 10.1046/j.1464-5491.2002.00675.x
   Autere J, 2004, HUM GENET, V115, P29, DOI 10.1007/s00439-004-1123-9
   Bandelt HJ, 2005, J MED GENET, V42, P957, DOI 10.1136/jmg.2005.033589
   Bandelt HJ, 2005, BIOCHEM BIOPH RES CO, V333, P122, DOI 10.1016/j.bbrc.2005.04.055
   Bandelt HJ, 2004, SCIENCE, V305, P1402
   Bandelt HJ, 2002, AM J HUM GENET, V71, P1150, DOI 10.1086/344397
   Booker LM, 2006, J UROLOGY, V175, P468, DOI 10.1016/S0022-5347(05)00163-1
   Bowmaker M, 2003, J BIOL CHEM, V278, P50961, DOI 10.1074/jbc.M308028200
   BROWN WM, 1980, P NATL ACAD SCI-BIOL, V77, P3605, DOI 10.1073/pnas.77.6.3605
   CANN RL, 1987, NATURE, V325, P31, DOI 10.1038/325031a0
   Carrieri G, 2001, HUM GENET, V108, P194, DOI 10.1007/s004390100463
   Casali C, 1999, J AM COLL CARDIOL, V33, P1584, DOI 10.1016/S0735-1097(99)00079-0
   CASTRO MG, 2005, IN PRESS INT J CARDI, V0, P0
   Cavalli LR, 1998, MUTAT RES-FUND MOL M, V398, P19, DOI 10.1016/S0027-5107(97)00223-6
   Chagnon P, 1999, AM J MED GENET, V85, P20, DOI 10.1002/(SICI)1096-8628(19990702)85:1<20::AID-AJMG6>3.0.CO;2-K
   Chakravarti A, 1999, NAT GENET, V21, P56, DOI 10.1038/4482
   Chinnery PF, 2000, NEUROLOGY, V55, P302, DOI 10.1212/WNL.55.2.302
   CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6
   Coskun PE, 2003, P NATL ACAD SCI USA, V100, P2174, DOI 10.1073/pnas.0630589100
   Cournil A, 2001, TRENDS GENET, V17, P233, DOI 10.1016/S0168-9525(01)02306-X
   DAurelio M, 2004, HUM MOL GENET, V13, P3171, DOI 10.1093/hmg/ddh326
   Dato S, 2004, EUR J HUM GENET, V12, P1080, DOI 10.1038/sj.ejhg.5201278
   De Benedictis G, 1999, FASEB J, V13, P1532, DOI 10.1096/fasebj.13.12.1532
   DENARO M, 1981, P NATL ACAD SCI-BIOL, V78, P5768, DOI 10.1073/pnas.78.9.5768
   DiMauro S, 1993, MITOCHONDRIAL DNA IN HUMAN PATHOLOGY, V0, P0
   Elson JL, 2006, HUM GENET, V119, P241, DOI 10.1007/s00439-005-0123-8
   Eyre-Walker A, 1999, P ROY SOC B-BIOL SCI, V266, P477, DOI 10.1098/rspb.1999.0662
   Finch CE, 2000, CHANCE DEV AGING, V0, P0
   Fish J, 2004, SCIENCE, V306, P2098, DOI 10.1126/science.1102077
   Forster R, 2003, ANN HUM GENET, V67, P2, DOI 10.1046/j.1469-1809.2003.00002.x
   Franceschi C, 2005, MECH AGEING DEV, V126, P351, DOI 10.1016/j.mad.2004.08.028
   Ghezzi D, 2005, EUR J HUM GENET, V13, P748, DOI 10.1038/sj.ejhg.5201425
   Gibson BW, 2005, INT J BIOCHEM CELL B, V37, P927, DOI 10.1016/j.biocel.2004.11.013
   GRAY MW, 1989, ANNU REV CELL BIOL, V5, P25, DOI 10.1146/annurev.cb.05.110189.000325
   Hagelberg E, 2000, P ROY SOC B-BIOL SCI, V267, P1595, DOI 10.1098/rspb.2000.1183
   Hagelberg E, 1999, P ROY SOC B-BIOL SCI, V266, P485, DOI 10.1098/rspb.1999.0663
   Herrnstadt C, 2004, MITOCHONDRION, V4, P791, DOI 10.1016/j.mito.2004.07.041
   Holt IJ, 2000, CELL, V100, P515, DOI 10.1016/S0092-8674(00)80688-1
   Huerta C, 2005, J NEUROL SCI, V236, P49, DOI 10.1016/j.jns.2005.04.016
   ITO T, 1992, JPN CIRC J, V56, P1045, DOI 10.1253/jcj.56.1045
   Kang DC, 2005, CLIN BIOCHEM, V38, P685, DOI 10.1016/j.clinbiochem.2005.04.014
   Kelley DE, 2002, DIABETES, V51, P2944, DOI 10.2337/diabetes.51.10.2944
   Kivisild T, 2006, GENETICS, V172, P373, DOI 10.1534/genetics.105.043901
   Kivisild T, 2004, AM J HUM GENET, V75, P752, DOI 10.1086/425161
   Kraytsberg Y, 2004, SCIENCE, V304, P981, DOI 10.1126/science.1096342
   Lander Harry M, 1996, METHODS (ORLANDO), V10, P15, DOI 10.1006/meth.1996.0073
   Macaulay V, 2005, SCIENCE, V308, P1034, DOI 10.1126/science.1109792
   Macaulay V, 1999, AM J HUM GENET, V64, P232, DOI 10.1086/302204
   Maechler P, 2001, NATURE, V414, P807, DOI 10.1038/414807a
   MERANTE F, 1994, AM J HUM GENET, V55, P437
   Michikawa Y, 1999, SCIENCE, V286, P774, DOI 10.1126/science.286.5440.774
   Mishmar D, 2003, P NATL ACAD SCI USA, V100, P171, DOI 10.1073/pnas.0136972100
   MITCHELL P, 1976, BIOCHEM SOC T, V4, P399, DOI 10.1042/bst0040399
   MIYATA T, 1982, J MOL EVOL, V19, P28, DOI 10.1007/BF02100221
   Mohlke KL, 2005, HUM GENET, V118, P245, DOI 10.1007/s00439-005-0046-4
   Niemi AK, 2005, EUR J HUM GENET, V13, P166, DOI 10.1038/sj.ejhg.5201308
   Niemi AK, 2005, EUR J HUM GENET, V13, P965, DOI 10.1038/sj.ejhg.5201438
   Niemi AK, 2003, HUM GENET, V112, P29, DOI 10.1007/s00439-002-0843-y
   Oikawa H, 2002, BIOCHEM BIOPH RES CO, V297, P341, DOI 10.1016/S0006-291X(02)02198-8
   Palanichamy MG, 2004, AM J HUM GENET, V75, P966, DOI 10.1086/425871
   Parr Ryan L, 2006, HUMAN GENOMICS, V2, P252
   Pereira L, 2005, INT J ANDROL, V28, P241, DOI 10.1111/j.1365-2605.2005.00539.x
   Petros JA, 2005, P NATL ACAD SCI USA, V102, P719, DOI 10.1073/pnas.0408894102
   Poulton J, 2002, HUM MOL GENET, V11, P1581, DOI 10.1093/hmg/11.13.1581
   Pyle A, 2005, ANN NEUROL, V57, P564, DOI 10.1002/ana.20417
   Reich DE, 2001, TRENDS GENET, V17, P502, DOI 10.1016/S0168-9525(01)02410-6
   ROBBERSON DL, 1972, P NATL ACAD SCI USA, V69, P737, DOI 10.1073/pnas.69.3.737
   ROFF DA, 1989, MOL BIOL EVOL, V6, P539
   Ross OA, 2003, EXP GERONTOL, V38, P397, DOI 10.1016/S0531-5565(02)00266-8
   Ross OA, 2001, EXP GERONTOL, V36, P1161, DOI 10.1016/S0531-5565(01)00094-8
   Ruiz-Pesini E, 2004, SCIENCE, V303, P223, DOI 10.1126/science.1088434
   Salas A, 2005, PLOS MED, V2, P1158, DOI 10.1371/journal.pmed.0020296
   Salas A, 2005, BIOCHEM BIOPH RES CO, V335, P891, DOI 10.1016/j.bbrc.2005.07.161
   Samuels DC, 2006, AM J HUM GENET, V78, P713, DOI 10.1086/502682
   Sato A, 2005, P NATL ACAD SCI USA, V102, P6057, DOI 10.1073/pnas.0408666102
   Schwartz M, 2003, BIOCHEM BIOPH RES CO, V310, P247, DOI 10.1016/j.bbrc.2003.09.037
   Schwartz M, 2002, NEW ENGL J MED, V347, P576, DOI 10.1056/NEJMoa020350
   Scott RA, 2005, COMP BIOCHEM PHYS B, V140, P497, DOI 10.1016/j.cbpc.2004.11.014
   SHERROD LR, 1999, NATL HEAD START ASS, V2, P412
   Torroni A, 1996, GENETICS, V144, P1835
   TORRONI A, 1994, J BIOENERG BIOMEMBR, V26, P261, DOI 10.1007/BF00763098
   TORRONI A, 2006, IN PRESS TRENDS GENE, V0, P0
   van der Walt JM, 2005, HUM GENET, V118, P115, DOI 10.1007/s00439-005-0032-x
   van der Walt JM, 2004, NEUROSCI LETT, V365, P28, DOI 10.1016/j.neulet.2004.04.051
   van der Walt JM, 2003, AM J HUM GENET, V72, P804, DOI 10.1086/373937
   VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368
   VANDENOUWELAND JMW, 1994, DIABETES, V43, P746, DOI 10.2337/diabetes.43.6.746
   Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751
   WALLACE DC, 1987, CURR GENET, V12, P81, DOI 10.1007/BF00434661
   WALLACE DC, 1994, P NATL ACAD SCI USA, V91, P8739, DOI 10.1073/pnas.91.19.8739
   Weiss KM, 2002, TRENDS GENET, V18, P19, DOI 10.1016/S0168-9525(01)02550-1
   Yang MY, 2002, CELL, V111, P495, DOI 10.1016/S0092-8674(02)01075-9
   Yasukawa T, 2005, MOL CELL, V18, P651, DOI 10.1016/j.molcel.2005.05.002
   ZEVIANI M, 1991, LANCET, V338, P143, DOI 10.1016/0140-6736(91)90136-D
   Zhang J, 2003, P NATL ACAD SCI USA, V100, P1116, DOI 10.1073/pnas.242719399
   Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a
   Zsurka G, 2005, NAT GENET, V37, P873, DOI 10.1038/ng1606
NR 98
TC 41
Z9 49
U1 0
U2 10
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
EI 1872-8278
J9 MITOCHONDRION
JI Mitochondrion
PD FEB-APR 15
PY 2007
VL 7
IS 1-2
BP 29
EP 38
DI 10.1016/j.mito.2006.11.013
PG 10
WC Cell Biology; Genetics & Heredity
SC Cell Biology; Genetics & Heredity
GA 157EM
UT WOS:000245701400006
PM 17306632
DA 2024-11-01
ER

PT J
AU Wortmann, SB
   Rodenburg, RJ
   Backx, AP
   Schmitt, E
   Smeitink, JAM
   Morava, E
AF Wortmann, S. B.
   Rodenburg, R. J.
   Backx, A. P.
   Schmitt, E.
   Smeitink, J. A. M.
   Morava, E.
TI Early cardiac involvement in children carrying the A3243G mtDNA mutation
SO ACTA PAEDIATRICA
LA English
DT Article
DE mitochondrial cardiomyopathy; mitochondrial diseases; mitochondrial DNA
ID mitochondrial-dna; encephalomyopathy; cardiomyopathy
AB The phenotypic spectrum of the mitochondrial A3243G DKA mutation is highly variable, particularly when occuring in childhood. In contrast to the classical presentation in adulthood (MELAS syndrome; mitochondria! myopathy, encephalopathy, lactic acidosis and stroke-like episodes) children show a different pattern of symptoms, often without the typical encephalopathy or psychomotor regression. We present six children carrying the A3243G mtDNA mutation with a heteroplasmy above 50 % in muscle tissue. The age of diagnosis ranged from 2 weeks up to 14.5 years. The clinical presentation was rather non-specific including muscle weakness, developmental delay and epilepsy. In this small pediatric group we detected presymptomatic cardiac involvement in five out of six children already at an early stage of disease. The cardiac pathology included cardiomyopathy and biventricular hypertrophy with rhythm disturbances (for example long QT-syndrome). The observed cardiac changes do not always increase the risk of cardiac deterioration; however, two of our patients died early on. Conclusion: We hypothesize that the A3243G mutation might be underdiagnosed, as patients could suffer from an unexplained cardiac death before the diagnosis is made. We advise performing regular repeated ECGs and echocardiography in all children carrying a A3243G mtDNA mutation independently from the presence of cardiac symptoms.
C1 Radboud Univ Nijmegen, Nijmegen Med Ctr, Dept Pediat, Nijmegen Ctr Mitochondrial Disorders, NL-6500 HB Nijmegen, Netherlands.
   Radboud Univ Nijmegen, Nijmegen Med Ctr, Lab Pediat & Neurol, Nijmegen Ctr Mitochondrial Disorders, NL-6500 HB Nijmegen, Netherlands.
   Katholisches Klinikum, Dept Neurol, Koblenz, Germany.
C3 Radboud University Nijmegen; Radboud University Nijmegen
RP Morava, E (corresponding author), Radboud Univ Nijmegen, Nijmegen Med Ctr, Dept Pediat, Nijmegen Ctr Mitochondrial Disorders, POB 9101, NL-6500 HB Nijmegen, Netherlands.
EM E.Morava@cukz.umcn.nl
CR Janssen AJM, 2006, CLIN CHEM, V52, P860, DOI 10.1373/clinchem.2005.062414
   Kärppä M, 2005, BRAIN, V128, P1861, DOI 10.1093/brain/awh515
   Kovalenko SA, 1996, BIOCHEM BIOPH RES CO, V222, P201, DOI 10.1006/bbrc.1996.0722
   Lev D, 2004, PEDIATR CARDIOL, V25, P443, DOI 10.1007/s00246-003-0490-7
   MANOUVRIER S, 1995, J MED GENET, V32, P654, DOI 10.1136/jmg.32.8.654
   Okajima Y, 1998, HEART, V80, P292, DOI 10.1136/hrt.80.3.292
   Okhuijsen-Kroes EJ, 2001, NEUROPEDIATRICS, V32, P183, DOI 10.1055/s-2001-17372
NR 7
TC 18
Z9 18
U1 0
U2 1
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 0803-5253
EI 
J9 ACTA PAEDIATR
JI Acta Paediatr.
PD MAR 15
PY 2007
VL 96
IS 3
BP 450
EP 452
DI 10.1111/j.1651-2227.2006.00158.x
PG 3
WC Pediatrics
SC Pediatrics
GA 143JG
UT WOS:000244716300029
PM 17407476
DA 2024-11-01
ER

PT J
AU Lau, KK
   Yang, SP
   Haddad, MN
   Butani, L
   Makker, SP
AF Lau, Keith K.
   Yang, Samuel P.
   Haddad, Maha N.
   Butani, Lavjay
   Makker, Sudesh P.
TI Mitochondrial encephalopathy with lactic acidosis and stroke-like episodes syndrome with hypothyroidism and focal segmental glomerulosclerosis in a paediatric patient
SO INTERNATIONAL UROLOGY AND NEPHROLOGY
LA English
DT Article
DE FSGS; Hypothyroidism; MELAS; Nephrotic syndrome; Paediatrics
ID encephalomyopathy melas; diabetes-mellitus; gene mutation; dna; disorders; complexes; myopathy; features; defects
AB Herein, we report on a paediatric patient with mitochondrial encephalopathy, lactic acidosis and stroke-like episodes (MELAS) who was hospitalized for acute on chronic renal insufficiency, seizures and deterioration of the level of consciousness. She also had hypertension, hypothyroidism and nephrotic range proteinuria. Kidney biopsy revealed many sclerotic glomeruli and focal segmental glomerulosclerosis (FSGS). Glomerulopathy is rare in patients with MELAS, and FSGS has been reported only in a few patients. The histopathological features of the renal biopsy suggested that the aetiology of the FSGS may have been secondary to chronic renal injury rather than from a primary immunologic cause. Moreover, our case is unique in that, the coexistence of MELAS, hypothalamic hypothyroidism and FSGS has not been reported in the past. The purpose of this report is to increase the awareness of health-care professionals, especially in the fields of paediatrics, neurology, endocrinology and nephrology, regarding the manifestations and complications of MELAS.
C1 Univ Calif Davis, Dept Paediat, Sacramento, CA 95817 USA.
C3 University of California System; University of California Davis
RP Lau, KK (corresponding author), Univ Calif Davis, Dept Paediat, 2516 Stockton Blvd, Sacramento, CA 95817 USA.
EM keith.lau@ucdmc.ucdavis.edu
CR Balestri P, 2000, J CHILD NEUROL, V15, P755, DOI 10.1177/088307380001501108
   BAN S, 1992, ACTA PATHOL JAPON, V42, P818
   CAMPOS Y, 1995, PEDIATR NEUROL, V13, P69, DOI 10.1016/0887-8994(95)00082-Q
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   HAMMANS SR, 1991, LANCET, V337, P1311, DOI 10.1016/0140-6736(91)92981-7
   Hotta O, 2001, KIDNEY INT, V59, P1236, DOI 10.1046/j.1523-1755.2001.0590041236.x
   Leonard JV, 2000, LANCET, V355, P389, DOI 10.1016/S0140-6736(99)05226-5
   McFarland R, 2002, LANCET NEUROL, V1, P343, DOI 10.1016/S1474-4422(02)00159-X
   Mochizuki H, 1996, CLIN NEPHROL, V46, P347
   Nakamura S, 1999, DIABETES RES CLIN PR, V44, P183, DOI 10.1016/S0168-8227(99)00051-0
   Naviaux R K, 2000, HUM REPROD, V15 Suppl 2, P44
   Oshima T, 1999, LARYNGOSCOPE, V109, P334, DOI 10.1097/00005537-199902000-00029
   Petermann AT, 2005, KIDNEY INT, V67, P157, DOI 10.1111/j.1523-1755.2005.00066.x
   Rosenthal EL, 1999, AM J OTOL, V20, P187
   Schapira AHV, 1999, EUR J CLIN INVEST, V29, P886
   SCHATZ G, 1995, BBA-MOL BASIS DIS, V1271, P123, DOI 10.1016/0925-4439(95)00018-Y
   SRERE PA, 1987, ANNU REV BIOCHEM, V56, P89, DOI 10.1146/annurev.bi.56.070187.000513
   TANAKA M, 1991, BIOCHEM BIOPH RES CO, V174, P861, DOI 10.1016/0006-291X(91)91497-Z
   Tay SKH, 2005, J CHILD NEUROL, V20, P142, DOI 10.1177/08830738050200022301
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   Yanagihara C, 2001, INTERNAL MED, V40, P662, DOI 10.2169/internalmedicine.40.662
   YANG CY, 1995, CLIN ENDOCRINOL, V43, P235, DOI 10.1111/j.1365-2265.1995.tb01922.x
   YONEDA M, 1989, J NEUROL SCI, V92, P143, DOI 10.1016/0022-510X(89)90132-9
NR 23
TC 17
Z9 17
U1 0
U2 3
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-1623
EI 
J9 INT UROL NEPHROL
JI Int. Urol. Nephrol.
PD SEP 15
PY 2007
VL 39
IS 3
BP 941
EP 946
DI 10.1007/s11255-006-9172-8
PG 6
WC Urology & Nephrology
SC Urology & Nephrology
GA 206WQ
UT WOS:000249214000047
PM 17294289
DA 2024-11-01
ER

PT J
AU Lin, CM
   Thajeb, P
AF Lin, Chih-Ming
   Thajeb, Peterus
TI Valproic acid aggravates epilepsy due to MELAS in a patient with an A3243G mutation of mitochondrial DNA
SO METABOLIC BRAIN DISEASE
LA English
DT Article
DE epilepsy; mitochondrial disease; valproate; valproic acid; MELAS
ID system buccal ganglia; c-oxidase deficiency; lactic-acidosis; helix-pomatia; encephalopathy; myopathy; episodes; diseases; failure; liver
AB Epilepsy is one of the most common presentations of patients with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS). MELAS is typically caused by an A-to-G substitution at nucleotide position 3243 of mitochondrial DNA. Valproic acid, a common anticonvulsant, can actually increase the frequency of seizures in individuals with MELAS. Here, we report a single case-study of a 38-year-old man who presented with focal seizures and had MELAS Syndrome due to the A3243G mitochondrial DNA mutation. Manifestation of epilepsia partialis continua was aggravated by use of valproic acid. Convulsions abated after discontinuation of valproic acid. Our experience suggests that valproic acid should be avoided for the treatment of epilepsy in individuals with mitochondrial disease.
C1 Mackay Mem Hosp, Dept Neurol, Taipei, Taiwan.
C3 Mackay Memorial Hospital
RP Lin, CM (corresponding author), Mackay Mem Hosp, Dept Neurol, 92 Chungshan N Rd,Sect 2, Taipei, Taiwan.
EM googlejoseph@yahoo.com.tw
CR ALTRUP U, 1992, EPILEPSIA, V33, P743, DOI 10.1111/j.1528-1157.1992.tb02356.x
   ALTRUP U, 1992, EPILEPSIA, V33, P753, DOI 10.1111/j.1528-1157.1992.tb02357.x
   Auré K, 2005, ANN PATHOL, V25, P270, DOI 10.1016/S0242-6498(05)80131-2
   CHABROL B, 1994, EUR J PEDIATR, V153, P133, DOI 10.1007/BF01959226
   Chinnery PF, 1997, BRAIN, V120, P1713, DOI 10.1093/brain/120.10.1713
   Dimauro S, 2005, ANN MED, V37, P222, DOI 10.1080/07853890510007368
   Krähenbühl S, 2000, LIVER, V20, P346, DOI 10.1034/j.1600-0676.2000.020004346.x
   Kunz WS, 2002, CURR OPIN NEUROL, V15, P179, DOI 10.1097/00019052-200204000-00009
   Lam CW, 1997, EUR J PEDIATR, V156, P562, DOI 10.1007/s004310050663
   LIOU CW, 1994, ACTA NEUROL SCAND, V90, P354
   Morris AAM, 1999, LIVER, V19, P357, DOI 10.1111/j.1478-3231.1999.tb00063.x
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   PONCHAUT S, 1995, EUR J PEDIATR, V154, P79, DOI 10.1007/BF01972980
   PONCHAUT S, 1992, BIOCHEM PHARMACOL, V43, P644, DOI 10.1016/0006-2952(92)90590-F
   Scaglia F, 2006, CNS DRUGS, V20, P443, DOI 10.2165/00023210-200620060-00002
NR 15
TC 56
Z9 68
U1 0
U2 2
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0885-7490
EI 1573-7365
J9 METAB BRAIN DIS
JI Metab. Brain Dis.
PD MAR 15
PY 2007
VL 22
IS 1
BP 105
EP 109
DI 10.1007/s11011-006-9039-9
PG 5
WC Endocrinology & Metabolism; Neurosciences
SC Endocrinology & Metabolism; Neurosciences & Neurology
GA 166HW
UT WOS:000246370800011
PM 17226098
DA 2024-11-01
ER

PT J
AU McKenzie, M
   Liolitsa, D
   Akinshina, N
   Campanella, M
   Sisodiya, S
   Hargreaves, I
   Nirmalananthan, N
   Sweeney, MG
   Abou-Sleiman, PM
   Wood, NW
   Hanna, MG
   Duchen, MR
AF McKenzie, Matthew
   Liolitsa, Danae
   Akinshina, Natalya
   Campanella, Michelangelo
   Sisodiya, Sanjay
   Hargreaves, Ian
   Nirmalananthan, Niranjanan
   Sweeney, Mary G.
   Abou-Sleiman, Patrick M.
   Wood, Nicholas W.
   Hanna, Michael G.
   Duchen, Michael R.
TI Mitochondrial <i>ND5</i> gene variation associated with encephalomyopathy and mitochondrial ATP consumption
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID hereditary optic neuropathy; stroke-like episodes; dna mutation; lactic-acidosis; melas; disease; encephalopathy; identification; fibroblasts; respiration
AB Mitochondrial encephalomyopathy and lactic acidosis with strokelike episodes ( MELAS) is a severe young onset stroke disorder without effective treatment. We have identified a MELAS patient harboring a 13528A -> G mitochondrial DNA ( mtDNA) mutation in the Complex I ND5 gene. This mutation was homoplasmic in mtDNA from patient muscle and nearly homoplasmic (99.9%) in blood. Fibroblasts from the patient exhibited decreased mitochondrial membrane potential (Delta psi(m)) and increased lactate production, consistent with impaired mitochondrial function. Transfer of patient mtDNA to a new nuclear background using transmitochondrial cybrid fusions confirmed the pathogenicity of the 13528A -> G mutation; Complex I-linked respiration and Delta psi(m) were both significantly reduced in patient mtDNA cybrids compared with controls. Inhibition of the adenine nucleotide translocase or the F1F0-ATPase with bongkrekic acid or oligomycin caused a loss of potential in patient mtDNA cybrid mitochondria, indicating a requirement for glycolytically generated ATP to maintain Delta psi(m). This was confirmed by inhibition of glycolysis with 2-deoxy-D-glucose, which caused depletion of ATP and mitochondrial depolarization in patient mtDNA cybrids. These data suggest that in response to impaired respiration due to the mtDNA mutation, mitochondria consume ATP to maintain Delta psi(m), representing a potential pathophysiological mechanism in human mitochondrial disease.
C1 [Akinshina, Natalya; Campanella, Michelangelo; Duchen, Michael R.] UCL, Dept Physiol, London WC1E 6BT, England.
   [McKenzie, Matthew] La Trobe Univ, Dept Biochem, Melbourne, Vic 3086, Australia.
   [Liolitsa, Danae; Nirmalananthan, Niranjanan; Hanna, Michael G.] UCL, Inst Neurol, MRC, Ctr Neuromuscular Dis, London WC1N 3BG, England.
   [Liolitsa, Danae; Hargreaves, Ian; Nirmalananthan, Niranjanan; Sweeney, Mary G.; Abou-Sleiman, Patrick M.; Wood, Nicholas W.; Hanna, Michael G.] UCL, Inst Neurol, Dept Mol Neurosci, London WC1N 3BG, England.
   [Sisodiya, Sanjay] UCL, Inst Neurol, Dept Clin & Expt Epilepsy, London WC1N 3BG, England.
C3 University of London; University College London; La Trobe University; University of London; University College London; University of London; University College London; University of London; University College London
RP Duchen, MR (corresponding author), UCL, Dept Physiol, Gower St, London WC1E 6BT, England.
EM m.duchen@ucl.ac.uk
FU Medical Research Council [G84/6699] Funding Source: Medline; Wellcome Trust Funding Source: Medline; MRC [G84/6699] Funding Source: UKRI
CR Appleby RD, 1999, EUR J BIOCHEM, V262, P108, DOI 10.1046/j.1432-1327.1999.00350.x
   AVNER PR, 1973, EUR J BIOCHEM, V32, P312, DOI 10.1111/j.1432-1033.1973.tb02612.x
   Batandier C, 2000, HUM MUTAT, V16, P532, DOI 10.1002/1098-1004(200012)16:6<532::AID-HUMU19>3.0.CO;2-P
   Bentlage HACM, 1996, HUM MOL GENET, V5, P197, DOI 10.1093/hmg/5.2.197
   Brown MD, 2000, J BIOL CHEM, V275, P39831, DOI 10.1074/jbc.M006476200
   Dimauro S, 2001, AM J MED GENET, V106, P18, DOI 10.1002/ajmg.1392
   Dimauro S, 2005, ANN MED, V37, P222, DOI 10.1080/07853890510007368
   Gajewski CD, 2003, MOL BIOL CELL, V14, P3628, DOI 10.1091/mbc.E02-12-0796
   GOTO Y, 1992, NEUROLOGY, V42, P545, DOI 10.1212/WNL.42.3.545
   Grover GJ, 2004, AM J PHYSIOL-HEART C, V287, PH1747, DOI 10.1152/ajpheart.01019.2003
   Herrnstadt C, 2002, AM J HUM GENET, V70, P1152, DOI 10.1086/339933
   Hofhaus G, 1996, J BIOL CHEM, V271, P13155, DOI 10.1074/jbc.271.22.13155
   Hudson G, 2005, AM J HUM GENET, V77, P1086, DOI 10.1086/498176
   Irwin WA, 2003, NAT GENET, V35, P367, DOI 10.1038/ng1270
   James AM, 1999, EUR J BIOCHEM, V259, P462, DOI 10.1046/j.1432-1327.1999.00066.x
   James AM, 1996, BIOCHEM J, V318, P401, DOI 10.1042/bj3180401
   KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480
   KOGA Y, 1995, MUSCLE NERVE, V0, PS119
   Leyssens A, 1996, J PHYSIOL-LONDON, V496, P111, DOI 10.1113/jphysiol.1996.sp021669
   Liolitsa D, 2003, ANN NEUROL, V53, P128, DOI 10.1002/ana.10435
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Man PYW, 2002, J MED GENET, V39, P162, DOI 10.1136/jmg.39.3.162
   McFarland R, 2002, NAT GENET, V30, P145, DOI 10.1038/ng819
   MOUDY AM, 1995, P NATL ACAD SCI USA, V92, P729, DOI 10.1073/pnas.92.3.729
   Pulkes T, 1999, ANN NEUROL, V46, P916, DOI 10.1002/1531-8249(199912)46:6<916::AID-ANA16>3.0.CO;2-R
   Santorelli FM, 1997, BIOCHEM BIOPH RES CO, V238, P326, DOI 10.1006/bbrc.1997.7167
   Saraste M, 1999, SCIENCE, V283, P1488, DOI 10.1126/science.283.5407.1488
   SCOTT ID, 1980, BIOCHEM J, V186, P21, DOI 10.1042/bj1860021
   Simbula G, 1997, AM J PHYSIOL-CELL PH, V273, PC479, DOI 10.1152/ajpcell.1997.273.2.C479
   St-Pierre J, 2000, P NATL ACAD SCI USA, V97, P8670, DOI 10.1073/pnas.140093597
   Trounce I A, 1996, METHODS ENZYMOL, V264, P484, DOI 10.1016/S0076-6879(96)64044-0
   Wallace DC, 2001, AM J MED GENET, V106, P71, DOI 10.1002/ajmg.1393
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
NR 33
TC 60
Z9 62
U1 0
U2 7
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD DEC 21
PY 2007
VL 282
IS 51
BP 36845
EP 36852
DI 10.1074/jbc.M704158200
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 241GX
UT WOS:000251646000009
PM 17940288
DA 2024-11-01
ER

PT J
AU Ling, JQ
   Roy, H
   Qin, DM
   Rubio, MAT
   Alfonzo, JD
   Fredrick, K
   Ibba, M
AF Ling, Jiqiang
   Roy, Herve
   Qin, Daoming
   Rubio, Mary Anne T.
   Alfonzo, Juan D.
   Fredrick, Kurt
   Ibba, Michael
TI Pathogenic mechanism of a human mitochondrial tRNA<SUP>Phe</SUP> mutation associated with myoclonic epilepsy with ragged red fibers syndrome
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
LA English
DT Article
DE aminoacyl-tRNA synthetase; translation; mitochondria
ID phenylalanyl-transfer-rna; elongation-factor tu; wobble modification deficiency; cytosolic transfer-rna; stroke-like episodes; mutant transfer-rnas; protein-synthesis; dna mutation; in-vitro; unmodified adenosine
AB Human mitochondrial tRNA (hmt-tRNA) mutations are associated with a variety of diseases including mitochondrial myopathies, diabetes, encephalopathies, and deafness. Because the current understanding of the precise molecular mechanisms of these mutations is limited, there is no efficient method to treat their associated mitochondrial diseases. Here, we use a variety of known mutations in hmt-tRNA(Phe) to investigate the mechanisms that lead to malfunctions. We tested the impact of hmt-tRNA(Phe) mutations on aminoacylation, structure, and translation elongation-factor binding. The majority of the mutants were pleiotropic, exhibiting defects in aminoacylation, global structure, and elongation-factor binding. One notable exception was the G34A anticodon mutation of hmt-tRNA(Phe) (mitochondrial DNA mutation G611A), which is associated with MERRF (myoclonic epilepsy with ragged red fibers). In vitro, the G34A mutation decreases aminoacylation activity by 100-fold, but does not affect global folding or recognition by elongation factor. Furthermore, G34A hmt-tRNA(Phe) does not undergo adenosine-to-inosine (A-to-I) editing, ruling out miscoding as a possible mechanism for mitochondrial malfunction. To improve the aminoacylation state of the mutant tRNA, we modified the tRNA binding domain of the nucleus-encoded human mitochondrial phenylalanyl-tRNA synthetase, which aminoacylates hmt-tRNA(Phe) with cognate phenylalanine. This variant enzyme displayed significantly improved aminoacylation efficiency for the G34A mutant, suggesting a general strategy to treat certain classes of mitochondrial diseases by modification of the corresponding nuclear gene.
C1 Ohio State Univ, Dept Microbiol, Columbus, OH 43210 USA.
   Ohio State Univ, Ohio State Biochem Program, Columbus, OH 43210 USA.
   Ohio State Univ, Ohio State RNA Grp, Columbus, OH 43210 USA.
C3 University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University
RP Ibba, M (corresponding author), Ohio State Univ, Dept Microbiol, 484 W 12th Ave, Columbus, OH 43210 USA.
EM ibba.1@osu.edu
FU NIGMS NIH HHS [GM072528, R01 GM072528] Funding Source: Medline
CR Agris PF, 2004, NUCLEIC ACIDS RES, V32, P223, DOI 10.1093/nar/gkh185
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   BOREN T, 1993, J MOL BIOL, V230, P739, DOI 10.1006/jmbi.1993.1196
   Börner GV, 2000, HUM MOL GENET, V9, P467, DOI 10.1093/hmg/9.4.467
   Bullard JN, 1999, J MOL BIOL, V288, P567, DOI 10.1006/jmbi.1999.2708
   Chen P, 2002, J MOL BIOL, V317, P481, DOI 10.1006/jmbi.2002.5435
   Chinnery PF, 1997, ANN NEUROL, V41, P408, DOI 10.1002/ana.410410319
   CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221
   Darin N, 2006, NEUROMUSCULAR DISORD, V16, P504, DOI 10.1016/j.nmd.2006.05.010
   Degoul F, 1998, HUM MOL GENET, V7, P347, DOI 10.1093/hmg/7.3.347
   Deschauer M, 2006, ARCH NEUROL-CHICAGO, V63, P902, DOI 10.1001/archneur.63.6.902
   DiMauro S, 2004, ANN NY ACAD SCI, V1011, P232, DOI 10.1196/annals.1293.023
   Feuermann M, 2003, EMBO REP, V4, P53, DOI 10.1038/sj.embor.embor713
   Flierl A, 1997, J BIOL CHEM, V272, P27189, DOI 10.1074/jbc.272.43.27189
   Florentz C, 2001, EMBO REP, V2, P481, DOI 10.1093/embo-reports/kve111
   Gerber AP, 2001, TRENDS BIOCHEM SCI, V26, P376, DOI 10.1016/S0968-0004(01)01827-8
   Gerber AP, 1999, SCIENCE, V286, P1146, DOI 10.1126/science.286.5442.1146
   Goldgur Y, 1997, STRUCTURE, V5, P59, DOI 10.1016/S0969-2126(97)00166-4
   Gromadski KB, 2004, MOL CELL, V13, P191, DOI 10.1016/S1097-2765(04)00005-X
   Hanna MG, 1998, J NEUROL NEUROSUR PS, V65, P512, DOI 10.1136/jnnp.65.4.512
   Helm M, 1999, BIOCHEMISTRY-US, V38, P13338, DOI 10.1021/bi991061g
   Helm M, 1999, NUCLEIC ACIDS RES, V27, P756, DOI 10.1093/nar/27.3.756
   Hunter SE, 2004, MITOCHONDRION, V4, P21, DOI 10.1016/j.mito.2004.04.003
   IBBA M, 1994, BIOCHEMISTRY-US, V33, P7107, DOI 10.1021/bi00189a013
   INAGAKI Y, 1995, J MOL BIOL, V251, P486, DOI 10.1006/jmbi.1995.0450
   Jacobs HT, 2005, TRENDS GENET, V21, P312, DOI 10.1016/j.tig.2005.04.003
   Kelley SO, 2000, NAT STRUCT BIOL, V7, P862, DOI 10.1038/79612
   KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480
   Kirino Y, 2005, P NATL ACAD SCI USA, V102, P7127, DOI 10.1073/pnas.0500563102
   Kirino Y, 2004, P NATL ACAD SCI USA, V101, P15070, DOI 10.1073/pnas.0405173101
   Kleinle S, 1998, BIOCHEM BIOPH RES CO, V247, P112, DOI 10.1006/bbrc.1998.8729
   Koga A, 2003, NEUROMUSCULAR DISORD, V13, P259, DOI 10.1016/S0960-8966(02)00267-5
   Kolesnikova OA, 2000, SCIENCE, V289, P1931, DOI 10.1126/science.289.5486.1931
   Kolesnikova OA, 2004, HUM MOL GENET, V13, P2519, DOI 10.1093/hmg/ddh267
   KUMAZAWA Y, 1991, BIOCHIM BIOPHYS ACTA, V1090, P167, DOI 10.1016/0167-4781(91)90097-6
   LAGERKVIST U, 1978, P NATL ACAD SCI USA, V75, P1759, DOI 10.1073/pnas.75.4.1759
   Levinger L, 2004, NUCLEIC ACIDS RES, V32, P5430, DOI 10.1093/nar/gkh884
   Levinger L, 2003, NUCLEIC ACIDS RES, V31, P1904, DOI 10.1093/nar/gkg282
   Levinger L, 2001, NUCLEIC ACIDS RES, V29, P4334, DOI 10.1093/nar/29.21.4334
   LING J, 2007, IN PRESS RNA, V0, P0
   Ling J, 2007, P NATL ACAD SCI USA, V104, P72, DOI 10.1073/pnas.0606272104
   Mahata B, 2006, SCIENCE, V314, P471, DOI 10.1126/science.1129754
   Mancuso M, 2004, NEUROLOGY, V62, P2119, DOI 10.1212/01.WNL.0000127608.48406.F1
   MORAES CT, 1993, NAT GENET, V4, P284, DOI 10.1038/ng0793-284
   Moslemi AR, 2004, NEUROMUSCULAR DISORD, V14, P46, DOI 10.1016/S0960-8966(03)00168-8
   Ogle JM, 2005, ANNU REV BIOCHEM, V74, P129, DOI 10.1146/annurev.biochem.74.061903.155440
   Park H, 2003, BIOCHEMISTRY-US, V42, P958, DOI 10.1021/bi026882r
   PETERSON ET, 1992, BIOCHEMISTRY-US, V31, P10380, DOI 10.1021/bi00157a028
   RINALDI T, 1994, CURR GENET, V25, P451, DOI 10.1007/BF00351785
   Rossmanith W, 1998, FEBS LETT, V433, P269, DOI 10.1016/S0014-5793(98)00928-4
   Roy H, 2004, EMBO J, V23, P4639, DOI 10.1038/sj.emboj.7600474
   Rubio MAT, 2006, J BIOL CHEM, V281, P115, DOI 10.1074/jbc.M510136200
   SAMPSON JR, 1992, BIOCHEMISTRY-US, V31, P4161, DOI 10.1021/bi00132a002
   SANNI A, 1991, P NATL ACAD SCI USA, V88, P8387, DOI 10.1073/pnas.88.19.8387
   SCHWARTZBACH CJ, 1989, J BIOL CHEM, V264, P19125
   SIBLER AP, 1986, FEBS LETT, V194, P131, DOI 10.1016/0014-5793(86)80064-3
   Sissler M, 2004, RNA, V10, P841, DOI 10.1261/rna.5267604
   Smith PM, 2004, BBA-BIOENERGETICS, V1659, P232, DOI 10.1016/j.bbabio.2004.09.003
   Sohm B, 2003, J MOL BIOL, V328, P995, DOI 10.1016/S0022-2836(03)00373-5
   Taivassalo T, 1999, HUM MOL GENET, V8, P1047, DOI 10.1093/hmg/8.6.1047
   Tanaka M, 2002, J BIOMED SCI, V9, P534, DOI 10.1007/BF02254980
   Tomari Y, 2003, J BIOL CHEM, V278, P16828, DOI 10.1074/jbc.M213216200
   Toompuu M, 2002, J BIOL CHEM, V277, P22240, DOI 10.1074/jbc.M200338200
   Tzen CY, 2001, KIDNEY INT, V59, P846, DOI 10.1046/j.1523-1755.2001.00567.x
   WAKITA K, 1994, NUCLEIC ACIDS RES, V22, P347, DOI 10.1093/nar/22.3.347
   Watanabe Y, 1997, BBA-GENE STRUCT EXPR, V1350, P119, DOI 10.1016/S0167-4781(96)00211-4
   Wittenhagen LM, 2003, TRENDS BIOCHEM SCI, V28, P605, DOI 10.1016/j.tibs.2003.09.006
   Wittenhagen LM, 2002, NAT STRUCT BIOL, V9, P586, DOI 10.1038/nsb820
   Woriax VL, 1995, BBA-GENE STRUCT EXPR, V1264, P347, DOI 10.1016/0167-4781(95)00176-X
   Yasukawa T, 2000, J BIOL CHEM, V275, P4251, DOI 10.1074/jbc.275.6.4251
   Yasukawa T, 2000, FEBS LETT, V467, P175, DOI 10.1016/S0014-5793(00)01145-5
   Yasukawa T, 2001, EMBO J, V20, P4794, DOI 10.1093/emboj/20.17.4794
NR 72
TC 35
Z9 47
U1 1
U2 12
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
EI 
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD SEP 25
PY 2007
VL 104
IS 39
BP 15299
EP 15304
DI 10.1073/pnas.0704441104
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 215KJ
UT WOS:000249806900025
PM 17878308
DA 2024-11-01
ER

PT J
AU Rodriguez, MC
   MacDonald, JR
   Mahoney, DJ
   Parise, G
   Beal, MF
   Tarnopolsky, MA
AF Rodriguez, M. Christine
   MacDonald, Jay R.
   Mahoney, Douglas J.
   Parise, Gianni
   Beal, M. Flint
   Tarnopolsky, Mark A.
TI Beneficial effects of creatine, CoQ<sub>10</sub>, and lipoic acid in mitochondrial disorders
SO MUSCLE & NERVE
LA English
DT Article
DE coenzyme Q(10); creatine; lipoic acid; mitochondrial cytopathy; randomized trial
ID double-blind; cofactor treatment; pediatric-patients; multiple vitamins; body-composition; coenzyme q(10); monohydrate; dna; myopathy; strength
AB Mitochondrial disorders share common cellular consequences: (1) decreased ATP production; (2) increased reliance on alternative anaerobic energy sources; and (3) increased production of reactive oxygen species. The purpose of the present study was to determine the effect of a combination therapy (creatine monohydrate, coenzyme Q(10), and lipoic acid to target the above-mentioned cellular consequences) on several outcome variables using a randomized, double-blind, placebo-controlled, crossover study design in patients with mitochondrial cytopathies. Three patients had mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS), four had mitochondrial DNA deletions (three patients with chronic progressive external ophthalmoplegia and one with Kearns-Sayre syndrome), and nine had a variety of other mitochondrial diseases not falling into the two former groups. The combination therapy resulted in lower resting plasma lactate and urinary 8-isoprostanes, as well as attenuation of the decline in peak ankle dorsiflexion strength in all patient groups, whereas higher fat-free mass was observed only in the MELAS group. Together, these results suggest that combination therapies targeting multiple final common pathways of mitochondrial dysfunction favorably influence surrogate markers of cellular energy dysfunction. Future studies with larger sample sizes in relatively homogeneous groups will be required to determine whether such combination therapies influence function and quality of life.
C1 McMaster Univ, Dept Pediat, Hamilton, ON L8N 3Z5, Canada.
   McMaster Univ, Dept Kinesiol, Hamilton, ON L8N 3Z5, Canada.
   McMaster Univ, Dept Med, Hamilton, ON L8N 3Z5, Canada.
   Cornell Univ, Weill Med Coll, Dept Neurol & Neurosci, New York, NY 10021 USA.
C3 McMaster University; McMaster University; McMaster University; Cornell University; Weill Cornell Medicine
RP Tarnopolsky, MA (corresponding author), McMaster Univ, Dept Pediat, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada.
EM tarnopol@mcmaster.ca
CR Artuch R, 1998, J INHERIT METAB DIS, V21, P837, DOI 10.1023/A:1005470702369
   Berbel-Garcia A, 2004, CLIN NEUROPHARMACOL, V27, P187, DOI 10.1097/01.wnf.0000137862.67131.bf
   Bogdanov MB, 1999, FREE RADICAL BIO MED, V27, P647, DOI 10.1016/S0891-5849(99)00113-6
   BRESOLIN N, 1990, J NEUROL SCI, V100, P70, DOI 10.1016/0022-510X(90)90015-F
   Brose A, 2003, J GERONTOL A-BIOL, V58, P11
   Burke DG, 2003, INT J SPORT NUTR EXE, V13, P294, DOI 10.1123/ijsnem.13.3.294
   Canter JA, 2005, FREE RADICAL BIO MED, V38, P678, DOI 10.1016/j.freeradbiomed.2004.11.031
   Chariot P, 1999, MOVEMENT DISORD, V14, P855, DOI 10.1002/1531-8257(199909)14:5<855::AID-MDS1023>3.0.CO;2-9
   Chen RS, 1997, EUR NEUROL, V37, P212, DOI 10.1159/000117445
   Geromel V, 2002, MOL GENET METAB, V77, P21, DOI 10.1016/S1096-7192(02)00145-2
   HARRIS RC, 1992, CLIN SCI, V83, P367, DOI 10.1042/cs0830367
   Klopstock T, 2000, NEUROLOGY, V55, P1748, DOI 10.1212/WNL.55.11.1748
   Komura K, 2003, PEDIATR NEUROL, V28, P53, DOI 10.1016/S0887-8994(02)00469-1
   Kornblum C, 2005, EUR J NEUROL, V12, P300, DOI 10.1111/j.1468-1331.2004.00970.x
   Lawler JM, 2002, BIOCHEM BIOPH RES CO, V290, P47, DOI 10.1006/bbrc.2001.6164
   Mahoney DJ, 2002, CURR OPIN CLIN NUTR, V5, P619, DOI 10.1097/00075197-200211000-00004
   Marangon K, 1999, FREE RADICAL BIO MED, V27, P1114, DOI 10.1016/S0891-5849(99)00155-0
   Marriage B, 2003, J AM DIET ASSOC, V103, P1029, DOI 10.1016/S0002-8223(03)00476-0
   Marriage BJ, 2004, MOL GENET METAB, V81, P263, DOI 10.1016/j.ymgme.2003.12.008
   MATTHEWS PM, 1993, NEUROLOGY, V43, P884, DOI 10.1212/WNL.43.5.884
   Migliore L, 2004, MUTAGENESIS, V19, P43, DOI 10.1093/mutage/geg036
   Milne GL, 2005, BIOMARKERS, V10, PS10, DOI 10.1080/13547500500216546
   Montine KS, 2004, CHEM PHYS LIPIDS, V128, P117, DOI 10.1016/j.chemphyslip.2003.10.010
   Montuschi P, 2004, FASEB J, V18, P1791, DOI 10.1096/fj.04-2330rev
   Napolitano A, 2000, NEUROL SCI, V21, PS981, DOI 10.1007/s100720070015
   Panetta J, 2004, J INHERIT METAB DIS, V27, P487, DOI 10.1023/B:BOLI.0000037354.66587.38
   PETERSON PL, 1995, BBA-MOL BASIS DIS, V1271, P275, DOI 10.1016/0925-4439(95)00039-7
   Rodriguez MC, 2003, FREE RADICAL BIO MED, V34, P1217, DOI 10.1016/S0891-5849(03)00141-2
   Schmiedel J, 2003, J NEUROL, V250, P267, DOI 10.1007/s00415-003-0978-3
   Sestili P, 2006, FREE RADICAL BIO MED, V40, P837, DOI 10.1016/j.freeradbiomed.2005.10.035
   Smith AR, 2004, CURR MED CHEM, V11, P1135, DOI 10.2174/0929867043365387
   Tanaka J, 1997, BRAIN DEV-JPN, V19, P262, DOI 10.1016/S0387-7604(97)00573-1
   Tarnopolsky M, 1999, NEUROLOGY, V52, P854, DOI 10.1212/WNL.52.4.854
   Tarnopolsky MA, 2005, MED SCI SPORT EXER, V37, P2086, DOI 10.1249/01.mss.0000177341.89478.06
   Tarnopolsky MA, 2004, NEUROLOGY, V62, P1771, DOI 10.1212/01.WNL.0000125178.18862.9D
   Tarnopolsky MA, 1999, MUSCLE NERVE, V22, P1228, DOI 10.1002/(SICI)1097-4598(199909)22:9<1228::AID-MUS9>3.3.CO;2-Y
   Tarnopolsky MA, 1997, MUSCLE NERVE, V20, P1502, DOI 10.1002/(SICI)1097-4598(199712)20:12<1502::AID-MUS4>3.0.CO;2-C
   Tarnopolsky MA, 2001, ANN NEUROL, V49, P561, DOI 10.1002/ana.1028.abs
   Yen MY, 2004, INVEST OPHTH VIS SCI, V45, P1688, DOI 10.1167/iovs.03-0568
NR 39
TC 195
Z9 214
U1 0
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0148-639X
EI 1097-4598
J9 MUSCLE NERVE
JI Muscle Nerve
PD FEB 15
PY 2007
VL 35
IS 2
BP 235
EP 242
DI 10.1002/mus.20688
PG 8
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 132LM
UT WOS:000243944300014
PM 17080429
DA 2024-11-01
ER

PT J
AU Ruiter, EM
   Siers, MH
   van den Elzen, C
   van Engelen, BG
   Smeitink, JAM
   Rodenburg, RJ
   Hol, FA
AF Ruiter, E. Mariken
   Siers, Marloes H.
   van den Elzen, Christa
   van Engelen, Baziel G.
   Smeitink, Jan A. M.
   Rodenburg, Richard J.
   Hol, Frans A.
TI The mitochondrial 13513G&gt;A mutation is most frequent in Leigh syndrome combined with reduced complex I activity, optic atrophy and/or Wolff-Parkinson-White
SO EUROPEAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
DE Leigh syndrome; MELAS; mitochondrial disease; mtDNA; pyrosequencing
ID dna g13513a mutation; preexcitation syndrome; nd5 subunit; melas; gene; deficiency; neuropathy; pathology; disease; nadh
AB The m.13513G > A transition in the mitochondrial gene encoding the ND5 subunit of respiratory chain complex I, can cause mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes ( MELAS) and has been reported to be a frequent cause of Leigh syndrome (LS). We determined the frequency of the mutation in a cohort of 123 patients with reduced complex I activity in muscle (n = 113) or fibroblast (n = 10) tissue. We describe a Pyrosequencing (TM) assay for rapid detection and quantification of the m. 13513G > A mutation. Two patients with the mutation were identified; both had LS, optical atrophy and a Wolff-Parkinson-White Syndrome (WPWS)-like cardiac conduction defect. The clinical presentation of the m. 13513G > A mutation is discussed. We conclude that the m. 13513G > A mutation seems not as frequent as previously suggested and is most likely to be present in patients with Leigh (-like) syndrome combined with a complex I deficiency, optic atrophy and/ or WPWS. In addition, we confirmed that the adjacent m.13514A > G mutation is a rare cause of LS or MELAS since no cases with this transition were found.
C1 Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, NL-6500 HB Nijmegen, Netherlands.
   Radboud Univ Nijmegen, Med Ctr, Dept Neurol, NL-6500 HB Nijmegen, Netherlands.
   Radboud Univ Nijmegen, Med Ctr, Dept Pediat, NL-6500 HB Nijmegen, Netherlands.
   Radboud Univ Nijmegen, Med Ctr, Nijmegen Ctr Mitochondrial Disorders, Lab Pediat & Neurol, NL-6500 HB Nijmegen, Netherlands.
C3 Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen
RP Ruiter, EM (corresponding author), Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, 849,UMC St Radboud,POB 9101, NL-6500 HB Nijmegen, Netherlands.
EM m.ruiter@antrg.umcn.nl
CR Bentlage HACM, 1996, NEUROLOGY, V47, P243, DOI 10.1212/WNL.47.1.243
   Biggin A, 2005, MOL GENET METAB, V84, P61, DOI 10.1016/j.ymgme.2004.09.011
   Budde SMS, 2002, MITOCHONDRION, V2, P109, DOI 10.1016/S1567-7249(02)00035-1
   Bugiani M, 2004, BBA-BIOENERGETICS, V1659, P136, DOI 10.1016/j.bbabio.2004.09.006
   Chol M, 2003, J MED GENET, V40, P188, DOI 10.1136/jmg.40.3.188
   Corona P, 2001, ANN NEUROL, V49, P106, DOI 10.1002/1531-8249(200101)49:1<106::AID-ANA16>3.0.CO;2-T
   Kirby DM, 2003, ANN NEUROL, V54, P473, DOI 10.1002/ana.10687
   Lebon S, 2003, J MED GENET, V40, P896, DOI 10.1136/jmg.40.12.896
   Liolitsa D, 2003, ANN NEUROL, V53, P128, DOI 10.1002/ana.10435
   Löwik MM, 2005, NEPHROL DIAL TRANSPL, V20, P336, DOI 10.1093/ndt/gfh546
   Mashima Y, 1996, CLIN GENET, V50, P535
   NIKOSKELAINEN EK, 1994, LANCET, V344, P857, DOI 10.1016/S0140-6736(94)92830-4
   Penisson-Besnier I, 2000, NEUROLOGY, V55, P317, DOI 10.1212/WNL.55.2.317
   Petruzzella V, 2003, NEUROLOGY, V61, P1017, DOI 10.1212/01.WNL.0000080363.10902.E9
   Pulkes T, 1999, ANN NEUROL, V46, P916, DOI 10.1002/1531-8249(199912)46:6<916::AID-ANA16>3.0.CO;2-R
   Ronaghi M, 2001, GENOME RES, V11, P3, DOI 10.1101/gr.11.1.3
   Santorelli FM, 1997, BIOCHEM BIOPH RES CO, V238, P326, DOI 10.1006/bbrc.1997.7167
   Smeitink J, 2001, NAT REV GENET, V2, P342, DOI 10.1038/35072063
   Smeitink J, 2001, J BIOENERG BIOMEMBR, V33, P259, DOI 10.1023/A:1010743321800
   Sudo A, 2004, J HUM GENET, V49, P92, DOI 10.1007/s10038-003-0116-1
   White HE, 2005, GENET TEST, V9, P190, DOI 10.1089/gte.2005.9.190
   Wilson FH, 2004, SCIENCE, V306, P1190, DOI 10.1126/science.1102521
NR 22
TC 49
Z9 55
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1018-4813
EI 
J9 EUR J HUM GENET
JI Eur. J. Hum. Genet.
PD FEB 15
PY 2007
VL 15
IS 2
BP 155
EP 161
DI 10.1038/sj.ejhg.5201735
PG 7
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 127DN
UT WOS:000243565600006
PM 17106447
DA 2024-11-01
ER

PT J
AU Adhihetty, PJ
   Taivassalo, T
   Haller, RG
   Walkinshaw, DR
   Hood, DA
AF Adhihetty, Peter J.
   Taivassalo, Tanja
   Haller, Ronald G.
   Walkinshaw, Donald R.
   Hood, David A.
TI The effect of training on the expression of mitochondrial biogenesis- and apoptosis-related proteins in skeletal muscle of patients with mtDNA defects
SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
LA English
DT Article
ID transcription factor-a; ragged-red fibers; contractile activity; antioxidant enzymes; cytochrome-c; oxidative capacity; coactivator pgc-1; mammalian-cells; thyroid-hormone; mutation load
AB The effect of training on the expression of mitochondrial biogenesis-and apoptosis-related proteins in skeletal muscle of patients with mtDNA defects. Am J Physiol Endocrinol Metab293: E672-E680, 2007. First published June 5, 2007; doi:10.1152/ajpendo.00043.2007. - Mitochondrial myopathy patients ( MMPs) have impaired oxidative phosphorylation and exercise intolerance. Endurance training of MMPs improves exercise tolerance, but also increases mutational load. To assess the regulation of mitochondrial content in MMPs, we measured proteins involved in 1) biogenesis, 2) oxidative stress, and 3) apoptosis in MMPs and healthy controls (HCs) both before and after endurance training. Before training, MMPs had a greater mitochondrial content, along with a 1.4-fold ( P < 0.05) higher expression of the biogenesis regulator peroxisome proliferator-activated receptor-gamma coactivator-1 alpha (PGC- 1 alpha). The DNA repair enzyme 8-oxoguanine DNA glycolase-1 (OGG-1), the antioxidant manganese superoxide dismutase (MnSOD), and the apoptotic proteins AIF and Bcl-2 were higher in MMPs compared with HCs. Aconitase, an enzyme sensitive to oxidative stress, was 52% lower ( P < 0.05) in MMPs when calculated based on an estimate of mitochondrial volume and oxidative stress-induced protein modifications tended to be higher in MMPs compared with HCs. Endurance training ( ET) induced increases in mitochondrial content in both HC subjects and MMPs, but there was no effect of training on the regulatory proteins Tfam or PGC- 1 alpha. In MMPs, training induced a selective reduction of OGG-1, an increase in MnSOD, and a reduction in aconitase activity. Thus, before training, MMPs exhibited an adaptive response of nuclear proteins indicative of a compensatory increase in mitochondrial content. Following training, several parallel adaptations occurred in MMPs and HCs, which may contribute to previously observed functional improvements of exercise in MMPs. However, our results indicate that muscle from MMPs may be exposed to greater levels of oxidative stress during the course of training. Further investigation is required to evaluate the long-term benefits of endurance training as a therapeutic intervention for mitochondrial myopathy patients.
C1 York Univ, Sch Kinesiol & Hlth Sci, N York, ON M3J 1P3, Canada.
   York Univ, Dept Biol, N York, ON M3J 1P3, Canada.
   Utah Southwestern Med Ctr, Inst Exercise & Environm Med, Dallas, TX USA.
   McGill Univ, Dept Kinesiol & Phys Educ, Montreal, PQ, Canada.
C3 York University - Canada; York University - Canada; McGill University
RP Hood, DA (corresponding author), York Univ, Sch Kinesiol & Hlth Sci, N York, ON M3J 1P3, Canada.
EM dhood@yorku.ca
CR Adhihetty PJ, 2003, EXP PHYSIOL, V88, P99, DOI 10.1113/eph8802505
   Baar K, 2002, FASEB J, V16, P1879, DOI 10.1096/fj.02-0367com
   Bengtsson J, 2001, PFLUG ARCH EUR J PHY, V443, P61, DOI 10.1007/s004240100628
   Biswas G, 1999, EMBO J, V18, P522, DOI 10.1093/emboj/18.3.522
   Bohr VA, 2002, GENE, V286, P127, DOI 10.1016/S0378-1119(01)00813-7
   BOULET L, 1992, AM J HUM GENET, V51, P1187
   CHOMYN A, 1991, MOL CELL BIOL, V11, P2236, DOI 10.1128/MCB.11.4.2236
   de Souza-Pinto NC, 2001, CANCER RES, V61, P5378
   Di Giovanni S, 2001, MOL CELL NEUROSCI, V17, P696, DOI 10.1006/mcne.2001.0970
   DiMauro S, 2005, CURR OPIN NEUROL, V18, P538, DOI 10.1097/01.wco.0000179761.63486.1a
   Dimauro S, 2005, ANN MED, V37, P222, DOI 10.1080/07853890510007368
   Ekstrand MI, 2004, HUM MOL GENET, V13, P935, DOI 10.1093/hmg/ddh109
   GARDNER PR, 1995, J BIOL CHEM, V270, P13399, DOI 10.1074/jbc.270.22.13399
   Gordon JW, 2001, J APPL PHYSIOL, V90, P389, DOI 10.1152/jappl.2001.90.1.389
   Grey JY, 2000, AM J PHYSIOL-CELL PH, V279, PC1393, DOI 10.1152/ajpcell.2000.279.5.C1393
   Hamilton KL, 2001, AM J PHYSIOL-HEART C, V281, PH1346, DOI 10.1152/ajpheart.2001.281.3.H1346
   HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614
   Huang CC, 2002, J BIOMED SCI, V9, P527, DOI 10.1007/BF02254979
   Hudson EK, 1998, FREE RADICAL RES, V29, P573, DOI 10.1080/10715769800300611
   Irrcher I, 2003, AM J PHYSIOL-CELL PH, V284, PC1669, DOI 10.1152/ajpcell.00409.2002
   Jeppesen TD, 2003, ANN NEUROL, V54, P86, DOI 10.1002/ana.10594
   Joseph AM, 2004, AM J PHYSIOL-CELL PH, V286, PC867, DOI 10.1152/ajpcell.00191.2003
   Kunishige M, 2003, MUSCLE NERVE, V28, P484, DOI 10.1002/mus.10466
   Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904
   Ljubicic V, 2004, J APPL PHYSIOL, V97, P976, DOI 10.1152/japplphysiol.00336.2004
   Mirabella M, 2000, BRAIN, V123, P93, DOI 10.1093/brain/123.1.93
   Miranda S, 1999, BIOCHEM BIOPH RES CO, V258, P44, DOI 10.1006/bbrc.1999.0580
   MULLERHOCKER J, 1990, J NEUROL SCI, V100, P14, DOI 10.1016/0022-510x(90)90006-9
   ORNATSKY OI, 1995, BIOCHEM J, V311, P119, DOI 10.1042/bj3110119
   PFANNER N, 1997, CURR BIOL, V7, P100
   Pilegaard H, 2005, METABOLISM, V54, P1048, DOI 10.1016/j.metabol.2005.03.008
   Rungi AA, 2002, BBA-MOL BASIS DIS, V1586, P146, DOI 10.1016/S0925-4439(01)00072-2
   Rusanen H, 2000, BBA-MOL BASIS DIS, V1500, P10, DOI 10.1016/S0925-4439(99)00081-2
   Schneider JJ, 2000, J ENDOCRINOL, V165, P9, DOI 10.1677/joe.0.1650009
   SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834
   SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771
   SHOUBRIDGE EA, 1994, J BIOENERG BIOMEMBR, V26, P301, DOI 10.1007/BF00763101
   SHULL S, 1991, J BIOL CHEM, V266, P24398
   Taivassalo T, 1999, MUSCLE NERVE, V22, P1239, DOI 10.1002/(SICI)1097-4598(199909)22:9<1239::AID-MUS11>3.0.CO;2-W
   Taivassalo T, 2001, ANN NEUROL, V50, P133, DOI 10.1002/ana.1050
   Taivassalo T, 2003, BRAIN, V126, P413, DOI 10.1093/brain/awg028
   Takahashi M, 1998, AM J PHYSIOL-CELL PH, V274, PC1380, DOI 10.1152/ajpcell.1998.274.5.C1380
   TERJUNG RL, 1979, BIOCHEM J, V178, P569, DOI 10.1042/bj1780569
   Umaki Y, 2002, ACTA NEUROPATHOL, V103, P163
   van Empel VPM, 2005, CIRC RES, V96, PE92, DOI 10.1161/01.RES.0000172081.30327.28
   Winder WW, 2000, J APPL PHYSIOL, V88, P2219, DOI 10.1152/jappl.2000.88.6.2219
   Wright DC, 2007, J BIOL CHEM, V282, P194, DOI 10.1074/jbc.M606116200
   Wu H, 2002, SCIENCE, V296, P349, DOI 10.1126/science.1071163
   Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X
   Zhang DK, 2000, GENOMICS, V69, P151, DOI 10.1006/geno.2000.6333
NR 50
TC 52
Z9 62
U1 0
U2 5
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0193-1849
EI 
J9 AM J PHYSIOL-ENDOC M
JI Am. J. Physiol.-Endocrinol. Metab.
PD SEP 15
PY 2007
VL 293
IS 3
BP E672
EP E680
DI 10.1152/ajpendo.00043.2007
PG 9
WC Endocrinology & Metabolism; Physiology
SC Endocrinology & Metabolism; Physiology
GA 208YJ
UT WOS:000249354800006
PM 17551003
DA 2024-11-01
ER

PT J
AU Whittaker, RG
   Schaefer, AM
   McFarland, R
   Taylor, RW
   Walker, M
   Turnbull, DM
AF Whittaker, R. G.
   Schaefer, A. M.
   McFarland, R.
   Taylor, R. W.
   Walker, M.
   Turnbull, D. M.
TI Prevalence and progression of diabetes in mitochondrial disease
SO DIABETOLOGIA
LA English
DT Article
DE diabetes; genotype; heteroplasmy; mitochondria; mutations; prevalence; progression
ID dna mutation; diagnosis; myopathy; melas
AB Aims/Hypothesis The aims of this study were (1) to determine the prevalence and rate of progression in diabetes secondary to mitochondrial DNA (mtDNA) mutations; and (2) to determine whether percentage heteroplasmy predicts clinical outcome in patients carrying the m.3243A > G mutation. Methods We prospectively assessed 242 patients attending a specialist neuromuscular clinic using a validated mitochondrial disease rating scale. Retrospective clinical data on these patients from up to 25 years of follow-up were also included. Percentage heteroplasmy in blood, urine and muscle was determined for the m.3243A > G group and correlated against clinical features. Results Patients carrying the m.3243A > G mutation formed the largest group of patients with diabetes (31/81 patients). The highest prevalence of diabetes was in the m.12258C > A group (2/2 patients), the lowest in the multiple mtDNA deletions group (3/43 patients). The earliest age of onset was in the m.3243A > G group (37.9 years) with the highest age of presentation in the multiple deletion group (56.3 years). Of patients presenting with m.3243A > G, 12.9% required insulin; an additional 32.3% progressed to insulin requirement over a mean of 4.2 years after presentation. Percentage heteroplasmy in blood, urine or muscle did not predict progression of diabetes or risk of developing complications. Early age of presentation with diabetes did predict poor clinical outcome. Conclusion/Interpretation Although patients carrying the m.3243A > G mutation account for the majority of cases of diabetes secondary to mtDNA mutations, several other genotypes are also associated with the development of diabetes, some with high penetrance. All show a gradual progression to insulin requirement. Percentage heteroplasmy is a poor predictor of severity of diabetes in the m.3243A > G group.
C1 Newcastle Univ, Mitochondrial Res Grp, Sch Neurol Neurobiol & Psychiat, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   Newcastle Univ, Diabet Res Grp, Sch Clin Med Sci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
C3 Newcastle University - UK; Newcastle University - UK
RP Whittaker, RG (corresponding author), Newcastle Univ, Mitochondrial Res Grp, Sch Neurol Neurobiol & Psychiat, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM r.whittaker@ncl.ac.uk
FU MRC [G108/539] Funding Source: UKRI
CR Adler AI, 2003, KIDNEY INT, V63, P225, DOI 10.1046/j.1523-1755.2003.00712.x
   ALBERTI KGM, 1999, DEFINITION DIAGNOS 1, V0, P0
   BALLINGER SW, 1992, NAT GENET, V1, P11, DOI 10.1038/ng0492-11
   Blakely EL, 2004, J MED GENET, V41, P0, DOI 10.1136/jmg.2003.011296
   Chinnery PF, 1999, AM J MED GENET, V85, P498
   Chinnery PF, 1997, BRAIN, V120, P1713, DOI 10.1093/brain/120.10.1713
   DUNBAR DR, 1993, HUM MOL GENET, V2, P1619, DOI 10.1093/hmg/2.10.1619
   HANNA MG, 1995, AM J HUM GENET, V56, P1026
   Kiechl S, 2004, J NEUROL NEUROSUR PS, V75, P1125, DOI 10.1136/jnnp.2003.025890
   Lynn S, 2003, DIABETOLOGIA, V46, P296, DOI 10.1007/s00125-002-1018-z
   Maassen JA, 2004, DIABETES, V53, PS103, DOI 10.2337/diabetes.53.2007.S103
   McDonnell MT, 2004, EUR J HUM GENET, V12, P778, DOI 10.1038/sj.ejhg.5201216
   McFarland R, 2004, ANN NEUROL, V55, P478, DOI 10.1002/ana.20004
   *NIH, 2005, NAT DIAB STAT FACT S, V0, P0
   Ohkubo K, 2001, CLIN CHEM, V47, P1641
   Rahman S, 2001, AM J HUM GENET, V68, P238, DOI 10.1086/316930
   Schaefer AM, 2006, NEUROLOGY, V66, P1932, DOI 10.1212/01.wnl.0000219759.72195.41
   SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/NEJM199307293290502
   Taylor RW, 2001, NUCLEIC ACIDS RES, V29, Part. no., DOI 10.1093/nar/29.15.e74
   Taylor RW, 2004, NEUROMUSCULAR DISORD, V14, P237, DOI 10.1016/j.nmd.2003.12.004
   Walker M, 2005, DIABETIC MED, V22, P18, DOI 10.1111/j.1464-5491.2005.1761f.x
NR 21
TC 55
Z9 59
U1 1
U2 4
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0012-186X
EI 1432-0428
J9 DIABETOLOGIA
JI Diabetologia
PD OCT 15
PY 2007
VL 50
IS 10
BP 2085
EP 2089
DI 10.1007/s00125-007-0779-9
PG 5
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 208DI
UT WOS:000249299600009
PM 17653689
DA 2024-11-01
ER

PT J
AU Schoeler, S
   Hertel, S
   Haroon, MF
   Winkler-Stuck, K
   Mawrin, C
   Kirches, E
AF Schoeler, S.
   Hertel, S.
   Haroon, M. F.
   Winkler-Stuck, K.
   Mawrin, C.
   Kirches, E.
TI Absence of major accumulation of mitochondrial ND5 mutations in Parkinson patient muscle
SO CLINICAL NEUROPATHOLOGY
LA English
DT Article
DE Parkinson; mitochondria; mtDNA; oxidative stress; complex I; ND5
ID complex-i; respiratory-chain; skeletal-muscle; disease; abnormality; defects
AB The pathogenesis of the selective loss of dopaminergic neurons in idiopathic Parkinson's disease (PD) has not been understood up to now. Respiratory chain dysfunction and accumulation of mitochondrial DNA deletions to biochemically relevant levels have been observed in the dopaminergic neurons. However, respiratory chain defects have also been reported in other tissues, pointing to a generalized component of oxidative stress in PD. Recently, somatic point mutations in a narrow region of the complex I polypeptide ND5 (codons 120 - 150) were suggested to separate PD patients from age-matched controls, using frontal cortex homogenates. Objective: The present study intended to analyze whether those recently described ND5 mutations may also generally occur in skeletal muscle tissue of PD patients, in which complex I dysfunction had been measured earlier with biochemical approaches. Material: Skeletal muscle biopsy samples of 5 PD individuals with a previously characterized biochemical complex I defect and of 5 age-matched controls were used. Method: DNA was extracted from the muscle samples. The relevant ND5 region was PCR-cloned using a high fidelity Pfu polymerase and a low number of PCR cycles (15). A mean number of 96 clones were randomly selected from the ampicillin plates and sequenced by the dye terminator method to allow the detection of low abundance mutations with a sensitivity around 1%. Results: Mutations between codons 120 and 150 were only slightly more frequent in PD versus controls (60 versus 40% of samples affected), while this ratio had been 100 versus 12.5% in frontal cortex. Conclusions: In contrast to results reported for PD frontal cortex, low-level ND5 mutations between codons 120 and 150 do not accumulate severely in biochemically affected skeletal muscle samples of PD patients.
C1 Otto Von Guericke Univ, Inst Neuropathol, D-39120 Magdeburg, Germany.
   Otto Von Guericke Univ, Neurol Hosp, D-39120 Magdeburg, Germany.
   Otto Von Guericke Univ, Inst Med Neurobiol, D-39120 Magdeburg, Germany.
   Univ Jena, Inst Neuropathol, Jena, Germany.
C3 Otto von Guericke University; Otto von Guericke University; Otto von Guericke University; Friedrich Schiller University of Jena
RP Kirches, E (corresponding author), Otto Von Guericke Univ, Inst Neuropathol, Leipziger Str 44, D-39120 Magdeburg, Germany.
EM Elmar.kirches@medizin.uni-magdeburg.de
CR Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   BINDOFF LA, 1991, J NEUROL SCI, V104, P203, DOI 10.1016/0022-510X(91)90311-T
   BLIN O, 1994, J NEUROL SCI, V125, P95, DOI 10.1016/0022-510X(94)90248-8
   CARDELLACH F, 1993, NEUROLOGY, V43, P1273
   Gu M, 1998, ANN NEUROL, V44, P177, DOI 10.1002/ana.410440207
   HATTORI N, 1991, ANN NEUROL, V30, P563, DOI 10.1002/ana.410300409
   Jenner P, 2003, ANN NEUROL, V53, PS26, DOI 10.1002/ana.10483
   Kraytsberg Y, 2006, NAT GENET, V38, P518, DOI 10.1038/ng1778
   MIZUNO Y, 1989, BIOCHEM BIOPH RES CO, V163, P1450, DOI 10.1016/0006-291X(89)91141-8
   NAKAGAWAHATTORI Y, 1992, J NEUROL SCI, V107, P29, DOI 10.1016/0022-510X(92)90205-Y
   Parker WD, 2005, BIOCHEM BIOPH RES CO, V326, P667, DOI 10.1016/j.bbrc.2004.11.093
   PARKER WD, 1989, ANN NEUROL, V26, P719, DOI 10.1002/ana.410260606
   SCHAPIRA AHV, 1989, LANCET, V1, P1269, DOI 10.1016/S0140-6736(89)92366-0
   SHOFFNER JM, 1991, ANN NEUROL, V30, P332, DOI 10.1002/ana.410300304
   Smigrodzki R, 2004, NEUROBIOL AGING, V25, P1273, DOI 10.1016/j.neurobiolaging.2004.02.020
   Swerdlow RH, 1996, ANN NEUROL, V40, P663, DOI 10.1002/ana.410400417
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   Wiedemann FR, 1999, ANN NY ACAD SCI, V893, P426, DOI 10.1111/j.1749-6632.1999.tb07870.x
   Winkler-Stuck K, 2005, J NEURAL TRANSM, V112, P499, DOI 10.1007/s00702-004-0195-y
NR 19
TC 2
Z9 2
U1 0
U2 4
PU DUSTRI-VERLAG DR KARL FEISTLE
PI DEISENHOFEN-MUENCHEN
PA BAHNHOFSTRASSE 9 POSTFACH 49, D-82032 DEISENHOFEN-MUENCHEN, GERMANY
SN 0722-5091
EI 
J9 CLIN NEUROPATHOL
JI Clin. Neuropathol.
PD JUL-AUG 15
PY 2007
VL 26
IS 4
BP 164
EP 168
DI 
PG 5
WC Clinical Neurology; Pathology
SC Neurosciences & Neurology; Pathology
GA 188HG
UT WOS:000247910400003
PM 17702497
DA 2024-11-01
ER

PT J
AU Kujoth, GC
   Bradshaw, PC
   Haroon, S
   Prolla, TA
AF Kujoth, Gregory C.
   Bradshaw, Patrick C.
   Haroon, Suraiya
   Prolla, Tomas A.
TI The role of mitochondrial DNA mutations in mammalian aging
SO PLOS GENETICS
LA English
DT Review
ID progressive external ophthalmoplegia; onset spinocerebellar ataxia; oxygen radical generation; multiple mtdna deletions; fatty-acid unsaturation; maximum life-span; polymerase-gamma; oxidative damage; point mutations; caloric restriction
AB Mitochondrial DNA (mtDNA) accumulates both base-substitution mutations and deletions with aging in several tissues in mammals. Here, we examine the evidence supporting a causative role for mtDNA mutations in mammalian aging. We describe and compare human diseases and mouse models associated with mitochondrial genome instability. We also discuss potential mechanisms for the generation of these mutations and the means by which they may mediate their pathological consequences. Strategies for slowing the accumulation and attenuating the effects of mtDNA mutations are discussed.
C1 Univ Wisconsin, Dept Genet & Med Genet, Madison, WI 53706 USA.
C3 University of Wisconsin System; University of Wisconsin Madison
RP Prolla, TA (corresponding author), Univ Wisconsin, Dept Genet & Med Genet, Madison, WI 53706 USA.
EM taprolla@wisc.edu
FU NIA NIH HHS [T32 AG00213, AG021905, T32 AG000213, R01 AG021905] Funding Source: Medline
CR ADACHI K, 1993, BIOCHEM BIOPH RES CO, V195, P945, DOI 10.1006/bbrc.1993.2135
   Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   ANDREEVA L, 1995, EUR J BIOCHEM, V230, P1125, DOI 10.1111/j.1432-1033.1995.tb20664.x
   Bannikova S, 2005, DNA CELL BIOL, V24, P710, DOI 10.1089/dna.2005.24.710
   Barja G, 2000, FASEB J, V14, P312, DOI 10.1096/fasebj.14.2.312
   Barja G, 2004, TRENDS NEUROSCI, V27, P595, DOI 10.1016/j.tins.2004.07.005
   Baruffini E, 2006, HUM MOL GENET, V15, P2846, DOI 10.1093/hmg/ddl219
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Berneburg M, 2005, J INVEST DERMATOL, V125, P213, DOI 10.1111/j.0022-202X.2005.23806.x
   BLOK RB, 1995, HUM GENET, V95, P75
   Brown TA, 2006, CELL CYCLE, V5, P917, DOI 10.4161/cc.5.9.2710
   Cao ZJ, 2001, NUCLEIC ACIDS RES, V29, P4502, DOI 10.1093/nar/29.21.4502
   Cassano P, 2004, ANN NY ACAD SCI, V1019, P269, DOI 10.1196/annals.1297.045
   Cerritelli SM, 2003, MOL CELL, V11, P807, DOI 10.1016/S1097-2765(03)00088-1
   Chang S, 2004, NAT GENET, V36, P877, DOI 10.1038/ng1389
   Chen LS, 2003, AGING CELL, V2, P191, DOI 10.1046/j.1474-9728.2003.00052.x
   Chinnery P, 2006, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD004426.pub2
   Cottrell DA, 2001, NEUROBIOL AGING, V22, P265, DOI 10.1016/S0197-4580(00)00234-7
   Danielson SR, 2002, J BIOL CHEM, V277, P5810, DOI 10.1074/jbc.M110119200
   Davidzon G, 2006, ANN NEUROL, V59, P859, DOI 10.1002/ana.20831
   De Sandre-Giovannoli A, 2003, SCIENCE, V300, P2055, DOI 10.1126/science.1084125
   de Souza-Pinto NC, 2001, CANCER RES, V61, P5378
   DeLaAsuncion JG, 1996, FASEB J, V10, P333, DOI 10.1096/fasebj.10.2.8641567
   Deschauer M, 2005, NEUROMUSCULAR DISORD, V15, P311, DOI 10.1016/j.nmd.2004.12.004
   DiMauro S, 2005, NEUROMUSCULAR DISORD, V15, P276, DOI 10.1016/j.nmd.2004.12.008
   Eicker J, 2003, PHOTOCH PHOTOBIO SCI, V2, P655, DOI 10.1039/b300808h
   Ekstrand MI, 2004, HUM MOL GENET, V13, P935, DOI 10.1093/hmg/ddh109
   Elson JL, 2001, AM J HUM GENET, V68, P802, DOI 10.1086/318801
   Eriksson M, 2003, NATURE, V423, P293, DOI 10.1038/nature01629
   Esposito LA, 1999, P NATL ACAD SCI USA, V96, P4820, DOI 10.1073/pnas.96.9.4820
   Estabrook RW, 1996, P NATL ACAD SCI USA, V93, P13552, DOI 10.1073/pnas.93.24.13552
   Fan L, 2006, J MOL BIOL, V358, P1229, DOI 10.1016/j.jmb.2006.02.073
   Fattal O, 2006, PSYCHOSOMATICS, V47, P1, DOI 10.1176/appi.psy.47.1.1
   Fayet G, 2002, NEUROMUSCULAR DISORD, V12, P484, DOI 10.1016/S0960-8966(01)00332-7
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   FLEMING JE, 1982, GERONTOLOGY, V28, P44, DOI 10.1159/000212510
   Gabellini D, 2002, CELL, V110, P339, DOI 10.1016/S0092-8674(02)00826-7
   Gago MF, 2006, NEUROMUSCULAR DISORD, V16, P507, DOI 10.1016/j.nmd.2006.05.016
   Gershon D, 2005, SCIENCE, V310, P441
   Goldman RD, 2004, P NATL ACAD SCI USA, V101, P8963, DOI 10.1073/pnas.0402943101
   Graham BH, 1997, NAT GENET, V16, P226, DOI 10.1038/ng0797-226
   Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100
   Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805
   Greaves LC, 2006, P NATL ACAD SCI USA, V103, P714, DOI 10.1073/pnas.0505903103
   Gredilla R, 2001, FASEB J, V15, P1589, DOI 10.1096/fj.00-0764fje
   Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309
   Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   Haripriya D, 2005, EXP GERONTOL, V40, P129, DOI 10.1016/j.exger.2004.10.006
   HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x
   Hirano M, 2001, NEUROLOGY, V57, P2163, DOI 10.1212/WNL.57.12.2163
   Holt IJ, 2000, CELL, V100, P515, DOI 10.1016/S0092-8674(00)80688-1
   HOLT IJ, 1989, NUCLEIC ACIDS RES, V17, P4465, DOI 10.1093/nar/17.12.4465
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   HRUSZKEWYCZ AM, 1990, MUTAT RES, V244, P123, DOI 10.1016/0165-7992(90)90060-W
   Hudson G, 2006, NEUROLOGY, V66, P1439, DOI 10.1212/01.wnl.0000210486.32196.24
   Hudson G, 2005, NEUROLOGY, V64, P371, DOI 10.1212/01.WNL.0000149767.51152.83
   Imam SZ, 2006, NEUROBIOL AGING, V27, P1129, DOI 10.1016/j.neurobiolaging.2005.06.002
   Inoue K, 2000, NAT GENET, V26, P176, DOI 10.1038/82826
   Inoue SI, 2006, HUM MOL GENET, V15, P1801, DOI 10.1093/hmg/ddl102
   Johnson AA, 2001, J BIOL CHEM, V276, P38097
   Johnson AA, 2001, J BIOL CHEM, V276, P38090
   Kajitani K, 2006, J NEUROSCI, V26, P1688, DOI 10.1523/JNEUROSCI.4948-05.2006
   KANG D, 1995, J BIOL CHEM, V270, P14659, DOI 10.1074/jbc.270.24.14659
   Kasahara A, 2006, HUM MOL GENET, V15, P871, DOI 10.1093/hmg/ddl005
   Kasahara T, 2006, MOL PSYCHIATR, V11, P577, DOI 10.1038/sj.mp.4001824
   Kato T, 2000, BIPOLAR DISORD, V2, P180, DOI 10.1034/j.1399-5618.2000.020305.x
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Khrapko K, 1997, P NATL ACAD SCI USA, V94, P13798, DOI 10.1073/pnas.94.25.13798
   Khrapko K, 2006, AGING CELL, V5, P279, DOI 10.1111/j.1474-9726.2006.00209.x
   Kiechl S, 2004, J NEUROL NEUROSUR PS, V75, P1125, DOI 10.1136/jnnp.2003.025890
   Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300
   Kokoszka JE, 2001, P NATL ACAD SCI USA, V98, P2278, DOI 10.1073/pnas.051627098
   Kollberg G, 2006, J NEUROPATH EXP NEUR, V65, P758, DOI 10.1097/01.jnen.0000229987.17548.6e
   Kraytsberg Y, 2006, NAT GENET, V38, P518, DOI 10.1038/ng1778
   Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125
   Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231
   Lee HR, 2006, J BIOL CHEM, V281, P36236, DOI 10.1074/jbc.M607964200
   Levy SE, 2000, GENE, V254, P57, DOI 10.1016/S0378-1119(00)00252-3
   Lewis S, 2002, J NEUROL SCI, V201, P39, DOI 10.1016/S0022-510X(02)00190-9
   Li H, 2000, P NATL ACAD SCI USA, V97, P3467, DOI 10.1073/pnas.97.7.3467
   Lin MT, 2002, HUM MOL GENET, V11, P133, DOI 10.1093/hmg/11.2.133
   Longley MJ, 2005, GENE, V354, P125, DOI 10.1016/j.gene.2005.03.029
   Longley MJ, 2001, J BIOL CHEM, V276, P38555, DOI 10.1074/jbc.M105230200
   Lönnqvist T, 1998, J NEUROL SCI, V161, P57, DOI 10.1016/S0022-510X(98)00249-4
   López-Lluch G, 2006, P NATL ACAD SCI USA, V103, P1768, DOI 10.1073/pnas.0510452103
   López-Torres M, 2002, FREE RADICAL BIO MED, V32, P882, DOI 10.1016/S0891-5849(02)00773-6
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Maier D, 2001, MOL BIOL CELL, V12, P821, DOI 10.1091/mbc.12.4.821
   Maki H, 2002, ANNU REV GENET, V36, P279, DOI 10.1146/annurev.genet.36.042602.094806
   Mancuso M, 2004, NEUROLOGY, V62, P316, DOI 10.1212/WNL.62.2.316
   Mason PA, 2003, NUCLEIC ACIDS RES, V31, P1052, DOI 10.1093/nar/gkg167
   Matsushima Y, 2004, J BIOL CHEM, V279, P26900, DOI 10.1074/jbc.M401643200
   Melov S, 1997, NUCLEIC ACIDS RES, V25, P974, DOI 10.1093/nar/25.5.974
   MELOV S, 1995, NUCLEIC ACIDS RES, V23, P4122, DOI 10.1093/nar/23.20.4122
   Melov S, 1999, NEUROBIOL AGING, V20, P565, DOI 10.1016/S0197-4580(99)00092-5
   Michikawa Y, 1999, SCIENCE, V286, P774, DOI 10.1126/science.286.5440.774
   Miller RA, 2005, SCIENCE, V310, P441, DOI 10.1126/science.310.5747.441
   MITA S, 1990, NUCLEIC ACIDS RES, V18, P561, DOI 10.1093/nar/18.3.561
   Mookerjee SA, 2005, CURR GENET, V47, P84, DOI 10.1007/s00294-004-0537-1
   Mootha VK, 2003, CELL, V115, P629, DOI 10.1016/S0092-8674(03)00926-7
   Mott JL, 2005, REJUV RES, V8, P216, DOI 10.1089/rej.2005.8.216
   Mott JL, 2004, BIOCHEM BIOPH RES CO, V319, P1210, DOI 10.1016/j.bbrc.2004.05.104
   Mott JL, 2001, MUTAT RES-FUND MOL M, V474, P35, DOI 10.1016/S0027-5107(00)00159-7
   Muller FL, 2004, J BIOL CHEM, V279, P49064, DOI 10.1074/jbc.M407715200
   Naïmi M, 2006, EUR J HUM GENET, V14, P917, DOI 10.1038/sj.ejhg.5201627
   Nakada K, 2004, BIOCHEM BIOPH RES CO, V323, P175, DOI 10.1016/j.bbrc.2004.08.073
   Nakada K, 2001, SEMIN CELL DEV BIOL, V12, P459, DOI 10.1006/scdb.2001.0283
   Nekhaeva E, 2002, P NATL ACAD SCI USA, V99, P5521, DOI 10.1073/pnas.072670199
   Nguyen KV, 2006, J HEPATOL, V45, P108, DOI 10.1016/j.jhep.2005.12.026
   Nguyen KV, 2005, NEUROLOGY, V65, P1493, DOI 10.1212/01.wnl.0000182814.55361.70
   Nikali K, 2005, HUM MOL GENET, V14, P2981, DOI 10.1093/hmg/ddi328
   Pamplona R, 2002, ANN NY ACAD SCI, V959, P475, DOI 10.1111/j.1749-6632.2002.tb02118.x
   Pamplona R, 1999, MECH AGEING DEV, V106, P283, DOI 10.1016/S0047-6374(98)00121-3
   PEPIN B, 1980, J NEUROL SCI, V45, P191, DOI 10.1016/0022-510X(80)90165-3
   Pinz KG, 2006, DNA REPAIR, V5, P121, DOI 10.1016/j.dnarep.2005.08.014
   Ponamarev MV, 2002, J BIOL CHEM, V277, P15225, DOI 10.1074/jbc.C200100200
   POULTON J, 1991, AM J HUM GENET, V48, P649
   Rachek LI, 2002, J BIOL CHEM, V277, P44932, DOI 10.1074/jbc.M208770200
   Rachek LI, 2004, NUCLEIC ACIDS RES, V32, P3240, DOI 10.1093/nar/gkh648
   Reyes A, 1998, MOL BIOL EVOL, V15, P957, DOI 10.1093/oxfordjournals.molbev.a026011
   Sakumi K, 2003, CANCER RES, V63, P902
   Samuels DC, 2004, TRENDS GENET, V20, P393, DOI 10.1016/j.tig.2004.07.003
   Santoro L, 2006, J NEUROL, V253, P869, DOI 10.1007/s00415-006-0082-6
   Sanz A, 2006, FASEB J, V20, P1064, DOI 10.1096/fj.05-5568com
   Sastre J, 1998, FREE RADICAL BIO MED, V24, P298, DOI 10.1016/S0891-5849(97)00228-1
   Schriner SE, 2005, SCIENCE, V308, P1909, DOI 10.1126/science.1106653
   SERVIDEI S, 1991, NEUROLOGY, V41, P1053, DOI 10.1212/WNL.41.7.1053
   Sharer JD, 2005, IUBMB LIFE, V57, P607, DOI 10.1080/15216540500217735
   Silva JP, 2000, NAT GENET, V26, P336, DOI 10.1038/81649
   Sligh JE, 2000, P NATL ACAD SCI USA, V97, P14461, DOI 10.1073/pnas.250491597
   Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59
   Song SW, 2005, P NATL ACAD SCI USA, V102, P4990, DOI 10.1073/pnas.0500253102
   Sörensen L, 2001, J NEUROSCI, V21, P8082, DOI 10.1523/JNEUROSCI.21-20-08082.2001
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spelbrink JN, 2000, J BIOL CHEM, V275, P24818, DOI 10.1074/jbc.M000559200
   Srivastava S, 2005, HUM MOL GENET, V14, P893, DOI 10.1093/hmg/ddi082
   Stork C, 2005, MOL PSYCHIATR, V10, P900, DOI 10.1038/sj.mp.4001711
   Stuart JA, 2006, BBA-BIOENERGETICS, V1757, P79, DOI 10.1016/j.bbabio.2006.01.003
   Stuart JA, 2005, FREE RADICAL BIO MED, V38, P737, DOI 10.1016/j.freeradbiomed.2004.12.003
   Taylor RW, 2003, J CLIN INVEST, V112, P1351, DOI 10.1172/JCI200319435
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   TRIFUNOVIC A, 2005, P NATL ACAD SCI USA, V429, P357
   Tsuzuki T, 2001, P NATL ACAD SCI USA, V98, P11456, DOI 10.1073/pnas.191086798
   Tyynismaa H, 2005, P NATL ACAD SCI USA, V102, P17687, DOI 10.1073/pnas.0505551102
   Tyynismaa H, 2004, HUM MOL GENET, V13, P3219, DOI 10.1093/hmg/ddh342
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2003, HUM MUTAT, V22, P175, DOI 10.1002/humu.10246
   Van Remmen H, 2003, PHYSIOL GENOMICS, V16, P29, DOI 10.1152/physiolgenomics.00122.2003
   Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751
   Wanagat J, 2001, FASEB J, V15, P322, DOI 10.1096/fj.00-0320com
   Wang ED, 1997, MUTAT RES-FUND MOL M, V377, P157, DOI 10.1016/S0027-5107(97)00091-2
   Wang JM, 1999, NAT GENET, V21, P133, DOI 10.1038/5089
   Wang JM, 2001, P NATL ACAD SCI USA, V98, P4038, DOI 10.1073/pnas.061038798
   Wang Y, 2001, P NATL ACAD SCI USA, V98, P4022, DOI 10.1073/pnas.061013598
   Wanrooij S, 2004, NUCLEIC ACIDS RES, V32, P3053, DOI 10.1093/nar/gkh634
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
   Wredenberg A, 2002, P NATL ACAD SCI USA, V99, P15066, DOI 10.1073/pnas.232591499
   Xu P, 2003, J BIOL CHEM, V278, P48422, DOI 10.1074/jbc.M307888200
   Yakubovskaya E, 2006, J BIOL CHEM, V281, P374, DOI 10.1074/jbc.M509730200
   Yamaguchi H, 2006, CELL DEATH DIFFER, V13, P551, DOI 10.1038/sj.cdd.4401788
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
   Zhang CF, 1998, HUM MUTAT, V11, P360
   Zhang D, 2005, AM J PHYSIOL-HEART C, V288, PH2476, DOI 10.1152/ajpheart.00670.2004
   Zhang D, 2003, CARDIOVASC RES, V57, P147, DOI 10.1016/S0008-6363(02)00695-8
   Zhang DK, 2000, GENOMICS, V69, P151, DOI 10.1006/geno.2000.6333
   Zhang J, 2003, P NATL ACAD SCI USA, V100, P1116, DOI 10.1073/pnas.242719399
   Zheng WM, 2006, MUTAT RES-FUND MOL M, V599, P11, DOI 10.1016/j.mrfmmm.2005.12.012
NR 168
TC 140
Z9 162
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7404
EI 
J9 PLOS GENET
JI PLoS Genet.
PD FEB 15
PY 2007
VL 3
IS 2
BP 161
EP 173
DI 10.1371/journal.pgen.0030024
PG 13
WC Genetics & Heredity
SC Genetics & Heredity
GA 143HR
UT WOS:000244711700007
PM 17319745
DA 2024-11-01
ER

PT J
AU Meulemans, A
   Seneca, S
   Smet, J
   De Paepe, B
   Lissens, W
   Van Coster, R
   Debeer, A
   De Meirleir, L
   Jaeken, J
AF Meulemans, Ann
   Seneca, Sara
   Smet, Joel
   De Paepe, Boel
   Lissens, Willy
   Van Coster, Rudy
   Debeer, Anne
   De Meirleir, Linda
   Jaeken, Jaak
TI A new family with the mitochondrial tRNAGLU gene mutation m.14709T&gt;C presenting with hydrops fetalis
SO EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY
LA English
DT Article
DE diabetes; hydrops fetalis; mitochondrial disease; mitochondrial tRNA(Glu); myopathy; m.14709T >C
ID t14709c point mutation; diabetes-mellitus; onset myopathy; dna; encephalomyopathy; patient; defect
AB Background: In the heterogeneous group of mitochondrial disorders, patients with the same genotype can show different phenotypes and the same phenotype can be caused by different genotypes. We describe a family with the m.14709T > C mutation and a clinical presentation of hydrops fetalis, in contrast to previous reports in which patients presented with myopathy and/or diabetes mellitus. Aim: To identify a mutation in the mtDNA of a family with a heterogeneous clinical presentation. Methods: Both biochemical and molecular analyses were performed. Results: Biochemical results showed a decreased complex I and IV activity in muscle tissue of the patients. A mosaic-staining pattern for complex I in the patients' fibroblasts was revealed using immunocytochemistry. Molecular analyses identified the m. 14709T > C mutation in the mitochondrial encoded tRNA(Glu) gene. Conclusion: We report 2 siblings with the m.14709T > C mutation in the mitochondrial tRNA(Glu) gene. The first patient showed hydrops fetalis, a new presentation within the clinical spectrum of this mutation, and the other a known presentation namely mild myopathy. (c) 2006 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.
C1 Katholieke Univ Leuven, Ctr Metab Dis, Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium.
   Dutch Speaking Free Univ Brussels, Ctr Med Genet, AZVUB, Brussels, Belgium.
   Dutch Speaking Free Univ Brussels, Dept Pediat Neurol, AZVUB, Brussels, Belgium.
   Univ Ghent, B-9000 Ghent, Belgium.
   Katholieke Univ Leuven, Dept Neonatol, Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium.
C3 KU Leuven; University Hospital Leuven; Vrije Universiteit Brussel; Vrije Universiteit Brussel; Ghent University; KU Leuven; University Hospital Leuven
RP Jaeken, J (corresponding author), Katholieke Univ Leuven, Ctr Metab Dis, Univ Hosp Gasthuisberg, Herestr 49, B-3000 Louvain, Belgium.
EM jaak.jaeken@uz.kuleuven.ac.be
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   BIRCHMACHIN MA, 1989, PEDIATR RES, V25, P553, DOI 10.1203/00006450-198905000-00025
   Damore ME, 1999, J PEDIATR ENDOCR MET, V12, P207
   De Paepe B, 2006, PEDIATR RES, V59, P2, DOI 10.1203/01.pdr.0000191294.34122.ab
   DIMAURO S, 1987, ANN NEUROL, V22, P498, DOI 10.1002/ana.410220409
   FISCHER JC, 1986, EUR J PEDIATR, V144, P441, DOI 10.1007/BF00441735
   HANNA MG, 1995, AM J HUM GENET, V56, P1026
   HAO HL, 1995, AM J HUM GENET, V56, P1017
   Kramer KA, 2005, CLIN CHEM, V51, P2110, DOI 10.1373/clinchem.2005.050146
   Mancuso M, 2005, J NEUROL SCI, V228, P93, DOI 10.1016/j.jns.2004.10.018
   McFarland R, 2004, ANN NEUROL, V55, P478, DOI 10.1002/ana.20004
   Perucca-Lostanlen D, 2002, BBA-MOL BASIS DIS, V1588, P210, DOI 10.1016/S0925-4439(02)00167-9
   RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8
   Schapira AHV, 2006, LANCET, V368, P70, DOI 10.1016/S0140-6736(06)68970-8
   SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415
   Srere PA, 1969, METHODS IN ENZYMOLOGY, V13, P3
   Van Coster R, 2001, PEDIATR RES, V50, P658, DOI 10.1203/00006450-200111000-00020
   Vialettes BH, 1997, DIABETES CARE, V20, P1731, DOI 10.2337/diacare.20.11.1731
NR 18
TC 13
Z9 13
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1090-3798
EI 1532-2130
J9 EUR J PAEDIATR NEURO
JI Eur. J. Paediatr. Neurol.
PD JAN 15
PY 2007
VL 11
IS 1
BP 17
EP 20
DI 10.1016/j.ejpn.2006.10.004
PG 4
WC Clinical Neurology; Pediatrics
SC Neurosciences & Neurology; Pediatrics
GA 135UB
UT WOS:000244178200003
PM 17161635
DA 2024-11-01
ER

PT J
AU Edvardson, S
   Shaag, A
   Kolesnikova, O
   Gomori, JM
   Tarassov, I
   Einbinder, T
   Saada, A
   Elpeleg, O
AF Edvardson, Simon
   Shaag, Avraham
   Kolesnikova, Olga
   Gomori, John Moshe
   Tarassov, Ivan
   Einbinder, Tom
   Saada, Ann
   Elpeleg, Orly
TI Deleterious mutation in the mitochondrial arginyl-transfer RNA synthetase gene is associated with pontocerebellar hypoplasia
SO AMERICAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID translation; deficiency; myopathy; import; mtdna; yeast
AB Homozygosity mapping was performed in a consanguineous Sephardic Jewish family with three patients who presented with severe infantile encephalopathy associated with pontocerebellar hypoplasia and multiple mitochondrial respiratory-chain defects. This resulted in the identification of an intronic mutation in RARS2, the gene encoding mitochondrial arginine-transfer RNA (tRNA) synthetase. The mutation was associated with the production of an abnormally short RARS2 transcript and a marked reduction of the mitochondrial tRNA(Arg) transcript in the patients' fibroblasts. We speculate that missplicing mutations in mitochondrial aminoacy1-tRNA synthethase genes preferentially affect the brain because of a tissue-specific vulnerability of the splicing machinery.
C1 Hebrew Univ Jerusalem, Hadassah Med Ctr, Metab Dis Unit, IL-91120 Jerusalem, Israel.
   Hebrew Univ Jerusalem, Hadassah Med Ctr, Pediat Neurol Unit, IL-91120 Jerusalem, Israel.
   Hebrew Univ Jerusalem, Hadassah Med Ctr, Dept Radiol, IL-91120 Jerusalem, Israel.
   Univ Strasbourg 1, CNRS, UMR 7156, Dept Genet Mol & Cellulaire, Strasbourg, France.
C3 Hebrew University of Jerusalem; Hadassah University Medical Center; Hebrew University of Jerusalem; Hadassah University Medical Center; Hebrew University of Jerusalem; Hadassah University Medical Center; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB)
RP Elpeleg, O (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Ctr, Metab Dis Unit, IL-91120 Jerusalem, Israel.
EM Elpeleg@hadassah.org.il
CR Bonnefond L, 2005, BIOCHEMISTRY-US, V44, P4805, DOI 10.1021/bi047527z
   Bykhovskaya Y, 2004, AM J HUM GENET, V74, P1303, DOI 10.1086/421530
   Cartegni L, 2003, NUCLEIC ACIDS RES, V31, P3568, DOI 10.1093/nar/gkg616
   Coenen MJH, 2004, NEW ENGL J MED, V351, P2080, DOI 10.1056/NEJMoa041878
   de Koning TJ, 1999, NEUROPEDIATRICS, V30, P93, DOI 10.1055/s-2007-973467
   Entelis N, 2002, GENET ENG P, V24, P191
   Entelis NS, 2001, ADV DRUG DELIVER REV, V49, P199, DOI 10.1016/S0169-409X(01)00135-1
   Johnson KR, 2001, NAT GENET, V27, P191, DOI 10.1038/84831
   Miller C, 2004, ANN NEUROL, V56, P734, DOI 10.1002/ana.20282
   Moreno-Loshuertos R, 2006, NAT GENET, V38, P1261, DOI 10.1038/ng1897
   Patel MS, 2006, AM J MED GENET A, V140A, P594, DOI 10.1002/ajmg.a.31095
   Saada A, 2003, MOL GENET METAB, V79, P1, DOI 10.1016/S1096-7192(03)00063-5
   Scheper GC, 2007, NAT GENET, V39, P534, DOI 10.1038/ng2013
   Schneider A, 2000, TRENDS CELL BIOL, V10, P509, DOI 10.1016/S0962-8924(00)01854-7
   Smeitink JAM, 2006, AM J HUM GENET, V79, P869, DOI 10.1086/508434
   TZAGOLOFF A, 1995, EUR J BIOCHEM, V230, P582
   Uusimaa J, 2004, PEDIATRICS, V114, P443, DOI 10.1542/peds.114.2.443
   Valente L, 2007, AM J HUM GENET, V80, P44, DOI 10.1086/510559
   VARSHNEY U, 1991, J BIOL CHEM, V266, P24712
   Woods CG, 2006, AM J HUM GENET, V78, P889, DOI 10.1086/503875
NR 20
TC 273
Z9 299
U1 0
U2 9
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0002-9297
EI 
J9 AM J HUM GENET
JI Am. J. Hum. Genet.
PD OCT 15
PY 2007
VL 81
IS 4
BP 857
EP 862
DI 10.1086/521227
PG 6
WC Genetics & Heredity
SC Genetics & Heredity
GA 208GK
UT WOS:000249307600028
PM 17847012
DA 2024-11-01
ER

